Scientific Abstract Listing and Meeting Information - American ... [PDF]

Scientific Abstract Listing and Meeting Information April 18–25, 2015 · Washington, DC Hotel Reservation Deadline: March 18, 2O15 Early Registration Deadline: March 27, 2O15

The 67th AAN Annual Meeting Experience innovative research, exceptional education programs, and boundless networking opportunities at the AAN Annual Meeting in Washington, DC, April 18–25, 2015.

2O15 Deadlines-At-A-Glance Late January, 2015: Abstract Notifications Available March 18, 2015: Annual Meeting Hotel Reservation Deadline

March 27, 2015: Annual Meeting Early Registration Deadline Location Walter E. Washington Convention Center Washington, DC

Headquarter Hotel Marriott Marquis Washington, DC

RED: 14AM Register Online Ad Place in AANnews and Others? 8.25 x 5.4375 4C + Bleed

Register Online

Customize Your Week with Easy Online Registration With online registration, you can: nn Register nn Book your hotel nn Plan your itinerary nn Search for programs by topic or day nn New! Choose from three registration packages!

See page 8 for details

AAN.com/view/AM15

Table of Contents Introduction

Wednesday, April 22

Plan to Attend the 67 AAN Annual Meeting . . 2 An Experience No Other Conference Can Match . 3 th

Look What’s New! . . . . . . . . . . . . . . 4 Look What’s Back by Popular Demand . . . . . 5 What’s Included with Your Registration? . . . . 6 Registration . . . . . . . . . . . . . . . . 8 2O15 Award Recipients . . . . . . . . . . . 11 2O15 Research Fellowships . . . . . . . . . 17

Meeting Schedule Overviews Meeting at a Glance . . . . . . . . . . .

18

I Talks Schedule . . . . . . . . . . . . . . 22 Understanding the Program Listings . . . . . 25 Scientific Session Schedule . . . . . . . . . 26 Annual Meeting Program Schedule . . . . . . 30 Annual Meeting Programs by Topic . . . . . 40

Saturday, April 18 Integrated Neuroscience Session I1��48 Integrated Neuroscience Session I2 . . . . . . 49

Sunday, April 19 Integrated Neuroscience Session I3��50 Section Topic Controversies S1 . . . . . . . . 51 Integrated Neuroscience Session I4��52

Monday, April 20 Integrated Neuroscience Session I5��53 Section Topic Controversies S2��54 Integrated Neuroscience Session I6 . . . . . . 55 Poster Session Schedule and Floor Plan . . . . 56 Poster Session I . . . . . . . . . . . . . . 57

Poster Session IV��88 Scientific Sessions S20–S28��96 Integrated Neuroscience Session I9��98 Integrated Neuroscience Session I10 . . . . . 99 Poster Session V ��100 Platform Blitz Sessions S29–S37 ��108

Thursday, April 23 Poster Session VI��110 Scientific Sessions S38–S45��118 Invited Science: Epilepsy . . . . . . . . . . 119 Integrated Neuroscience Session I11 ��120 Integrated Neuroscience Session I12 . . . . . 121 Poster Session VII ��122 Scientific Sessions S46–S53��132

Other Interests Highlights for Students, Residents, and Fellows 134 Connect at Social Events . . . . . . . . . . 136 Things to do in DC . . . . . . . . . . . . 138 AAN 2015 Annual Meeting On Demand . . . 140 General Information . . . . . . . . . . . . 142

Hotels and Travel Hotel Reservations . . . . . . . . . . . . 146 Travel Information . . . . . . . . . . . . . 147 Hotel Street Map and Amenities . . . . . . 148

Meeting Listings 67th Annual Meeting Exhibitors . . . . . . . 151 67th Annual Meeting Committee Members . . 153 Meeting Management and Contacts . . . . . 156

Tuesday, April 21 Poster Session II . . . . . . . . . . . . . . 65 Section Topic Controversies S3 . . . . . . . . 73 Scientific Sessions S4–S11 ��74 Invited Science: Stroke . . . . . . . . . . . 75 Integrated Neuroscience Session I7��76 Integrated Neuroscience Session I8 . . . . . . 77 Poster Session III��78 Scientific Sessions S12–S19��86

Program current as of February 10, 2015. Program subject to change. Fast, Easy, Online Registration · AAN.com/view/AM15

1

Plan to Attend the 67th AAN Annual Meeting

“Welcome to the 67th AAN Annual Meeting! The 2014 meeting in Philadelphia broke attendance records and brought together the world’s best minds in neurology—and I have no doubt the 2015 meeting will be just as spectacular. As we all know, neuroscience research is essential for our patients and profession, and there is no better place than an AAN Annual Meeting to experience the very best science and latest research covering the breadth of the neurology profession. The always popular Scientific Program is included free with your registration and includes a variety of sessions covering hot topics, critical issues, latest scientific advances and highlights, in addition to more than 2,500 cutting-edge abstracts presented within the poster and platform sessions. We’re thrilled to be bringing the world’s largest gathering of neurology professionals to the U.S. capital this spring, and hope you’ll join us—either for a few, or all eight days—to be a part of this truly unique experience that no other conference can match. I look forward to seeing you in Washington, DC.” -Stefan M. Pulst, MD, FAAN Chair, Meeting Management Committee

An Experience No Other Conference Can Match The AAN Annual Meeting delivers an experience no other conference can match. That’s because at an AAN Annual Meeting you not only can choose courses based on your area of interest, but you also have access to a wide array of courses offering updates and review of topics such as multiple sclerosis, epilepsy, movement disorders, stroke, child neurology, and many more. Customize the meeting for the schedule that works best for you and/or your practice. With so many exceptional education programs and scientific sessions available in a variety of subspecialties, plus unparalleled networking opportunities—all week long—the AAN Annual Meeting can be tailored to be a perfect fit for you no matter what your interest, career stage, or schedule.

Advancing Neurology. Working for You! ¡¡ For Neurologists The Annual Meeting is the place for top CME programming, innovative scientific research, and opportunities to meet up with neurology’s thought leaders from around the world. New Silver and Gold Registration Packages provide great value for your CME programming, providing access to all education courses for one flat rate. ¡¡ For Students and Junior Members The Annual Meeting is essential, providing exposure to a variety of interests and unmatched networking opportunities. Students and Junior members get significant discounts on registration and course fees. Learn more about highlights for students, residents, and fellows on page 134.

Fast, Easy, Online Registration · AAN.com/view/AM15

¡¡ For Other Physicians and Advanced Practice Providers New! Customize the meeting to your needs with new tracks offering focused education and scientific programming. Learn more about the new Clinical Research Track, the new Advanced Practice Provider Track, and the always popular Subspecialty in Focus Track on page 25.

Come for 3 days or stay for all 8. Make the meeting your own!

3

Look What’s New! Best Science from Subspecialty Meetings in Stroke and Epilepsy We are bringing you the best science, even if it wasn’t presented here first. Top abstracts previously presented at the International Stroke Conference and the American Epilepsy Society Annual Meeting will be presented by their authors in 20-minute platform sessions. Select abstracts from their “best of” lineups emphasize basic, clinical, and translational sciences as they evolve toward a more complete understanding of stroke and epilepsy pathophysiology with the overall goal of developing more effective prevention and treatment. See pages 75 and 119 for more information.

Neuroscience Is Essential Keep your eye out for this exciting new promotional effort to launch at the Annual Meeting reinforcing why neuroscience is essential to neurology professionals and patients! See page 54 for more information.

Specialized Learning Tracks ¡¡ Clinical Research Track C Offers suggested programs geared towards academic neurologists early in the development of a clinical research career or who are considering one. ¡¡ Advanced Practice Provider Track A The APP Track is comprised of current education courses suggested to provide APPs a “deep dive” into general neurology, including the Advance Practice Provider Symposium on Sunday, April 19. Learn more about the tracks on page 25.

Customized Registration Packages The Innovation room is your destination for I Talks, a lively, supplemental learning experience at the Annual Meeting, through a variety of one- to two-hour presentations throughout the week, the Walter E. Washington Convention Center. Look for lectures, presentations, group discussions, and hands-on activities using advanced multimedia formats that bring learning to life. See a full schedule on page 22.

The Value of a Neurologist Monday, April 20, 5:30 p.m.–6:30 p.m.

Can neurologists objectively demonstrate that we provide value (quality and financial) when added to a care team? At this hot topics in education session attendees will learn how an AAN work group used third party payer claims data to identify the value of neurologic care in the disease areas of stroke, MS, epilepsy, pediatric epilepsy, headache, and Alzheimer’s disease. ¡¡ Explore how the “value” of care is being defined by payers and purchasers. ¡¡ Learn how the AAN is approaching an effort to determine the value of care provided by neurologists in the health care system. ¡¡ Identify the benefits and limitations of using claims data to determine value of care. ¡¡ Discover areas where data show where neurologists provide value above other physicians' patient care.

4

Choose the one that’s right for you! ¡¡ Meeting Registration Education courses available for additional fees. ¡¡ Silver Registration Package Includes Meeting Registration plus full access to the 2015 Annual Meeting Education Program*. ¡¡ Gold Registration Package—BEST VALUE! Gain full access to the 2015 Annual Meeting Education Program*, plus Annual Meeting On Demand, the digital library of the Annual Meeting. With the Gold Registration Package you have the flexibility to attend sessions in-person or on demand, access to the syllabi summaries of more than 160 programs, and the ultimate CME earning power both during the meeting and after! * Skills Workshops, Skills Pavilions, and Leadership Courses excluded from Silver and Gold Registration Package pricing. Attendee must identify courses to be included as part of Silver and Gold Registration Package. Courses are subject to closure due to reaching maximum capacity. Attendee is only permitted to select courses that he/she plans to be in the room for. Attendee will not be able to register for courses with conflicting time schedules.

2O15 AAN Annual Meeting Scientific Abstract Listing and Meeting Information

Look What’s Back by Popular Demand ePosters

Highlights in the Field

Look for select scientific posters to be presented on large monitors, allowing authors to best highlight visually compelling components such as images, videos, and 3D models.

Get essential updates covering the past year in your subspecialty or topic of interest. Sections will provide overviews in their areas, featuring scientific and educational abstracts, journal articles, subspecialty society updates, tips, resources, and more.

Section Topic Controversies AAN Sections will debate controversies related to a specific section topic, including Stroke and Vascular Neurology, Sleep Medicine, Neuro-oncology, and Child Neurology. This lively format will feature two speakers arguing a side of the topic, followed by a rebuttal and question and answer period.

Platform Blitzes Following a similar format to the popular Emerging Science Session, these dynamic sessions will feature fiveminute author presentations followed by five-minutes of questions and answers. The session will conclude with all authors participating in a panel discussion.

Extend Your Experience with These Annual Meeting Resources ¡¡ Academy Central: Your one-stop shop for AAN products, services, and more ¡¡ American Brain Foundation: Support cures for brain disease and see the future of neurology ¡¡ Neurology Career Center in Academy Central and the Exhibit Hall: Meet employers, search for jobs, and get career tools ¡¡ Resident/Medical Student Rush Line: Free education program tickets, first-come, first-served ¡¡ Annual Meeting Mobile App: LITE version available now. Full version available in March 2015. ¡¡ Annual Meeting On Demand: The digital library of content from the 2015 AAN Annual Meeting presentations (Now included with the Gold Registration Package) ¡¡ Residents Experience: A unique place to network, find information, and participate in informal presentations specifically geared to those in the early stages of their career ¡¡ International Experience: Provides an opportunity for international attendees to network and participate in discussions on a variety of topics


5

F What’s Included with Your Registration? When planning your week, be sure and take advantage of these FREE education, scientific, practice, advocacy programs, and social events—going on all week long and at no additional cost to you!

FREE programs to help you: ¡¡ Stay current with the latest research and scientific sessions ¡¡ Network with colleagues ¡¡ Participate in Academy business Saturday, April 18

F I1 S New Windows into the Brain:

Technological Advances in Frontline Neurologic Diagnosis via the Visual and Oculomotor Systems 8:00 a.m.–12:00 p.m. Management of Asymptomatic F I2 Cerebrovascular Lesions 1:00 p.m.–5:00 p.m. F I Webs, Apps, and Social Media: There’s an AAN Tool for That! 3:00 p.m.–5:00 p.m.

S

Sunday, April 19

F I Creating Innovative,

Interactive Teaching Modules 8:00 a.m.–8:30 a.m. Clinical Research: F C170 Introduction and Methods 8:00 a.m.–12:00 p.m. Dopamine-mediated F I3 Neural Plasticity in Motor and Non-motor Circuits 8:00 a.m.–12:00 p.m. F C171 Opioids and Marijuana in Your Practice 8:30 a.m.–12:00 p.m. F I The Business of Neurology 9:00 a.m.–11:00 a.m. F I Neurology Jeopardy: Things You May Not Know About Publishing in the Journal or Its Spin-offs 11:30 a.m.–12:30 p.m.

C

S

F I Annual Meeting Orientation Session 1:00 p.m.–1:30 p.m.

F S1 Section Topic Controversies:

Antiplatelets, Anticoagulants, or Stenting for Acute Treatment of Cervical/Cranial Dissection? 1:00 p.m.–2:30 p.m. F C43 Advanced Practice Provider Symposium (registration required) 1:00 p.m.–4:00 p.m. Clinical Research: Drug F C172 Development and Clinical Trials 1:00 p.m.–5:00 p.m. Infectious, Paraneoplastic, F I4 and Autoimmune Encephalopathies: Advances in Clinical Diagnosis and Emerging Insights about Pathogenesis 1:00 p.m.–5:00 p.m. F I Providing High Value Neurologic Care 2:00 p.m.–4:00 p.m. F I Quality in Neurology— Can We Measure and Improve It? 4:30 p.m.–5:30 p.m. F Capitol City Celebration 6:00 p.m.–10:00 p.m.

A

C

S

Monday, April 20

F I Leadership Meeting

6:30 a.m.–7:30 a.m. F C59 Leadership in Neurology: Be a Champion for Your Patients and Protector of Your Subspecialty with Payers, Policymakers, and the Public 6:30 a.m.–8:00 a.m. F C60 Resident and Fellow Career Breakfast: The Early Years (registration required) 6:30 a.m.–8:30 a.m. F I AAN Business Meeting 8:00 a.m.–8:30 a.m. Pediatric Neurotrauma: F I5 From Coma to Concussions 8:00 a.m.–12:00 p.m.

S

6

F C173 Clinical Reasoning:

From a Novice to an Expert 8:30 a.m.–12:00 p.m. F I Is AAN Member Participation in Physician-assisted Suicide Ethical? 9:00 a.m.–10:30 a.m. F I Neuroexam SHORTCUTS: Learn from the Experts 11:00 a.m.–1:00 p.m. F I Neurologist Burnout: What is it? Do I Have it? What can I do about it? 12:00 p.m.–12:30 p.m. F S2 Section Topic Controversies: Testing in Prodromal Neurological Disease: Friend or Foe? 1:00 p.m.–2:30 p.m. Future Therapies: F I6 How We Will Be Treating, Preventing, and Curing Epilepsy in the Year 2025 1:00 p.m.–5:00 p.m. F C174 All You Need to Know About Health Information Technology to Avoid Taking a HIT 1:00 p.m.–5:00 p.m. F ABPN Maintenance Of Certification Information Session 1:30 p.m.–3:00 p.m. F I Conquering ICD-10 1:30 p.m.–3:30 p.m. F C175 Qualitative Research: The ‘How‘ and ‘Why’ of Education 2:00 p.m.–4:30 p.m. F P1 Poster Session I 2:00 p.m.–6:30 p.m.

S


F = Included with registration $ = Registration fee required I = I Talk Session F I AAN’s Axon Registry:

Data Powering Neurology’s Future 4:00 p.m.–5:00 p.m. F Student Interest Groups in Neurology (SIGN) Meeting 4:00 p.m.–6:45 p.m. F Exhibit Hall Opening Reception 4:30 p.m.–6:30 p.m. F Consortium of Neurology Residents and Fellows Meeting 5:00 p.m.–6:30 p.m. F I Hot Topics in Education: The Value of a Neurologist 5:30 p.m.–6:30 p.m. F Residents and Fellows Career Forum and Reception 6:30 p.m.–9:00 p.m.

F I8 Advances in ALS and Other

Motor Neuron Diseases 1:00 p.m.–5:00 p.m. F I Case Report 2.0: Implementing the "CARE" Case Report Guidelines for the Digital Era 1:30 p.m.–3:30 p.m. F P3 Poster Session III 2:00 p.m.–6:30 p.m. F Scientific Platform Sessions 3:15 p.m.–5:00 p.m. F I How to Hug a Porcupine: Relationship Building with Congress and Why It’s Important 4:00 p.m.–5:00 p.m. F Hot Topics Plenary Session 5:30 p.m.–6:45 p.m.

Tuesday, April 21

Wednesday, April 22

F P2 Poster Session II

F P4 Poster Session IV

7:30 a.m.–12:00 p.m. F Presidential Plenary Session 9:00 a.m.–12:00 p.m.

F Exhibit Hall

11:30 a.m.–5:00 p.m. F I Policy and Advocacy Hour with the GRC 12:00 p.m.–1:00 p.m. F S3 Section Topic Controversies: Should All Brain Tumor Patients Receive Prophylactic Antiepileptic Drugs? 1:00 p.m.–2:30 p.m. F Scientific Platform Sessions 1:00 p.m.–2:45 p.m. F Invited Science: Stroke 1:00 p.m.–2:45 p.m. F I7 The Global Burden of Neurological Infections: Epidemiology, Treatment, and Prevention 1:00 p.m.–5:00 p.m.

7:30 a.m.–12:00 p.m. F I Annual Meeting Orientation Session 8:00 a.m.–8:30 a.m. F Contemporary Clinical Issues Plenary Session 9:00 a.m.–12:00 p.m. F Exhibit Hall 11:30 a.m.–5:00 p.m. F I Neurology Compensation and Productivity Survey and Dashboard Report 12:30 p.m.–1:30 p.m. F I How to Avoid “Death by PowerPoint” and Workshop 1:30 p.m.–3:30 p.m. F Scientific Platform Sessions 2:00 p.m.–3:45 p.m. F I9 Treating Dementia in an Age of Mixed Disease 2:00 p.m.–6:00 p.m. The Dynamic Brain in F I10 Health and Disease: Plasticity and Reprogramming 2:00 p.m.–6:00 p.m. F P5 Poster Session V 2:00 p.m.–6:30 p.m. F I Your Abstract Has Been Accepted: Now What? Working with the Media 4:00 p.m.–5:00 p.m. F Scientific Platform Blitz Sessions 4:00 p.m.–5:45 p.m. F Highlights in the Field Sessions 6:00 p.m.–7:00 p.m.

C


A = Advanced Practice Provider Track C = Clinical Research Track S = Subspecialty in Focus Track F E merging Science

6:15 p.m.–7:45 p.m.

Thursday, April 23

F P6 Poster Session VI

7:30 a.m.–12:00 p.m. F Frontiers in Neuroscience Plenary Session 9:00 a.m.–12:00 p.m. F Exhibit Hall 11:30 a.m.–3:00 p.m. F I AAN’s Axon Registry: Data Powering Neurology’s Future 12:00 p.m.–1:00 p.m. F Scientific Platform Sessions 1:00 p.m.–2:45 p.m. F Invited Science: Epilepsy 1:00 p.m.–2:45 p.m. The Promise of Novel F I11 Biomarker Approaches in Advancing Treatment 1:00 p.m.–5:00 p.m. F I12 Obesity and Neurological Disorders 1:00 p.m.–5:00 p.m. F I AAN Digital Scavenger Hunt 1:30 p.m.–2:30 p.m. F P7 Poster Session VII 2:00 p.m.–6:30 p.m. F I Your Abstract Has Been Accepted: Now What? Tips for a Successful Presentation 3:00 p.m.–4:00 p.m. F Scientific Platform Sessions 3:15 p.m.–5:00 p.m. F I Lessons Learned from an Ebola Patient 5:00 p.m.–5:30 p.m. F Highlights in the Field Sessions 5:30 p.m.–6:30 p.m. F Controversies in Neurology Plenary Session 5:30 p.m.–7:00 p.m.

C

Friday, April 24

F Clinical Trials Plenary Session 12:00 p.m.–1:30 p.m. F Neurology Year in Review Plenary Session 4:30 p.m.–6:00 p.m. F Closing Party 6:00 p.m.–8:00 p.m.

7

Registration

The field of neurology is rapidly changing, and there’s nowhere like the AAN Annual Meeting to make sure you’re up-to-date. The 67th AAN Annual Meeting in Washington, DC, offers innovative research, exceptional education programs, and boundless networking opportunities. Log in to the registration site where you can: ¡¡ Register quickly and easily ¡¡ Make your hotel selection and reservation ¡¡ Print your schedule and not miss a thing at the meeting!

¡¡ Create your itinerary incorporating your education programs, scientific sessions, and other Annual Meeting events

Ways to Save

Registration Options

The Annual Meeting offers a great value for the quality and quantity of programming. Try some of these savings tips: ¡¡ Renew your AAN membership or join the AAN now for maximum savings on registration and course fees at AAN.com/view/membership. ¡¡ Register now to avoid increased rates after the March 27, 2015, early registration deadline. ¡¡ Purchase education programs individually or select the Silver or Gold Registration Package option and register for any course of interest for one flat rate.1

Meeting Registration: Meeting Registration with education courses available for an additional fee. Silver Registration Package1: The Silver Registration Package includes all education courses for one flat rate. Choose this registration option before the meeting or on-site. You can change to another course at any time, including at the meeting, with no change fee. However, you will not be able to register for courses with conflicting time schedules. Gold Registration Package1: Silver Registration Package as described above plus Annual Meeting On Demand, the comprehensive digital library of Annual Meeting presentations.

Registration Fees

Member Type

Students Senior/Honorary Junior and Non-neurologist Member* Neurologist Member** Nonmember

Meeting Registration2 Before March 27, 2015

Silver Registration Package3 Before March 27, 2015

Gold Registration Package3 Before March 27, 2015

$0 $0

$300 $695

$499 $1,094

$0 $0

$370 $780

$569 $1,179

$100

$400

$599

$130

$500

$699

$305

$1,000

$1,399

$420

$1,200

$1,599

$610

$2,000

$2,499

$840

$2,300

$2,799

1 Skills Workshops, Skills Pavilions, and Leadership Courses excluded from Silver and Gold Registration Package pricing. Attendee must identify courses to be included as part of Silver and Gold Registration Package. Courses are subject to closure due to reaching maximum capacity. Attendee is only permitted to select courses that he/she plans to be in the room for. Attendee will not be able to register for courses with conflicting time schedules. 2 Includes meeting access only, education courses must be paid for individually.

8

Meeting Silver Registration Gold Registration Registration2 Package3 Package3 After March 27, 2015 After March 27, 2015 After March 27, 2015

3 Includes access to meeting and ability to register for education courses at no additional cost. * Junior Intern, Resident or Junior Fellow, Business Administrator, Non-neurologist Clinician, Nurse Practitioner, Physician Assistant, Research Scientist, Research Scientist Fellow, Research Coordinator ** Active, Associate, Fellow


Three Easy Ways to Register Online Fast, easy online registration available at AAN.com/view/register

Online registration walks you step-by-step through completing your registration, reserving a hotel, and personalizing your itinerary with top-tier education courses, scientific sessions, special Annual Meeting events, and more!

Fax/Mail A printable registration form is available at AAN.com/view/register

Download and print a registration form to complete and mail or fax to: Mail: Fax: AAN Registration/CMR (415) 293-4071 33 New Montgomery, Suite 1100 San Francisco, CA 94105 Deadline: March 27, 2015 Registrations received after March 27, 2015, will be processed at a higher rate. Questions Online: AAN.com/view/register Email: [email protected]

Telephone US/Canada: (800) 676-4226 International: (415) 979-2283

Fees Meeting Registration Fee The meeting registration fee is mandatory for all registrants and is determined by AAN member type. For attendees selecting the Silver and Gold Registration Packages, the meeting registration fee is included in the price. Education Programs Purchase programs individually or select the Silver or Gold Registration Package to register for any course of interest for one flat rate (Note: Skills Workshops, Skills Pavilions, and Leadership Courses excluded from Silver and Gold Registration Package pricing. Attendee must identify courses to be included as part of Silver and Gold Registration Package. Courses are subject to closure due to reaching maximum capacity. Attendee is only permitted to select courses that he/she plans to be in the room for. Attendee will not be able to register for courses with conflicting time schedules.). Fast, Easy, Online Registration · AAN.com/view/AM15

In addition, Junior Members who register for two Education Programs at full price will receive 50% off the cost of a third education program of equal or lesser value. Changes in Education Programs Select education programs carefully. An administrative fee of $20 ($30 after March 27, 2015) will be charged for program cancellations without a replacement program. Many programs and events are included with your registration. See page 6 for details. Cancelled or Closed Programs Education programs may be closed due to reaching maximum capacity or cancelled due to insufficient enrollment. In the event of cancellation, registration for the cancelled course will be fully refunded. The AAN is not responsible for airfare, hotel, or other costs incurred by participants in the event of program or registration closure or cancellation. Cancellations/Refunds of Registration Until March 27, 2015—Refund less $50 administrative fee March 28–April 10, 2015—Refund less $100 administrative fee After April 10, 2015—No refund ¡¡ All cancellations must be submitted in writing to [email protected] or faxed to (415) 293-4071. ¡¡ No-shows will not receive a refund. ¡¡ Name substitutions are not permitted. ¡¡ No refunds will be processed for amounts of $20 or less. Special Accommodations Deadline: March 27, 2015 The Walter E. Washington Convention Center and the AAN are in compliance with the Americans with Disabilities Act or Human Rights Code and strive to accommodate all visitors. Information booths, designated parking, and assisted listening devices are available. If you require special accommodation to attend the Annual Meeting, submit your request while registering online or contact Laurie Dixon no later than March 27, 2015, at [email protected] or (612) 928-6154. Kosher meals may be provided at any breakfast or lunch, and must be arranged on or before March 27, 2015, through the registration website or by contacting AAN Registration/CMR at [email protected], (800) 676-4226, or (415) 979-2283. There is a $50 surcharge per meal. On-site requests cannot be accommodated. Group Registration Deadline: April 2, 2015 Group registrations are those in which 10 or more individuals’ fees are paid for with one check or credit card. Special registration instructions are available online at AAN.com/view/register or by contacting CMR’s Group Registration at (800) 676-4226 (US/Canada) or (415) 979-2283 (International) or email [email protected] . See page 146 for housing information.

9

Proud Sponsor of the 2015 AAN Annual Meeting

Come visit us at

BOOTH 1428

© 2015 Genentech USA, Inc. All rights reserved. NEU/012615/0011

2O15 Award Recipients The research we celebrate, with the recipients below, has generated paradigm-changing discoveries in epilepsy, fundamental insights in multiple sclerosis, and pioneering breakthroughs in pain, to name a few of the transformative advances conceived by these luminaries. We honor those researchers and pay tribute to all those who play a role in the search for cures for brain disease, from mentors to colleagues to those just starting out on their journey.

AAN Alliance Awards Founders Award Sponsored by the American Brain Foundation and endowed by the Alliance Founders and S. Weir Mitchell Permanent Endowment. Recipient: Aasef Shaikh, MD, PhD / Lakewood, OH Impaired Motor Learning in a Disorder of the Inferior Olive: Is the Cerebellum Confused? S7: Movement Disorders: Genetics Tuesday, April 21, 1:00 p.m. S. Weir Mitchell Award Sponsored by the American Brain Foundation and endowed by the Alliance Founders and S. Weir Mitchell Permanent Endowment. Recipients: Isaac Marin-Valencia, MD / Dallas, TX Acetate Metabolism Prevails Over Glucose Oxidation in Brain PDH Deficiency S25: General Neurology Wednesday, April 22, 2:00 p.m.

A.B. Baker Award for Lifetime Achievement in Neurologic Education Funded by an endowment created by matching funds from the A.B. Baker Family Trust and Novartis Pharmaceuticals. Recipient: Eduardo E. Benarroch, MD, FAAN / Rochester, MN C173: Clinical Reasoning: From a Novice to an Expert Monday, April 20, 8:30 a.m.

AAN Award for Creative Expression of Human Values in Neurology Sponsored by the Neurology Ethics, Law, and Humanities Committee. Recipient: Lealani Mae Y. Acosta, MD / Nashville, TN

Dreifuss-Penry Epilepsy Award Sponsored by the American Academy of Neurology and endowed by members of the AAN Epilepsy Section; Abbott Laboratories, Inc.; Cephalon, Inc.; Cyberonics, Inc.; Elan Pharmaceuticals, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals; Ortho-McNeil Neurologics; Pfizer Inc; Shire US, Inc; and UCB Pharma.

John Dystel Prize for Multiple Sclerosis Research Presented by the American Academy of Neurology and the National Multiple Sclerosis Society and made possible through a special contribution from the John Dystel Multiple Sclerosis Research Fund at the National Multiple Sclerosis Society. Recipient: Alastair Compston, MBBS, PhD / Cambridge, UK S20: Treatment Mechanisms in Multiple Sclerosis Wednesday, April 22, 2:00 p.m.

Sheila Essey Award: An Award for ALS Research Presented by the American Academy of Neurology and the ALS Association and supported through the philanthropy of the Essey Family Fund and the ALS Association. Recipient: Robert Bowser, PhD / Phoenix, AZ Adriano Chio, MD, FAAN / Turin, Italy S24: ALS: Mechanisms and Biomarkers Wednesday, April 22, 2:00 p.m.

American Brain Foundation Chair’s Award Sponsored by the American Brain Foundation. Recipient: TBD

Norman Geschwind Prize in Behavioral Neurology Sponsored by the American Academy of Neurology and the AAN Behavioral Neurology Section and endowed through Dr. Geschwind's family, friends, and colleagues; Pfizer Inc; and the Society for Behavioral and Cognitive Neurology. Recipient: Andrew Kayser, MD, PhD / San Francisco, CA S41: Aging, Dementia, Cognitive, and Behavioral Neurology: Imaging: Aging and Alzheimer's Disease Thursday, April 23, 1:00 p.m.

Recipient: Annapurna Poduri, MD, MPH / Boston, MA S22: Epilepsy/Clinical Neurophysiology (EEG): Basic Science and Intraoperative Monitoring Wednesday, April 22, 2:00 p.m. Fast, Easy, Online Registration · AAN.com/view/AM15

11

2O15 Award Recipients Mitchell B. Max Award for Neuropathic Pain

Medical Student Essay Awards

Sponsored by the American Academy of Neurology and endowed by the United States Cancer Pain Relief Committee, the Mayday Fund, and friends of Dr. Mitchell Max.

Sponsored by the American Academy of Neurology.

Recipient: Robert Dworkin, PhD / Rochester, NY S10: Pain and Palliative Care Tuesday, April 21, 1:00 p.m.

Association of Indian Neurologists in America (AINA) Lifetime Achievement Award Endowed by the Association of Indian Neurologists of America (AINA). Recipient: Pradeep K. Sahota, MD, FAAN / Columbia, MO During the AINA Business Meeting Tuesday, April 21, 7:15 p.m.

International Scholarship Award Sponsored by the American Academy of Neurology International Subcommittee. Recipients: Mohammadkazem Bakhshandeh Bali / Tehran, Iran Lucio D'Anna / Portogruaro, Italy Hui-Fu Wang / Qingdao, China Lei Chen / Chengdu, China Antonella Macerollo / London, England Charlotte Zerna / Dresden, Germany Rebekah Ahmed / Sydney, Australia Venugopalan Vishnu / Chandigarh, India Chamroeun Hun / Phnom Penh, Cambodia Manjunath Mahadevappa Poojar / Bangalore, India Lucia Schottlaender / London, England Ai Huey Tan / Cheras, Malaysia Fatai Akemokwe / Benin City, Nigeria International Experience Sunday, April 19, 1:00 p.m.

Lawrence C. McHenry Award: An Award for the History of Neurology Sponsored by the American Academy of Neurology. Recipient: Michel Shamy, MD, MA, FRCPC / Ottawa, ON, Canada Uncertainty, Bias and Assumption in the Management of BSE, 1984-1996 S44: History of Neurology Thursday, April 23, 1:00 p.m.

12

Extended Neuroscience Award Recipient: Sara Shams / Stockholm, Sweden Cerebrospinal Fluid Profiles with Cerebral Microbleeds in Dementia Poster Session II: P2.333 Tuesday, April 21, 7:30 a.m. G. Milton Shy Award in Clinical Neurology Recipient: Stuart McCarter / Minneapolis, MN Diagnostic REM Sleep Muscle Activity Cutoff Values for Idiopathic REM Sleep Behavior Disorder Poster Session II: P2.334 Tuesday, April 21, 7:30 a.m. Roland P. Mackay Award in Historical Aspects Recipient: Travis Urban / Galveston, TX Charcot's Pupils: A Legacy of Charcot's Abilities as Teacher and Mentor Poster Session II: P2.335 Tuesday, April 21, 7:30 a.m. Saul R. Korey Award in Experimental Neurology Recipient: David Fischer / Boston, MA The Neuroanatomical Basis of Coma in Humans: Using Functional Connectivity to Assess the Network Effects of Brainstem Lesions Poster Session II: P2.336 Tuesday, April 21, 7:30 a.m.

Minority Scholars Program Sponsored by a grant from the Allergan Foundation. Recipients: Carlos Eduardo Estrada Alamo / Harvard Medical School Jorge Torres / The David Geffen School of Medicine, UCLA Mehida Alexandre / Yale School of Medicine Duriel Hardy / Duke University School of Medicine Emmanuel J. Perez / University of Miami Miller School of Medicine Paola Mendez-Gomez / University of Texas Health Science Center, San Antonio, Texas Peter Hadar / Perelman School of Medicine, University of Pennsylvania Michael Gonzaga / Meharry Medical College Shamelia Loiseau / University of Rochester School of Medicine


I can feel good about being a part of a single-minded team of ed em ployees, all equally committ to the quality of our products, no matter where in the world they are made.

I can…

because Mylan’s priority is to meet or exceed industry standards. Our own teams conduct ongoing reviews to help assure quality and integrity of products, start to finish, and strive to continually improve for optimal quality and consistency. Everyone at Mylan has the same priority: you.

Visit Mylan.com

Veronique Mylan Senior Plant Director

See what we have to offer at the 2015 AAN Annual Meeting this April—Booth #1529

©2015 Mylan Inc. All rights reserved. NON-2015-0005

2O15 Award Recipients Adys Mendizabal / Temple University School of Medicine David Mendez / UT Southwestern Stefanie Gopaul / Charles R. Drew University, David Geffen School of Medicine, UCLA Roger Murayi / Perelman School of Medicine, University of Pennsylvania Victoria Adeseye / University of Texas Health Science Center at Houston Necrisha Roach/ The Ohio State University College of Medicine

Movement Disorders Research Award Sponsored by the American Academy of Neurology, the Parkinson's Disease Foundation, and the AAN Movement Disorders Section and endowed by the Parkinson's Disease Foundation. Recipient: Christopher Goetz, MD, FAAN / Chicago, IL S40: Movement Disorders: Functional Imaging in Parkinson's Disease Thursday, April 23, 1:00 p.m.

Neuro-oncology Investigator Award Sponsored by the American Academy of Neurology and the AAN Neuro-oncology Section and supported by friends of Dr. Jerome Posner. Recipient: Elizabeth Gerstner, MD, MS / Boston, MA S18: Neuro-oncology: Imaging and Quality of Life Tuesday, April 21, 3:15 p.m.

Neuroscience Research Prize Sponsored by the American Academy of Neurology and the Child Neurology Society. Recipients: Yinge Zhao / Rego Park, NY Lauren Houle / Boca Raton, FL Monica Lee / Albertson, NY Poster Session III: P3.320–P3.322 Tuesday, April 21, 2:00 p.m.

Child Neurology Neuroscience Research Prize Sponsored by the American Academy of Neurology and the Child Neurology Society. Recipient: Amrita Mohanty / Woodbury, MN Note: The recipient will attend the 44th Child Neurology Society Annual Meeting in Washington, DC

Palatucci Advocacy Leadership Forum Advocate of the Year Sponsored by the AAN Government Relations Committee. Recipient: Javier Cardenas, MD / Phoenix, AZ

Michael S. Pessin Stroke Leadership Prize Sponsored by the American Academy of Neurology and endowed by Dr. Pessin's family, friends, and colleagues. Recipient: Lauren Sansing, MD, MS / New Haven, CT S13: Cerebrovascular Disease and Interventional Neurology: Epidemiology and Risk Factors Tuesday, April 21, 3:15 p.m.

Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases Sponsored by the American Academy of Neurology, the American Brain Foundation, and funded through the philanthropy of the Potamkin Family. Recipients: Reisa Sperling, MD / Boston, MA Peter Davies, PhD / New York, NY S8: Aging, Dementia, Cognitive, and Behavioral Neurology: Basic Science Tuesday, April 21, 1:00 p.m.

Donn Dexter, MD, FAAN, Eau Claire, WI 2014 Palatucci Advocacy Leadership Forum Advocate of the Year Recipient

“It’s an honor to be selected. The training I received has allowed me to become a much better advocate for my patients, practice, profession, and community. It also dramatically revitalized my career and served to inspire me in a way I haven’t experienced since my residency. Another fantastic feature is meeting a group of passionate, intelligent, and committed neurologists who will continue to inspire and motivate me.” 14


COME VISIT OUR BOOTH! Learn more about APTIOM at Booth 1929

Under license from is a registered trademark of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Inc., is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ©2015 Sunovion Pharmaceuticals Inc. All rights reserved. 2/15 APT053-15

2O15 Award Recipients American Academy of Neurology President’s Award

Sleep Science Award Sponsored by the American Academy of Neurology and the AAN Sleep Section and endowed by Cephalon, Inc.

Sponsored by the American Academy of Neurology.

Recipient: Thomas Scammell, MD / Boston, MA S53: Sleep Thursday, April 23, 3:30 p.m.

Recipient: John C. Mazziotta, MD, PhD, FAAN / Los Angeles, CA

Neuroendocrine Research Award Sponsored by the American Academy of Neurology and supported by friends of Dr. Andrew Herzog. Recipient: Michael Rogawski, MD, PhD / Sacramento, CA Presented at the Neuroendocrinology Section meeting

Bruce S. Schoenberg International Award in Neuroepidemiology Endowed by GlaxoSmithKline, Inc. Recipient: Stojan Peric, MD, PhD / Belgrade, Serbia Clinical and Epidemiological Features of GuillainBarre Syndrome in the Western Balkans S45: Neuroepidemiology: Multiple Sclerosis, Cerebrovascular, and Aging Thursday, April 23, 1:00 p.m.

Jon Stolk Award in Movement Disorders for Young Investigators Sponsored by the American Academy of Neurology and endowed by Kyowa Pharmaceutical, Inc., Lineberry Research, Quintiles, and Dr. Dennis Gillings. Recipient: Allison Willis, MD, MS / Philadelphia, PA S48: Parkinson's Disease Thursday, April 23, 3:15 p.m.

Safety and Quality Award Recipient: TBD

Harold Wolff-John Graham: An Award for Headache/Facial Pain Research Sponsored by the American Academy of Neurology and endowed by Endo Pharmaceuticals. Recipient: Henrik Schytz, MD, PhD / Glostrup, Denmark S51: Headache: Epidemiology and Clinical Thursday, April 23, 3:15 p.m.

Kenneth M. Viste Jr., MD Patient Advocate of the Year Award Endowed by gifts from Dr. Viste’s colleagues, friends, and patients. Recipient: Ira Shoulson, MD, FAAN / Washington, DC

H. Richard Tyler Award Sponsored by the American Academy of Neurology and the AAN Archive Committee. Recipient: Adolfo Ramirez Zamora, MD / Albany, NY General History Section Meeting Tuesday, April 21, 12:00 p.m.

Wayne A. Hening Sleep Medicine Investigator Award Sponsored by the American Academy of Neurology and endowed by UCB, Inc., Lilly USA, Elite Home Medical & Respiratory, Inc., Raleigh Neurology Associates, and friends of Dr. Wayne A. Hening. Recipient: Mark Wu, MD, PhD / Baltimore, MD S53: Sleep Thursday, April 23, 3:15 p.m.

Aleksandar Videnovic, MD, MSc, Boston, MA 2014 Wayne A. Hening Sleep Medicine Investigator Award Recipient

“I am indebted to many colleagues for their support and counsel. Special gratitude goes to Drs. Christopher Goetz, Phyllis Zee, and Cynthia Comella whose work motivated me to pursue a career in academic neurology and influenced my research directions. Their support became fundamental for my development as a clinician scientist.” 16


2O15 Research Fellowships Clinical Research Training Fellowships Sponsored by the American Academy of Neurology, the American Brain Foundation, and TEVA CNS. Recipients: Felicia Chow, MD University of California, San Francisco Albert Davis, MD Washington University in St. Louis Gregory Day, MD, MSc Washington University in St. Louis

Clinical Research Training Fellowship in the Neurological Application of Neurotoxins Funded by the Allergan Foundation. Recipients: Wei Hu, MD, PhD University of Florida David Schmerler, DO University of Cincinnati

Corey Fehnel, MD Rhode Island Hospital/Brown University

Clinical Research Training Fellowship in ALS Research

Carolyn Fredericks, MD University of California, San Francisco

Sponsored by the American Academy of Neurology, the American Brain Foundation and the ALS Association.

Emily Gilmore, MD Yale University Todd Herrington, MD Massachusetts General Hospital Inge Meijer, MD CHUSJ- Montreal University Dona Murphey, MD Baylor College of Medicine Nigel Pedersen, MBBS Beth Israel Deaconess Medical Center William Renthal, MD Harvard Medical School Mathula Thangarajh, MD, PhD Children's National Medical Center, Washington, DC

Susan S. Spencer Clinical Research Training Fellowship in Epilepsy Sponsored by the American Academy of Neurology, the American Brain Foundation, the American Epilepsy Society, and the Epilepsy Foundation. Recipient: Leigh Sepeta, PhD Children's National Medical Center

Practice Research Training Fellowship

Recipient: Hristelina Ilieva, MD Johns Hopkins School of Medicine

Clinical Research Training Fellowship in MS Funded by Genzyme, a Sanofi Company. Recipient: Vanessa Beynon, MD Brigham and Women's Hospital

Clinician-Scientist Development Award in Multiple Sclerosis Cosponsored by the American Academy of Neurology, the American Brain Foundation and the National MS Society. Recipient: Michael Kornberg, MD, PhD Johns Hopkins School of Medicine

Lawrence M. Brass, MD, Stroke Research Fellowship Sponsored by the American Academy of Neurology, the American Brain Foundation and the American Heart Association/American Stroke Association. Recipient: Sunil Sheth, MD University of California, Los Angeles, CA

Sponsored by the American Academy of Neurology and the American Brain Foundation. Recipient: Benjamin Tolchin, MD Brigham and Women's Hospital, Harvard Medical School


17

Meeting at a Glance Saturday April 18

Sunday April 19

6:00 a.m. C22–C25 6:30 a.m.–8:00 a.m.

7:00 a.m.

8:00 a.m.

C1

C2–C7 I1

C8

C9

C26–27 C170

8:00 a.m.– 11:00 a.m.

8:00 a.m.– 12:00 p.m.

8:00 a.m.– 4:00 p.m.

8:00 a.m.– 5:00 p.m.

8:00 a.m.– 11:00 a.m.

Integrated Neuroscience

C28–34 I3 8:00 a.m.– Integrated

8:00 a.m.– 12:00 p.m.

12:00 p.m.

8:00 a.m.–12:00 p.m.

9:00 a.m.

C35–38

Neuroscience

8:00 a.m.– 5:00 p.m.

8:00 a.m.–12:00 p.m.

C171 8:30 a.m.–12:00 p.m.

C39 9:00 a.m.–5:00 p.m. (must apply)

10:00 a.m.

C40–C41 10:00 a.m.–12:00 p.m.

11:00 a.m.

12:00 p.m. OPEN HOUR 12:00 p.m.–1:00 p.m.

1:00 p.m.

C10–16 1:00 p.m.–5:00 p.m.

2:00 p.m.

3:00 p.m.

I2

OPEN HOUR 12:00 p.m.–1:00 p.m. S1


Section Topic Controversies

1:00 p.m.–5:00 p.m.

1:00 p.m.–2:30 p.m.

C17–21

C53–54

3:00 p.m.–5:00 p.m.

3:00 p.m.–5:00 p.m.

C42

C43

1:00 p.m.– 4:00 p.m

1:00 p.m.– 1:00 p.m.– 4:00 p.m 5:00 p.m.

C172

C44– 52 1:00 p.m.– 5:00 p.m.

4:00 p.m.

5:00 p.m.

6:00 p.m.

Capitol City Celebration 6:00 p.m.–10:00 p.m.

7:00 p.m.

8:00 p.m. 18

I4

Integrated Neuroscience 1:00 p.m.–5:00 p.m.

Monday April 20

Tuesday April 21

C55–C58

C59

C60

C88–C93

Run/Walk for Brain Research

6:30 a.m.–8:00 a.m.

6:30 a.m.–8:00 a.m.

6:30 a.m.–8:30 a.m. (registration required)

6:30 a.m.–8:00 a.m.

6:30 a.m.–8:30 a.m.

State Society Leadership Roundtable

P2

7:00 a.m.–8:30 a.m.

Poster Session II

AAN Business Mtg 8:00 a.m.–8:30 a.m.

7:30 a.m.–12:00 p.m.

C61–62

C63–71

8:00 a.m.–11:00 a.m.

8:00 a.m.–12:00 p.m.

C76

I5 Integrated

Neuroscience

C72–75 8:00 a.m.–5:00 p.m.

C173 8:30 a.m.–12:00 p.m.

Presidential Plenary Session

8:00 a.m.–12:00 p.m.

9:00 a.m.–5:00 p.m. (must apply)

9:00 a.m.–12:00 p.m.

C77 10:00 a.m.–12:00 p.m.

Exhibit Hall 11:30 a.m.–5:00 p.m.

OPEN HOUR 12:00 p.m.–1:00 p.m.

OPEN HOUR 12:00 p.m.–1:00 p.m. S2

Section Topic Controversies 1:00 p.m.–2:30 p.m.

C174

C78–86

1:00 p.m.–5:00 p.m.

1:00 p.m.–5:00 p.m.

AAN/ABPN MOC Information Session


I6

S3 Scientific Invited C94 Section Topic Platform Science: 1:00 p.m.– 4:00 p.m. Controversies Sessions Stroke

1:00 p.m.–5:00 p.m.

1:00 p.m.–2:30 p.m.

C175 2:00 p.m.–4:30 p.m.

1:30 p.m.–3:00 p.m.

P1

P3

2:00 p.m.–6:30 p.m.

2:00 p.m.–6:30 p.m.

Poster Session I

1:00 p.m.– 2:45 p.m.

1:00 p.m.– 2:45 p.m.

C95 –99 1:00 p.m.– 5:00 p.m.

I7–8


Poster Session III

Scientific Platform

Sessions 3:15 p.m.– 5:00 p.m.

Exhibit Hall Opening Reception 4:30 p.m.–6:30 p.m.

Hot Topics Plenary Session

Hot Topics in Education

5:30 p.m.–6:45 p.m.

5:30 p.m.–6:30 p.m.

Paid Programs/Events Residents and Fellows Career Forum and Reception 6:30 p.m.–9:00 p.m.

Industry Therapeutic Updates 7:00 p.m.–10:00 p.m.

Programs/Events Included with Registration Additional Events

19

Meeting at a Glance Wednesday April 22

Thursday April 23

6:00 a.m.

7:00 a.m.

8:00 a.m.

C100–C106

C113–C118

6:30 a.m.–8:00 a.m.

6:30 a.m.–8:00 a.m.

P4

Poster Session IV

P6 Poster Session VI

7:30 a.m.–12:00 p.m.

7:30 a.m.–12:00 p.m.

9:00 a.m.

Contemporary Clinical Issues Plenary Session

Frontiers in Neuroscience Plenary Session

9:00 a.m.–12:00 p.m.

9:00 a.m.–12:00 p.m.

10:00 a.m.

11:00 a.m. Exhibit Hall

12:00 p.m.

Exhibit Hall

11:30 a.m.–5:00 p.m.

OPEN HOUR

11:30 a.m.–3:00 p.m.

Awards Luncheon


12:00 p.m.–1:30 p.m.

1:00 p.m.

2:00 p.m.

3:00 p.m.

Scientific Platform Sessions Scientific Platform Sessions

C107–112 2:00 p.m.–6:00 p.m.

2:00 p.m.–3:45 p.m.

I9–10

P5

2:00 p.m.–6:00 p.m.

2:00 p.m.–6:30 p.m.


Poster Session V

1:00 p.m.– 2:45 p.m.

Invited Science: C119–124 Epilepsy 1:00 p.m.–5:00 p.m. 1:00 p.m.–2:45 p.m.

I11–12


P7

Poster Session VII 2:00 p.m.–6:30 p.m.

Scientific Platform Sessions

4:00 p.m.

3:15 p.m.–5:00 p.m.

Platform Blitz Sessions 4:00 p.m.–5:45 p.m.

5:00 p.m. Highlights in the Field Sessions

6:00 p.m. Emerging Science

7:00 p.m.

Highlights in the Field Sessions 6:00 p.m.–7:00 p.m.

6:15 p.m.–7:45 p.m.

Industry Therapeutic Updates 7:00 p.m.–10:00 p.m.

8:00 p.m. 20

5:30 p.m.–6:30 p.m.

Controversies in Neuroscience Plenary Session 5:30 p.m.–7:00 p.m.

C125–130 6:00 p.m.–9:00 p.m.

Friday April 24

Saturday April 25

C131–C135

C154–C158

6:30 a.m.–8:00 a.m.

6:30 a.m.–8:00 a.m.

C136–140

C141–147

C159

C160–166

8:00 a.m.–12:00 p.m.

8:00 a.m.–4:00 p.m.

8:00 a.m.–11:00 a.m.

8:00 a.m.–12:00 p.m.

C167–169 10:00 a.m.–12:00 p.m.

Clinical Trials Plenary Session 12:00 p.m.–1:30 p.m.

C148

C149–153

1:00 p.m.–3:00 p.m.

1:00 p.m.–4:00 p.m.


Neurology Year in Review Plenary Session 4:30 p.m.–6:00 p.m.

Closing Party 6:00 p.m.–8:00 p.m. Celebrate the end of a great meeting at a special early-evening happy hour event! ¡ Enjoy music, drinks, and socializing with colleagues ¡ Make plans to explore beautiful Washington, DC, afterwards

Paid Programs/Events Programs/Events Included with Registration Additional Events

21

I I Talks Schedule Saturday, April 18

Sunday, April 19

7:00 a.m.

Monday, April 20 Leadership Meeting 7:00 a.m.–8:00 a.m.

8:00 a.m.

9:00 a.m.

Creating Innovative, Interactive Teaching Modules 8:00 a.m.–8:30 a.m.

AAN Business Meeting

The Business of Neurology

Is AAN Member Participation in Physician-assisted Suicide Ethical?

9:00 a.m.–11:00 a.m. Hosted by the Business and Research Administrators in Neurology Society, this two-hour interactive session will facilitate discussions on how to most effectively incorporate Advance Practice Providers in your practice. Speakers will also assist attendees in deciphering quality metrics, explain how it can be used to your benefit when negotiating with payers.

10:00 a.m.

11:00 a.m.

8:00 a.m.–8:30 a.m.

9:00 a.m.–10:30 a.m. Will address the definition, ethical framework, and current legal landscape of Physician-assisted Suicide. Presented by the Ethics, Law and Humanities Committee.

Neuroexam: Learn from the Experts Neurology Jeopardy: Things You May Not Know About Publishing in the Journal or Its Spin-Offs

12:00 p.m.

11:30 a.m.–12:30 p.m.

1:00 p.m.

Annual Meeting Orientation Session

11:00 a.m.–1:00 p.m.

1:00 p.m.–1:30 p.m.

Conquering ICD-10

2:00 p.m.

3:00 p.m.

4:00 p.m.

5:00 p.m.

Providing High Value Neurologic Care

Webs, Apps, and Social Media: There’s the AAN for That! 3:00 p.m.–5:00 p.m. Interactive session will help attendees learn: ¡ How use the AAN Annual Meeting app ¡ What a QR code is, how to use a QR code to download content ¡ How to set up a social media app and why some physicians find it useful ¡ How to use the Neurology ® app for tablet devices

2:00 p.m.–4:00 p.m. This two-hour session will highlight findings from the AAN’s recent studies in the value of neurology; learn how neurologists are succeeding in transitioning to high quality, lower cost care; and strategize for the future of health care payment and delivery.

1:30 p.m.–3:30 p.m. As of October 1, 2015, the ICD-10 code set will be required for all transactions involving reimbursement from the Center for Medicare and Medicaid Services, as well as third-party payers. This session will address the importance of ICD-10, coding basics for the most common neurologic disorders, electronic resources, and preparation of office business procedures to accommodate ICD 10.

AAN’s Axon Registry: Data Powering Neurology’s Future Quality in Neurology— Can We Measure and Improve It?

4:00 p.m.–5:00 p.m. An overview of the AAN’s new registry, including its value to members, value to the AAN, timeline, and next steps.

4:30 p.m.–5:30 p.m. An explaination of quality measures, how data and measures can drive improvement in practice.

Hot Topics in Education: The Value of a Neurologist

6:00 p.m.

5:30 p.m.–6:30 p.m.

7:00 p.m. 22


The Innovation Room is your destination for a lively, supplemental new Annual Meeting learning experience through a variety of lectures, presentations, group discussions, and hands-on activities using advanced media formats that bring learning to life!

Tuesday, April 21

Wednesday, April 22

Thursday, April 23 and Friday, April 24 Additional information will be made available as more sessions are developed and added. Keep a watch online for more exciting content.

Annual Meeting Orientation Session 8:00 a.m.–8:30 a.m.

Check back often at AAN.com/view/ITalk for schedule updates!

Plenary Session

Plenary Session

Plenary Session

Policy and Advocacy Hour with the GRC

Neurology Compensation and Productivity Survey and Dashboard Report

AAN’s Axon Registry: Data Powering Neurology’s Future

12:00 p.m.–1:00 p.m. Find out what the Government Relations Committee is doing for AAN members and how to get involved.

12:00 p.m.–1:00 p.m. Learn about the only survey and report dedicated solely to neurology compensation and productivity.

12:00 p.m.–1:00 p.m. An overview of the AAN’s new registry, including its value to members, value to the AAN, timeline, and next steps.

Case Report 2.0: Implementing the "CARE" Guidelines

How to Avoid “Death by PowerPoint” and Workshop

1:30 p.m.–3:30 p.m. Editors of the journal Neurology will provide didactic teaching about journal writing, the CARE guidelines, and the editorial process, as well as a practical hands-on workshop on the writing of a case report. Attendees will be expected to bring a case with them, and editorial team members will assist attendees in the crafting of a case report worthy of submission to a journal. The course will be appropriate for residents, fellows, and others who will be writing case reports for publication.

1:30 p.m.–3:30 p.m. Explore basic guidelines on how to effectively use PowerPoint as a tool to enhance learning. Using an interactive and engaging teaching format called write/think-pair-share, where participants are asked to engage with the person sitting next to them every 10 minutes throughout the presentation, the program will cover general principles, things to avoid, and best practices.

AAN Digital Scavenger Hunt 1:30 p.m.–2:30 p.m.

Your Abstract Has Been Accepted: Now What? Tips for a Successful Presentation 3:00 p.m.–3:45 p.m.

How to Hug a Porcupine: Relationship Building with Congress and Why It’s Important

Your Abstract Has Been Accepted: Now What? Working with the Media 4:00 p.m.–4:45 p.m.

4:00 p.m.–5:00 p.m.

Your Abstract Has Been Accepted: Now What? Part I 5:30 p.m.–6:15 p.m.

23

NEW

Three Registration Packages Available

Choose the one that works best for you! • Meeting Registration with education courses available for additional fees. • Silver Registration Package includes meeting registration plus full access to the 2015 Annual Meeting education program.* •

Gold Registration Package and BEST VALUE!

Get full access to the 2015 Annual Meeting education program,* plus Annual Meeting On Demand, the digital library of the Annual Meeting. Gold Registration Package offers: •

Flexibility: Attend sessions in-person or on demand

•

Access to the syllabi summaries of more than 160 programs

•

Ultimate CME earning power: Earn CME during the meeting or afterwards via Annual Meeting On Demand!

Register Today at AAN.com/view/AM15 *Skills Workshops, Skills Pavilions, and Leadership Courses excluded from Silver and Gold Registration Package pricing. Attendee must identify courses to be included as part of Silver and Gold Registration Package. Courses are subject to closure due to reaching maximum capacity. Attendee is only permitted to select courses that he/she plans to be in the room for. Attendee will not be able to register for courses with conflicting time schedules.

Understanding the Program Listings To help simplify the Annual Meeting, all education programs are labeled as courses regardless of day or time offered or duration of program.

Program Types

C I P S

New Course Feature Icons

Course Integrated Neuroscience Session (scientific session combining invited speakers, data blitz presentations, and poster discussion; included with meeting registration) Poster Session (a hall of posters on a variety of topics)

F The program is included with your registration $ A registration fee is required I The program is an I Talk and included with registration

L The program is one of the AAN

Leadership Development sessions

A The course is part of the

Scientific Platform Session (didactic session featuring abstracts)

Advanced Practice Provider track

C The program is part of the Clinical Research track S The program is part of a Subspecialty in Focus track

Program Tracks

To assist in your course planning, we’ve designed program tracks consisting of pre-selected courses of interest geared toward advanced practice providers, academic neurologists, or those with subspecialty interests. Refer to the Meeting Program Schedule for specific times. Advance Practice Provider Track

Clinical Research Track

Subspecialty in Focus Tracks

The APP track consists of suggested courses for neurologic advanced practice providers to provide a “deep dive” into general neurology.

This track offers suggested programs geared toward academic neurologists early in the development of a clinical research career or who are considering one.

The Subspecialty in Focus Track is a series of six special, intensive topic-specific tracks designed for subspecialists, combining an education course with an Integrated Neuroscience Session.

A C5 Resident Basic Science I: Neuropathology

A C13 Resident Basic Science II: Neuroanatomy

A C30 Resident Basic Science III: Neuropharmacology

A C37 Neurology Update I A C38 Genetics in Neurology A C43 Advanced Practice Provider Symposium

A C68 Neuroimaging for the General Neurologist: Brain

A C124 Neuroimaging for the

General Neurologist: Spine and Peripheral Nerve

A C143 Neurology Update II

C C9 Research Career

Development Symposium: How to Be Successful in Academic Neuroscience

C C170 Clinical Research:

Introductions and Methods

S Cerebrovascular Disease Includes: C7 and I2

S Neuro-ophthalmology/ Neuro-otology Includes: C16 and I1

C C172 Clinical Research: Drug

S Movement Disorders

C Futures in Clinical Research

S Neuro-infectious Disease/

C Futures in Clinical Research

S Child Neurology/

C I10 The Dynamic Brain in

S Epilepsy

Development and Clinical Trials Luncheon April 20, 12:00 p.m.–2:00 p.m. Luncheon Mentoring Sessions April 21, 12:00 p.m.–2:00 p.m. Health and Disease: Plasticity and Reprogramming

Includes: C52 and I3

Neuro-oncology Includes: C28 and I4

Sports Neurology Includes: C83 and I5 Includes: C63 and I6

C I11 The Promise of Novel Biomarker Approaches in Advancing Treatment


25

Scientific Session Schedule Saturday, April 18, 2015 8:00 a.m.–12:00 p.m. New Windows into the Brain: F I1 Technological Advances in Frontline Neurologic Diagnosis via the Visual and Oculomotor Systems . . . 48

S

1:00 p.m.–5:00 p.m. Management of Asymptomatic F I2 Cerebrovascular Lesions . . . . . . . . . . . . . . . . . 49

S

Sunday, April 19, 2015 8:00 a.m.–12:00 p.m. Dopamine-mediated Neural Plasticity in Motor and F I3 Non-motor Circuits . . . . . . . . . . . . . . . . . . . . 50

S

1:00 p.m.–2:30 p.m. F S1 Section Topic Controversies: Antiplatelets, Anticoagulants, or Stenting for Acute Treatment of Cervical/Cranial Dissection? . . . . . . . . . . . . . . . 51 1:00 p.m.–5:00 p.m. Infectious, Paraneoplastic, and Autoimmune F I4 Encephalopathies: Advances in Clinical Diagnosis and Emerging Insights about Pathogenesis . . . . . . . 52

S

Monday, April 20, 2015 8:00 a.m.–12:00 p.m. Pediatric Neurotrauma: F I5 From Coma to Concussions . . . . . . . . . . . . . . . 53

S

1:00 p.m.–2:30 p.m. F S2 Section Topic Controversies: Testing in Prodromal Neurological Disease: Friend or Foe? . . . . . . . . . . 54 1:00 p.m.–5:00 p.m. Future Therapies: How We Will Be Treating, F I6 Preventing, and Curing Epilepsy in the Year 2025 . . . 55

S

2:00 p.m.–6:30 p.m. F P1 Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57

Tuesday, April 21, 2015 7:30 a.m.–12:00 p.m. F P2 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65 9:00 a.m.–12:00 p.m. F Presidential Plenary Session . . . . . . . . . . . . . . . . 33 1:00 p.m.–2:30 p.m. F S3 Section Topic Controversies: Should All Brain Tumor Patients Receive Prophylactic Antiepileptic Drugs? . . 73

26

F = Included with registration $ = Registration fee required I = I Talk Session

1:00 p.m.–2:45 p.m. F Scientific Platform Sessions . . . . . . . . . . . . . . . . . . 74 S4 Clinical Trial Outcomes in Multiple Sclerosis S5 Cerebrovascular Disease and Interventional Neurology: Recovery and Outcome S6 Epilepsy/Clinical Neurophysiology (EEG): Health Services and Women’s Issues S7 Movement Disorders: Genetics ¡ Presentation of the Founders Award S8 Aging, Dementia, Cognitive, and Behavioral Neurology: Basic Science ¡ Presentation of the Potamkin Prize for Research in Pick’s, Alzheimer’s Disease, and Related Diseases S9 General Neurology: Neurological Treatments and Therapeutics S10 Pain and Palliative Care ¡ Presentation of the Mitchell B. Max Award for Neuropathic Pain S11 Practice, Policy, and Ethics 1:00 p.m.–2:45 p.m. Invited Science: Stroke F

. . . . . . . . 75

1:00 p.m.–5:00 p.m. F I7 The Global Burden of Neurological Infections: Epidemiology, Treatment, and Prevention . . . . . . . . 76 F I8 Advances in ALS and Other Motor Neuron Diseases . 77 2:00 p.m.–6:30 p.m. F P3 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78 3:15 p.m.–5:00 p.m. F Scientific Platform Sessions . . . . . . . . . . . . . . . . . . 86 S12 Neuroimmune Mechanisms in Multiple Sclerosis S13 Cerebrovascular Disease and Interventional Neurology: Epidemiology and Risk Factors ¡ Presentation of the Michael S. Pessin Stroke Leadership Prize S14 Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy S15 Movement Disorders: Huntington’s Disease, Dystonia, and Atypical Parkinsonism S16 Aging, Dementia, Cognitive, and Behavioral Neurology: Clinical Science S17 Muscle and Anterior Horn Cell Diseases: Mechanisms and Biomarkers S18 Neuro-oncology: Imaging and Quality of Life ¡ Presentation of the Neuro-oncology Investigator Award S19 Neurologic Education 5:30 p.m.–6:45 p.m. F Hot Topics Plenary Session . . . . . . . . . . . . . . . . . 34


A = Advanced Practice Provider Track C = Clinical Research Track S = Subspecialty in Focus Track

Wednesday, April 22, 2015 7:30 a.m.–12:00 p.m. F P4 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 9:00 a.m.–12:00 p.m. F Contemporary Clinical Issues Plenary Session . . . . . . 35 2:00 p.m.–3:45 p.m. F Scientific Platform Sessions . . . . . . . . . . . . . . . . . . 96 S20 Treatment Mechanisms in Multiple Sclerosis ¡ Presentation of the John Dystel Prize for Multiple Sclerosis Research S21 Cerebrovascular Disease and Interventional Neurology: Prehospital and Acute Ischemic Stroke Treatment S22 Epilepsy/Clinical Neurophysiology (EEG): Basic Science and Intraoperative Monitoring ¡ Presentation of the Dreifuss-Penry Epilepsy Award S23 Headache: Epidemiology and Clinical S24 ALS: Mechanisms and Biomarkers ¡ Presentation of the Sheila Essey Award: An Award for ALS Research S25 General Neurology ¡ Presentation of the S. Weir Mitchell Award S26 Neuro-ophthalmology/Neuro-otology S27 Neuro Trauma, Critical Care, and Sports Neurology S28 Neuro-rehabilitation 2:00 p.m.–6:00 p.m. F I9 Treating Dementia in an Age of Mixed Disease . . . . 98 The Dynamic Brain in Health and Disease: F I10 Plasticity and Reprogramming . . . . . . . . . . . . . . 99

C

2:00 p.m.–6:30 p.m. F P5 Poster Session V . . . . . . . . . . . . . . . . . . . . .100 4:00 p.m.–5:45 p.m. F Platform Blitz Sessions . . . . . . . . . . . . . . . . . . . . 108 S29 Neuroimaging Correlates in Multiple Sclerosis S30 Cerebrovascular Disease and Interventional Neurology: Diagnostics, Biomarkers, and Genetics S31 Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Therapy S32 Movement Disorders: Tremor, Ataxia, and More S33 Aging, Dementia, Cognitive, and Behavioral Neurology: Biomarkers and Pathology S34 Neuromuscular Update S35 Child Neurology and Developmental Neurology S36 Neuroepidemiology: Movement Disorders, ALS, and Aging S37 Global Health and Infectious Disease


iPosters! The virtual poster hall transforms your poster hall into a mobile experience—both during the Annual Meeting and after. ¡ Online, interactive, fully searchable database ¡ 5- to 7-minute audio author summaries of poster ¡ Available for 6 months after the meeting iPoster participation is subject to author permissions

Sponsored by:

Scientific Session Schedule 6:00 p.m.–7:00 p.m. F Highlights in the Field Sessions H1 Sleep H2 Movement Disorders H3 Global Health H4 Stroke and Vascular Neurology H5 Multiple Sclerosis H6 Sports Neurology H7 Neuromuscular H8 Clinical Neurophysiology and Autonomic Nervous System H9 Neuro-oncology H10 Women’s Issues in Neurology H11 Critical Care and Emergency Neurology

1:00 p.m.–5:00 p.m. The Promise of Novel Biomarker Approaches in F I11 Advancing Treatment . . . . . . . . . . . . . . . . . . 120 F I12 Obesity and Neurological Disorders . . . . . . . . . . 121

C

2:00 p.m.–6:30 p.m. F P7 Poster Session VII . . . . . . . . . . . . . . . . . . . .122

6:15 p.m.–7:45 p.m. Emerging Science . . . . . . . . . . . . . . . . . . . . . 22 F

Thursday, April 23, 2015 7:30 a.m.–12:00 p.m. F P6 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 9:00 a.m.–12:00 p.m. F Frontiers in Neuroscience Plenary Session . . . . . . . . 36 1:00 p.m.–2:45 p.m. F Scientific Platform Sessions . . . . . . . . . . . . . . . . . 118 S38 Diet and Hormonal Factors in Multiple Sclerosis S39 Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage S40 Movement Disorders: Functional Imaging in Parkinson’s Disease ¡ Presentation of the Movement Disorders Research Award S41 Aging, Dementia, Cognitive, and Behavioral Neurology: Imaging: Aging and Alzheimer’s Disease ¡ Presentation of the Norman Geschwind Prize in Behavioral Neurology S42 New Developments in Peripheral Neuropathies S43 Neuro-oncology: Basic Science and Clinical Trials S44 History of Neurology ¡ Presentation of the Lawrence C. McHenry Award: An Award for the History of Neurology S45 Neuroepidemiology: Multiple Sclerosis, Cerebrovascular, and Aging ¡ Presentation of the Bruce S. Schoenberg International Award in Neuroepidemiology 1:00 p.m.–2:45 p.m. Invited Science: Epilepsy F

28

�� 119

3:15 p.m.–5:00 p.m. F Scientific Platform Sessions . . . . . . . . . . . . . . . . . 132 S46 Neuromyelitis Optica S47 Cerebrovascular Disease and Interventional Neurology S48 Parkinson’s Disease ¡ Presentation of the John Stolk Award in Movement Disorders for Young Investigator S49 Aging, Dementia, Cognitive, and Behavioral Neurology: Imaging: Behavioral Neurology and Non-Alzheimer’s Disease Dementias S50 Treatment Trials in Neuromuscular Diseases S51 Headache: Imaging and Physiology Presentation of the Harold Wolff-John Graham: An ¡ Award for Headache/Facial Pain Research S52 General Neurology: Neural Networks and Neuromodulation S53 Sleep Presentation of the Sleep Science Award ¡ Presentation of the Wayne A. Hening Sleep ¡ Medicine Investigator Award 5:30 p.m.–6:30 p.m. F Highlights in the Field Sessions H12 Geriatric Neurology H13 Neuro-ophthalmology and Neuro-otology H14 Neural Repair and Rehabilitation H15 Behavioral Neurology H16 Neuroendocrinology H17 Headache and Facial Pain H18 Epilepsy 5:30 p.m.–7:00 p.m. F Controversies in Neurology Plenary Session . . . . . . 37

Friday, April 24, 2015 12:00 p.m.–1:30 p.m. F Clinical Trials Plenary Session . . . . . . . . . . . . . . . . 38 4:30 p.m.–6:00 p.m. F Neurology Year in Review Plenary Session . . . . . . . . 39


Annual Meeting App Coming Soon The Mobile App puts all the information you need conveniently on your phone or tablet:

View your itinerary ¡ Find room locations ¡ Access program slides and syllabi ¡ More ¡ A LITE version is available now, which allows you to browse programs, speakers, and convention details. Full version to be available prior to the meeting. Available for ® iPhone , iPad , or Android ®

®

Supported by:

Annual Meeting Program Schedule Saturday, April 18, 2015

Sunday, April 19, 2015

8:00 a.m.–11:00 a.m. $ C1 Status Epilepticus

6:30 a.m.–8:00 a.m. $ C22 Neuro Flash: Epilepsy $ C23 Neuro-oncologic Emergencies $ C24 Balance and Gait Disorders $ C25 Cognitive Psychology of Neurologic Errors: Chalk Talk

8:00 a.m.–12:00 p.m. $ C2 Small Fiber Neuropathies: Sensory, Autonomic, and Both $ C3 Deep Brain Stimulation Management $ C4 Neuromyelitis Optica: Scientific and Clinical Update Resident Basic Science I: Neuropathology $ C5 C6 The Practice of Neurology: Issues in $ Coding and Reimbursement Current Management of Incidental and $ C7 Asymptomatic Cerebrovascular Lesions New Windows into the Brain: Technological F I1 Advances in Frontline Neurologic Diagnosis via the Visual and Oculomotor Systems . . . . . . . . . 48

A

8:00 a.m.–8:30 a.m. F I Creating Innovative, Interactive Teaching Modules . . . . . . . . . . . . . . . . . . . . 22

S

8:00 a.m.–11:00 a.m. $ C26 Controversies in Neuroethics $ C27 Controversies in Multiple Sclerosis Therapy

S

8:00 a.m.–4:00 p.m. $ C8 Clerkship and Program Directors Conference 8:00 a.m.–5:00 p.m. Research Career Development Symposium: $ C9 How to Be Successful in Academic Neuroscience

C

C S A

1:00 p.m.–5:00 p.m. $ C10 Critical Care EEG Monitoring $ C11 Neuromuscular Junction Disorders $ C12 Neurologic Complications of Medical Disease Resident Basic Science II: Neuroanatomy $ C13 $ C14 Advanced Neurologic Coding $ C15 Severe TBI: From ICU to Rehabilitation Pitfalls and Pearls: Avoiding Common Diagnostic $ C16 Errors in Neuro-ophthalmology and Neuro-otology Management of Asymptomatic F I2 Cerebrovascular Lesions . . . . . . . . . . . . . . . . . 49

A S S

3:00 p.m.–5:00 p.m. F I Webs, Apps, and Social Media: There’s an AAN Tool for That! . . . . . . . . . . . . . . 22 $ C17 The Neurology of Social Behavior $ C18 Therapy of Movement Disorders: A Case-based Approach $ C19 Mitochondrial Disorders in Neurology $ C20 Canalith Repositioning for Benign Paroxysmal Positional Vertigo C21 Challenging Headache Cases $ 5:30 p.m.–7:30 p.m. AUPN Clerkship Directors Workshop F

8:00 a.m.–12:00 p.m. Clinical Research: Introduction and Methods F C170 Infectious, Paraneoplastic, Autoimmune? $ C28 Diagnosis and Treatment of Rapidly Progressive Encephalopathies $ C29 Primer of Behavioral Neurology Resident Basic Science III: $ C30 Neuropharmacology $ C31 Sports Concussion and Other Mild Concussive Injuries C32 Teleneurology and Technologies $ $ C33 Hot Topics in Sleep Neurology $ C34 Child Neurology I Dopamine-mediated Neural Plasticity F I3 in Motor and Non-motor Circuits . . . . . . . . . . . . 50

S

8:00 a.m.–5:00 p.m. $ C35 Clinical Epilepsy $ C36 Peripheral Neuropathy Neurology Update I $ C37 Genetics in Neurology $ C38

A A

8:30 a.m.–12:00 p.m. F C171 Opioids and Marijuana in Your Practice 9:00 a.m.–11:00 a.m. F I The Business of Neurology . . . . . . . . . . . . . 22 9:00 a.m.–5:00 p.m. C39 Leadership for Women (must apply)

L

10:00 a.m.–12:00 p.m. $ C40 You Make the Call—an Interactive, Multimedia, Case-based Approach to Learning EMG $ C41 Therapy of Stroke 11:30 a.m.–12:30 p.m. F I Neurology Jeopardy: Things You May Not Know About Publishing in the Journal or Its Spin-offs . . . . 22

30


F = Included with registration $ = Registration fee required


I = I Talk Session 1:00 p.m.–1:30 p.m. F I Annual Meeting Orientation Session . . . . . . . . 22 1:00 p.m.–2:30 p.m. F S1 Section Topic Controversies: Antiplatelets, Anticoagulants, or Stenting for Acute Treatment of Cervical/Cranial Dissection? . . . . . . . 51 1:00 p.m.–4:00 p.m. $ C42 Therapy of Headache Advanced Practice Provider Symposium F C43 (registration required)

A

1:00 p.m.–5:00 p.m. Clinical Research: Drug Development F C172 and Clinical Trials $ C44 Practical Psychopharmacology for Neurologists $ C45 Neuro-otology $ C46 Hot Topics in Headaches and Related Disorders $ C47 Sports Neurology: Non-concussion Overview $ C48 How to Run a Practice: Business Strategies for Neurology Private Practices, Academic Centers, and the Future $ C49 Approach to Sleep Symptoms: Sleepy or Sleepless $ C50 Child Neurology II $ C51 Diagnostic Dilemmas in Multiple Sclerosis Dopaminergic and Nondopaminergic $ C52 Influences on the Changing Landscape of Parkinson’s Disease Infectious, Paraneoplastic, and Autoimmune F I4 Encephalopathies: Advances in Clinical Diagnosis and Emerging Insights about Pathogenesis . . . . . . . 52

C

S S

2:00 p.m.–4:00 p.m. F I Providing High Value Neurologic Care . . . . . . . 22 3:00 p.m.–5:00 p.m. $ C53 Palliative Care for the Practicing Neurologist $ C54 Cognitive-motor Disorders: Chalk Talk

Meeting Attendee Janice Wong, MD Boston, MA

“For me, it’s learning the research ideas for the future. I’m a junior resident, so I’m enjoying all the sessions, especially the genetic talks.”


4:30 p.m.–5:30 p.m. F I Quality in Neurology—Can We Measure and Improve It? . . . . . . . . . . . . . . . . . 22 6:00 p.m.–10:00 p.m. F Capitol City Celebration Join your friends and colleagues for an exciting evening filled with entertainment. Each registered attendee will receive one free ticket to these events. Guest tickets are available through registration for $50

Monday, April 20, 2015 6:30 a.m.–8:00 a.m. $ C55 Neuro Flash: Approach to Acute CNS Infections $ C56 Vascular Cognitive Impairment and Dementia: Current Status and Future $ C57 Therapy of Epilepsy $ C58 Neurological Disorders of Famous Composers F C59 Leadership in Neurology: Be a Champion for Your Patients and Protector of Your Specialty with Payers, Policymakers, and the Public 6:30 a.m.–8:30 a.m. F C60 Resident and Fellow Career Breakfast: The Early Years (registration required) 7:00 a.m.–8:00 a.m. F I Leadership Meeting . . . . . . . . . . . . . . . . . 22 7:00 a.m.–8:30 a.m. State Society Leadership Roundtable F Leadership representatives of state neurological societies are invited to discuss challenges, strategies, and practices related to state society creation and maintenance. Discussion will be facilitated by Academy staff. Participants will learn from the experiences of established societies and be introduced to the resources available from the Academy. 8:00 a.m.–8:30 a.m. F I AAN Business Meeting . . . . . . . . . . . . . . . . . . 22 A AN members are encouraged to attend and vote on the proposed bylaws amendment as well as the slate of nominees for AAN officer and director positions for the 2015-2017 term. 8:00 a.m.–11:00 a.m. $ C61 Clinical E-pearls $ C62 Interpretation of Polysomnography for the Practicing Neurologist 8:00 a.m.–12:00 p.m. Treating the New-onset Epilepsy Patient $ C63 $ C64 Clinical EMG I

S

31

Annual Meeting Program Schedule $ C65 Botulinum Toxins: Practical Issues and Clinical $ C66 $ C67 $ C68 $ C69 $ C70 $ C71 F I5

Uses for Neurologists Multiple Sclerosis Overview I: Basic and Translational Science Infections of the Nervous System I: Common Infections Neuroimaging for the General Neurologist: Brain Introduction to Primary Headache Disorders Bedside Evidence-based Medicine: How to Find and Deconstruct Articles in Order to Take Care of Patients Neuro-oncology: Primary Brain Tumors Pediatric Neurotrauma: From Coma to Concussions . . . . . . . . . . . . . . . 53

A

S

8:00 a.m.–5:00 p.m. $ C72 Dementia Overview $ C73 Therapy in Neurology $ C74 Cerebrovascular Disease $ C75 Neurophysiologic Intraoperative Monitoring Skills Workshop

9:00 a.m.–5:00 p.m. C76 Advanced Leadership for Women (must apply)

L

10:00 a.m.–12:00 p.m. $ C77 Update on Ataxias 11:00 a.m.–1:00 p.m. F I Neuroexam: Learn from the Experts . . . . . . . . 22 1:00 p.m.–2:30 p.m. F S2 Section Topic Controversies: Testing in Prodromal Neurological Disease: Friend or Foe? . . . . . . . . . . 54

32

L

S

1:30 p.m.–3:00 p.m. AAN/ABPN MOC Information Session F 1:30 p.m.–3:30 p.m. F I Conquering ICD-10 . . . . . . . . . . . . . . . . . . 22 2:00 p.m.–4:30 p.m. F C175 Qualitative Research: The “How” and “Why” of Education 2:00 p.m.–6:30 p.m. F P1 Poster Session I . . . . . . . . . . . . . . . . . . . . . 57

4:00 p.m.–6:45 p.m. Student Interest Groups in Neurology (SIGN) Meeting F

9:00 a.m.–10:30 a.m. F I Is AAN Member Participation in Physician-assisted Suicide Ethical? . . . . . . . . . . . . . . . . . . . . . . 22

S

Treatment of Dystonia Skills Pavilion Improving Your Leadership Skills: $ C86 A Practical Approach Future Therapies: How We Will Be Treating, F I6 Preventing, and Curing Epilepsy in the Year 2025 . . . 55

4:00 p.m.–5:00 p.m. F I AAN’s Axon Registry: Data Powering Neurology’s Future . . . . . . . . . . . 22

8:30 a.m.–12:00 p.m. F C173 Clinical Reasoning: From a Novice to an Expert

1:00 p.m.–5:00 p.m. F C174 All You Need to Know About Health Information Technology to Avoid Taking a HIT $ C78 Clinical EMG II $ C79 Overview of Parkinson’s Disease and Movement Disorders $ C80 Multiple Sclerosis Overview II: Clinical Advances $ C81 Infections of the Nervous System II: Advanced and Emerging Infections $ C82 Emergency Room Neuro-ophthalmology Concussion Assessment and $ C83 Management in the Youth Athlete $ C84 Neurologic Complications of Systemic Cancer

$ C85 Clinical Usefulness of Botulinum Toxin and

4:30 p.m.–6:30 p.m. Exhibit Hall Opening Reception F 5:00 p.m.–6:30 p.m. Consortium of Neurology Residents and Fellows Meeting F 5:30 p.m.–6:30 p.m. F I Hot Topics in Education: The Value of a Neurologist 6:30 p.m.–9:00 p.m. Residents and Fellows Career Forum and Reception F

Tuesday, April 21, 2015 6:30 a.m.–8:00 a.m. $ C88 Morning Report: Multiple Sclerosis $ C89 Now You See It, Now You Know It—Pathognomonic Neuro-ophthalmology Findings $ C90 Approach to the Shaky Patient $ C91 Career Development for Clinician Educators $ C92 Important Drug Interactions for Neurologists and Psychiatrists $ C93 Brain Computer Interfaces: Frontiers in Neurology and Neuroscience 6:30 a.m.–8:30 a.m. $ 2015 AAN Run/Walk for Brain Research . . . . . . . . . . . . . . . 136 7:30 a.m.–12:00 p.m. F P2 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65


F = Included with registration $ = Registration fee required I = I Talk Session

9:00 a.m.–12:00 p.m. F Presidential Plenary Session Features the AAN’s premier lecture awards for clinically relevant research and a presentation by a leading lecturer. Top researchers speak on some of the most significant findings in neurology in 2015. Moderator: Lisa M. DeAngelis, MD, FAAN Chair, Science Committee

P residential Lecture Timothy A. Pedley, MD, FAAN Columbia University New York, NY . Houston Merritt Lecture H Advances in the World of Epilepsy: Really?!?! Daniel H. Lowenstein, MD University of California San Francisco San Francisco, CA George C. Cotzias Lecture Endowed by Roche Pharmaceuticals. Degenerative Ataxias: From Genes to Therapies Stefan M. Pulst, MD, FAAN University of Utah Salt Lake City, UT Sidney Carter Award in Child Neurology Endowed by an Anonymous Donor. Multiple Sclerosis in Children Brenda Banwell, MD Children’s Hospital of Philadelphia Philadelphia, PA Robert Wartenberg Lecture What Has Deep Brain Stimulation Taught Us About the Neurology of Depression? Helen S. Mayberg, MD Emory University School of Medicine Atlanta, GA 11:30 a.m.–5:00 p.m. Exhibit Hall F 12:00 p.m.–1:00 p.m. F I Policy and Advocacy Hour with the GRC . . . . . . 22 1:00 p.m.–2:30 p.m. F S3 Section Topic Controversies: Should All Brain Tumor Patients Receive Prophylactic Antiepileptic Drugs? . . 73



1:00 p.m.–2:45 p.m. F Scientific Platform Sessions . . . . . . . . . . . . . . . . . . 74 S4 Clinical Trial Outcomes in Multiple Sclerosis S5 Cerebrovascular Disease and Interventional Neurology: Recovery and Outcome S6 Epilepsy/Clinical Neurophysiology (EEG): Health Services and Women’s Issues S7 Movement Disorders: Genetics ¡ Presentation of the Founders Award S8 Aging, Dementia, Cognitive, and Behavioral Neurology: Basic Science ¡ Presentation of the Potamkin Prize for Research in Pick’s, Alzheimer’s Disease, and Related Diseases S9 General Neurology: Neurological Treatments and Therapeutics S10 Pain and Palliative Care ¡ Presentation of the Mitchell B. Max Award for Neuropathic Pain S11 Practice, Policy, and Ethics 1:00 p.m.–2:45 p.m. Invited Science: Stroke F

. . . . . . . . 75

1:00 p.m.–4:00 p.m. $ C94 EEG in Children: Developmental Maturation, Variants, Epilepsy Syndromes, and Identification of Surgical Candidates 1:00 p.m.–5:00 p.m. $ C95 Sports Concussion Skills Pavilion $ C96 Evaluation and Management of Autonomic Disorders $ C97 Neurologic Issues in Pregnancy $ C98 Myelopathies $ C99 Neuro-ophthalmology and Neurovestibular Exam Lab Skills Pavilion F I7 The Global Burden of Neurological Infections: Epidemiology, Treatment, and Prevention . . . . . . . . 76 F I8 Advances in ALS and Other Motor Neuron Diseases . 77 1:30 p.m.–3:30 p.m. F I Case Report 2.0: Implementing the “CARE” Guidelines . . . . . . . . . . 22 2:00 p.m.–6:30 p.m. F P3 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78 3:15 p.m.–5:00 p.m. F Scientific Platform Sessions . . . . . . . . . . . . . . . . . . 86 S12 Neuroimmune Mechanisms in Multiple Sclerosis S13 Cerebrovascular Disease and Interventional Neurology: Epidemiology and Risk Factors ¡ Presentation of the Michael S. Pessin Stroke Leadership Prize S14 Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy S15 Movement Disorders: Huntington’s Disease, Dystonia, and Atypical Parkinsonism 33

Annual Meeting Program Schedule S16

Aging, Dementia, Cognitive, and Behavioral Neurology: Clinical Science S17 Muscle and Anterior Horn Cell Diseases: Mechanisms and Biomarkers S18 Neuro-oncology: Imaging and Quality of Life ¡ Presentation of the Neuro-oncology Investigator Award S19 Neurologic Education

7:00 p.m.–10:00 p.m. F Industry Therapeutic Updates . . . . . . . . . . . . . . . . . . 131 Industry-sponsored, non-CME programs will be offered and are open to attendees at no charge. They will provide an opportunity for pharmaceutical companies, device companies, or other neurologic-related organizations to share information regarding their current therapies and projects in the pipeline in accordance with standards set for industry by the FDA.

4:00 p.m.–5:00 p.m. F I How to Hug a Porcupine: Relationship Building with Congress and Why It’s Important . . . . 22 5:30 p.m.–6:15 p.m. F I Your Abstract Has Been Accepted: Now What? Part I . . . . . . . . . . . . . . . . . . . . 22 5:30 p.m.–6:45 p.m. F Hot Topics Plenary Session Features translational research related to clinical issues of importance. Five outstanding physician-scientists provide summaries of their recent research findings and describe the clinical implications of the results.

oderator: Randolph S. Marshall, MD, FAAN M Member, Science Committee

Wednesday, April 22, 2015 6:30 a.m.–8:00 a.m. $ C100 Mild Cognitive Impairment: Implications for Clinicians $ C101 Hyperkinetic Movement Disorders: Diagnosis and Treatment $ C102 Syndromes of Autonomic Dysfunction in Children and Adolescents $ C103 Global Health Challenges: Neurology in Developing Countries $ C104 Pseudotumor Cerebri $ C105 Neurohospitalist 2.0: Next Steps in the Evolution $ C106 Neuro Flash: Acute Stroke Management 7:30 a.m.–12:00 p.m. F P4 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 8:00 a.m.–8:30 a.m. F I Annual Meeting Orientation Session . . . . . . . . 22

Presenters:

Therapeutics in Neuromuscular Disease Brian K. Kaspar, PhD Nationwide Children’s Hospital, Columbus, OH

3-D Cultures for Alzheimer’s Disease Doo Yeon Kim, PhD Mass General Institute for Neurodegenerative Disease, Charleston, MA S ex-specific Programming of Neurodevelopment by Stress Tracy L. Bale, PhD University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

RNA-targeted Therapies for Neurologic Disease Timothy M. Miller, MD, PhD Washington University School of Medicine St. Louis, MO

igesting the Gut Microbiome: D Role in CNS Demyelinating Disease

Meeting Attendee Mohamed El Hag, MD (Resident) Cleveland, OH

“[The Annual Meeting Science Programs give me] a lot of exposure to different researchers and to different work that people do in the field of neurology. When you come to this place, you are exposed to everything: The cutting-edge science, the new techniques, the basically new science, the new indications, the new guidelines.”

Lloyd H. Kasper, MD Dartmouth Medical School, Lebanon, NH

34




I = I Talk Session

9:00 a.m.–12:00 p.m. F Contemporary Clinical Issues Plenary Session Highlights issues most critical to practicing neurologists, including abstracts related to new therapeutic developments, clinical applications of basic and translational research, and innovative technical developments. Commentary and discussion follow each presentation.

oderator: Lisa M. DeAngelis, MD, FAAN M Chair, Science Committee

Abstract Presenters/Discussant:

dults with Migraine Have Atypical Correlations A between Brain Cortical Thickness and Pain Thresholds Presenter: Todd J. Schwedt, MD Mayo Clinic, Phoenix, AZ Discussant: Peter Goadsby, MD, PhD

University of California, San Francisco San Francisco, CA

AV9-mediated Gene Therapy in a A SMARD1 Mouse Model Presenter: Stefania Corti, MD, University of Milan Milan, Italy Discussant: Massimo Pandolfo, MD, FAAN Universite Libre De Bruxelles, Brussels, Belgium

B lood Pressure Control and Risk of Recurrent Lobar Intracerebral Hemorrhage Presenter: Christopher D. Anderson, MD, MMSc Massachusetts General Hospital, Boston, MA Discussant: Kevin N. Sheth, MD, FAHA, FCCM

Yale School of Medicine New Haven, CT

Invited Speakers:

Decade of Autism Genetics: Building a A Foundation for Targeted Treatment Development Daniel H. Geschwind, MD, PhD, University of California, Los Angeles, Los Angeles, CA Gray Zones in the Gray Population: Assessment of Cognition in Late Life Steven T. DeKosky, MD, FAAN University of Virginia in Charlottesville, VA

Pain in a Dish Brian Wainger, MD, PhD Massachusetts General Hospital, Boston, MA


11:30 a.m.–5:00 p.m. Exhibit Hall F 12:00 p.m.–1:00 p.m. F I Neurology Compensation and Productivity Survey and Dashboard Report . . . . . . . . . . . . . . 22 12:00 p.m.–1:30 p.m. $ Awards Luncheon . . . . . . . . . . . . . . . . . . . . 137 1:30 p.m.–3:30 p.m. F I How to Avoid “Death by PowerPoint” and Workshop . . . . . . . . . . . . . . . . . . . . . . 22 2:00 p.m.–3:45 p.m. F Scientific Platform Sessions . . . . . . . . . . . . . . . . . . 96 S20 Treatment Mechanisms in Multiple Sclerosis ¡ Presentation of the John Dystel Prize for Multiple Sclerosis Research S21 Cerebrovascular Disease and Interventional Neurology: Prehospital and Acute Ischemic Stroke Treatment S22 Epilepsy/Clinical Neurophysiology (EEG): Basic Science and Intraoperative Monitoring ¡ Presentation of the Dreifuss-Penry Epilepsy Award S23 Headache: Epidemiology and Clinical S24 ALS: Mechanisms and Biomarkers ¡ Presentation of the Sheila Essey Award: An Award for ALS Research S25 General Neurology ¡ Presentation of the S. Weir Mitchell Award S26 Neuro-ophthalmology/Neuro-otology S27 Neuro Trauma, Critical Care, and Sports Neurology S28 Neuro-rehabilitation 2:00 p.m.–6:00 p.m. $ C107 History of Neurology: The History of Neurologic Disease from Cortex to Peripheral Nerve $ C108 Autism Spectrum Disorders—What We Know and Where We Are Going $ C109 Functional Neurologic Disorders $ C110 Differential Diagnosis of Neurologic Infections $ C111 Neuromuscular Ultrasound Skills Pavilion $ C112 Skills for Stroke Emergent Treatment Skills Pavilion F I9 Treating Dementia in an Age of Mixed Disease . . . . 98 The Dynamic Brain in Health and Disease: Plasticity F I10 and Reprogramming . . . . . . . . . . . . . . . . . . . 99

C

2:00 p.m.–6:30 p.m. F P5 Poster Session V . . . . . . . . . . . . . . . . . . . . .100 4:00 p.m.–4:45 p.m. F I Your Abstract Has Been Accepted: Now What? Working with the Media . . . . . . . . . . 22

35

Annual Meeting Program Schedule 4:00 p.m.–5:45 p.m. F Platform Blitz Sessions . . . . . . . . . . . . . . . . . . . . 108 S29 Neuroimaging Correlates in Multiple Sclerosis S30 Cerebrovascular Disease and Interventional Neurology: Diagnostics, Biomarkers, and Genetics S31 Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Therapy S32 Movement Disorders: Tremor, Ataxia, and More S33 Aging, Dementia, Cognitive, and Behavioral Neurology: Biomarkers and Pathology S34 Neuromuscular Update S35 Child Neurology and Developmental Neurology S36 Neuroepidemiology: Movement Disorders, ALS, and Aging S37 Global Health and Infectious Disease 6:00 p.m.–7:00 p.m. F Highlights in the Field Sessions H1 Sleep H2 Movement Disorders H3 Global Health H4 Stroke and Vascular Neurology H5 Multiple Sclerosis H6 Sports Neurology H7 Neuromuscular H8 Clinical Neurophysiology and Autonomic Nervous System H9 Neuro-oncology H10 Women’s Issues in Neurology H11 Critical Care and Emergency Neurology 6:15 p.m.–7:45 p.m. Emerging Science . . . . . . . . . . . . . . . . . . . . . 22 F 7:00 p.m.–10:00 p.m. F Industry Therapeutic Updates . . . . . . . . . . . . . . . . . . 131 Industry-sponsored, non-CME programs will be offered and are open to attendees at no charge. They will provide an opportunity for pharmaceutical companies, device companies, or other neurologic-related organizations to share information regarding their current therapies and projects in the pipeline in accordance with standards set for industry by the FDA.

Thursday, April 23, 2015 6:30 a.m.–8:00 a.m. $ C113 Neuro Flash: Neuro-ophthalmology $ C114 Morning Report: Behavioral Neurology $ C115 Morning Report: Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Post-laminectomy Syndrome $ C116 Prognostication in the Era of Hypothermia $ C117 REM Sleep Behavior Disorder $ C118 What Neurologists Really Need to Know About Normal Pressure Hydrocephalus 7:30 a.m.–12:00 p.m. F P6 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 36

9:00 a.m.–12:00 p.m. F Frontiers in Neuroscience Plenary Session Focuses on translational research related to clinical issues of importance. Six physician scientists outline their recent research findings, along with the clinical implications. Moderator: Paul M. George, MD, PhD, MSE

Member, Science Committee

Presenters: T ransmission of α-Synuclein in Parkinson’s Disease: Pathogenesis and Implications for Therapy V irginia M-Y Lee, PhD University of Pennsylvania Philadelphia, PA Antemortem Signatures of Neurodegenerative Proteinopathies Keith A. Josephs Jr., MD Mayo Clinic Rochester, MN Developing Antisense Oligomers as a Genetic Therapy for Duchenne Muscular Dystrophy Francesco Muntoni, MD University College London Institute of Child Health, London, United Kingdom Immune Mechanisms in Neurologic Diseases Howard L. Weiner, MD Brigham and Women’s Hospital Boston, MA T owards a New Connectional Anatomy of the Human Brain Marco Catani, MD King’s College London London, United Kingdom Epilepsy: How Genetic Insights Are Transforming Clinical Practice Ingrid Scheffer, AO, MBBS, PhD, FRACP, FAHMS, FAA Melbourne Brain Centre Heidelberg, Victoria, Australia 11:30 a.m.–3:00 p.m. F Exhibit Hall 12:00 p.m.–1:00 p.m. F I AAN’s Axon Registry: Data Powering Neurology’s Future . . . . . . . . . . . 22 1:00 p.m.–2:45 p.m. F Scientific Platform Sessions . . . . . . . . . . . . . . . . . 118 S38 Diet and Hormonal Factors in Multiple Sclerosis S39 Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage


F = Included with registration $ = Registration fee required I = I Talk Session S40 Movement Disorders: Functional Imaging in Parkinson’s Disease ¡ Presentation of the Movement Disorders Research Award S41 Aging, Dementia, Cognitive, and Behavioral Neurology: Imaging: Aging and Alzheimer’s Disease ¡ Presentation of the Norman Geschwind Prize in Behavioral Neurology S42 New Developments in Peripheral Neuropathies S43 Neuro-oncology: Basic Science and Clinical Trials S44 History of Neurology ¡ Presentation of the Lawrence C. McHenry Award: An Award for the History of Neurology S45 Neuroepidemiology: Multiple Sclerosis, Cerebrovascular, and Aging ¡ Presentation of the Bruce S. Schoenberg International Award in Neuroepidemiology 1:00 p.m.–2:45 p.m. Invited Science: Epilepsy F

�� 119

1:00 p.m.–5:00 p.m. $ C119 Borderlands of Neurology and Internal Medicine: Chalk Talk $ C120 Emergency Neurology $ C121 Core Concepts in Pain Management $ C122 Epilepsy Skills Pavilion $ C123 Neuromuscular Bedside Rounds Skills Pavilion Neuroimaging for the General Neurologist: $ C124 Spine and Peripheral Nerve The Promise of Novel Biomarker Approaches F I11 in Advancing Treatment . . . . . . . . . . . . . . . . .120 F I12 Obesity and Neurological Disorders . . . . . . . . . . 121

A C

2:00 p.m.–6:30 p.m. F P7 Poster Session VII . . . . . . . . . . . . . . . . . . . .122 3:00 p.m.–3:45 p.m. F I Your Abstract Has Been Accepted: Now What? Tips for a Successful Presentation . . . . 22 3:15 p.m.–5:00 p.m. F Scientific Platform Sessions . . . . . . . . . . . . . . . . . 132 S46 Neuromyelitis Optica S47 Cerebrovascular Disease and Interventional Neurology S48 Parkinson’s Disease ¡ Presentation of the John Stolk Award in Movement Disorders for Young Investigator S49 Aging, Dementia, Cognitive, and Behavioral Neurology: Imaging: Behavioral Neurology and Non-Alzheimer’s Disease Dementias S50 Treatment Trials in Neuromuscular Diseases S51 Headache: Imaging and Physiology ¡ Presentation of the Harold Wolff-John Graham: An Award for Headache/Facial Pain Research S52 General Neurology: Neural Networks and Neuromodulation S53 Sleep Presentation of the Sleep Science Award ¡ Presentation of the Wayne A. Hening Sleep ¡ Medicine Investigator Award Fast, Easy, Online Registration · AAN.com/view/AM15


5:30 p.m.–6:30 p.m. F Highlights in the Field Sessions H12 Geriatric Neurology H13 Neuro-ophthalmology and Neuro-otology H14 Neural Repair and Rehabilitation H15 Behavioral Neurology H16 Neuroendocrinology H17 Headache and Facial Pain H18 Epilepsy 5:30 p.m.–7:00 p.m. F Controversies in Neurology Plenary Session The program features experts discussing the most current and controversial issues in neuroscience. It is set up as a debate format in which two speakers argue one side of a single topic, followed by a rebuttal. Each round concludes with a 10-minute question and answer period.

oderators: M Joseph Jankovic, MD, FAAN Member, Science Committee, and Walter A. Rocca, MD, MPH Chair, Clinical Research Subcommittee, Member, Science Committee Presenters: S hould Whole Exome Sequencing be Part of Neurologic Care Today? Pro: Christine Klein, MD, University of Luebeck Luebeck, Germany Con: Claes Wahlestedt, MD, PhD University of Miami Miller School of Medicine, Miami, FL Is the Science of Stem Cells Ready for Clinical Trials in Neurologic Disease? Pro: Clive Svendsen, PhD Cedars-Sinai Medical Center, Los Angeles, CA Con: C. Warren Olanow, MD, FAAN Mt. Sinai Medical Center New York, NY S hould Neurologists Prescribe Opioids for Chronic Pain? Pro: Charles E. Argoff, MD Albany Medical Center, Albany, NY Con: Gary M. Franklin, MD, MPH, FAAN University of Washington, Seattle, WA

37

Annual Meeting Program Schedule 6:00 p.m.–9:00 p.m. $ C125 Case Studies: Dementia $ C126 Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease $ C127 Case Studies: Unusual Movement Disorders $ C128 Case Studies: Multiple Sclerosis $ C129 Test Your Knowledge: A Case-based Approach to Neuroimaging $ C130 Case Studies: Neurologic Consultations in Cancer Patients

Friday, April 24, 2015 6:30 a.m.–8:00 a.m. $ C131 Neuro Flash: Child Neurology $ C132 Differential Diagnosis of Dementia: Linking Clinical Syndromes to Biomarkers C133 The Interface Between Infection and Cerebrovascular $ Disease $ C134 The Dystonias: Diagnosis, Treatment, and Update on Causes C135 Neurotoxicology $ 8:00 a.m.–12:00 p.m. $ C136 Assessment of Rapidly Progressive Dementias and Related Neurologic Conditions $ C137 Multiple Sclerosis Therapy I: Symptom Management $ C138 Continuum ® Test Your Knowledge: A Multiple-choice Question Review $ C139 Stroke in Young Adults $ C140 Sleep for the Practicing Neurologist 8:00 a.m.–4:00 p.m. $ C141 Movement Disorders $ C142 Clinical EEG Neurology Update II $ C143 $ C144 Neuro-ophthalmology $ C145 Neurologic Intensive Care $ C146 Spine Neurology: Assessment and Management of Common Spine Disorders C147 EMG Skills Workshop: Basic $

A

2016 Education Course Proposal Process 2016 Annual Meeting: Vancouver, BC, Canada

The AAN invites you to submit an Education Program suggestion for the 68th Annual Meeting. Proposals are due by May 15, 2015. To submit your proposal, please visit AAN.com/view/SubmitProgram.

38

12:00 p.m.–1:30 p.m. F Clinical Trials Plenary Session This midday seminar covers important clinical topics identified from other society meetings that affect patient care. The latest updates within several clinical trials conducted over the course of the last year will be presented with an open panel discussion at the conclusion.

oderators: M Natalia S. Rost, MD, FAAN Vice Chair, Science Committee, and Petra Kaufmann, MD Member, Clinical Reasearch Subcommittee Presenters: mifampridine Phosphate (FirdapseTM) A is safe and Effective in a Pivotal Phase 3 Trial in LEMS Patients Shin J. Oh, MD, FAAN University of Alabama at Birmingham Birmingham, AL E ffect of MD1003 (High Doses of Biotin) in Progressive Multiple Sclerosis: Results of a Pivotal Phase III Randomized Double Blind Placebo Controlled Study Ayman Tourbah, MD, PhD CHU de Reims, Reims, France Idebenone Reduces Loss of Respiratory Function in Duchenne Muscular Dystrophy—Outcome of a Phase III Double Blind, Randomised, Placebocontrolled Trial (DELOS) Gunnar Buyse, PhD, MD University Hospitals K.U. Leuven, Leuven, Belgium T he Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlandsv (MR CLEAN): Update and Clinical Implications Diedrik Dippel, MD Erasmus MC University Medical Center Rotterdam, The Netherlands Phenytoin is Neuroprotective in Acute Optic Neuritis: Results of Phase 2 Randomized Controlled Trial Raju Kapoor, MD National Hospital London, United Kingdom 1:00 p.m.–3:00 p.m. $ C148 Therapy of Neuromuscular Disease 1:00 p.m.–4:00 p.m. $ C149 Improving Accuracy of Dementia Diagnosis: Case Studies with Both Imaging and Neuropathology


F = Included with registration $ = Registration fee required I = I Talk Session $ C150 Principles of Genomic Medicine: Clinical Exome

Sequencing in Neurologic Disease $ C151 Multiple Sclerosis Therapy II: Disease-modifying Treatment $ C152 The Intractable Headache Patient $ C153 Practical Legal Issues for Neurologists 4:30 p.m.–6:00 p.m. F Neurology Year in Review Plenary Session This plenary session will feature six speakers, each focusing on the latest research that has happened in the last year within a specific subspecialty topic. Moderator: Lisa M. DeAngelis, MD, FAAN Chair, Science Committee Neuro-oncology Memorial Sloan-Kettering Cancer Center New York, NY ovement Disorders M Michael S. Okun, MD, FAAN University of Florida, Gainesville, FL

euro-rehabilitation N Bruce H. Dobkin, MD, FAAN University of California, Los Angeles Los Angeles, CA Vertigo


Saturday, April 25, 2015 6:30 a.m.–8:00 a.m. $ C154 Attention Deficit Hyperactivity Disorder Across the Lifespan $ C155 Physical Exercise and Cognitive Training in Neurological Disorders $ C156 Neuro Flash: Sleep Medicine $ C157 Paroxysmal Movement Disorders $ C158 Neuro Flash: MRI and Multiple Sclerosis 8:00 a.m.–11:00 a.m. $ C159 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia 8:00 a.m.–12:00 p.m. $ C160 Non-Alzheimer’s Dementia $ C161 Clinical Approach to Muscle Disease $ C162 Nonmotor Manifestations of Parkinson Disease $ C163 Autoimmune Neurology $ C164 Chronic Migraine Education Program $ C165 Consultations in the Medical Surgical ICU $ C166 How to Analyze Spells by Video-EEG 10:00 a.m.–12:00 p.m. $ C167 Preventing a First Stroke: What Every Neurologist Needs to Know $ C168 Controversies in Brain Death Determination $ C169 Multiple Sclerosis Essentials

David Newman-Toker, MD, PhD, FAAN Johns Hopkins University School of Medicine Baltimore, MD Pediatric Neurology Nina F. Schor, MD, PhD University of Rochester Medical Center Rochester, NY ultiple Sclerosis and Neuromyelitis Optica M Jeffrey Allan Cohen, MD Cleveland Clinic Cleveland, OH 6:00 p.m.–8:00 p.m. F Closing Party Celebrate the end of a great meeting at a special earlyevening happy hour event!

¡¡ Enjoy music, drinks, and socializing with colleagues ¡¡ Make plans to explore beautiful Washington, DC, afterwards


Meeting Attendee Ishida Kyto, MD New York

“I really appreciate the speakers who gave a high-level interpretation of the clinical trials. We all know the data. It’s the interpretation that really helps us start a discussion and collaborate nationally.”

39

Annual Meeting Programs by Topic C Course

H Highlights Session

I Integrated Neuroscience Session

Aging, Dementia, Cognitive, and Behavioral Neurology

$ C15 $ C17 $ C29 $ C44 $ C54 $ C56 $ C72 F P1 F P2 F S8 F I8 F S16 F $ C100 F P4 F F I9 F I10 F P5 F S33 $ C114 $ C118 F P6 F F S41 F I11 F I12 F P7 F S49 F H12 F H15

40

C

S Scientific Session

$ C125 Case Studies: Dementia $ C132 Differential Diagnosis of Dementia: Linking Clinical

Severe TBI: From ICU to Rehabilitation The Neurology of Social Behavior Primer of Behavioral Neurology Practical Psychopharmacology for Neurologists Cognitive-motor Disorders: Chalk Talk Vascular Cognitive Impairment and Dementia: Current Status and Future Dementia Overview Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65 Aging, Dementia, Cognitive, and Behavioral Neurology: Basic Science . . . . . . . . 74 Advances in ALS and Other Motor Neuron Diseases . 77 Aging, Dementia, Cognitive, and Behavioral Neurology: Clinical Science . . . . . . 86 Hot Topics Plenary Session . . . . . . . . . . . . . 34 Mild Cognitive Impairment: Implications for Clinicians Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 Contemporary Clinical Issues Plenary Session . 35 Treating Dementia in an Age of Mixed Disease . . . . 98 The Dynamic Brain in Health and Disease: Plasticity and Reprogramming . . . . . . . . . . . . . . 99 Poster Session V . . . . . . . . . . . . . . . . . . . . .100 Aging, Dementia, Cognitive, and Behavioral Neurology: Biomarkers and Pathology Platform Blitz . . . . . . . .108 Morning Report: Behavioral Neurology What Neurologists Really Need to Know About Normal Pressure Hydrocephalus Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 Frontiers in Neuroscience Plenary Session . . . 36 Aging, Dementia, Cognitive, and Behavioral Neurology: Imaging: Aging and Alzheimer’s Disease . . . . . . . . 118 The Promise of Novel Biomarker Approaches in Advancing Treatment . . . . . . . . . . . . . . . . . . 120 Obesity and Neurological Disorders . . . . . . . . . . 121 Poster Session VII . . . . . . . . . . . . . . . . . . . .122 Aging, Dementia, Cognitive, and Behavioral Neurology: Imaging: Behavioral Neurology and Non-Alzheimer’s Disease Dementias . . . . . . . . . . . . . . . . . . . 132 Geriatric Neurology . . . . . . . . . . . . . . . . . . . 37 Behavioral Neurology . . . . . . . . . . . . . . . . . . 37

C

P Poster Session

$ C136 $ C149 $ C154 $ C160

Syndromes to Biomarkers Assessment of Rapidly Progressive Dementias and Related Neurologic Conditions Improving Accuracy of Dementia Diagnosis: Case Studies with Both Imaging and Neuropathology Attention Deficit Hyperactivity Disorder Across the Lifespan Non-Alzheimer’s Dementia

Cerebrovascular Disease and Interventional Neurology

$ C7

S Current Management of Incidental and

Asymptomatic Cerebrovascular Lesions New Windows into the Brain: F I1 Technological Advances in Frontline Neurologic Diagnosis via the Visual and Oculomotor Systems . . . 48 Management of Asymptomatic Cerebrovascular F I2 Lesions . . . . . . . . . . . . . . . . . . . . . . . . . . 49 $ C41 Therapy of Stroke F S1 Section Topic Controversies: Antiplatelets, Anticoagulants, or Stenting for Acute Treatment of Cervical/Cranial Dissection? . . . 51 $ C74 Cerebrovascular Disease

S S

Meeting Attendee Kathleen M. Fitzgerald, MD Eugene, OR

“[The Annual Meeting Science Programs] are amazing. The poster sessions are inspiring. You get these young researchers just starting, and they come out with beautiful things that just blow you away.”




I = I Talk Session F P1 F P2 F S5 F F P3 F S13 $ C105 $ C106 F P4 F F S21 $ C112 F I9 F I10 F P5 F S30 F H4 $ C116 F P6 F S39 F I11 F I12 F P7 F S47 $ C133 $ C139 F $ C167

Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65 Cerebrovascular Disease and Interventional Neurology: Recovery and Outcome . . . . . . . . . . . . . . . . . . 74 Invited Science: Stroke . . . . . . . . . . 75 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78 Cerebrovascular Disease and Interventional Neurology: Epidemiology and Risk Factors . . . . . . . 86 Neurohospitalist 2.0: Next Steps in the Evolution Neuro Flash: Acute Stroke Management Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 Contemporary Clinical Issues Plenary Session . 35 Cerebrovascular Disease and Interventional Neurology: Prehospital and Acute Ischemic Stroke Treatment . . . . . . . . . . . . . . . . . . . . . 96 Skills for Stroke Emergent Treatment Skills Pavilion Treating Dementia in an Age of Mixed Disease . . . . 98 The Dynamic Brain in Health and Disease: Plasticity and Reprogramming . . . . . . . . . . . . . . 99 Poster Session V . . . . . . . . . . . . . . . . . . . . .100 Cerebrovascular Disease and Interventional Neurology: Diagnostics, Biomarkers, and Genetics Platform Blitz . . . . . . . . . . . . . . . . . 108 Stroke and Vascular Neurology . . . . . . . . . . . . . 36 Prognostication in the Era of Hypothermia Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage . . . . . . . . . 118 The Promise of Novel Biomarker Approaches in Advancing Treatment . . . . . . . . . .120 Obesity and Neurological Disorders . . . . . . . . . . 121 Poster Session VII . . . . . . . . . . . . . . . . . . . .122 Cerebrovascular Disease and Interventional Neurology . . . . . . . . . . . . . . . . 132 The Interface Between Infection and Cerebrovascular Disease Stroke in Young Adults Clinical Trials Plenary Session . . . . . . . . . . . 38 Preventing a First Stroke: What Every Neurologist Needs to Know

C

C

Child Neurology and Developmental Neurology

$ C34 Child Neurology I $ C50 Child Neurology II F I5 S Pediatric Neurotrauma: $ C83

From Coma to Concussions . . . . . . . . . . . . . . . 53 Concussion Assessment and Management in the Youth Athlete

S


F P2 F F S3 $ C94 $ C102 F $ C108 F I10 F S35 F P6 F $ C131 $ C139 F $ C154

Poster Session II . . . . . . . . . . . . . . . . . . . . . 65 Presidential Plenary Session . . . . . . . . . . . . 33 Section Topic Controversies: Should All Brain Tumor Patients Receive Prophylactic Antiepileptic Drugs? . . 73 EEG in Children: Developmental Maturation, Variants, Epilepsy Syndromes, and Identification of Surgical Candidates Syndromes of Autonomic Dysfunction in Children and Adolescents Contemporary Clinical Issues Plenary Session . 35 Autism Spectrum Disorders—What We Know and Where We Are Going The Dynamic Brain in Health and Disease: Plasticity and Reprogramming . . . . . . . . . . . . . . 99 Child Neurology and Developmental Neurology Platform Blitz . . . . . . . . . . . . . . . . .109 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 Frontiers in Neuroscience Plenary Session . . . 36 Neuro Flash: Child Neurology Stroke in Young Adults Neurology Year in Review Plenary Session . . . 39 Attention Deficit Hyperactivity Disorder Across the Lifespan

C

Epilepsy/Clinical Neurophysiology (EEG)

$ C1 $ C10 $ C22 $ C35 $ C57 $ C63 $ C75

Status Epilepticus Critical Care EEG Monitoring Neuro Flash: Epilepsy Clinical Epilepsy Therapy of Epilepsy Treating the New-onset Epilepsy Patient Neurophysiologic Intraoperative Monitoring Skills Workshop Future Therapies: How We Will Be Treating, F I6 Preventing, and Curing Epilepsy in the Year 2025 . . . 55 F P1 Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57 F P2 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65 Presidential Plenary Session . . . . . . . . . . . . 33 F S6 Epilepsy/Clinical Neurophysiology (EEG): F Health Services and Women’s Issues . . . . . . . . . . 74 $ C94 EEG in Children: Developmental Maturation, Variants, Epilepsy Syndromes, and Identification of Surgical Candidates F P3 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78 F S14 Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy . . . . . . . . . . . . . . . . . . . . . . 86 F P4 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 F S22 Epilepsy/Clinical Neurophysiology (EEG): Basic Science and Intraoperative Monitoring . . . . . . 96

S S

41

Annual Meeting Programs by Topic F P5 Poster Session V . . . . . . . . . . . . . . . . . . . . .100 F S31 Epilepsy/Clinical Neurophysiology (EEG):

F P5 Poster Session V . . . . . . . . . . . . . . . . . . . . .100 F S36 Neuroepidemiology: Movement Disorders,

F H8

F H10 F P6 F F S45

F P6 F F $ C122 F P7 F H18 $ C142 $ C166

Epilepsy Therapy Platform Blitz . . . . . . . . . . . . .108 Clinical Neurophysiology and Autonomic Nervous System . . . . . . . . . . . . . . . . . . . . . 36 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 Frontiers in Neuroscience Plenary Session . . . 36 Invited Science: Epilepsy . . . . . . . 119 Epilepsy Skills Pavilion Poster Session VII . . . . . . . . . . . . . . . . . . . .122 Epilepsy . . . . . . . . . . . . . . . . . . . . . . . . . . 37 Clinical EEG How to Analyze Spells by Video-EEG

General Neurology

$ C12 $ C14 $ C19 $ C25 F C171 $ C37 $ C38 $ C44 $ C61 $ C66 $ C68 $ C73 F P1 $ C87 $ C92 F P2 F F S9 $ C97 F $ C102 $ C103 F P4 F F S25 $ C109 42

Neurologic Complications of Medical Disease Advanced Neurologic Coding Mitochondrial Disorders in Neurology Cognitive Psychology of Neurologic Errors: Chalk Talk Opioids and Marijuana in Your Practice Neurology Update I Genetics in Neurology Practical Psychopharmacology for Neurologists Clinical E-pearls Multiple Sclerosis Overview I: Basic and Translational Science Neuroimaging for the General Neurologist: Brain Therapy in Neurology Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57 Hot Topics in Education Important Drug Interactions for Neurologists and Psychiatrists Poster Session II . . . . . . . . . . . . . . . . . . . . . 65 Presidential Plenary Session . . . . . . . . . . . . 33 General Neurology: Neurological Treatments and Therapeutics . . . . . . . 75 Neurologic Issues in Pregnancy Hot Topics Plenary Session . . . . . . . . . . . . . 34 Syndromes of Autonomic Dysfunction in Children and Adolescents Global Health Challenges: Neurology in Developing Countries Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 Contemporary Clinical Issues Plenary Session . 35 General Neurology . . . . . . . . . . . . . . . . . . . . 97 Functional Neurologic Disorders

A A

A

$ C119 $ C120 $ C124 F I11 F S52 F H16 F $ C129 $ C135 $ C138 $ C143 $ C149 $ C150 $ C158 $ C163 $ C168

ALS, and Aging Platform Blitz . . . . . . . . . . . . . .109 Women’s Issues in Neurology . . . . . . . . . . . . . . 36 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 Frontiers in Neuroscience Plenary Session . . . 36 Neuroepidemiology: Multiple Sclerosis, Cerebrovascular, and Aging . . . . . . . . . . . . . . . 119 Borderlands of Neurology and Internal Medicine: Chalk Talk Emergency Neurology Neuroimaging for the General Neurologist: Spine and Peripheral Nerve The Promise of Novel Biomarker Approaches in Advancing Treatment . . . . . . . . . . . . . . . . .120 General Neurology: Neural Networks and Neuromodulation . . . . . . . . . . . . . . . . . .133 Neuroendocrinology . . . . . . . . . . . . . . . . . . . 37 Controversies in Neurology Plenary Session . . 37 Test Your Knowledge: A Case-based Approach to Neuroimaging Neurotoxicology Continuum ® Test Your Knowledge: A Multiple-choice Question Review Neurology Update II Improving Accuracy of Dementia Diagnosis: Case Studies with Both Imaging and Neuropathology Principles of Genomic Medicine: Clinical Exome Sequencing in Neurologic Disease Neuro Flash: MRI and Multiple Sclerosis Autoimmune Neurology Controversies in Brain Death Determination

A C

A

Global Health and Infectious Disease

$ C28

S Infectious, Paraneoplastic, Autoimmune?

Diagnosis and Treatment of Rapidly Progressive Encephalopathies Infectious, Paraneoplastic, and Autoimmune F I4 Encephalopathies: Advances in Clinical Diagnosis and Emerging Insights about Pathogenesis . . . . . . . 52 $ C55 Neuro Flash: Approach to Acute CNS Infections $ C67 Infections of the Nervous System I: Common Infections C81 Infections of the Nervous System II: $ Advanced and Emerging Infections F P2 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65 F I7 The Global Burden of Neurological Infections: Epidemiology, Treatment, and Prevention . . . . . . . . 76

S




I = I Talk Session Meeting Attendee David B. Watson, MD Morgantown, WV

“I attended the Global Health Challenges: Neurology in Developing Countries. It was eye opening to learn about the global burden of disease and, specifically, the difficulties in treating epilepsy in developing countries. It won't affect my current practice, but reminds me of the need to think outside of the small world in which I practice. It also reignited an interest in participating in short-term medical mission work like I was able to do in medical school.”

$ C103 Global Health Challenges: $ C110 F S37 F H3 F P6 $ C133

Neurology in Developing Countries Differential Diagnosis of Neurologic Infections Global Health and Infectious Disease Platform Blitz . 109 Global Health . . . . . . . . . . . . . . . . . . . . . . . 36 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 The Interface Between Infection and Cerebrovascular Disease

Headache

$ C21 $ C42 $ C46 $ C69 F P1 F P3 F F S23 F I12 F S51 F H17 $ C152 $ C164

Challenging Headache Cases Therapy of Headache Hot Topics in Headaches and Related Disorders Introduction to Primary Headache Disorders Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78 Contemporary Clinical Issues Plenary Session . . 35 Headache: Imaging and Physiology . . . . . . . . . . . 96 Obesity and Neurological Disorders . . . . . . . . . . 121 Headache: Epidemiology and Clinical . . . . . . . . . .133 Headache and Facial Pain . . . . . . . . . . . . . . . . 37 The Intractable Headache Patient Chronic Migraine Education Program


Movement Disorders

$ C3 Deep Brain Stimulation Management $ C18 Therapy of Movement Disorders:

A Case-based Approach C24 Balance and Gait Disorders $ Dopamine-mediated Neural Plasticity F I3 in Motor and Non-motor Circuits . . . . . . . . . . . . 50 Dopaminergic and Nondopaminergic $ C52 Influences on the Changing Landscape of Parkinson’s Disease $ C54 Cognitive-motor Disorders: Chalk Talk $ C65 Botulinum Toxins: Practical Issues and Clinical Uses for Neurologists $ C77 Update on Ataxias F S2 Section Topic Controversies: Testing in Prodromal Neurological Disease: Friend or Foe? . . . . 54 $ C79 Overview of Parkinson’s Disease and Movement Disorders $ C85 Clinical Usefulness of Botulinum Toxin and Treatment of Dystonia Skills Pavilion F P1 Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57 $ C90 Approach to the Shaky Patient F P2 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65 Presidential Plenary Session . . . . . . . . . . . . 33 F S7 Movement Disorders: Genetics . . . . . . . . . . . . . 74 F F P3 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78 F S15 Movement Disorders: Huntington’s Disease, Dystonia, and Atypical Parkinsonism . . . . . . . . . . 86 $ C101 Hyperkinetic Movement Disorders: Diagnosis and Treatment F P4 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 The Dynamic Brain in Health and Disease: Plasticity F I10 and Reprogramming . . . . . . . . . . . . . . . . . . . 99 F P5 Poster Session V . . . . . . . . . . . . . . . . . . . . .100 F S32 Movement Disorders: Tremor, Ataxia, and More Platform Blitz . . . . . . . . . . . . . . . . . . . 108 F H2 Movement Disorders . . . . . . . . . . . . . . . . . . 36 F P6 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 Frontiers in Neuroscience Plenary Session . . . 36 F F S40 Movement Disorders: Functional Imaging in Parkinson’s Disease . . . . . . . . . . . . . . . . . . 118 The Promise of Novel Biomarker Approaches F I11 in Advancing Treatment . . . . . . . . . . . . . . . . .120 F P7 Poster Session VII . . . . . . . . . . . . . . . . . . . .122 F S48 Parkinson’s Disease . . . . . . . . . . . . . . . . . . .132 $ C127 Case Studies: Unusual Movement Disorders $ C131 Neuro Flash: Child Neurology

S S

C

C

43

Annual Meeting Programs by Topic $ C134 The Dystonias: Diagnosis, Treatment,

and Update on Causes $ C141 Movement Disorders Neurology Year in Review Plenary Session . . . 39 F C157 Paroxysmal Movement Disorders $ $ C162 Nonmotor Manifestations of Parkinson Disease MS and CNS Inflammatory Disease

$ C4 $ C27 $ C51 $ C66 $ C80 F P1 $ C88 F P2 F F S4 F P3 F S12 F F P4 F S20 F P5 F S29 F H5 F P6 F F S38 F I11 F P7 F S46 $ C128 $ C137 F $ C151 F $ C158 $ C169

Neuromyelitis Optica: Scientific and Clinical Update Controversies in Multiple Sclerosis Therapy Diagnostic Dilemmas in Multiple Sclerosis Multiple Sclerosis Overview I: Basic and Translational Science Multiple Sclerosis Overview II: Clinical Advances Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57 Morning Report: Multiple Sclerosis Poster Session II . . . . . . . . . . . . . . . . . . . . . 65 Presidential Plenary Session . . . . . . . . . . . . 33 Clinical Trial Outcomes in Multiple Sclerosis . . . . . . 74 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78 Neuroimmune Mechanisms in Multiple Sclerosis . . . 86 Hot Topics Plenary Session . . . . . . . . . . . . . 34 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 Treatment Mechanisms in Multiple Sclerosis . . . . . 96 Poster Session V . . . . . . . . . . . . . . . . . . . . .100 Neuroimaging Correlates in Multiple Sclerosis Platform Blitz . . . . . . . . . . . . 108 Multiple Sclerosis . . . . . . . . . . . . . . . . . . . . 36 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 Frontiers in Neuroscience Plenary Session . . . 36 Diet and Hormonal Factors in Multiple Sclerosis . . . 118 The Promise of Novel Biomarker Approaches in Advancing Treatment . . . . . . . . . . . . . . . . .120 Poster Session VII . . . . . . . . . . . . . . . . . . . .122 Neuromyelitis Optica . . . . . . . . . . . . . . . . . . 132 Case Studies: Multiple Sclerosis Multiple Sclerosis Therapy I: Symptom Management Clinical Trials Plenary Session . . . . . . . . . . . 38 Multiple Sclerosis Therapy II: Disease-modifying Treatment Neurology Year in Review Plenary Session . . . 39 Neuro Flash: MRI and Multiple Sclerosis Multiple Sclerosis Essentials

C

Neuro Trauma, Critical Care, and Sports Neurology

$ C10 $ C15 $ C31 $ C47 F I5 $ C82 $ C83 $ C95 F S27 F H6 F H11 $ C120 F P7 $ C145 $ C165

S S

Neuromuscular and Clinical Neurophysiology (EMG)

$ C2 $ C11 $ C36 $ C40 $ C64 $ C78 F P1 F P2 $ C96 F I8 F P3 F S17 F F P4 F S24 $ C111 F P5 F S34 F H7 F H8 F P6

44

Critical Care EEG Monitoring Severe TBI: From ICU to Rehabilitation Sports Concussion and Other Mild Concussive Injuries Sports Neurology: Non-concussion Overview Pediatric Neurotrauma: From Coma to Concussions . . . . . . . . . . . . . . . 53 Emergency Room Neuro-ophthalmology Concussion Assessment and Management in the Youth Athlete Sports Concussion Skills Pavilion Neuro Trauma, Critical Care, and Sports Neurology . . 97 Sports Neurology . . . . . . . . . . . . . . . . . . . . 36 Critical Care and Emergency Neurology . . . . . . . . 36 Emergency Neurology Poster Session VII . . . . . . . . . . . . . . . . . . . .122 Neurologic Intensive Care Consultations in the Medical Surgical ICU

Small Fiber Neuropathies: Sensory, Autonomic and Both Neuromuscular Junction Disorders Peripheral Neuropathy You Make the Call—an Interactive, Multimedia, Case-based Approach to Learning EMG Clinical EMG I Clinical EMG II Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57 Poster Session II . . . . . . . . . . . . . . . . . . . . . 65 Evaluation and Management of Autonomic Disorders Advances in ALS and Other Motor Neuron Diseases . . 77 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78 Muscle and Anterior Horn Cell Diseases: Mechanisms and Biomarkers . . . . . . . . . . . . . . 87 Hot Topics Plenary Session . . . . . . . . . . . . . 34 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 ALS: Mechanisms and Biomarkers . . . . . . . . . . . 96 Neuromuscular Ultrasound Skills Pavilion Poster Session V . . . . . . . . . . . . . . . . . . . . .100 Neuromuscular Update Platform Blitz . . . . . . . . . 109 Neuromuscular . . . . . . . . . . . . . . . . . . . . . . 36 Clinical Neurophysiology and Autonomic Nervous System . . . . . . . . . . . . . . . . . . . . . 36 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110




I = I Talk Session Frontiers in Neuroscience Plenary Session . . . 36 F F S42 New Developments in Peripheral Neuropathies . . . . 118 $ C123 Neuromuscular Bedside Rounds Skills Pavilion F I11 C The Promise of Novel Biomarker Approaches

$ C45 $ C82 F P1 $ C89

F P7 F S50 $ C126

$ C99

$ C147 F $ C148 $ C161

in Advancing Treatment . . . . . . . . . . . . . . . . .120 Poster Session VII . . . . . . . . . . . . . . . . . . . .122 Treatment Trials in Neuromuscular Diseases . . . . . 132 Case Studies: Unusual Diagnostic and Management of Cases in Neuromuscular Disease EMG Skills Workshop: Basic Clinical Trials Plenary Session . . . . . . . . . . . 38 Therapy of Neuromuscular Disease Clinical Approach to Muscle Disease

Neuro-oncology

$ C23 Neuro-oncologic Emergencies $ C28 S Infectious, Paraneoplastic, Autoimmune? F I4 $ C71 $ C84 F S3 F P3 F S18 F P4 F I10 F H9 F S43 F I11 $ C130 F

Diagnosis and Treatment of Rapidly Progressive Encephalopathies Infectious, Paraneoplastic, and Autoimmune Encephalopathies: Advances in Clinical Diagnosis and Emerging Insights about Pathogenesis . . . . . . . 52 Neuro-oncology: Primary Brain Tumors Neurologic Complications of Systemic Cancer Section Topic Controversies: Should All Brain Tumor Patients Receive Prophylactic Antiepileptic Drugs? . . 73 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78 Neuro-oncology: Imaging and Quality of Life . . . . . . 87 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 The Dynamic Brain in Health and Disease: Plasticity and Reprogramming . . . . . . . . . . . . . . 99 Neuro-oncology . . . . . . . . . . . . . . . . . . . . . 36 Neuro-oncology: Basic Science and Clinical Trials . . . 119 The Promise of Novel Biomarker Approaches in Advancing Treatment . . . . . . . . . . . . . . . . .120 Case Studies: Neurologic Consultations in Cancer Patients Neurology Year in Review Plenary Session . . . 39

S

Neuro-rehabilitation

$ C15 Severe TBI: From ICU to Rehabilitation $ C93 Brain Computer Interfaces: Frontiers in $ C98 F S28 F I10 F P5 $ C115

C C

Neuro-ophthalmology/Neuro-otology

F I1

$ C104 F S26 F P5 $ C113 F I12 F H13 $ C144 F $ C159

S New Windows into the Brain:

Technological Advances in Frontline Neurologic Diagnosis via the Visual and Oculomotor Systems . . . 48 Pitfalls and Pearls: Avoiding Common $ C16 Diagnostic Errors in Neuro-ophthalmology & Neuro-otology $ C20 Canalith Repositioning for Benign Paroxysmal Positional Vertigo

S


Neuro-otology Emergency Room Neuro-ophthalmology Poster Session I . . . . . . . . . . . . . . . . . . . . . . 57 Now You See It, Now You Know It— Pathognomonic Neuro-ophthalmology Findings Neuro-ophthalmology and Neurovestibular Exam Lab Skills Pavilion Pseudotumor Cerebri Neuro-ophthalmology/Neuro-otology . . . . . . . . . . 97 Poster Session V . . . . . . . . . . . . . . . . . . . . .100 Neuro Flash: Neuro-ophthalmology Obesity and Neurological Disorders . . . . . . . . . . 121 Neuro-ophthalmology and Neuro-otology . . . . . . . 37 Neuro-ophthalmology Neurology Year in Review Plenary Session . . . 39 Eye Movement Disorders: A Systematic Approach to the Evaluation of Diplopia

F P7 F H14 $ C146 F $ C155

Neurology and Neuroscience Myelopathies Neuro-rehabilitation . . . . . . . . . . . . . . . . . . . 97 The Dynamic Brain in Health and Disease: Plasticity and Reprogramming . . . . . . . . . . . . . . 99 Poster Session V . . . . . . . . . . . . . . . . . . . . .100 Morning Report: Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Post-laminectomy Syndrome Poster Session VII . . . . . . . . . . . . . . . . . . . .122 Neural Repair and Rehabilitation . . . . . . . . . . . . 37 Spine Neurology: Assessment and Management of Common Spine Disorders Neurology Year in Review Plenary Session . . . 39 Physical Exercise and Cognitive Training in Neurological Disorders

C

Pain and Palliative Care

$ C53 F S10 F P3 F $ C115

Palliative Care for the Practicing Neurologist Pain and Palliative Care . . . . . . . . . . . . . . . . . 75 Poster Session III . . . . . . . . . . . . . . . . . . . . . 78 Contemporary Clinical Issues Plenary Session . 35 Morning Report: Lumbar Radiculopathy, Lumbar Spinal Stenosis, Low Back Pain, and Post-laminectomy Syndrome

45

Annual Meeting Programs by Topic $ C121 Core Concepts in Pain Management Controversies in Neurology Plenary Session . . 37 F $ C146 Spine Neurology: Assessment and Management of Common Spine Disorders

$ C8 $ C14 $ C26 $ C32 F C171 C39 F C43

$ C48 $ C53 F C59 F C60 $ C70 C76 $ C86

F F C174 F S11 $ C105 F P7 $ C153 $ C168

46

The Practice of Neurology: Issues in Coding and Reimbursement Clerkship and Program Directors Conference Advanced Neurologic Coding Controversies in Neuroethics Teleneurology and Technologies Opioids and Marijuana in Your Practice Leadership for Women (must apply) Advanced Practice Provider Symposium (registration required) How to Run a Practice: Business Strategies for Neurology Private Practices, Academic Centers, and the Future Palliative Care for the Practicing Neurologist Leadership in Neurology: Be a Champion for Your Patients and Protector of Your Specialty with Payers, Policymakers, and the Public Resident and Fellow Career Breakfast: The Early Years (registration required) Bedside Evidence-based Medicine: How to Find and Deconstruct Articles in Order to Take Care of Patients Advanced Leadership for Women (must apply) Improving Your Leadership Skills: A Practical Approach I Hot Topics in Education: The Value of a Neurologist . . . . . . . . . . . . . . . . 22 All You Need to Know About Health Information Technology to Avoid Taking a HIT Practice, Policy, and Ethics . . . . . . . . . . . . . . . . 75 Neurohospitalist 2.0: Next Steps in the Evolution Poster Session VII . . . . . . . . . . . . . . . . . . . .122 Practical Legal Issues for Neurologists Controversies in Brain Death Determination

L

A

L L

$ C5 $ C9

A Resident Basic Science I: Neuropathology C Research Career Development Symposium:

How to Be Successful in Academic Neuroscience C13 Resident Basic Science II: Neuroanatomy $ $ C25 Cognitive Psychology of Neurologic Errors: Chalk Talk Resident Basic Science III: Neuropharmacology $ C30 Clinical Research: Introduction and Methods F C170 C39 Leadership for Women (must apply) Clinical Research: F C172 Drug Development and Clinical Trials $ C58 Neurological Disorders of Famous Composers F C173 Clinical Reasoning: From a Novice to an Expert C76 Advanced Leadership for Women (must apply) Improving Your Leadership Skills: $ C86 A Practical Approach F C175 Qualitative Research: The “How” and “Why” of Education $ C91 Career Development for Clinician Educators F S19 Neurologic Education . . . . . . . . . . . . . . . . . . . 87 F P4 Poster Session IV . . . . . . . . . . . . . . . . . . . . . 88 $ C107 History of Neurology: The History of Neurologic Disease from Cortex to Peripheral Nerve F P6 Poster Session VI . . . . . . . . . . . . . . . . . . . . 110 F S44 History of Neurology . . . . . . . . . . . . . . . . . . . 119 The Promise of Novel Biomarker F I11 Approaches in Advancing Treatment . . . . . . . . . .120

A

Practice, Policy, and Ethics

$ C6

Research Methodology, Education, and History

A C

L

C

L L

C

Sleep

$ C33 Hot Topics in Sleep Neurology $ C49 Approach to Sleep Symptoms: Sleepy or Sleepless $ C62 Interpretation of Polysomnography for F S2 F H1 $ C117 F I12 F P7 F S53 $ C140 $ C156

the Practicing Neurologist Section Topic Controversies: Testing in Prodromal Neurological Disease: Friend or Foe? . . . . . . . . . . 54 Sleep . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 REM Sleep Behavior Disorder Obesity and Neurological Disorders . . . . . . . . . . 121 Poster Session VII . . . . . . . . . . . . . . . . . . . .122 Sleep . . . . . . . . . . . . . . . . . . . . . . . . . . .133 Sleep for the Practicing Neurologist Neuro Flash: Sleep Medicine


Capitol City CELEBRATION Sunday, April 19 6:OO p.m.–1O:OO p.m. Join your friends and colleagues for an exciting evening filled with entertainment, including:

Neurobowl®

6:OO p.m.–8:OO p.m.

This popular event is one of the Annual Meeting’s premier happenings. Neurobowl® showcases the best and brightest in neurology competing for the coveted Neurobowl® trophy in an entertaining game-show format.

Main Stage Music: Doctor’s Orders 8:OO p.m.–1O:OO p.m.

This energetic 10-piece variety band based in the Washington, DC/Baltimore area will have you on your feet with its diverse repertoire covering everything from Top 40 to ‘70s to ‘80s to standards. Fronted by dynamic singer/saxophonist Kyle Johnson and Miriamm Wright— of Peaches and Herb fame—”the chemistry of the band is obvious from the first chord,” says guitarist Bill McCarron. “It’s not like it’s really a conscious effort on our part, we just have a blast playing together.” No doubt, you’ll have a blast listening to them.

Neuro Jazz

8:3O p.m.–9:3O p.m.

Swing out to your favorite jazz standards while enjoying a scrumptious dessert. This four-piece ensemble, led by AAN member Phillip Pearl, MD, FAAN, will have your toes tapping and fingers snapping to some of the most enduring tunes of our time.

Integrated Neuroscience Session I1

S New Windows into the Brain:

Saturday, April 18 8:00 a.m.–12:00 p.m.

Technological Advances in Frontline Neurologic Diagnosis via the Visual and Oculomotor Systems This program is offered in partnership with the North American Neuro-ophthalmology Society and the AAN Neuro-ophthalmology/Neuro-otology Section.

Coordinators: Kevin A. Kerber, MD, and Beau Bruce, MD Part I

8:00 a.m.–9:45 a.m.

8:00 a.m.–8:05 a.m.

Introduction

8:05 a.m.–8:35 a.m.

Invited Speaker

8:35 a.m.–8:40 a.m.

I1-1A Data Blitz

9:55 a.m.–10:25 a.m.

Kevin A. Kerber, MD, and Beau Bruce, MD

Retinal Microvascular Signs and Age-related Macular Degeneration Are Associated with Incident Cerebral Microbleeds According to Location in Older People: The AGES-Reykjavik Study Jie Ding, Chengxuan Qiu, Sigurdur Sigurdsson, Qian Zhang, Gudny Eiriksdottir, Vilmundur Gudnason, Mark Van Buchem, Mary Frances Cotch, Lenore Launer

Audience Q&A Invited Speaker

Stop Radiating and Start Re-Positioning: Implementing Optimal Management of BPPV Kevin A. Kerber, MD

9:25 a.m.–9:30 a.m.

Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit James Grotta

10:30 a.m.–10:35 a.m. I1-3B Data Blitz

Early Diagnosis of Posterior Fossa Stroke with Brainstem Evoked Potentials Iftekhar Ahmed, Nikki Duggal, Neeta Duggal

10:35 a.m.–10:45 a.m. Audience Q&A 10:45 a.m.–11:15 a.m. Invited Speaker

The Future of Sideline Assessment: Tackling Concussion and TBI Right Between the Eyes Laura J. Balcer, MD, MSCE, FAAN

11:15 a.m.–11:20 a.m. I1-4A Data Blitz

Sideline Testing in Youth and Collegiate Athletes: What Does Vision Add to the Concussion Puzzle? Avri Bohm, Lisena Hasanaj, John-Ross Rizzo, Liliana Serrano, Rachel Nolan, Nicholas Moehringer, Nikki Webb, Courtney Civitano, Dennis Cardone, Arlene Silverio, Steven Galetta, Laura Balcer


A Systematic Video Analysis of Concussion in the National Rugby League Andrew Gardner, Grant Iverson, Magdalena Wojtowicz, Christopher Levi, Michael Makdissi, Tanya Quinn, Sandy Shultz, David Wright, Peter Stanwell

I1-2A Data Blitz

Comparative Study Between Benign Paroxysmal Positional Vertigo (BPPV) of the Horizontal Canal (H-BPPV) and Posterior Canal (P-BPPV) Ana Bisonni, Guillermo Videla, Juan Ignacio Rojas, Edgardo Cristiano

9:30 a.m.–9:35 a.m.

I1-2B Data Blitz

9:35 a.m.–9:45 a.m. 9:45 a.m.–9:55 a.m.

Audience Q&A Break

Invited Speaker


I1-1B Data Blitz

Molecular Imaging of the Human Retina by Raman Spectroscopy Elena Martinez-Lapiscina, Oscar Batet, Antoni Gonzalez, Albert Campos, Iker Bilbao, Dídac Perez, Elena Fraga-Pumar, Rubén Torres-Torres, Yago Rossello, Bernardo Sanchez-Dalmau, Ivan Amat-Roldan, Pablo Villoslada

8:45 a.m.–8:55 a.m. 8:55 a.m.–9:25 a.m.

9:55 a.m.–11:35 a.m.

In Pursuit of the ‘Eye ECG’: Eye Movement Based Stroke Diagnosis in Acute Vertigo David E. Newman-Toker, MD, PhD, FAAN

Windows to the Brain: Non-mydriatic Ocular Fundus Photography in Neurological Emergencies Beau Bruce, MD

8:40 a.m.–8:45 a.m.

Part II

11:25 a.m.–11:35 a.m. Audience Q&A

NIH Stroke Scale Assessment via Tablet-based Mobile Telestroke During Ambulance Transport Is Feasible—Pilot Data from the Improving Treatment with Rapid Evaluation of Acute Stroke via Mobile Telemedecine (iTREAT) Study Matthew Padrick, Sherita Chapman, Timothy McMurri, Prachi Mehndiratta, Christina Chee, Brian Gunnell, Chance Kimble, Jack Cote, Jason Lippman, Virginia Burke, David Catell-Gordon, Karen Rheuban, Nina Solenski, Debra Perina, Bradford Worrall, Andrew Southerland

Guided Poster Rounds I1-5A

Retinal Segmentation Distinguishes Neuromyelitis Optica from Multiple Sclerosis Using Optical Coherence Tomography Regardless of Antibody Status Richard Loeb, Ashley Finch, Adil Javed, Jacqueline Bernard

I1-5B

A Radiographic Target Sign for Abnormal Vertebral Artery Flow in Stroke Patients with Acute Vestibular Syndrome Jorge Kattah, Jeffrey DeSanto, Ali Saber Tehrani, John Pula, David Newman-Toker

11:35 a.m.–12:00 p.m. Nunley, Christopher Ryan, Judith Saxton, Trevor Orchard, Tina Costacou, Howard Aizenstein, John Ryan, Rachel Miller, Caterina Rosano

Campos, Iker Bilbao, Dídac Perez, Elena Fraga-Pumar, Rubén Torres-Torres, Yago Rossello, Bernardo Sanchez-Dalmau, Ivan Amat-Roldan, Pablo Villoslada

I1-5E

I1-5H

Quix Test Predicts Canal Sidedness in BPPV Kevin Coughlin, Krysten Sherrod, Jason Miles, Ryan Fitzgerald, Garrett Barr, Jonathan Salud, Shawn Adams, Charles Maitland

I1-5F

Determining Inter-rater Reliability of Eye Tracking Methods for Use with Persons with Severe Traumatic Brain Injury Lorene Leung, Rachel Cohn, Therese O'Neil-Pirozzi, Yelena Guller, Swathi Iyer, Hong Pan, Emily Stern, Joseph Giacino

Retinal Microvascular Signs and Age-related Macular Degeneration Are Associated with Incident Cerebral Microbleeds According to Location in Older People: The AGES-Reykjavik Study Jie Ding, Chengxuan Qiu, Sigurdur Sigurdsson, Qian Zhang, Gudny Eiriksdottir, Vilmundur Gudnason, Mark Van Buchem, Mary Frances Cotch, Lenore Launer

I1-5D

I1-5G

I1-5C

Early Development of Proliferative Retinopathy Increases Risk of Cognitive Dysfunction in Middle-aged Adults with Type 1 Diabetes Karen

48

Molecular Imaging of the human Retina by Raman Spectroscopy Elena Martinez-Lapiscina, Oscar Batet, Antoni Gonzalez, Albert

Comparative Study Between Benign Paroxysmal Positional Vertigo (BPPV) of the Horizontal Canal (H-BPPV) and Posterior Canal (P-BPPV) Ana Bisonni, Guillermo Videla, Juan Ignacio Rojas, Edgardo Cristiano

I1-5I

NIH Stroke Scale Assessment via Tablet-based Mobile Telestroke During Ambulance Transport Is Feasible—Pilot Data from the Improving Treatment with Rapid Evaluation of Acute Stroke via Mobile Telemedecine (iTREAT) study Matthew Padrick, Sherita Chapman, Timothy McMurry, Prachi Mehndiratta, Christina Chee, Brian Gunnell, Chance Kimble, Jack Cote, Jason Lippman, Virginia Burke, David Catell-Gordon, Karen Rheuban, Nina Solenski, Debra Perina, Bradford Worrall, Andrew Southerland

I1-5J

Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit James Grotta

I1-5K

Early Diagnosis of Posterior Fossa Stroke with Brainstem Evoked Potentials Nikki Duggal, Iftekhar Ahmed, Neeta Duggal

I1-5L

Sideline Testing in Youth and Collegiate Athletes: What Does Vision Add to the Concussion Puzzle? Avri Bohm, Lisena Hasanaj, John-Ross Rizzo, Liliana Serrano, Rachel Nolan, Nicholas Moehringer, Nikki Webb, Courtney Civitano, Dennis Cardone, Arlene Silverio, Steven Galetta, Laura Balcer

I1-5M



I2

S Management of Asymptomatic

1:00 p.m.–5:00 p.m.

Cerebrovascular Lesions

This program is offered in partnership with the American Heart Association/American Stoke Association and the AAN Stroke and Vascular Neurology Section. Coordinators: Robert D. Brown, MD, FAAN, and J. P. Mohr, MD, FAAN Part I

1:00 p.m.–2:45 p.m.

1:00 p.m.–1:05 p.m.

Introduction

1:05 p.m.–1:35 p.m.

Invited Speaker

Antonio Culebras, MD, FAAN, FAHA

Asymptomatic Carotid Disease: Uncertainties in Management and Future Directions in Research. CREST -2 Visited James F. Meschia, MD, FAAN

1:35 p.m.–1:40 p.m.

I2-1A Data Blitz

1:40 p.m.–1:45 p.m.

I2-1B Data Blitz

Are Patients with Carotid Stenosis Receiving Optimal Medical Therapy? Sebastian Koch, Seemant Chaturvedi, Jose Romano Cognitive Implications of Revascularization in Asymptomatic Carotid Stenosis Chun-Jen Lin, Feng-Chi Chang, Pei-Chi Tu, Pei-Ning Wang, I-Hui Lee

1:45 p.m.–1:55 p.m.

Audience Q&A

1:55 p.m.–2:25 p.m.

Invited Speaker

2:25 p.m.–2:30 p.m.

I2-2A Data Blitz

2:30 p.m.–2:35 p.m.

I2-2B Data Blitz

2:35 p.m.–2:45 p.m.

Audience Q&A

2:45 p.m.–2:55 p.m.

Break

Intracranial Cavernous Malformations: Natural History, Genetics, Management, and Future Directions in Research Michael Lawton, MD Angiographically Occult Micro-arteriovenous Malformation as a Rare Cause of Recurrent Intracerebral Hemorrhage Anand Patel, Ajay Tunguturi, Ajit Puri, Majaz Moonis Exceptional Aggressiveness of Cerebral Cavernous Malformation Disease Associated with PDCD10 Mutations Tania Rebeiz, Abdul Ghani Mikati, Amy Akers, Lingiioa Zhang, Issam Awad

Part II

2:55 p.m.–4:35 p.m.

2:55 p.m.–3:25 p.m.

Invited Speaker

3:25 p.m.–3:30 p.m.

I2-3A Data Blitz

3:30 p.m.–3:35 p.m.

I2-3B Data Blitz

3:35 p.m.–3:45 p.m.

Audience Q&A

3:45 p.m.–4:15 p.m.

Invited Speaker

4:15 p.m.–4:20 p.m.

I2-4A Data Blitz

4:20 p.m.–4:25 p.m.

I2-4B Data Blitz

4:25 p.m.–4:35 p.m.

Audience Q&A

Unruptured Brain Arteriovenous Malformations: Management, Controversies, and Future Directions in Research. The ARUBA Experience J. P. Mohr, MD, FAAN Predictors of Seizure Presentation Associated with Cerebral Arteriovenous Malformations in a Prospective Cohort of 1,007 Patients Dale Ding, Robert Starke, Mark Quigg, Chun-Po Yen, Colin Przybylowski, Blair Dodson, Jason Sheehan Withdrawn

Unruptured Intracranial Aneurysms: Uncertainties in Management and Future Directions in Research Robert D. Brown, MD, FAAN Prevalence of Asymptomatic Cerebral Aneurysm in General Population and Ischemic Stroke Patient Ji Hwa Kim, Yeo-Jin Oh, Sang Won Han, Jong Yun Lee, Kyung-Yul Lee Impact of Menopausal Age on Size of Unruptured Intracranial Aneurysms and Their Outcomes with Endovascular Therapy Sushrut Dharmadhikari, Kunakorn Atchaneeyasakul, Norman Ajiboye, Sudheer Ambekar, Dileep Yavagal


Prevalence and Healing Rates of Duplex Detected Carotid Plaque Ulcers Sushrut Dharmadhikari, Ari Bennett, Jose Romano, Nelly Campo, Sebastian Koch

I2-5B Coated-platelet

Levels Are Associated with Stenosis Progression in Patients with Carotid Atherosclerosis Angelia Kirkpatrick, Andrea Vincent, Nhan Nguyen, George Dale, Calin Prodan

I2-5C

A Population-based Study of the Incidence and Case Fatality of Intracerebral Hemorrhage of Undetermined Etiology Afzal Mohammad, Mushtaq Qureshi, Ahmed Malik, Mariam Suri, Muhammad Suri, Adnan Qureshi

4:35 p.m.–5:00 p.m. I2-5D

Accurate Outcome Predictions for Intracerebral Hemorrhage Patients Are More Likely Than Inaccurate Predictions to be Influenced by Comorbidities Not Included in Clinical Scales David Hwang, Cameron Dell, Mary Sparks, Tiffany Watson, Carl Langefeld, Mary Comeau, Jonathan Rosand, Thomas Battey, Sebastian Koch, Mario Perez, Michael James, Jessica McFarlin, Jennifer Osborne, Daniel Woo, Steven Kittner, Kevin Sheth

I2-5E

Patients Consenting to or Declining Extended Follow-up (Up to Ten Years) in the Carotid Revascularization Endarterectomy (CEA) versus Stenting (CAS) Trial (CREST) Alice Sheffet, Ariane Mackey, William Brooks, Wayne Clark, Michael Hill, Jenifer Voeks, Susan Hughes, MeeLee Tom, Mary Longbottom, Virginia Howard, Thomas Brott


I2-5F

Are patients with Carotid Stenosis Receiving Optimal Medical Therapy? Sebastian Koch, Seemant Chaturvedi, Jose Romano

I2-5G

Cognitive Implications of Revascularization in Asymptomatic Carotid Stenosis Chun-Jen Lin, Feng-Chi Chang, Pei-Chi Tu, Pei-Ning Wang, I-Hui Lee

I2-5H

Angiographically Occult Micro-arteriovenous Malformation as a Rare Cause of Recurrent Intracerebral Hemorrhage Anand Patel, Ajay Tunguturi, Ajit Puri, Majaz Moonis

I2-5I

Exceptional Aggressiveness of Cerebral Cavernous Malformation Disease Associated with PDCD10 Mutations Tania Rebeiz, Abdul Ghani Mikati, Amy Akers, Lingiioa Zhang, Issam Awad

I2-5J

Predictors of Seizure Presentation Associated with Cerebral Arteriovenous Malformations in a Prospective Cohort of 1,007 Patients Dale Ding, Robert Starke, Mark Quigg, Chun-Po Yen, Colin Przybylowski, Blair Dodson, Jason Sheehan

I2-5K Withdrawn I2-5L

Prevalence of Asymptomatic Cerebral Aneurysm in General Population and Ischemic Stroke Patient Ji Hwa Kim, Yeo-Jin Oh, Sang Won Han, Jong Yun Lee, Kyung-Yul Lee

I2-5M

Impact of Menopausal age on Size of Unruptured Intracranial Aneurysms and Their Outcomes with Endovascular Therapy Sushrut Dharmadhikari, Kunakorn Atchaneeyasakul, Norman Ajiboye, Sudheer Ambekar, Dileep Yavagal

49

Saturday April 18

Integrated Neuroscience Session


S Dopamine-mediated Neural Plasticity in

Sunday, April 19 8:00 a.m.–12:00 p.m.

Motor and Non-motor Circuits

This program is offered in partnership with the International Parkinson and Movement Disorders Society and the AAN Movement Disorders Section. Coordinators: Irene Litvan, MD, FAAN, and David G. Standaert, MD, PhD, FAAN Part I

8:00 a.m.–9:45 a.m.

8:00 a.m.–8:05 a.m.

Introduction

8:05 a.m.–8:35 a.m.

Invited Speaker

9:55 a.m.–10:25 a.m.

Irene Litvan, MD, FAAN, and David G. Standaert, MD, PhD, FAAN

I3-1A Data Blitz

I3-1B Data Blitz

Parkinson’s Disease Progression Is Associated with Increased Putaminal Serotonin to Dopamine Transporter Ratio: Relevance for Dyskinesias Andreas Roussakis, Marios Politis, David Towey, Paola Piccini

8:45 a.m.–8:55 a.m.

Audience Q&A

8:55 a.m.–9:25 a.m.

Invited Speaker

I3-2B Data Blitz

Brain Structural and Functional Abnormalities in Parkinson’s Disease Patients with Freezing of Gait Elisabetta Sarasso, Federica Agosta, Elisa Canu, Maria Antonietta Volontè, Lidia Sarro, Sebastiano Galantucci, Roberto Gatti, Andrea Falini, Giancarlo Comi, Massimo Filippi

Audience Q&A

9:45 a.m.–9:55 a.m.

Break

Global Long-term Registry on Efficacy and Safety of Levodopa-carbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease in Routine Care (GLORIA)—Interim Results on Non-motor Symptoms Angelo Antonini, K. Ray Chaudhuri, Ashley Yegin, Lars Bergmann, Werner Poewe


Resting Connectivity Functional MRI in Understanding Cognitive Impairment in Parkinson's Disease Nina Browner

I3-2A Data Blitz

9:35 a.m.–9:45 a.m.



Reorganization of Cortico-striatal Circuits in Healthy G2019S LRRK2 Carriers Rick Helmich, Avner Thaler, Bart van Nuenen, Tanya Gurevich, Anat Mirelman, Karen Marder, Susan Bressman, Avi Orr-Urtreger, Nir Giladi, Bastiaan Bloem, Ivan Toni

9:30 a.m.–9:35 a.m.

Neuroanatomical Correlates of Cognitive Functioning Across the Parkinson's Disease Cognitive Spectrum Doug Merkitch, Glenn Stebbins, Bryan Bernard, Jennifer Goldman

Dopamine-dependent Systems and Their Behavioral Consequences in Parkinson's Disease: Functional Imaging Studies James Rowe, BA, BM, BCh, PhD

Cellular Mechanisms and Circuitry Involved in Dopamine-dependent Plasticity Alexandra Nelson, MD, PhD

9:25 a.m.–9:30 a.m.

Invited Speaker


Putaminal Dopamine Turnover Predicts Levodopa-induced Motor Complications in De Novo Parkinson’s Disease Matthias Löhle, Julia Mende, Martin Wolz, Bettina Beuthien-Baumann, Liane Oehme, Jörg van den Hoff, Jörg Kotzerke, Heinz Reichmann, Alexander Storch

8:40 a.m.–8:45 a.m.

9:55 a.m.–11:35 a.m.

Non-motor Aspects of Dopamine-dependent Plasticity in Parkinson’s Disease Daniel Weintraub, MD

Cellular Mechanisms of Striatal Plasticity in Movement Disorders David G. Standaert, MD, PhD, FAAN

8:35 a.m.–8:40 a.m.

Part II


Impulse Control Disorders Are Associated with REM Sleep Behavior Disorder in Patients with Parkinson’s Disease: A Video-polysomnographic Study Maria Livia Fantini, Maurizio Zibetti, Michela Figorilli, Beudin Patricia, Ana Marques, Debilly Bérangère, Derost Philippe, Miguel Ulla, Nicolas Vitello, Tiphaine Vidal, Monica Puligheddu, Alessandro Cicolin, Leonardo Lopiano, Franck Durif



De-novo Amantadine Treatment Delays Onset of Dyskinesias in Patients with Parkinson Disease Maja Relja

I3-5B

Self-ratings of Impulsive and Compulsive Behaviors Decrease in Parkinson’s Patients Following Deep Brain Stimulation of the Subthalamic Nucleus Katherine Kudyba Morone, Wylie Scott, Daniel Claassen, Nelleke Van Wouwe, Kristen Kanoff, Olivia Roman, Lauren Griffin, Joseph Neimat

I3-5C

Learning Processes in Parkinson’s Disease and Healthy Aging Madeleine Sharp, Karin Foerde, Nathaniel Daw, Daphna Shohamy

I3-5D

Effects of Aerobic Exercise on Striatum and Substantia Nigra in Parkinson’s Disease Ergun Uc, Vincent Magnotta, Hans Johnson, Kasra Zarei, Martin Cassell, Joel Bruss, Kevin Doerschug, Teri Thomsen, Joel Kline, Steven Anderson, Matthew Rizzo, Arthur Kramer, Michelle Voss, Jeffrey Dawson, Warren Darling

50

11:35 a.m.–12:00 p.m. I3-5E

Incidence of Impulsive and Compulsive Behavior Type Adverse Events with Long-term Rotigotine: A Post-hoc Analysis Angelo Antonini, Mahnaz Asgharnejad, Lars Bauer, Frank Grieger, Babak Boroojerdi

I3-5F

Putaminal Dopamine Turnover Predicts Levodopa-induced Motor Complications in De Novo Parkinson’s Disease Matthias Löhle, Julia Mende, Martin Wolz, Bettina BeuthienBaumann, Liane Oehme, Jörg van den Hoff, Jörg Kotzerke, Heinz Reichmann, Alexander Storch

I3-5G

Parkinson’s Disease Progression Is Associated with Increased Putaminal Serotonin to Dopamine Transporter Ratio: Relevance for Dyskinesias Andreas Roussakis, Marios Politis, David Towey, Paola Piccini

I3-5H

Reorganization of Corticostriatal Circuits in Healthy G2019S LRRK2 carriers Rick Helmich, Avner Thaler, Bart van Nuenen, Tanya Gurevich, Anat Mirelman, Karen Marder, Susan Bressman, Avi Orr-Urtreger, Nir Giladi, Bastiaan Bloem, Ivan Toni

I3-5I

Brain Structural and Functional Abnormalities in Parkinson’s Disease Patients with Freezing of Gait Elisabetta Sarasso, Federica Agosta, Elisa Canu, Maria Antonietta Volontè, Lidia Sarro, Sebastiano Galantucci, Roberto Gatti, Andrea Falini, Giancarlo Comi, Massimo Filippi

I3-5J Neuroanatomical

Correlates of Cognitive Functioning Across the Parkinson's Disease Cognitive Spectrum Doug Merkitch, Glenn Stebbins, Bryan Bernard, Jennifer Goldman

I3-5K

Global Long-term Registry on Efficacy and Safety of Levodopacarbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease in Routine Care (GLORIA)—Interim Results on Nonmotor Symptoms Angelo Antonini, K. Ray Chaudhuri, Ashley Yegin, Lars Bergmann, Werner Poewe

I3-5L

Resting Connectivity Functional MRI in Understanding Cognitive Impairment in Parkinson's Disease Nina Browner

I3-5M

Impulse Control Disorders Are Associated with REM Sleep Behavior Disorder in Patients with Parkinson’s Disease: A Video-polysomnographic Study Maria Livia Fantini, Maurizio Zibetti, Michela Figorilli, Beudin Patricia, Ana Marques, Debilly Bérangère, Derost Philippe, Miguel Ulla, Nicolas Vitello, Tiphaine Vidal, Monica Puligheddu, Alessandro Cicolin, Leonardo Lopiano, Franck Durif


Section Topic Controversies S1 Section Topic Controversies:

Antiplatelets, Anticoagulants, or Stenting for Acute Treatment of Cervical/Cranial Dissection?

1:00 p.m.–2:30 p.m.

1:00 p.m.–1:05 p.m. Introduction Antonio Culebras, MD, FAAN, FAHA

1:55 p.m.–2:05 p.m. Rebuttal Louis R. Caplan, MD, FAAN

1:05 p.m.–1:30 p.m.

Cervical/Cranial Arterial Dissection: Medical Treatment Louis R. Caplan, MD, FAAN

2:05 p.m.–2:15 p.m. Rebuttal Dileep Yavagal, MD

1:30 p.m.–1:55 p.m.

Cervical/Cranial Arterial Dissection: Stenting Dileep Yavagal, MD

2:15 p.m.–2:30 p.m.

Sunday April 19

Moderator: Antonio Culebras, MD, FAAN, FAHA

Open Discussion and Questions Antonio Culebras, MD, FAAN, FAHA

RED: 15AM Gives Back Ad_Lbstract Listing, halfpage horizontal Usage: High resolution PDF for Abstract Listing Spec: 8.25” x 5.4375”, +.125” bleeds, BW

Give Back to Our 2015 Annual Meeting Host City

The AAN is partnering with two charitable organizations to help give back to the Washington, DC, community during the 2015 AAN Annual Meeting. Throughout the week of the Annual Meeting, drop off unused toiletry items in the AAN Gives Back booth to be donated to Neediest Kids and Children’s Inn at NIH. Your donations will help children and their families receive vital medical treatments and students receive necessities to help them achieve academic success.

A Program of The National Center for Children and Families (NCCF)

Monetary donations are also being accepted for Neediest Kids at the AAN Gives Back booth and online at AAN.com/view/AANGivesBack. The AAN will match up to $5,000 for donations received now through April 25. LEARN MORE AND DONATE AT

AAN.com/view/AANGivesBack


Sunday, April 19

S Infectious, Paraneoplastic, and Autoimmune

1:00 p.m.–5:00 p.m.

Encephalopathies: Advances in Clinical Diagnosis and Emerging Insights about Pathogenesis This program is offered in partnership with the Society for Neuro-oncology and the AAN Neuro-infectious Disease and Neuro-oncology Sections.

Coordinators: Michael R. Wilson, MD, and Josep O. Dalmau, MD, PhD Part I

1:00 p.m.–2:45 p.m.

1:00 p.m.–1:05 p.m.

Introduction

1:05 p.m.–1:35 p.m.

Invited Speaker

Michael R. Wilson, MD, and Josep O. Dalmau, MD, PhD

I4-1A Data Blitz

Activation of HERV-K and Response to Antiretroviral Therapy in Patients with HIV Infection and Motor Neuron Disease Bryan Smith, Richa Tyagi, Wenxue Li, Mary Wright, Rose McConnell, Elyse Singer, Ty Nguyen, Tanya Lehky, Thomas Uldrick, Priscila Goncalves, Tariq Alfahad, Joseph Berger, Avindra Nath

1:40 p.m.–1:45 p.m.

I4-1B Data Blitz

Evaluation of Neurofilament Heavy Chain as a Marker of Neuroaxonal Pathology and Prognosis in Acute Encephalitis Johann Sellner, Nicholas Davies, Robin Howard, Axel Petzold

1:45 p.m.–1:55 p.m.

Audience Q&A

1:55 p.m.–2:25 p.m.

Invited Speaker

2:25 p.m.–2:30 p.m.

I4-2A Data Blitz

Chronic Complications of Encephalitis: HIV and Beyond Felicia Chow, MD, MAS Rapidly Progressive Dementia and Myoclonus with Elevated CSF IgG Index in Young Adult Immigrants: Treatable, but Not Always with Immunosuppression Cheryl Jay, Lara Zimmermann, Karen DaSilva

2:30 p.m.–2:35 p.m.

I4-2B Data Blitz

Role of C-Jun N-terminal Kinase (JNK) Signaling in Varicella Zoster Virus Infection of Neurons Arun Venkatesan, Labchan Rajbhandari, Sravya Kurapati, Tomohiko Sadaoka, Jeffrey Cohen

2:35 p.m.–2:45 p.m.

Audience Q&A

2:45 p.m.–2:55 p.m.

Break

2:55 p.m.–4:35 p.m.

2:55 p.m.–3:25 p.m.

Invited Speaker

3:25 p.m.–3:30 p.m.

I4-3A Data Blitz

3:30 p.m.–3:35 p.m.

I4-3B Data Blitz

Autoimmune Encephalitis at the Confluence of Neuronal and Glial Autoimmunity Markus Reindl, PhD

Next-generation Sequencing for Encephalitis Diagnostics: Case Examples Joseph DeRisi, PhD

1:35 p.m.–1:40 p.m.

Part II

Spectrum of MOG Autoantibody-associated Inflammatory Diseases in Pediatric Patients Silvia Tenembaum, Patrick Waters, Maria Leite, Mark Woodhall, Juan Princich, Martin Segura, Maria Talarico, Marina Szlago, Angela Vincent Risk Factors and Final Diagnoses of Patients First Diagnosed as Infectious Acute Disseminated Encephalomyelitis (ADEM): A Single-center Study Diederik Koelman, Tanuja Chitnis, Farrah Mateen

3:35 p.m.–3:45 p.m.

Audience Q&A

3:45 p.m.–4:15 p.m.

Invited Speaker

4:15 p.m.–4:20 p.m.

I4-4A Data Blitz

4:20 p.m.–4:25 p.m.

I4-4B Data Blitz

4:25 p.m.–4:35 p.m.

Audience Q&A

Walking on the Gray Side: When Your Patient Does Not Fit the Model Francesc Graus, MD Methotrexate Experience in Eight Pediatric Patients with Anti-N-methyl-DAspartate-receptor Encephalitis Alfredo Ramirez, Antonio Bravo-Oro, Ildefonso Rodriguez-Leyva, Carlos Abud-Mendoza Autoimmune Cerebellar Ataxia: Treatment Responses and Outcomes in 118 Patients Amy Jones, Sean Pittock, Vanda Lennon, Scott Eggers, J. Ahlskog, Andrew McKeon


Autoimmune Encephalitis in the ICU: Serological Spectrum, Clinical Courses, Complications and Outcomes Andrew McKeon, Manoj Mittal, Sara Hocker, Sean Pittock, Eelco Wijdicks, Alejandro Rabinstein

I4-5B

Clinical Features, Diagnostic Findings, and Treatment of Adult-onset Opsoclonus-myoclonus Syndrome: A Case Series Pooja Raibagkar, Shamik Bhattacharyya, Olga Rosenvald Szenberg, Ivana Vodopivec, Shirley Wray

I4-5C

Gait Disturbance as the Initial Presenting Symptom in Young Children with Anti-NMDA Receptor (Anti-NMDAR) Encephalitis: A Case Series Anusha Yeshokumar, Jessica Klein, Kristin Baranano, Carlos Pardo-Villamizar

52

4:35 p.m.–5:00 p.m. I4-5D Neurological

Manifestations of Acute Dengue Virus Infection: A Study from Tropical Country—India Devashish Ruikar, Sita Jayalakshmi, Mohandas Surath

I4-5E

Quantitative Detection of Human Herpesvirus-6 with Digital Droplet PCR in a Patient with Post-transplant HHV6 Encephalitis Bridgette Jeanne Billioux, Steven Jacobson

I4-5F

Activation of HERV-K and Response to Antiretroviral Therapy in Patients with HIV Infection and Motor Neuron Disease Bryan Smith, Richa Tyagi, Wenxue Li, Mary Wright, Rose McConnell, Elyse Singer, Ty Nguyen, Tanya Lehky, Thomas Uldrick, Priscila Goncalves, Tariq Alfahad, Joseph Berger, Avindra Nath

I4-5H

Rapidly Progressive Dementia and Myoclonus with Elevated CSF IgG Index in Young Adult Immigrants: Treatable, but Not Always with Immunosuppression Cheryl Jay, Lara Zimmermann, Karen DaSilva

I4-5K

I4-5I

I4-5L

Role of C-Jun N-terminal Kinase (JNK) Signaling in Varicella Zoster Virus Infection of Neurons Arun Venkatesan, Labchan Rajbhandari, Sravya Kurapati, Tomohiko Sadaoka, Jeffrey Cohen

I4-5J

Spectrum of MOG Autoantibody-associated Inflammatory Diseases in Pediatric Patients Silvia Tenembaum, Patrick Waters, Maria Leite, Mark Woodhall, Juan Princich, Martin Segura, Maria Talarico, Marina Szlago, Angela Vincent

Risk Factors and Final Diagnoses of Patients First Diagnosed as Infectious Acute Disseminated Encephalomyelitis (ADEM): A Singlecenter Study Diederik Koelman, Tanuja Chitnis, Farrah Mateen Methotrexate Experience in Eight Pediatric Patients with Anti-N-methyl-D-Aspartate-receptor Encephalitis Alfredo Ramirez, Antonio Bravo-Oro, Ildefonso Rodriguez-Leyva, Carlos Abud-Mendoza

I4-5M

Autoimmune Cerebellar Ataxia: Treatment Responses and Outcomes in 118 Patients Amy Jones, Sean Pittock, Vanda Lennon, Scott Eggers, J. Ahlskog, Andrew McKeon

I4-5G

Evaluation of Neurofilament Heavy Chain as a Marker of Neuroaxonal Pathology and Prognosis in Acute Encephalitis Johann Sellner, Nicholas Davies, Robin Howard, Axel Petzold



S Pediatric Neurotrauma:

Monday, April 20 8:00 a.m.–12:00 p.m.

From Coma to Concussions

This program is offered in partnership with the Child Neurology Society and the AAN Child Neurology and Sports Neurology Sections. Coordinators: Mark Wainwright, MD, PhD, and Christopher Giza, MD 8:00 a.m.–9:45 a.m.

Part II

9:55 a.m.–11:35 a.m.

8:00 a.m.–8:05 a.m.

Introduction

9:55 a.m.–10:25 a.m. Invited Speaker

8:05 a.m.–8:35 a.m.

Invited Speaker


8:35 a.m.–8:40 a.m.

I5-1A Data Blitz

Mark Wainwright, MD, PhD, and Christopher Giza, MD Pediatric TBI Physiology and Neurocritical Care Mark Wainwright, MD, PhD Neuronal Plasmalemmal Disruptions Are Exacerbated in Perivascular Domains Following Repetitive Traumatic Brain Injury in Swine John Duda, James Harris, Emory Kuo, D. Cullen

8:40 a.m.–8:45 a.m.

I5-1B Data Blitz

8:45 a.m.–8:55 a.m.

Audience Q&A

8:55 a.m.–9:25 a.m.

Invited Speaker

9:25 a.m.–9:30 a.m.

I5-2A Data Blitz

Efficacy of Minocycline in Female Rats after Mild Diffuse Traumatic Brain Injury L. Turtzo, Neekita Janaria, Jacob Lescher, William Tu, Joseph Frank

EEG Monitoring for Moderate/Severe Pediatric TBI Nicholas Abend, MD Activation of Plasmacytoid Dendritic Cells in Neuromyelitis Optica Patients Rafael Dias-Carneiro, Marilia Andrade, Felipe Von Glehn Silva, Alliny Dionete, Adriel Moraes, Carlos Otavio Brandao, Vinicius Boldrini, Alfredo Damasceno, Fernando Pradella, Guilherme Morais, Paula Russini, Alessandro Farias, Benito Damasceno, Charles Tilbery, Leonilda Santos

9:30 a.m.–9:35 a.m.

I5-2B Data Blitz

9:35 a.m.–9:45 a.m.

Audience Q&A

9:45 a.m.–9:55 a.m.

Break

Neurologic Exam Findings and Clinical Manifestations of Post-concussion Syndrome in a Pediatric Population Devon Cohen, Francis Conidi

Neuroimaging of Pediatric TBI TBD

Changes in Resting State Functional Connectivity Across a Season of High School Football Michael Clark, Samuel Kuzminski, Kevin Guskiewicz, Jeffrey Petrella


DTI Changes in Bilateral Uncinate Fasiculus Following Acute, but Not Chronic Symptomatic Concussion in Adolescence Rejean Guerriero, Marie Drottar, William Meehan III, P. Grant, Rebekah Mannix


Translational Science of Pediatric TBI and Mechanism-based Interventions Christopher Giza, MD


Sleep and Concussion Review and Evaluation (SCORE): Sleep Disorders in Pediatric Sports-related Concussions Ping-Ru Ko, Carey Lockhart, John Lockhart, Maida Chen


Physicians' Management Practices and Perceived Health Risks when Postconcussion Symptoms Persist Sean Rose, Anastasia Fischer, Geoffrey Heyer



Induced Normothermia in Severe Traumatic Brain Injury Patients Deborah Green-LaRoche, Tudor Sturzoiu, Helena Lau, Anna Marisa Cervantes-Arslanian, Joseph Burns

I5-5B

Psychiatric Symptoms as a Predictor of Outcome in Patients with Post-concussive Syndrome Arun Chhabra, Allison Weathers, Bichun Ouyang

I5-5C

Characteristics of Post-concussive Headaches in Children Presenting to the Neurology Clinic Karameh Kuemmerle

I5-5D

Pathological Correlation of Diffusion Tensor Imaging and Magnetization Transfer Biomarkers in a Preclinical Model of Mild Traumatic Brain Injury Rashida Williams, William Tu, Jacob Lescher, Christine Turtzo, Joseph Frank

Monday April 20

Part I

11:35 a.m.–12:00 p.m. I5-5E

Younger Children Recover Faster and Have Less Premorbid Conditions Than Adolescents with Concussion Rejean Guerriero, Karameh Hawash, Michael Pepin, Robert Wolff, William Meehan III

I5-5F

Neuronal Plasmalemmal Disruptions Are Exacerbated in Perivascular Domains Following Repetitive Traumatic Brain Injury in Swine John Duda, James Harris, Emory Kuo, D. Cullen

I5-5G

Efficacy of Minocycline in Female Rats after Mild Diffuse Traumatic Brain Injury L. Turtzo, Neekita Janaria, Jacob Lescher, William Tu, Joseph Frank


I5-5H

Activation of Plasmacytoid Dendritic Cells in Neuromyelitis Optica Patients Rafael Dias-Carneiro, Marilia Andrade, Felipe Von Glehn Silva, Alliny Dionete, Adriel Moraes, Carlos Otavio Brandao, Vinicius Boldrini, Alfredo Damasceno, Fernando Pradella, Guilherme Morais, Paula Russini, Alessandro Farias, Benito Damasceno, Charles Tilbery, Leonilda Santos

I5-5I

Neurologic Exam Findings and Clinical Manifestations of Postconcussion Syndrome in a Pediatric Population Devon Cohen, Francis Conidi

I5-5J


I5-5K


I5-5L

Sleep and Concussion Review and Evaluation (SCORE): Sleep Disorders in Pediatric Sports-related Concussions Ping-Ru Ko, Carey Lockhart, John Lockhart, Maida Chen

I5-5M


53

Section Topic Controversies

Monday, April 20

S2 Section Topic Controversies: Testing in Prodromal Neurological Disease: Friend or Foe?

1:00 p.m.–2:30 p.m.

Moderator: Michael J. Howell, MD 1:00 p.m.–1:10 p.m.

Welcome and Introduction of Prodromal Syndromes Michael Howell, MD

2:00 p.m.–2:25 p.m.

Open Discussion and Questions A. Jon Stoessl, MD, FAAN, and Ken Marek, MD

1:10 p.m.–1:35 p.m.

Prodromal Parkinson’s Disease, Huntington’s Disease and Alzheimer’s Disease Ken Marek, MD

2:25 p.m.–2:30 p.m.

Summary, Conclusion, and Adjournment Michael Howell, MD

1:35 p.m.–2:00 p.m.

Imaging Studies in Preclinical Parkinson’s Disease and Genetic Testing A. Jon Stoessl, MD, FAAN

Neuroscience Is… “Neuroscience Is…” is a nationwide campaign by the American Academy of Neurology to build public awareness and demonstrate the importance of neuroscience research in the care of neurology patients and the development of cures for brain diseases.

Neuroscience is Essential Why do you think Neuroscience is essential? Stop by our video booth in the Poster Hall and tell us. AAN.com/view/NeuroscienceIsEssential


S Future Therapies: How We Will Be Treating,

1:00 p.m.–5:00 p.m.

Preventing, and Curing Epilepsy in the Year 2025 This program is offered in partnership with the American Epilepsy Society and the AAN Epilepsy Section.

Coordinators: Amy R. Brooks-Kayal, MD, and Anne Anderson, MD 1:00 p.m.–2:45 p.m.

1:00 p.m.–1:05 p.m.

Introduction

1:05 p.m.–1:35 p.m.

Invited Speaker

Amy R. Brooks-Kayal, MD, and Anne Anderson, MD Development of Anti-inflammatory and Immune Modulatory Therapies for Epilepsy Karen Wilcox, PhD

1:35 p.m.–1:40 p.m.

I6-1A Data Blitz

1:40 p.m.–1:45 p.m.

I6-1B Data Blitz

1:45 p.m.–1:55 p.m.

Audience Q&A

1:55 p.m.–2:25 p.m.

Invited Speaker

Indomethacin Increases the Latency to Seizure Onset and Decreased the Number of Seizures in Zebrafish Seizure Model Patricia Barbalho, Iscia Lopes-Cendes, Claudia Maurer-Morelli Role of NOX2 in Seizure Susceptibility of Mice Following Systemic Inflammation Hung-Ming Wu, Wan-Yu Huang

Cell Signaling Modulators as Novel Disease Modifying Therapies for Epilepsy Anne Anderson, MD

2:25 p.m.–2:30 p.m.

I6-2A Data Blitz

Everolimus Long-term Safety and Efficacy in Patients with Subependymal Giant Cell Astrocytoma (SEGA) Associated with Tuberous Sclerosis Complex (TSC): Final Analysis of a Phase 2 Study David Franz, Marguerite Care, Katherine Holland-Bouley, Karen Agricola, Cynthia Tudor, Noah Berkowitz, Sara Miao, Severine Peyrard, Darcy Krueger

2:30 p.m.–2:35 p.m.

I6-2B Data Blitz

Targeted Treatment of Migrating Partial Seizures of Infancy with Quinidine David Bearden, Alanna Strong, Dennis Dlugos, Marissa DiGiovine, Ethan Goldberg

2:35 p.m.–2:45 p.m.

Audience Q&A

2:45 p.m.–2:55 p.m.

Break

Part II

2:55 p.m.–4:35 p.m.

2:55 p.m.–3:25 p.m.

Invited Speaker

3:25 p.m.–3:30 p.m.

I6-3A Data Blitz

3:30 p.m.–3:35 p.m.

I6-3B Data Blitz

Lighting the Way: Optogenetic Approaches for Treatment of Epilepsy Ivan Soltesz, PhD Decreased Amygdala Resting State Functional Connectivity in Patients with Left Temporal Lobe Epilepsy Jane Allendorfer, Rodolphe Nenert, Basia Szaflarski, Nancy Cohen, Jeffrey Binder, Zhifeng Kou, Roy Martin, Lawrence Ver Hoef, Jerzy Szaflarski Using Neural Networks to Predict the Effects and Guide the Application of Transcranial Direct Current Stimulation David Fischer, Peter Fried, Alvaro PascualLeone, Michael Fox

3:35 p.m.–3:45 p.m.

Audience Q&A

3:45 p.m.–4:15 p.m.

Invited Speaker

4:15 p.m.–4:20 p.m.

I6-4A Data Blitz

4:20 p.m.–4:25 p.m.

I6-4B Data Blitz

4:25 p.m.–4:35 p.m.

Audience Q&A

Seizure Detection/Prediction Devices and Therapies Gregory A. Worrell, MD Combining Electroencephalographic Time-frequency and Source Analysis Methods for Improve Epileptogenic Zones Localization Elena Cuspineda Bravo, Eduardo Martinez Montes, Ana Olivares Torres, Calixto Machado Novel Ambulatory EMG-based GTC Seizure Detection Device for Home and Hospital Use Jose Cavazos, Michael Girouard, Luke Whitmire


4:35 p.m.–5:00 p.m.

Assessment of the Anticonvulsant Effects and Tolerability Profile of Cannabidiol: GW Pharmaceuticals’ Preclinical Program Nicholas Jones, Andrew Hill, Thomas Hill, Isabelle Peres, Rebecca Hadid, Stephen Wright, Gary Stephens, Claire Williams, Benjamin Whalley

I6-5E

I6-5B

I6-5F

Intractable Reflex Epilepsy Treated Successfully with Deep Brain Stimulation Anteneh Feyissa, Squire Stead, Jamie Van Gompel, Jeffrey Britton

I6-5C Optogenetic

Neuromodulation Genko Oyama, Nobutaka Hattori

I6-5D

B and Plasma Cells and Meningeal Follicles Are a Part of NeuroInflammatory Mechanisms Associated with Rasmussen’s Encephalitis: New Clues About Pathogenesis Anupama Kumar, Maria Reyes-Mantilla, Adam Hartman, Carlos Pardo-Villamizar, Carlos PardoVillamizar

Does a Standardized Multidisciplinary Approach Improve Outcomes for Children with NMDA Receptor Antibody Encephalitis? A Preliminary Assessment of a Single Center Experience Mered Parnes, Amber Stocco, Trung Nguyen, Jun Teruya, Jeanine Graf, Eyal Muscal Indomethacin Increases the Latency to Seizure Onset and Decreased the Number of Seizures in Zebrafish Seizure Model Patricia Barbalho, Iscia Lopes-Cendes, Claudia Maurer-Morelli

I6-5G

Role of NOX2 in Seizure Susceptibility of Mice Following Systemic Inflammation Hung-Ming Wu, Wan-Yu Huang


I6-5H

Everolimus Long-term Safety and Efficacy in Patients with Subependymal Giant Cell Astrocytoma (SEGA) Associated with Tuberous Sclerosis Complex (TSC): Final Analysis of a Phase 2 Study David Franz, Marguerite Care, Katherine Holland-Bouley, Karen Agricola, Cynthia Tudor, Noah Berkowitz, Sara Miao, Severine Peyrard, Darcy Krueger

I6-5I

Targeted Treatment of Migrating Partial Seizures of Infancy with Quinidine David Bearden, Alanna Strong, Dennis Dlugos, Marissa DiGiovine, Ethan Goldberg

I6-5J

Decreased Amygdala Resting State Functional Connectivity in Patients with Left Temporal Lobe Epilepsy Jane Allendorfer, Rodolphe Nenert, Basia Szaflarski, Nancy Cohen, Jeffrey Binder, Zhifeng Kou, Roy Martin, Lawrence Ver Hoef, Jerzy Szaflarski

I6-5K

Using Neural Networks to Predict the Effects and Guide the Application of Transcranial Direct Current Stimulation David Fischer, Peter Fried, Alvaro Pascual-Leone, Michael Fox

I6-5L Combining

Electroencephalographic Time-frequency and Source Analysis Methods for Improve Epileptogenic Zones Localization Elena Cuspineda Bravo, Eduardo Martinez Montes, Ana Olivares Torres, Calixto Machado

I6-5M

Novel Ambulatory EMGbased GTC Seizure Detection Device for Home and Hospital Use Jose Cavazos, Michael Girouard, Luke Whitmire

55

Monday April 20

Part I

Poster Session Schedule and Floor Plan Monday, April 20

Tuesday, April 21

Wednesday, April 22

2:00 p.m.–6:30 p.m. F P1 Poster Session I��57

7:30 a.m.–12:00 p.m. F P2 Poster Session II��65

7:30 a.m.–12:00 p.m. F P4 Poster Session IV ��88

2:00 p.m.–6:30 p.m. F P3 Poster Session III��78

2:00 p.m.–6:30 p.m. F P5 Poster Session V��100

First Authors stand by Posters from 5:00 p.m.–6:30 p.m.

First Authors stand by Posters from 7:30 a.m.–9:00 a.m.




Thursday, April 23 7:30 a.m.–12:00 p.m. F P6 Poster Session VI �� 110


2:00 p.m.–6:30 p.m. F P7 Poster Session VII ��122


HALL A

Escalator to Concourse Level

U

11 12 13 14 15

1 2 3 4 5 6 7 8 9 10

ePosters

56

66 67 68 69 70 71 72 73 74 84 83 82 81 80 79 78 77 76 75 14 0 13 9 13 8 13 7 13 6 13 5 17 5 17 6 17 7 17 8 17 9 18 0

14 8 14 7 14 6 14 5 14 4 14 3 14 2 14 1 16 7 16 8 16 9 17 0 17 1 17 2 17 3 17 4

12 5 12 6 12 7 12 8 12 9 13 0 13 1 13 2 13 3 13 4 19 0 18 9 18 8 18 7 18 6 18 5 18 4 18 3 18 2 18 1 23 1 23 2 23 3 23 4 23 5 23 6 23 7 23 8 23 9 24 0 25 0 24 9 24 8 24 7 24 6 24 5 24 4 24 3 24 2 24 1 29 1 29 2 29 3 29 4 29 5 29 6 29 7 29 8 29 9 30 0 31 0 30 9 30 8 30 7 30 6 30 5 30 4 30 3 30 2 30 1 35 1 35 2 35 3 35 4 35 5 35 6 35 7 35 8 35 9 36 0

56 57 58 59 60 61 62 63 64 65 94 93 92 91 90 89 88 87 86 85 11 5 11 6 11 7 11 8 11 9 12 0 12 1 12 2 12 3 12 4 20 0 19 9 19 8 19 7 19 6 19 5 19 4 19 3 19 2 19 1 22 1 22 2 22 3 22 4 22 5 22 6 22 7 22 8 22 9 23 0 26 0 25 9 25 8 25 7 25 6 25 5 25 4 25 3 25 2 25 1 28 1 28 2 28 3 28 4 28 5 28 6 28 7 28 8 28 9 29 0 32 0 31 9 31 8 31 7 31 6 31 5 31 4 31 3 31 2 31 1 34 1 34 2 34 3 34 4 34 5 34 6 34 7 34 8 34 9 35 0

48 49 50 51 52 53 54 55 10 4 10 3 10 2 10 1 10 0 99 98 97 96 95 10 5 10 6 10 7 10 8 10 9 11 0 11 1 11 2 11 3 11 4 33 1 33 2 33 3 33 4 33 5 33 6 33 7 33 8 33 9 34 0

33 0 32 9 32 8 32 7 32 6 32 5 32 4 32 3 32 2 32 1

27 1 27 2 27 3 27 4 27 5 27 6 27 7 27 8 27 9 28 0

27 0 26 9 26 8 26 7 26 6 26 5 26 4 26 3 26 2 26 1

21 1 21 2 21 3 21 4 21 5 21 6 21 7 21 8 21 9 22 0

21 0 20 9 20 8 20 7 20 6 20 5 20 4 20 3 20 2 20 1

15 8 15 9 16 0 16 1 16 2 16 3 16 4 16 5 16 6

15 7 15 6 15 5 15 4 15 3 15 2 15 1 15 0 14 9

E

29 28 27 26 25 24 23 22 21

20 19 18 17 16

39 38 37 36 35 34 33 32 31 30

Discussion Posters

47 46 45 44 43 42 41 40

Neuroscience Is... Video Booth


Poster Session I

Monday, April 20

P1 Poster Session I First Authors stand by Posters from 5:00 p.m.–6:30 p.m. Poster Discussion Session: Cerebrovascular Disease and Interventional Neurology

2:00 p.m.–6:30 p.m.

Ten posters in seven neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will lead a tour of attendees and facilitate questions with poster authors during the 90-minute author standby time.

Predictors of Seizure Improvement Following Stereotactic Radiosurgery for Cerebral Arteriovenous Malformations in a Prospective Cohort of 229 Patients with AVM-associated Epilepsy Dale Ding, Mark Quigg, Robert Starke, Chun-Po Yen, Colin Przybylowski, Blair Dodson, Jason Sheehan

P1.002 Collateral Score and

Neurologic Worsening in Patients with Carotid Dissection Judy Jia, Chunyun Cai, Mohammad Rahbar, Renga Pandurengan, Amrou Sarraj

P1.003 Susceptibility Weighted

Imaging the of Brain in Infective Endocarditis Matthew Schrag, Teddy Youn, Joseph Schindler, David Greer, Ajay Malhotra

P1.004 Metabolic Syndrome and

Ischemic Stroke Risk by Sex: Metaanalysis Michelle Lin, Gustavo Saposnik, Qiyun Shi, Amy Towfighi

P1.005 Electrical Stimulation of

Neural Stem Cells Improves Stroke Recovery Paul George, Tonya Bliss, Swapnil Mehta, Thuy Hua, GuoHua Sun, Gary Steinberg

P1.006 Younger Acute Ischemic

Stroke Patients Are at Higher Risk for 30day Readmission Duy Le, Konrad Schlick, Shlee Song, Mani Nezhad, Jonathan Eskenazi Markewitz, Kara Melmed, Tamara Majic, Patrick Lyden

P1.007 Prevalence of Patent Foramen Ovale in Cryptogenic Strokes of North Indian Population Gayathri Petluri, Dheeraj Khurana, Sudesh Prabhakar, Ajay Bahl

P1.009 Prevention of Catheter

Associated Urinary Tract Infections in Stroke Patients Sushanth Aroor, Pamela Branson, Ashby Turner, Jessica Lee

P1.010

Predictors for Failure to Follow-up in Clinic After Ischemic Stroke Nicholas Osteraas, Laurel Cherian, Shawna Cutting, James Conners, Sarah Song, Vivien Lee

P1.008 Analysis of Concurrent

Cerebral Venous Thrombosis and Dural Arteriovenous Fistula Michelle Johansen, Andrew Southerland, Bradford Worrall

e-Poster Session: Cerebrovascular Disease and Interventional Neurology I Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch screen displays.

P1.011

Improvement in Rates of Thrombolytic Therapy in Acute Stroke by a Telestroke Program in Rural Northern Wisconsin Rebecca Kartje, Susan Klemm, Lori Heil, Nina Antoniotti, Thomas Martin

P1.012

Endovascular Management and Outcome of Acute Middle Cerebral Artery Stroke in the Setting of Spontaneous Carotid Dissection Deepak Gulati, Amin Aghaebrahim, Andrew Ducruet, Brian Jankowitz, Tudor Jovin, Ashutosh Jadhav

Cerebrovascular Disease and Interventional Neurology: Case Reports P1.021

A Rare Case of Transient Ischemic Attacks and Acute Ischemic Stroke from Left Intracranial Arteries Encased in Meningioma Sahawat Tantikittichaikul, Pavis Laengvejkal, Ahmed Eldokla, Jongyeol Kim

P1.022

Creutzfeldt-Jakob Disease Presenting as Stroke: Case Report and Literature Review Annemarie Van Heuven, Mike Boggild, Richard White

P1.023

Bilateral Frontal Cerebral Infarctions Presenting as Ascending Weakness: Case Report Christina Mijalski, Muhib Khan, Brian Silver

P1.013

Greater Risk for Decompressive Craniectomy in Large-artery Strokes Due to Cervical Artery Thamolwan Surakiatchanukul, Gloria Koskey, Timothy McMurry, Ronald Grider, Lillian Currie, Heather Turner, Bradford Worrall, Andrew Southerland

P1.014

Digital Subtraction Angiography (DSA) Arch Run in Place of CT Vessel and Perfusion Imaging: Proof of Concept David Campbell, Ashutosh Jadhav

P1.015

Cerebral Microbleeds Determine Long-term Mortality in Acute Ischemic Stroke Patients with Lacunar Subtype Tae-Jin Song, Chang Younkyung, Minjung Youn, Ji Hoe Heo, Yong Jae Kim

P1.024

Stroke in a Young Woman Caused by Carotid Web Joseph Petrsoric, Lauren DeNiro, Daniel Labovitz

P1.025

The Unusual Suspect Katelyn Smith, Jafar Kafaie

P1.026

Left Ventricular Noncompaction with Normal Heart Function: A Rare Cause of Cardioembolic Stroke in a Young Adult Clotilde Hainline, Daniel Antoniello

P1.027

Bilateral Common Carotid Artery Thrombi Following Cisplatin-based Chemotherapy Firas Kaddouh, Ajay Tunguturi, Anand Patel, Elizabeth DeGrush, Max Mandelbaum, Evdokia Eleftheriou, Richard Goddeau


P1.016

Value of Eye Movement Exam in Aiding Precise Localization in Stroke Namir Khandker, David Schmerler, Supriya Mahajan, Alessandro Serra, Daniel Strbian

P1.018

P1.017

Bilateral Watershed Territory Infarct in Non-hemodynamic Significant Stenoses: Hypereosinophilic Syndrome (HES) and the Impaired Cerebral Washout Theory Mohamed-Ali Babi, Mark Gorman, Margaret Kennedy, Samir Ambrale, Salman Aljerdi, Christopher Commichau

P1.019

P1.028

P1.032

Transient Neurologic Deficit Presenting with Cortical Vein Thrombosis Caused by Intracranial Hypotension: Case Report Joao Mc-ONeil Plancher, Matthew Flaherty

P1.029

Manifestations of an Uncommon Pontine Insult, Eight-and-a-half Syndrome Robert Mannel, Fahed Saada, Nader Antonios

P1.030 Fluctuating Mental Status and Fever of Unknown Origin Annie Daniel, Justine Brink, Catherine Hosley

P1.031

Atypical Isolated Nuclear Oculomotor Nerve Syndrome: A Diagnostic Challenge Carlos Kamiya Matsuoka, Bing Liao

Systems and Care Process Parameters as Determinants of Onset-totreatment Times in Acute Ischemic Stroke: A Simulation Study Drew Levy, David Norris, Darren Tayama An Executable Graphical Model for in Silico Prototyping of Processes for Acute Stroke Care David Norris, Drew Levy

P1.020

Stroke in Young Adults: A 4-year Retrospective Hospital-based Study, First Report from United Arab Emirates Majid AlAmeri, Abdulla AlNuaimi, Taoufik Alsaadi

Cystinosis Associated Vasculopathy Masquerading as Atypical Migraine Headache Daniel Smith, Hani Kushlaf

P1.033

Pineal Apoplexy with Cerebral Infarction Adam Truong, Michael Young, Nassim Naderi, Arnold Brizuela, Jason Handwerker, Lama Al-Khoury

P1.034

Symptomatic Cerebral Air Embolism After Central Venous Catheter Removal Jannatul Ferdous, Sahawat Tantikittichaikul, Rashedul Hasan, Ahmed Eldokla, Jongyeol Kim

P1.035

Diffuse Cerebral Vasospasm Following Endoscopic Colloid Cyst Resection Ahmad Shawagfeh, Ahmed Yassin, Nicholas Levine, Ivo Tremont

57

Monday April 20

P1.001

Poster Session I P1.036

Progressive Focal Weakness, Aphasia, and Somnolence John Werner, Christa San Luis, Heather Ames, Rebecca Gottesman, Wendy Ziai

P1.037

DWI Negative Stroke: Learning Points for Imaging in Acute Stroke Krishna Nalleballe, Neville Jadeja, Pradeep Bollu, Sanjeeva Onteddu

P1.038

Diabetic Striatopathy with Isolated Sensorimotor Symptoms Masquerading as Intraparenchymal Hemorrhage Matthew Ehrlich, Andrew Southerland, Bradford Worrall, Nina Solenski

P1.039

Primary Cerebral Epithelioid Hemangiomas Nicholas Osteraas, Laurel Cherian, James Conners, Vivien Lee

P1.040 Bilateral Ascending Weakness in a Patient with Azygous Anterior Cerebral Artery Stroke Emiliya Melkumova, Jared Noroozi, Charlotte Zisman, Ramandeep Sahni

P1.041

Ipsilateral Glossoplegia and Hemiplegia: Acute Medullary and Cervical Cord Ischemic Stroke Riddhiben Patel, Salman Rashid, Aimee Luat, Mitchel Williams, Kumar Rajamani

Cerebrovascular Disease and Interventional Neurology: The Spectrum of Small Vessel Cerebrovascular Disease P1.042 Recurrent Vascular Events

and Death Following Small Vessel Ischemic Stroke in the Short, Intermediate and Long-term Over 8 Years Deidre De Silva, Natasha Fabiana, John Allen, Fung-Peng Woon, Hui-Meng Chang, Kamran Ikram, Tien-Yin Wong, Meng-Cheong Wong

P1.043 Extensive Workup for Embolic Sources in Lacunar Strokes: Prevalence in an Academic Setting Yan Wang, Yoon Choi, Joshuae Gallardo, Ifeoma Nwaneri, James Brorson

P1.044 Association of Cerebral

Microbleeds with Higher Morbidity and Mortality in Ischemic Stroke? Roomana Ahad, Iftekhar Ahmed, Graham Lee, Neeta Duggal

P1.045 Aggressive Statin Therapy

(AST) and Brain Atrophy/Associated Leucoaraiosis: MRI 6 Years Observational Study Gobinathan Devathasan, William Senna, Lea Dosado

P1.046 Serum Uric Acid Is Positively

Associated with Cerebral White Matter Hyperintensities in Patients with Acute Lacunar Infarction: Subgroup Analysis of the Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse) Study Sang Won Han, Jong Yun Lee, Kyung-Yul Lee, Joong Hyun Park, Jae Hyeon Park

P1.047

Epidemiology of Cerebral Amyloid Angiopathy: A Single Center Experience Prachi Mehndiratta, Christina Chee, Bradford Worrall

P1.048 Crossed Subcortical

Aphasia Chantale Murray, Carlos Kase, Thanh Nguyen, Kevin Bickart

58

2:00 p.m.–6:30 p.m.

P1.049

Searching Factors to Predict for Vascular Aging Dong-Jin Shin, Shin Dong Hoon

P1.050

Presence of Decreased Intraepidermal Nerve Fiber Density Consistent with Small Fiber Neuropathy in Patients with Central Post-stroke Pain Yefim Yushvayev-Cavalier, Colum Amory, Gary Bernardini, Charles Argoff

Cerebrovascular Disease and Interventional Neurology: Atrial Fibrillation and Cardioembolic Stroke P1.051

N-terminal Pro-B-type Natriuretic Peptide Predicts Long-term Mortality but Not Stroke Recurrence in Acute Ischemic Stroke Patients with a Cardioembolic Source Seung-Jae Lee, Dong-Geun Lee, Tae-Ick Chung

P1.060 Embolic Stroke of

Undetermined Source (ESUS): A Single Center Study from Argentina Lucia Pertierra, Maximiliano Hawkes, Mauricio Farez, Maia Gomez-Scheneider, Jose Pastor-Rueda, Ismael Calandri, Virginia Pujol-Lereis, Sebastián Ameriso

Cerebrovascular Disease and Interventional Neurology: Epidemiology P1.061

Stroke Patterns and Shortterm Mortality in Marijuana Users and Non-users: A Cross-sectional Study Manoj Mittal, Nivedita Adabala

P1.062 The Role of Discharge

Disposition in the Interventional Management of Stroke (IMSIII) Trial Samir Belagaje, Rishi Gupta, Lydia Foster, Brett Kissela, Joseph Broderick

P1.073

Demographic Characteristics and Prognostic Factors in Acute Ischemic Stroke in a Tertiary Care Hospital in Nepal Bikram Gajurel, Krishna Oli

P1.074

Port Harcourt Stroke Registry: A Prospective Hospital Based Study Christiana Okunoye, God'spower Asekomeh, Alagoma Iyagba, Arthur Onwuchekwa

P1.075

Chronic Kidney Disease as a Predisposing and Severity Factor in Ischemic Stroke at the Hospital Admission Martin Tourreilles, Javier Rolle, Sebastian Casas, Claudia Gonzalez, Lorena Cabrera, Andres Perez, Patricio Blaya, Marcelo Mattiazzi

P1.076

Prevalence and Etiology of Acute Ischemic Events During Hemodialysis Laurel Cherian, James Conners, Shawna Cutting, Vivien Lee, Sarah Song

Effect of Atrial Fibrillation on Brain Atrophy and Cognitive Deficits in Persons Aged ≥65 Years: Analysis of Cardiovascular Health Study Morad Chughtai, Cara Bezzina, Ahmed Malik, Adnan Qureshi

P1.063 Delay of Percutaneous

P1.053

Disparities in Acute Stroke Care Despite Primary Stroke Center Growth Sergio Gonzles, Dylan Thibault, Allison Willis

Comparison of Siriraj Stroke Score with Computerized Tomography in Establishing the Type of the Stroke Among Pakistani Population Attiya Rahman, Qaiser Jamal

P1.065 Effect of Incident Stroke

P1.079

P1.052

Paroxysmal Atrial Fibrillation Detection Rates in Cryptogenic Stroke Patients Selected by Stroke Specialists for Prolonged Cardiac Monitoring Hisham Salahuddin, Syed Zaidi, Gretchen Tietjen, Jennifer Cummings, Mouhammad Jumaa

P1.054 High Frequency of

Short Paroxysms of Newly Detected Atrial Fibrillation After Stroke and TIA. Systematic Review and Metaanalysis Patricia Riccio, Luciano Alberto Sposato, Vladimir Hachinski, Gustavo Saposnik

P1.055 Patients with Known

Atrial Fibrilation and First Ischemic Stroke. Assessing of Anticoagulation Status Virginia Parisi, María Lucía Rattagan, Gabriel Persi, Emilia Gatto

P1.056 A Dedicated Stroke Prevention in Atrial Fibrillation (SPAF) Clinic for the Acute Assessment and Initiation of Anticoagulation in Patients with Atrial Fibrillation Evan Jolliffe, Ian Rosemergy, Jeremiah Lanford, David Abernethy

P1.057

The Role of Urinary Tract Infection in Atrial Fibrillation-related Ischemic Strokes, A Retrospective Study Awss Zidan, Ruham A-Nasany, Ahmed Bedair, Ilya Bragin, Adham Kamel

P1.058 Risk of Ischemic Stroke

During Periods of Warfarin Discontinuation for Surgical Procedures: A Longitudinal Study of 4060 Patients with Atrial Fibrillation Nauman Jahangir, Ahmed Malik, Muhammad Suri, Adnan Qureshi

P1.059

Ischemic Stroke in Patients with Elevated Body Mass Index While on Novel Anticoagulants: A Case Series Report Haris Kamal, Kelly Smith, Ashkan Mowla, Peyman Shirani, Robert Sawyer Jr., Andrew Fanous, Marilou Ching

Gastrostomy Tube (PEG) Placement in Patients with Ischemic Stroke in a Large Urban Hospital Bhrugav Raval, Appaji Rayi, Molly Jacob, Machteld Hillen

P1.064 Increasing Rural-urban

on Sleep Quality and Hypopnea-apnea Index: Analysis of Sleep Heart Health Study Ahmed Malik, Malik Adil, Muhammad Suri, Shayaan Khan, Adnan Qureshi

P1.066 Effect of “Snoring Alone”

and “Snoring Plus Phenomenon” on Cardiovascular Diseases, or Fatal or Nonfatal Stroke Yousef Mohammad, Ahmed Malik, Omar Saeed, Muhammad Suri, Adnan Qureshi

P1.067

Risk of Stroke in Imaging-proven Subclavian Steal Syndrome Harrison Bai, Zhili Wang, Yingjie Zou, Xin Zhao, Luo Zhou, Yanqiao Xiao, Yi Shu, Dongxu Chou, Xiao Bo, Scott Kasner, Liming Tan, Yang Li

P1.077

Factors Predictive of Hospice Care in Patients with Ischemic Stroke Fahd Sultan, Jessica Lee

P1.078

Ischemic Stroke in Pregnancy and Postpartum: A Descriptive Case Series Eliza Miller, Shadi Yaghi, Amelia Boehme, Joshua Willey, Mitchell Elkind, Randolph Marshall

P1.080 Sex Differences in TIA

Presentation and Frequency of DWI Abnormalities on MRI Nicholas Billow, Elie Harmouche, Michael Ross, Samir Belagaje, Aaron Anderson, Strikant Rangaraju, James Greene, Paul MacDonald, Fadi Nahab

Neuroepidemiology: Cerebrovascular Disease

P1.068 Withdrawn

Racial Differences and Outcomes of Strokes in Patients on Hemodialysis: A 10-year Retrospective Study Mohammad Sunbulli, Monica Dhakar, Kumar Rajamani

P1.069

The Impact of Pre-stroke Smoking on Post-stroke Mortality Alicia Zha, Sunil Mutgi, Shaheryar Hafeez, Reza Behrouz

P1.082 Risk of Stroke Following

P1.070

P1.083

Asymptomatic Compression of Brainstem by Basilar or Vertebral Arteries: A Case Series of 20 Patients Ali Daneshmand, David Thaler

P1.071

Effect of Weight Loss Surgery on Cardiovascular Death, Nonfatal Myocardial Infarction, or Nonfatal Stroke in Overweight and Obese Post-menopausal Women Omar Saeed, Ahmed Malik, Adnan Qureshi

P1.072

Childhood Stroke: Comparison of Strokes Identified in Administrative Databases with Those Identified in a Population-based Study John Taylor, Jane Khoury, Yingying Xu, Heidi Sucharew, Kathleen Alwell, Charles Moomaw, Paul Horn, Samrat Yeramaneni, Katrina Peariso, Pooja Khatri, Joseph Broderick, Brett Kissela, Dawn Kleindorfer

P1.081

Hypertensive Encephalopathy Michael Lerario, Alexander Merkler, Gino Gialdini, Neal Parikh, Babak Navi, Hooman Kamel Accuracy of Mobile Devices for Acute Stroke Head CT Interpretation Among Neurologists in Training Priyank Khandelwal, Clotilde Balucani, Leah Steinberg, Jeremy Weedon, Sebina Bulic, Elie Dancour, Kester Phillips, Carlos Escasena, Jihan Grant, Steven Levine

P1.084 Delay in Presentation to

Hospital After Acute Stroke: A Multiethnic Population in New York City Ivan MatosDiaz, John Liang, Amy Walker, David Lucido, Irene Boniece

P1.085

Temporal Trends of Outcomes for Acute Kidney Injury in Acute Intracerebral Hemorrhage from 2002 to 2012: An Analysis of Nationwide Inpatient Sample Data Abhimanyu Mahajan, Achint Patel, Girish Nadkarni, Charuhas Thakar


Poster Session I

P1.086 A Four-year Experience of

Symptomatic Intracranial Hemorrhage Rate Following Intravenous Tissue Plasminogen Activator at a Comprehensive Stroke Center Jeffrey Wagner, Alessandro Orlando, Christopher Fanale, Michelle Whaley, Kathryn McCarthy, David Bar-Or

P1.087

Secondary Stroke Prevention Prescribing in a National Cohort Karen Albright, Amelia Boehme, Virginia Howard, George Howard, Suzanne Judd, David Rhodes, Aaron Anderson, Leslie McClure, Monika Safford, Nita Limdi, Justin Blackburn

P1.088

Elevated Blood Pressure, Cerebrovascular Reactivity, and the Default-mode Brain Network: Findings from the Coronary Artery Risk Development in Young Adults (CARDIA) Brain MRI Substudy Thaddeus Haight, Nick Bryan, Guray Erus, Christos Davatzikos, David Jacobs, Mark D'Esposito, Cora Lewis, Lenore Launer

P1.089 The Changing Epidemiology of Stroke in Acquired Immune Deficiency Syndrome (AIDS) Phillip Kucab, Pratik Bhattacharya

P1.090 Recurrence Risk and

Cognitive Decline in African-American and Hispanic Survivors of Intracerebral Hemorrhage Alessandro Biffi, Christopher Anderson, Thomas Battey, Alison Ayres, Kristin Schwab, Anand Viswanathan, Steven Greenberg, Jonathan Rosand

Neuroepidemiology: Cerebrovascular Disease, Critical Care, Epilepsy, Child Neurology, and Sleep P1.091 New Imaging-based Definition of Stroke Boosts Annual Incidence of Recurrent Ischemic Stroke in the United States by 80% Michelle Lin, Bruce Ovbiagele, Helena Chui, Amy Towfighi

P1.092 Differences in Ischemic

and Hemorrhagic Strokes in Sri Lanka: 7-year Data from the Ragama Stroke Registry Udaya Ranawaka, Anushka Peiris, K Thirumavalavan, Gayani Premawansa, Anuradhani Kasthuriratne

P1.093 Population-based Study of Cerebral Microbleeds in Older Adults Living in Rural Ecuador (the Atahualpa Project) Victor Del Brulto, Mauricio Zambrano, Robertino Mera, Oscar Del Brutto

P1.094

Stroke in a Global World: Geographical Differences in Stroke Subtypes and Age at Onset in Two Different Populations from Europe and South America Jardiel Casanova-Lanchipa, Francisco Carod, Luis Miguel Cruz-Ramirez, Noelia Sanchez-Perez, Fatima SiacaraAguayo, Isabel Gomez-Moreno, Lourdes Gomez Romero, Luciane Coral, Daniele Trizotto, CM Moreira

P1.095

Clinical and Demographic Factors Associated with Poor Outcome Differ from Those Associated with Withdrawal of Life Support After Cardiac Arrest Sachin Agarwal, Teresa May, Amelia Boehme, Alexandra Reynolds, Priyank Patel, Barbara McCrum, Soojin Park, Jan Claassen, Richard Riker, David Seder

P1.096

Premorbid Status Independently Dictates Good Outcome After Status Epilepticus Among Comatose Survivors of Cardiac Arrest Alexandra Reynolds, Andres Rodriguez-Ruiz, Amelia Boehme, Priyank Patel, Teresa May, Christina Falo, Stephan Mayer, Hyunmi Choi, Soojin Park, Jan Claassen, Sachin Agarwal

P1.097 Critical Care Course of

Patients with Acute Basilar Artery Occlusion Julio Chalela, Khaled Asi, Joao Gomes

P1.098

Epidemiology of Epilepsy in Belarusian Population: A Pilot Study Andrei Ivashynka, Tatsiana Dokukina

P1.099 Reliability and Validity of the

P1.109

Pediatric Onset Multiple Sclerosis Patients Tend to Have Slower Disease Progression Jasem Al-Hashel, Samar Ahmed, Raed Alroughani

P1.110

Relapse Sequela Is Not Rare in Aggressive Forms of Relapsing MS Throughout the First Decade of Disease Chris Hackett, Edward Gettings, Carol Schramke, Santosh Ramanathan, Thomas Scott

P1.111

The CNS Antigen-specific B Cell Response Correlates with GA Responsiveness in Remitting-relapsing Multiple Sclerosis Patients Damiano Rovituso, Claudia Kaiser, Michael Schroeter, Christoph Kleinschnitz, Stefanie Kuerten

Brief Problem Monitor: An Abbreviated Form of the Child Behavior Checklist Brian Piper, Hilary Gray, Jacob Raber, Melissa Birkett

P1.112

P1.100

P1.113

Sleep Duration Is Associated with Worse Neurocognitive Function in Hispanic/Latinos: Results of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Alberto Ramos, Wassim Tarraf, Martha Daviglus, Sonia Davis, Linda Gallo, Yasmin Mossavar-Rahmani, Frank Penedo, Susan Redline, Tatjana Rundek, Ralph Sacco, Daniela Sotres-Alvarez, Clinton Wright, Phyllis Zee, Hector Gonzalez

Neuroepidemiology: MS and CNS Inflammatory Disease P1.101

Testicular Hypofunction and Multiple Sclerosis Risk: A Record-linkage Study Julia Pakpoor, Raph Goldacre, Klaus Schmierer, Gavin Giovannoni, Michael Goldacre

P1.102

Cancer Risk Associated with Disease-modifying Drugs in Multiple Sclerosis: A French Registry-based Study Mathilde Lefilliatre, Nathalie Derache, Elodie Guillaume, Karine Droulon, Guy Launoy, Gilles Defer

P1.103

NMDA Receptor Encephalitis in Veterans Gurjeet Singh, Evan Lott, John Greenlee, Stacey Clardy

P1.104

Neuromyelitis Optica in Veterans Victor Wang, Thomas Clardy, John Rose, James Burns, Noel Carlson, John Greenlee, Stacey Clardy

Characterizations of the 2013 Lublin MS Phenotypes in a Single-center Dataset Edward Gettings, Chris Hackett, Carol Schramke, Thomas Scott Quality of Life Perceptions Correlate with Longitudinal Clinical Relapse Reduction Metrics in Patients Treated with Subcutaneous Interferon Beta-1a Given Three Times a Week Barbara Teter, Katelyn Kavak, Fernando Dangond, Bianca Weinstock-Guttman

MS and CNS Inflammatory Diseases: Symptoms, Specific Symptomatic Treatment, Comorbidities, and Costs P1.114

Comorbidity Is Associated with Increased Pain and Fatigue in Multiple Sclerosis Kirsten Fiest, John Fisk, Scott Patten, Helen Tremlett, Christina Wolfson, Sharon Warren, Kyla McKay, Lindsay Berrigan, Ruth-Ann Marrie

P1.108

Clinical Predictors of Disease Progression in Multiple Sclerosis Patients with Relapsing Onset in a Nationwide Cohort Raed Alroughani, Saeed Akhtar, Samar Ahmed, Jasem Al-Hashel


P1.123

Prolonged-release Fampridine as Adjunct Therapy to Active Enabled Motor Training in Multiple Sclerosis Patients: A Pilot, Double-blind, Placebocontrolled Study Francois Jacques, Adrian Schembri, Avi Nativ, Chantal Paquette, Pawel Kalinowski

P1.124

A Pilot Study of Dalfampridine for Improving Upper Extremity Function in Multiple Sclerosis Patients Mark Tullman, Kara Knetzer, M'Aggie Maranzana, Delea Payne-Gates, Heather Popham, Amber Salter, Barry Singer

P1.125

Results from a Randomized Double-blind Crossover Study Comparing Oral L-carnitine Versus Placebo and a Subsequent Physical Rehabilitation Program for the Treatment of Fatigue in Multiple Sclerosis Jean-Christophe Ouallet, Julien Asselineau, David Laplaud, Sandrine Wiertlewski, Sophie Pittion, Marc Debouverie, Christine Lebrun Frenay, Mickael Cohen, Philippe Cabre, Severine Jeannin, Genevieve Chene, David Brassat, Aurore Saubusse, Dieynaba Djigo, Jeremy Chateauraynaud, Bruno Brochet

P1.127

Impaired Cardiac Interoception in Patients with Multiple Sclerosis Sol Esteves, Lucas Sedeño, Vladimiro Sinay, Diana Bruno, Fatima Pagani Cassara, Blas Couto, Federico Adolfi, Ezequiel Mikulan, Giselle Kozono, Marcos Pietto, Facundo Manes, Maria Roca, Agustín Ibañez

P1.118

Demographics and Clinical Characteristics of Pediatric Onset Multiple Sclerosis Raed Alroughani, Samar Ahmed, Jasem Al-Hashel

Changing Course of Multiple Sclerosis (MS) After Stroke: Excessive Disease Activity in a MS Patient After Cerebral Infarction Walter Poellmann, Michaela Starck, Tania Kuempfel, Juergen Koehler

P1.116

P1.106

P1.107

P1.122

Adverse Impact of Comorbidity on Mortality in Multiple Sclerosis Ruth-Ann Marrie, Stella Leung, James Marriott, Michael Cossoy, Lawrence Elliott, James Blanchard, Nancy Yu

P1.115

Cardiovascular Autonomic Dysfunction in Multiple Sclerosis: A Metanalysis and Systematic Review Juan Racosta, Luciano Alberto Sposato, Sarah Morrow, Lauren Cipriano, Kurt Kimpiski, Marcelo Kremenchutzky

Risk Factors and Final Diagnoses of Patients First Diagnosed as Infectious Acute Disseminated Encephalomyelitis (ADEM): A Single-center Study Diederik Koelman, Tanuja Chitnis, Farrah Mateen

Toxoplasma Gondii Seropositivity Is Negatively Associated with Multiple Sclerosis Frauke Stascheit, Friedemann Paul, Ulrike Grittner, Lutz Harms, Berit Rosche

Prolonged-release Fampridine Post-marketing Experience in Alsace, France Carole Berthe, Jean-Claude Ongagna, Sylvie Courtois, Claude Gaultier, Audrey Kopf, Marie-Celine Fleury, Aurelien Benoilid, Nicolas Collongues, Frederic Blanc, Christian Zaenker, Jerome De Seze

Multiple Sclerosis Prevalence in the United States Insured Population Jonathan Campbell, Piyameth Dilokthornsakul, Kavita Nair, John Corboy, Robert Valuck

P1.105

P1.121

P1.117

A Phenome-wide Examination Uncovers the Comorbidity Burden in Severe Multiple Sclerosis Zongqi Xia, Matthew Goodman, Brian Healy, Tanuja Chitnis, Philip De Jager, Howard Weiner

P1.119

Multiple Sclerosis and Cancer Deeya Gaindh, Katelyn Kavak, Barbara Teter, Muhammad Nadeem, Bianca Weinstock-Guttman

P1.126

Effect of Montelukast on Gastrointestinal Tolerability in Patients with Relapsing Forms of Multiple Sclerosis Receiving Delayed-release Dimethyl Fumarate: A Multicenter, Randomized, Double-blind, Placebo-controlled Study (MITIGATE) Carlo Tornatore, John Walsh, Monica Mann, Jie Li, Christian Von Hehn

P1.128

Prevalence of Sleep Disturbances, Fatigue, Anxiety and Depression in Multiple Sclerosis (MS) Sven Rupprecht, Steffen Kluckow, Maryam Yahiaoui-Doktor, Orhan Aktas, Andrew Chan, Alexander Dressel, Juergen Faiss, Klaus Gehring, Frank Hoffmann, Ulf Kallweit, Wolfgang Koehler, Andreas Kowalik, Michael Lang, Chrstoph Lassek, Sabine Lobenstein, Wilfried Lüer, Mike Matzke, Geert Mayer, Joachim Piatkowski, Udo Polzer, Sebastian Schimrigk, Barbara Schwandt, Carsten Sievers, Konstanze Tinschert, Klaus Uwe Zettl, Sylvia Kotterba, Matthias Schwab

P1.120

Temporomandibular Disorders (TMD) and Multiple Sclerosis (MS) Lucas Carvalho, Andre Matta, Osvaldo Nascimento

59

Monday April 20



Multiple Sclerosis and Sleep Disorders: Exploration of Sleep Disordered Breathing -Apnea Hypopnea Index NonREM Versus REM in a Community Cohort of Patients with Multiple Sclerosis Who Report Fatigue Mark Gudesblatt, Steven Xian, Myassar Zarif, Barbara Bumstead, Smitha Thotam, Lori Fafard, Konstantina Bardhi, Marijean Buhse

P1.141

Wernicke’s Encephalopathy as a Mimicker of a Brainstem Relapse in a Multiple Sclerosis Patient Ariel Antezana, Joseph Herbert, Ilya Kister, Steven Galetta

P1.152

MS and CNS Inflammatory Diseases: Treatment Mechanisms of Action

P1.153

P1.130

P1.142

P1.131

P1.143

Longitudinal Evaluation of Falls and Fall Prevention Strategies in Multiple Sclerosis Michelle Cameron, Miho Asano, Elizabeth Peterson, Marcia Finlayson Homonymous Hemianopsia in Multiple Sclerosis (MS)—a Rare Symptom with Need for Etiological Clarification Walter Poellmann, Wolfgang Walter Feneberg, Claudia Busch, Renate Hofreiter, Juergen Koehler

P1.132

Impulsivity Traits in Patients with Multiple Sclerosis in Bogotá, Colombia Jaime Toro, Lisseth Burbano, Camilo Diaz-Cruz, Saúl Reyes, Luisa Blanco, Luis Orozco-Cabal

P1.133

Helminth Infections Associated with Multiple Sclerosis Induce Regulatory B Cells. Investigating the Role of IL-35 Jorge Correale, Mauricio Farez

P1.134

The Framingham Cardiovascular Risk Score in Multiple Sclerosis Marcello Moccia, Roberta Lanzillo, Raffaele Palladino, Giorgia Teresa Maniscalco, Anna De Rosa, Cinzia Valeria Russo, Marco Massarelli, Antonio Carotenuto, Emanuela Postiglione, Oreste Caporale, Maria Triassi, Vincenzo Brescia Morra

P1.135

Pharmacokinetics, Safety and Tolerability of Siponimod (BAF312) in Subjects with Different Levels of Hepatic Impairment Compared to Demographically Matched Healthy Subjects Kasra ShakeriNejad, Vassilios Aslanis, Uday Kiran Veldandi, Anne Gardin, Andreas Zaehringer, Angela Dodman, Zhenzhong Su, Eric Legangneux

P1.136

Effect of Age and Sex on Cost of Multiple Sclerosis-related Relapse Defined by Inpatient Stays Chris Kozma, Amy Phillips, Julie Locklear

P1.137

Cost-effectiveness (CE) of Fingolimod Vs. Intramuscular Interferon Beta-1a in the Treatment of Relapsingremitting Multiple Sclerosis (RRMS) Tara Nazareth, John Ko, Jipan Xie, William Reichmann, Chen Zhao, Rahul Sasane

P1.138

Prevalence of Complications in Multiple Sclerosis in Hospitalized Patient Among Different Age Groups Chirag Savani, Parisha Bhatia, Akash Vadhavana, Achint Patel, Dave Mihir, Vishal Jani

2:00 p.m.–6:30 p.m.

Immune Regulatory Effects of FTY720 on Dendritic Cells Maria Antonietta Mazzola, Lily Aly, Russell Griffin, Parham Nejad, Howard Weiner, Roopali Gandhi Immune Regulatory Effects of FTY720 on Human T Cells Maria Antonietta Mazzola, Hasan Rajabi, Russell Griffin, Lily Aly, Bonny Patel, Bonnie Glanz, Tanuja Chitnis, Howard Weiner, Roopali Gandhi

P1.144

Comparative Gene Expression Profiling Between a Generic (M356) and Brand Copaxone® (Glatiramer Acetate Injection) Josephine D’Alessandro, Jay Duffner, Joel Pradines, Christopher Honan, Thomas Prod’homme, Tanmoy Ganguly, Ganesh Kaundinya

P1.145

Demonstration of Equivalence Between a Generic (M356) and Brand Copaxone® (Glatiramer Acetate Injection) James Anderson, Tanmoy Ganguly, Ishan Capila, Christine Bell, Jim Prescott, Jon Lansing, Joe Glajch, John Bishop, Ganesh Kaundinya

P1.146 Immunomonitoring

Lymphocyte Subpopulations in the Different Clinical Forms of Multiple Sclerosis. The Effect of Natalizumab and Interferon-β Aina Teniente-Serra, Laia Grau-Lopez, M José Mansilla, Marco Fernandez-Sanmartin, Anna Ester-Condins, Cristina Ramo, Eva Martinez-Caceres

P1.147

Evaluation of Immunogenicity in Patients with Multiple Sclerosis Treated with Daclizumab HYP Lakshmi Amaravadi, Alvydas Mikulskis, Nisha Lucas, Katherine Riester, Marianne Sweetser, Jacob Elkins

P1.148

Daclizumab High-yield Process (DAC HYP) Has No Effect on Activity of the Cytochrome P450 (CYP) Enzymes: Results of a Drug Cocktail Interaction Study in Subjects with Multiple Sclerosis (MS) Jonathan Tran, Ahmed Othman, Yaoshi Wu, Paul Wolstencroft, Jacob Elkins

P1.149

Early, Sustained and Reversible Pharmacodynamic Effects of Daclizumab HYP in MS Support Mechanism of Action Via Modulation of the IL-2 Pathway Lakshmi Amaravadi, Devangi Mehta, Katherine Riester, James Sheridan, Jacob Elkins

P1.139

Economic Cost of an MS Relapse (PEARL Study) Stefan Vormfelde, Tjalf Ziemssen

The NRF2 Transcriptional Target, OSGIN1, Contributes to the Cytoprotective Properties of Monomethyl Fumarate Melanie Brennan, Maria Matos, Chao Sun, Suzanne Szak, Robert Scannevin

P1.140

P1.151

Marijuana Usage and Disability in MS in the NARCOMS Registry Stacey Cofield, Amber Salter, Tuula Tyry, Christina Crowe, Sandre McNeal, Gary Cutter, Robert Fox, Ruth-Ann Marrie

60

P1.150

Long-term Axonal Repair: Outcomes in Treatment-refractory MS Stratified by Treatment and Baseline Demographics Prior to Alemtuzumab (ALE) Samuel Hunter, Heli Hunter, Daniel Kantor

The Effect of Mesenchymal Stem Cell Transplantation on Diffusion Tensor Imaging from T2 Lesional Tissue Erik Offerman, Elizabeth Fisher, Jian Lin, Ken Sakaie, Sarah Pope Planchon, Michael Phillips, Mark Lowe, Jeffrey Cohen, Daniel Ontaneda Fingolimod Reduces Axonal Transection During Demyelination Brian Bai, Simon Lunn, Robin Avila, Jing Wang, Doug Chmura, Emily Benson, Grahame Kidd, Satish Medicetty, Bruce Trapp

P1.154

Long-term Fingolimod Treatment of Multiple Sclerosis Induces Phenotypical Immunsenescence Nicole Schwanitz, Andreas Boldt, Muriel Stoppe, Johannes Orthgiess, Stefan Borte, Ulrich Sack, Florian Then Bergh

P1.155

Peripheral Immune Cell Profiles in Fingolimod Treated Multiple Sclerosis Patients Following Short-term Drug Interruption Leslie Fitz-Gerald, Ayman Rezk, Rui Li, Mukanthu Nyirenda, David Haegert, Paul Giacomini, Amit Bar-Or, Jack Antel

P1.156

Differential Effects of Fingolimod on Gene Expression of Helper and Cytotoxic T-cells in the Blood of MS Patients Michael Hecker, Brit Fitzner, Dirk Koczan, Jörg Friess, Luisa Roch, Ina Schröder, Kristin Flechtner, Hans-Jürgen Thiesen, Alexander Winkelmann, Uwe Zettl

P1.157

Fingolimod Effects on CD8 Cells in Multiple Sclerosis Anthony Reder, Suad Causevic, Zhe Wang, Fernando Testai, Xuan Feng

P1.158

Comparison of Fingolimod and Interferon-beta Effects on Th1/Th2-related Chemokine Receptors on Peripheral T Cells in Patients with Multiple Sclerosis Yuko Shimizu, Ryotaro Ikeguchi, Kohei Ota, Kazuo Kitagawa

P1.159

Fingolimod Up-regulates BDNF Expression Within the CNS and Downregulates Tissue Pathology in a Pre-clinical Model of Chronic Neuroinflammation Paul Smith, Valerie Dubost, Volker Brinkmann, Magali Jivkov, Catherine Huck, Diethilde Theil

P1.160

Effect of Fingolimod on an Animal Surgical Wound Healing Model: A Non-immunosupressive Profile Ricardo Ginestal, Alberto Cifuentes, Marta Rodriguez-Mancheno, David Cebrian, Francisca Garcia-Moreno, Juan Manuel Bellon

P1.161

Laquinimod Suppresses CNS Autoimmunity by Activation of Natural Killer Cells Stefan Nessler, Martina Ott, Christiane Wegner, Liat Hayardeny, Evelyn Ullrich, Wolfgang Bruck

P1.162

Pioglitazone Treatment Enhances Myelin Debris Phagocytosis and Immunoregulatory Functions of Monocytes from MS Patients Muktha Natrajan, Kory Johnson, Abdel Elkahloun, Robin Franklin, Bibiana Bielekova

P1.163

Dimethyl Fumarate Alters Microglia Phenotype and Protects Neurons Against Proinflammatory Toxic Microenvironments Haiyan Peng, Maria Matos, Brian Wipke, H Arnold, Robert Scannevin

P1.164

Effects of Oral Dimethyl Fumarate on Intestinal Immune Regulation in Autoimmune Neuroinflammation Ralf Linker, Stefanie Joerg, Aiden Haghikia, DeHyung Lee, Arndt Manzel, Ralf Gold, Anna Hammer

Movement Disorders: Parkinson's Disease DBS P1.165

Effects of Randomized STNDBS on Gait in Patients with Parkinson’s Disease Karlo Lizarraga, Jonathan Jagid, Bruno Gallo, Corneliu Luca

P1.166

Does the Use of Intraoperative Microelectrode Recording Influence the Final Location of Lead Implant in Deep Brain Stimulation in Parkinson’s Disease Patients? Sujan Reddy, Albert Fenoy, Erin Furr-Stimming, William Ondo, Mya Schiess, Raja Mehanna

P1.167

Characteristics of Neuronal Oscillatory Activity in the Ventrolateral Thalamus in Patients with Parkinsonian Tremor and Essential Tremor Ping Zhuang, Mark Hallett, Tingting Liu, Yuqing Zhang, Jianyu Li, Yongjie Li

P1.168

Unilateral Vs. Bilateral Subthalamic Stimulation in Parkinson's Disease Sara Duffus, Ugonma Chukwueke, Roy Strowd, Jennifer Green, Ihtsham Haq, Jessica Tate, Maja Herco, Adrian Laxton, Stephen Tatter, Mustafa Siddiqui

P1.169

Self-ratings of Impulsive and Compulsive Behaviors Decrease in Parkinson's Patients Following Deep Brain Stimulation of the Subthalamic Nucleus Katherine Kudyba Morone, Wylie Scott, Daniel Claassen, Nelleke Van Wouwe, Kristen Kanoff, Olivia Roman, Lauren Griffin, Joseph Neimat

P1.170

Distinct Phenotypes of Speech and Voice Disorders in Parkinson’s Disease After Subthalamic Nucleus Deep Brain Stimulation Takashi Tsuboi, Yasuhiro Tanaka, Hirohisa Watanabe, Gen Sobue

P1.171

Vercise DBS Registry: A Prospective, Multi-center International Registry for Parkinson’s Disease Günther Deuschl, Jan Vesper, Sherry Lin, Nic Van Dyck, Roshini Jain

P1.172

Accuracy of Deep Brain Stimulation Electrode Implanted by Frameless System Using Postoperative Computer Tomography Jan Bardon, David Krahulik, Martin Nevrly, Pavel Otruba, Petr Kanovsky


Poster Session I

P1.173

VANTAGE Trial: A Prospective, Multi-center Trial Evaluating Deep Brain Stimulation with a New Multiple-source, Constant-current Rechargeable System in Parkinson’s Disease Lars Timmermann, Roshini Jain, Thomas Brücke, Fernando Seijo, Esther Suarez San Martin, Claire Haegelen, Marc Verin, Mohammed Maarouf, Michael Barbe, Steven Gill, Alan Whone, Mauro Porta, Domenico Servello, François Alesch

P1.174

Patient-centered Outcomes of Deep Brain Stimulation in Parkinson’s Disease Jessica Karl, Bichum Ouyang, Leonard Verhagen Metman

Movement Disorders: Parkinson Plus Syndromes P1.175

PET Evidence for Distinct Features of Tau Parkinsonism and Parkinsonism with Alphasynucleinopathy Chong Lee, Jason Lee, Joon Mo Koo, Sujeong Kim, Seok Min Kim, Doris Doudet

P1.176

Are the Mechanisms of Nigral Cells Neurodegeneration in Typical and Atypical Parkinsonism Different—MRI and Mössbauer Spectroscopy Studies Andrzej Friedman, Radoslaw Kulinski, Jolanta Galazka-Friedman

P1.177

Alpha-synuclein Pathology in Colonic Biopsy of a Suspected Multiple System Atrophy Patient—a Case Report Umer Akbar, Edward Stopa, Douglas Anthony, John Donahue, Joseph Friedman

P1.178

Basal Ganglia Abnormalities in Diabetic Uremic Syndrome Koji Fujita, Yusuke Osaki, Takashi Abe, Masafumi Harada, Yuishin Izumi, Ryuji Kaji

P1.179

In Vivo Evidence for Transsynaptic Degeneration in the Striatum of MSA-P Patients: PET Studies with [18F] FP-CIT and [18F]FDG Joon Mo Koo, Chong S. Lee, Sujeong Kim, Seok Min Kim, Deniz Kirik

P1.180

A Geographical Cluster of Progressive Supranuclear Palsy in Northern France Lawrence Golbe, Dominique Caparros-Lefebvre, Luc Buee, Valerie BueeScherrer, Vincent Deramecourt, Claude Alain Maurage, Andrew Lees

P1.181

The Impact of White Matter Damage on Cognition in PSP Syndrome: A DT MRI Study Francesca Caso, Federica Agosta, Maria Antonietta Volontè, Alessandra Marcone, Massimiliano Copetti, Francesca Spagnolo, Monica Falautano, Andrea Falini, Giancarlo Comi, Massimo Filippi

P1.182

Coenzyme Q10 Levels Are Reduced in the Cerebellum of Multiple System Atrophy Patients Lucia Schottlaender, Conceicao Bettencourt, Aoife Kiely, Annapurna Chalasani, Viruna Neergheen, Janice Holton, Iain Hargreaves, Henry Houlden

P1.183

Need for Improved Bone Mineral Density Screening in Parkinsonism Melissa Nicoletti, Jessica Rowe, Lisa Shulman, Stephen Reich, F. Rainer Von Coelln, Melissa Armstrong

Movement Disorders: Parkinson's Disease Pharmacotherapy P1.184

Summary of Safety from Clinical Trial Experience with IPX066, Extended-release Carbidopa-levodopa, in Parkinson’s Disease Margery Mark, Rohit Dhall, David Kreitzman, Sherron Kell, Sarita Khanna, Ann Hsu, Suneel Gupta

P1.185

Comparison of Safety from Phase 3 Clinical Trials of IPX066, an Extended-release Carbidopa-levodopa Formulation, in Parkinson’s Disease Rohit Dhall, Margery Mark, David Kreitzman, Sherron Kell, Sarita Khanna, Ann Hsu, Suneel Gupta

P1.186

Re-evaluating Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson’s Disease: A 3-center, Placebocontrolled, Pilot Study (The REST PD Trial) Shnehal Patel, Thien Thien Lim, Benzi Kluger, Ramon Rodriguez, Irene Malaty, Rafael Palacio, Oluwadamilola Ojo, Yogesh Gujrati, Camille Swartz, Benjamin Nutter, Carol Hennessy, Hubert Fernandez

P1.187

Pharmacokinetics and Safety of ND0612L (Levodopa/Carbidopa for Subcutaneous Infusion): Results from a Phase II Study in Moderate to Severe Parkinson’s Disease Nir Giladi, Yossi Caraco, Tanya Gureritch, Ruth Djaldetti, Yael Cohen, Oron Yacobi-Zeevi, Sheila Oren

P1.188

De-novo Amantadine Treatment Delays Onset of Dyskinesias in Patients with Parkinson Disease Maja Relja

P1.189

Efficacy of Apomorphine Subcutaneous Injections for the Management of Morning Akinesia in Parkinson’s Disease Stuart Isaacson, William Ondo, Fernando Pagan, Mark Lew

P1.190

Rotigotine in Patients with PD and Unsatisfactory Early-morning Motor Symptom Control: A Post-hoc Analysis of Efficacy and Safety by Dose Babak Boroojerdi, Mahnaz Asgharnejad, Arturo Benitez, Erwin Surmann, Lars Bauer

P1.191

Comparison of Efficacy from Phase 3 Clinical Trials of IPX066, an Extended-release Carbidopalevodopa Formulation, in Parkinson’s Disease Lawrence Elmer, Ramon Gil, Dee Silver, Ann Hsu, Sarita Khanna, Sherron Kell, Suneel Gupta

P1.192

Global Long-term Registry on Efficacy and Safety of LevodopaCarbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease in Routine Care (GLORIA)—Interim Results in a Subgroup of Patients with Dyskinesia at Baseline Werner Poewe, K Ray Chaudhuri, Lars Bergmann, Ashley Yegin, Stephanie Dubow, Angelo Antonini

P1.194

The NINDS Parkinson’s Disease Biomarkers Program Katrina Gwinn, Karen David, Coryse Hillaire-Clarke, McAuliffe Matt, Debra Babcock, Beth-Anne Sieber, Margaret Sutherland

P1.195

Handling Missing Values in the MDS-UPDRS Christopher Goetz, Sheng Luo, Lu Wang, Barbara Tilley, Nancy LaPelle, Glenn Stebbins

P1.196

Continuous Motion Sensor Assessment of Parkinson’s Disease During Activities of Daily Living Christopher Pulliam, Dustin Heldman, Elizabeth Brokaw, Michelle Burack, Thomas Mera

P1.197

Early Recruitment in Connect. Parkinson, a National, Randomized, Controlled Trial of Telemedicine for Parkinson Disease Ryan Korn, Meredith Achey, Christopher Beck, Denise Beran, Cynthia Boyd, Peter Schmidt, Allison Willis, Sara Riggare, Richard Simone, Kevin Biglan, E. Ray Dorsey

P1.198

Correlation Between Unified Parkinson’s Disease Rating Scale and Global Impression of Change Scales Khashayar Dashtipour, Jack Chen, Pejman Dalaie, Karen Frei, Kayvan Kani, Camellia Kani

P1.199

Database of Evidence-based Ranked Parkinson Disease Variants Jeffery Vance, Liyong Wang, Gary Beecham, Christine Van Broeckhoven, Karen Nuytemans

P1.207 Tactile Unawareness in

Acute Right Hemispheric Stroke Daniel Antoniello, Reena Gottesman

P1.208 Lateral Eye Deviation and

Post-stroke Spatial Neglect A. Barrett, Shreyas Shirodkar, Brian Yao, Peii Chen

P1.209 Anatomical and

Psychophysical Comparison of Subjective Verticals in Patients with Right Brain Damage Arnaud Saj, Jacques Honore, Berenger Braem, Marc Rousseaux

P1.210

Self-report of Correct Inner Speech Predicts Naming Success, Brain Activity and Treatment Outcomes in People with Aphasia William Hayward, Mackenzie Fama, Kelli Sullivan, Sarah Snider, Elizabeth Lacey, Rhonda Friedman, Peter Turkeltaub

P1.211

"I Know It but I Can't Say It": Using Self-report to Understand the Experience of Inner Speech in Aphasia Mackenzie Fama, Sarah Snider, William Hayward, Rhonda Friedman, Peter Turkeltaub

P1.200 Incidence and Time Trends of

P1.201 Computerized Assessment

Aging, Dementia, Cognitive, and Behavioral Neurology: Frontotemporal Degenerations: Clinical Aspects and Biomarkers

Drug-induced Parkinsonism: A Populationbased Study over 30 Years (1976–2005) Rodolfo Savica, Brandon Grossardt, James Bower, J. Ahlskog, Walter Rocca of Apathy in Parkinson's Disease Shows Specific Motivational and Planning Deficits Whitney Fitts, Lauren Massimo, Nicholas Lim, Murray Grossman, Nabila Dahodwala

P1.202 Prospective, Comparative

Study on Cost-effectiveness of Homebased Motor Monitoring System and Office-based Medical Assessment in Advanced Parkinson´s Disease Esther Cubo Delgado, Natividad Mariscal-Pérez, Berta Solano, Virginia Becerra, Jana Arribas

Aging, Dementia, Cognitive, and Behavioral Neurology: Attention and Aphasia P1.203 Increased Early Processing of Task-irrelevant Auditory Stimuli in Older Adults Kirk Daffner, Erich Tusch, Anne Fox, Fabio Porto, Brittany Alperin, Phillip Holcomb

P1.204 The Influence of Executive

Capacity and Age on Attention to Novel Auditory Events Kirk Daffner, Anne Fox, Erich Tusch, Fabio Porto, Brittany Alperin, Phillip Holcomb

P1.193

P1.205 Dementia and the Cocktail


Response Inhibition and Bimanual Coordination: A Cerebral Interhemispheric Disconnection Ali Shoraka, Dana Otzel, Eduardo Zilli, Glen Finney, Leilani Doty, Kenneth Heilman, Adam Falchook

Transcranial Direct Current Stimulation for the Treatment of Primary Progressive Aphasia Felix Gervits, Sharon Ash, Marianna Diloyan, Brianna Morgan, H. Coslett, Murray Grossman, Roy Hamilton

Movement Disorders: Parkinson's Disease Research Methods IPad App for Daily Parkinson Diary Codrin Lungu, Bona Kim, Mark Hallett, Kara Lukasiewicz, John Harrington, Anne Altemus, Jeff Baldwin

P1.206 Effects of Aging on Crossed

Party Salwa Kamourieh, Rodrigo Braga, Robert Leech, Richard Wise

P1.212

P1.213

Cerebrospinal Fluid Biomarkers and [11C]Pittsburgh Compound-B PET Concordance in Alzheimer Disease Vs. Frontotemporal Dementia Syndromes Jee Bang, Rik Ossenkoppele, Leslie Shaw, Zachary Miller, William Seeley, Lea Grinberg, Anna Karydas, Adam Boxer, Maria Luisa Gorno-Tempini, John Trojanowski, Bruce Miller, William Jagust, Howard Rosen, Gil Rabinovici

P1.214

The Neuropsychiatric Inventory Questionnaire (NPI-Q2): Quantitative and Qualitative Differences Between Alzheimer Disease and Frontotemporal Dementia Lydia Hatfield, Teri Swezey, Matthew Harris, Daniel Kaufer

P1.215

BvFTD Phenocopy Syndrome: Myth or Reality? Catherine Belin, Didier Maillet, Gabriel Pop, Antoine Carpentier

P1.216

Pick's Disease Caused by a Novel MAPT Mutation Zbigniew Wszolek, Pawel Tacik, Michael DeTure, Kelly Ross, Wenlang Lin, Monica Sanchez Contreras, Aleksandra Wojtas, Matthew Baker, Yari Carlomango, Patricia Brown, Audrey Strongosky, Catherine Labbe, Shinsuke Fujioka, Naomi Kouri, Melissa Murray, Rosa Rademakers, Owen Ross, Dennis Dickson

61

Monday April 20



Survival in Primary Progressive Aphasia: Comparison with BvFTD and FTD-ALS Sara Mitchell, Christina Caso, Megan Quimby, Kathleen Kelly, Chenjie Xia, Elena Ratti, Kimiko Domoto-Reilly, Scott McGinnis, Daisy Hochberg, Jeanette Gunther, Matthew Frosch, Bradford Dickerson

P1.218

Seizures and Myoclonus in the Early Stages of Frontotemporal Dementia Alexander Beagle, Sonja Darwish, Elissaios Karageorgiou, Keith Vossel

P1.219

The Role of Age and Genetic Markers on Cerebrospinal Fluid Tau Levels in Pathology-confirmed Frontotemporal Degeneration Murray Grossman, Corey McMillan, David Irwin, Vivianna Van Deerlin, Leslie Shaw, Virginia Lee, John Trojanowski

P1.220 Utility and Neuroanatomical

Correlates of the FTLD-NACC Neuropsychology Module in the Differential Diagnosis of Behavioral Variant Frontotemporal Dementia and Alzheimer’s Disease Katya Rascovsky, Eileen Moran, Laura Baehr, David Irwin, Corey McMillan, Murray Grossman

P1.221

Confirmation of Grey Matter Disease Distributions in a Colombian Cohort of Patients with Frontotemporal Degeneration Pablo Alexander Reyes, Diana Matallana, Felipe Uriza, Carlos Cano, Murray Grossman, Corey McMillan, Katya Rascovsky

Aging, Dementia, Cognitive, and Behavioral Neurology: Frontotemporal Degenerations: Cognition and Behavior P1.222 Cognitive-behavioral

Changes in Amyotrophic Lateral Sclerosis: Prevalence, Progression, and Impact on Patients and Caregivers Meredith Bock, Y-Nhy Duong, Anthony Kim, Jennifer Murphy, Catherine Lomen-Hoerth

P1.223 Behavioral Change in ALS

as a Phenotypic Marker of Disease Subtypes Tom Burke, Marwa Elamin, Peter Bede, Marta Pinto Grau, Alice Vajda, Russel McLaughlin, Niall Pender, Orla Hardiman

P1.224 Decision-making in

Amyotrophic Lateral Sclerosis Katya Rascovsky, Joseph Kable, Eileen Moran, Christopher Olm, Rebecca Kazinka, Leo McCluskey, Lauren Elman, Ashley Boller, Robin Clark, Corey McMillan, Murray Grossman

P1.225 Eating Behavior and Metabolic Changes Across the Spectrum of Motor Neuron Disease and Frontotemporal Dementia Rebekah Ahmed, Elana Henning, Lauren Bartley, Glenda Halliday, Olivier Piguet, Sadaf Farooqi, John Hodges, Matthew Kiernan

P1.226

Grammar Comprehension and Executive Function in Patients with the Behavioral Variant of Frontotemporal Degeneration (bvFTD) Rebecca Williams, Sharon Ash, Katya Rascovsky, Murray Grossman

62

2:00 p.m.–6:30 p.m.

P1.227 Matching Behavioral

Variant Frontotemporal Dementia and Alzheimer Disease Groups on Dementia Severity Mariel Deutsch, Michelle Mather, Elvira Jimenez, Mario Mendez

P1.228

Connected Speech Production in the Nonfluent Variant of Primary Progressive Aphasia and Its Relationship with White Matter Damage Elisa Canu, Federica Agosta, Sebastiano Galantucci, Eleonora Catricalà, Pilar Ferraro, Giuseppe Magnani, Alessandra Marcone, Elisabetta Coppi, Giancarlo Comi, Andrea Falini, Massimo Filippi

P1.229 Prosodic Expression in

Frontotemporal Dementia Peter Pressman, Robert Levenson, Bruce Miller, Maria Gorno Tempini

P1.230 Baseline Autonomic

Dysfunction Relates to Cognitive Empathy Impairment in Behavioral Variant Frontotemporal Dementia Virginia Sturm, Alice Hua, Sandy Lwi, Katherine Rankin, Howard Rosen, Bruce Miller, Robert Levenson, William Seeley

P1.231 A Case of Semantic Dementia with Picks Pathology Alyssa Caplan, Jon Elofson, Claire Lis, Howard Rosen, Maria Gorno Tempini, Lea Grinberg, Bruce Miller

Epilepsy/Clinical Neurophysiology (EEG): Pharmaceuticals P1.232

Perampanel Discontinuation Is Not Associated with Self-reported Withdrawal Symptoms in Patients Completing Phase III Clinical Studies Michael Rogawski, Haichen Yang, Reginald Fant, Betsy Williams, Dongyuan Xing, Cindy Dobrinsky, Antonio Laurenza

P1.233

Abuse Potential of Antiepileptic Drugs: A Review Using TM the VigiBase Pharmacovigilance Database Barry Gidal, David Blum

P1.234 Changes in Quality of

Life (QoL) and Depressive Symptoms in a Long-term Open-label Extension (OLE) of Eslicarbazepine Acetate (ESL) Monotherapy Studies in Adults with Refractory Partial-onset Seizures (POS) Frank Gilliam, Hailong Cheng, David Blum

P1.235 Lacosamide Does Not Affect Depression and Anxiety in Patients with Epilepsy Brian Moseley, Devlin Cole, Ogonna Iwuora, Jeffrey Strawn, Michael Privitera

P1.236 Intravenous Fosphenytoin in Obese Patients: An Evaluation of Dosing Strategies, Safety and Efficacy Sarah Clark, Megan Leloux, Sara Hocker, Ross Dierkhising, Gregory Cascino

P1.237

Comparison of Leviteracetam Dosing Regimens in End-stage Renal Disease Patients Undergoing Intermittent Hemodialysis Harn Shiue, Kara Sands, Maria Taylor

P1.238 Co-administration of Valproic Acid and Lamotrigine in the Treatment of Refractory Epilepsy Mei Jiang

P1.239 Safety and Tolerability of

Lacosamide Monotherapy in Elderly: A Subgroup Analysis from Lacosamide Trials in Diabetic Neuropathic Pain Edward Faught, Marc De Backer, Klaus Eckhardt, Frank Tennigkeit, Sabine Bongardt, David Rudd, David Sen, Konrad Werhahn

P1.240 Cross-titration of Lacosamide with a Sodium Channel Blocker in Patients with Partial Onset Seizures on a Stable Dose Regimen of Levetiracetam: Safety and Efficacy Michel Baulac, William Byrnes, Paulette Williams, Kimberly Doggett, Elizabeth Webster, Marc De Backer, Peter Dedeken

P1.241 Carbamazepine

Monotherapy: Relationship Between Drug Compliance, Serum Levels and Seizure Control Mustapha Danesi, Adedunni Olusanya, Francis Ojini, Njide Okubadejo

P1.242 Effect of Adjunctive

Rufinamide in Pediatric Patients with Inadequately Controlled Lennox-Gastaut Syndrome (LGS): Interim Pharmacokinetic and Safety Results from Study 303 Jose Ferreira, Alexis Arzimanoglou, Shannon Mendes, Betsy Williams, David Critchley, Edgar Schuck, Dinesh Kumar, Francesco Bibbiani

P1.243 Progression to Adjunctive

Therapy Among Commerciallyinsured Patients with Partial Onset Epilepsy Richard Brook, Fulton Velez, Jacob Young

P1.244 Adherence and Resource

Utilization with Extended-release Oxtellar XR® or Immediate-release Oxcarbazepine (OXC-IR) Treatment in Clinical Practice: A Standardized Case Record Review Welton O'Neal, Elizabeth Hur, Katie Andersen, Trevor Resnick

P1.245 Population Pharmacokinetic

Modeling of Extended-release Topiramate (SPN-538, Trokendi XR®) in Children with Epilepsy Scott Brittain, Janet Johnson

P1.246 Topiramate and Zonisamide

Are Not Effective in Secondary Prevention of Infantile Spasms Rajsekar Rajaraman, Johnson Lay, Raman Sankar, Shaun Hussain

P1.247

Long-term Efficacy, Safety, and Impact on Quality of Life of USL255, Qudexy™ XR (Topiramate) Extendedrelease Capsules: PREVAIL OLE Robert Hogan, Ian Blatt, Annie Clark, Bob Anders, Mark Halvorsen, Steve Chung

P1.248 Investigations of USL255, Qudexy™ XR (Topiramate) Extendedrelease Capsules, Sprinkled onto Soft Food or Delivered via Enteral Feeding Tubes Mary Holmay, Annie Clark, Bob Anders, John Pellock

P1.249

Is Half-life a Clinically Relevant Measure for Extended-release Drugs? Data Comparing Immediate- and Extended-release Topiramate (USL255; Qudexy™ XR) Barry Gidal, Annie Clark, Bob Anders

P1.250 Eslicarbazepine Acetate (ESL) Monotherapy in Adults with Partial-onset Seizures (POS): An Analysis of Pooled Data from Two Phase III Studies, with Use of a Historical Control Ladislav Pazdera, Jacqueline French, Michael Sperling, Mercedes Jacobson, Hailong Cheng, David Blum

P1.251

Assessment of Antiepileptic Pharmacotherapy for Seizure Control in Geriatric Patients: New Onset Vs. Long-standing Epilepsy Golshan Fahimi, Shahram Izadyar, Rebecca O'Dwyer

P1.252 Effect of Adjunctive

Perampanel on Growth and Development in Adolescents with Inadequately Controlled Partial Seizures J. Eric Pina-Garza, Haichen Yang, Betsy Williams, Dinesh Kumar, Antonio Laurenza

P1.253 Vigabatrin Efficacy

and Safety in Iranian Epileptic Children Mohammadkazem Bakhshandeh Bali, Mohammad Ghofrani

P1.254 Subgroup Analysis by

Race in Perampanel Phase III Clinical Studies Antonio Laurenza, Haichen Yang, Betsy Williams, Steven Huang, Michael Sperling

P1.255 Pharmacokinetic,

Pharmacodynamic and Cognitive Effects of Adjunctive Perampanel in Adolescents with Inadequately Controlled Partial Seizures Ziad Hussein, Barry Gidal, Haichen Yang, Betsy Williams, Dinesh Kumar, Antonio Laurenza, Jim Ferry, Kimford Meador

P1.256 Potential Effect of Perampanel on Photosensitivity in Healthy Subjects and Patients from Phase III Clinical Studies Haichen Yang, Betsy Williams, Dongyuan Xing, Antonio Laurenza

P1.257 Clobazam Vs. Clonazepam for Adults with Epilepsy: Long-term Results from a UK Primary Care Database Martin Brodie, Steve Chung, Alan Wade, Celine Quelen, Alice Guiraud-Diawara, Clement Francois, Patrice Verpillat, Vivienne Shen, Daniel Jones, Jouko Isojarvi

P1.258 Retention Rate and Efficacy of Clobazem in Comparison to Other Newer Anticonvulsants in Patients with Epilepsy Steve Chung, Thandar Aung

P1.259

Effects of Hepatic Impairment on Clobazam Pharmacokinetics: An Integrative, Model-based Approach Ene Ette, Ihor Bekersky, Hui-May Chu, Dwain Tolbert

P1.260 Clobazam for Dravet

Syndrome: Designing a Clinical Study Using Pharmacokinetic/Pharmacodynamic Modeling Deborah Lee, Rachel Omasta, Colleen Canavan, Mahlaqa Patel, Thomas Stothoff, Guangbin Peng, Dwain Tolbert

P1.261

Long-term Utilization Differences Between Children Treated with Clobazam Vs. Clonazepam for Epilepsy in the UK Steve Chung, Martin Brodie, Alan Wade, Celine Quelen, Alice GuiraudDiawara, Clement Francois, Patrice Verpillat, Vivienne Shen, Daniel Jones, Jouko Isojarvi


Poster Session I

Autonomic Disorders: Synucleinopathies P1.262 A Comparative Analysis

of Autonomic Testing and Diagnostic Consensus Criteria in Autopsy-confirmed Multiple System Atrophy Wolfgang Singer, Ann Schmeichel, Joseph Parisi, Eduardo Benarroch, Robert Fealey, Paola Sandroni, J. Ahlskog, James Bower, Joseph Matsumoto, Phillip Low

P1.263 Alpha-Synuclein and

Autonomic Neuropathy Progression in a Longitudinal Study of Parkinson Disease Christopher Gibbons, Ningshan Wang, Jenniffer Garcia, Roy Freeman

P1.264 Clinical Characteristics

and Survival in Multiple System Atrophy Elizabeth Coon, Mariana Suarez, J. Ahlskog, Jayawant Mandrekar, Phillip Low, Wolfgang Singer

P1.273

Autoimmune Autonomic Ganglionopathy - Symptom Antibody Correlations Christopher Gibbons, Roy Freeman

P1.274

Prolonged QTc Interval in Patients Seropositive for Ganglionic (α-3) Acetylcholine Receptor Autoantibody William Cheshire, Kalpathi Venkatachalam, Mohamad Yamani, Vanda Lennon

P1.275

Acute Autonomic and Sensory Neuropathy: A Case Report Joel Gutierrez, Jose-Alberto Palma, Vijay Vishwanath, Horacio Kaufmann

P1.276

Prevalence of Ganglionic AChR Antibodies in Postural Tachycardia Syndrome (POTS) Steven Vernino, Steve Hopkins, Luis Okamoto, Bonnie Black, Cindy Dorminy, Sachin Paranjape, Satish Raj

P1.277 Evidence of Mast Cell

P1.265 Survival in

Activation Disorder in Postural Tachycardia Syndrome Charlene Hoffman-Snyder, John Lewis, Lucinda Harris, Priya Dhawan, Brent Goodman

P1.266 Decreased Cerebrospinal

P1.278

Synucleinopathies David Goldstein, Courtney Holmes, Yehonatan Sharabi, Tianxia Wu Fluid Levels of Chromogranin a in Early Stages of Parkinson’s Disease May Predict Earlier Development of Orthostatic Hypotension Michaela Kaiserova, Hana Prikrylova Vranova, Jan Galuszka, David Stejskal, Katerina Mensikova, Jana Zapletalova, Jan Mares, Petr Kanovsky

P1.267

Pure Autonomic Failure Predictors of Conversion to Clinical CNS Involvement Sarah Berini, Elizabeth Coon, Phillip Low, Wolfgang Singer

P1.268 Cardiovascular Dysautonomia in Prodromal α-Synucleinopathy: Peripheral Versus Central Autonomic Degeneration Sven Rupprecht, Christiane Dahms, Otto Witte, Albrecht Guenther, Matthias Schwab

P1.269

Identifying an Objective Benchmark to Initiate Pharmacologic Treatment of Orthostatic Hypotension in Parkinson Disease Jose-Alberto Palma, Jose Martinez, Lucy Norcliffe-Kaufmann, Juan Gomez-Esteban, Beatriz Tijero Merino, Koldo Berganzo Corrales, Horacio Kaufmann

P1.270

Progressive Retinal Structure Abnormalities in Multiple System Atrophy Jose-Alberto Palma, Carlos Mendoza-Santiesteban, Jose Martinez, Lucy Norcliffe-Kaufmann, Thomas Hedges, Horacio Kaufmann

P1.271

Cranial Nerve Pathology in Multiple System Atrophy (MSA): Implications for the in Vivo Evaluation of Disease Matthew Cykowski, Elizabeth Coon, Phillip Low, Eduardo Benarroch, Suzanne Powell, Joseph Parisi

Autonomic Disorders: Autonomic Neuropathies and Postural Tachycardia Syndrome P1.272 Autoantibodies in the Postural

Tachycardia Syndrome Wolfgang Singer, Christopher Klein, Phillip Low, Vanda Lennon

Autonomic Dysfunction in Guillain Barre Syndrome: Development of a Risk Score Scale Miguel Wilken, Mauricio Farez, Federico Carpani, Fabio Adrian Barroso

P1.279 Sleep Disorders in

Patients with Postural Tachycardia Syndrome Mitchell Miglis, Srikanth Muppidi, Safwan Jaradeh

P1.280 Gastrointestinal

Manifestations of Postural Orthostatic Tachycardia Syndrome Karen Morgenshtern, Collin Culbertson, Liz Wang, Anindita Deb, Anna Hohler

P1.281

Vestibular Symptoms Are Common in Postural Tachycardia Syndrome (PoTS) Brent Goodman, Priya Dhawan, Jamie Bogle, David Barrs, Charlene Hoffman-Snyder

Autonomic Disorders: Other P1.282

Normative Values for Sudomotor Axon Reflex Testing Using QSWEAT™ David Sletten, Andrew Grandinetti, Stephen Weigand, Tonette Gehrking, Jade Gehrking, Phillip Low, Wolfgang Singer

P1.283 Falls During a 10-week

Placebo-controlled Study of Droxidopa for Neurogenic Orthostatic Hypotension in Parkinson’s Disease Gerry Rowse, Stephane Heritier, L. Arthur Hewitt

P1.284 Integrated Efficacy and

Safety Analyses of Droxidopa for Symptomatic Neurogenic Orthostatic Hypotension Robert Hauser, Cameron Szakacs, Horacio Kaufmann

P1.285 Composite Autonomic

Symptom Scale 31 Shows Impaired Autonomic Bladder and Pupillary Function in Multiple Sclerosis Patients Julia Koehn, Tassanai Intravooth, Hösl Katharina, DeHyung Lee, Ralf Linker, Max Hilz, Wolfgang Singer


P1.286 Active Standing Reveals

Subtle Cardiac Autonomic Dysfunction in Patients with Traumatic Brain Injury Max Hilz, Markus Jörg, Tassanai Intravooth, Katharina Hösl, Julia Koehn

P1.287 The Effects of Statin Therapy

on Adrenal and Sexual Functions in Male Patients with Hyperlipidemia Selda Korkmaz, Osman Baspinar, Fahri Bayram, Yasin Simsek, Halit Diri, Tugce Bilecenoglu, Murat Aksu

P1.288 Autonomic Neurophysiological Evaluation in Transthyretin-related Amyloidosis: Heart Rate Variability Is Impaired Mostly in Patients with Absent Sympathetic Skin Response Rodolfo Callejas, Bruno Estanol

P1.289

Cognitive and Motor Function of Orthostatic Hypotension Patient Taking Alpha-blocker for Benign Prostate Hypertrophy—Preliminary Study Hee Kwon Park, Jong-Hyun Ahn, JiWon Kwon, Soo-Jeong Kim, Eung-Seok Lee, Cindy Yoon, Eun-Ki Kim, Joung-Ho Rha

P1.290 Delayed Central Hyperthermia Responsive to Bromocriptine Rawan Albadareen, Scott Belliston, Kathrin Husmann, Yunxia Wang

P1.298 Tolosa-Hunt Syndrome

with Facial Nerve Involvement Mohsen Pirastehfar, Jin Luo

P1.299 New Etiology for Orthostatic Headache Ryan Smith, Carrie Robertson, Ivan Garza

P1.300 Breath-Powered™ Nasal

Delivery of 22 Mg Powdered Sumatriptan (AVP-825): Migraine Disability and Functional Outcome in a Phase 3 Study (TARGET) Peter McAllister, Roger Cady, Egilius Spierings, John Messina, Per Djupesland, Joao Siffert, Scott Siegert, Ramy Mahmoud

P1.301 Characteristics of

Post Concussive Headaches in Children Presenting to the Neurology Clinic Karameh Kuemmerle

P1.302 Mutational Analysis of

Whole Blood Transcriptome in Patients with Migraine with Aura: A Case-control Study Agustin Oterino, Maria Toriello, Anna Esteve-Codina, Heath Simon, Silvia Montes, Rosa Martinez-Nieto, Jesus Castillo, Jenifer Fernandez, Silvia Gutierrez, Vicente Quintanilla, Enar Pons, Enrique Palacio

P1.303 Compliance with ICMJE Trial

Headache

Registration Requirements in the Headache Medicine Literature Melissa Rayhill, Roni Sharon, Elizabeth Loder

P1.291 Brain Structural and

P1.304 Headache in Patients with

P1.292 Non-invasive Vagus

P1.305 Exercise-induced Intracranial

P1.293 Herpes Simplex Virus Type 1

P1.306 Efficacy and Safety of

P1.294 Evaluation of Retinal Nerve

P1.307 Primary Headaches as a

P1.295

P1.308 Intractable Headache

Neurometabolic Correlates of Visual Snow Disorder Christoph Schankin, Farooq Maniyar, Till Sprenger, Denise Chou, Michael Eller, Peter Goadsby Nerve Stimulator (gammaCore®) Was Not Associated with Meaningful Cardiovascular Adverse Effects Emily Engel, Justyna Blake, Eric Liebler Dorsal Root Ganglionitis in a 34-year-old Male with Occipital Neuralgia Refractory to Medical and Radiofrequency Ablation Therapies: A Clinicopathological Report and Literature Review Jaivir Rathore, Konstantin Slavin, Ranvir Rathore, Andrei Rakic, Tibor Valyi-Nagy

Fiber Layer Thickness (RNFLT) with Ocular Coherence Tomography Spectral Domain (OCT-SD) in Migraine Patients Ester Reggio, Clara Chisari, Giulia Ferrigno, Francesco Patti, Mario Zappia Metabotropic Glutamate Receptor Antagonism Reduces Trigeminovascular Nociceptive Transmission Maggie Waung, Simon Akerman, Annabelle Bergenfeld, Peter Goadsby

P1.296 Case Series: Putting a

Stop to Post-traumatic Headache with Onabotulinumtoxin A Regina Krel, Neha Mirchandani, Fernanda Wajnsztajn, Christopher Stoebe, Warren Spinner

P1.297 Clinical Benefit of

Incobotulinumtoxin-A for the Treatment of Chronic Migraine Luis Javier Lopez Del Val, Elena Lopez Garcia, Sonia Santos Lasaosa, Elena Bellosta Diago

Acute Ischemic Stroke and Frequency of IV TPA Administration John Wedlake, Vijay Pandav, Jordan Mayberry, Aminata Traore, David Thompson, Evgeny Sidorov Hypertension Due to Insufficient Jugular Vein Drainage Treated with a Stent Pamela Correia, A. Angelillo-Waeber, S Binaghi, Ph. Maeder, Patrik Michel OnabotulinumtoxinA in a Long-Term, Open-Label Study for the Prophylaxis of Headaches in Adult Chronic Migraine Patients: An Interim Analysis of the COMPEL Study Andrew Blumenfeld, Richard Stark, Albert Reppine, Michael Halstead, Fred Holdbrook, Sheena Aurora Cause of Non-traumatic Ecchymosis: A 120-year Systematic Review and Pooled Analysis of Published Case Studies Addie Peretz, Yohannes Woldeamanuel, Robert Cowan Heralding Anti-NMDA Receptor Encephalitis Clotilde Hainline, Angeliki Vgontzas, Cinthi Pillai, Matthew Robbins

P1.309 Alexia with Agraphia as a Rare Presentation of Migraine Omer Suhaib, Anthony Vaughn

P1.310

Increased Intracranial Pressure as a Presentation of Lyme Disease in Children: A Case Series Rawad Obeid, Sriram Ramgopal, Catalina Cleves, Andrew Nowak

P1.311

Prevalence of Headaches in Patients with Seizure Disorders Cristina Wohlgehagen, Brannon Vines, Jerzy Szaflarski

63

Monday April 20


Poster Session I Secondary Traumatic Stress Increases Hypervigilance Via Increases in Proteins Implicated in Peripheral and Central Sensitization of Trigeminal Nerves: Potential Role in Migraine Pathogenesis Paul Durham, Jordan Hawkins, Moore Nicholas, David Miley

Neuro-ophthalmology/ Neuro-otology I

P1.313

P1.312

2:00 p.m.–6:30 p.m.

P1.327

P1.336

P1.320 Effects of Intervention on Optical Imaging of Papilledema in the Idiopathic Intracranial Hypertension Treatment Trial Mark Kupersmith

The Pulfrich Phenomenon: An Objective Signature-biomarker of MS Pathophysiology Millad Sobhanian, Rohit Agarwal, Amy Conger, Darrel Conger, Robert Rennaker, Laura Balcer, Owen White, Randy Kardon, Shin Beh, Teresa Frohman, Elliot Frohman

Therapeutic Effectiveness of Sphenopalatine Ganglion (SPG) Stimulation for Cluster Headache—Pathway Registry Study Interim Results at 6 Months Jose Miguel Lainez, Tim Jurgens, Rigmor Jensen, Holger Kaube, Andreas Boger, Charly Gaul, Amy Goodman, Anthony Caparso, Arne May

P1.321

P1.328

P1.337 Efficacy of Multimodal

P1.314

Definition of and Comparison of the "Headache Problem" in Veterans of the Iraq (OIF) and Afghanistan (OEF) Wars with and Without Traumatic Brain Injury (TBI) Using Parameters of Headache Frequency and Intensity James Couch, Kenneth Stewart

P1.322

P1.315

P1.323

Pooled Analyses of Randomized, Double-blind, Placebocontrolled Studies of a Breath Powered™ Nasal Delivery Device Containing 22 Mg Sumatriptan Powder (AVP-825) in the Treatment of Episodic Migraine Roger Cady, Per Djupesland, Ramy Mahmoud, John Messina, Laszlo Mechtler, Scott Siegert, Joao Siffert

P1.316

Sexual Function in Female Patients with Migraine Derya Uluduz, Sevin Ayan, Harika Ertem, Ugur Uygunoglu, Baki Goksan, Sabahattin Saip, Aksel Siva

Saccadic Eye Movements in Parkinson’s Disease: An Eye-tracking and FMRI Study Joao Lemos, Daniela Pereira, Luciano Almendra, Diliana Rebelo, Joao Castelhano, Gil Cunha, Cristina Januario, Antonio Goncalves, Luis Cunha, Miguel Castelo-Branco Prevalence, Demographics, and Clinical Characteristics of Vertigo Disorders in a Specialized Multidisciplinary Outpatient Clinic Jan Burmeister, Eva Bock, Marcus Gerwig, Markus Frings, Diana Arweiler-Harbeck, H. Diener, Mark Obermann 20/40 or Better Visual Acuity After Optic Neuritis: Not as Good as We Once Thought Rachel Nolan, Kristin Galetta, Kannan Narayana, James Wilson, Peter Calabresi, Elliot Frohman, Steven Galetta, Laura Balcer

P1.324

Vertical Video Head Impulse Tests in Patients with Internuclear Ophthalmoplegia Seung-Han Lee, GwanYeol Cho, Yoon-Chang Oh, Jae-Hwan Choi, Kwang-Dong Choi

P1.317

Intraventricular Blood and Pneumocephalus After Epidural Blood Patch Adam Chen, Machteld Hillen

OCT Shows Different Relationships Between Macular Layers and Peripapillary RNFL in Acute Versus Chronic Papillitis and Papilledema Fawzi Abukhalil, Mark Morrow

P1.318

P1.326

Botox (onabotulinumtoxinA) for Treatment of Post Traumatic Chronic Migraine Headaches (PTCMH) in Veterans Abhishek Roka, Ashvin Zachariah, Erika Badiali, Sally Zachariah

P1.319

Depressive and Anxiety Disorders in Migraine and Chronic Migraine Letizia Borges, Jose Speciali, Facundo Ruiz Junior

P1.325

Optical Coherence Tomography and Visual Evoked Potentials in Monitoring MS Evolution Letizia Leocani, Marco Pisa, Giovanni Di Maggio, Roberto Santangelo, Stefania Medaglini, Mariaemma Rodegher, Bruno Colombo, Lucia Moiola, Ubaldo Del Carro, Vittorio Martinelli, Giancarlo Comi

CSF Characteristics in Patients with High Frisén Papilledema Grades from the IIHTT John Pula, Jorge Kattah, Luis Mejico, Michael McDermott, Michael Wall

P1.329 Retinal Ganglion Cell and

Intravenous Dexamethasone in Acute Management of Vestibular Neuritis: A Randomized, Placebocontrolled, Single Blind Trial Ivan Adamec, Magdalena Krbot Skoric, Tereza Gabelic, Barbara Barun, Josip Ljevak, Andreja Bujan Kovač, Ivana Jurjevic, Mario Habek Therapy for the Treatment of Chronic Vertigo and Dizziness Mark Obermann, Eva Bock, Nikolay Sabev, Nils Lehmann, HansChristoph Diener

Inner Plexiform Layer Loss Correlate with Visual Acuity Loss in LHON: A Highresolution, Longitudinal, Segmentation OCT Analysis Stephen Moster, Mark Moster, Robert Sergott

P1.338

P1.330 Visual Performance Testing

P1.339 Conjunctival Biopsy to

in Children with Attention Deficit Hyperactivity Disorder Bridget Mueller, Natali Baner, Danielle Leong, Karen Fleiss, Nicholas Moehringer, Steven Galetta, John Wells, Laura Balcer

Association of 25-hydroxyvitamin D Levels with RNFL Thickness and Clinical Tests of Visual Function in Acute Optic Neuritis Gorm PihlJensen, Jette Lautrup Frederiksen Battisti Diagnose Neurosarcoidosis in Patients with Inflammatory Nervous System Disease of Unknown Etiology Michael Pichler, Eoin Flanagan, Allen Aksamit, Jacqueline Leavitt, Diva Salomao, Mark Keegan

P1.331

Otolith Dysfunction in Benign Paroxysmal Positional Vertigo: Bilateral Abnormalities of Ocular and Cervical VEMPs Persist After Successful Repositioning Maneuvers Tae-Ho Yang, Sun-Young Oh

P1.332

Inferior Cerebellar Peduncular Lesion Causes a Distinct Vestibular Syndrome Kwang-Dong Choi, Jae-Hwan Choi, Seung-Han Lee

P1.333 Rapidly Progressive Bilateral

Optic Nerve and Retinal Infarctions Due to Rhinocerebral Mucormycosis Isha Duggal, Ulrike Kaunzner, Carolina Maciel, Alexandra Miller, Alexander Merkler, Marc Dinkin

P1.334 OCT Shows Consistent

Relationships Between Macular Layers and Peripapillary RNFL in Chronic Demyelinating and Compressive Optic Neuropathies Mark Morrow, Fawzi Abukhalil

P1.335 Visual Field Assessment in the “Split-brain” Patient: Effect of the Method/ laterality of Obtaining Patient Responses on Apparent Visual Field Defect Size J. Alexander Fraser, Jorge Burneo

NEW Advanced Practice Provider Track Debuts at 2015 Annual Meeting

A 64

Nurse practitioners and physician assistants won’t want to miss this new track consisting of current education programs suggested to offer a “deep dive” into general neurology. Only AAN members save with deep discounts on Annual Meeting registration, so if you’re not a member, join today at the special nurse practitioner/physician assistant rate of only $100—that’s just a fraction of the price of the $4,000+ in exclusive discounts and other member benefits! Renew or join today AAN.com/membership.


Poster Session II

Tuesday, April 21

P2 First Poster Session II 7:30 a.m.–12:00 p.m. Authors stand by Posters from 7:30 a.m.–9:00 a.m. Poster Discussion Session: Neuromuscular and Clinical Neurophysiology (EMG): Genetics Ten posters in seven neurologic topics have been selected for discussion. Posters will be grouped in a separate area where topic experts will lead a tour of attendees and facilitate questions with poster authors during the 90-minute author standby time.

P2.004 Electrical Impedance

P2.002 Peripheral Nerve Lymphoma:

P2.005 ATXN2 PolyQ Intermediate

in Tertiary Referral Frequently Assists in Diagnosis and Therapeutic Management Cris Ida, P. James B. Dyck, Duygu Selcen, John Bodensteiner, Michelle Mauermann, Peter Dyck, Christopher Klein Clinical, Electrophysiological, Radiographic and Pathological Findings P. James B. Dyck, Narupat Suanprasert, Michelle Mauermann, Kimberly Amrami, Robert Spinner, Peter Dyck

P2.003 Disease Manifestations in

a Spinal and Bulbar Muscular Atrophy Patient After Feminization for Gender Reassignment Tyler Lanman, Dara Bakar, Ailbhe Burke, Angela Kokkinis, Alice Schindler, Laura Bott, George Harmison, Kenneth Fischbeck, Christopher Grunseich

Myography as a Pharmacodynamic Biomarker in Spinal Muscular Atrophy William Arnold, Vicki McGovern, Jia Li, Xiaohui Li, Stephen Kolb, Seward Rutkove, Arthur Burghes Repeat Modifies ALS Phenotype and Survival Adriano Chio, Andrea Calvo, Cristina Moglia, Antonio Canosa, Gabriella Restagno, Maura Brunetti, Marco Barberis, Amelia Conte, Giuseppe Marangi, Serena Lattante, Marcella Zollino, Mario Sabatelli, Lucia Corrado, Gabriele Mora, Letizia Mazzini, Sandra D'Alfonso

P2.006 Utrophin Modulators to Treat

Duchenne Muscular Dystrophy (DMD): Phase 1b Clinical Trial Results of SMT C1100 Jon Tinsley, Francesco Muntoni, Stefan Spinty, Helen Roper, Imelda Hughes, Valeria Ricotti, Alison Bracchi, Bina Tejura, David Roblin, Gary Layton, Kay Davies

P2.007 Milder Phenotype in

Facioscapulohumeral Muscular Dystrophy Patients with the Largest Residual D4Z4 Fragments Jeffrey Statland, Colleen Donlin-Smith, Stephen Tapscott, Silvere van der Maarel, Alrabi Tawil

P2.009 Human Skeletal Muscle

Satellite Cells Are a Manageable Tool for Gene Therapy Simone Spuler, Andreas Marg, Helena Escobar, Andreas Spuler, Zsuzsanna Izsvak, Carmen Birchmeier

P2.010

Diabetic Neuropathy and the Sensory Neuron: New Molecular Targets Masaki Kobayashi, Chu Cheng, Cristiane de la Hoz, Douglas Zochodne

P2.008 Protein Misfolding in

Dysferlinopathy: The Novel Animal Model Dysf-MMex38 Leonie Victoria Heidt, Michael Bader, Simone Spuler, Verena Schöwel

Tuesday April 21

P2.001 Pediatric Nerve Biopsy

e-Poster Session: Neuromuscular and Clinical Neurophysiology (EMG) Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch screen displays.

P2.011

Myotoxic Effects of Statins in Primary Human Muscle Cells Stefanie Grunwald, Oliver Popp, Nicole Jedraszczak, Giannino Patone, Gunnar Dittmar, Simone Spuler

P2.012

An Atypical Presentation of Neurolymphomatosis: A Case Report and Literature Review Ann Murray, Frank Bittner, Kymberly Gyure, Chandler Park, Amelia Adcock

P2.013

Clinical Characteristics of Elderly Patients with Amyotrophic Lateral Sclerosis Tami Nussbaum, Irena Artman, Vivian Drory

Neuromuscular Disease: Genetics and Outcomes P2.021 Congenital Myasthenic

Syndrome (CMS) Caused by Novel Mutation in LRP4. Phenotypic Heterogeneity and Defects in Neuromuscular Transmission (NMT) Identified in a Second Kinship Duygu Selcen, Xinming Shen, Bisei Ohkawara, Kathleen McEvoy, Kinji Ohno, Andrew Engel

P2.014

Congenital Myasthenic Syndrome Due to DOK7 Mutations in a Family from Chile Jorge Bevilacqua, Marian Lara, Jorge Díaz, Ricardo Maselli

P2.017

P2.015

P2.018

Real-time MRI for Evaluation of Dysphagia in Inclusion Body Myositis (IBM) Per-Ole Carstens, Shou Zhang, Arno Olthoff, Eva Bremen, Joachim Lotz, Jens Frahm, Jens Schmidt

P2.016

Mechanism for Proximal Median Neuropathy as a Complication of Reverse Shoulder Arthroplasty: Nerve Strain Calculated from a Computerized 3-D Model Cadaver Brachial Plexus Reiner Henson See, Bashar Katirji, David Preston, Barbara Shapiro

P2.022 The Enlarging Spectrum

of Nav1.7 Mutations Associated with Neurological Pain Syndromes Hayet Salhi, Pascale Fanen, Benoit Funalot, Valérie Raclin, Yasmine Baba Amer, Samar Ayache, Francois-Jer Authier, Jean-Pascal Lefaucheur, Alain Creange, Alain Creange

P2.023 Diagnosis of Congenital

Myasthenic Syndromes by Target Capture/ next Generation Sequencing Jie Lin, Xia Tian, Victor Zhang, Jing Wang, Lee-jun Wong


The Spectrum of Hirayama Disease: Three Patients’ Magnetic Resonance Imaging and Electrodiagnostic Studies Alison Walsh, Goran Rakocevic Developing a Techniquespecific Nomogram for Temporal Discrimination Threshold Testing Vesper Fe Marie Ramos, Alina Esquenazi, Monica Anne Faye Villegas, Tianxia Wu, Mark Hallett

P2.020 Clinical Response of

Neuromuscular Patients to IVIG: An Interim Analysis of the INSIGHTS Registry Todd Levine, Jonathan Katz, Richard Barohn, David Saperstein, Mazen Dimachkie, Gil Wolfe, Lara Katzin, Tahseen Mozaffar, Leslie Vaughn, Michelle Greer

P2.019

Interposition in the Median and Ulnar Nerve; a 40-year Followup Stefan Meng, Hanno Millesi, Robert Schmidhammer, Gregor Kasprian, Anna Grisold, Wolfgang Grisold

P2.024 Phenotypic Variation Resulting from GMPPB Mutations with Genotype Phenotype Observations Braden Jensen, Steven Moore, Carrie Stephan, Katherine Mathews

P2.025 Hematopoietic Stem Cell

Transplantation in Adult Onset Adrenoleukodystrophy Florian Eichler, Adam Chen

P2.026 Compound Heterozygosis of

a Splice Site and the Common Ashkenazi Jewish Mutation in GBE1 Causes Adult Onset Polyglucosan Body Disease Orhan H. Akman, Yasemin Kurt, Mary Wallace, Raphael Schiffmann, Salvatore DiMauro

P2.027 Molecular Combing Compared to Southern Blot in Measuring D4Z4 Contractions in FSHD Jessica Vasale, Michael Jocson, Fatih Boyar, Khalida Liaquat, Carol Hoffman, Vladimira Sulcova, David Tsao, Kerri Hensley, Yan Liu, Patricia Chan, Renius Owen, Corey Braastad, Weimin Sun, Arturo Anguiano, Malgorzata Jaremko, Zhenyuan Wang, Funda Suer, Sat Dev Batish, Charles Strom, Joseph Higgins

65

Poster Session II P2.028 Variability of Expression

in MYH14 Distal SMA Phenotype: A Single-family, Multi-generational Evaluation Stanley Iyadurai, John Kissel, Corey Ruhno, Vicki McGovern, Jennifer Roggenbuck, Arthur Burghes, Stephen Kolb, William Arnold

P2.029 Periodic Muscle Paralysis—a

Different Perspective Tudor Munteanu, Janice Redmond, Yvonne Langan, Francesca Brett

Neuropathy: Genetics and Outcomes P2.030 A Novel TFG Mutation Causes Charcot-Marie-Tooth Disease Type 2 and Impairs TFG Function Pei-Chien Tsai, BingWen Soong, Kon-Ping Lin, Yi-Chung Lee

P2.031 Peripheral Neuropathy in

a Family with Sandhoff Disease and SH3TC2 Deficiency Dara Bakar, Tyler Lanman, Christopher Grunseich, Ke-lian Chen, Alice Schindler, Ami Mankodi, Ryan Traslavina, Tanya Lehky, Eva Baker, Nicholas Maragakis, Cynthia Tifft, Kenneth Fischbeck

P2.032 Evaluating the Diagnostic Yield of a Multi-gene Panel for Charcot-Marie-Tooth and Related Neuropathies Courtney Downtain Pickersgill, Sharon Suchy, Tracy Brandt

P2.033 Charcot-Marie-Tooth

Disease Type-2P Is Associated with a Missense Mutation in the RING Domain of LRSAM1 Meng Zhu, Sezgi Arpag, Audra Hamilton, Robin Yawn, Stephan Zuchner, Jun Li

P2.034 Genotypic and Phenotypic

Presentation of TTR- FAP in Turkey Hacer Durmus, Zeliha Matur, Mehves Poda, Mert Murat Atmaca, Piraye Serdaroglu, Feza Deymeer, Yesim Parman

P2.035 Sensory Neuropathy in

Children Presenting with Behr Syndrome Due to OPA1 Mutations Yann Pereon, Karine Boyer, Cyril Gitiaux, Guillaume Nicolas, Armelle Magot, Michele Mayer, Magalie Barth, Dominique Bonneau, Diana Rodriguez, Isabelle Desguerre, Sylvie Nguyen The Tich

P2.036 CMT 4H: A Novel Mutation Sharika Rajan, David Chad, Dinesh Nair

P2.037 Two Siblings with

Genetically Proven HNPP and Autonomic Neuropathy Ilene Ruhoy, John Oakley, Suman Jayadev, Michael Weiss

P2.038 Sensitivity and Specificity of

the “Ears of the Lynx” MRI Sign in Spastic Paraparesis with SPG Mutations Joseph Masdeu, Belen Pascual, Marcondes Franca, Jr., Michael Gregory, Michlene Daniels, Nicholas Patronas, Camilo Toro, Maria Bassi, Perrine Charles

P2.039 Novel SEPT9 Mutation

Underlying Hereditary Neuralgic Amyotrophy: Variability of Expression and Invariant Features in Multi-generational Family Jennifer Roggenbuck, John Kissel, Stanley Iyadurai

66

7:30 a.m.–12:00 p.m.

Muscle Disease: Genetics, Pathogenesis, and Pathology P2.040 Carnitine Responsive Lipid

Storage Myopathy: A Case Report Seref Demirkaya, Ahmet Cetiz, Hakan Akgun, Bülent Kurt, Oguzhan Oz, Ümit Ulas

P2.041 Mutations in MEGF10 in

a Patient Presenting with Late Onset Myopathy and Respiratory Distress Nizar Chahin, Duygu Selcen, Myra Roche, Karen Weck, Kirk Wilhelmsen, James Evans, Jonathan Berg

P2.042 Variants in the COL6A1,

COL6A2, and COL6A3 Genes in Collagen VI-related Congenital Muscular Dystrophy Malgorzata Jaremko, Keith Morneau, Tiffany Smith, Zhenyuan Wang, Funda Suer, Carol Hoffman, Khalida Liaquat, Michele McCarthy, Jennifer Lapierre, Valerie Storozuk, Marc Meservey, Sat Dev Batish, Joseph Higgins

P2.043 Myoshi Myopathy: A Rare

Mutation in a Brazilian Patient—Case Report Alzira Carvalho, Miriam Eva Koch

P2.044 Genetic Analysis Reveals

That GNE Myopathy Is an Underdiagnosed Neuromuscular Disorder Marjan Huizing, May Christine Malicdan, Frank Celeste, Thierry Vilboux, Carla Ciccone, William Gahl, Nuria Carrillo-Carrasco

P2.045 Neuromyotonia: An

P2.050 Frequency of the Expanded

P2.057 Multicenter Epidemiological

P2.051 Screening of CHCHD10

P2.058 Adherence to the AAN ALS

Hexanucleotide G4C2 Repeat in the C9ORF72 Gene and Clinical Features of Patients Presenting to ALS Referral Centers in Buenos Aires, Argentina: Preliminary Results Gisella Gargiulo Monachelli, Claire LeBlond, Mariela Bettini, Javier VazquezVarela, Maria Alejandra Figueredo, Andrea Lautre, Patrick Dion, Maria Laura Garau, Marcelo Kauffman, Marcelo Francisco Rugiero, Maria Claudia Gonzalez Deniselle, Miguel Pagano, Guy Rouleau in an Italian Cohort of ALS/ALS-FTD Patients Giulietta Riboldi, Dario Ronchi, Roberto Del Bo, Nicola Ticozzi, Marina Scarlato, Daniela Galimberti, Benedetta Del Menico, Simona Brajkovic, Stefania Corti, Vincenzo Silani, Nereo Bresolin, Giacomo Comi

P2.052 CHCHD10 Gene Mutations in

ALS Patients of Italian Ancestry Adriano Chio, Andrea Calvo, Marco Barberis, Maura Brunetti, Gabriella Restagno, Gabriele Mora, Mario Sabatelli, Stefania Battistini, Francesca Conforti, Claudia Caponnetto, Jessica Mandrioli, Paola Mandich, Marcella Zollino, Giuseppe Borghero, Maria Murru, Maria Monsurro, Paolo Volanti, Isabella Simone, Giancarlo Logroscino, Fabrizio Salvi, Nilo Riva, Janel Johnson, Bryan Traynor, Silvana Penco, Christian Lunetta

P2.053 Replication Study of MATR3 in

Unusual Presentation in Inflammatory Myopathy Rosana Scola, Renata Dal-Prá Ducci, Paulo Lorenzoni, Lineu Werneck

Familial and Sporadic Amyotrophic Lateral Sclerosis Nicolas Dupre, Claire Leblond, Dan Spiegelman, Anna Szuto, Pierre Provencher, Patrick Dion, Guy Rouleau

P2.046 Disease Progression of GNE

P2.054 Hsa-miR-424 and Has-

Myopathy Melanie Quintana, Joseph Shrader, Galen Joe, Mark Fitzgerald, William Gahl, John McKew, Scott Berry, Nuria Carrillo-Carrasco

P2.047 Premature Senescence in

Primary Muscle Cultures of Myotonic Dystrophy Type 2 Is Not Associated with P16 Induction Giovanni Meola, Laura Valentina Renna, Annalisa Botta, Giulia Rossi, Barbara Fossati, Elena Costa, Rosanna Cardani

P2.048 The Metabolic Footprint of

Dysferlinopathy Verena Schoewel, Sarah Keller, Severine Kunz, Michael Boschmann, Christian Herrmann, Guido Mastrobuoni, Hadi Al-Hasani, Stefan Kempa, Simone Spuler

ALS: Genetics and Clinical Outcomes P2.049 HFE P.His63Asp

Polymorphism Is Not a Modifier of ALS Phenotype Gabriele Mora, Marco Barberis, Gabriella Restagno, Maura Brunetti, Mario Sabatelli, Marcella Zollino, Stefania Battistini, Francesca Conforti, Claudia Caponnetto, Paola Mandich, Jessica Mandrioli, Silvana Penco, Christian Lunetta, Giuseppe Borghero, Maria Murru, Maria Monsurro, Gioacchino Tedeschi, Paolo Volanti, Isabella Simone, Giancarlo Logroscino, Francesco Logullo, Fabrizio Salvi, Nilo Riva, Bryan Traynor, Andrea Calvo, Adriano Chio

miR-206 Are Overexpressed in the Skeletal Muscle and Plasma of Patients with Amyotrophic Lateral Sclerosis (ALS) Helen Andrade, Milena Albuquerque, Thiago Peluzzo, Danyella Dogni, Anamarli Nucci, Iscia Lopes-Cendes, Marcondes Franca, Jr., Simoni Avansini

P2.055 Genetic Analysis of MATR3

in a Taiwanese Cohort with Amyotrophic Lateral Sclerosis Yi-Chung Lee, Bing-Wen Soong

P2.056 Screening of the Intronic

Expansion in the C9 orf72 Gene and the ATXN2 Mutation in Argentine Patients Diagnosed with Amyotrophic Lateral Sclerosis Belén Tillard, Elisa Cisneros, Cintia Marchesoni, Ana Pardal, Lucía Schottlaender, Henry Houlden, Shoai M, Ernesto Fulgenzi, Eugenia Conti, Di Pace José, Edgar Carnero, Manuel Perez Akly, Martín Nogués, Osvaldo Uchitel, Bruno de Ambrosi, Andrea Lautre, Fabio Adrian Barroso, Alberto Dubrovsky, Laura Pirra, Agustin Jauregui, Paula Landriscina, Alejandro Rodriguez, Paula Goyeneche, Claudio Mazia, Valeria Lujan Salutto, Pedro Nofal, Zulma Salazar, Patricio Brand, Ezequiel Surace, Ricardo Reisin

Study of Amyotrophic Lateral Sclerosis in the City of Buenos Aires Pérez Akly Manuel, Gustavo Albanese, Fabio Adrian Barroso, Mariana Bendersky, Mariela Bettini, Marianna Di Egidio, Ernesto Fulgenzi, Luís Fiorotto, Gisella Gargiulo Monachelli, Agustín Jáuregui, Paula Landriscina, Claudio Mazia, Mario Melcom, Ricardo Reisin, Roberto Rey, Gabriel Rodríguez, Marcelo Francisco Rugiero, Valeria Lujan Salutto, Belén Tillard Quality Measures for OEF/OIF Veterans with Amyotrophic Lateral Sclerosis Shon Michael, Cynthia Brandt, Perry Miller, Huned Patwa

P2.059 Autologous Transplantation

of Mesenchymal Stem Cells Secreting Neurotrophic Factors (Nurown™) in ALS: Results of a Phase 2 Clinical Trial Panayiota Petrou, Marc Gotkine, Yael Gothelf, Yossef Levy, Daniel Offen, Adi Vaknin-Dembinsky, Zohar Argov, Tamir Ben-Hur, Eldad Melamed, Dimitrios Karussis

ALS and Motor Neuron Disease P2.060 Progressive Callosal Damage in Amyotrophic Lateral Sclerosis Milena Albuquerque, Thiago Rezende, Helen Andrade, Anamarli Nucci, Marcondes Franca, Jr.

P2.061

Phenotypes and Genotypes of Mitochondrial Disease—Findings from a National Mitochondrial Disease Cohort Yi Shiau Ng, Grainne Gorman, Victoria Nesbitt, Robert Pitceathly, John Grady, Andrew Schaefer, Alexandra Bright, Catherine Feeney, Shamima Rahman, Joanna Poulton, Robert Taylor, Michael Hanna, Douglas Turnbull, Robert McFarland

P2.062 Vitamin D3 Treatment

Protects Motor Neuron Cells from Oxidative Stress and ALS-related SOD1 Mutation Dominique Soroka, Chafic Karam, Nikolay Dokholyan

P2.063 Cardiac Impairment in GNE

Myopathy Luhe Mian, May Christine Malicdan, Satoru Noguchi, William Gahl, Marjan Huizing

P2.064 Texture Analysis of MRI

Reveals Basal Ganglia Damage in Patients with Amyotrophic Lateral Sclerosis (ALS) Milena Albuquerque, Lara Anjos, Helen Andrade, Marcia Oliveira, Gabriela Castellano, Marcondes Franca, Jr., Anamarli Nucci

P2.065 Chronological Process of

Cardiac Sympathetic Function in Patients with Amyotrophic Lateral Sclerosis Yuji Tanaka, Megumi Yamada, Akihiro Koumura, Yuichi Hayashi, Akio Kimura, Takashi Inuzuka

P2.066 C9orf 72 Repeat Expansions

in a Canadian Provincial Cohort Anil Venkitachalam, Stacey Hume, Setareh Ashtiani, Susan Christian, Oksana Suchowersky

P2.067 Does a Past History of Cancer

Portend Slower Progression of ALS? Emily Brady, Erin Manning, Mona Shahbazi, Lindsay Kaplan, Dale Lange


Poster Session II

P2.068 Spinal Fluid GFAP as Marker of Astrocyte Activation in Patients with MND Felix Benninger, Mica Glat, Daniel Offen, Israel Steiner

P2.069 Vitamin D Levels in Serum

of Amyotrophic Lateral Sclerosis Patients Rosa Cortese, Eustachio D'Errico, Alessandro Introna, Gabriella Schirosi, Antonio Scarafino, Eugenio Distaso, Pietro Nazzaro, Stefano Zoccolella, Isabella Simone

Neurological Consequences of Autoimmune Disease P2.070 Recurrent Guillain Barre

Syndrome—a Report of Three Cases with Clinical Electrophysiological and CSF Profile Abubaker Almadani, Ayman Alboudi, Suhail Alrukn, Pournamy Sarathchandran, Jihad Inshasi

P2.071 Clinical Features of Anti-

NMDAR Antibody-positive Patients Predominantly Presenting Chronic Psychosis with Acute Exacerbations Keiko Tanaka

P2.072 Guillain-Barre Syndrome and

Lambert Eaton Myasthenic Syndrome Coexisting in a Paraneoplastic Neurologic Syndrome? Milena Rodriguez Alvarez, Mark Younan, Irfanali Kugasia, Vipul Shah, David Sternman, Lisa Thompson

P2.073 Scoliosis in Childhood-

onset Stiff Person Syndrome Tanaporn Rasameesoraj, Bashar Katirji, Michael Devereaux

P2.074

Posterior Reversible Encephalopathy Syndrome in Guillain-Barre Syndrome: A Case Report and Literature Review Adam Chen, Jennifer Kim, Galen Henderson, Aaron Berkowitz

P2.075 Neuro-Behçet's Syndrome:

Case Reports Emphasizing Challenges of Early Diagnosis Efrata Feldman

P2.076

A Case of Neuro-Behcet’s Disease Presenting with Central Neurogenic Hyperventilation Ayham Alkhachroum, Saba Saeed, Jaspreet Kaur, Tanzila Shams, Michael De Georgia

P2.077 Spinal Cord Infarction as the

Initial Presentation of Systemic Lupus Erythematosus Amanda Michael, Ghazala Hayat

P2.078 Rhabdomyolysis in Stiff

Person Syndrome: Case Report Suhas Gangadhara, Shreyas Gangadhara, Chetan Gandhy, Derrick Robertson

Epilepsy/Clinical Neurophysiology (EEG): EEG P2.079 Reproducible Direct Cortical Somatosensory Evoked Potentials (SSEP) Recorded at Bedside in Epilepsy Patients Scheherazade Le, Josef Parvizi, Kimford Meador

P2.080 Evaluation of EEG Patterns in

out of Hospital Cardiac Arrests (OHCA) Due to Overdose as Predictor of Good Patient Outcomes Megan Mantica, Maria Baldwin

P2.081 Alpha1/theta Ratio from

Quantitative EEG (qEEG) as a Reliable Marker for Mild Cognitive Impairment (MCI) in Patients with Parkinson’s Disease (PD) HAbib Bousleiman, Menorca Chaturvedi, Ute Gschwandtner, Florian Hatz, Christian Schindler, Ronan Zimmermann, Peter Fuhr

P2.082 Treatment of PLEDs-related

Reversible Brain MRI Changes May Predict a Good Neurological Outcome in the Absence of Structural Brain Lesions Anza Memon, Aashit Shah, Maysaa Basha

P2.083 A Retrospective Descriptive

Study of Continuous Electroencephalographic Monitoring in Patients Requiring Extracorporeal Membrane Oxygenation in the Pediatric and Neonatal Intensive Care Unit Arnold Sansevere, Rejean Guerriero, Ivan Sanchez Fernandez, Jacquelyn Klehm, Tobias Loddenkemper

P2.084 Registration of the Brain

Activity Under the Influence of Artificial Electromagnetic Radiation Dmitry Reznikov

P2.085 Correlation of EEG Findings

Epilepsy/Clinical Neurophysiology (EEG): EEG and Video EEG P2.089 To Determine the Incidence

of Seizures Detected on Continuous EEG (cEEG) Monitoring and Time of Onset to the First Seizure on Prolonged CEEG in Adult Patients in Neuro Intensive Care Unit (NICU) Chirag Shukla, Gerald Banks

P2.090 Interictal Discharges

Associated with Ventricular Bradycardia Nicholas Lanciano, Gena Ghearing, Alexandra Popescu

P2.091 Continuous EEG Monitoring

Is an Important Tool in Managing Critically Ill Patients in Intensive Care Units Sudhir Aggarwal, Jyoti Pillai

P2.092 The Added Value of EEG in

the Prognosis of Newly Diagnosed Patients with Epilepsy Abdulraheem Al Zahrani, Fawzi Babtain, Abdulaziz Bajafer, Abdullatif Al Zahrani, Harsha Bhatia, Muthusamy Velmurugan

and Prognosis in Patients on Therapeutic Hypothermia After Cardiac Arrest Yana Krutoshinskaya, Susan Manganaro, Regina Krel, Lourdes Bello-Espinosa

P2.093 The Correlation of Epileptiform

P2.086 Acute Effect of Levetiracetam

P2.094 Bereitschaftspotential

on Interictal Epileptiform Discharges in Persons with Idiopathic Generalized Epilepsy Paul Jarvis, Jodi Spaulding, Joseph McSherry, Keith Nagle

P2.087 Combining Electroenceph-

alographic Time-frequency and Source Analysis Methods for Improve Epileptogenic Zones Localization Elena Cuspineda Bravo, Eduardo Martinez Montes, Ana Olivares Torres, Calixto Machado

P2.088 Electrographic Patterns

in Patients with Posterior Reversible Encephalopathy Syndrome (PRES) and Seizures Rahul Shah, Carlos Kamiya Matsuoka, Bing Liao, Sudhakar Tummala

Discharges in Sleep with Ictal Onset in Schizencephaly Marjan Dolatshahi, Alexei Yankovsky, Marcus Ng as a Possible Marker for Non-epileptic Psychogenic Pseudo-myoclonus? Helen Barkan

P2.098 Evaluating Peri-ictal Mood Changes in Patients in an Epilepsy Monitoring Unit Mary Richert, Mark Kvarta, Scott Thompson, Jennifer Hopp

Neurogenetics and Ataxia P2.099 Investigation into the

Molecular Mechanisms Underlying Idiopathic Intracranial Hypertension Zerin Alimajstorovic

P2.100

Sudden Adult Death Syndrome: An Uncommon or Simply Unrecognised Clinical Entity in Young, Asymptomatic Adults with M.3243A>G Disease? Grainne Gorman, Yi Shiau Ng, Nichola Lax, Charlotte Alston, Andrew Schaefer, Aleksandar Radunovic, Ali Alhakim, John Bourke, Robert Taylor, Robert McFarland, Douglas Turnbull

P2.101

Heterozygous Variant in the ITPR1 Gene - Responsible of Cerebellar Ataxia Phenotype Tudor Munteanu, Janice Redmond

P2.102

Late-onset Spastic Paraplegia Type 10 (SPG10) Family Presenting with Bulbar Symptoms—Primary Lateral Sclerosis (PLS) Mimic Seiji Kaji, Ryosuke Miyamoto, Yusuke Osaki, Hiroyuki Nodera, Toshitaka Kawarai, Yuishin Izumi, Ryuji Kaji

P2.095 Novel Ambulatory EMG-based GTC Seizure Detection Device for Home and Hospital Use Jose Cavazos, Michael Girouard, Luke Whitmire

Ehlers-Danlos Syndrome (Overlap of Classical and Vascular Type) with Rare Neuromuscular Phenotype Ravinder Singh, Atchayaram Nalini, Narayanappa Gayathri, Chnadrajit Prasad, Preethish Kumar Veeramani, Kiran Polavarapu, Devaraddi Navali

P2.096 Is There a Role for Cardiac

P2.104

Telemetry in the Epilepsy Monitoring Unit: Two Case Reports of Convulsive Cardiac Asystole Previously Mistaken for Seizure Disorders Aradia Fu, Laura Lehnhoff

P2.097 Yield of Monitoring in an Adult Epilepsy Monitoring Unit Shubhi Agrawal, Lauren Turco, Shweta Goswami, Michele Faulkner, Sanjay Singh

P2.103

Hydrocephalus in Neurofibromatosis—Three Cases with Different Etiologies Janet Elgallab, Jerome Graber

P2.105

Congenital Unilateral Facial Nerve Hypoplasia and Parotid Gland Agenesis Kumar Sannagowdara, Matthew Harmelink, Christopher Inglese, Mohit Maheshwari

P2.106

Poster Session QR Codes The QR code is one of the most popular types of two-dimensional barcodes. The QR tag can be scanned by smart phones or tablets and will link the attendee to the selected poster via AAN’s mobile access. Once the QR tag is scanned, the attendee’s mobile device will link to the poster title, authors, and links to the abstract, poster PDF, and audio file. An attendee can scan a multitude of posters to see the corresponding content. Please note that each poster presenter needs to provide permission for his or her poster information to be accessible in the online poster viewing site.


Difference Between the Blood-brain Barrier and Blood-nerve Barrier: Analyses Using New Human in Vitro Blood-brain and Blood-nerve Barrier Models Abe Masaaki, Yasuteru Sano, Hideaki Nishihara, Hironori Sano, Yukio Takeshita, Toshihiko Maeda, Takashi Kanda

P2.107

Ataxia Without Headache: Atypical Presentation of Spontaneous Intracranial Hypotension Joseph Nguyen, Divisha Raheja, Max Lowden

P2.108

Schizencephaly and Agenesis of the Corpus Callosum Mihaela Vlaicu, Sophie Gerber, Mathieu Rodallec, Stéphane Palfi

Movement Disorders: Ataxias P2.109

ANO10 Mutations Cause Ataxia and Coenzyme Q10 Deficiency Emanuele Barca, Andrea Balreira, Boczonadi Veronika, Angela Pyle, Boglarka Bansagi, Marie Appleton, Claire Graham, Iain Hargreaves, Vedrana Rasic, Hanns Lochmuller, Helen Griffin, Robert Taylor, Ali Naini, Patrick Chinnery, Michio Hirano, Catarina Quinzii Hirano, Rita Horvath

67

Tuesday April 21


Poster Session II P2.110

Boucher Neuhäuser Syndrome: Cerebellar Degeneration, Chorioretinal Dystrophy and Hypogonadotropic Hypogonadism—Two Novel Cases and a Review of 40 Cases from the Literature Alexander Tarnutzer, Christina GerthKahlert, Dagmar Timmann-Braun, Dae-In Chang, Florian Harmuth, Peter Bauer, Dominik Straumann, Matthis Synofzik

P2.111

Autoimmune Cerebellar Ataxia: Treatment Responses and Outcomes in 118 Patients Amy Jones, Sean Pittock, Vanda Lennon, Scott Eggers, J. Ahlskog, Andrew McKeon

P2.112

A Case of Ataxia and Dystonia in the Setting of a Renal Oncocytoma Ian Bledsoe, Cynthia Comella

P2.113

Whole-exome Sequencing as a Diagnostic Tool in a Family with Episodic Ataxia Type 1 Zbigniew Wszolek, Pawel Tacik, Kimberly Guthrie, Audrey Strongosky, Daniel Broderick, Douglas Riegert-Johnson, Alexander Parker, Owen Ross

P2.114

Novel Mutations in TGM6 with Clinical and Genetic Characterization Bing-Wen Soong, Pei-chien Tsai, Yi-Chu Liao, Yi-Chung Lee

P2.115

Unusual Presentation of a Not So Rare Disease: Implications for the Differential Diagnosis of Generalized Dystonia Luiza Piovesana, Fabio Torres, Paula Azevedo, Marcelo Nunes, Thais Amaral, Madalena Rosa, Marcondes Franca, Jr., Iscia Lopes-Cendes, Anelyssa D'Abreu

P2.116

Two Novel Ataxia Phenotypes in the French-Canadian Population Marie Beaudin, Laurence Martineau, Nicolas Chrestian, Charles-Antoine Guay, Anne Noreau, Gabrielle Houle, Pierre Provencher, Guy Rouleau, Nicolas Dupre

P2.117

A Case of Rapid-onset Dystonia-Parkinsonism (RDP) with Prominent Ataxia Kathleen Sweadner, Jared Cook, Beverly Snively, Laurie Ozelius, Camilo Toro, Allison Brashear

P2.118

A Novel KCNMA1 Mutation Associated with Progressive Cerebellar Ataxia Julia Staisch, Xiaofei Du, Tomoya Kubota, João de Souza, Francisco Bezanilla, Christopher Gomez

Movement Disorders: Fredriech's Ataxia and Cerebellum P2.119

Diagnosis of Friedreich’s Ataxia in Late-onset Progressive Cerebellar Ataxia Roisin Lonergan, Damien Ferguson *Joint first author with RL, Susan Byrne, David Bradley, Yvonne Langan, Janice Redmond

P2.120

Longitudinal Study of Gait Dysfunction in Friedreich's Ataxia Using the GAITRite Walkway System Theresa Zesiewicz, Clifton Gooch, Seok Kim, Jennifer Farmer, Israt Jahan, Yangxin Huang, Jason Salemi, Kelly Sullivan, Jeannie Stephenson

P2.121

Magnetic Resonance Is More Sensitive Than Echocardiography to Detect Cardiomyopathy in Friedreich’s Ataxia Alberto Martinez, Ingrid Faber, Thiago Rezende, Cynthia Bonilha Da Silva, Thiago Venâncio, Anelyssa D'Abreu, Iscia Lopes-Cendes, Otávio Coelho-Filho, Marcondes Franca, Jr.

68

7:30 a.m.–12:00 p.m.

P2.122

Gene Expression Profile in Peripheral Blood Cells of Friedreich Ataxia Patients Agessandro Abrahao, Jose Luiz Pedroso, Patricia de Carvalho Aguiar, Orlando Barsottini

P2.123

Correlation of GAITRite Walkway System and Biodex Balance System Measures to the FARS Score in Friedreich's Ataxia Patients: A Validation Study Theresa Zesiewicz, Seok Kim, Clifton Gooch, Jennifer Farmer, Yangxin Huang, Jason Salemi, Israt Jahan, Kelly Sullivan, Lynn Wecker, Jeannie Stephenson

P2.124

Progressive Pyramidal and Callosal Damage in Friedreich’s Ataxia Thiago Rezende, Cynthia Silva, Alberto Martinez, Anelyssa D'Abreu, Iscia Lopes-Cendes, Fernando Cendes, Marcondes Franca, Jr.

P2.125

The Splenium of the Corpus Callosum Sign in Fragile X Associated Tremor Ataxia Syndrome (FXTAS) Meghan Hermanson, Miral Jhaveri, Glenn Stebbins, Emily Dunn, Doug Merkitch, Elizabeth BerryKravis, Deborah Hall

P2.126

Mutation of Senataxin Alters Disease-specific Transcriptional Networks in Patients with Ataxia with Oculomotor Apraxia Type 2 Brent Fogel, Ellen Cho, Amanda Wahnich, Fuying Gao, Olivier Becherel, Xizhe Wang, Francesca Fike, Leslie Chen, Chiara Criscuolo, Giuseppe De Michele, Alessandro Filla, Abigail Collins, Angelika Hahn, Richard Gatti, Genevieve Konopka, Susan Perlman, Martin Lavin, Daniel Geschwind, Giovanni Coppola

P2.127

Holmes Tremor. Etiology, Associated Symptoms, Neuroimaging and Treatment in a Series of Twenty Cases Gabriela Raina, Maria Graciela Cersosimo, Silvia Folgar, Juan Giugni, Cristian Calandra, Juan Pablo Paviolo, Veronica Tkachuk, Lorena Tschopp, Daniela Calvo, Alejandro Pellene, Claudia Uribe Roca, Miriam Velez, Rolando Giannaula, Manuel Fernandez Pardal, Federico Micheli

P2.132

Spinocerebellar Ataxia 36 in Three Taiwanese Families Yi-Chu Liao, YiChung Lee, Pei-Chien Tsai, Bing-Wen Soong

P2.144

P2.133

P2.145

Bilateral Caudate Atrophy Distinguishes Dystonic Vs Non-dystonic Patients with Machado-Joseph Disease Thiago Rezende, Alberto Martinez, Marcelo Nunes, Rachel Guimaraes, Anelyssa D'Abreu, Iscia Lopes-Cendes, Marcondes Franca, Jr.

P2.134

Survey of NonmotorsSymptoms in Patients with Spinocerebellar Ataxia Type 10 Adriana Moro, Mariana Moscovich, Renato Munhoz, Walter Arruda, Salmo Raskin, Tetsuo Ashizawa, Helio Afonso Teive

P2.135

Frequencies of Mutations in 20 Genes Associated with Hereditary Ataxia: Experience from a US Clinical Laboratory Zhenyuan Wang, Marc Meservey, Michele McCarthy, Sat Dev Batish, Malgorzata Jaremko, Funda Suer, Joseph Higgins

Movement Disorders: Genetics P2.136

Frequency of DTY1 and DYT6 Mutations in a Large Cohort of Brazilian Patients with Dystonia Luiza Piovesana, Fabio Torres, Paula Azevedo, Thais Amaral, Madalena Rosa, Iscia Lopes-Cendes, Anelyssa D'Abreu

P2.137

Unique Astrocyte Pathology in a Case of Rapid Onset DystoniaParkinsonism (DYT12) with Novel Mutation in ATP1A3 Jacinda Sampson, Tamar Michaeli, Sarah Teed, Brenton Wright, Stanley Fahn, James Goldman, Jean Paul Vonsattel

P2.138

Dystonia-spasticity in a Patient with a Novel SLC25A12 Mutation Mered Parnes, Laurie Robak, Joshua Shulman, Amber Stocco, Joseph Jankovic

Movement Disorders: Spinocerebellar Ataxias

Dystonia-causing Mutations as a Contribution to the Etiology of Spasmodic Dysphonia Claudio De Gusmao, Nutan Sharma, Andrew Moses, Trisha Multhaupt-Buell, Phillip Song, Tania Fuchs, Ramon Franco, Laurie Ozelius

P2.128

P2.140

Clinical Impact of C9orf72 Repeat Expansion in Spinocerebellar Ataxias Karla Figueroa, Vikram Shakkottai, Henry Paulson, Susan Perlman, George Wilmot, Khalaf Bushara, Christopher Gomez, Jeremy Schmahmann, Michael Geschwind, Theresa Zesiewicz, S Subramony, ShengHan Kuo, Tetsuo Ashizawa, Stefan Pulst

P2.129

Spinocerebellar Ataxia Type 3 (Machado-Joseph Disease) in Israel: Clinical Phenotype and Genotype of a Jew Yemenite Subpopulation Roy Zaltzman, Reuven Sharony, Colin Klein, Carlos Gordon

P2.130

Improved Sway Velocities and Directional Balance Improvement in Two Individuals with Spinal Cerebellar Ataxia with Balance-based Torso-weighting: A Case Series Report Cynthia Gibson-Horn, Susan Perlman

P2.131

Executive and Motor Impairment Correlation in SCA-3 Jee Bang, Joseph Winer, Katherine Possin, Joel Kramer, Michael Geschwind

P2.139

22q11.2 Deletion Syndrome Presenting as Parkinson Disease Aliya Rehman, Radhika Dhamija, Matthew Barrett ER Stress Marker GRP78 Colocalizes with LRRK2 in Human Parkinson’s Disease Deepak Gupta, Zhaoyang Feng

Movement Disorders: Parkinson's Disease Genetics and Biomarkers P2.146

Using a Drosophila GBA Deficiency Model to Understand the Role of GBA in Parkinson’s Disease Marie Davis, Kien Trinh, Ruth Thomas, Brittany Whittley, Thomas Montine, Leo Pallanck

P2.147

Optical Coherence Tomography in LRRK2-associated Parkinson Disease Cristina Duque, Cristina Januário, Joao Lemos, Pedro Luis Martins da Fonseca, António Correia, Luísa Ribeiro, Rui Bernardes, António Freire

P2.148

The Frequency of PARKIN, LRRK2, GBA in Early Onset Parkinson Disease Patients Who Receive Deep Brain Stimulation Gian Pal, Deborah Hall, Bichun Ouyang, Jessica Phelps, Roy Alcalay, Helen Mejia Santana, Luci Blasucci, Christopher Goetz, Cynthia Comella, Amy Colcher, Karen Marder

P2.149 Peripheral

ß-glucocerebrosidase Enzyme Activity and Lipidomics in ß-glucocerebrosidase (GBA1) Mutation Parkinson Disease Amanda Glickman, Olaf Bodamer, Britt Johnson, William Nichols, Mariel Pullman, Robert Ortega, Brooke Johannes, Deborah Raymond, Laurie Ozelius, Jacek Bielawski, Susan Bressman, Lina Obeid, Yusuf Hannun, Rachel Saunders-Pullman

P2.150

REM Sleep Behavior Disorder (RBD) May Not Be a Promising Marker for Development of LRRK2 PD as Measured by RBD Sleep Questionnaire Robert Ortega, Roy Alcalay, Anat Mirelman, Cuiling Wang, Marta San Luciano, Deborah Raymond, Amanda Glickman, Brooke Johannes, Helen Mejia-Santana, Karen Marder, Nir Giladi, Susan Bressman, Rachel Saunders-Pullman

ADCY5-related Movement Disorder: Broader Spectrum and Genotype/ phenotype Correlations Including New Cases Dong-Hui Chen, Emily Bonkowski, Olena Korvatska, Fuki Hisama, Jennifer Friedman, Marie Davis, Phillip Swanson, Alona Gad, Laura Amendola, Xindi Guo, Michael Weiss, Ali Torkamani, Thomas Bird, Wendy Raskind

P2.151

P2.141

ATP1A3-related Disorders: A Broadening of the Phenotypic and Genotypic Presentation Allison Brashear, Jared Cook, Beverly Snively, Kathleen Sweadner, Laurie Ozelius

P2.153

P2.142

Genetic Screening Study in 1005 Subjects with Isolated Cervical Dystonia Mark LeDoux, Satya Vemula, Jianfeng Xiao

P2.154

P2.143

P2.155

Prevalence and Severity of Non-motor Manifestations in Patients with Gaucher Disease and Heterozygous GBA1 Mutation Carriers Jenny Kim, Dahima Cintron, Edythe Wiggs, Catherine Groden, Ellen Sidransky, Grisel Lopez

Using Non-motor Features to Define Clinical and Biomarker Patterns of Early Drug-naïve Parkinson Disease Samay Jain, Seo Young Park, Diane Comer

P2.152

Cardiovascular Risk Factors Associate with Cholinergic Denervation in Parkinson Disease Vikas Kotagal, Martijn Muller, Robert Koeppe, Peter Scott, Roger Albin, Kirk Frey, Nicolaas Bohnen Objective Measurement of Upper Extremity Motor Function in the Parkinson’s Progression Markers Initiative Lama Chahine, Liz Uribe, Penelope Hogarth, Danna Jennings Predictors of Parkinson Disease Dementia in a Brazilian Sample Lidiane Campos, Rachel Guimaraes, Luiza Piovesana, Paula Azevedo, Anelyssa D'Abreu Rewriting History—The Experience of Disease Progression in Parkinson Disease Lisa Shulman, Brenda Hanna-Pladdy, F. Rainer Von Coelln, Erik Barr, Melissa Armstrong, Stephen Reich, Ann Gruber-Baldini


Poster Session II

Aging, Dementia, Cognitive, and Behavioral Neurology: Genetics of Neurodegenerative Disorders P2.156

Three-way Interaction of 5-HTTLPR, BDNF Vall66Met and COMT Val158Met Polymorphisms and Its Effect on Regional Gray Matter Volume in Patients with Major Depressive Disorder Milutin Kostic, Elisa Canu, Ana Munjiza, Federica Agosta, Ivana Novakovic, Dobricic Valerija, Vera Miler Jerkovic, Tatjana Pekmezovic, Dusica Lecic Tosevski, Massimo Filippi

P2.157

Common and Rare Genetic Variations in the Mortalin Gene (HSPA9) and the Risk of Alzheimer’s Disease and Parkinson’s Disease Sun J. Chung, Juyeon Kim, Young Jin Kim, Kiju Kim, Sooyeoun You, Mi-Jung Kim, Seong Yoon Kim, Jae-Hong Lee

P2.158

Lack of AGG Interspersions in the Fragile X Mental Retardation 1 (FMR1) Gene Is Not Associated with Cognitive Impairment or Motor Dysfunction Erin Robertson, Aisha Ali, Lili Zhou, David Bennett, Elizabeth Berry-Kravis, Deborah Hall

P2.159

Bridging Integrator 1 (BIN1) Genotypes Induce Alzheimer’s Disease Related Brain Atrophy, Abnormal Glucose and Aβ Metabolisms in ADNI Cohort HuiFu Wang, Jin-Tai Yu, Lan Tan

P2.160

A Novel Splice Site Mutation in GRN (p.A237fs [A>T]) in a Large Italian Family with FTD from the Apulia-FTD Registry Rosa Capozzo, Celeste Sassi, Chyntia Crews, Chiara Zecca, Simona Arcuti, Massimiliano Copetti, Vincenzo Brescia, Andrew Singleton, Giancarlo Logroscino

P2.161

The Novel P.K317N Mutation in MAPT Gene with Clinicopathological Phenotype of Globular Glial Tauopathy Zbigniew Wszolek, Pawel Tacik, Michael DeTure, Wenlang Lin, Monica Sanchez Contreras, Aleksandra Wojtas, Shinsuke Fujioka, Matthew Baker, Ronald Walton, Yari Carlomango, Patricia Brown, Audrey Strongosky, Naomi Kouri, Melissa Murray, Keith Josephs, Rosa Rademakers, Owen Ross, Dennis Dickson

P2.162

Colombian Familial Dementia with Frontotemporal Features Associated with a Presenilin-1 Mutation Andrea Lopez, Diana Matallana, Pablo Reyes, Felipe Uriza, Angela Martinez, Jose Manuel Santacruz, Angela Iragorri, Ignacio Zarante, Cristian Triviño, Carlos Cano, Vivianna Van Deerlin, Eunran Suh, Elizabeth McCarty-Wood, Corey McMillan, Murray Grossman, Katya Rascovsky

P2.163

Assessing the Effect of the Brain-derived Neurotrophic Factor (BDNF) Val66Met Polymorphism on MRNA Transcript Levels, Alzheimer’s Disease (AD) Risk and Cognitive Performance Jeremy Burgess, Minerva Carrasquillo, Fanggeng Zou, High Seng Chai, Curtis Younkin, Mariet Allen, Daniel Serie, Julia Crook, Vernon Pankratz, Asha Nair, Sumit Middha, Sooraj Maharjan, Thuy Nguyen, Kimberly Malphrus, Sarah Lincoln, Gina Bisceglio, Yan Asmann, Otto Pedraza, Rosebud Roberts, John Lucas, Glenn Smith, Robert Ivnik, Mary Machulda, Neill Graff-Radford, Ronald Petersen, Dennis Dickson, Steven Younkin, Nilufer Taner

P2.164

Clinicopathologic Phenotypes of Four Cases with MAPT P301L Mutation Zbigniew Wszolek, Pawel Tacik, Monica Sanchez Contreras, Aleksandra Wojtas, Kelly Ross, Shinsuke Fujioka, Michael DeTure, Wenlang Lin, Matthew Baker, Patricia Brown, Audrey Strongosky, Naomi Kouri, Melissa Murray, Keith Josephs, Rosa Rademakers, Owen Ross, Dennis Dickson

P2.165

Molecular Network Analysis Suggests a Crucial Role of C9orf72 in the Pathogenesis of Amyotrophic Lateral Sclerosis/Frontotemporal Dementia Junichi Satoh, Yoshihiro Kino

Aging, Dementia, Cognitive, and Behavioral Neurology: Memory, Olfaction, and Alzheimer's Disease Risk Factors P2.166

Recovered Recall Memory After Surgical Removal of Pineal Tumor and Decompression of the Fornix Toshihiro Hayashi, Mizuho Yoshida, Kurumi Fujii, Kensuke Kawai, Shoji Tsuji, Atsushi Iwata

P2.167

In Vivo Evidence for Long-term Potentiation in Older Adults Fabio Porto, Anne Fox, Erich Tusch, Farzaneh Sorond, Abdul Mohammed, Kirk Daffner

P2.168

Semantic Memory, but Not Episodic Memory, Is Modulated by Cognitive Reserve in Patients with MCI and AD Richard Darby, Michael Brickhouse, David Wolk, Bradford Dickerson

P2.169

Olfactory Impairment in Alzheimer’s Disease Is Associated with Widespread Reductions in Deep Gray Matter Volume Jesper Hagemeier, Usama Rafique, Chaitanya Amrutkar, Matthew Woodward, Niels Bergsland, Michael Dwyer, Ralph Benedict, Robert Zivadinov, Kinga Szigeti

P2.170

Validation of Olfactory Deficit as a Biomarker of Alzheimer's Disease Chaitanya Amrutkar, Matthew Woodward, Harshit Shah, Ralph Benedict, Sanjanaa Rajakrishnan, Rachelle Doody, Li Yan, Kinga Szigeti

P2.171

MRI Correlation of Odor Identification Deficit as a Biomarker for Alzheimer’s Disease Usama Ahmad Rafique, Jesper Hagemeier, Matthew Woodward, Niels Bergsland, Ralph Benedict, Robert Zivadinov, Kinga Szigeti

P2.172

Psychological Stress and Age-related Memory Decline Richard Caselli, Amylou Dueck, Dona Locke, Bryan Woodruff, Charlene Hoffman-Snyder, Yonas Geda

P2.173

Self-reported Sleep Problems and Incidence of Dementia Angeliki Tsapanou, Yian Gu, Nikolaos Scarmeas, Yaakov Stern

P2.174

Increased Risk for Cognitive Decline in Aging Associated with Cytomegalovirus Exposure in a Populationbased Cohort Eric McDade, Vishwajit Nimgaonkar, Robert Yolken, Tianxiu Wang, Lora McClain, Chung-Chou Chang, Beth Snitz, Mary Ganguli


Aging, Dementia, Cognitive, and Behavioral Neurology: Other Dementias and Co-morbidity

MS and CNS Inflammatory Diseases: In Vitro Studies, Experimental, and Animal Models

P2.175

P2.186

Clinical, Neuropsychological and Neuropathology Characteristics of Mixed Dementia Among Subjects with Autopsy Confirmed Concomitant Alzheimer’s Pathology Jagan Pillai, Sam Butler, Aaron Bonner-Jackson, James Leverenz

P2.176

The Neuropathology of Patients with Dementia and Non-dementia in the Oldest-old Gamze Balci Camsari, Neill Graff-Radford, Ronald Petersen, David Knopman, Bradley Boeve, Joseph Parisi, Dennis Dickson, Melissa Murray

P2.177

Prevalence of Traumatic Brain Injury in Early Versus Late-onset Alzheimer's Disease Jeannie Zhang, Andrew Lin, Elvira Jimenez, Pongsatorn Paholpak, Edmond Teng, Mario Mendez

P2.178

Preliminary Results of the NINDS/NIBIB Consensus Meeting to Evaluate Pathological Criteria for the Diagnosis of CTE Ann McKee, Victor Alvarez, Kevin Bieniek, Nigel Cairns, John Crary, Kristen Dams-O'Connor, Rebecca Folkerth, C. Dirk Keene, Irene Litvan, Thomas Montine, Philip Montenigro, Daniel Perl, Thor Stein, William Stewart, Yorghos Tripodis, Jean Paul Vonsattel, Wayne Gordon, Dennis Dickson

P2.179

Epilepsy in Lewy Body Disease (LBD) Nuria Campora, Maria Fernandez, Barbara Rosso, Waleska Berrios, Maria del Carmen Garcia, Edgardo Cristiano, Angel Golimstok

P2.180 Amyloid-β PET Imaging of

Alzheimer Pathology in Parkinson Disease Dementia Rizwan Akhtar, Laura Brennan, Sharon Xie, Michael Pontocorvo, Howard Hurtig, John Trojanowski, Daniel Weintraub, Andrew Siderowf

P2.181

Striatal Dopamine Transporter Binding Correlates with Education in Dementia with Lewy Bodies Guillaume Lamotte, Rémy Morello, Adrien Lebasnier, Denis Agostini, Gérard Bouvard, Vincent De La Sayette, Gilles Defer

P2.182

Brain 18F-FDG PET Hypo-and Hypermetabolic Patterns in Dementia with Lewy-bodies Leonardo Iaccarino, Chiara Cerami, Sandro Iannaccone, Giuseppe Magnani, Stefano Cappa, Daniela Perani

P2.183

Cognitive Profiles of Performance in Parkinson's Disease: Results of a Preliminary Study Rolando Giannaula, Pablo Sanz, Lorena Rodríguez Cerasuolo, Alejandra Alfonso, Santiago Pagano Ajolfi, Juan Maiques, Lina Grasso

P2.184

Clinical Spectrum of NIID (Neuronal Intranuclear Inclusion Disease) Hisatomo Kowa, Kenji Sekiguchi, Hiroaki Sekiya, Fumio Kanda, Tatsushi Toda

P2.185

Hereditary Diffuse Leukoencephalopathy with Spheroids (HDLS) Due to CSF1R Mutations: Towards Early Disease Recognition Darin Okuda, Bibiana Bielekova, Rena Godfrey, Braeden Newton, William Gahl, Camilo Toro

Ingested (oral) Anti-IL-12/23 Inhibits EAE Staley Brod, Victoria Bauer

P2.187

Treatment of Experimental Allergic Encephalomyelitis with 7,8 Dihydroxyflavone: Evidence for Neuroprotection Vamshi Nimmagadda, Tapas Makar, Kristal Lam, Susan Judge, David Trisler, Christopher Bever

P2.188

Inhibition of Lymphocyte VLA-4 Expression by DMF Exposure in Experimental Autoimmune Encephalomyelitis (EAE) Jerold Chun, Yasuyuki Kihara, Aran Groves

P2.189

ACTH1-39 Protection of Oligodendrocytes from Damage Relevant to Multiple Sclerosis Involves Both Direct and Indirect Mechanisms Robert Lisak, Liljana Nedelkoska, Joyce Benjamins

P2.190

Helicobacter Pylori Infection Reduces Disease Severity in an Experimental Model of Multiple Sclerosis Bruno Gran, James Crooks, Katherine Cook, Khiyam Hussain, Kate O'Brien, Manjit Braitch, Huner Kareem, Cris Constantinescu, Karen Robinson

P2.191

Cyclophilin D Inhibitor NIM811 Ameliorates Clinical Disease Severity in Experimental Allergic Encephalomyelitis (EAE) Unsong Oh, Hanadi Ajam Oughli

P2.192

Selective Depletion of T Regulatory Cells Reduces but Does Not Eliminate the Ability of Glatiramer Acetate to Ameliorate Experimental Autoimmune Encephalomyelitis Rina Aharoni, Feferman Tali, Guy Shakhar, Michael Sela, Ruth Arnon

P2.193

Inflammation and Oxidative Stress Induced by Cigarette Smoke Exposure in EAE Walter Royal, Joseph Bryant, Tapas Makar, Horea Rus, Ming Guo, Nimmagadda Vamshi, Harry Davis

P2.194

FGFR1 Is a Negative Regulator of LINGO-1 Expression in EAE Ranjithkumar Rajendran, Mario Giraldo Velasquez, Christine StadelmannNessler, Martin Berghoff

P2.195

Exacerbated Experimental Autoimmune Encephalomyelitis in Ceramide Synthase 6 Knockout Mice Is Associated with Enhanced Activation/ Migration of Neutrophils Christoph Mayer, Max Eberle, Philipp Ebel, Julia Barthelmes, Nadja Tafferner, Nerea Ferreirós Bouzas, Thomas Ulshoefer, Marina Henke, Annika Männer de Bazo, Christian Foerch, Andreas Weigert, Sabine Grösch, Gerd Geisslinger, Klaus Willecke, Susanne Schiffmann

P2.196

Passive Transfer of NMO-IgG Does Not Exacerbate EAE in AQP4 Null Mice Melina Jones, Michael Levy

P2.197

Galectin-4 Dependant Myelin Sulfatides Regulation of T Cell Function During Autoimmune Demyelination Marcin Mycko, Beata Sliwinska, Maria Cichalewska, Hanna Cwiklinska, Cedric Raine, Krzysztof Selmaj

69

Tuesday April 21


Poster Session II P2.198

Correlation of Spinal Cord and CSF Biomarkers to Clinical and Radiological Measures of CNS Injury in a Mouse Model of Multiple Sclerosis Andrew Pachner, Francesca Gilli, Xi Chen, Barjor Gimi

P2.199 24-Hydroxy-cholesterol

Synthesis Rate Measured in Blood in a Preclinical Mouse Model Suggests a Noninvasive Biomarker of Brain Demyelination and Remyelination Mahalakshmi Shankaran, Ellen Tsang, Hussein Mohammed, Po-yin Anne Wong, Joan Protasio, Frédéric Bernard, Rui Chang, Tammy Dellovade, Scott Turner

P2.200 Passive Transfer of Glycine

Receptor-antibody IgG Induces Anxiety-like Behavior in Mice Alexander Carvajal, Leslie Jacobson, Linda Clover, Bethan Lang, Louise Upton, Angela Vincent

P2.201 Astrocytic ECGF1/TP and

VEGF-A Drive Blood-brain Barrier Opening in Inflammatory CNS Lesions Candice Chapouly, Azeb Argaw, Sam Horng, Kamilah Castro, Jingya Zhang, Linnea Asp, Benjamin Laitman, John Mariani, Elena Zaslavsky, German Nudelman, Gareth John

P2.202 The Protection of A2aR on

BBB Permeability from Th1 Cytokines in MS Marwan Alahiri, Ying Liu, Bianca Ulloa, Saud Sadiq

P2.203 Excitatory Synapses: A

Hotspot for Neuronal Injury in Multiple Sclerosis Gray Matter Matthew Bellizzi, Harris Gelbard

P2.204 Combinatorial Actions

of Tgfβ and Activin Ligands Promote Oligodendrocyte Development and CNS Myelination Dipankar Dutta, Andleeb Zameer, John Mariani, Jingya Zhang, Linnea Asp, Jimmy Huynh, Sean Mahase, Benjamin Laitman, Azeb Tadesse Argaw, Nesanet Mitiku, Patrizia Casaccia, Fernand Hayot, Gareth John

MS and CNS Inflammatory Diseases: Risk Factors for MS Disease and Course P2.205 The MS Microbiome

Consortium (MSMC): An Academic Multidisciplinary Collaborative Effort to Elucidate the Role of the Gut Microbiota in MS Ilana Katz Sand, Sergio Baranzini, Rob Knight, Rebecca Straus Farber, Yadira Bencosme, Rachel Kanner, Refujia Gomez, Sarkis Mazmanian, Patrizia Casaccia, Bruce Cree

P2.206 Effect of Vitamin D Level in the Gut Microbiome of MS Patients Stephanie Tankou, Lynn Bry, George Gerber, Ning Lin, Bonnie Glanz, Sandra Cook, Fiona Stuart, Mira Weiner, Kirsy Melo, Roopali Ghandi, Howard Weiner

P2.207 Hypovitaminosis D and the

Risk of Multiple Sclerosis in Blacks and Hispanics Annette Langer-Gould, Lie Chen, Robyn Lucas, Anny Xiang, Lisa Barcellos

7:30 a.m.–12:00 p.m.

P2.208 Lower 25-hydroxyvitamin D

Levels in Patients with a Clinically Isolated Syndrome Compared to Healthy Controls Are Not Associated with Lower Levels of Bioavailable Vitamin D Janina Behrens, Ludwig Rasche, Rene Giess, Catherina Pfuhl, Katharina Wakonig, Eric Freitag, Katrin Deuschle, Judith Bellmann-Strobl, Friedemann Paul, Klemens Ruprecht, Jan Dörr

P2.209 Multiple Sclerosis Patients

Differ from Healthy Controls on Antioxidant and Anti-inflammatory Nutrients from Self-reported Diet History Sandra Cassard, Pavan Bhargava, Sonya Steele, Nisha Revirajan, Emmanuelle Waubant, Ellen Mowry

P2.210 Fatty Acids Directly Impact

CNS Autoimmunity Via the Small Intestine Aiden Haghikia, Stefanie Jörg, Duscha Alexander, Johannes Berg, Anna Hammer, Denis Akkad, Dominik Müller, Ralf Gold, Ralf Linker

P2.211

Effectiveness of Modified Dietary Habits on Body Composition and Fatigue-associated Symptoms in Relapsing-remitting Multiple Sclerosis Patients Rocco Totaro, Caterina Di Massimo, Daniela De Amicis, Carla Di Scanno, Caterina Di Carmine, Cinzia Raparelli, Carmine Marini, Maria Giuliana Tozzi Ciancarelli

Novel Candidate Genes in Familial Multiple Sclerosis Esther Melamed, Yuying You, Rui Chen, Sergio Baranzini, Lawrence Steinman, Michael Snyder, May Han

P2.220 Segmental Sharing Analysis

of Multiple Sclerosis Patients and Controls from the Faroe Islands Stefanie Binzer, Kerstin Imrell, Michael Binzer, Kirsten Kyvik, Jan Hillert, Egon Stenager

P2.221 Ancestry, Haplogroups and

HLA-DRB1 Alleles of Multiple Sclerosis in Bogotá, Colombia Jaime Toro, Lisseth Burbano, Camilo Diaz-Cruz, Saúl Reyes, David Cuéllar-Giraldo, Diana Narváez, Fabián Cortés, Helena Groot

P2.222 Smoking: Effects on the

Progression of Multiple Sclerosis—a Cohort Study of Patients Treated with Immunomodulatory Therapy Jette Frederiksen, Vera Crone

P2.223 Spinal Cord Involvement in

Incident Multiple Sclerosis Suggests Ethnic Differences Lilyana Amezcua, Brandon Beaber, Annette Langer-Gould

P2.231 SCN2A Related Early Onset Epileptic Encephalopathy Responsive to Phenobarbital Fiona Baumer, Jurriaan Peters, Christelle Achkar, Phillip Pearl

P2.232 BCAP31 Mutation Causing

Congenital Dystonia and Central Hypomyelination Discovered Using Exome Sequencing Padmaja Vittal, Deborah Hall, Elizabeth Berry-Kravis

P2.233 Utility of Whole Exome

Sequencing in Evaluation of Juvenile Onset Motor Neuron Disease Sonika Agarwal, Timothy Lotze, Lorraine Potocki, Suzanne Woodbury, Talia Collier, Adekunle Adesina

P2.234 Everolimus Long-term Safety

and Efficacy in Patients with Subependymal Giant Cell Astrocytoma (SEGA) Associated with Tuberous Sclerosis Complex (TSC): Final Analysis of a Phase 2 Study David Franz, Marguerite Care, Katherine HollandBouley, Karen Agricola, Cynthia Tudor, Noah Berkowitz, Sara Miao, Severine Peyrard, Darcy Krueger

P2.235 Long-term Efficacy and

Body Mass Index (BMI) and Multiple Sclerosis Progression Aliza Ben-Zacharia

Ataxia Due to Novel Mutations in ACO2 Emanuele Barca, Hanchard Neil, Ali Naini, Darryl De Vivo, Salvatore DiMauro

Safety of Everolimus for the Treatment of Subependymal Giant Cell Astrocytoma (SEGA) Associated with Tuberous Sclerosis Complex (TSC) in EXIST-1: Approximately 3.5 Years of Exposure David Franz, Elena Belousova, Steven Sparagana, E Bebin, Michael Frost, Rachel Kuperman, Olaf Witt, Michael Kohrman, J Flamini, Joyce Wu, Paolo Curatolo, Petrus de Vries, Noah Berkowitz, Julie Niolat, Sergiusz Jozwiak

P2.213 Does Alcohol and Red Wine

P2.225 Congenital Heart Disease in

P2.236 Homozygous Non-sense

P2.212 The Relationship Between

Consumption Play a Role in Multiple Sclerosis Disease Course? Camilo DiazCruz, Muhammad Taimur Malik, Alicia Chua, Tamara Kaplan, Bonnie Glanz, Howard Weiner, Brian Healy, Tanuja Chitnis

P2.214 Latitude and HLA-

DRB1 Alleles Independently Affect the Emergence of Cerebrospinal Fluid IgG Abnormalities in Multiple Sclerosis Masaaki Niino, Shinya Sato, Toshiyuki Fukazawa, Satoshi Yoshimura, Shin Hisahara, Takuya Matsushita, Noriko Isobe, Kazuto Yoshida, Hideki Houzen, Yusei Miyazaki, Shun Shimohama, Seiji Kikuchi, Jun-ichi Kira

P2.215 High Inbreeding in the Faroe

Islands Does Not Appear to Constitute a Risk Factor for Multiple Sclerosis Stefanie Binzer, Kerstin Imrell, Michael Binzer, Kirsten Kyvik, Jan Hillert, Egon Stenager

P2.216 Increasing Incidence of

Multiple Sclerosis Among Women in Buenos Aires: A 21-year Health Maintenance Organization Based Study Juan Rojas, Liliana Patrucco, Jimena Miguez, Diego Giunta, Jose Peroni, Edgardo Cristiano

P2.217 Delayed Onset and Reduced

Disease Severity of Spontaneous CNS Autoimmunity by Conjugated Linoleic Acid-rich Diet Luisa Klotz, Stephanie Hucke, Marvin Hartwig, Berit Grützke, Ivan Kuzmanov, Tanja Kuhlmann, Heinz Wiendl

P2.218 Potential Contribution of

Novel Single Nucleotide Variants to Neurodegeneration in MS Michael Levin, Sangmin Lee

70

P2.219 Exome Sequencing Unravels

Child Neurology and Developmental Neurology: Genetics P2.224 Early-onset Cerebellar

Neurofibromatosis-1 A. David Rothner, Manikum Moodley, Lauren Mientkiewicz, Francine Erenberg

P2.226 Mapk/Erk Activation in an

Mutation in Atlastin-1 Gene Caused Pure Hereditary Spastic Paraplegia Bohlega Saeed, Ahmad Abulaban, Samya Hagos, Aisha Qahtani, Salma Wakil

Animal Model of Social Deficits; a Possible Link to Autism Alirexa Faridar, Dorothy Jones-Davis, Eric Rider, Jiang Li, Ilan Gobius, Laura Marcom, Linda Richards, Elliott Sherr

P2.237 Novel Mutations in Schwartz-

P2.227 Phenotypic, Molecular,

Physical Impairment, Activity Limitation and Quality of Life in Duchenne Muscular Dystrophy (DMD): A Prospective Natural History Study Nathalie Goemans, Brenda Wong, Craig McDonald, Ali Jones, Caroline Mason, Giles Campion

Functional, and Structural Aspects of Novel DCX and LIS1 Mutations Causing the Subcortical Band Heterotopia/ lissencephaly (SBH/LIS) Spectrum Dina Amrom, Gary Brouhard, Susanne Bechstedt, Katerina Toropova, François Dubeau, Frederick Andermann, Denis Melançon, Donatella Tampieri, Samara Reck-Peterson, Eva Andermann

P2.228 Exome Sequencing Identifies

Carbamazepine Responsive Episodic Dystonia and Hallucination Due to Pyruvate Dehydrogenase E2 Mutation Salman Rashid, Meghan Harper-Shankie, Fatema Serajee, Ahm Huq

P2.229 Interaction Between Maternal

5-HTT Genotype and Prenatal Stress Exposure, Confirmation in Two Independent Samples David Beversdorf, Patrick Hecht, Michael Tilley, Melissa Hudson, Susan Connors, Xudong Liu

P2.230 Drisapersen: An Overview

of the Exon-51 Skipping Antisense Oligonucleotide Clinical Program to Date in Duchenne Muscular Dystrophy (DMD) Craig McDonald, Nathalie Goemans, Thomas Voit, Rosamund Wilson, Claire Wardell, Giles Campion

Jampel Syndrome with Successes in Medical Management Manan Shah, Mena Scavina

P2.238 Evaluating the Progression of

P2.239 Identification of Serum

Biomarkers for Duchenne Muscular Dystrophy Stavros Giannakopoulos, Afrodite Lourbakos, Giles Campion, Sjef De Kimpe

P2.240 Pooled Analyses of Efficacy

Parameters in Patients with Duchenne Muscular Dystrophy (DMD): Results from the Drisapersen (DRIS) Clinical Trial Program Nathalie Goemans, Thomas Voit, Craig McDonald, Rosamund Wilson, Claire Wardell, Giles Campion

P2.241 Two Novel Compound

Heterozygous Mutations in ACAD9 in a Patient with Infantile-onset Hypertrophic Cardiomyopathy, Hypotonia, and Lactic Acidosis Valentina Emmanuele, Melissa Wasserstein, Jiuhong Pang, Sindu Krishna, Kurenai Tanji, Peter Nagy, Michio Hirano


Poster Session II

P2.242 Compound Heterozygous

Autosomal Recessive Hereditary Spastic Paraplegia with Thin Corpus Callosum in Two Sisters of Non-consanguineous Extraction in the North-West of Ireland John Quealy, Kevin Murphy

Child Neurology and Developmental Neurology: Cognition, Behavior and Genetics P2.243 A Functional MRI Study

of Exploratory Behaviors in Early Adolescence Andrew Kayser, Zdena Op de Macks, Ronald Dahl, Michael Frank

P2.244 Withdrawn P2.245 Social Cognition as a

Predictor of Social Competence in Children and Adolescents After Epilepsy Surgery Karishma Khullar, Paul Horn, Katherine Holland, Hansel Greiner, Francesco Mangano, Anna Byars

P2.246 Case of Congenital Hypotonia Due to a Rare Genetic Deletion: 46,XX (del)14q32.2q32.3 Matthew Harmelink, Kumar Sannagowdara, Nadir Khan

P2.247 Bilateral Striatal Necrosis in a Chinese Family, a New Type? Bi Hongyan

P2.248 The Effect of Perinatal Stroke

on Spatial Orientation Kara Murias, Irene Liu, Sana Tariq, Jason Barton, Adam Kirton, Giuseppe Iaria

P2.249 Hospital Care for Mental

Health Conditions and Substance Abuse in Children with Underlying Neurological Disorders Taylor Gianangelo, Allison Willis, Dylan Thibault

P2.250 FMRI Correlates of

Sustained Attention in Pediatric Multiple Sclerosis Ermelinda De Meo, Maria Rocca, Lucia Moiola, Angelo Ghezzi, Pierangelo Veggiotti, Ruggero Capra, Maria Amato, Agnese Fiorino, Lorena Pippolo, Maria Carmela Pera, Giancarlo Comi, Andrea Falini, Massimo Filippi

P2.251 Retrospective Chart Review

of Neurodevelopmental Outcomes in Children with Congenital Cerebellar Malformations Elana Pinchefsky, Christine Saint-Martin, Michael Shevell, Myriam Srour

P2.252 Spinal Muscular Atrophy

and Progressive Myoclonic Epilepsy: A Lysosomal Disorder Due to Mutation of Acid Ceramidase Joanna Gan, Brooke Hjelm, Jane Tian, Richard Lewis, Michele Tagliati, Tyler Pierson

Cerebrovascular Disease and Interventional Neurology: Genetics and Stroke P2.253 Ischemic Stroke as the

Presenting Symptom in a Young Patient with Essential Thrombocythemia Caused by CALR Gene Mutation Nicolaas Anderson, Katherine Bonsell

P2.254 Acute Ischemic Stroke Due to

P2.255 Development of a Lacune:

What Do We Find in CADASIL? Swati Sathe, Edward Beninati, Eytan Raz, Matilde Inglese

P2.256 Amyloid Beta Related Angiitis in the Setting of Anticoagulation Cynthia Costa, Rawan Albadareen, Jayashree Sundararajan, Jeffrey Burns

P2.257 Late Adult Onset MELAS,

Presenting as Non-convulsive Status and Atypical Strokes Bhrugav Raval, Mohammad El-Ghanem, Machteld Hillen

P2.258 Recurrent Right Middle

Cerebral Artery Territory Infarctions in a Patient with JAK2 (V617F) Point Mutation Positive Polycythemia Rubra Vera Sharmila Suri Mohanram, Premkumar Nattanmai Chandrasekaran

P2.259 Evaluation of Clinico-

radiological, Molecular and Histological Diagnosis of M.3243A>G-related MELAS Syndrome Yi Shiau Ng, Grainne Gorman, Andrew Schaefer, Robert Taylor, Robert McFarland, Douglas Turnbull

P2.260 Central Retinal Artery

Occlusion in Patients with Sickle Cell Disease Hashim Zeb, Morad Chughtai, Ahmed Malik, Adnan Qureshi, Fareed Suri

P2.261

Comparison of Hypercoagulable Evaluation in Perinatal and Pediatric Ischemic Stroke David Doan, Andrew Barreto, Kasey Gildersleeve, Amrou Sarraj, Ian Butler

P2.262 Aspirin Resistance Is

Associated with Increased Stroke Severity and Infarction Volume Mi Sun Oh, KyungHo Yu, Byung-Chul Lee

Cerebrovascular Disease and Interventional Neurology: Carotid Disease and IMT P2.263 Low Fixed Dose of IV Heparin as Adjunct to Internal Carotid Artery Angioplasty and Stent Placement in Patients with Recent Ischemic Symptoms: A Prospective Protocol Muhammad Suri, Nauman Jahangir, Mushtaq Qureshi, Adnan Qureshi

P2.264 Carotid Plaque Thickness Is

Positively Associated with Decreased Bone Mineral Density Sang Won Han, Joong Hyun Park, Jae Hyeon Park, Jong Yun Lee, Kyung-Yul Lee

P2.265 Are Patients with Carotid Stenosis Receiving Optimal Medical Therapy? Sebastian Koch, Seemant Chaturvedi, Jose Romano

P2.266 Acute Glaucoma Exacerbation Following Carotid Artery Stenting Amer Malik, Keith DeSousa, Sushrut Dharmadhikari, Gillian Gordon-Perue, Rahul Dave, Jose Romano, Dileep Yavagal

P2.267 Outcomes of Elective Carotid

Stenting in the Octogenarians Aws Alawi, Sonal Mehta, Randall Edgell, Eliahu Feen, Amer Alshekhlee

Left Ventricular Noncompaction Syndrome from a Novel Mutation of the Lamin A/C Gene Nuttawan Vongveeranonchai, Shivam Mittal, Ciro Ramos Estebanez, Michael De Georgia


P2.268 Patients Consenting to or

Declining Extended Follow-up (Up to Ten Years) in the Carotid Revascularization Endarterectomy (CEA) Versus Stenting (CAS) Trial (CREST) Alice Sheffet, Ariane Mackey, William Brooks, Wayne Clark, Michael Hill, Jenifer Voeks, Susan Hughes, MeeLee Tom, Mary Longbottom, Virginia Howard, Thomas Brott

P2.269 Carotid Intima-media

Thickness, but Neither Framingham Risk Score nor Omnibus Risk Score, Is Associated with Stroke Among Nigerian African Hypertensive Patients Mayowa Owolabi, Onoja Akpa, Atinuke Agunloye

P2.270 Prevalence and Healing

Rates of Duplex Detected Carotid Plaque Ulcers Sushrut Dharmadhikari, Ari Bennett, Jose Romano, Nelly Campo, Sebastian Koch

P2.271 Evaluation of the Patients with Internal Carotid Artery Occlusion by ESSEN Score Yongbo Zhang, Ying Lv, Yan Fei Han, Jimei Li

P2.272 Cognitive Implications of

Revascularization in Asymptomatic Carotid Stenosis Chun-Jen Lin, Feng-Chi Chang, Pei-Chi Tu, Pei-Ning Wang, I-Hui Lee

P2.280 Should TCDs Be Routinely

Used for Evaluating Intracranial Circulation for Screening High Risk Patients Prior to Cardiac Surgery? Quang Vu, Laura Bishop, Matthew Edwards, Charles Tegeler, Aarti Sarwal

P2.281 Ischemic and Hemorrhagic

Cerebrovascular Events After Left Ventricular Assist Devices Pouya TahsiliFahadan, David Curfman, Albert Davis, Noushin Yahyavi-Firouz-Abadi, Michael Nassif, Shane LaRue, Gregory Ewald, Allyson Zazulia

Cerebrovascular Disease and Interventional Neurology: RCVS and Malignant Cerebral Edema P2.282 Reversible Cerebral

Vasoconstriction Syndrome Following a Carotid Endarterectomy Ajay Tunguturi, Anand Patel, David Paydarfar

P2.283 Magnesium for the

Symptomatic Treatment of Reversible Cerebral Vasoconstriction Syndrome (RCVS): Case Report Christina Mijalski, Brian Silver, Muhib Khan

P2.284 Recreational Drug Use and

Cerebrovascular Disease and Interventional Neurology: PFO and Other Cardiac Disease

RCVS: Should Toxicity Screens Become Standard in RCVS Diagnostics? Neha Mirchandani, Imad Khan, Fernanda Wajnsztajn

P2.273 Recurrent Ischemic Strokes

P2.285 A Rare Complication in a

and Headaches Originating from Lambl’s Excrescence Oana Dumitrascu, Evgeny Tsimerinov

P2.274 Clinical Characteristics of PFO Stroke in Pregnancy Lei Chen, Wenjun Deng, T Wickham, David McMullin D, Lo Eng H, Ferdinando Buonanno, MingMing Ning

P2.275 Cerebral Ischemic Events

Associated with Transcatheter Aortic Valve Replacement (TAVR): A Systematic Review Nabeel Herial, Najwa Mohammad, Chughtai Morad, Mushtaq Qureshi, Adnan Qureshi

P2.276 Outcomes of In-hospital

Cardiopulmonary Resuscitation in Stroke Patients Admitted in the United States, Years 2005-2011 Mohammad Qureshi, Malik Adil, Gabriel Vidal, Ahmed Malik, Fahad Saeed, Mushtaq Qureshi, Adnan Qureshi

P2.277 Metabolomic Analysis of

PFO-related Stroke Shows Immediate and Persistent Decrease of Homocysteine Post PFO Closure Wenjun Deng, Chris Beecher, Charles Burant, Mary Lopez, Frank De Jong, Igor Palacios, Ignacio Inglessis, Scott Silverman, Kathleen Feeney, Mikaela Elia, Thomas Wickham, David McMullin, G William Dec, Ferdinand Buonanno, Eng Lo, MingMing Ning

P2.278 The Need for Performance

Protocols for TEE and TCD in Detection of Right to Left Shunts James Frey, Carol Darbonne, Jason Chang, Mohamed Teleb

Tuesday April 21


Common Setting: Ondansetron-related Hemorrhagic Reversible Posterior Leukoencephalopathy Syndrome (PRES) Following Gastric Bypass MohamedAli Babi, Salman Aljerdi, Mark Gorman, Ryan Clouser, Gilman Allen, Christopher Commichau

P2.286 Management of Refractory

ICP with Hypothermia in a Case of Malignant Posterior Reversible Encephalopathy Syndrome Shaista Alam, Nicole Mahdi, Fred Rincon

P2.287 Improvement in Midline

Shift Is Associated with Survival After Decompressive HemiCraniectomy in Large Hemispheric Infarctions Joanna Ramiro, Rajat Dhar, Eliahu Feen, Abhay Kumar

P2.288 Hemispheric Differences

in Malignant Middle Cerebral Artery Stroke Thor Stead, Vaibhav Rastogi, Rachel Penumudi, Damon Lamb, John Williamson, Vishunmurthy Hedna

P2.289 Angiographic and Clinical

Correlates of Cerebral Hemodynamic Changes with Diamox Challenge Assessed by Quantitative Magnetic Resonance Angiography Mersedeh Bahr Hosseini, Sophia Shakur, Sepideh Amin-Hanjani,, Fady Charbel, Ali Alaraj

P2.290 Mixed Vasopressin

Antagonism as a Directed Therapy for Cerebral Edema in Acute Stroke Patients Vishnumurthy Hedna, Mushtaq Qureshi, Najwa Mohammad, Adnan Qureshi

P2.279 Enterobacter Cloacae

Endocarditis Presenting as an Ischemic Stroke Robert Mannel, Scott Silliman

71

Poster Session II

7:30 a.m.–12:00 p.m.

Cerebrovascular Disease and Interventional Neurology: Inflammation and Immunology

P2.303 Assessment of Stroke

P2.291 Susac’s Syndrome: Review of

P2.304 Exploring Self-reported

Clinical and Imaging Findings Sarita Said Said, Jennifer Lee, Shyamsunder Sabat, T. Thomas Zacharia

P2.292 FDG-PET as a Radiological

Biomarker in Patients with Takayasu Arteritis Balakrishnan Shankar, Elango Kalaimani, Ranganathan Lakshmi Narasimhan, Govindaraj Srinivasan Raman, Bhanu Kesavamurthy

P2.293 Primary Angiitis of the Central Nervous System (PACNS) Presenting with Intracerebral Hemorrhage Moayd Alkhalifah, Pierre Fayad, Matthew Omojola, Michelene Hearth-Holmes, Rodney McComb

P2.294 Delays in Diagnosis and

Treatment of Central Nervous System Vasculitis Lead to Poor Outcomes Amanda Jagolino, Adeola Olowu, Chunyan Cai, Mohammad Rahbar, Chad Tremont, Sean Savitz, Amrou Sarraj

P2.295 Temporal Trends of Mortality in Acute Ischemic Stroke in Systemic Lupus Erythematosus: A Propensitymatched Analysis of Nationwide Inpatient Data Achint Patel, Girish Nadkarni, Abhimanyu Mahajan, Ioannis Konstantinidis, Priya Simoes, Alexandre Benjo, Shiv Kumar Agarwal, Krishna Pakanati, Madhav Menon, Narender Annapureddy

P2.296 Methotrexate Neurotoxicity

Knowledge and Attitudes Among Riyadh Medical Students: A Cross-sectional Study Mohamed Alzawahmah Lifestyle and Career Choices Among Vascular Neurology Fellows Sebina Bulic, Steven Levine, Priyank Khandelwal, Elaine Auerbach, Nerses Sanossian

P2.305 Cerebral Blood Flow in TIA

Patients Presenting Acutely: Implications for Stroke Prevention in Qatar Leopold Streletz, Naveed Akhtar, Ahmed El Sotouhy, Saadat Kamran, Darine Dimassi, Damian Jenkinson, Ibtisam Ali, Ahmed Khattab

P2.306 Transient Ischemic Attacks in

Post-menopausal Women with History of Migraines Have Lower Risk for Subsequent Ischemic Strokes Haseeb Rahman, Ahmed Malik, Abraham Thomas, Adnan Qureshi

P2.307 Is CT Scan in Patients

with Suspected TIA Necessary: A Quality Improvement Initiative Sanam Baghshomali, Laura Bishop, Brian Hiestand, Patrick Reynolds, Cheryl Bushnell

P2.308 Epidemiology of Ischemic

Strokes and Transient Ischemic Attacks in the Oldest Old Rocio Garcia Santibanez, Maryna Skliut

P2.309 Nationwide Patterns of

Magnetic Resonance Imaging Utilization Among Stroke and Transient Ischemic Attack Patients in the Emergency Department Alvin Ng, Katherine Fu, Shuhan He, Steven Cen, William Mack, David Liebeskind, Nerses Sanossian

Mimicking Stroke Quynh Pham, David Ermak

HIV, PML, and CMV

P2.297 Meningovascular

P2.310 S.O.S. Progressive Multifocal

Neurosyphilis Presenting as Ischemic Stroke in an HIV Positive Patient Anita Tipirneni, Gillian Gordon-Perue, Keith DeSousa, Sebastian Koch, Jose Romano, Amer Malik

P2.298 Withdrawn P2.299 HMGB1 Contributes to

Inflammatory Response Through RAGE After Acute Intracerebral Hemorrhage in Rats Dan Li

Cerebrovascular Disease and Interventional Neurology: Education and TIA P2.300 Impact of Community Stroke Education and Comprehensive Stroke Care in South Texas Ameer Hassan, Wondwossen Tekle, Christina Sanchez, Vishal Jani, Lisa Jones-Fullingim

P2.301 Stroke Knowledge in the

Population of São Bernardo Basic Health Unit (Belo Horizonte, Brazil) Fidel Meira, Daiane Magalhães, Luiz Silva, Felipe Machado, Lucas Oliveira, Cecilia Monteiro, Ariana Chagas, Luiza Andres, Ana Silva

P2.302 Stroke Awareness in

Outpatients Diego Nadile, Maria Gonzalez Toledo, Yamila Gomez, Francisco Muñoz Giacomelli, Matias Delfitto, Javier Moschini, Fatima Pagani Cassara, Agustina Tamargo, Alejandro Thomson, Francisco Klein

72

Leukoencephalopathy: Teleneurology for a Rare Disease Shruti Agnihotri, Igor Koralnik

P2.311

A Case of Recurrent PML Associated with Cortical Intra-neuronal JC Virus Inclusions in a Woman with HIV Josef Gutman, Karen Weidenheim, Patrick LaSala, Jerome Graber

P2.312

Quantitative Susceptibility Mapping Suggests a Paramagnetic Effect in Progressive Multifocal Leukoencephalopathy Clarisse CarraDalliere, Nicolas Menjot de Champfleur, Xavier Ayrignac, Deverdun Jeremy, Pierre Labauge

P2.313

Cystatin C Is Associated with Neurocognitive Impairment in Older HIV+ Adults Marissa Sakoda, Pariya Fazeli, Scott Letendre, Dilip Jeste, Igor Grant, David Moore

P2.314

Endothelial Function and CNS Measures in Primary HIV Infection Pre-and Post Early ART Sebastian Urday, Zaina Zayyad, Julia Peterson, Felicia Chow, Kevin Robertson, Richard Price, Priscilla Hsue, Serena Spudich

P2.315

Frequency of HIV-associated Neurological Disorders over Four Years of Follow-up: Results from the Multicenter AIDS Cohort Study Ned Sacktor, Sandra Reynolds, Richard Skolasky, Cynthia Munro, James Becker, Eileen Martin, Ann Ragin, Andrew Levine, Eric Miller

P2.316

Cerebrospinal Fluid (CSF) Findings of Patients with HIV Associated Neurocognitive Disorders (HAND) Patricia McNamara, Padraic Dunne, Brian Lawlor, Janice Redmond, Colin Doherty, Derek Doherty, Colm Bergin

P2.317

Peripheral Neuropathy Is Common and Associated with Functional Impairment in HIV+ and HIV- Individuals in Rural Uganda Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Xiangrong Kong, Kevin Robertson, Ronald Gray, Maria Wawer, Ned Sacktor

P2.318

Opsoclonus Myoclonus Ataxia Syndrome Due to Mycobacterium Tuberculosis Rhombencephalitis in a Patient with HIV Juan Parada, Immer Armendariz Betancour

P2.328 Quality Indicators for

the Assessment and Management of Neurological Patients. The Quality and Safety ABC Program. Experience Neurological Center, the American British Cowdray Medical Center. México Aurelio Mendez-Dominguez, Roberto Alfonso De Leo-Vargas, Alejandro Alfonso-Diaz, Guillermo Reyes-Caballero, Patricia ConchaHein, Claudia Cabrera

P2.329 VCJD in the United States— Analysis of 4 Cases Devry Saenz, Danah Marafie, Atul Maheshwari, Haitham Hussein

P2.330 Polysomnographic

P2.319

Assessment of Sleep Disorders in Rural Areas of Low- and Middle-income Countries. A Feasibility Study in Atahualpa (Rural Coastal Ecuador) Pablo Castillo, Melanie Lawson, Bethlehem ShimeliseChamblin, Kelsie Phelan, Elizabeth Cusick, Jadry Gruen, Mauricio Zambrano, Oscar Del Brutto

Global Neurology

P2.331 Clinical Spectrum of Ciguatera

CMV Transverse Myelitis Presenting as Partial Brown-Sequard Syndrome Yinan Zhang, Divyanshu Dubey, Pradeep Modur

P2.320 Unintentional Injuries Among

People with Epilepsy in Bhutan Tali Sorets, Erica McKenzie, Joe Cohen, Sydney Cash, Edward Leung, Damber Nirola, Sonam Deki, Lhab Tshering, Emma Wolper, Farrah Mateen

P2.321 Nodding Syndrome in Uganda:

Poisoning in the Family After Consuming Amberjack Fish Nancy Rosales, Rachana Gandhi, Efrain Salgado

P2.332 Nocardial Intramedullary

Abscess; A Case Report and Review of Literature Sarah Lapointe, Catherine Legault, Robert Altman

Risk Factors at Disease Onset Rajarshi Mazumder, Valerie Palmer, Peter Spencer, Peter King, Ryan Stadnik, Michael Lasarev, Margaret Kabahenda, David Kitara, Diane Stadler

Medical Student Essay Award Recipients

P2.322 Rapidly Progressive Dementia

Profiles with Cerebral Microbleeds in Dementia Sara Shams

and Myoclonus with Elevated CSF IgG Index in Young Adult Immigrants: Treatable, but Not Always with Immunosuppression Cheryl Jay, Lara Zimmermann, Karen DaSilva

P2.323 Health Beliefs Regarding

Cerebral Palsy in Botswana: A Qualitative Study Payal Patel, James Baier, Esther Barinov, Esha Kurana, Baphaleng Monokwane, David Bearden

P2.324 Neuropsychiatric Disorders

Among Syrian and Iraqi Refugees in Jordan, 2012-2013: A Retrospective, Cohort Study Erica McKenzie, Paul Spiegel, Adam Khalifa, Farrah Mateen

P2.333 Cerebrospinal Fluid

P2.334 Diagnostic REM Sleep Muscle Activity Cutoff Values for Idiopathic REM Sleep Behavior Disorder Stuart McCarter

P2.335 Charcot's Pupils: A

Legacy of Charcot's Abilities as Teacher and Mentor Travis Urban

P2.336 The Neuroanatomical Basis of Coma in Humans: Using Functional Connectivity to Assess the Network Effects of Brainstem Lesions David Fischer

P2.325 Cerebral Palsy in

Children in Botswana: Outcomes and Comorbidities Esther Baranov, James Baier, Baphaleng Monokwane, Esha Khurana, David Bearden

P2.326 Defining the Epilepsy

Management Gap in a Prospective Cohort in Bhutan Erica McKenzie, Damber Nirola, Lhab Tshering, Sonam Deki, Joe Cohen, Sydney Cash, Emma Wolper, Edward Leung, Tali Sorets, Andrew Lim, Hannah McLane, Chencho Dorji, Farrah Mateen

P2.327 Closing the Treatment Gap for Neurological Diseases in Less Resourced Countries Vijay Chandra, Anwar Nazneen


Section Topic Controversies S3 Section Topic Controversies: Should All Brain Tumor Patients Receive Prophylactic Antiepileptic Drugs?

1:00 p.m.–2:30 p.m.

1:00 p.m.–1:05 p.m. Introduction Howard Colman, MD, PhD, and Nicole Ullrich, MD, PhD 1:05 p.m.–1:25 p.m.

Seizures in Adult and Pediatric Brain Tumor Patients—Unique Features and Scope of the Problem Howard Colman, MD, PhD, and Nicole Ullrich, MD, PhD

1:25 p.m.–2:10 p.m.

Should all Brain Tumor Patients Receive Prophylactic Anti-epileptic Drugs Debate Jeffrey J. Raizer, MD, and Elizabeth Wells, MD

2:10 p.m.–2:30 p.m.

Open Discussion, Questions, Conclusions, Summary and Adjournment Howard Colman, MD, PhD, and Nicole Ullrich, MD, PhD

CESC: 15AM Women in Leadership Ad, Horizontal Halfpage> AMRAP Placed in AMRAP 8.25”x5.4375” + .125” Bleed, 2C

Take Your Commitment to Your Profession to the Next Level 2015 AAN Leadership Programs

Whether you want to be a mentor or an advocate, to guide or inspire others, you need to cultivate the skills to be an effective leader.

Monday, April 20, 2015, 1:00 p.m.–5:00 p.m. Improving Your Leadership Skills: A Practical Approach Leadership has been defined as “having a sound vision and convincing others to follow you.” This course will assist you in implementing the vision and offer practical tips and case examples on how to persuade others to follow. Directors: Terrence L. Cascino, MD, FAAN, Rochester, MN Ralph L. Sacco, MD, MS, FAHA, FAAN, Miami, FL

Tuesday April 21

Moderators: Nicole Ullrich, MD, and Howard Colman, MD

Scientific Sessions S4 Clinical Trial Outcomes in Multiple Sclerosis 1:00 p.m. S4.001 Peginterferon Beta-1a Is Effective as Early as Twelve Weeks Following Treatment Initiation in Patients with Relapsing Multiple Sclerosis Scott Newsome, Bernd Kieseier, Shulian Shang, Shifang Liu, Serena Hung, Bjoern Sperling 1:15 p.m. S4.002 Long-term Safety and Tolerability of Peginterferon Beta-1a: Interim Analysis from ATTAIN, a Phase 3 Extension Study Marcelo Kremenchutzky, Shifang Liu, Yue Cui, Serena Hung, Ali Seddighzadeh, Vladimir Evilevitch

S5 Cerebrovascular Disease and Interventional Neurology: Recovery and Outcome 1:00 p.m. S5.001 Comparison of Prognosis in Terms of Recurrent Vascular Events, Death and Functional Outcome Following Ischemic Stroke Due to Lacunar Versus Non-lacunar Etiology at Serial Time-points over 8 Years Deidre De Silva, Natasha Fabiana, John Allen, Fung Peng Woon, Hui-Meng Chang, Kamran Ikram, Tien-Yin Wong, Meng-Cheong Wong

1:30 p.m. S4.003 Daclizumab HYP Versus Interferon Beta-1a in Relapsing-remitting Multiple Sclerosis: Primary Results of the DECIDE Study Ludwig Kappos, Krzysztof Selmaj, Douglas Arnold, Eva Havrdova, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Marianne Sweetser, Katherine Riester, Jacob Elkins

1:15 p.m. S5.002 Deep Repetitive Transcranial Magnetic Stimulation and Cycling Improve Lower Limb Function in Chronic Stroke: A Randomized, Placebo-controlled, Crossover Study Raffaella Chieffo, Fabio Giatsidis, Elise Houdayer, Mario Fichera, Arturo Nuara, Elisabetta Coppi, Laura Ferrari, Giovanni Di Maggio, Roberto Santangelo, Antonella Poggi, Maria Sessa, Mauro Comola, Abraham Zangen, Giancarlo Comi, Letizia Leocani

1:45 p.m. S4.004 MS Patients Under Daclizumab Therapy Mount Normal Immune Responses to Influenza Vaccination Yen-Chih Lin, Paige Winokur, Andrew Blake, Tianxia Wu, Jody Manischewitz, Lisa King, Elena Romm, Hana Golding, Bibiana Bielekova

1:30 p.m. S5.003 Stroke Survivors and Caregivers Preferences for Mobile APPs: A Nationwide Population-based Survey Gilles Nadege, Sarah Zelonis, Laura Beving, Dee Burton, Christina Ventura-DiPersia, Saroj Kunnakkat, Clotilde Balucani, Amy Jensen, Steven Levine

2:00 p.m. S4.005 First Dose Effects of Fingolimod: An In-depth Analysis of the First 2500 START Patients Volker Limmroth, Wilhelm Haverkamp, Ralf Dechend, Susanne Hoyer, Michael Lang, Judith Haas, Richter Stephan, Bert Wagner, Stephan Schmidt, Tjalf Ziemssen

1:45 p.m. S5.004 Evaluating the Impact of Insurance Precertification on Discharge of Stroke Patients to Skilled Nursing Facility or Inpatient Rehabilitation Center. Andrew Smith, Ashish Kulhari, Julie Wolfram, Anthony Furlan

2:15 p.m. S4.006 Long-term Safety of Fingolimod: An Interim Analysis of the LONGTERMS Cohort Jeffrey Cohen, Philipp Von Rosenstiel, Rebecca Gottschalk, Ashish Pradhan, Ying Zhang, Ludwig Kappos 2:30 p.m. S4.007 Durable Effect of Alemtuzumab on Clinical Outcomes in Treatmentnaive Relapsing-remitting Multiple Sclerosis Patients: Four-year Followup of CARE-MS I Alastair Compston, Gavin Giovannoni, Douglas Arnold, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Jeffrey Palmer, Michael Panzara, Alasdair Coles

74

2:00 p.m. S5.005 Body Weight and Survival After Stroke: Exploring the “Obesity Paradox” in the Framingham Study Hugo Javier Aparicio, Jayandra Himali, Alexa Beiser, Carlos Kase, Philip Wolf, Sudha Seshadri 2:15 p.m. S5.006 Smoker's Paradox in Hospitalizations with Acute Ischemic Stroke: An Analysis of Nationwide Inpatient Sample Data Achint Patel, Vishal Jani, Girish Nadkarni, Mihir Dave, Abhimanyu Mahajan, Mounzer Yassin-Kassab, Syed Hussain 2:30 p.m. S5.007 HDAC4 Shuttling Promotes Neuronal Remodeling After Stroke Amjad Shehadah, Haifa Kassis, Michael Chopp, Cynthia Roberts, Zheng Gang Zhang

Tuesday, April 21 S6 Epilepsy/Clinical Neurophysiology (EEG): Health Services and Women's Issues 1:00 p.m. S6.001 Mullerian Inhibitory Substance (MIS) Levels Are Associated with Seizure Occurrence in Women with Epilepsy Cynthia Harden, Page Pennell, Jacqueline French, Anne Davis, Connie Lau, Rutendo Kashambwa, Benjamin Kaufman, Emilia Bagliella, Ariel Kirshenbaum 1:15 p.m. S6.002 Re-analyses of Outcomes from Fetal Valproate Exposure in the NEAD Study Kimford Meador, Gus Baker, Ryan May, Nancy Browning, Morris Cohen, Rebecca Bromley, Jill Clayton-Smith, Laura Kalayjian, Andres Kanner, Joyce Liporace, Page Pennell, Michael Privitera, David Loring 1:30 p.m. S6.003 Contraceptive Practices of Women with Epilepsy: Findings of the Epilepsy Birth Control Registry Andrew Herzog, Hannah Mandle, Anne Davis, W. Hauser 1:45 p.m. S6.004 Improving the Prescription of Folic Acid to Women Taking Antiepileptic Drugs Anumeha Sharma, Jennifer Cavitt, Michael Privitera, Brian Moseley 2:00 p.m. S6.005 The Single Seizure Clinic Model: Does It Work? Effects on Wait-times and Patient Outcomes Rizvi Syed, Lizbeth Hernandez-Ronquillo, Gary Hunter, Farzad Moien Afshari, Karen Waterhouse, Jose Tellez-Zenteno 2:15 p.m. S6.006 The Association Between Antiepileptic Drug Dosing Frequency at Monotherapy Initiation and Direct Health Care Costs in the United States Fulton Velez, Jennifer Korsnes 2:30 p.m. S6.007 Development and Validation of an Epilepsy Epidemiologic Case Definition for Use with Australian Administrative Health Data Michael Tan, Ian Wilson, Vanessa Braganza, Sophie Ignatiadis, Raymond Boston, Vijaya Sundararajan, Mark Cook, Wendyl D'Souza

S7 Movement Disorders: Genetics 1:00 p.m. Presentation of Founders Award Recipient: Aasef Shaikh, MD, PhD Lakewood, OH

1:15 p.m. S7.002 Phosphorylated PS1292 LRRK2 to Total LRRK2 Concentration Ratio in Urine Exosomes Distinguishes LRRK2-PD and Idiopathic PD Roy Alcalay, Kyle Fraser, Andrew West 1:30 p.m. S7.003 Glucocerebrosidase Activity in Parkinson Disease with and Without GBA Mutations Roy Alcalay, Oren Levy, Cheryl Waters, Stanley Fahn, Blair Ford, Sheng-Han Kuo, Pietro Mazzoni, Karen Marder, Michael Pauciulo, William Nichols, Ziv Gan-Or, Guy Rouleau, Wendy Chung, Pavlina Wolf, Petra Oliva, Joan Keutzer, Xiaokui Zhang 1:45 p.m. S7.004 Zebrafish (Danio Rerio) as a Model for Glucocerebrosidase 1 (GBA1) Deficiency Oliver Bandmann, Marcus Keatinge, Marc Da Costa, Aswin Menke, Yu-Chia Chen, Pertti Panula 2:00 p.m. S7.005 Association Studies of Neuropathologically Confirmed Cases and Controls Reveals That the PARK10 Locus Is a Major Contributor to Sporadic Parkinson Disease. Jeffery Vance, Gary Beecham, Dennis Dickson, William Scott, Gerard Schellenberg, Karen Nuytemans, Eric Larson, Joseph Buxbaum, John Trojanowski, Vivianna Van Deerlin, Howard Hurtig, Deborah Mash, Thomas Beach, Juan Troncoso, Olga Pletnikova, Matthew Frosch, Bernardino Ghetti, Tatiana Foroud, Lawrence Honig, Karen Marder, Jean Paul Vonsattel, Samuel Goldman, Harry Vinters, Owen Ross, Zbigniew Wszolek, Liyong Wang, Derek Dykxhoorn, Margaret PericakVance, Thomas Montine, James Leverenz, Ted Dawson, Eden Martin

S8 Aging, Dementia, Cognitive, and Behavioral Neurology: Basic Science 1:00 p.m. Presentation of Potamkin Prize for Research in Pick’s, Alzheimer’s, and Related Diseases Recipients: Reisa Sperling, MD Boston, MA Peter Davies, PhD New York, NY

1:30 p.m. S8.003 Adiponectin Deficiency Induced Cognitive Impairment in Aging Mice Through Reductions in Insulin Sensitivity and AMPK Activation Roy Chun-Laam Ng 1:45 p.m. S8.004 Lack of Exacerbation of Neurodegeneration in a Double Transgenic Mouse Model of Mutant LRRK2 and Tau Fadi Mikhail, Noel Calingasan, Lichuan Yang, Luca Parolari, Aarthi Subramanian, M. Beal 2:00 p.m. S8.005 Autophagy Activators Rescue and Alleviate the Pathogenesis of a FTLD-TDP Model with TDP-43 Proteinopathies IFang Wang, KuenJer Tsai, Che-Kun Shen 2:15 p.m. S8.006 Mutant PS1 and Altered Glycolipids Synthesis Tatsuro Mutoh, Sayuri Shima, Akihiro Ueda, Kunihiko Asakura, Araki Wataru, Eri Muto, Massimo Masserini, Shinji Ito 2:30 p.m. S8.007 Reactivation of Lysosomal Calcium Efflux Rescues Abnormal Lysosomal Storage in FIG4 Deficient Cells Jianlong Zou, Bo Hu, Sezgi Arpag, Audra Hamilton, Carlos Vanoye, Jun Li

2:15 p.m. S7.006 Variants Associated with Gaucher Disease in Multiple System Atrophy Jun Mitsui, Takashi Matsukawa, Hidenao Sasaki, Ichiro Yabe, Masaaki Matsushima, Alexandra Durr, Alexis Brice, Hiroshi Takashima, Shoji Tsuji 2:30 p.m. S7.007 Short Hairpin RNA Targeting Endogenous Alpha-synuclein Prevents Degeneration of Dopaminergic Neurons in the Rat Rotenone Model of Parkinson's Disease Edward Burton, Alevtina Zharikov, Victor Tapias, Jason Cannon, Qing Bai, J. Greenamyre


Invited Science: Stroke

S9 General Neurology: Neurological Treatments and Therapeutics 1:00 p.m. S9.001 Translational Genetics to Identify the Druggable Space of Neurological Diseases Nikolaos Patsopoulos, Garrett Wong 1:15 p.m. S9.002 Anti-CD52 Treatment Induces CD39+ Regulatory Cells and Suppresses EAE Disease Progression Anudeep Pand, Yan Wang, Eli Kasper, Kiel Telesford, Javier Ochoa-Repáraz, Azizul Haque, Lloyd Kasper, Sakhina Begum-Haque 1:30 p.m. S9.003 Phase 2 Open-label Extension Study of Patisiran, an Investigational RNAi Therapeutic for the Treatment of Familial Amyloid Polyneuropathy Teresa Coelho, Ole Suhr, Isabel Conceicao, Marcia Waddington Cruz, Hartmut Schmidt, Buades Juan, Josep Campistol, Jean Pouget, John Berk, Rick Falzone, Lindsey White, Brian Bettencourt, Jeff Cehelsky, Sara Nochur, Akshay Vaishnaw, Jared Gollob, David Adams 1:45 p.m. S9.004 Acetyl-DL-leucine for Treatment Niemann-Pick Type C: A Case Series Michael Strupp, Tatiana Bremova 2:00 p.m. S9.005 Infliximab for the Treatment of CNS Sarcoidosis: Clinical and Radiological Outcomes Gelfand Jeffrey, Laura Koth, Stephen Hauser, Ari Green 2:15 p.m. S9.006 Identification and Evaluation of Potential Remyelination Therapeutics for Multiple Sclerosis Brian Bai, Simon Lunn, Robin Avila, Satish Medicetty, Bruce Trapp 2:30 p.m. S9.007 Development of Therapeutic Area-specific Data Standards for Brain Diseases Jon Neville, Steve Kopko, Bess LeRoy, Mark Gordon, Susan De Santi, Andreas Jeromin, Ellen Mowry, Mark Austin, Patricia Cole, Kenneth Marek, Gerald Novak, Klaus Romero, Bob Stafford, Emily Hartley, Amy Palmer, Rhonda Facile, Kewei Chen, Adam Fleisher, Joanne Odenkirchen, Enrique Avilés, Fred Lublin, Eric Reiman, Geoffrey Manley, Lynn Hudson, Diane Stephenson

S10 Pain and Palliative Care 1:00 p.m. Presentation of Mitchell B. Max Award for Neuropathic Pain Recipient: Robert Dworkin, PhD Rochester, NY

1:15 p.m. S10.002 Clinical and Molecular Profiling of Muscle Pain in Myotonic Dystrophy Type 2 Vinko Palada, Rabih Moshourab, Stefan Kempa, Michael Boschmann, Gary Lewin, Simone Spuler 1:30 p.m. S10.003 Alterations in Brain Gray Matter Volume Are Associated with Reduced Evoked-pain Connectivity Following Acute Pregabalin Administration Tudor Puiu, Anson Kairys, Lynne Pauer, Tobias SchmidtWilcke, Eric Ichesco, Johnson Hampson, Vitaly Napadow, Daniel Clauw, Richard Harris 1:45 p.m. S10.004 Gene Therapy for Neuropathic Pain by Silencing of TNF-α Expression with Lentiviral Vectors Targeting the Dorsal Root Ganglion in Mice. Nobuhiro Ogawa, Tomoya Terashima, Hiromichi Kawai, Hideto Kojima, Kazuhiro Oka, Lawrence Chan, Hiroshi Maegawa 2:00 p.m. S10.005 Chronic Regional Pain Syndrome: A Preliminary Report on Molecular Mechanisms and Structural Correlates Beth Murinson, Zelda Ghersin, Eli Peled 2:15 p.m. S10.006 Do Social Media Improve Dissemination of Clinical Practice Guidelines (CPG)? Thomas Getchius, Rebecca Penfold-Murray, Julie Cox, Richard Dubinsky, Christopher Bever, Gary Gronseth, Pushpa Narayanaswami

S11 Practice, Policy, and Ethics 1:00 p.m. S11.001 Perfect Care Improves Value for Ischemic Stroke Patients, Hospitals, and Payors Michael Dobbs, Sarah Heck, Kelley Elkins, Julia Blackburn, Bernard Boulanger 1:15 p.m. S11.002 Successful Reduction of Unnecessary Indwelling Catheter Utilization in Acute Ischemic Stroke Patients at a Certified Primary Stroke Center Fahed Saada, Scott Silliman

Notes from the International Stroke Conference: Late-Breaking News on Endovascular Trials for Acute Ischemic Stroke*

Tuesday, April 21, 1:00 p.m.–2:45 p.m.

1:00 p.m–1:15 p.m. MR CLEAN The Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands: Updated Results

1:15 p.m–1:30 p.m. EXTEND-IA (Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial) Trial

1:30 p.m. S11.003 Time Delays in Patient Placement: A Common Occurrence with a Simplified Solution Ilan Danan, Emiliya Melkumova, Robert Fekete

1:30 p.m–1:45 p.m.

1:45 p.m. S11.004 Implementation of a Novel “Brain Code” Medication Distribution System for Neurological Emergencies at a Tertiary Care Hospital Jamie LaBuzetta, Frank Chu, Anushirvan Minokadeh, Brian Lemkuil, Kevin Box, Navaz Karanjia

1:45 p.m–2:00 p.m.

2:00 p.m. S11.005 Analysis of Patient Portal Message Content in an Academic Multi-specialty Neurology Practice Michael Boffa, Allison Weathers, Bichum Ouyang 2:15 p.m. S11.006 Who Is My Physician? How to Improve Communication Between Patients and Health Care Providers. Michelle Molina, Jared Noroozi, Charlotte Zisman, Jin Li 2:30 p.m. S11.007 Engaging Residents in Stroke Quality Measures with Financial Incentives and Electronic Checklist Marissa Dean, Salman Rashid, Wilhelmine Wiese-Rometsch, Camelia Arsene, Corinne Hamstra, Suzanne White, Syed Hussain

2:30 p.m. S10.007 Advance Directives and Palliative Care in ALS Patients. The Piedmont and Valle D’Aosta Register Experience Andrea Calvo, Umberto Manera, Antonio Canosa, Davide Bertuzzo, Stefania Cammarosano, Cristina Moglia, Antonio Ilardi, Adriano Chio


SWIFT-PRIME (Solitaire™ FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke) Trial ESCAPE (Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times) Trial

2:00 p.m–2:15 p.m. REVASCAT (RandomizEd trial of reVasculArization with Solitaire™ FR device vs. best mediCal therapy in the treatment of Acute stroke due to anTerior circulation large vessel occlusion presenting within eight-hours of symptom onset) Trial

2:15 p.m–2:30 p.m. From MERCI to MR CLEAN: Lessons Learned About the Role of Mechanical Thrombectomy in Acute Ischemic Stroke

2:30 p.m–2:45 p.m. Facilitated Discussion with the Expert Panel

*Program subject to change

75

Tuesday April 21

1:00 p.m.–2:45 p.m.


Tuesday, April 21

The Global Burden of Neurological Infections: Epidemiology, Treatment, and Prevention

1:00 p.m.–5:00 p.m.

Coordinators: Avindra Nath, MBBS, FAAN, and Igor J. Koralnik, MD Part I

1:00 p.m.–2:45 p.m.

Part II

2:55 p.m.–4:35 p.m.

1:00 p.m.–1:05 p.m.

Introduction

2:55 p.m.–3:25 p.m.

Invited Speaker

1:05 p.m.–1: 35 p.m.

Invited Speaker

3:25 p.m.–3:30 p.m.

I7-3A Data Blitz

1:35 p.m.–1:40 p.m.

I7-1A Data Blitz

3:30 p.m.–3:35 p.m.

I7-3B Data Blitz

1:40 p.m.–1:45 p.m.

I7-1B Data Blitz

1:45 p.m.–1:55 p.m.

Audience Q&A

3:35 p.m.–3:45 p.m.

Audience Q&A

1:55 p.m.–2:25 p.m.

Invited Speaker

3:45 p.m.–4:15 p.m.

Invited Speaker

2:25 p.m.–2:30 p.m.

I7-2A Data Blitz

4:15 p.m.–4:20 p.m.

I7-4A Data Blitz

2:30 p.m.–2:35 p.m.

I7-2B Data Blitz

4:20 p.m.–4:25 p.m.

I7-4B Data Blitz

4:25 p.m.–4:35 p.m.

Audience Q&A

Avindra Nath, MBBS, FAAN, and Igor J. Koralnik, MD

Human African Trypanosomiasis (Sleeping Sickness) Peter G E Kennedy, MD

HIV Infection Serena Spudich, MD

The Changing Epidemiology of Stroke in Acquired Immune Deficiency Syndrome (AIDS) Phillip Kucab, Pratik Bhattacharya Cerebral Palsy in Children in Botswana: Outcomes and Comorbidities Esther Baranov, James Baier, Baphaleng Monokwane, Esha Khurana, David Bearden

Etiologies of New Onset Seizure in HIV-infected Zambian Adults Omar Siddiqi, Melissa Elafros, Izukanje Sikazwe, Chris Bositis, Igor Koralnik, Michael Potchen, William Theodore, Lisa Kalungwana, Gretchen Birbeck Higher Framingham Risk Score Is Associated with HIV-associated Dementia in Rural Uganda Ned Sacktor, Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Xiangrong Kong, Kevin Robertson, Ronald Gray, Maria Wawer

Chronic Meningitis Joseph R. Zunt, MD

West Nile Virus CNS Disease Kenneth L. Tyler, MD, FAAN

Neurocysticercosis and Epilepsy in Bhutan: A Cross-sectional Study Kate Brizzi, Damber Nirola, Erica McKenzie, Sonam Deki, Lhab Tshering, Sonam Pelden, Tshokey Tshokey, Chencho Dorji, Farrah Mateen

VCJD in the United States—Analysis of 4 Cases Devry Saenz, Danah Marafie, Atul Maheshwari, Haitham Hussein HIV Associated Neurocognitive Disorders (HAND) in Nigeria: Clinical Rating Versus Global Deficit Score Methods Jibreel Jumare, Akolo Christopher, Mariana Cherner, Anya Umlauf, Kanayo Okwuasaba, Lindsay Eyzaguirre, Ruxton Adebiyi, Dakum Paul, Joyce Johnson, Terence Hendrix, Alash'le Abimiku, William Blattner, Walter Royal

2:35 p.m.–2:45 p.m.

Audience Q&A

2:45 p.m.–2:55 p.m.

Break

HTLV-1-associated Myelopathy/tropical Spastic Paraparesis: Clinical and Neuroimaging Findings Francisco Carod, Hudson Mesquita


Myriad Manifestations of a Global Infectious Disease Aparna Prabhu, Ramya Raghupathi, Jonathan Dissin

I7-5B

Closing the Treatment Gap for Neurological Diseases in Less Resourced Countries Vijay Chandra, Anwar Nazneen

I7-5C

Peripheral Neuropathy Is Common and Associated with Functional Impairment in HIV+ and HIV- Individuals in Rural Uganda Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Xiangrong Kong, Kevin Robertson, Ronald Gray, Maria Wawer, Ned Sacktor

I7-5D

Clinical, Laboratory Findings and Complications of Scrub Typhus- Meningoencephalitis: Case Series Prasanna Venkatesan Eswaradass, C Eswaradass

76

4:35 p.m.–5:00 p.m. I7-5E

Detection of Human T-cell Lymphotropic Virus Type I Proteins in Exosomes from HAM/TSP Patient CSF by Novel Nanotrap Technology Monique Anderson, Benjamin Lepene, Fatah Kashanchi, Steven Jacobson

I7-5F

The Changing Epidemiology of Stroke in Acquired Immune Deficiency Syndrome (AIDS) Phillip Kucab, Pratik Bhattacharya

I7-5G

Cerebral Palsy in Children in Botswana: Outcomes and Comorbidities Esther Baranov, James Baier, Baphaleng Monokwane, Esha Khurana, David Bearden

I7-5H

VCJD in the United States—Analysis of 4 Cases Devry Saenz, Danah Marafie, Atul Maheshwari, Haitham Hussein

I7-5I

HIV Associated Neurocognitive Disorders (HAND) in Nigeria: Clinical Rating Versus Global Deficit Score Methods Jibreel Jumare, Akolo Christopher, Mariana Cherner, Anya Umlauf, Kanayo Okwuasaba, Lindsay Eyzaguirre, Ruxton Adebiyi, Dakum Paul, Joyce Johnson, Terence Hendrix, Alash'le Abimiku, William Blattner, Walter Royal

I7-5J

Etiologies of New Onset Seizure in HIV-infected Zambian Adults Omar Siddiqi, Melissa Elafros, Izukanje Sikazwe, Chris Bositis, Igor Koralnik, Michael Potchen, William Theodore, Lisa Kalungwana, Gretchen Birbeck

I7-5K

Higher Framingham Risk Score Is Associated with HIV-associated Dementia in Rural Uganda Ned Sacktor, Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Xiangrong Kong, Kevin Robertson, Ronald Gray, Maria Wawer

I7-5L

Neurocysticercosis and Epilepsy in Bhutan: A Cross-sectional Study Kate Brizzi, Damber Nirola, Erica McKenzie, Sonam Deki, Lhab Tshering, Sonam Pelden, Tshokey Tshokey, Chencho Dorji, Farrah Mateen

I7-5M HTLV-1-associated

Myelopathy/tropical Spastic Paraparesis: Clinical and Neuroimaging Findings Francisco Carod, Hudson Mesquita



Advances in ALS and Other Motor Neuron Diseases

1:00 p.m.–5:00 p.m.

Coordinators: Catherine Lomen-Hoerth, MD, PhD, and Tahseen Mozaffar, MD, FAAN 1:00 p.m.–2:45 p.m.

Part II

2:55 p.m.–4:35 p.m.

1:00 p.m.–1:05 p.m.

Introduction

2:55 p.m.–3:25 p.m.

Invited Speaker

1:05 p.m.–1:35 p.m.

Invited Speaker

3:25 p.m.–3:30 p.m.

I8-3A Data Blitz

1:35 p.m.–1:40 p.m.

I8-1A Data Blitz

3:30 p.m.–3:35 p.m.

I8-3B Data Blitz

Catherine Lomen-Hoerth, MD, PhD, and Tahseen Mozaffar, MD, FAAN ALS Clinical Trials: What Have We Learned Merit E. Cudkowicz, MD, MSC Transplantation of an IPSC-derived CD15+CXCR4+VLA4+ Neural Stem Cell Subpopulation as a New Therapy for ALS Chiara Simone, Monica Nizzardo, Federica Rizzo, Monica Bucchia, Agnese Ramirez, Nereo Bresolin, Giacomo Comi, Stefania Corti

1:40 p.m.–1:45 p.m.

I8-1B Data Blitz

A Single-center, Randomized, Double-blind, Placebo-controlled, Six-month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 Benjamin Brooks, Elena Bravver, Mohammed Sanjak, Velma Langford, Cynthia Lary, Mohamed Alwan, Joanne Nemeth, Priscilla Russo, Nicole Smith, Nicole Lucas, Mindy Nichols, Sharon Belcher, Kathryn Wright, Amber Ward, Scott Holsten, Michael Fischer, William Bockenek, Urvi Desai, Scott C Lindblom, Thomas Pacicco, Kazuko Matsuda, Joanna Dojillo

1:45 p.m.–1:55 p.m.

Audience Q&A

1:55 p.m.–2:25 p.m.

Invited Speaker

Advances in Our Understanding of the Basic Science of ALS Robert H. Brown Jr., MD, DPhil

2:25 p.m.–2:30 p.m.

I8-2A Data Blitz

Transthyretin as Potential Biomarker for C9ORF72-related Diseases Marka Van Blitterswijk, NiCole Finch, Matthew Baker, Xue Wang, Kevin Bieniek, Mariely Dejesus-Hernandez, Tania Gendron, Yan Asmann, Michael Heckman, Patricia Brown, Keith Josephs, Joseph Parisi, David Knopman, Ronald Petersen, Leonard Petrucelli, Bradley Boeve, Neill Graff-Radford, Kevin Boylan, Dennis Dickson, Rosa Rademakers

2:30 p.m.–2:35 p.m.

Taking the Genetics of ALS to the Next Step Orla Hardiman, MD, FRCP, FAAN Large-scale Exome Sequencing in ALS Identifies New Risk Genes and Pathways Matthew Harms, Elizabeth Cirulli, Brittany Lasseigne, Tim Harris, Richard Myers, David Goldstein ATXN2 PolyQ Intermediate Repeat Modifies ALS Phenotype and Survival Adriano Chio, Andrea Calvo, Cristina Moglia, Antonio Canosa, Gabriella Restagno, Maura Brunetti, Marco Barberis, Amelia Conte, Giuseppe Marangi, Serena Lattante, Marcella Zollino, Mario Sabatelli, Lucia Corrado, Gabriele Mora, Letizia Mazzini, Sandra D'Alfonso

3:35 p.m.–3:45 p.m.

Audience Q&A

3:45 p.m.–4:15 p.m.

Invited Speaker

4:15 p.m.–4:20 p.m.

I8-4A Data Blitz

4:20 p.m.–4:25 p.m.

I8-4B Data Blitz

4:25 p.m.–4:35 p.m.

Audience Q&A

The Overlap of ALS and Frontotemporal dementia Michael J. Strong, MD, FAAN Grey and White Matter MRI Signatures of the Frontotemporal Lobar Degeneration Continuum Massimo Filippi, Federica Agosta, Sebastiano Galantucci, Giuseppe Magnani, Alessandra Marcone, Daniele Martinelli, M. Antonietta Volonte, Nilo Riva, Sandro Iannaccone, Pilar Ferraro, Francesca Caso, Adriano Chio, Andrea Falini, Giancarlo Comi Longitudinal Assessment of Frontal Cognitive Impairment in Patients with Motor Neuron Disease Pilar Maria Ferraro, Federica Agosta, Edoardo Spinelli, Elisa Canu, Nilo Riva, Massimiliano Copetti, Andrea Falini, Giancarlo Comi, Massimo Filippi

I8-2B Data Blitz

The ALS/FTD C9ORF72 Hexanucleotide Expansion Disrupts Nucleocytoplasmic Transport Thomas Lloyd, Ke Zhang, Chris Donnelly, Jeffrey Rothstein

2:35 p.m.–2:45 p.m.

Audience Q&A

2:45 p.m.–2:55 p.m.

Break


ALS and Military Occupation: A Population-based Case-control Study in the Danish Registries Ryan Seals, Marianthi-Anna Kioumourtzoglou, Johnni Hansen, Ole Gredal, Marc Weisskopf

I8-5B

Head Injury Does Not Alter Disease Progression or Neuropathological Outcomes in ALS Christina Fournier, Marla Gearing, Saila Upadhyayula, Mitch Klein, Jonathan Glass

I8-5C

Threshold Tracking TMS: A Novel Diagnostic Technique for Amyotrophic Lateral Sclerosis Nimeshan Geevasinga, Parvathi Menon, Con Yiannikas, James Howells, Matthew Kiernan, Steve Vucic

I8-5D

Advance Directives and Palliative Care in ALS Patients. The Piedmont and Valle D’Aosta Register Experience Andrea Calvo, Umberto Manera, Antonio Canosa, Davide Bertuzzo, Stefania Cammarosano, Cristina Moglia, Antonio Ilardi, Adriano Chio

4:35 p.m.–5:00 p.m. I8-5E

The ALSUntangled Table of Evidence Richard Bedlack

I8-5F

Transplantation of an IPSC-derived CD15+CXCR4+VLA4+ Neural Stem Cell Subpopulation as a New Therapy for ALS Chiara Simone, Monica Nizzardo, Federica Rizzo, Monica Bucchia, Agnese Ramirez, Nereo Bresolin, Giacomo Comi, Stefania Corti

I8-5G

A Single-center, Randomized, Double-blind, Placebocontrolled, Six-month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DBOLE-1 Benjamin Brooks, Elena Bravver, Mohammed Sanjak, Velma Langford, Cynthia Lary, Mohamed Alwan, Joanne Nemeth, Priscilla Russo, Nicole Smith, Nicole Lucas, Mindy Nichols, Sharon Belcher, Kathryn Wright, Amber Ward,


Scott Holsten, Michael Fischer, William Bockenek, Urvi Desai, Scott C Lindblom, Thomas Pacicco, Kazuko Matsuda, Joanna Dojillo

I8-5H

Transthyretin as Potential Biomarker for C9ORF72-related Diseases Marka Van Blitterswijk, NiCole Finch, Matthew Baker, Xue Wang, Kevin Bieniek, Mariely Dejesus-Hernandez, Tania Gendron, Yan Asmann, Michael Heckman, Patricia Brown, Keith Josephs, Joseph Parisi, David Knopman, Ronald Petersen, Leonard Petrucelli, Bradley Boeve, Neill Graff-Radford, Kevin Boylan, Dennis Dickson, Rosa Rademakers

I8-5I

The ALS/FTD C9ORF72 Hexanucleotide Expansion Disrupts Nucleocytoplasmic Transport Thomas Lloyd, Ke Zhang, Chris Donnelly, Jeffrey Rothstein

I8-5J

Large-scale Exome Sequencing in ALS Identifies New Risk Genes and Pathways Matthew Harms, Elizabeth Cirulli, Brittany Lasseigne, Tim Harris, Richard Myers, David Goldstein

I8-5K

ATXN2 PolyQ Intermediate Repeat Modifies ALS Phenotype and Survival Adriano Chio, Andrea Calvo, Cristina Moglia, Antonio Canosa, Gabriella Restagno, Maura Brunetti, Marco Barberis, Amelia Conte, Giuseppe Marangi, Serena Lattante, Marcella Zollino, Mario Sabatelli, Lucia Corrado, Gabriele Mora, Letizia Mazzini, Sandra D'Alfonso

I8-5L

Grey and White Matter MRI Signatures of the Frontotemporal Lobar Degeneration Continuum Massimo Filippi, Federica Agosta, Sebastiano Galantucci, Giuseppe Magnani, Alessandra Marcone, Daniele Martinelli, M. Antonietta Volonte, Nilo Riva, Sandro Iannaccone, Pilar Ferraro, Francesca Caso, Adriano Chio, Andrea Falini, Giancarlo Comi

I8-5M

Longitudinal Assessment of Frontal Cognitive Impairment in Patients with Motor Neuron Disease Pilar Maria Ferraro, Federica Agosta, Edoardo Spinelli, Elisa Canu, Nilo Riva, Massimiliano Copetti, Andrea Falini, Giancarlo Comi, Massimo Filippi

77

Tuesday April 21

Part I

Poster Session III

Tuesday, April 21

P3 Poster Session III First Authors stand by Posters from 5:00 p.m.–6:30 p.m. Poster Discussion Session: Movement Disorders

2:00 p.m.–6:30 p.m.


P3.001 Identifying Parkinson Disease with Non-motor Features and CSF Biomarkers: A Case-control Study Samay Jain, Seo Young Park, Diane Comer, Deborah Rudoy, Larry Ivanco

P3.002 A New Screening Tool

for Behavioral Disturbances in HD: The Huntington’s Disease-behavioral Questionnaire (HD-BQ) Jody Corey-Bloom, Andrew Herndon, Anastasia Lam, Daniel Goble, Paul Gilbert

P3.003 New Observations in the

Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) Phenotype Avram Fraint, Padmaja Vittal, Aimee Szewka, Bryan Bernard, Elizabeth Berry-Kravis, Deborah Hall

P3.004 Global Long-term Registry on

Efficacy and Safety of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson’s Disease in Routine Care (GLORIA)—Interim Results on Non-motor Symptoms Angelo Antonini, K. Ray Chaudhuri, Ashley Yegin, Lars Bergmann, Werner Poewe

P3.005 Embouchure Dystonia:

Phenomenology, Natural History and Mimicks Pichet Termsarasab, Steven Frucht

P3.007 Non-motor Symptoms in Early Drug-naive Parkinson Disease Rui Liu, David Umbach, Shyamal Peddada, Zongli Xu, Alexander Tröster, Xuemei Huang, Honglei Chen

P3.008 Analysis of Heart Rate

Variability in Functional Movement Disorder Patients Victoria Liu, Carine Maurer, Kathrin LaFaver, Ryan Toledo, Mark Hallett

P3.006 Neuroanatomical Correlates

of Cognitive Functioning Across the Parkinson's Disease Cognitive Spectrum Doug Merkitch, Glenn Stebbins, Bryan Bernard, Jennifer Goldman

P3.009 XCiDaBLE: An Observational,

Prospective Trial Evaluating Xeomin (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States— Final Results from the Cervical Dystonia Cohort Hubert Fernandez, Fernando Pagan, Fabio Danisi, David Greeley, Kapil Sethi, Amit Verma

P3.010

Reorganization of Corticostriatal Circuits in Healthy G2019S LRRK2 Carriers Rick Helmich, Avner Thaler, Bart van Nuenen, Tanya Gurevich, Anat Mirelman, Karen Marder, Susan Bressman, Avi Orr-Urtreger, Nir Giladi, Bastiaan Bloem, Ivan Toni

e-Poster Session: Movement Disorders Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch screen displays.

P3.011

Abnormal Climbing Fiberpurkinje Cell Synaptic Connections in the Essential Tremor Cerebellum Sheng-Han Kuo, Chi-Ying Lin, Elan Louis, Phyllis Faust, Arnulf Koeppen, Jean Paul Vonsattel

P3.012

Intracranial Germinoma Associated Rubral Tremor Mimicking Neuro-Behcet Disease: Importance of a Tissue Diagnosis Roy Strowd, Peter Burger, Matthias Holdhoff, Lawrence Kleinberg, Alessandro Olivi, Carlos Pardo-Villamizar, Michael Okun, Nicoline Shiess

P3.013

5-Meo-DALT-induced Cyclic Myoclonus Thananan Thammongkolchai, Pichet Termsarasab, Ayham Alkhachroum, Yogesh Gujrati, Steven Frucht, Bashar Katirji

Movement Disorders: Myoclonus, Paroxysmal Dyskinesias, and Parkinson's Disease

P3.014

Zonisamide Responsive Familial Myoclonus Dystonia Pavan Tummala, Pratap Chand

P3.015

Ultrasound as Diagnostic Tool for Diaphragmatic Myoclonus: A Case Report Vesper Fe Marie Ramos, Barbara Karp, Codrin Lungu, Katharine Alter, Mark Hallett

P3.016

Impaired DNA Damage Response in the Pathogenesis of Multiple System Atrophy: A Histopathological Study Rhea Yan Ying Tan, Kiyobumi Ota, Hidehiro Mizusawa, Takanori Yokota, Kinya Ishikawa

P3.023 Motor Abilities and Driving

as an Unusual Presentation of Multiple Sclerosis Samar Ahmed, Jasem Al-Hashel, R Khan, Raed Alroughani

Performance in Parkinson’s Disease (PD) Ion Beratis, Nikos Andronas, Dionysia Kontaxopoulou, Stella Fragkiadaki, Athanasia Liozidou, Alexandra Economou, John Papatriantafyllou, Panagiotis Papantoniou, Leonidas Stefanis, George Yannis, Sokratis Papageorgiou

P3.022 Demographics, Comorbidities

P3.024 Levodopa/Carbidopa

P3.021 Spinal Segmental Myoclonus

and Clinical Features in Hospitalized Patients with Myoclonus Debra Ehrlich, Matthew Swan, Matthew Robbins, Steven Herskovitz, Mark Milstein

78

Intestinal Gel Infusion Therapy in Advanced Parkinson Disease—the Saudi Arabian Experience Bohlega Saeed, Thamer Alkhairallah, Fahad Alajlan, Hussam Abou Al-Shaar, Nael Hasan, Khalid Alkahtani

P3.017

White Matter Abnormalities as a Marker of Parkinson’s Disease Cognitive Impairment: A Diffusion Tensor Imaging Study Jennifer Goldman, Doug Merkitch, Bryan Bernard, Glenn Stebbins

P3.019 Withdrawn P3.020 Increased Pain Sensitivity

P3.018

and Increased Impulsivity Appear Related: Pain-related FMRI in Parkinson’s Disease Bradley Avery, Robert Coghill, Ihtsham Haq

P3.025 The Effects of Comorbid

P3.027 MODERATO, a Randomized,

Helicobacter Pylori Infection Is Associated with Worse Severity of Parkinson’s Disease Ai Huey Tan, Sanjiv Mahadeva, Abdul Malik Thalha, Chiun Khang Kiew, Chia Ming Yeat, Sheang Wen Ng, Sheau Phing Ang, Siew Kian Chow, Mun Fai Loke, Jamunarani Vadivelu, Norlinah Ibrahim, Hoi Sen Yong, Chong-Tin Tan, Susan Fox, Connie Marras, Anthony Lang, Shen Yang Lim

Traumatic Brain Injury on Motor and Non-motor Symptoms of Parkinson’s Disease Catherine Stachnik, Brandon Barton

P3.026 Rotigotine in Combination

with the MAO-B Inhibitor Selegiline in Early Parkinson’s Disease: A Post-hoc Analysis Mahnaz Asgharnejad, Lars Bauer, Frank Grieger, Babak Boroojerdi

Double-blind, Placebo-controlled Study to Assess the Effect of Rasagiline on Mild Cognitive Impairment in Patients with Parkinson’s Disease: An Ongoing Study Daniel Weintraub, Robert Hauser, Azhar Choudhry

Movement Disorders: Tics, Dyskinesias, and Chorea P3.028 Isolated Lingual Dyskinesias

in Multiple Sclerosis Jung Park, Katharine Alter, Mark Hallett


Poster Session III

P3.029 Co-occurrence of Klinefelter Syndrome and Tourettism: A Case Report Leonardo Brito De Almeida, Michael Okun, Irene Malaty

P3.030 Mutations in the AMPA

Receptor Complex Protein FRRS1L Cause an Inherited Huntington-like Choreadementia Syndrome Mustafa Salih, Marianna Madeo, Lauren Fields, Tyler Jepperson, Mohammed Seidahmed, Heba El Khashab, Muddathir Hamad, Michael Kruer

P3.031 A Movement Disorders

Paradox: Case Report of a Patient with Gene-positive Huntington’s Disease Who Presented with DaTScan Positive and Levodopa Responsive Parkinson’s Disease Ryan Hadden, Victor Sung

P3.032 Refractory Dyskinetic

Movements Associated with NMDA Encephalitis Abdulrahman Alwaki, Christopher Goshgarian, Khadija Irshad, Arun Chandok

P3.033 Hemichorea in a Patient with Diabetic Ketoacidosis Ahmed Yassin, Sheetal Shroff, Shrestha Patel, Asif Parker, Megan Berman, George Jackson

P3.042 Assessing Migraine: An

Enquiry into Prophylactic Treatment Patterns by Diagnosis: The AMEND Study Anoop Reddy, Amanda Policastro, Albert Reppine, John Sekab, Chris Purdy, Laura Dalfonso, Raf Magar

P3.043 Headache in Patients with

Celiac Disease and Its Response to Glutenfree Diet Ameghino Lucía, Mauricio Farez, Ismael Calandri, Maria Goicochea

P3.044 Overdiagnosis of Idiopathic Intracranial Hypertension (IIH) Adeniyi Fisayo, Valerie Biousse, Nancy Newman, Beau Bruce

P3.045 Not Everything That

Worsens on Standing Is Intracranial Hypotension! Kaustubh Limaye, Zabeend Mahuwala, Ricky Lee

P3.046 Development of an Interactive Educational Bedside Assessment Tool with Validation in Headache Clinic Daniel Fok, Aravind Ganesh, Rahul Mehta, Nathalie Jette, Lara Cooke

P3.047 Breath Powered™ Nasal

in Chorea Complicating Common Variable Immune Deficiency (CVID) with Subcutaneous Immunoglobulin (SCIG) Infusions Ravdeep Kaur, Leslie Cristiano, Guha Krishnaswamy

Delivery of 22 Mg Sumatriptan Powder (AVP-825): An Exploratory Analysis of Response in Migraine Patients Grouped by Baseline Headache Intensity from the Phase 3 TARGET Study Roger Cady, Peter McAllister, Egilius Spierings, John Messina, Per Djupesland, Scott Siegert, Ken Shulman, Ramy Mahmoud

P3.035 Paroxysmal Kinesigenic

P3.048 Subarachnoid

P3.034 Prolonged Remission

Dyskinesia in Taiwan: A Genetic and Clinical Study of 57 Patients Yo-Tsen Liu, Yi-Chung Lee, Chien Chen, Shang-Yeong Kwan, Bing-Wen Soong

P3.036 ADCY5 Genetic Screening

in Benign Early Onset Chorea Niccolò Mencacci, Roberto Erro, Joshua Hersheson, Sarah Wiethoff, Nicholas Wood, Henry Houlden, Kailash Bhatia

Headache P3.037 Idiopathic Stabbing Headache in Children and Adolescents Gabriel Mandel

Pneumocephalus: A Cause of Severe Headache as a Result of Obstetric Epidural Anesthesia Fahed Saada, Robert Mannel, Suparna Krishnaiengar

P3.049 SUNCT Responding to

Botulinum Toxin Subhashie Wijemanne, Joseph Jankovic

P3.050 The Association Between

Functional Abdominal Symptoms and Migraine in Adult Patients Providing More Evidence That Abdominal Migraine Occurs in Adults Christi Pendergraft, David Gordon, David Thompson

P3.038 Characterization of

P3.051

P3.039 Refractory Chronic Cluster

P3.052 Status Migrainosus:

Headache Features in FMR1 Premutation Carriers Stuart Bergman-Bock, Maura Walsh, Elizabeth Berry-Kravis, Deborah Hall Headache: A Consensus Statetment on Clinical Definition from the European Headache Federation Dimos Dimitrios Mitsikostas

P3.040 Comparison of Serum

S100B and Neuron Specific Enolase Levels in Episodic Migrane and Chronic Migrane Patients and Their Value for Etiopathogenesis Muhammed Berilgen, Murat Gonen, Bülent Müngen, Caner Demir, Sevim Ozdogan

P3.041 Long-term Safety of the ATI

Neurostimulation System for the Treatment of Cluster Headache Anthony Caparso, Soren Hillerup, Jorgen Rostgaard, Alexandre Assaf, Tim Jurgens, Mads Barloese, Miguel Lainez, Michelle-Olivia Bigazzi, Amy Goodman, Rigmor Jensen, Arne May

Cost-effective Approach to the Chemodenervation Using Onabotulinum ToxinA: An Observational Study Prityi Rani, Jessy Walia, Niranjan Singh, Irving Asher Predictors of Longer Hospital Stay Sumul Modi, Devanshi Dharaiya

P3.053 Autonomic Dysfunction in

Adolescents with Headaches Augusto Morales, Stoichita Andreea, Jessica Demarest

P3.054 High-volume Suboccipital Nerve Injections for Chronic Cluster Headache with Long-term Efficacy Data Todd Rozen

P3.055 Amitriptyline in

the Management of Cluster Headache Natarajan Visvanathan, Mutharasu Chinnu, Radha Mahadevan

P3.056 Outcome of 370 Patients with

Trigeminal Neuralgia Who Underwent Microvascular Decompression with Silastic Graft Between 1997 and 2014 Corlos Bangel


P3.057 Evolution of the Impact of

Headache in an Exceptional Context of External Operations, Studied Through a Military Population in Afghanistan, Assigned to the Staff of the Kaia's Military Field Hospital Laurent Guilloton, Ondine Bruneau, Marion Trousselard, Pierre Antoine Blanc, Thierry de Greslan, Alain Drouet, Fabien Zagnoli

P3.058 Neurologic Complications of Osler-Weber-Rendu Syndrome: A Case Report and Literature Review Salman Farooq, Ashkan Mowla, Mahmoud AbdelRazek, Azher Iqbal, Robert Sawyer

P3.059 Secondary Efficacy Outcomes from COMPASS: A Comparison of Breath Powered™ Device Containing 22 Mg Sumatriptan Powder (AVP-825) Versus Oral 100 Mg Sumatriptan in Episodic Migraine Stephen Silberstein, Stewart Tepper, Roger Cady, John Messina, Ramy Mahmoud, Per Djupesland, Paul Shin, Joao Siffert

P3.060 Sjögren’s Syndrome, an Underdiagnosed Etiology of Facial Pain? Hossein Ansari

P3.061

Novel SLC20A2 Gene Mutations Causing Idiopathic Basal Ganglia Calcification in Two Italian Patients Presenting with Migraine Elisa Rubino, Elisa Giorgio, Innocenzo Rainero, Patrizia Ferrero, Salvatore Gallone, Lorenzo Pinessi, Laura Orsi, Salvatore Gentile, Sergio Duca, Alfredo Brusco

P3.062 Cluster Headache—a

Nationwide Study of 387 Cases Maria Eduarda Nobre De M Costa

P3.063 Intracranial Hypotension

Manifesting as Recurrent Thunderclap Headache with Aphasia Michael Ruff

P3.064 Central Vestibular

System Modulation in Vestibular Migraine—a Voxel-based Morphometry Study Sebastian Wurthmann, Steffen Naegel, Nina Theysohn, H. Diener, Mark Obermann

P3.065 An Unusual Case of Post-

traumatic Headache Complicated by Intracranial Hypotension Sara Siavoshi, Carrie Dougherty, Jessica Ailani

P3.066 A FORMal Analysis: An

Analysis of UCNS Certified Headache Center Patient Intake Forms Roni Sharon, Paul Mathew, Joseph Viknevich, Melissa Rayhill, Larry Charleston

Cerebrovascular Disease and Interventional Neurology: Ischemic Stroke Outcome P3.067 The Effects of Clinical

Variables on Functional Outcomes in Patients Undergoing Decompressive Hemicraniectomy for Malignant MCA Infarctions Kader Abdelerahman, Varoon Thavapalan, Carissa Pineda, Fred Rincon, Rodney Bell, Matthew Vibbert

P3.068 Recanalization and Initial Poor Collateral Circulation Determine the Effect of Collateral Recruitment on Functional Outcomes Benjamin Yong Qiang Tan, Kong Yee, Hock Luen Teoh, Raymond Seet, Bernard Chan, Rahul Rathakrishnan, Derek Soon, Vijay Sharma, Leonard Yeo

P3.069 A Mobile Application for

Predicting 90-day Outcomes After IV Thrombolysis in Ischemic Stroke Karin Nystrom, David Asuzu, Hardik Amin, Joseph Schindler, Charles Wira, David Greer, Nai Fang Chi, Janet Halliday, Kevin Sheth

P3.070 Mechanisms and Outcomes

of Ischemic Stroke in Pregnancy and Postpartum: A Retrospective Crosssectional Study Eliza Miller, Shadi Yaghi, Amelia Boehme, Joshua Willey, Mitchell Elkind, Randolph Marshall

P3.071 Effect of Cigarette Smoking

on Outcomes of Acute Ischemic Stroke Treated with Intravenous Thrombolysis: Is There Any Paradox in the Brain? Haitham Hussein, Nicki Niemann, Logan Stuck, Adnan Qureshi

P3.072 Predictors of Early Mortality

and Bad Outcome in Ischemic Stroke Ariel Luzzi, Maria Zurru, Claudia Alonzo, Laura Brescacin, Santiago Pigretti, Luis Camera, Pedro Colla Machado, Gabriel Waisman, Edgardo Cristiano

P3.073 Does Emergency Department

Length of Stay Affect the 90-day Functional Outcome After Acute Ischemic Stroke? Anand Patel, Artin Minaeian, Ajay Tunguturi, Richard Goddeau, Nils Henninger

P3.074

Elevated VLDL Is Associated with Cardioembolic Stroke and Improved Functional Outcome in Patients with Acute Ischemic Stroke Alexander George, Dominique Monlezun, Jr, Alyana Samai, Elizabeth Waring, Lauren Dowell, Melisa Valmoria, Sheryl Martin-Schild

P3.075 Does the Grade of Diastolic

Dysfunction Predict Short-term Outcomes of Acute Ischemic Stroke Patients? Melisa Valmoria, Dominique Monlezun, Jr, Marco Elegante, Lauren Dowell, Elizabeth Warren, Alexander George, Ramy El-Khoury, Sheryl Martin-Schild

P3.076

Persistent Elevation of Factor VIII and Long-term Patient Outcomes in Ischemic Stroke Alyana Samai, Amelia Boehme, Alexander George, Lauren Dowell, Laurie Schluter, Ramy El Khoury, Sheryl Martin-Schild

Cerebrovascular Disease and Interventional Neurology: Hemorrhagic and Ischemic Stroke P3.077 Clinical Outcomes of

Metastatic Intra-cerebral Hemorrhage and Role of Acute Radiotherapy Umair Afzal, Michael Mendoza, Julius Latorre

P3.078 Seasonal and Barometric

Variations in the Incidence of Lobar and Deep Intracerebral Hemorrhage Asaf Honig, Ruth Eliahu, Ronen Leker

79

Tuesday April 21

2:00 p.m.–6:30 p.m.

Poster Session III2:00 p.m.–6:30 p.m. P3.079 On What Type of ICH Patient

Do Neurologists Order EEG? Alissa Gadpaille, Amelia Boehme, Karen Albright, Kara Sands, Harn Shiue, Mark Harrigan

P3.080 Seizures in Subcortical

Ischemic and Hemorrhagic Strokes Robin Dharia, Carissa Pineda

P3.081 Effect of Weekend Admission on Inhospital Outcomes Among Children with Ischemic and Hemorrhagic Strokes Malik Adil, Gabriel Vidal, Ahmed Malik, Mushtaq Qureshi, Adnan Qureshi

P3.082 A Population-based Study

of the Incidence and Case Fatality of Intracerebral Hemorrhage of Undetermined Etiology Afzal Mohammad, Mushtaq Qureshi, Ahmed Malik, Mariam Suri, Muhammad Suri, Adnan Qureshi

P3.083 Implication of Deep Versus

Cortical Ischemia on DWI-aspects in Anterior Circulation Large Vessel Occlusion Ischemic Stroke Christopher Streib, Srikant Rangaraju, Ashutosh Jadhav, Tudor Jovin

P3.084 CT Angiogram Helps to Predict Ischemic Stroke in Dizzy Patients, but NOT Better Than the Clinical Examination Karen Chen, Andrea Schneider, Elisabeth Marsh

P3.085 Embolic Stroke with

Spontaneous Recanalization Sourabh Lahoti, Sankalp Gokhale, Louis Caplan, Patrik Michel, Yves Samson, Charlotte Rosso, Kaustubh Limaye, Archana Hinduja, Aneesh Singhal, Syed Ali, Richard Kryscio, Nikita Dedhia, Shirish Hastak, David Liebeskind, L Pettigrew

P3.091 Validation of the ICH Score and Predicting ICH Outcomes in the Modern Neurological Intensive Care Unit Omran Kaskar, Larry Goldstein, Michael James

P3.092 Time-to-INR Reversal,

Predictors of Hematoma Expansion and In-hospital Mortality in Warfarin-related Intracerebral Hemorrhage Richa Patel, Hesham Masoud, Helena Lau, Jose Romero, Viken Babikian, Joseph Burns, Carlos Kase, Ashkan Shoamanesh

P3.093 Admission Hypomagnesemia

Predicts Primary Intracerebral Hemorrhage Volume Harn Shiue, Amelia Boehme, Kara Sands, Sheryl Martin-Schild, Angela Hays Shapshak, Michael Lyerly, Alissa Gadpaille, Ayaz Khawaja, April Sisson, Muhammad Alvi, Alexander George, Mark Harrigan

P3.094 Significance of Hemodynamic

P3.086 Intraventricular Hemorrhage

P3.095 Accessing Care for

Intracerebral Hemorrhage: An Unexpected Paradox? Michael Lyerly, Karen Albright, Reza Bavarsad Shahripour, Kara Sands, Harn Shiue, April Sisson, Mark Harrigan

P3.096 Warfarin and Antiplatelet

Symptom of ICH Patient Characteristics and EEG Utilization Alissa Gadpaille, Karen Albright, Amelia Boehme, Muhammad Alvi, Kara Sands, Ayaz Khawaja, Harn Shiue, Mark Harrigan

Medication Use Are Independently Associated with Poor Functional Outcomes Following Spontaneous Intracerebral Hemorrhage Santosh Murthy, Yogesh Moradiya, Jesse Dawson, Kennedy Lees, Daniel Hanley, Wendy Ziai

P3.088 Troponin Elevation

P3.097 CT Angiography

in Spontaneous Intracranial Hemorrhage Pavan Tummala, Nabil Makhlouf, Abhay Kumar

P3.089 Review of Primary

Intraventricular Hemorrhage Reveals Dichotomous Outcomes Bilaal Sirdar, Sarah Song, Kathryn Ess, Renee Jhu, Shawna Cutting

P3.090 Predictors and Outcome of

Mechanical Ventilation for Patients with Primary Intracerebral Hemorrhage Ayaz Khawaja, Amelia Boehme, Angela Hays Shapshak, David Miller, Reza Bavarsad Shahripour, Muhammad Alvi, Gyanendra Kumar, Mark Harrigan

80

P3.101

Interdisciplinary Project Aimed at Reducing the Duration of Intravenous Nicardipine in Intracerebral Hemorrhage Patients Lynn Do, Justin Petrovic, Carmil Azran, Kathryn Crozier, S. Josephson

P3.102

Apolipoprotein E4 Allele Increases Total Cholesterol and Lowdensity Lipoprotein Levels in Primary Intracerebral Hemorrhage Chia-Ling Phuah, Miriam Raffeld, Alison Ayres, Alessandro Biffi, Anand Viswanathan, Steven Greenberg, Jonathan Rosand, Christopher Anderson

Attend the AAN Business Meeting at 8:00 a.m. on Monday, April 20, during the 2015 AAN Annual Meeting in Washington, DC, to make your voice heard on matters of importance to you, and cast your vote for the 2015 AAN Board of Directors. Learn more about the nominees at AAN.com/view/BoardSlate .

and Heart Rate Variability in the Acute Phase of Spontaneous Intra-Cerebral Hemorrhage Michael Mendoza, Sameer Sharma, Julius Gene Latorre

P3.087 Seizure as the Presenting

Incidence of Ischemic Strokes in the Minimally Invasive Surgery Plus Rt-PA for Intracerebral Hemorrhage Evacuation (MISTIE II) Phase II Clinical Trial Lucia Rivera Lara, Saman NekoovaghtTak, Rachel Dlugash, Nichol McBee, Mario Zuccarello, Daniel Hanley, Wendy Ziai

Have a Voice in Your Academy

Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage Growth Is Associated with Worse Functional Outcomes After Intracerebral Hemorrhage Matthew Maas, Anna Romanova, Michael Berman, Brandon Francis, Eric Liotta, Andrew Naidech

P3.100

in Spontaneous Intracerebral Hemorrhage Swarna Rajagopalan, Laura Cifrese, S Azizi

P3.098 Prophylactic Anticonvulsants

in Intracerebral Hemorrhage Jason Mackey, Ashley Blatsioris, Elizabeth Moser, Ravan Carter, Angie Reagan Secrest, Abigail Hulin, Darren O'Neill, Aaron CohenGadol, Thomas Leipzig, Linda Williams

P3.099 Decompressive

Hemicraniectomy for Spontaneous Supratentorial Intracerebral Hemorrhage: A Descriptive Analysis Kasey Gildersleeve, Mohammad Hirzallah, Renga Pandurengan, Nicole Gonzales

P3.103

The Prevalence of Admission Leukocytosis and Systemic Inflammatory Response Syndrome (SIRS) in Intracerebral Hemorrhage (ICH) Patients and Its Association with Primary Infection Shaheryar Hafeez, Alicia Zha, Noah Grose, Sunil Mutgi, Reza Behrouz

Cerebrovascular Disease and Interventional Neurology: Subarachnoid Hemorrhage P3.104

Neurocritical Care Outcomes in Angiogram-negative Subarachnoid Hemorrhage Michael Errico, Alejandro Spiotta, Aquilla Turk, III, Raymond Turner, Imran Chaudry, Julio Chalela

P3.105

Global Cerebral Edema After Subarachnoid Hemorrhage Is Associated with a Peripheral Immune Response Kaushik Parsha, Suhas Bajgur, Nasim Rezanejad, Nancy Edwards, Tiffany Chang, Kiwon Lee, Sean Savitz, Huimahn Choi

P3.106

Outcomes in Subarachnoid Hemorrhage After the Introduction of a Neurocritical Care Service Jamie LaBuzetta, Cynthia Gonzalez, Josh Duckworth, Brian Lemkuil, Anushirvan Minokadeh, Navaz Karanjia

P3.107

Clinical Spectrum of Nontraumatic Convexity Subarachnoid Hemorrhage Vivien Lee, James Conners, Sayona John, Rajeev Garg

P3.108

Treatment of Ruptured Intracranial Aneurysms with the Pipeline Embolization Device Norman Ajiboye

P3.109

Alpha-1 Antitrypsin Deficiency in Cerebral Aneurysms Ali Mahta, Michael Weaver, Francis Kueppers

P3.110

Effect of Age on Transcranial Doppler Velocities in Patients with SAH Michelle Nunes, Ivan Silva, Ari Wachsman, Joao Gomes, Javier Provencio

P3.111

Hormone Replacement Therapy and the Risk of Subarachnoid Hemorrhage in Post-menopausal Women Omar Saeed, Ahmed Malik, Adnan Qureshi

P3.112

Ultra Early Vasospasm Following Subarachnoid Hemorrhage Associated with Increased Morbidity and Mortality Poor Outcome Fawaz Al-Mufti, Michael Schmidt, Emma Mayer, Shouri Lahiri, Neha Dangayach, Soojin Park, Sachin Agarwal, Stephan Mayer, Jan Claassen

Cerebrovascular Disease and Interventional Neurology: Subarachnoid Hemorrhage and Miscellany P3.113

A Population-based Study of the Incidence and Case Fatality of Non-aneurysmal Subarachnoid Hemorrhage Adnan Qureshi, Nauman Jahangir, Mushtaq Qureshi, Archie Defillo, Ahmed Malik, Muhammad Suri

P3.114

Impact of Menopausal Age on Size of Unruptured Intracranial Aneurysms and Their Outcomes with Endovascular Therapy Sushrut Dharmadhikari, Kunakorn Atchaneeyasakul, Norman Ajiboye, Sudheer Ambekar, Dileep Yavagal

P3.115

Ruptured Giant Middle Cerebral Artery Aneurysm in Infancy Reem Al Youbi, Mohammed Jan

P3.116

A Decade After International Subarachnoid Aneurysm Trial: Coiling as a First Choice Treatment in the Management of Intracranial Aneurysms—Technical Feasibility and Early Management Outcomes Gurmeen Kaur, Gaurav Goel, Vipul Gupta, Swati Chinchure, Aditya Gupta, Ajaya Jha

P3.117

Loading Doses of Aspirin and Clopidogrel Prior to Enterprise Stent-assisted Repair of Intracranial Aneurysm—a Pilot Study Yahia Lodi, Varun Reddy, Ashok Devasenapathy, Karmel Shehadeh, Anas Hourini, Chun-An Chou

P3.118

Outcome of Aneurysmal Subarachnoid Hemorrhage at a Comprehensive Stroke Center Wengui Yu, Kimberly Alva, Tamara Majic, Tapan Kavi, Asma Moheet, Wouter Schievink, Michael Alexander

P3.119

Alpha Variability for Prediction of Delayed Cerebral Ischemia Can Be Improved with Quantitative Measurement Shawniqua Williams

P3.120

Venus Sinus Stenting for Pseudotumor Cerebri: A Multicenter Experience with Various Stents and Deployment Techniques Sudeepta Dandapat, Fazeel Siddiqui, Mushtaq Qureshi, Augusto Elias, Sushant Kale, Adnan Qureshi


Poster Session III

P3.121

MRI Features in Ischemic Stroke Patients with Early Epileptic Seizures Alla Borisovna Guekht, Alexander Yakovlev, Tatiana Danilova, Roman Luzin, Vladislav Gaskin, Ildar Kamalov, Dina Khasanova

P3.122

Stroke Patients and Diagnostic Testing, Take Two—the Weekend Waiting Game! Sally Mathias, Jessica Lee

Neuro-oncology: Glioma Therapeutics P3.123

Transplanted MGMTP140K Gene-modified CD34+ Cells in Patients with Newly Diagnosed Glioblastoma Chemo Protect Bone Marrow and Lead to Prolonged Survival Maciej Mrugala, Jennifer Adair, Brian Beard, Daniel Silbergeld, Lia Halasz, Jason Rockhill, HansPeter Kiem

P3.124

Changes in the Apparent Diffusion Coefficient (ADC) on MRI in Bevacizumab-treated Glioblastoma Alissa Thomas, Myron Zhang, Bryanna Gulotta, Kaitlin Woo, Zhigang Zhang, Thomas Kaley, Sasan Karimi, Julio Arevalo Perez, Igor Gavrilovic, Robert Young

P3.125

Phase II Study of Verubulin (Azixa, MPC-6827) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma Multiforme Patients: Incomplete Report on Safety, Tolerability, and Responses Jay-Jiguang Zhu, Santosh Kesari, Lawrence Recht

P3.126

Salvage Therapy with Lomustine for Temozolomide Refractory Recurrent Anaplastic Astrocytoma: A Retrospective Study Marc Chamberlain

P3.127

Treatment Responses in Adult Brainstem Gliomas with IDH1/2 Mutations Sarah Hodges, Patrick Malafronte, William Skinner, Corey Carter, Jonathan Gilhooly, Brett Theeler

P3.128

Temporal Trend in Postoperative Seizure Prophylaxis Use in Glioma Patients Sarah Lapointe, Marie Florescu, Chanez Djeffal, Karl Bélanger, Dang Nguyen

P3.129

Antimitotic NovoTTF Therapy for a Progressive Glioblastoma Patient with Fournier Gangrene: Non-interference with Wound Healing and Why It Works Eric Wong, Loretta Barron, James Hwong, Andrew Wagner

Neuro-oncology: CNS Metastases and Other Neurologic Complications of Cancer P3.133

Newly Diagnosed Single Brain Mass—Implementation and Performance of a Hospital-wide Management Pathway Isabel Arrillaga-Romany, Aneesh Singhal, Susann Jarhult, Corey Gill, Aurelie Cordier, Benjamin White, SooAe Jones, Michelle Pisapia, Daniel Cahill, William Curry, Joshua Goldstein, Tracy Batchelor

P3.134

High-dose Methotrexate for Metastatic Breast Cancer to the Central Nervous System: A Single-institution Review of Forty-six Patients Margaret Schwartz, Sean Grimm, Priya Kumthekar, Simran Singh, Sherese Fralin, Irene Helenowski, Alfred Rademaker, Lynnette Onuselogu, Jeffrey Raizer

P3.135

Clinical Experience of 519 Cases with Leptomeningeal Metastasis Jae-Won Hyun, In Hye Jeong, Su-Hyun Kim, Ho Kim

P3.136

Neurological Complications of Ipilimumab Therapy in Patients with Metastatic Melanoma Aline Herlopian, Fade Mahmoud, Ryan David, Rohan Samant, Murat Gokden, Laura Hutchins, Shirley Ong

P3.137

Intramedullary Metastasis from Ovarian Cancer: A Systematic Review of the Literature Damoun Safarpour, Fattaneh Tavassoli, Bahman Jabbari

P3.138

Encephaloclastic Cyst Induced by Intraventricular Topotecan Divya Mella, Carlos Kamiya Matsuoka, Bing Liao, Sudhakar Tummala, John De Groot

P3.139

Multiple Embolic Brain Metastases, Strokes and Intracranial Hemorrhage from a Cardiac Malignant Mesenchymal Tumor: A Case Report Amy Chan, Matthew Schrag, Anita Huttner, Joachim Baehring

P3.140

Peripheral Facial Nerve Palsy Caused by Perineural Spread from a Parotid Tumor Anna Grisold, Leyla Alpaslan, Stefan Meng, Wolfgang Grisold

P3.141 Calcineurin-inhibitor-induced

Pain Syndrome Clinically Mimicking Guillain-Barre’ Syndrome in a Pediatric Transplant Patient Aldo Doerner Rinaldi, Jennifer Bain, Staci Arnold, Monica Bhatia, Rama Ayyala, Jahannaz Dastgir

P3.131

Acute Reversible Toxic Leukoencephalopathy Due to the Chemotherapeutic Agent Folfox in a Patient with Negative IVS14+1G>A Mutation in the DPD (dihydropyrimidine Dehydrogenase) Gene Bradley Molyneaux, Premkumar Nattanmai Chandrasekaran

P3.132

Neuro-oncology: CNS Lymphoma and Other Hematologic Malignancies

P3.130

Identification of CSNK1E and MELK as Essential Kinases to GBM and as Future Therapeutic Targets Lily Pham, Yanping Liang, Zhi Sheng Ipilimumab for Recurrent Glioblastoma (GBM) Lauren Schaff, Andrew Lassman, Samuel Goldlust, Timothy Cloughesy, Samuel Singer, Fabio Iwamoto The Utility of Comprehensive Genetic Analysis of Gliomas in Clinical Practice Aya Haggiagi, Christina Corpuz, Andrew Lassman, Fabio Iwamoto

P3.142

P3.143 Methotrexate

Encephalopathy as a Cause of Alternating Hemiplegia Charles Sullivan, John Quealy, Jurate Olsevskaite, Peter MacEneaney, Clodagh Ryan, Orna O'Toole


P3.144

Co-morbid Lymphomatosis Cerebri and Testicular Lymphoma in a Case of Rapidly Progressive Dementia Matthew Tremblay, Matthew Ashley, Harry Vinters, Ming Guo

P3.145

Neurological Manifestations of Erdheim Chester Disease: A Case Series of 3 Patients Bhavesh Trikamji, Shrikant Mishra

P3.146

Rare Case of Central Nervous System Invasion of Mantle Cell Lymphoma with Serial Negative Magnetic Resonances: Case Report and Literature Review Ryna Then, Margi Patel

P3.147

Relapse Patterns in Primary CNS Diffuse Large B-cell Lymphoma Nancy Wang, Corey Gill, Rebecca Betensky, Tracy Batchelor

P3.148

Neurologic Manifestations of Intravascular Large B-cell Lymphoma Pouya Tahsili-Fahadan, Armin Rashidi, Patrick Cimino, Bob Bucelli, Salah Keyrouz

P3.149

A Rare Complication of Paraneoplastic Autoimmune Disorder in Langerhans Cell Histiocytosis Thandar Aung, Christopher Dardis

P3.150

Diffuse Leptomeningeal RosaiDorfman Disease: A Case Report Mitra Afshari, Jeffrey Raizer

P3.151

Case Report: Neurolymphomatosis Mimicking GuillainBarre Syndrome in a Patient with Splenic Marginal Zone Lymphoma Kathryn Stevens, Christopher Groth

P3.152

Marginal Zone Lymphoma Associated with Paraneoplastic Cerebellar Degeneration Alexandra Issa, Ramakrishna Battini, Jerome Graber

Neuromuscular Disease: Therapeutics P3.153

The Safety Profile of Home Infusion of Intravenous Immunoglobulin in Neuroimmunological Disorders Ankit Pahwa, Melissa Allan, Howard Sander, Nizar Souayah

P3.154

Trans-splicing as a Therapeutic Approach for Dysferlindeficient Muscular Dystrophies Susanne Philippi, Stephanie Lorain, Guillaume Precigout, Simone Spuler, Luis Garcia

P3.155

Botulinum Toxin A for Treatment of Sialorrhea in Neurologic Diseases: 2-year Prospective Study Pierangelo Barbero, Carlo Alberto Artusi, Stefania De Mercanti, Marco Tinivella, Marco Busso, Marinella Clerico, Luca Durelli

P3.156

Retrospective Efficacy Evaluation of Immunoglobulin Infusions (IVIG) in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Alison Walsh, Marinos Dalakas, Goran Rakocevic

P3.158

Local and Remote Spread of Botulinum Toxin Effect; the Role of Concurrent Medications and Treatment with Pyridostigmine John Kelemen

P3.159

Starting Steroids Dose, Need for Additional Immunosuppression and Long-term Outcome in Myasthenia Gravis Marcelo Rugiero, Mariela Bettini, Marcelo Chaves, Maria Araoz, Edgardo Cristiano

P3.160

Rescue Treatment in Guillain Barre Syndrome: Is It Useful? Ayman Alboudi, Abubaker Almadani, Jihad Inshasi, Suhail Alrukn, Shareefa Abdool, Pournamy Sarathchandran

Neuromuscular Disease: Diagnostic Testing P3.161

Reliability and Validity of of the FSHD Composite Outcome Measure Katy Eichinger, Shree Pandya, Colleen Donlin-Smith, Chad Heatwole, Alrabi Tawil, Jeffrey Statland

P3.162

Electrical Impedance Myography and Quantitative Ultrasonography: Tools to Quantify Tongue Health Courtney McIlduff, Sung Yim, Tom Geisbush, Aleksandar Mijailovic, Adam Pacheck, Seward Rutkove

P3.163

Electrical Impedance Myography (EIM) in Congenital Muscular Dystrophy (CMD): Two-year Follow-up Data Tanya Lehky, Daniel Schwartz, Janannaz Dastgir, Carsten Bonnemann

P3.164

Confirmation Bias and Specificity of Electromyography for Radiculopathy Pushpa Narayanaswami, Tom Geisbush, Lyell Jones, Michael Weiss, Tahseen Mozaffar, Seward Rutkove

P3.165

Stimulated Jitter Analysis (Stim-JA) for Neuromuscular Junction (NMJ) Disorders in Children Jenny Lin, Sumit Verma

P3.166

What Does the Six Minute Walk Test Reflect in Myotonic Dystrophy Type 1 (DM1)? Katy Eichinger, Jeanne Dekdebrun, Charles Thornton, Richard Moxley, Shree Pandya

P3.167

Ultrasound to Improve the Diagnostic Yield of Sural Nerve Conduction Studies David White

P3.168

A Carpal Tunnel Syndrome Grading System Including CSI-diagnosed Mild Cases: Relation to Presenting Features and Outcomes Simran Singh, Dilip Pandey, Lawrence Zeidman

P3.169

MuSK Autoantibodies in Myasthenia Gravis: Experience with >28,000 Specimens Tested in a Clinical Laboratory Amy Goldberger, Brian Sansoucy, Keith Morneau, Kaylan Burnham, Sat Dev Batish, Funda Suer, Zhenyuan Wang, Malgorzata Jaremko, Joseph Higgins

P3.157 Pharyngoesophageal

Dilation and Botulinum Toxin Therapy for Dysphagia in Patients with Inclusion Body Myositis Christopher Parres

81

Tuesday April 21


Poster Session III2:00 p.m.–6:30 p.m. Neuromuscular Disease: Clinical Neurophysiology P3.170

Defective Fast Inactivation Recovery of Nav1.4 in Congenital Myasthenic Syndrome Christoph Lossin, William Arnold, Daniel Feldman, Sandra Ramirez, Liuyuan He, Darine Kassar, Adam Quick, Tara Klassen, Marian Lara, Joanna Nguyen, John Kissel, Ricardo Maselli

P3.171

Abnormal Gating of Axonal Slow Potassium Current in Crampfasciculation Syndrome Yoshimitsu Shimatani, Hiroyuki Nodera, Shibuta Yoshiko, Miyazaki Yoshimichi, Sonoko Misawa, Satoshi Kuwabara, Ryuji Kaji

P3.172

Cranial EMG Helps Differentiate SBMA from ALS Regardless of Bulbar Symptoms Rajat Lahoria, Christopher Klein, Nathan Young, Nathan Staff, Margherita Milone, Eric Sorenson, William Litchy

P3.173

Multipoint Incremental Motor Unit Number Estimation of the Extensor Digitorum Brevis and Abductor Hallucis Muscles Jeff Shije, Shafeeq Ladha

P3.174

Electrophysiological Predictors of Seropositive and Seronegative Myasthenia Gravis Rachana Gandhi, Evelio Velis, Efrain Salgado, Nestor Galvez-Jimenez

P3.175

Sequential Transcranial Magnetic Stimulation Demonstrates Dynamic Changes on Neck Flexion in Monomelic Amyotrophy / Hirayama Disease Preethish Kumar Veeramani, Atchayaram Nalini, Chandrajit Prasad, Kiran Polavarapu

P3.176

Normative Nerve Conduction Study (NCS) Data in the Saudi Population Jameel Rasheedi, Qurban Ali, Zaitoon Shivji, Manzoor Shah, Yousef AlSaid, Aymaan Al-Falah, Alaa Subhi, Ahmed Basndwah, Edward Cupler

P3.177

Post-denervation Muscle Hypertrophy: A Rare Complication of Brachial Plexopathy Pedro Vivar Cruz, Kourosh Rezania, Peter Pytel, Rex Haydon, Raymond Roos

P3.178

Success Rate of Obtaining Baseline Somatosensory and Motor Evoked Potentials in Consecutive Cranial and Spinal Surgeries Brian Droker, Parastou Shilian, Andres Gonzalez

Neuropathy: Clinical Neurophysiology and Outcome P3.179

Clinical and Electrophysiological Features of Multifocal Motor Neuropathy Cullen O'Gorman, Eric Sorenson

P3.180

Recurrent Isolated Sixth Nerve Palsy in Relapsing-remitting Chronic Inflammatory Demyelinating Polyneuropathy Najwa Al-Bustani, Michael Weiss

P3.181

Charcot-Marie-Tooth Disease: Clinical and Genetic Spectrum in a Tunisian Series Amira Nasri, Imen Kacem, Youssef Sidhom, Yosr Hizem, Mouna Ben Djebara, Amina Gargouri, Eric Leguern, Riadh Gouider

82

P3.182

Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) and Leprosy Neuropathy: A Comparative Nerve Conduction Study Aline Oliveira, Gilberto Andrade, Patricia Onofre, Vanessa Marques, Wilson Marques

P3.183

The Usefulness of Proximal Radial Motor Conduction in Acute Compressive Radial Neuropathy Bum Chun Suh, Kun Hyun Kim, Hyung Jun Park, KeeDuk Park, Pil-Wook Chung, Heui-Soo Moon, Yong Bum Kim, Won Tae Yoon

P3.184

A Case of Immune-mediated Polyneuropathy in a Patient with Paraprotein-associated Systemic Capillary Leak Syndrome Kara Stavros, Charlotte Cunningham-Rundles, David Simpson

P3.185

Eosinophilic Granulomatosis with Polyangiitis Presenting with Polyneuropathy—a Case Series Fernando Santos-Pinheiro, Yuebing Li

P3.186

Asymptomatic Neuropathy at the Elbow—a Marker for Diabetes Akshay Shah, Said Beydoun

P3.187

Therapeutic Effects of Cinacalcet on Diabetic Peripheral Neuropathy Hye Won Kim, Cheol Whee Park

P3.188

Bortezomib—New Option for Aggressive Chronic Inflammatory Demyelinating Polyradiculoneuritis Kalliopi Pitarokoili, Anke Reinacher-Schick, Min-Suk Yoon, Ralf Gold

P3.194

Prevalence of Depression and Anxiety Among Patients with Epilepsy Attending the Epilepsy Clinic at Sheikh Khalifa Medical City, UAE: A Cross Sectional Study Khadija El-Hammasi, Mufeed Raoof, Tarek Shahrour, Mustafa Shakra, Lamya Turkawi, Buthaina Almaskari, Taoufik Alsaadi

P3.205 The Yale Seizure Cluster

P3.195

Qatar Ayman Al Jurdi, Abdullah El Zafarany, Faten Aqeel, Abuhadra Nour, Mujahed Laswi, Yasser Alsamman, Basim Uthman, Dirk Deleu, Hassan Jassim Al Hail, Boulenouar Mesraoua, Naveed Akhtar, Ziyad Mahfoud, Gayane Melikyan, Naim Haddad

Reduction of Treatmentlimiting Non-psychotic Behavioral Adverse Events Associated with Levetiracetam (LEV): An Open-label, Prospective Study of Patients with Epilepsy Switching from LEV to Brivaracetam (BRV) Treatment Stephen Yates, Toufic Fakhoury, Wei Liang, Klaus Eckhardt, Joseph D'Souza

P3.196

Gender Differences in the Incidence of Psychiatric Co-morbidity in Patients with Epilepsy Justine Chan, Jing Chen, Kanishk Makhija, Michele Faulkner, Sanjay Singh Assessment of Anxiety, Depression, and Quality of Life in Patients with Epilepsy Using Three Spanish Validated Scores: GAD-7, PHQ-9 and QOLIE-10-P Rodolfo Callejas, Ildefonso Rodriguez-Leyva

MS and CNS Inflammatory Diseases: Tools for Clinical Assessment and Therapeutic Response

Suicide Risk and Epilepsy. Four-year Follow Up Tamargo Agustina, Analia Calle, Elena Fontela, Maria Gonzalez Toledo, Diego Nadile, Fatima Pagani Cassara, Alejandro Thomson, Patricia Acosta, Alfredo Thomson

P3.199

P3.191

Comparative Cognitive Effects of Lacosamide Versus Carbamazepine David Loring, Kimford Meador, Alan Boyd, William Byrnes, Deanne Dilley, Simon Borghs, Marc De Backer, Tyler Story, Peter Dedeken, Elizabeth Webster

P3.192

A Comparison of Instruments to Measure Depressive Symptoms Among Patients with Refractory Partial-onset Seizures T. Christopher Bond, Fulton Velez, Kathryn Anastassopoulos, Xuezhe Wang, Joyce Cramer, Hailong Cheng, Rui Sousa, David Blum

P3.193

Baseline Depressive Symptoms as Predictive of Seizure Frequency Reduction Among Epilepsy Patients with Partial-onset Seizures: A Pooled Analysis of Phase III Clinical Trials of Adjunctive Treatment with Eslicarbazepine Acetate T. Christopher Bond, Fulton Velez, Kathryn Anastassopoulos, Xuezhe Wang, Joyce Cramer, Hailong Cheng, Rui Sousa, David Blum

Model for Investigation of Epilepsy in Developing Countries Chamroeun Hun, Tola Hok, Ros Sina, LyKheng Heng, PrakPiseth Riengsay, Samleng Chan, Devender Bhalla

P3.198

P3.189

Topiramate (TPM) Input Rate and Impaired Verbal Fluency: Observations with Different Formulations Susan Marino, Scott Brittain, Serguei Pakhomov

P3.207 Epilepsy in Cambodia—a

P3.208 Insurance Disparity in Utilizing

Epilepsy/Clinical Neurophysiology (EEG): Health Services

P3.190

P3.206 Mapping Epilepsy in

P3.197

Epilepsy/Clinical Neurophysiology (EEG): Cognition and Behavioral Health “Speechless” After a Seizure: A Rare Case of Postictal Aphemia Gulshan Uppal, Niravkumar Barot, Paul Van Ness

Study: Prevalence, Characteristics, and Impact on Healthcare Utilization Tenzin Choezom, Shiliang Zhang, Hitten Zaveri, Sreya Radhakrishna, Angela Gauthier, Rasesh Joshi, Jennifer Bonito, Lawrence Hirsch, Kamil Detyniecki

Making Epilepsy Treatment More Affordable: Can Rationalizing Prescriptions Reduce Cost? Mamta Singh, Saloni Kapoor, Victor Patterson, Asuri Prasad, V Sreenivas

P3.200 Effectiveness of Problem-

based Online CME in Improving the Diagnosis and Management of LennoxGastaut Syndrome Ron Schaumburg, Nimish Mehta

P3.201 Lacosamide Monotherapy

Treatment Pathways in Epilepsy Patients in a US Managed Care Population Tracy Durgin, Rolin Wade, Chi-Chang Chen, Dionne Hines, Charles Makin

P3.202 Beyond Access: Disparities

in Epilepsy Quality of Care According to Insurance Status Diego Mendez, Jonathan Jesus, Rogger Andrade, Joel Weissman, Daniel Hoch, Lidia Maria Moura

P3.203 Use of Best Practice Alerts in

Electronic Medical Records to Improve Care for Women of Childbearing Age Taking Anti-seizure Medications Lu Lin, Castleman David, Catherine Glover, Jill Vieley, Paul Van Ness

P3.204 Acceptance of a

Telemanagement System to Support Epilepsy Self-care Arif Kabir, McKenzie Bedra, Lania Cooper, Alan Krumholz, Joseph Finkelstein

Continuous EEG Monitoring Among Hospitalizations with Epilepsy: Analysis from Nationwide Inpatient Sample Mihir Dave, Achint Patel, Chirag Savani, Parisha Bhatia, Matthew Eccher

P3.209 Remote Tracking of Walking Activity in MS Patients in a Real-world Setting James McIninch, Shoibal Datta, Pronabesh DasMahapatra, Emil Chiauzzi, Rishi Bhalerao, Alicia Spector, Sherrie Goldstein, Liz Morgan, Jane Relton

P3.210 Propensity Score Adjustment

for Comparative Efficacy Studies of Disease Modifying Agents in Multiple Sclerosis Carrie Hersh, Claire Hara-Cleaver, Jeffrey Cohen, Robert Bermel, Daniel Ontaneda

P3.211

Creating an Integrated Multiple Sclerosis Clinical Trial Analysis Database Kartik Raghupathi, Emily James, Amy Pace, Carmen Castrillo, Fabio Pellegrini

P3.212 Effects of Nintendo Wii Fit

Plus® Balance Program Training on Postural Stability in Multiple Sclerosis Patients: A Pilot Study Francesco Patti, Vincenzo Cimino, Silvia Messina, Gianfranco Raciti, Clara Chisari, Valeria Dibilio, Carmela Leone, Donata Veca, Anna Russo, Francesco Zagari, Mario Zappia

P3.213

Automated Quantification of Motor Dysfunction in Multiple Sclerosis Using Depth-sensing Computer Vision Marcus D'Souza, Jessica Burggraaff, Peter Kontschieder, Jonas Dorn, Christian Kamm, Prejaas Tewarie, Cecily Morrison, Thomas Vogel, Abigail Sellen, Antonio Criminisi, Frank Dahlke, Bernard Uitdehaag, Ludwig Kappos

P3.214 Novel, Easy-to-use Prediction Tool Accurately Estimates Probability of "aggressive MS" at 2-year Follow Up Ilya Kister, Gary Cutter, Amber Salter, Joseph Herbert, Eric Chamot


P3.215

Patient-reported Outcome (PRO) Measures Used in Secondaryprogressive Multiple Sclerosis (SPMS) Studies: A Systematic Review Chunhyun Park, Crystal Watson

P3.227 Rabin Color Cone Contrast

P3.216 Waveform Entropy of Motor

P3.228 Quantitative Measurement

Evoked Potentials—a Sensitive Indicator of Corticospinal Tract Damage Luke Canham, Nick Kane, Agyepong Oware, Peter Walsh, Kelly Blake, Jenny Homewood, Jonathan Witherick, Kirsty Inglis, David Cottrell

Testing and Retinal Structure in Multiple Sclerosis Arnow Samuel, Hao Yiu, Christopher Songster, Denise Bolivar, Jeffrey Gelfand, Ari Green of Vibration as a Clinical Biomarker of Neurodegeneration in MS Sonya Bakshi, Brandon Loughridge, Sonya Steele, Joan Ohayon, Tianxia Wu, Blake Dewey, Govind Nair, Daniel Reich, Irene Cortese

P3.217

An Exploratory Analysis of Predictors of Disease-modifying Drug Adherence Using Data from a Panel Survey of Patients with Multiple Sclerosis Julie Locklear, Amy Phillips, Chris Kozma

P3.229 Association of Wellness

P3.218 Screening for Cognitive

P3.230 Differences in Treatment

Impairment in the Neurologist's Office Sarah Morrow, Lynn McEwan, Jamie Steckley, Daniel Mendonca, Heather Rosehart, Marcelo Kremenchutzky

P3.219 The Multiple Sclerosis at

Home Access (MAHA) Project Kathleen Healey, Toby Warden, Neil Jouvenat, Mac McLaughlin, Rana Zabad

P3.220 Usability and Acceptability

of the ASSESS MS Movement Recording Tool in Multiple Sclerosis Using Depthsensing Computer Vision Cecily Morrison, Marcus D`Souza, Kit Huckvale, Jonas Dorn, Jessica Burggraaff, Christian Kamm, Saskia Steinheimer, Peter Kontschieder, Thomas Vogel, Antonio Criminisi, Bernard Uitdehaag, Frank Dahlke, Ludwig Kappos, Abigail Sellen

P3.221 Experiences with A Self

Developed Accelerometer in Multiple Sclerosis Tunde Csepany, Lilla Racz, Csilla Ver, Laszlo Kardos, Judit Soltesz, Andrea Matyas, Gergely Hofgart, Laszlo Csiba

P3.222 National Swedish MS

Register Based Study: The Symbol Digit Modalities Test as a Predictor of Work Disability Virginija Karrenbauer, Philip Brenner, Jan Hillert, Petter Tinghög

P3.223 Development of a

Comprehensive Motor Function Assessment Battery for Multiple Sclerosis Using Perceptive Computing Alexander Brandt, Janina Behrens, Karen Otte, Sebastian Mansow-Model, Elona Gusho, Sebastian Mertens, Anuschka Grobelny, Theresa Krüger, Friedemann Paul

P3.224 Education Effect of Online Video/slide Program on Recognition of Disease Progression in Multiple Sclerosis Stacey Ullman, Aliza BenZacharia, Stephen Krieger

P3.225 Relationship Between

Cognitive Status and Perception of Ease of Use of an Electronic Autoinjector for Subcutaneous Interferon Beta-1a Ajay Gupta, Fernando Dangond, Brooke Hayward, Gabriel Pardo

P3.226 Composite Cerebellar

Functional Severity Score (CCFS) Is Specific to Cerebellar Dysfunction in Multiple Sclerosis Maya Tchikviladzé, Jean Christophe Corvol, Catherine Lubetzki, Caroline Papeix, Alexandra Durr, Sophie Tezenas Du Montcel

Practices in MS Patients Using Self Reported Disability Scores and MS Characteristics Mary Rensel, Youran Fan, Suji Baskar Strategies in Multiple Sclerosis According to Experience: A Survey of Multiple Sclerosis Experts and General Neurologists Murat Kurtuncu, Tuncer Asli, Zeynep Caliskan, Serhan Sevgi, Husnu Efendi, Sagduyu Kocaman Ayse, A. Cemal Ozcan, Murat Terzi, Turan Omer, Sabahattin Saip, Rana Karabudak, Aksel Siva

P3.231 Differences in the Diagnosis

and Follow Up of Multiple Sclerosis Patients According to the Experience of Neurologists: Results of a National Survey Asli Tuncer, Murat Kurtuncu, Zeynep Caliskan, Serhan Sevgi, Husnu Efendi, Ayse Sagduyu, Cemal Ozcan, Murat Terzi, Omer Turan, Sabahattin Saip, Aksel Siva, Rana Karabudak

P3.232 A Pragmatic Literature

Review of Network Meta-analyses of Disease-modifying Drugs in the Treatment of Multiple Sclerosis Amy Phillips, Rachel Beckerman, Nathaniel Smith, Julie Locklear, Yushan Jiang, Caroline Solon

P3.233 Assessing Cognition in MS

Clinical Trials: The Cognitive Assessment Interview (CAI) Allison Marzillano, Brittany Speed, Bianca Cersosimo, Kathleen Sherman, Michael Shaw, Wendy Fang, Lamia Haider, Patricia Melville, Lauren Krupp, Leigh Charvet

P3.234 Consensus Opinion of

US Neurologists on Practice Patterns in Radiologically or Clinically Isolated Syndromes and Relapsing-remitting Multiple Sclerosis Carlo Tornatore, J. Theodore Phillips, Omar Khan, Aaron Miller

P3.235 The State of Multiple

Sclerosis Survey: Relationship of Expectations, Decision-making, Communication, and Satisfaction with Treatment Sibyl Wray, Maggie Alexander, Martin Duddy, David Jones, Nancy Law, Gilmore O'Neill, Antonio Uccelli, Robert Weissert, Mar Tintoré

P3.236 How Satisfied with Their

Treatment Are Patients with MS? Psychometric Evaluation of the Treatment Satisfaction Questionnaire for Medication (TSQM) Patrick Vermersch, Jeremy Hobart, Catherine Dive-Pouletty, Sylvie Bozzi, Patricia Coyle

Poster Session III P3.238 Treatment Satisfaction over

Time for United States (US) Patients with Multiple Sclerosis (MS) Treated with Natalizumab Crystal Watson, John Foley, Kavita Nair, Judith Stephenson, Timothy Niecko, Sonalee Agarwal

MS and CNS Inflammatory Diseases: Treatment Efficacy, Safety, and Tolerability P3.239 Efficacy of Delayed-release

Dimethyl Fumarate for Relapsingremitting Multiple Sclerosis (RRMS) in “Non-responders” to Prior Treatment with Interferon Beta Oscar Fernandez, Gavin Giovannoni, Robert Fox, Ralf Gold, J. Theodore Phillips, Minhua Yang, Annie Zhang, Nuwan Kurukulasuriya

P3.240 Dimethyl Fumarate Associated Lymphopenia in Clinical Practice Erin Longbrake, Anne Cross

P3.241 Safety and Efficacy of

Dimethyl Fumarate in Patients with Multiple Sclerosis—Real World Experience Claudia Chaves, Caitlin Dionne, Rik Ganguly, Ann Camac

P3.242 Results of a Delphi Panel to

Address Management of Gastrointestinal Side Effects Observed with Use of Delayedrelease Dimethyl Fumarate J. Theodore Phillips, April Erwin, Stephanie Agrella, Marcelo Kremenchutzky, John Kramer, Jonathan Kendter, Heather Abourjaily, Jitesh Rana, Robert Fox

P3.243 Systematic Review and Mixed Treatment Comparison of Delayed-release Dimethyl Fumarate and Other Diseasemodifying Therapies in Treatment-naïve Patients with Relapsing-remitting Multiple Sclerosis Robert Fox, Michael Hutchinson, Eva Havrdova, Nuwan Kurukulasuriya, Kashif Siddiqui, Sujata Sarda

P3.244 Comparison of Fingolimod

and Dimethyl Fumarate in the Treatment of Multiple Sclerosis: One Year Experience Brandi Vollmer, Julie Seibert, Stefan Sillou, Patrick Dowdle, John Corboy, Timothy Vollmer, Kavita Nair, Enrique Alvarez

P3.245 Assessing Comparative

Outcomes from Teriflunomide and Dimethyl Fumarate Studies in Relapsing MS: Use of “Number Needed to Treat” Analysis Thomas Leist, Mark Freedman, Aaron Miller, Catherine Dive-Pouletty, Xavier Montalban

P3.246 Impact of Fingolimod on

Achieving No Evidence of Disease Activity and Worsening (NEDA)-4 in Previously Treated Patients with High Disease Activity Nicola De Stefano, Till Sprenger, Maria Pia Sormani, Eva Havrdova, ErnstWilhelm Radue, Niklas Bergvall, Daniela Piani Meier, Davorka Tomic, Ludwig Kappos

P3.247 Comparison of First-line

Fingolimod Efficacy Compared with Firstline Interferon-beta or Glatiramer Therapy in MS Patients with Active Disease Using Propensity-matched Registry Data Tim Spelman, Niklas Bergvall, Guillermo Izquierdo, Raed Alroughani, Pamela McCombe, Ricardo Fernández Bolaños, Dana Horakova, Eva Havrdova, Celia OrejaGuevara, Jeannette Lechner-Scott, Mark Slee, Maria Trojano, Helmut Butzkueven

P3.248 Relapse Outcomes in Patients with Multiple Sclerosis Treated with Fingolimod After Previous Treatment with Injectable Disease-modifying Therapies Jacqueline Nicholas, Tobias Derfuss, Daniel Ontaneda, Xiangyi Meng, Kathleen Hawker


Fingolimod: The French Grand-Est Cohort Ayman Tourbah, Eric Berger, Marc Debouverie, Jerome De Seze, Etienne Godet, Thibault Moreau

P3.250 Cardiac Safety Profile

During First-dose Monitoring Period of Fingolimod (Gilenya) Treatment in Patients with Relapsing Remiting MS: Data from the Argentinean Registry (REAL). Interim Results Gaston Kuperman

P3.251 36 Month PANGAEA: A

5-year Non-interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients in Daily Clinical Practice Tjalf Ziemssen, Hans-Joerg Schwarz, Alexander Fuchs, Christian Cornelissen

P3.252 Multifocal Sequential Relapse

Following Cessation of Fingolimod Therapy: A Case Report Jason Appleton, Gordon Mazibrada

P3.253 Effectiveness of Fingolimod

Compared with Interferons and Glatiramer Acetate for the Treatment of Multiple Sclerosis: A Matched Comparison of Treatments from the PANGAEA and PEARL Studies Hans-Peter Duerr, Jonathan Alsop, Niklas Bergvall, Christian Cornelissen, Stefan Viktor Vormfelde, Tjalf Ziemssen

P3.254 Comparison of Relapse Rates in Multiple Sclerosis Patients Switching from Glatiramer Acetate to Fingolimod Versus Those Remaining on Glatiramer Acetate Li Yunfeng, Tara Nazareth, Huanxue Zhou, Ko John, Kathleen Hawker, Stephen Arcona, Rahul Sasane

P3.255 Interim Analysis II from REAL Study: Quality of Life and Persistence with Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients in Argentina Gastn Kuperman

P3.256 Similar Local Tolerability

Profiles Following Double-blind Treatment with Generic or Branded Glatiramer Acetate in Multiple Sclerosis Krzysztof Selmaj, Frederik Barkhof, Christian Wolf, Anna Belova, Janine Oberye, Evelyn van den Tweel, Roel Mulder, Norbert Koper, Gerrit Voortman, Jeffrey Cohen

P3.237 Impact of Global Education

on Decision-making Related to Disease Modifying Therapy in Multiple Sclerosis Ron Schaumburg, Stephen Krieger


83

Tuesday April 21


Poster Session III2:00 p.m.–6:30 p.m. P3.257 Pharmacokinetics of

Daclizumab High-yield Process (DAC HYP) with Repeated Administration of the Clinical Subcutaneous Regimen in Subjects with Relapsing-remitting Multiple Sclerosis Jonathan Tran, Ahmed Othman, Yaoshi Wu, Alvydas Mikulskis, Paul Wolstencroft, Jacob Elkins

P3.258 The Effect of Dosing Interval

Extension and Patient Weight on Long-term Natalizumab Pharmacokinetics John Foley, Ryan Metzger, Tamara Hoyt, Angelene Christensen

P3.262 Safety, Tolerability, and

Efficacy of Rituximab in the Treatment of Multiple Sclerosis: 285 Patients Treated in a Single Center Julie Seibert, Jace Blackburn, Brandi Vollmer, Jeffrey Bennett, John Corboy, Augusto Miravalle, Teri Schreiner, Timothy Vollmer, Enrique Alvarez

P3.263 Experience with Long-term

Rituximab Use in a Multiple Sclerosis Clinic Megan Barra, Khac Huy Vo, James Stankiewicz

P3.264 An Open Labeled

Estimation of Treatment Effectiveness with Versus Without an MS Relapse (PEARL Study) Stefan Vormfelde, Tjalf Ziemssen

Observational Study of Rituximab and Plasma Exchange (PLEX) in Progressive Multiple Sclerosis (MS) Sara Qureshi, Jaspreet Abraham, Diana Logan, Teresa Frohman, Elliot Frohman

P3.260 Improvement in Disability with

P3.265 Listeria Meningitis

P3.259 Disability, Health Status, and

Alemtuzumab Is Associated with Quality of Life Improvement Over 3 Years in Patients Who Relapsed on Prior Therapy Mariko Kita, Jeffrey Cohen, Thibault Moreau, Eva Havrdova, Rafael Arroyo-Gonzalez, Joseph Herbert, Linda Kasten, David Margolin, Gavin Giovannoni

P3.261

Complicating Alemtuzumab Treatment for Multiple Sclerosis Antonios Bayas, Andreas Rank, Markus Naumann

P3.266 Rebound of Cognitive

Impairment After Natalizumab Discontinuation in Multiple Sclerosis Patients Pietro Iaffaldano, Rosa Viterbo, Damiano Paolicelli, Vita Direnzo, Mariangela D'Onghia, Maria Trojano

Durable Effect of Alemtuzumab on Disability Improvement in Patients with Relapsing-remitting Multiple Sclerosis Who Relapsed on a Prior Therapy Christopher LaGanke, Bruce Hughes, Regina Berkovich, JeffreyListing, Cohen, halfpage horizontal RED: 15AM Award Luncheon Ad_Abstract Gavin Giovannoni, Linda Kasten, Usage: High resolution PDF for Abstract ListingDavid Margolin, Eva Havrdova Spec: 8.25” x 5.4375”, +.125” bleeds, 4C

P3.267 Safety and Efficacy of

Extended Dose Natalizumab in Multiple Sclerosis: An Ongoing Multicenter Study Lana Zhovtis Ryerson, Joseph Herbert, Ilya Kister, John Foley, Bianca Weinstock-Guttman, Carmelo Tornatore, Krupa Pandey, Gina Remington, Darin Okuda, Channa Kolb, Elliot Frohman

P3.268 Post-marketing Safety Profile of Interferon Beta-1a Subcutaneously in Patients with Multiple Sclerosis Treated in the US: A Retrospective Cohort Study Meredith Smith, Meritxell Sabidó Espin, Anton Trochanov, Mark Samuelson, Sandra Guedes, Florent-Frederic Richy

P3.269 Risk of Disease Progression

After Starting Dimethyl Fumurate (DMF): Data from the Providence Multiple Sclerosis Center’s DMF Registry Kyle Smoot, Kiren Kresa-Reahl, Chiayi Chen, Tamela Stuchiner, Bobbie Lee Roth, Stanley Cohan

P3.270 Cumulative Review of

Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a Ali-Frederic Ben-Amor, Anton Trochanov

P3.272 Decreased Relapse Activity

for Those Who Switch to Natalizumab from Alternative Disease Modifying Therapies: An Observational Study Robert McQueen, Terrie Livingstone, Timothy Vollmer, John Corboy, Kavita Nair, Jonathan Campbell

P3.273 Spontaneous Intracerebral

Hemorrhage During Natalizumab Treatment for Relapsing Remitting Multiple Sclerosis Carrie Hersh, Jeffrey Cohen

P3.274

Natalizumab Treatment Preserves Cognitive Function and Stabilizes MS Cortical Pathology Lior Or Bach, Shmuel Miron, Anat Achiron

P3.275 Improved Cognition

and Depression in Patients with MS After Two Years of Treatment with Natalizumab Annett Kunkel, Juergen Faiss, Wolfgang Koehler, Martin Fischer

P3.276 Physical Aspects of Quality

of Life (QoL) over 3 Years in Patients with Multiple Sclerosis (MS) Initiating Natalizumab Treatment Earlier Versus Later in the Course of Disease Kavita Nair, John Foley, Judith Stephenson, Timothy Niecko, Sonalee Agarwal, Crystal Watson

P3.271 Observational Prospective

Study in Multiple Sclerosis Patients Treated with Dimethylfumarate Jennifer Aboab, Romain Deschamps, Antoine Gueguen, Michael Obadia, Antoine Moulignier, Olivier Gout

2015 Awards Luncheon Wednesday, April 22 • 12:00 p.m.–1:30 p.m.

Join AAN leaders as they honor the recipients of the 2015 AAN and American Brain Foundation awards. From enterprising high school students to world-renowned researchers, this program recognizes some of the top accomplishments in neuroscience research. Walter F. Mondale has been named the 2015 Public Leadership in Neurology Award recipient and will accept the award during the awards luncheon. This award honors an individual or group outside of the medical profession who is dedicated to advancing public understanding and awareness of neurologic disease, being effective advocates for neuroscience research, and making significant contributions to improve patient care.

Poster Session III

P3.277 Effect of Fingolimod on No

Evidence of Disease Activity (NEDA-4) and Safety in Young Adult Patients with Relapsing-remitting Multiple Sclerosis Angelo Ghezzi, Goeril Karlsson, Dieter Haering, Jutta Gärtner, Tanuja Chitnis, Daniela Pohl, Norman Putzki

P3.278 Glatiramer Acetate and

Pregnancy in Women with Multiple Sclerosis—Results from the German Multiple Sclerosis and Pregnancy Registry Kerstin Hellwig, Sandra Herbstritt, Ralf Gold

P3.279 Open-label Study of Autologous

Bone-marrow-derived Mesenchymal Stem Cells in Multiple Sclerosis Cristina Ramo, Jose Vicente Hervas, Enrique Andreu, Felipe Prosper, Susana Inoges, Jaime Kulisevsky, Roberto Belvís

P3.280 Is Baseline MRI Predictive

of Response to Fingolimod Treatment in Multiple Sclerosis? Camilo Diaz-Cruz, Brian Healy, Muhammad Taimur Malik, Svetlana Egorova, Mariann Polgar-Turcsanyi, Mark Anderson, Shahamat Tauhid, Gloria Kim, Rohit Bakshi, Tanuja Chitnis

P3.288 Effectiveness of Switching

to Rituximab over Fingolimod or Dimethyl Fumarate After Natalizumab in Preventing Disease Activity in Multiple Sclerosis Enrique Alvarez, Brandi Vollmer, Blacburn Jace, John Corboy, Timothy Vollmer, Stefan Sillou, Kavita Nair, Julie Seibert

P3.289 The Safety and Efficacy of

Switching from Natalizumab to Dimethy Fumarate: Real World Experience Faria Amjad, Nasima Afsari, Carmelo Tornatore

P3.290 Efficacy of Oral Multiple

Sclerosis Therapies in Patients Switching from Natalizumab NgocHanh Vu, Harold Moses, Subramaniam Sriram, Siddharama Pawate

P3.291 Risk of Rebound in Multiple

Sclerosis After a Switch from Natalizumab to Fingolimod. Early Onset Versus Delayed Onset Rocio Hernandez Clares, Ruben Carrasco Torres, Ester Carreon, Encarnación Andreu, Jose Meca La Llana, Jjavier Martin Fernandez

P3.292 Early Cyclophosphamide

Among Multiple Sclerosis Patients Newly Initiating Treatment with a Self-injectable Versus Oral Disease-modifying Drug Julie Locklear, Amy Phillips, Michael Munsell, Molly Frean, Joseph Menzin

Pulses Therapy Is Able to Reduce Disease Reactivation After Natalizumab Discontinuation: Preliminary Results from a Multicentric Database Marco Capobianco, Marianna Lo Re, Francesca Sangalli, Lucia Moiola, Paola Perini, Paolo Gallo, Leandro Provinciali, Maura Danni, Anna Repice, Luca Massacesi, Francesco Patti, Silvia Messina, Antonio Bertolotto

P3.282 Characteristics of Switchers

P3.293 Real-world Clinical Outcomes

P3.281 An Assessment of Adherence

to Newer Therapies in the NARCOMS Registry Amber Salter, Stacey Cofield, Stephen Glenski, Tuula Tyry, Gary Cutter, Robert Fox, Ruth-Ann Marrie

P3.283 Demographic and Clinical

Assessment of Multiple Sclerosis Patients Undergoing Immunomodulatory Treatment in Poland Slawomir Wawrzyniak, Dorota Koziarska, Alina Kulakowska, Monika Adamczyk-Sowa

P3.284 Disease Course in Multiple

Sclerosis (MS) Patients Switching from Fingolimod to Natalizumab Helmut Butzkueven, Ludwig Kappos, Maria Trojano, Yi Chen, Qunming Dong, Harold Koendgen, Shibeshih Belachew

P3.285 Functional System Changes Associated with Relapse: The CombiRx Experience Stacey Cofield, Fred Lublin, Gary Cutter, Tarah Gustafson, Jerry Wolinsky

P3.286 Evaluation of the Tolerability

Profile of Peginterferon Beta-1a Using the Delphi Technique Leslie Leahy, Diego Centonze, June Halper, DeRen Huang, Scott Newsome, Chris Robertson, Xiaojun You, Bjorn Sperling

P3.287 Natalizumab Discontinuation

Study: Taper Protocol May Prevent Disease Reactivation Bianca Weinstock-Guttman, Jesper Hagemeier, Vasu Saini, Katelyn Kavak, Kara Patrick, Deepa Ramasamy, Nadeem Muhammad, Ellen Carl, David Hojnacki, Robert Zivadinov

in Relapsing-remitting Multiple Sclerosis Patients Who Switch from Natalizumab to Delayed-release Dimethyl Fumarate: A Multicenter, Retrospective, Observational Study (STRATEGY) Stanley Cohan, Jonathan Calkwood, Christopher LaGanke, Carlo Tornatore, Harold Moses, Kyle Smoot, Monica Mann, Ven Meka, Macaulay Okwuokenye, Christophe Hotermans, Leslie Meltzer

P3.294 Relapse and Rebound Risks

After Natalizumab Discontinuation in Patients with Multiple Sclerosis Claudia Chaves, Rik Ganguly, Caitlin Dionne, Ann Camac

P3.295 An Analysis of Monthly

Surveillance 3T MRI in MS Patients Switched from Long-term Natalizamab to Teriflunomide in a Controlled, Prospective Study Keith Edwards, Stanley Cohan, Francisco Gomez, James Thomas

P3.296 Switching from Natalizumab

to Fingolimod. Clinical and Radiological Response. A Centre’s Experience Rocio Hernandez Clares, Ester Carreon Guarnizo, Encarnación Andreu Reinón, Ruben Carrasco Torres, Adelaida Leon Hernandez, Gema Salgado, Pepe Meca Lallana

P3.298 Antiretroviral Central

P3.312

P3.299 Efficacy of Pregabalin in the

P3.313

P3.300 Pain Prevalence in the

P3.314

Nervous System Penetration Does Not Reduce Chronic Pain in People Living with HIV Nathaniel Robbins, Kanokporn Chaiklang, Khuanchai Supparatpinyo Treatment of Prediabetic Neuropathic Pain Alejandra Gonzalez-Duarte, Karla Cárdenas-Soto, Mónica Lem, Roy Freeman Elderly Jelena Pavlovic, Cuiling Wang, Mindy Katz, Carol Derby, Molly Zimmerman, Richard Lipton

P3.301 Neurology and Palliative Care: A Barriers Analysis Ludo Vanopdenbosch, David Oliver

P3.302 Total Intracranial Volume and Current Total Brain Volume Are Linked to Level of Pain in Older Adults Ali Ezzati, Mindy Katz, Michael Lipton, Richard Lipton

P3.303 Tanezumab Does Not Cause

Sympathetic Nervous System Dysfunction in Clinical Osteoarthritis Studies Mark Brown, Martin Koltzenburg, Ha Nguyen, Christine West, Kenneth Verburg

P3.304 The Efficacy of Pregabalin for Treating Pain Associated with Diabetic Peripheral Neuropathy in Patients with Type I or Type II Diabetes Mellitus Bruce Parsons, Chunming Li, Birol Emir

P3.305 Provocative Infrared

Telethermography in Knee Osteoarthritis: The Role of the Sympathetic Nervous System in Pain Trevor Gerson, Meryem Saracoglu, Sara Connolly, Amy Kirsling, R Harden

P3.306 Effects of Acupuncture on

Neuropathic Pain: A Systematic Review and Meta-analysis Alexandra Dimitrova, Charles Murchison, Barry Oken

P3.307 Prevalence of B12 Deficiency in Patients Presenting with Non-specific Pain and Other Sensory Symptoms: A Clinical Observational Study Karadan Ummer, Mohan Noone

P3.308 Gamma Knife Radiosurgery

for Trigeminal Neuralgia. A Long-term Study on Outcome and Predictors of Pain Relief Vijayakumar Javalkar, Shihao Zhang, Osama Ahmed, Anil Nanda

Differential Effects of Pain and Weakness on Function in Chiari Malformation and Syrinx; A Longitudinal Study Fredric Cantor, Aerial Spencer, Jessica Mack, John Heiss

P3.315

Skin Hyperpigmentation in Complex Regional Pain Syndrome (CRPS) Robert Knobler

P3.316

Severe Ascending Muscle Spasms Associated with Diffuse Perineural Tarlov Cysts Damoun Safarpour, Sarah Mulukutla, Baber Khokhar, Bahman Jabbari

P3.317 Withdrawn P3.318

Palliative Sedation in a Case of Severe Progressive Dystonia and Intractable Pain Neha Kramer, Jacob Strand, Sara Hocker, Keith Swetz

P3.319

Exploring Misconceptions in Palliative Care in a Multi-disciplinary ALS Clinic Lindsay Kaplan

Neuroscience Research Prize Recipients P3.320 Modulating the Innate

Immune System Through the Stimulation of TLR9 with CpG ODN as a Therapy for Alzheimer’s Disease in a TgSwDI Mouse Model in Both Acute and Long-term Studies Monica Lee

P3.321 Investigation of

Autophagy in Huntington’s disease using a Mutant Huntington Knock-in Striatal Cell Line Lauren Houle

P3.322 A Novel Peptide Alters

the Alzheimer’s β-amyloid Equilibrium to Protect Against Aβ Oligomer Neurotoxicity Yinge Zhao

Referrals to Pain Management Ilya Bragin, Dmitry Dvoskin, Awss Zidan, Rosamma Joseph, Parakulam Sebastian Thomas

P3.310 Pain Intensity and Pain

Pain and Palliative Care P3.297 Pain Control Is an Independent

P3.311


Comparison of Patients with Chronic Non-cancer Pain Taking and Not Taking Chronic Opioid Therapy Peter Przekop, Allison Przekop, Mark Haviland

P3.309 Characteristics of Neurology

Interference in Older Adults: Role of Gender, Obesity and Inflammation Vahid Eslami, Mindy Katz, Robert White, Erin Sundermann, Julie Jiang, Ali Ezzati, Richard Lipton

Predictor of Self-reported Mental Health Among Patients with Chronic Neurological Conditions Lidia Maria Moura, Eli Schwamm, Lee Schwamm

A Retrospective Analysis of and Proposed Framework for Palliative Care Discussions in Patients with Multiple System Atrophy Anita Dayal, Teneille Gofton

Using a Patient Registry to Improve Understanding of the Variability, Progression, and Treatment of Pain Christina Cook, Risa Tyo, Steven Gershon, Michael Burdi

85

Tuesday April 21


Scientific Sessions S12 Neuroimmune Mechanisms in Multiple Sclerosis 3:15 p.m. S12.001 Increased Intrathecal Inflammation in Progressive Multiple Sclerosis Mika Komori, Andrew Blake, Yen-Chih Lin, Peter Kosa, Danish Ghazali, Paige Winokur, Muktha Natrajan, Simone Wuest, Elena Romm, Tianxia Wu, Bibiana Bielekova

S13 Cerebrovascular Disease and Interventional Neurology: Epidemiology and Risk Factors 3:15 p.m. Presentation of Michael S. Pessin Stroke Leadership Prize Recipient: Lauren Sansing, MD, MS New Haven, CT

3:30 p.m. S12.002 Immune Infiltrates Expressing Podoplanin (PDPN) Are Present in Multiple Sclerosis but Not Glioblastoma Alyssa Nylander, Sriram Ramanan, Danielle Debartolo, Calvin Park, David Hafler, David Pitt

3:30 p.m. S13.002 Subclinical Cerebral Vessel Lesions and Risk of Stroke: The Northern Manhattan Study Emmanuel Perez, Chuanhui Dong, Charles DeCarli, Mitsuhiro Yoshita, Clinton Wright, Maria Santiago, Mitchell Elkind, Ralph Sacco

3:45 p.m. S12.003 The Role of Fractalkine (CX3CL1) in Regulation of CD4+ Cell Migration to the Central Nervous System in Patients with Relapsing-remitting Multiple Sclerosis Silva Markovic Plese, Kevin Blauth, Xin Zhang, Manisha Chopra

3:45 p.m. S13.003 The Risk of a Diagnosis of Cancer After Ischemic Stroke: Two Year Follow-up Study of 3247 Cancer Free Ischemic Stroke Patients Adnan Qureshi, Ahmed Malik, Omar Saeed, Adil Malik, Muhammad Suri

4:00 p.m. S12.004 Vascular and Angiogenic Factors in a Non-human Primate Model of Multiple Sclerosis (MS): Human Biomarker Cross-reactivity with EAE in the Common Marmoset Emily Leibovitch, Giovanna Manzano, Steven Jacobson 4:15 p.m. S12.005 Relative Expression of Anti-oxidant Genes in Adult Human Progenitor and Mature Oligodendrocytes Qiao Ling Cui, Pavel Gris, Timothy Kennedy, Jack Antel 4:30 p.m. S12.006 The Effect of IL-10 on M2-activated Human Microglia Luke Healy, Craig Moore, Hanane Touil, Samuel Ludwin, Amit Bar-Or, Jack Antel 4:45 p.m. S12.007 Detection of Human T-cell Lymphotropic Virus Type I Proteins in Exosomes from HAM/TSP Patient CSF by Novel Nanotrap Technology Monique Anderson, Benjamin Lepene, Fatah Kashanchi, Steven Jacobson

4:00 p.m. S13.004 Rapid Weather Changes Are Associated with Increased Ischemic Stroke Risk: A Case Crossover Study Florian Rakers, Rene Schiffner, Sven Rupprecht, Antje Brandstädt, Otto Witte, Peter Schlattmann, Matthias Schwab 4:15 p.m. S13.005 The Preventable Stroke: Definition and Implications Mark Fisher, Lisa Moores, Mohamad N. Alsharif, Krunal Shah, Annlia Paganini-Hill 4:30 p.m. S13.006 CARES (Changing and Advancing Risk Factor Control Through Educations After Stroke): A Pilot Trial of a Transitions in Care Postdischarge Telephone Intervention for Stroke Patients Lillie Hudson, Marilyn Corrales, Lilian Moreno, Natalie Valle, Ali Razmara, Tara Dutta, Liliana Ramirez-Gomez, Amy Towfighi 4:45 p.m. S13.007 A Culturally Tailored Education Intervention for Korean Seniors Increases Stroke Knowledge Sarah Song, John Son, Frances Barry, Heejung Park, Heeeun Park, Connie Chung, Joseph Chung, Chi-Hong Tsieng, Gery Ryan, Barbara Vickrey

Tuesday, April 21 S14 Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy 3:15 p.m. S14.001 The Implantation Effect: Seizure Frequency in Patients That Have Underwent Intracranial Surgical Implantation Versus Superficial Scalp Monitoring Michael Lane, Barbara Jobst, Cynthia Kahlenberg, Vijay Thadani, Krzysztof Bujarski, David Roberts 3:30 p.m. S14.002 Increased Cerebral Oxygenation Precedes Generalized Tonic Clonic Seizures Brian Moseley, Jeffrey Britton, Elson So 3:45 p.m. S14.003 Transcutaneous PCO2 and Seizures in the Epilepsy Monitoring Unit: Associations with Markers of Seizure Severity Derek J. Chong, Palak Patel, Alla Ahmed, Nilofer Khan, Bryan Still, Evan Marzouk, Daniel Friedman, Orrin Devinsky 4:00 p.m. S14.004 The EpiNet Collaboration: Do Neurologists Around the World Agree when Diagnosing Epilepsy?— Results of a Multinational Study. Peter Bergin, Ettore Beghi, Wendyl D'Souza, Lynette Sadleir, Manjari Tripathi, Mark Richardson, Elisa Bianchi 4:15 p.m. S14.005 “Review of Systems" Questionnaire as a Predictive Tool for Psychogenic Non-epileptic Seizures. Liliana Robles, Sharon Chiang, Holly Rutherford, Zulfi Haneef 4:30 p.m. S14.006 Episodic Memory Deficits Are Related to Gray Matter Volume and Functional Connectivity Abnormalities in Temporal Lobe Epilepsy Gaelle Doucet, Xiao-Song He, Paul Barnett, Christopher Skidmore, Ashwini Sharan, Michael Sperling, Joseph Tracy 4:45 p.m. S14.007 Decreased Amygdala Resting State Functional Connectivity in Patients with Left Temporal Lobe Epilepsy Jane Allendorfer, Rodolphe Nenert, Basia Szaflarski, Nancy Cohen, Jeffrey Binder, Zhifeng Kou, Roy Martin, Lawrence Ver Hoef, Jerzy Szaflarski

S15 Movement Disorders: Huntington's Disease, Dystonia, and Atypical Parkinsonism

S16 Aging, Dementia, Cognitive, and Behavioral Neurology: Clinical Science

3:15 p.m. S15.001 Reliability of the Severity Subscale of the Revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2) Cynthia Comella, Joel Perlmutter, H. Jinnah, Stewart Factor, Christopher Goetz, Charles Adler, Richard Barbano, Susan Fox, Joseph Jankovic, Ramon Rodriguez, William Severt, Stephen Reich, Natividad Stover, Wendy Galpern, Ami Rosen, Glenn Stebbins

3:15 p.m. S16.001 Glutamic Acid Decarboxylase Antibody Encephalitis Mimicking Creutzfeldt-Jakob Disease: A Case Report and Literature Review Frank Bittner, Ann Murray, Javier Gonzalez

3:30 p.m. S15.002 Can the Mutant Huntingtin Gene Product Spread from Cell to Cell: Evidence from Neuronal Allografts in Huntington's Disease Patients Francesca Cicchetti, Steve Lacroix, Giulia Cisbani, Nicolas Vallières, Martine Saint-Pierre, Isabelle St-Amour, Ranna Tolouei, Jeremy Skepper, Robert Hauser, Diego Mantovani, Roger Barker, Thomas Freeman 3:45 p.m. S15.003 Thalamic Volume Is Reduced in Multiple Types of Dystonia Jeffrey Waugh, Jake Kuster, Jacob Levenstein, N Makris, Trisha Multhaupt-Buell, Lewis Sudarsky, Hans Breiter, Nutan Sharma, Anne Blood 4:00 p.m. S15.004 Monitoring Loss of Striatal Phosphodiesterase 10A (PDE10A) with [18F]MNI-659 and PET: A Biomarker of Early Huntington Disease (HD) Progression. David Russell, Danna Jennings, Olivier Barret, Gilles Tamagnan, Vincent Carroll, David Alagille, Thomas Morley, Caroline Papin, John Seibyl, Kenneth Marek 4:15 p.m. S15.005 No Excess of Loss-of-function of COQ2 Variants in Pathologically Confirmed Multiple System Atrophy Lucia Schottlaender, Henry Houlden 4:30 p.m. S15.006 Prevalence of Depression and Anxiety in Atypical Parkinsonian Patients. Leonardo Brito De Almeida, Michael Okun, Nikolaus McFarland 4:45 p.m. S15.007 Longitudinal Voxel-based Analysis of Brain Atrophy over 6 and 12 Months in CBD and PSP from Two Multicenter Studies Shubir Dutt, Richard Binney, Hilary Heuer, Priyanka Bhatt, Dana Waltzman, Suneth Attygalle, Phi Luong, Lisa Voltarelli, Jonathan Elofson, Namita Multani, Carmela Tartaglia, Irene Litvan, Scott McGinnis, Bradford Dickerson, Joel Kramer, Bruce Miller, Clifford Jack, Howard Rosen, Adam Boxer

86

3:30 p.m. S16.002 Atrial Fibrillation in Patients with Neuropathological Diagnosis of Primary Alzheimer’s Disease Patricia Riccio, Luciano Alberto Sposato, Estefania Ruiz Vargas, Jon Toledo, John Trojanowski, Vladimir Hachinski 3:45 p.m. S16.003 Multimorbidity and Increased Risk of Mild Cognitive Impairment Maria Vassilaki, Ruth Cha, Jennifer St. Sauver, Michelle Mielke, Yonas Geda, Mary Machulda, David Knopman, Ronald Petersen, Rosebud Roberts 4:00 p.m. S16.004 Predicting the Risk of Mild Cognitive Impairment in the Mayo Clinic Study of Aging Michelle Mielke, Vernon Pankratz, Rosebud Roberts, David Knopman, Clifford Jack, Yonas Geda, Walter Rocca, Ronald Petersen 4:15 p.m. S16.005 APOEε2 Is Associated with Milder Clinical and Pathological Alzheimer’s Disease Alberto Serrano-Pozo, Jing Qian, Sarah Monsell, Rebecca Betensky, Bradley Hyman 4:30 p.m. S16.006 EHT™ Coffee Extract: A Neuroprotective Agent and Modulator of PP2A Methylation with Anti-inflammatory and Antioxidant Properties Kristen Huber, Michael Voronkov, Jose Fernandez, Karl Rouzard, Akira Iishi, Eduardo Perez, Maxwell Stock, Jeff Stock 4:45 p.m. S16.007 Dextromethorphan/Quinidine (AVP-923) Efficacy and Safety for Treatment of Agitation in Persons with Alzheimer’s Disease: Results From a Phase 2 Study (NCT01584440) Jeffrey Cummings, Constantine Lyketsos, Pierre Tariot, Elaine Peskind, Uyen Nguyen, Nadine Knowles, Paul Shin, Joao Siffert


3:15 p.m–5:00 p.m.

3:15 p.m. S17.001 A Quantitative Analysis of Muscle Microvasculature in Areas of Perifascicular Fiber Atrophy (PFA) and Adjacent Unaffected Fascicular Areas (UFA) in Dermatomyositis (DM). Rajat Lahoria, Andrew Engel 3:30 p.m. S17.002 Necrotizing Autoimmune Myopathy: Comparison of Clinical Features and Treatment Outcomes Among Different Etiologies Charles Kassardjian, Vanda Lennon, Margherita Milone 3:45 p.m. S17.003 Orally-administered TRPV1 and TRPA1 Activators Inhibit Electrically-induced Muscle Cramps in Normal Healthy Volunteers Glenn Short, Brooke Hegarty, Roderick MacKinnon, Bruce Bean, Christoph Westphal, Jennifer Cermak 4:00 p.m. S17.004 Regulatory Factors of Autophagy and Triglyceride Accumulation in Lipid Storage Myopathies Corrado Angelini, Anna Nascimbeni, Elisabetta Tasca 4:15 p.m. S17.005 Biomarkers of Disease Severity in Myotonic Dystrophy During Skeletal Muscle Rehabilitation Corrado Angelini, Chiara Fritegotto, Paola Cudia 4:30 p.m. S17.006 Astrocyte Mediated Toxicity Leads to Motor Neuron Death in Spinal Muscular Atrophy Dimitra Papadimitriou, Sudarshan Phani, Arnaud Jacquier, Virginia LeVerche, Radhika Pradhan, Shingo Kariya, Umrao Monani, Diane Re, Serge Przedborski 4:45 p.m. S17.007 A Unique Presentation of a Novel Mutation in the SETX Gene Anna Bjornsdottir, Yunis Mayasi, Martin Sigurdsson, Johnny Salameh 5:00 p.m. S17.008 The Diagnostic Utility of Nerve Conduction Studies and Skin Biopsy for Diabetic Neuropathy (DPN): A Bayesian Analysis A. Smith, Margaret Lessard, J. Singleton

S18 Neuro-oncology: Imaging and Quality of Life 3:15 p.m. Presentation of Neuro-oncology Investigator Award Recipient: Elizabeth Gerstner, MD, MS Boston, MA

3:30 p.m. S18.002 Non-invasive Monitoring of Treatment Response in IDHmutant Glioma Patients by 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate Ovidiu Andronesi, Franziska Loebel, Wolfgang Bogner, Malgorzata Marjanska, Jorg Dietrich, Tracy Batchelor, Elizabeth Gerstner, Andrew Chi, Bruce Rosen, Daniel Cahill 3:45 p.m. S18.003 Structural Brain Changes in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma Isabel Arrillaga-Romany, Kourosh Jafari-Khouzani, Yi-Bin Chen, Bruce Rosen, Tracy Batchelor, Jorg Dietrich 4:00 p.m. S18.004 A Retrospective Study of Home Hospice Care in Primary Malignant Brain Tumors Eli Diamond, David Russell, Kathyrn Bowles, Maria Kryza-Lacombe, Jeanne Dennis, Paulina Kim, Holly Prigerson 4:15 p.m. S18.005 Quality of Life and Symptoms in Terminal High-grade Glioma Joel Phillips, Tobias Walbert 4:30 p.m. S18.006 Pregnancy in Glioma Patients Jacqueline Stone, Jerome Graber, Thomas Kaley 4:45 p.m. S18.007 Complementary and Alternative Medicine in the Primary Brain Tumor Population and Its Association with Health-reported Quality of Life Dina Randazzo, Mary Affronti, Eric Lipp, Frances McSherry, James Herndon, II, Charlene Flahiff, Elizabeth Miller, Sarah Woodring, Maria Freeman, Patrick Healy, Janet Minchew, Susan Boulton, Annick DesJardins, Tulika Ranjan, Gordana Vlahovic, Henry Friedman, Katherine Peters

S19 Neurologic Education 3:15 p.m. S19.001 Neurology Resident Documentation Using an Electronic Medical Record (EMR) in the Outpatient Continuity Clinic and Its Financial Implications John Liang, David Lucido, Weiyi Gao, Jean Peng, Vicki Shanker 3:30 p.m. S19.002 A Curriculum for the Milestones Shamik Bhattacharyya, Tracey Milligan 3:45 p.m. S19.003 Validation of the Alzheimer’s Prevention and Risk Knowledge Score (APRKS) Richard Isaacson, Jessica Gordon, Alon Seifan 4:00 p.m. S19.004 Milestone-compatible Neurology Resident Assessments: A Role for Observable Practice Activities Lyell Jones, Elliot Dimberg, Christopher Boes, Scott Eggers, David Dodick, Jeremy Cutsforth-Gregory, Andrea Leep Hunderfund, David Capobianco

The Resident Experience Saturday, April 18 through Friday, April 24

The Resident Experience offers a unique opportunity for Medical students, Residents, and Fellows to explore an array of career resources and network with peers. Participants can learn more about AAN resources and attend special presentations.

4:15 p.m. S19.005 Procedural Headache Medicine in Neurology Training: A Survey of US Residency Program Directors Matthew Robbins, Carrie Robertson, Jessica Ailani, Morris Levin, Deborah Friedman, David Dodick

Tuesday April 21

S17 Muscle and Anterior Horn Cell Diseases: Mechanisms and Biomarkers

4:30 p.m. S19.006 Internet Teaching of the Neurologic Examination and OSCE Performance in the Neurology Clerkship Cara Harth, Yaqi Xue, Jie Yang 4:45 p.m. S19.007 Formal Faculty Assessment of Bedside Skills for 3rd Year Medical Students on the Neurology Clerkship: The Year Two Experience Robert Thompson Stone, Christopher Mooney, Erika Wexler, Jonathan Mink, Ralph Jozefowicz


87

Poster Session IV

Wednesday, April 22

P4 First Poster Session IV Authors stand by Posters from 7:30 a.m.–9:00 a.m. Poster Discussion Session: MS and CNS Inflammatory Diseases

7:30 a.m.–12:00 p.m.


P4.001 Effect of Fingolimod Versus

Interferon-beta1a on No Evidence of Disease Activity or Worsening (NEDA4) in the TRANSFORMS Study Xavier Montalban, Jeffrey Cohen, Frederik Barkhof, Bhupendra Khatri, Hans Hartung, Shannon Ritter, Daniela Piani Meier, Davorka Tomic, Ludwig Kappos

P4.002 Treatment with ATX-

MS-1467 Persistently Triggers IL-10, But Not Pro-inflammatory Cytokine Release and Induces a Population of Lag3+CD4+ Cells in a Humanized HLA/TCR Mouse Model Adriano Soares de Souza, Stefan Rudin, Dongzi Yu, Shinji Okitsu, Blake Tomkinson, Tammy Dellovade

P4.003 An Open Label Add-on Trial of

P4.005 Fampridine Modulates

P4.008 Comparative Effects of

P4.004 Combined Analysis of

P4.006 Failure of Early Lesion

P4.009 Decreased Amino Acid

Cetirizine for Neuromyelitis Optica Ilana Katz Sand, Michelle Fabian, Lawrence Cook, Mirna Chehade, Madhan Masilamani, Thomas Kraus, Colleen Farrell, Shelly Phelps, Mary Ellen Riffle, John Rose, Thomas Moran, Fred Lublin DIR and PSIR Images Discloses a High Cortical Lesion Load in Multiple Sclerosis Cortex Alice Favaretto, Davide Poggiali, Andrea Lazzarotto, Giuseppe Rolma, Francesco Causin, Francesca Rinaldi, Paola Perini, Paolo Gallo

Thalamic Resting State Functional Connectivity and Ameliorates Fatigue in Multiple Sclerosis Patients Maria Rocca, Paola Valsasina, Bruno Colombo, Paolo Preziosa, Vittorio Martinelli, Andrea Falini, Giancarlo Comi, Massimo Filippi Repair in Multiple Sclerosis Lesions with Persistent Phase RIM Martina Absinta, Pascal Sati, Massimo Filippi, Joan Ohayon, Irene Cortese, Daniel Reich

P4.007 Daclizumab HYP Versus

Interferon β-1a Across Patient Demographic and Disease Activity Subgroups in the DECIDE Phase 3 Study Heinz Wiendl, Eva Havrdova, John Rose, Katherine Riester, Claire Tsao, Steven Greenberg

Dimethyl and Monomethyl Fumarate (DMF/ MMF) on Human Myeloid Cells Laurence Poliquin-Lasnier, Mackenzie A. MichellRobinson, Lindsay Osso, Nika Zorko, Craig Moore, Luke M. Healy, Anne-Marie Trudelle, Paul Giacomini, Amit Bar-Or, Jack Antel Catabolism in Multiple Sclerosis Affects Immune Homeostasis Jorge Correale, Mauricio Farez

P4.010

Humoral Responses to Systemic and Organ Specific Autoantigens in Multiple Sclerosis Kishore Malyavantham, Bianca Weinstock-Guttman, Lakshmanan Suresh, Robert Zivadinov, Thomas Shanahan, Darlene Badgett, Murali Ramanathan

e-Poster Session: MS and CNS Inflammatory Diseases I Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch screen displays.

P4.011

B Cells Responding to Viral Antigens Can Provoke a T Cell Response Against Myelin Antigens nicholas sanderson, Maria Zimmermann, Raija Lindberg, Ludwig Kappos, Tobias Derfuss

P4.012

Slowly Eroding Lesions in Multiple Sclerosis Varun Sethi, Govind Nair, Blake Dewey, Colin Shea, Arun Venkataraman, Tianxia Wu, Kelly Yang, Daniel Reich

P4.013

The Topographical Model of Multiple Sclerosis: A New Visualization of Disease Course Stephen Krieger

MS and CNS Inflammatory Diseases: Pediatric MS and MS Variants P4.021 The Epidemiology of Pediatric Multiple Sclerosis in the United States Using Data from the Pediatric Health Information System (PHIS) Amy Lavery, Brenda Banwell, Amy Waldman

88

P4.014

Vitamin D as a Predictor of Functional Deficits in Multiple Sclerosis Kathryn Fitzgerald, Kassandra Munger, Mark Freedman, Hans Hartung, David Miller, Xavier Montalban, Gilles Edan, Frederik Barkhof, Rupert Sandbrink, Ludwig Kappos, Gustavo Suarez, Christoph Pohl, Alberto Ascherio

P4.015

Quantifying Visual Pathway Axonal and Myelin Loss in Neuromyelitis Optic Praveena Manogaran, Shannon Kolind, Irene Vavasour, Alex Lange, David Li, Anthony Traboulsee

P4.022 Binocular Low-contrast

Acuity and the Symbol Digit Modalities Test Improve the Ability of the Multiple Sclerosis Functional Composite to Predict Disease in Pediatric Multiple Sclerosis Amy Waldman, Salim Chahin, Brenda Banwell, Grant Liu, Laura Balcer

P4.023 Self-efficacy and Functional Disability as Barriers to Physical Activity Participation in Pediatric Multiple Sclerosis Carolyn Sawicki, Stephanie Grover, Dominique Kinnett-Hopkins, Robert Motl, Marcia Finlayson, Jane Schneiderman, E. Ann Yeh

P4.016

Long-term Evolution of Magnetization Transfer Ratio in Multiple Sclerosis Lesions Yufan Zheng, Richard Rudick, Jar-Chi Lee, Elizabeth Fisher

P4.017

Relationship Between Timed 25-foot Walk Impairment and Diffusion Tensor Imaging Markers in Multiple Sclerosis Sylvia Klineova, Rebecca Farber, Colleen Farrell, Matilde Inglese, Catarina Saiote, Bradley Delman, Lawrence Tanenbaum, Fred Lublin, Stephen Krieger

P4.018

Clinical Course, Radiologic Features, and Treatment Response in Patients with Tumefactive Demyelinating Lesions in Toronto Kristen Krysko, Liesly Lee, Paul O'Connor

P4.024 Risk of a Second Clinical

Attack in Pediatric Patients with a First Demyelinating Clinical Attack Suggestive of Multiple Sclerosis Pietro Iaffaldano, Giuseppe Lucisano, Angelo Ghezzi, Giancarlo Comi, Vincenzo Brescia Morra, Francesco Patti, Alessandra Lugaresi, Carlo Pozzilli, Maria Amato, Helmut Butzkueven, Raed Alroughani, Vahid Shaygannejad, Seyed Aidin Sajedi, Guillermo Izquierdo, Giuseppe Salemi, Enrico Millefiorini, Giacomo Lus, Marta Simone, Vito Lepore, Maria Trojano, on behalf of Italian iMedWeb Registry, and MSBase Investigators

P4.019 Progressive

Autoimmune Neuromyotonia with Low Voltage-gated Potassium Channel-complex IgG and CASPR2IgG Following Remote Inflammatory Polyradiculoneuropathy Jenny Linnoila, Charles Kassardjian, Cullen O'Gorman, Nathan Staff, William Litchy, Margherita Milone, Vanda Lennon, Christopher Klein

P4.020 Retinal Segmentation

Distinguishes Neuromyelitis Optica from Multiple Sclerosis Using Optical Coherence Tomography Regardless of Antibody Status Richard Loeb, Ashley Finch, Adil Javed, Jacqueline Bernard

P4.025 Cognitive Impairment Is

Associated with Behavioral Problems in Pediatric Multiple Sclerosis (MS) Bianca Cersosimo, Colleen Schwarz, Nikita Gupta, Nneka Amadiume, Anita Belman, Lauren Krupp, Leigh Charvet

P4.026 Vision, Fatigue, and Quality

of Life in Pediatric Multiple Sclerosis and Monophasic Demyelinating Diseases Salim Chahin, Brenda Banwell, Laura Balcer, Amy Waldman


Poster Session IV

P4.027 Gut Microbiome in Early

Pediatric Multiple Sclerosis: A Case-control Study Helen Tremlett, Douglas Fadrosh, Susan Lynch, Janace Hart, Jennifer Graves, Sabeen Lulu, Gregory Aaen, Anita Belman, Leslie Benson, Charlie Casper, Tanuja Chitnis, Mark Gorman, Lauren Krupp, Timothy Lotze, Jayne Ness, Shelly Roalstad, Moses Rodriguez, John Rose, Jan-Mendelt Tillema, Bianca Weinstock-Guttman, Emmanuelle Waubant

P4.028 Inhibition of Adult

Neurogenesis in a Marburg´s Variant of Multiple Sclerosis Celia Oreja-Guevara, Julia García-López, Rafael SánchezSánchez, Aida Orviz-García, Ines GonzálezSuárez, Alberto Rábano, Ulises GómezPinedo, Jorge Matías-Guiu

P4.029 Perivascular Inflammation

in Baló-like Concentric Sclerosis— Preliminary Results from a 7T MRI Case Series Janina Behrens, Tim Sinnecker, Joseph Kuchling, Lutz Harms, Klemens Ruprecht, Thoralf Niendorf, Friedemann Paul, Jan Dörr, Jens Wuerfel

MS and CNS Inflammatory Diseases: Progressive Multifocal Leukoencephalopathy Risk P4.030 Natalizumab-related PML Is

Possible Even with Recent Negative JCV Antibody Testing Marie-Sarah Brosseau, Gary Stobbe, Deb Cramer, Hillary Lipe, Annette Wundes

P4.031 Anti-JC Virus (JCV) Antibody

P4.035 Use of IL- 2 for Management of Natalizumab-associated Progressive Multifocal Leukoencephalopathy Yinan Zhang, Divyanshu Dubey, Allen DeSena, Donna Graves, Elliot Frohman, Benjamin Greenberg

P4.036 A Longitudinal Assessment

of John Cunningham Virus (JCV) Index in a Real-world MS Population Tamara Hoyt, Angelene Christensen, Angela Foley, Ryan Metzger

P4.037

Correlation Between Anti-JCV and Anti-CMV Antibodies Michael Auer, Wegene Borena, Holm-von Laer Dorothee, Florian Deisenhammer

P4.038 Co-incidence of Anti-

JCV and Anti-CMV Antibodies in MS Patients Florian Deisenhammer, Michael Auer, Wegene Borena, Dorothee Holm-von Laer

P4.039 CD62L (L-selectin) Is Not

a Reliable Biomarker for Predicting Risk of Progressive Multifocal Leukoencephalopathy in Natalizumabtreated Multiple Sclerosis Patients Linda Lieberman, Wanyong Zeng, Tatiana Plavina, Carol Singh, Kevin Otipoby, Christine Loh, Leonid Gorelik, Ellen Cahir McFarland

in Multiple Sclerosis Patients in Italy. Report of the Italian Group for MS-PML Study Cinzia Cordioli, Nicola De Rossi, Simonetta Gerevini, Maria Pia Amato, Fabio Bandini, Paola Cavalla, Marco Capobianco, Luciano Deotto, Milena Alessandra De Riz, Ernesta Ferrari, Maria Letizia Fusco, Angelo Ghezzi, Luigi Maria Grimaldi, Alessandra Lugaresi, Lucia Moiola, Patrizia Susanna Mar Perrone, Luca Prosperini, Monica Rezzonico, Marco Rovaris, Giuseppe Salemi, Marco Salvetti, Claudio Solaro, Carla Tortorella, Ruggero Capra

P4.041

Recurrent Opticospinal Inflammatory Disease in Association to Ipilimumab Rana Zabad, Neil Jouvenat, Alissa Marr

P4.042 Swelling of the Outer Retinal

P4.043 The TIGIT/CD226/CD155

Axis Is Differentially Expressed in MS and Glioblastoma: Implications for Autoimmunity and Tumor Immune Escape Daniel Lowther, Sriram Ramanan, Danielle DeBartolo, Calvin Park, Xiangguo Duan, David Hafler, David Pitt

P4.044 Distinct MRI Patterns

Differentiate Multiple Sclerosis with Cavitary Lesions and Vanishing White Matter Disease Xavier Ayrignac, Nicolas Menjot de Champfleur, Sophie Menjot de Champfleur, Astrid Corlobe, Clarisse CarraDalliere, Pierre Labauge


P4.057 Neuropsychological Profile

of Patients with Immune Mediated Encephalopathy Marcos Fernandez Suarez, Ramiro Fernandez Castaño, Romina Tirigay, Daniel Politis, Raul Melano, Ricardo Allegri

P4.058 Characteristics of

Autoimmune Encephalitis at Two Teaching Hospitals Divyanshu Dubey, Anshudha Sawhney, Benjamin Greenberg, Worthy Warnack, Pravin Khemani, Steven Vernino

P4.047 Cartilage and the

Brain: Encephalitis in Relapsing Polychondritis Johanna Hamel, Andrew Goodman

Late Cerebellar Atrophy and Long-term Outcome in Anti-NMDA Receptor Encephalitis Takahiro Iizuka, Hidehiro Someko, Hiroki Oonuma, Atsuko Kubo, Masaaki Nakamura, Daisuke Ishima, Juntaro Kaneko, Eiji Kitamura, Ray Masuda, Josep Dalmau, Kazutoshi Nishiyama

P4.048 Plasmapheresis in

P4.060 Serum Antibodies Isolated

Corticosteroid-resistant Acute Disseminated Demyelination: Report of Two Adult Cases Shailee Shah, Sharon Stoll, Thomas Leist

P4.049 Ma2 Autoantibody-negative Multifocal Paraneoplastic Neurological Disorder Associated with Metastatic Testicular Cancer Jenny Linnoila, Vanda Lennon, Sean Pittock

P4.050 Hereditary Diffuse

P4.051

Layers in Acute Optic Neuritis Rhian Raftopoulos, Chieh-Li Chen, Simon Hickman, Ahmed Toosy, Claudia WheelerKingshott, Daniel Altmann, Shahrukh Mallik, David Paling, Marios Yiannakas, Klaus Schmierer, Rose Sheridan, Basil Sharrack, Gavin Giovannoni, Laura Balcer, David Miller, Hiroshi Ishikawa, Raju Kapoor

P4.034 Natalizumab-related PML

in the ICU: Serological Spectrum, Clinical Courses, Complications, and Outcomes Andrew McKeon, Manoj Mittal, Sara Hocker, Sean Pittock, Eelco Wijdicks, Alejandro Rabinstein

P4.040 Differential Diagnosis of

P4.032 Optimizing the Natalizumab

of Progressive Multifocal Leukoencephalopathy in a Natalizumabtreated Patient Stefania De Mercanti, Carlo Alberto Artusi, Marinella Clerico, Marco Iudicello, Alessandro Vacca, Eleonora Virgilio, Luca Durelli

P4.046 Autoimmune Encephalitis

Leukoencephalopathy with Spheroids: A Volumetric Comparison with Multiple Sclerosis and Healthy Controls Tobias Granberg, Oluf Andersen, Cristina Sundal, Virginija Danylaité Karrenbauer

Transverse Myelitis: Retrospective Cohort Study in Argentina Alejandro Köhler, Francisco Varela, Lucas Alessandro, Ismael Calandri, Mauricio Farez, Jorge Correale

P4.033 Atypical Presentation

Features of Limbic Form of Hashimoto’s Encephalopathy Toru Kishitani, Akiko Matsunaga, Masamichi Ikawa, Tomomi Kame, Osamu Yamamura, Tadanori Hamano, Osamu Watanabe, Keiko Tanaka, Yasunari Nakamoto, Makoto Yoneda

MS and CNS Inflammatory Diseases: CNS Inflammatory Diseases and Differential Diagnosis

Index Differentiates Risk of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-treated Multiple Sclerosis (MS) Patients with No Prior Immunosuppressant (IS) Use: An Updated Analysis Geoffrey Kuesters, Tatiana Plavina, Sophia Lee, Denise Campagnolo, Sandra Richman, Shibeshih Belachew, Meena Subramanyam Dose Interval to Reduce PML Risk— Lessons from the Pharmacokinetics of Therapy Discontinuation John Foley, Ryan Metzger, Tamara Hoyt, Angelene Christensen

P4.045 Clinical and Immunological

Combined Therapy with Infliximab and Methotrexate in a Case of Neurosarcoidosis with Chiasmatic Involvement at Onset Begoa Palazon, Rocio Hernandez Clares, Ester Carreon Guarnizo, Maria Cerdan, Judith Jimenez Veiga, Gema Salgado, Javier Martin, Jose Meca La Llana

P4.052 Auricular Polychondritis

Presenting as Non-infectious, Non-paraneoplastic Limbic Encephalitis Scheherazade Le, James Ho, Rowza Rumma

P4.053 Acute Evidence of

CNS Inflammation in Patients with Mitochondrial Diseases Yael Hacohen, Sona Narula, Amy Waldman, Sarah Hopkins, James Brenton, Amit Bar-Or, Angela Vincent, Brenda Banwell

P4.054 ALD Connect: A

Patient Powered Research Network Harmonizes Efforts to Cure Adrenoleukodystrophy Keith Van Haren, Florian Eichler, Ben Lenail, Ali Fatemi, Kathleen Zackowski, Gerald Raymond, Amber Salzman, Inna Tsvang, Joshua Bonkowsky, Robert Brown, John Fink, Kathleen O'Sullivan-Fortin, Rachel Salzman, Alexander Sherman

P4.055 Unusual Association of Acute

Motor and Sensory Axonal Polyneuropathy (AMSAN) with EBV in the Absence of a Preceding Illness: A Case Report Abdalla Hassan, Prajwal Boddu, Azmatullah Hussaini, Raina Gupta

P4.056 A Case Report of Rheumatoid

Meningitis, an Unusual Complication of Rheumatoid Arthritis Bhaskar Roy, Justine Brink, Ekaterina Bakradze, Fatmah Al Zahmi, Dean Uphoff, Isaac Silverman

P4.059

from Neuro-Behcet’s Disease Patients Mediate Neuronal Death and Cognitive Impairment Erdem Tuzun, Ece Erdag, Ceren Sahin, Cem Kucukali, Mehmet Kaya, Murat Kurtuncu, Recai Turkoglu, Feyza Aricioglu

P4.061

Screen for Novel Antiastrocytic Antibodies in Patients with Autoimmune and Paraneoplastic Encephalitis Kyong Shin, Melina Jones, Michael Levy

P4.062 A Rare Presentation of Neuro-

Behcet's Disease (NBD) David Harris, Syed Omar Shah, Jacqueline Urtecho, Rodney Bell

P4.063 Single Cell PCR Analysis of

the Intrathecal Plasma Cell Repertoire in Autoimmune Encephalitis Manish Malviya, Nico Melzer, Christian Elger, Heinz Wiendl, Hans Hartung, Norbert Goebels

P4.064 Acute Bulbar Palsy as

Presentation of Anti-NMDA Receptor Encephalitis: A Case Report Takahiro Iizuka, Masaaki Nakamura, Daisuke Ishima, Juntaro Kaneko, Josep Dalmau, Kazutoshi Nishiyama

P4.065 Patient with Established,

Seropositive Neuromyelitis Optica Presenting in Status Epilepticus Due to NMDA Receptor Antibodies Ashutosh Kumar, Victor Sung, John Rinker, William Meador

P4.066 Successful Treatment of NMDA Receptor Antibody Associated Encephalitis Using Intrathecal Methotrexate Chengwei Peng, Siddharama Pawate

P4.067

CNS Demyelination During Anti TNF-alpha Therapy Kristine Dahl, Jette Lautrup Frederiksen Battisti

P4.068 TNF-alpha Inhibitor

Associated Myelopathies: A Neurological Complication in Patients with Rheumatologic Disorders Paula Barreras, Maureen Mealy, Carlos Pardo-Villamizar

P4.069 Distinguishing Slow

Flow Spinal Arteriovenous Fistulas from Idiopathic Transverse Myelitis: A Retrospective Study of 94 Patients Jasmine Dudankar, James Chen, Maureen Mealy, Phillipe Gailloud, Carlos Pardo-Villamizar, Michael Levy

P4.070

Acute HIV Infection in a Child Presenting with Transverse Myelitis and Subsequent Neuromyelitis Optica Diagnosis Amanda Moen, Daniel Olson, Mark Abzug, Jeffrey Bennett, Teri Schreiner

89

Wednesday April 22

7:30 a.m.–12:00 p.m.

Poster Session IV P4.071

7:30 a.m.–12:00 p.m.

Prevalence of Optical Coherence Tomography (OCT) Abnormalities in a Cohort of HLTV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Patients Nathan Tagg, Sonya Bakshi, Winston Liu, Emily Leibovitch, Govind Nair, Joan Ohayon, Daniel Reich, Steven Jacobson, Irene Cortese

P4.082 Pre-symptomatic Detection of

P4.072

P4.083 Role of ATP-binding Cassette

Diagnostic and Therapeutic Management of Non-traumatic Acute Myelopathy Based on Clinical Experience with 66 Cases Begoa Palazon, Ester Carreon Guarnizo, Rocio Hernandez Clares, Gema Salgado, Judith Jimenez Veiga, Javier Martin, Jose Meca La Llana

P4.073 Myelitis. Clinical and

Radiological Differences Between Multiple Sclerosis and Other Etiologies Silvia Presas, Laia Grau-Lopez, Jose Vicente Hervas, Anna Massuet-Vilamajo, Cristina Ramo

P4.074

Extra-pontine Lesions of CLIPPERS (Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids) Hiroaki Sekiya, Kenji Sekiguchi, Hisatomo Kowa, Yukiko Morinaga, Tomoo Itoh, Fumio Kanda, Tatsushi Toda

P4.075

A Case of Duane Syndrome, Developmental Venous Anomalies, Hydrocephalus, and Multiple Sclerosis: Possible Link or Just a Coincidence? Ahmed Obeidat, Aram Zabeti

P4.076

How Often Is CADASIL Diagnosed as Multiple Sclerosis? Swati Sathe, Edward Nunziato

Aging, Dementia, Cognitive, and Behavioral Neurology: Basic and Pre-clinical Studies P4.077 Evaluations of the Effect of

Subchronic Administration of Crude Khat Extract (Catha Edulis F.) on Learning and Memory in Mice Mohammed Faiz, Ephrem Engidawork, Teshome Nedi

P4.078

Selective Reduction of Oxidative Stress Markers in the SAMP8 Mouse Brain by a Distinct Spearmint Extract with Antioxidant Properties Susan Farr, Brenda Fonseca, Kelli Herrlinger, Kristin Nieman, Michael Ceddia, Linda Fullmer, Michael Niehoff, Brandon Lewis, Andrew Welleford, D Butterfield, John Morley

P4.079

Adolescent Exposure of Genetic Mutant Mice to Cannabis Produces Cognitive Deficits Bagrat Abazyan, Sofya Abazyan, Olga Mychko, Alexey Shevelkin, Chunxia Yang, Atsushi Kamiya, Mikhail Pletnikov

P4.080 The Interactive Effects of

Ketamine and Magnesium on Brainderived Neurotrophic Factor (BDNF) and Depressive-like Behavior Sara Razmjou, Darcy Litteljohn, Shawn Hayley

P4.081 In Vivo Drug Discovery

for Tauopathy Using Novel Zebrafish Models Edward Burton, Qing Bai

90

Cytoplasmic TDP-43 Accumulation Using Tissue-engineered Skin Model Derived from C9ORF72-FALS Patients Nicolas Dupre, Bastien Paré, Lydia TouzelDeschênes, Peter Gould, Stephan Saikali, Jean-Pierre Bouchard, Patrick Dion, François Berthod, Guy Rouleau, Francois Gros-Louis Transporters in Efflux of Amyloid-ß at the Human Blood-brain Barrier Yasuteru Sano, Masaaki Abe, Hideaki Nishihara, Yukio Takeshita, Takashi Kanda

P4.084 PACAP Deficit and Cognitive

Function in Mild Cognitive Impairment and Alzheimer Dementia Pengcheng Han, Richard Caselli, Leslie Baxter, Geidy Serrano, Thomas Beach, Eric Reiman, Jiong Shi

Aging, Dementia, Cognitive, and Behavioral Neurology: Prognosis and Longitudinal Course of Dementia P4.085 Neuroimaging-based Staging of Pathological Spread in Patients with Known Tau Pathology Corey McMillan, David Irwin, Laura Baehr, Kylie Ternes, Christopher Olm, Vivianna Van Deerlin, Virginia Lee, John Trojanowski, Murray Grossman

P4.086 A Multi-center Cross-

validation of FDG- and Amyloid-PET as in Vivo Biomarkers for the Prediction of MCI Progression Leonardo Iaccarino, Konstantinos Chiotis, Pierpaolo Alongi, Chiara Cerami, Alessandra Marcone, Valentino Bettinardi, Sandro Iannaccone, Stefano Cappa, Agneta Nordberg, Daniela Perani

P4.087 Prognostic Significant

of Subtypes of MCI for Dementia and Mortality: Data from the NEDICES Cohort Alvaro Sanchez-Ferro, Felix Bermejo-Pareja, Israel Contador, Rocio Trincado, David Lora, Alex Mitchell, Jesús Hernández-Gallego, Sara Llamas, Alberto Villarejo Galende, Julian Benito-Leon

P4.088 Self-administered

Gerocognitive Examination (SAGE) Score Changes over Time in Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI), Dementia Converters, and Alzheimer’s Disease (AD) Patients Douglas Scharre, Shu-Ing Chang, Haikady Nagaraja, Maria Kataki, Natalie Wheeler, Anahita Adeli

P4.089 Hippocampal Volume as a

Biomarker for Enrichment in Clinical Trials in Amnestic Mild Cognitive Impairment: A Comparison of Performance Characteristics in ADNI-1 and AddNeuroMed Gerald Novak, Andy Simmons, Eric Westman, Patricia Cole, Mark Gordon, Enchi Liu, Simon Lovestone, Diane Stephenson

P4.090 Grey Matter and White

Matter MRI Markers of Cognitive Progression in Early and Late Onset Variants of Alzheimer’s Disease Federica Agosta, Francesca Caso, Daniele Mattavelli, Massimiliano Copetti, Giuseppe Magnani, Elisa Canu, Alessandra Marcone, Monica Falautano, Giancarlo Comi, Andrea Falini, Massimo Filippi

P4.091 Brain Structural Correlates of

Trajectories to Cognitive Impairment in the Cardiovascular Health Study—Cognition Study James Becker, Mikhail Popov, Fabrizio Lecci, H. Gach, Brian Junker, Lewis Kuller, Oscar Lopez

P4.092 Empirically Defining

Trajectories of Late-life Cognitive and Functional Decline and Classifying Potential Trajectory Class Membership Helen Hochstetler, Paula Trzepacz, Shufang Wang, Peng Yu, Michael Case, JeannieMarie Leoutsakos, David Henley, Elisabeth Degenhardt, Constantine Lyketsos

P4.093 Combining Novel Verbal

Fluency Scores and Structural MRI for Prognosis of MCI David Clark, Ellen Woo, Kristy Hwang, Sona Babakchanian, Jennifer Eastman, Leslie Ramirez, Liana Apostolova

P4.094 Predictors of Convertion

from CDR 0,5 to CDR 1 Using a Mutimodal Assesment in a Latin American Population. A Study of ADNI-ARG Ricardo Allegri, Marcos Fernandez Suarez, Federico Nahas, Fernando Ventrice, Maria Russo, Ezequiel Surace, Maria Clarens, Maria Martin, Fernanda Tapajoz, Paula Harris, Patricio Chrem Mendez, Ramon Leiguarda, Carlos Romero, Silvia Vazquez, Gustavo Sevlever

P4.095 Longitudinal Assessment of

Frontal Cognitive Impairment in Patients with Motor Neuron Disease Pilar Maria Ferraro, Federica Agosta, Edoardo Spinelli, Elisa Canu, Nilo Riva, Massimiliano Copetti, Andrea Falini, Giancarlo Comi, Massimo Filippi

Aging, Dementia, Cognitive, and Behavioral Neurology: Rapidly Progressive and Inflammatory Dementias P4.096 Rapidly Progressive Dementia

P4.102

Reversible Amyloid CSF Biomarker in Immune Mediated Encephalopathy Marcos Fernandez Suarez, Ezequiel Surace, Miguel Riudavets, Silvia Vazquez, Gustavo Sevlever, Ricardo Allegri

P4.103

Characterization of the First American Case of Familial Prion Disease Due to the PRNP-G114V Mutation Fadi Mikhail, Crystal Busch, Eric Norstrom, Peter Pytel, Pierluigi Gambetti, James Mastrianni

P4.104

Limbic Encephalitis Exacerbations and Remissions Charted by Microglial PET Scan: A Case Study Rhonna Shatz, Harry Chugani

Neuromuscular Disease: Basic Science P4.105

Aging-associated Motor Axon Nav1.8 Channelopathy in Mice Christian Krarup, Mette Rosberg, Susana Herrero, Dennis Klein, Rudolf Martini, Mihai Moldovan

P4.106

Epidermal Innervation of the Rat Footpad and Correlation with Pain Behavior Following Partial Sciatic Nerve Injury Joost Jongen, Malik Bechakra, Barthold Schuttenhelm, Tiziana Pederzani

P4.107

Neuroprotective Effects of Laquinimod in Lewis Rat Experimental Autoimmune Neuritis Kalliopi Pitarokoili, Björn Ambrosius, Lisa Schrewe, Liat Hayardeny Nisimov, Michael Hayden, Ralf Gold

P4.108 Immunohistochemical

Analysis of ErbB4, a Causative Gene Product for ALS19, in the Spinal Cord of Sporadic ALS Patients Yuji Takahashi, Ayako Shioya, Chihiro Matsumoto, Terunori Sano, Shigeo Murayama, Miho Murata, Yuko Saito

and Brain Atrophy Caused by Primary Central Nervous System Extranodal NK/Tcell Lymphoma, Nasal Type Yoshimitsu Shimatani, Ryosuke Miyamoto, Shigeo Murayama, Yuishin Izumi, Oki Ryosuke, Ryuji Kaji

P4.109

P4.097 Use of the RBANS and NPI-Q

P4.110

in Autoimmune Encephalopathy Brendan Kelley, Robin Bratt

P4.098 A Genetic Form of Creutzfeldt Jakob Disease: A Case Report Tereza Svrcinova, Jan Mares, Zuzana Mouchova, Petr Kanovsky

P4.099 Thiamine Depletion in

Sugar Catabolism: Yet Another Cause of Wernicke-Korsakoff Syndrome Michael Lane, Sanjay Anandaram, Elijah Stommel

P4.100

Genetic Prion Disease Caused by a Q160X PRNP Mutation Presenting with an Orbitofrontal Syndrome Julio Rojas, Jamie Fong, Giovanni Coppola, Andrea Legati, Anna Karydas, Katherine Rankin, Jee Bang, Zachary Miller, Michael Geschwind

P4.101

Protean Manifestations of IgG Encephalopathy. A Potentially Reversible Cause of Rapidly Declining Mental Status? Roomana Ahad, Govind Pandompatam, Iftekhar Ahmed

Identification of Widespread Alterations in RNA Metabolism in Sporadic Inclusion-body Myositis Using SILACbased Quantitative Proteomics Maximilian Berger, Tobias Opialla, Andreas Marg, Stefan Kempa, Simone Spuler Identification of Splicing Changes in the Blood and Muscle in Congenital Myotonic Dystrophy Nicholas Johnson, Russell Butterfield, Katie Mayne, Diane Dunn, Stefan Pulst, Robert Weiss

P4.111

Identification of High Glucose Induced Cell Signaling Human in Schwann Cells Zhao Zhong Chong, Hongxin Chen, Tong Liu, Hong Li, Nizar Souayah

P4.112

Neuregulin 1 Type III Overexpression Alters Neuromuscular Junctions (NMJ) and Myelin Thickness in the Heterozygous R98C Knock-in Mouse Model of CMT1B Yunhong Bai, Chiara Pisciotta, Suola Wang, Xingyao Wu, Markus H Schwab, Klaus Armin Nave, Michael Shy

P4.113 The Effect of Hyperglycemia on Human Schwann Cells Hongxin Chen, Howard Sander, Nizar Souayah P4.114

Multiparametric Recordings of the Nerve Action Potential Mark Stecker, Melanie Wegener


Poster Session IV

Neuromuscular Disease: Health Services and Outcome Measures

Development and Validation of the Chronic Acquired Polyneuropathy- Patient Reported Index (CAP-PRI) to Measure Quality of Life in Patients with Chronic Immune-mediated Polyneuropathies Kelly Gwathmey, Vera Bril, Carolina Barnett, Eduardo Ng, Thomas Brannagan, Michael Hehir, William David, Karissa Gable, Jennifer Dineen, Jeff Guptill, Lisa Hobson-Webb, Reza Sadjadi, Mark Conaway, Amruta Joshi, Ted Burns

P4.133

Effects of Automed Sputum ALS: Health Services and Aspirating Device for the Patients with Congenital Muscular Dystrophy Using TPPV Outcomes Measures Takayasu Fukudome, Hidenori Matsuo P4.125 Caregiver Burden Does Not P4.117 Incentivizing Clinical Registry Affect Patient Survival in Amyotrophic Participation—Findings from the Muscular Lateral Sclerosis; Investigating Factors Dystrophy Association U.S. Neuromuscular Contributing to Burden Tom Burke, Marwa Disease Registry Jodi Wolff, Valerie Cwik Elamin, Miriam Galvin, Orla Hardiman, Niall Pender P4.118 Patient Reported Quality of Life Measures in Limb-girdle Muscular P4.126 Quality Measure-driven Dystrophy: Correlation with Clinical Interdisciplinary Template for Care of Outcomes Tina Duong, Carolina Tesi Veterans with ALS Ileana Howard, Eilis Rocha, Heather Gordish-Dressman, Lauren Bodreau, Richard Bedlack Morgenroth, Robert Leshner, Susan Sparks P4.127 Feasibility Study of the P4.119 Development and Preliminary Use of Telemedicine in the Care of ALS Validation of a New Impairment Measure Patients Michael Pulley, Alan Berger, for Myasthenia Gravis Carolina Barnett Wayne Hodges, Rebecca Brittain Tapia, Vera Bril, Moira Kapral, Abhaya Kulkarni, Aileen Davis

P4.135

P4.115

Trends in Outcome and Hospitalization Charges of Infantile Botulism in the United States: A Comparative Analysis Between Kids' Inpatient Database (KID) and National Inpatient Sample (NIS) Ankit Pahwa, Tamara Opila, Mohammad El-Ghanem, Nizar Souayah

P4.124

P4.116

Have a Voice in Your Academy Attend the AAN Business Meeting at 8:00 a.m. on Monday, April 20, during the 2015 AAN Annual Meeting in Washington, DC, to make your voice heard on matters of importance to you, and cast your vote for the 2015 AAN Board of Directors. Learn more about the nominees at AAN.com/view/BoardSlate .

P4.121

A Description of Pain in Amyotrophic Lateral Sclerosis Helen Stephens, Susan Walsh, Divisha Raheja, Zachary Simmons

P4.120

The Effect of Gender and Bimodal Age Distribution on Hospitalization Charges and Outcomes for Myasthenia Gravis Patients Treated with Intravenous Immunoglobulin Compared to Plasmapheresis Tamara Opila, Howard Sander, Nizar Souayah

P4.122

Diaphragm Ultrasound: A Potential Outcome Measure in Amyotrophic Lateral Sclerosis Karen Karwa, Angela Malek, David Stickler

P4.123

The Reliability of Patient Reported Outcome Measures (PROMs) for Inflammatory Myopathies Obtained in the Home Infusion Care Model Gretchen Ayer, Lisa Christopher-Stine, Shafeeq Ladha, Tahseen Mozaffar, Yuen So, Nicholas Silvestri

P4.128

Utility of Screening for Monoclonal Gammopathy in ALS Tara Quesnell, Mazen Dimachkie, Mamatha Pasnoor, Richard Barohn, Laura Herbelin, Arthur Dick, Yunxia Wang, Melanie Glenn, Omar Jawdat, April McVey, Jeffrey Statland

P4.129

A Corticospinal Tract Model to Explain Clinical Deficits in ALS Rahul Remanan, Janki Panchal, Vahid Tohidi, Lindsay Kaplan, Shara Holzberg, Mona Shahbazi, Dale Lange

P4.130

The NIH C9ORF72 ALSFTD Study: Correlation of Clinical and Physiological Measures Mary Kay Floeter, Laura Braun, Devin Bageac, Bryan Traynor, Tanya Lehky, Olivia Schanz

P4.131

How Common Are "ALS Reversals?" Richard Bedlack, Timothy Vaughan, Paul Wicks, James Heywood, Ervin Sinani, Roger Selsov, Eric Macklin, Alexander Sherman

P4.132

Evaluating Clinical Staging for ALS Saugat Dey, Guillermo Alexander, Terry Heiman-Patterson


Models of ALS Disease Onset and Progression: Insights from the Pre-fALS Study Michael Benatar, Robert Carlile, Eliana Reyes, Sumaira Hussain, Natasha Garcia, Peter Andersen, Christine Stanislaw, Joanne Wuu

P4.134

The ALSUntangled Table of Evidence Richard Bedlack

Neuroepidemiology: ALS Prospective Incidence of ALS in a Canadian Population Natalie Parks, Timothy Benstead, Ian Grant

P4.136

Potential Risk Factors Among Adults with Amyotrophic Lateral Sclerosis (ALS) Leah Bryan, Paul Mehta, Vinicius Antao, Wendy Kaye, Marchelle Sanchez, Oleg Muravov, D. Kevin Horton

P4.137

Case-control Assessment of Potential Familial and Environmental Risk Factors for Amyotrophic Lateral Sclerosis in Minnesota Caitlin Harper, Eric Sorenson

P4.138

Association of Amyotrophic Lateral Sclerosis (ALS) with Solvent and Chemical Exposure During Military Deployment John Beard, David Umbach, Kelli Allen, Jean Keller, Dale Sandler, Silke Schmidt, Lawrence Engel, Freya Kamel

P4.139

Social Deprivation and Population Density Are Not Associated with Areal Risk of Amyotrophic Lateral Sclerosis James Rooney, Mark Heverin, Alice Vajda, Katy Tobin, Arlene Crampsie, Anthony Staines, Orla Hardiman

P4.140

Cardiovascular Disease and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-based Study Marianthi-Anna Kioumourtzoglou, Ryan Seals, Ole Gredal, Johnni Hansen, Marc Weisskopf

P4.141

Diabetes, Obesity and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-based Study Marianthi-Anna Kioumourtzoglou, Ran Rotem, Ryan Seals, Ole Gredal, Johnni Hansen, Marc Weisskopf

P4.142

Possible Environmental Causes of Amyotrophic Lateral Sclerosis in Northern New England: A Preliminary Analysis Tracie Caller, Patricia Henegan, Angeline Andrew, Elijah Stommel

P4.143

Ethnic Differences in the Phenotype and Outcome of Amyotrophic Lateral Sclerosis: A Meta-analysis of Population-based Studies Benoit Marin, Giancarlo Logroscino, Farid Boumediene, Anais Labrunie, Marie Claude Babron, Anne-Louise Leutenegger, Pierre-Marie Preux, Ettore Beghi

P4.144

Amyotrophic Lateral Sclerosis (ALS) with Laboratory Abnormalities of Unknown Significance (LAUS)—Where Does It Begin and Where Does It End? Benjamin Brooks, Elena Bravver, Velma Langford, Mohamed Alwan, Nicole Smith, Nicole Lucas, Mindy Nichols, Sharon Belcher, Cynthia Lary, Joanne Nemeth, Priscilla Russo, Kathryn Wright, Amber Ward, Scott Holsten, Michael Fischer, William Bockenek, Urvi Desai, Scott C Lindblom, Thomas Pacicco, Mohammed Sanjak

Neuroepidemiology: Movement Disorders, ALS, and Neuromuscular P4.145

Familial, Autosomal-dominant Neurodegenerative Parkinsonism with Cognitive Deterioration Spanning Five Generations in a Genetically Isolated Population of South-eastern Moravia, Czech Republic Katerina Mensikova, Marek Godava, Petr Kanovsky, Pavel Otruba, Michaela Kaiserova, Miroslav Vastik, Lenka Mikulicova, Tereza Bartonikova, Radek Vrtel, Radek Vodicka, Sandra Kurcova, Petr Jugas, Josef Ovecka, Ludmila Sachova, Frantisek Dvorsky

P4.146

Estimating the Proportion of Essential Tremor and Parkinson’s Disease Patients Referred for Deep Brain Stimulation: Five-year Data from Columbia University Medical Center (20092014) Meir Kestenbaum, Elan Louis

P4.147

What Factors Are Associated with Racial Differences in Mild Parkinsonian Signs? Chinwe Nwadiogbu, Nabila Dahodwala, Whitney Fitts, Helen Partridge, Jason Karlawish

P4.148

Diabetes Severity Is Associated with Worse Parkinsonism Nabila Dahodwala, Doria Gold, Chinwe Nwadiogbu, Whitney Fitts, Jason Karlawish

P4.149

Antiparkinson Drug Use in Response to Practice Parameter Publication, Drug Availability, and ‘Unofficial’ Prescribing Forces James Crispo, Yannick Fortin, Lise Bjerre, Dafna Kohen, Donald Mattison, Santiago PerezLloret, Matthew Emons, Allison Willis, Daniel Krewski

P4.150

Recruiting Patients for Research, Clinical Trials, and Epidemiological Studies Using the National Amyotrophic Lateral Sclerosis (ALS) Registry Paul Mehta, Vinicius Antao, D. Kevin Horton

P4.151

Ethnic Differences in the Incidence of Amyotrophic Lateral Sclerosis: A Meta-analysis of Population-based Studies Benoit Marin, Boumediene Farid, Giancarlo Logroscino, Babron Marie Claude, Leutenegger Anne Louise, Pierre-Marie Preux, Ettore Beghi

P4.152

Evaluation of the Application of the European Guidelines for Diagnosis and Clinical Care of Amyotrophic Lateral Sclerosis Philippe Couratier, Ettore Beghi, Christophe Vial, Emilien Bernard, Geraldine Lautrette, Pierre Clavelou, Nathalie Guy Renouil, Gwendal Lemasson, Emmanuel Rousso, Sabrina Debruxelles, Pascal Cintas, Marie Christine Arne Bes, Jean-Christophe Antoine, Jean-Phillippe Camdessanche, Rudelle Candice, Marie Nicol, Giancarlo Logroscino, Pierre-Marie Preux, Benoit Marin

P4.153

Transglutaminase 6 Antibodies in the Serum of Patients with Amyotrophic Lateral Sclerosis Vivian Drory, Avi Gadoth, Margolit Bleiberg, Tirza Klein, Beatrice Nefussy

91

Wednesday April 22


Poster Session IV P4.154

Epidemiology of CharcotMarie-Tooth in Lebanon: Clinical, Genetic and Electrophysiological Correlation_ Pilot Study Rosette Jabbour, Salam Koussa, Valerie Delague, Andre Megarbane, Samir Atweh

Neurological Consequences of Medical Disease P4.155

Functional Network Connectivity in Comatose Survivors of Cardiac Arrest Yousef Hannawi, Haris Sair, Shanshan Li, Joshua Kornbluth, Audrey Vanhaudenhuyse, Steven Laureys, Russell Chabanne, Betty Jean, Habib Benali, Vincent Perlbarg, Charles-Edouard Luyt, Louis Puybasset, James Pekar, Brian Caffo, Robert Stevens

P4.156

Neuropathy After Gastric Bypass Surgery: A Review of 8 Cases Kewei Yu, Jindong Xu, Guangbin Xia

P4.157

Neurologic Complications After Abdominal Aortic Aneurysm Repair: A Comparison Between Endovascular and Open Procedure Mary Elizabeth Kovacik Eicher, Faisal Aziz, Milind Kothari

P4.158

Neurological Complications and Organ Rejection in Transplant. Is There a Connection? Maria Gonzalez Toledo, Analia Calle, Diego Nadile, Fatima Pagani Cassara, Agustina Tamargo, Alejandro Thomson, Alfredo Thomson

P4.159

The Man Who Stopped Speaking: An Unusual Presentation of an Osmotic Demyelination Syndrome in a Patient with Panhypopituitarism Shivika Chandra, Katherine Peicher, Shwetha Sudhakar, Jeena Varghese

P4.160

Inflammatory Polyneuropathy After Bariatric Surgery—Two Case Reports Joana Dias, Cecilia Vidal, Raquel Silveira, Marcos De Freitas

P4.161

Repeated Exposure to Hypobaria in U2 Pilots Is Associated with Reduced Aggregate Cortical Thickness Daniel Simmons, Andrew Bursaw, Paul Sherman, Peter Kochunov, Stephen McGuire

P4.162

Dysphagia Secondary to Diffuse Idiopathic Skeletal Hyperostosis Aradhana Mehta, Nidhi Mehta

P4.163

Horizontal Gaze Palsy and Progressive Scoliosis (HGPPS); Case Report Fatmah Alzahmi

P4.164

Intravascular Lymphoma Masquerading as Neuromyelitis Optica Spectrum Disorder: An Atypical Presentation Christina Hupman, Carlos Singer

7:30 a.m.–12:00 p.m.

P4.166

Neural Correlates of Residual Brain Activity in PVS Patients by Means of P300 Paradigm Using the Subject’s Own Name Ana Olivares Torres, Jorge Iglesias Fuster, Elena Cuspineda Bravo, Javier Sanchez Lopez, Cecilia Perez Gesen, Daymara del Río Bazan, Carlos Beltran Leon, Calixto Machado Curbelo

P4.167

Comparisons of Ultrasonographic Measurements Between Patients with and Without Carpal Tunnel Syndrome Jung Bin Shin, Seong Woo Kim, Hyoung Seop Kim, Ha Ra Jeon

P4.168

Pattern of Tongue Weakness and Subjective Speech and Swallowing Deficits in Unilateral Hypoglossal Nerve Palsy: Case Series of 8 Patients Yeyao Joe Yu, Pierre Bourque

P4.169

Isolated Hypoglossal Nerve Palsy as Initial Presentation of Pancreatic Cancer Nabil Khandker, Nimalya Ganeshalingam, Scott Vota, Claudia Testa

P4.170

Modified Clinical Examination of Hypoglossal Nerve Sankar Bandyopadhyay

P4.171

EEG Patterns as Predictors of Outcome in Patients with Vegetative State and Minimally Conscious State Tinatin Kherkheulidze, Maia Beridze, Maka Khaburdzania

P4.172

Faciobrachial Dystonic Seizures in a Patient Without Limbic Encephalitis Yuri Bronstein, Mitchell Danesh, Marko Petrovic, Nazely Ashikian, Robert Arbuckle

P4.173

Clinical Manifestations of Neurobrucellosis: The Importance of Diagnosis at Early Stages Greta Sahakyan

Discrepant Clinical Signs Among Patients with Organic Neurological Disease—Prospective Study Orwa Aboud, Ayman Al-salaimeh, Kinshuk Sahaya, Archana Hinduja

P4.181

Redefining True Leukocytosis in the Traumatic Lumbar Puncture Rizvi Syed, Mohsen Ghafarian, Farzad Moien Afshari

P4.182

Diagnostic Yield and Clinical Impact of Brain Biopsy for Cryptogenic Neurological Disease: A Systematic Review and Meta-analysis of 831 Cases Harrison Bai, Yingjie Zou, Zhili Wang, Xin Zhao, Yanqiao Xiao, yiqun Jiang, Dongxu Chou, Yi Shu, Xiang Jun, Xiao Bo, Liming Tan, Yang Li

P4.183

Utilizing Additive Manufacturing in Medical Education of Neuropathology: A Feasibility Study Korak Sarkar, Gustavo Alvarez-Suchini, Puneet Ralhan, David Ripley, John Welin

P4.184

Inter-rater Reliability of Automated Pupillometer Assessments Weidan Zhao, DaiWai Olson, Sonja Stutzman, Ciji Saju, Margaret Wilson, Venkatesh Aiyagari

P4.185

New Windows into the Brain: Technological Advances in Detecting and Treating Neurological Disorders Julian Bailes

Research Methodology and Education P4.186

Comprehensive Opportunities for Research and Teaching Experience (CORTEX): A Mentorship Program JoseRafael Zuzuarregui, Anna Hohler

P4.174

P4.187

Neurodiagnosis and Health Outcomes

P4.188

Gender-specific Differences in Adult Type I Chiari Malformation Morphometrics Paige Marty, Aintzane Urbizu, Alfons Macaya, Juan Sahuquillo, Maria Antonia Poca, Bryn Martin

P4.175

Application of Teleneurology to Outpatient Care in a Major Metropolitan Area Steven Schreiber, Christopher Lo

P4.176

A Neurohospitalist-staffed Discharge Clinic: Bridging and Shortening the Gap from Inpatient to Outpatient Neurology Care Maulik Shah, Vanja Douglas, Brian Scott, John Betjemann, S. Josephson

Neurodiagnostics

Prevalence of Unrecognized Depression in Patients Admitted in Medical and Surgical Departments of a Tertiary Care Hospital: A Comparative Analysis, Karachi, Pakistan Attiya Rahman, Adnan Aziz, Qaiser Jamal, Muhammad Siddiqui

P4.165

P4.178

Music and Motor-related Neuronal Activity During Deep Brain Stimulation Rebecca Achey, Darlene Lobel, Damir Janigro

P4.180

P4.177

An Inquiry of Brain Computer Interfaces for Home Usage Stylianos Avramidis, Mirjam Palosaari Eladhari, Theodoros Avramidis

Overcoming Framing Bias in Stroke Neurologists’ Assessments of the Minimally Clinically Important Difference for Novel Acute Ischemic Stroke Therapies Jessica Cranston, Brett Kaplan, Jeffrey Saver A Comprehensive Simulation Curriculum for Neurology Residents— Preparing for Future Challenges in Neurology Priyanka Sabharwal, Sami Saba, Demian Szyld, Barry Czeisler, Koto Ishida, Aaron Lord, Janet Rucker, Laura Balcer, Howard Sander, Steven Galetta

P4.189

The Impact of Care Integration in Patients with High Complexity, Low Frequency Neurologic Diagnoses on Outcomes, Costs, and Family Engagement David Urion, Jennifer McCrave, Richard Antonelli

P4.190

The TOS2 Study: An International Multi-centre Audit Assessing the Standard of Neurological Examination Jason Appleton, Andreea Ilinca, Arne Lindgren, Andreas Puschmann, Majed Habahbeh, Khurram Siddiqui, Rajith De Silva, Matthew Jones, Richard Butterworth, Mark Willmot, Tom Hayton, Michael Lunn, Peter Nightingale, David Nicholl

P4.191

Expert Clinical Reasoning Is Not Just Local But Hyperlocal—Insights into Context Specificity from a Multicentre Neurology Script Concordance Test Nigel Tan, Kevin Tan, Gominda Ponnamperuma, Sanchalika Acharyya, Derek Heng, Charmaine Manauis, Dong Haur Phua, Derek Soon

P4.192

Student Perceptions of a Selfregulated Learning Program in a Neurology Clerkship Douglas Larsen

P4.193

Impact of a Novel Videobased Curriculum for Teaching Clinical Reasoning in Neurology Roy Strowd, Rachel Marie Salas, Anthony Kwan, Charlene Gamaldo

P4.194

The Columbia Evidence Based Neurology Manual: A Step Towards Evidence Based Practice Christina Blum, Eliza Miller, Joshua Willey

P4.195 A Randomized-controlled Trial Comparing Efficacy and User Satisfaction of Audio Podcasts Versus a Traditional Lecture on Multiple Sclerosis in Family Medicine Resident Education Tyson Brust, Lara Cooke, Michael Yeung P4.196

Use of Drugs by Medical Students Before the Exams Paola Fontanetti, Fernanda Sá, Marcella Souza, Arnaldo Godoy

P4.197

Effective Learning Resources for a Neuroscience and Behavior Course for First Year Medical Students—Get Neurology out of the Textboxes Rainald Schmidt-Kastner

P4.198

Improving Patient Attendance in Neurology Outpatient Resident Clinic Mariam Wasim, Ravi Vakani, George Barrio

P4.199

Is Clinical Neurology Exposure Increasing in Medical Schools Throughout the United States? Jeffrey Kornitzer, Machteld Hillen, Caroline Hayes-Rosen, Andrea Hidalgo, Wenzhuan He

P4.200 Improving Neurology

Resident Satisfaction and ACGME Survey Parameters by Initiating Weekly Program Director Meetings Kelly Baldwin

P4.201 Medical Student Consumerism During Neurology Clerkship: Sentiment Comparison of Student Emails with Sample Admissions Essay Robert Fekete

P4.202 Clinical Research Continuum: Big Data FOR and FROM Clinical Trials Alexander Sherman

P4.203 Assessing Individual

Learning Styles in Neurology Residency Education Jeanie McGee

P4.204 How Well Do Neurology

Residents Recognize Neurological Illness? An Analysis of the Close the Loop Resident Clinical Acumen Assessment Project Rachel Brandstadter, Christine Hannigan, Sarah Zubkov, Stephen Krieger

P4.179

Characterizing Self-reported Mental and Physical Health Scores in an Ambulatory General Neurology Practice: Feasibility and Preliminary Results Lee Schwamm, Eli Schwamm, Lidia Maria Moura

92


Poster Session IV

P4.205 Automation of Clinical

Assessments via Machine Learning and Paired Comparisons Jonas Dorn, Marcus D'Souza, Peter Kontschieder, Cecily Morrison, Jessica Burggraaff, Christian Kamm, Prejaas Tewarie, Thomas Vogel, Abigail Sellen, Antonio Criminisi, Frank Dahlke, Bernard Uitdehaag, Ludwig Kappos, Peter Chin

P4.206 Are Informal “Sign-out

Rounds” Beneficial for 3rd Year Medical Students on the Neurology Clerkship? Erika Wexler, Ruth Schneider, Marina Rubin, Andrew Huffer, Wolfgang Muhlhofer, Agust Hilmarsson, Tobias Kulik, Clifford Meyers, Robert Thompson-Stone, Ralph Jozefowicz

P4.207 A Voluntary Stress-

management Workshop for Neurology Residents: Design, Implementation, and Impact Sarah Dolgonos, Kamil Detyniecki

P4.208 What Is Your EEG Number?

Resident Training and Competency Lynn Liu, Adam Juersivich, Thomas Wychowski

P4.209 Structure of Neuroscience Clerkships in Medical Schools and Matching in the Neurosciences Dara Albert, Rimas Lukas, James Brorson, Christina Amidei, Karan Dixit, Han Yin

Neuro-oncology: Quality of Life and Symptom Management P4.210

Placebo-controlled, Doubleblind, Randomized Pilot Study to Evaluate the Effects of Low-dose Naltrexone on Quality of Life and Fatigue in Newly Diagnosed High-grade Glioma Katherine Peters, Mary Affronti, Sarah Woodring, Eric Lipp, Patrick Healy, Frances McSherry, James Herndon, Charlene Flahiff, Elizabeth Miller, Maria Freeman, Janet Minchew, Ben Zalutsky, Bonnie Taylor, Susan Boulton, Dina Randazzo, Annick DesJardins, Gordana Vlahovic, Darell Bigner, Henry Friedman

P4.211

Acetazolamide for Treatment of Drop Attacks Due to Symptomatic Plateau Waves: A Case Report Surabhi Ranjan, David Schiff

P4.217

Awake Craniotomy— Utility, Seizures, After-discharges and Tolerance Gowri Lakshminarayan, Jaime Lopez

P4.218

Treatment of Brain Radiation Necrosis with Hyperbaric Oxygen: Report of 6 Cases Shivam Mittal, David Rowe, Mitchell Machtay, Syed Ali, Warren Selman, Andrew Sloan, Lisa Rogers

P4.219 Electroencephalography

Correlates of Intracranial Hypertension in 4 Patients with Leptomeningeal Metastases Carl Gold, Nicole Odom, Aya Haggiagi, Lauren Schaff, Yazmin Odia

Neuro-oncology: Rare Tumors P4.220 Predicting Death from

Ganglioglioma in Children: A Retrospective Series of 40 Patients at the Barrow Neurological Institute Glynnis Zieman, Christopher Dardis, Andrea Gomes, Adrienne Scheck, Jennifer Eschbacher, Stephen Coons, Lynn Ashby

P4.221 Chordoma Whole Genome Sequencing Thomas Cusack, Christopher Dardis

P4.222 Retrospective Analysis of

Chordoma Patients 1998-Present at the Barrow Neurologic Institute: Features and Findings Thomas Cusack, Christopher Dardis

P4.223 A Rare Case of Metastatic

Esthesioneuroblastoma Cynthia Armand, Mary Welch

P4.224 SRC Proto-oncogene Mutation Found in an Adult Atypical Teratoid/ Rhabdoid Tumor: A Case Report Kaye Sedarsky, Meryl Severson, Patrick Cooper, William Skinner, Patrick Malafronte, Brett Theeler

P4.225 Gliomatosis Cerebri

Masquerades as a Granulomatous Process Jamie Labuzetta, Asheen Rama, Brian Lemkuil, Navaz Karanjia

P4.226 Glioblastoma Multiforme

Neuro-oncology: Paraneoplastic Disorders P4.230 Unusual Case of Motor

Neuron Disease as a Paraneoplastic Process Clement Pillainayagam, Divya Mella, Jennifer Johnson, Karin Woodman

P4.231 An Unusual Cause of

Recurrent Ischemic Stroke: Trousseau’s Syndrome from Gastric Cancer Neville Jadeja, Jenny Johnson, Ainie Soetanto, Krishna Nalleballe, Lauren DeNiro, Irfan Qureshi, Jerome Graber

P4.232 Guillain-Barre Syndrome After Treatment with Dabrafenib for Metastatic Recurrent Melaloma Catherine Maurice, Butler Marcus, Warren Mason

P4.233 Treatment Responsive

GABA(B)-receptor Limbic Encephalitis Presenting as New Onset Super-refractory Status Epilepticus (NORSE) in a Deployed U.S. Soldier Jeffrey Hainsworth, Akira Shishido, Craig Carroll, Rebecca Fasano, Brett Theeler

P4.234 Progressive Peripheral

Neuropathy and Gait Ataxia as the Initial Manifestation of Breast Cancer Shira McMahan, Ramon Lugo, Nestor GalvezJimenez, Efrain Salgado, Dennys Reyes

P4.235 Paraneoplastic Syndrome

Masking as Peripheral Vertigo Joseph Nguyen, Robert Knipe, Divisha Raheja, Max Lowden

P4.236 CRMP-5 Antibody in Para-

neoplastic Optic Neuritis and Sensory Motor Neuropathy Associated with Small Cell Lung Cancer Ai Sumida, Hilary Glazer, Micheline McCarthy, Yolanda Reyes-Iglesias

P4.237 Anti-Ri Antibody Associated Paraneoplastic Brainstem and Cerebellar Dysfunction as the Presenting Sign of Small Cell Lung Carcinoma Yuanquan Yang, Helen Shum, Missak Haigentz, Eric Mariuma, Mark Suhrland, Sara Maleki, Nattasha Acevedo, Edwin Gulko, Jack Farinhas, Mary Welch

P4.212

Quality of Life in Adults with Gliomas: Literature Review Kateryna Kurako, Efrain Salgado

Masquerading as a Tumefactive Demyelinating Lesion: A Case Report Kunal Agrawal, Ted Rothstein, Mohamad Koubeissi

P4.238 A Rare Case of Primary

P4.213

P4.227 Peripheral Primitive

P4.239 Concomitant Opsoclonus

The Longitudinal Evaluation of Quality of Life in Patients with Newly Diagnosed Malignant Glioma Nancy Ann Oberheim Bush, Emelia Barani, Margaretta Page, Annette Molinaro, Nicholas Butowski, Susan Chang, Jennifer Clarke

P4.214

Safety of Posterior Fossa Parenchymal Biopsy Oliver Tobin

P4.215

Systemic Chemotherapy Decreases Resting Brain Glucose Metabolism Jorg Dietrich, Victor Gerbaudo, Alexander Zaitsev, Jon Hainer, Wendy Plesniak, Ron Kikinis, Laura Horky

P4.216

Successful Treatment of Intracranial Inflammatory Pseudotumor with Cyclophosphamide Tiffani Stroup, Adil Javed, Nancy Arndt, Rimas Lukas, Kourosh Rezania, Sean Polster

Neuroectodermal Tumor of the Central Nervous System / Extraosseous Ewing’s Sarcoma (pPNET): Analysis of a Series of Cases Lucas Alessandro, Lucia Pertierra, Ismael Calandri, Sebastian Cerrato, Bernadette Calabrese, Naomi Arakaki, Alejandro Muggeri, Blanca Diez, Gustavo Sevlever

P4.228 Primary Pineal Malignant

Melanoma Treated with Radiotherapy and Associated with Loss of BAP1: A Case Report Nattasha Acevedo-Ramirez, Jerome Graber, Patrick LaSala, Karen Weidenheim, Madhur Garg

P4.229 Biomarkers for Brain

Tumors—a Feasibility Study Using Mass Spectrometric Proteomic Analysis Yin Liu, Lawrence Sandberg, Clifford Herrmann, Ravi Raghavan


Mediastinal Seminoma (PMS) Associated with Anti-Hu Paraneoplastic Syndrome (PS) Faria Amjad, Carmelo Tornatore and Ataxia and Limbic Encephalitis Due to Dual Anti-Ri and Anti-Yo Positive Antibodies Jennifer Kim, Jennifer Lyons

Neuro-oncology: Basic Science P4.240 Loss of Foxp3+ Regulatory T Cell Function in Glioblastoma Daniel Lowther, Amanda Hernandez, Xiangguo Duan, Murat Gunel, David Hafler

P4.241

Identification of Novel Therapeutic Targets for Glioblastoma Stem Cells Sarah Young, Yanping Liang, Susan Murphy, Sujuan Guo, Zhi Sheng

P4.242 Neurotrophin Receptors TrkB and TrkC Promote Brain Tumor Initiating Cells Growth and Are Novel Targets for Glioma Therapy Rajappa Kenchappa

P4.243 The Association Between

Expression of Neurotrophic Factors in Peripheral Blood Mononuclear Cells and Cognitive Functions in Lung Cancer Patients Slawomir Michalak, Joanna Rybacka–Mossakowska, Joanna Gazdulska, Iwona Golda-Gocka, Wojciech Kozubski, Rodryg Ramlau

P4.244 In Vitro and in Vivo Effects of

Ionizing Radiation on Cell Cycle Progression and Self-renewal of Subventricular Zone Neural Precursors Hongxin Chen, Sonia De Toledo, Matthew Goodus, Edouard Azzam, Steve Levison, Nizar Souayah

P4.245 Soluble AXL: A Possible

Circulating Biomarker for Tumor Burden in Neurofibromatosis Type 1 Ming-Jen Lee, Gunnar Johansson, Po-Chun Peng, Po-Yuan Huang, Hsiung-Fei Chien, Kuo-Tai Hua, MinLiang Kuo, Chin-Tin Chen

P4.246 Control of VEGF Release

Via TGF-β Superfamily Members in Glioblastoma Katharina Seystahl, Isabel Tritschler, Emese Szabo, Dorothee Gramatzki, Ghazaleh Tabatabai, Michael Weller

P4.247

An Oncolytic Myxoma Virus Construct (M011L Knock-out) Induces Apoptosis and Is a Potent Proapoptotic Therapy in Both Human and Immunocompetent Murine Glioblastoma Cancer Stem Cells Models Alexandra Pisklakova

P4.248 Targeting Iron Homeostasis for the Treatment of Glioblastoma Multiforme John Leschke, Christopher Chitambar

P4.249 Late Activation of Human

Microglial Cells by High Dose Ionizing Radiation Nizar Souayah, Hongxin Chen, Sonia De Toledo, Edouard Azzam

Epilepsy/Clinical Neurophysiology (EEG): Basic Science and Pharmaceuticals P4.250 Decreased Epileptic Discharge of Pubertal CA1 Hippocampus Is Due to Increased Expression of α4βδ GABA-A Receptors Lisa Merlin, Lie Yang, Sheryl Smith

P4.251

Role of NOX2 in Seizure Susceptibility of Mice Following Systemic Inflammation Hung-Ming Wu, Wan-Yu Huang

P4.252 Characterization of the

Epilepsy Gene DEPDC5 in a Mouse Embryonic Stem Cell Model Massimo Pandolfo, Chantal Depondt, Angélique Arts, Simona Donatello

P4.253 Compound Heterozygosity

of Two MECP2 Deletions with Paternal Inheritance of a Late-truncating Mutation in a Female with Atypical Rett Syndrome Amanda Lindy, Melissa Rumple, Melanie Morrow, Anita Shanmugham, Tamara Zach, Dianalee McKnight

P4.254 Computer Simulation to Test the Concept of Dose Forgiveness in the Era of Extended-release (XR) Drugs Scott Brittain

93

Wednesday April 22


Poster Session IV P4.255 Assessment of

the Anticonvulsant Effects and Tolerability Profile of Cannabidiol: GW Pharmaceuticals’ Preclinical Program Nicholas Jones, Andrew Hill, Thomas Hill, Isabelle Peres, Rebecca Hadid, Stephen Wright, Gary Stephens, Claire Williams, Benjamin Whalley

P4.256 Impact of Inhaled Marijuana on CEEG Spike Count in a 33-year-old Man with Idiopathic Epilepsy: A Case Report Hannah Park, Julie Roth

P4.257 Pharmacokinetic Evaluations of Oral and Intravenous Carbamazepine Using a Model-based Approach Dwain Tolbert, William Ravis, Aziz Karim

P4.258 Population Pharmacokinetic

(PK) Evaluation and Missed Dose Simulations for Eslicarbazepine Acetate (ESL) Monotherapy Soujanya Sunkaraneni, Luann Phillips, Vaishali Chudasama, Elizabeth Ludwig, David Blum, Jill FiedlerKelly

P4.259 Clobazam Drug-drug

Interactions: A Mechanism-based Characterization Using a Model-based Approach Dwain Tolbert, Ihor Bekersky, Hui-May Chu, Ene Ette

Epilepsy/Clinical Neurophysiology (EEG): Pharmaceuticals P4.260 Conversion to Lacosamide

Monotherapy: Post-hoc Analysis on Responder and Seizure Freedom Rates by Patients’ Baseline Characteristics Philippe Ryvlin, Michael Sperling, Steve Chung, John Stern, Robert Wechsler, Svetlana Dimova, Marc De Backer, Tyler Story, Melissa Brock, Cindy McShea, Paulette Williams, Konrad Werhahn

P4.261

High Predictability of Plasma Lacosamide and No Relevant Differences by Age and Gender Following Normalization Carina Schaefer, Willi Cawello, Jens-Otto Andreas

P4.262 Safety and Effectiveness of

Lacosamide as a First Add-on (FAO) or Later Add-on (LAO) Treatment of Partial-onset Seizures (POS) in Adults: An Open-label Trial Plamen Tzvetanov, Wendy Waldman Zadeh, Antonio Escartin, William Byrnes, Frank Tennigkeit, Peter Dedeken, Marc De Backer, Simon Borghs, Ting Li

P4.263 Immediate Steady-state

Concentrations in Plasma After Oral or Intravenous Lacosamide Loading Dose Carina Schaefer, Willi Cawello, JensOtto Andreas

P4.264 Tolerability of Lacosamide 200 Mg/day Starting Dose: Post-hoc Analysis of Conversion to Lacosamide Monotherapy Study Konrad Werhahn, Svetlana Dimova, Cindy McShea, Paulette Williams, Melissa Brock, William Byrnes, Marc De Backer, Edward Faught

94

7:30 a.m.–12:00 p.m.

P4.265 Safety and Effectiveness of

Lacosamide as Adjunctive Treatment for Partial-onset Seizures (POS) in Hispanic/ Latino Patients from Mexico: Post-hoc Analysis of an Open-label Trial Hugo Ceja Moreno, Plamen Tzvetanov, Wendy Waldman Zadeh, Antonio Escartin, William Byrnes, Frank Tennigkeit, Simon Borghs, Cindy McShea, Peter Dedeken, Marc De Backer, Imane Wild

P4.266 Lacosamide Added to a

Baseline Monotherapy in Patients with Partial-onset Seizures (POS): Efficacy and Safety Across Center Types in the VITOBA Study Matthias Noack-Rink, Christian Brandt, Thomas Mayer, Stephan Arnold, Uwe Runge, Francisco Ramirez, Thomas Lauterbach, Peter Dedeken

P4.267

Lacosamide Added to an Existing Monotherapy in Epilepsy Patients with Partial-onset Seizures: A Subgroup Analysis of Elderly Patients in the VITOBA Study Uwe Runge, Stephan Arnold, Thomas Mayer, Matthias Noack-Rink, Francisco Ramirez, Marc De Backer, Frank Tennigkeit, Konrad Werhahn

P4.268 Generic Antiepileptic Drugs: A Review of Issues Surrounding Formulation Switching Huy Nguyen, Annie Clark, Mark Halvorsen, Mary Holmay, Gregory Gilmet

P4.269 Galenic Formulation

of Midazolam (MDZ) Intranasal(IN): Evaluation of Plasma Levels and Tolerance in Healthy Volunteers in Argentina Maria Pacha, Martin Kriebaum, Oscar Martinez, Guillermo Bramuglia, Maria Kravetz, Fabian Buontempo, Esteban Otamendi, Diego Chiappetta

P4.270 Profound Hypothermia

Secondary to Clobazam Use in Epilepsy: A Novel Association Bennett Lavenstein, Marc Difazio, Scott Demarest

P4.271 Evaluation of Safety in

Exceeding Maximum Doses of Commonly Used Antiepileptic Drugs in Pediatric Patients Sunita Misra, Shannon DiCarlo, Mindl Messinger, Gary Clark

P4.272 Effect of an Antiepileptic

Drug (AED) Holiday in the Epilepsy Monitoring Unit (EMU) on Subsequent Seizure Frequency After Reinstituting in Medically Refractory Epilepsy Patients—a Prospective Observational Controlled Study Geetika Bajpai

P4.273 Antiepileptic Drugs

Withdrawal: Risk Factors for Seizure Relapses in a Brazilian Sample Victor Calil da Silveira, Pedro Sudbrack Oliveira, Cristiane Afonso, Luiza Tavares Ramos

P4.274

Fracture Risk Associated with Enzyme-inducing Antiepileptic Drugs in Patients with Epilepsy: A Systematic Review J. Alexander Fraser, Jorge Burneo, Lisa-Ann Fraser

P4.275 A Cost-comparison Model

to Estimate the Potential Health Care Cost Impact of Increased Sodium Channel Blocker Use Among Adjunctively-treated Patients with Partial-onset Seizures Fulton Velez, Viktor Dansk, Malin Berling, Maria Malmenäs

P4.276

In Vitro Pharmacokinetic Profile of Brivaracetam (BRV) Reveals Low Risk of Drug-drug Interaction (DDI) and Unrestricted Brain Permeability Hugues Chanteux, Sophie Kervyn, Brigitte Gerin, Maria Rosa, Nathalie Latour, Armel Stockis, Jean-Marie Nicolas

P4.277 Incidence of Falls,

Fractures, and Injuries with Adjunctive Eslicarbazepine Acetate (ESL) in Patients with Refractory Partial-onset Seizures (POS): A Pooled Analysis of Three Placebocontrolled Trials William Rosenfeld, Selim Benbadis, Pavel Klein, Luigi Specchio, Pedro Kowacs, Helena Gama, Francisco Rocha, Raymond Claus, David Blum

P4.278 Idiosyncratic Interactions

Between the Ketogenic Diet and Valproic Acid: A Case Series Inna Hughes, Kelly Russo, David Wang

P4.279 Antiepileptic Medications

and Depression in Patients with Epilepsy (PWE) Ihab Ahmed, Sunil Nair, Kimberly Cole, Anum Riaz, Imran Ali

Cerebrovascular Disease and Interventional Neurology: Acute Ischemic Stroke Care P4.280 Strategies for Optimizing

Acute Ischemic Stroke Care by Reducing Door to Needle Time in a Major Academic Center Justin Abraham, Caitlin Oksienik, Rodney Bell, Christopher Skidmore, Diana Tzeng, Carissa Pineda

P4.281 Outcomes of Intravenous

Tissue Plasminogen Activator in Nonagenarians with Acute Ischemic Stroke Varun Chaubal, Elizabeth Wise, Kari Moore, Ann Jerde, Bystrek Laura, Kerri Remmel, Wei Liu

P4.282 Bridging in Acute Ischemic

Stroke in India—Experience of Indo-US Stroke Project Dheeraj Khurana, PN Sylaja, Jeyaraj Pandian, MV Padma, Subhash Kaul, Deepti Arora, Tijy Thankachan, Parmdeep Kaur, Aneesh Singhal

P4.283 Prospective Study of Acute

Ischemic Stroke Sub-types in a Tertiary Care Hospital in South India Butchi Garuda, Aruna Kumari Uppaturi, T. Sateesh Kumar, S. Gopi

P4.284 Safety and Effectiveness

of Intravenous Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients on Aspirin and Clopidogrel Mushtaq Qureshi, Shayaan Khan, Nauman Jahangir, Ahmed Malik, Michelle Thampson, Asif Khan, Muhammad Suri, Adnan Qureshi

P4.285 Routine Troponin

Measurements Are Unnecessary in Acute Ischemic Stroke Evaluations Farwa Ali, Jimmy Young, Alejandro Rabinstein, Kelly Flemming, Jennifer Fugate

P4.286 Elevated Cardiac Troponin-T in Acute Ischemic Stroke Han-kyeol Kim, Ji Hwa Kim, Kyung-Yul Lee

P4.287 Utility of

Electroencephalography in the Care of Acute Ischemic Stroke Patients Tara Kimbrough, Dominique Monlezun, Jr, Nicole Ulrich, Nelson Mandrell, Joel Lanceta, Alyana Samai, Maria Chavez-Keatts, Adam Friedant, Lauren Dowell, Ramy El Khoury, Sheryl Martin-Schild

P4.288 The Impact of Door to Stroke Unit Time on Post-stroke Complications Rate: A Single Center Experience Ali Al-Khathaami, Mohammed Al-Jumah, Suleiman Kojan, Ashraf Elmetwally, Mohammed Alskaini, Naser Alotaibi

Cerebrovascular Disease and Interventional Neurology: Acute Ischemic Stroke Treatment P4.289 Use of Recombinant Tissue

Plasminogen Activator in Young Patients with Ischemic Stroke Luciana Leon, Pablo Bonardo, Julieta Mazziotti, Lorena Jure, Andrea Sotelo, Eduardo Bendersky, Alberto Zinnerman, Pedro Nofal, Luciano Alberto Sposato, Patricia Riccio, Ricardo Reisin, Manuel Fernandez Pardal, Alejandra Martinez

P4.290 Early Dramatic Recovery

After Endovascular Reperfusion in Acute Ischemic Stroke Andrey Lima, Diogo Haussen, Samir Belagaje, Aaron Anderson, Fadi Nahab, Srikant Rangaraju, Michael Frankel, Raul Nogueira

P4.291 Primary Acute Stroke

Thrombectomy in 3 Hours from Middle Cerebral Artery Occlusion—a Pilot Study Yahia Lodi, Varun Reddy, Ashok Devasenapathy, Karmel Shehadeh, Anas Hourini, Chun-An Chou

P4.292 Does Resident Level

of Training Affect Time to TPA Treatment? Laura Bishop, Amy Guzik

P4.293 Application of the 2013

AHA/ASA Guidelines for Use of TPA in Acute Ischemic Stroke at Assaf Harofeh Medical Center, a Tertiary Medical Center in Israel Carmel Armon, Itzhak Kimiagar, Shani Kalmanovich Avnery, Ofer Gonen, Zvika Sacagiu, Evelina Shevtzov, Youval Leonov, Alex Blatt, Shmuel Bar-Hayim

P4.294 Outcomes in Wake-up Strokes Receiving Intra-arterial Therapy Varuh Naragum, Shabbir Hussain Merchant, Qaisar Shah

P4.295 Unchanged Utilization of

Endovascular Treatment in Acute Ischemic Stroke Patients in the Post IMS-III Era Ameer Hassan, Cara Bezzina, Ahmed Malik, Lisa Jones-Fullingim, Christina Sanchez, Wondwossen Tekle, Adnan Qureshi

P4.296 Thrombolysis in Strokes

of Uncertain Onset—Can CT Perfusion Scanning Help Us Make Safe and Effective Decisions David Collas, Sumanjit Gill

P4.297 Predictors of Hematoma

Volume in the Patients Treated with Intravenous Alteplase Sung Hyuk Heo, Ji Hoon Lee, Dokyung Lee, Kyoung Jin Hwang, Dae-Il Chang, Seon Hee Bu, Jong Min Song, Ho-Geol Woo


Poster Session IV


of Acute Middle Cerebral Artery Occlusion: Comparison of Percutaneous Transluminal Angioplasty and Mechanical Embolectomy Roman Herzig, Katerina Blejcharova, Martin Roubec, Martin Kuliha, Daniel Sanak, Eva Vitkova, Dagmar Krajickova, Ales Tomek, Daniel Vaclavik, Vaclav Prochazka, Martin Kocher, Antonin Krajina, Frantisek Charvat, Jana Zapletalova, David Skoloudik

Cerebrovascular Disease and Interventional Neurology: Acute Interventional Treatment for Ischemic Stroke P4.299 Arterial Reocclusion and

Distal Embolization During Endovascular Treatment Using New Generation Stent Retrievers in Acute Ischemic Stroke Patients Nabeel Herial, Mushtaq Qureshi, Asif Khan, Nauman Jahangir, Hashim Zeb, Nazli Janjua, Muhammad Suri, Adnan Qureshi

P4.300 Correlation Between

Flat Panel Computed Tomography and Conventional Computed Tomography for Detection of Post Endovascular Treatment Hemorrhages Asif Khan, Seyedmehdi Payabvash, Mushtaq Qureshi, Omar Saeed, Muhammad Suri, Adnan Qureshi

P4.301 Temporary Discontinuation

of Warfarin for Endovascular Procedures and Risk of Ischemic Stroke Ahmed Malik, Mushtaq Qureshi, Hashim Zeb, Archie Defillo, Michelle Thompson, Muhammad Suri, Adnan Qureshi

P4.302 “Reverse Locked-in

Syndrome”: A Rare Presentation After Endovascular Recanalization of Top-of-thebasilar Artery Occlusion Pooja Raibagkar, Jennifer Kim, Tamara Kaplan, Ram Chavali, Meaghan Nitka, Sherry Chou, Brian Edlow

P4.303 Significance of Periclot MMP-

9 in Ischemic Stroke Patients Undergoing Intra-arterial Interventions Anne Song, Briana Prager, Chanda Brennan, Ken Uchino, Muhammad Hussain, Peter Rasmussen, Damir Janigro

P4.304 Intra-arterial Therapy Is Safe

and Effective in Patients Aged ≥ 80 Donald Frei, Jan Leonard, Kristin Salottolo, Christopher Fanale, Jeffrey Wagner, Michelle Whaley, Kathryn McCarthy, David Loy, David Bar-Or

P4.305 Predictors of Outcome of

Acute Ischemic Stroke Patients Less Than Eighty Years Old Compared to Those Eighty Years Old and Older Who Underwent Stent Retriever Thrombectomy for Middle Cerebral Artery Occlusion—a Pilot Study Varun Reddy, Yahia Lodi, Ashok Devasenapathy, Karmel Shehadeh, Anas Hourini, Chun-An Chou

P4.306 Why Are Most Stroke Patients Deemed Poor Candidates for Intraaterial Therapy? A Prospective Study Dushyant Damania, Anthony Noto, Nancy Kung, Jason Liew, Heather Finley, Rajiv Mangla, Amrendra Miranpuri, Bogachan Sahin, Babak Jahromi

P4.307 Occurrence of Femoral

P4.318

Dorsal Lead Migrations in a Dystonia Patient Following Deep Brain Stimulation Wei Hu, Alberto Bona, Daniel Martinez-Ramirez, Aparna Wagle Shukla, Kelly Foote, Michael Okun

P4.330 Does Oral Zinc

Cerebrovascular Disease and Interventional Neurology: Acute Stroke, Prehospital, and Telemedicine

P4.319

Prospective Trial Evaluating Xeomin (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States— Final Results from the Blepharospasm Cohort Hubert Fernandez, Joseph Jankovic, John Holds, Daniel Lin, John Burns, Kapil Sethi, Amit Verma

Nerve Injury Among Patients Undergoing Transfemoral Percutaneous Catheterization Procedures in United States Mohammad El-Ghanem, Adnan Qureshi

P4.308 Time Is Brain: A Quality

Improvement Project to Improve Stroke Outcomes by Educating EMS Karanbir Singh, Pooja Sofat, Noureldin Abdelhamid, Deeya Gaindh, Ghasan Ahmad, Mohammad Masud, Robert Sawyer, Nicholas Silvestri

P4.309 Reducing Door-to-needle

Times for Treatment of Acute Ischemic Stroke: Quality Improvement Initiative at a High-volume Comprehensive Stroke Center Biggya Sapkota, Abdelazim Sirelkhatim, Thomas Devlin, Nataria Pitiyanuvath, Caryl Dellinger, Francis Fesmire

P4.310

Early Triage of Acute Ischemic Stroke Patients Using Mobile Stroke Unit Shortens Time to Intra-arterial Therapy Andrew Buletko, Russell Cerejo, Ather Taqui, Ahmed Itrat, Seby John, Gabor Toth, Ken Uchino, Muhammad Hussain, Peter Rasmussen

P4.311

Protocol Driven Stroke Ward and Stroke Registry Results in Increased Rate of Thrombolysis in Acute Stroke Care Naveed Akhtar, Saadat Kamran, S Joseph, M Santos, P Bourke, A D'Souza, Yahia Imam, Ashfaq Shuaib

P4.312

Posterior Versus Anterior Circulation Strokes: Differences at a Community Level Nancy Kung, Dushyant Damania, Jason Liew, Curtis Benesch, Babak Jahromi

P4.313

Longer Ambulance Transport Time Is Associated with Worse Outcomes in “Drip and Ship” Stroke Patients Thomas Kodankandath, Rohan Arora, Jane Shaji, Reuben Burshtein, Richard Libman, Nina Kohn, Michele Gribko, Jeffrey Katz

P4.314

The Speed and Reliability of Pre-hospital Point-of-care Laboratory Testing on the Mobile Stroke Treatment Unit Natalie Organek, Ather Taqui, Russell Cerejo, Ahmed Itrat, Andrew Buletko, Sung Cho, Lila Sheikhi, Stacey Winners, Peter Rasmussen, Muhammad Hussain, Ken Uchino


Thrombolysis in the Very Elderly: Application to Telestroke Networks Charlotte Zerna, Kristian Barlinn, Jessica Kepplinger, Lars-Peder Pallesen, Timo Siepmann, Heinz Reichmann, Volker Puetz, Ulf Bodechtel

Movement Disorders: Dystonia P4.317

Hyoid Muscle Dystonia: A Previously Undescribed Segmental Dystonia of the Neck Erin Norby, Edythe Strand, Joseph Duffy, Dale Ekbom, Diana Orbelo, Joseph Matsumoto


Advanced Neuroimaging Techniques to Assess Brain Structural Abnormalities in Writer’s Cramp Primary Dystonia Lidia Sarro, Federica Agosta, Alexandra Tomic, Paola Valsasina, Marina Svetel, Sebastiano Galantucci, Alessandro Sodero, Nikola Kresojevic, Vladimir Kostic, Massimo Filippi

P4.320 Athlete’s Dystonia Jeremy Cutsforth-Gregory, James Bower

P4.321 Long-term Motor Learning

in Focal Hand Dystonia (FHD) Prachaya Srivanitchapoom, Ejaz Shamim, Suk Yun Kang, Seung-Hyun Jin, Elise Houdayer, Pierre Diomi, Nivethida Thirugnanasambandam, Tianxia Wu, Sherry Vorbach, Biset-Meunier Sabine, Mark Hallett

P4.322 Cortical Assesment in

Craniocervical Dystonia Larissa Vilany, Thiago Rezende, Luiza Piovesana, Lidiane Campos, Paula Azevedo, Fabio Torres, Marcondes Franca, Jr., Augusto AmatoFilho, Iscia Lopes-Cendes, Fernando Cendes, Anelyssa D'Abreu

P4.323 Activation of a Small Cluster

of Excitatory Neurons in the Medial Medulla Induces a Phenotype That Resembles Cervical Dystonia Brian Ellison, Audrey Worley, Tamara Samardzic, Veronica VanderHorst

Supplementation Augment the Effect of Botulinum Neurotoxin in Dystonia? Yuan Xing, Padraig O'Suilleabhain

P4.331 XCiDaBLE: An Observational,

P4.332 Regional Differences in

Botulinum Neurotoxin-A (BoNT-A) Injection Practices and Techniques in the Treatment of Cervical Dystonia: A Comparison Between the US and Europe Peter Misra, Richard Trosch, Pascal Maisonobe, Savary Om

P4.333 Randomised Double-blind

Clinical Trial of Botulinum Toxin Subtype A2 (A2NTX) in Comparison with Subtype A1 (onabotulinumtoxinA) (ClinicalTrials.gov NCT01910363) Ryuji Kaji, Ai Miyashiro, Nori Sato, Toshiaki Takeuchi, Seiji Kaji, Taiki Furumoto

P4.334 Safety Profile of Repeat

OnabotulinumtoxinA Doses of 400U for the Treatment of Upper Limb Spasticity Lynn James, Rozalina Dimitrova, Grace Pan, Charles Asare, Catherine Thompson

P4.335 Limbic Encephalitis

Associated with Anti-voltagegated Potassium Channel Complex Antibodies Mimicking Creutzfeldt-Jakob Disease Ming-Jai Liu, Gregory Chang

P4.324 The Impact of Cervical

Wednesday April 22

P4.298 Endovascular Treatment

Dystonia on Work Productivity: An Analysis from the CD Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (CD PROBE) Eric Molho, Mark Stacy, Patrick Gillard, P. Charles, Charles Adler, Joseph Jankovic, Marc Schwartz, Mitchell Brin

P4.325 Spasmodic Dysphonia Primary Dystonia Is Associated with Cortical and Subcortical Alterations: A Multimodal Imaging Study Lidia Sarro, Federica Agosta, Alexandra Tomic, Paola Valsasina, Marina Svetel, Sebastiano Galantucci, Alessandro Sodero, Nikola Kresojevic, Vladimir Kostic, Massimo Filippi

P4.326 Abnormal Activation of

Motion Perception-related Brain Networks in Primary Dystonia Koji Fujita, Wataru Sako, An Vo, Aziz Ulug, David Eidelberg

P4.327 Effect of OnabotulinumtoxinA

on Pain in Patients with Cervical Dystonia: Results from CD PROBE Atul Patel, Marc Schwartz, Aubrey Manack, Mitchell Brin, P. Charles

P4.328 A Structured Interview

Evaluating Botulinum Toxin Type A Treatments for Blepharospasm Kapil Sethi, John Fezza, John Burns, Julie Woodward, Daniel Truong, Thomas Hedges, Philippe Taupin, Amit Verma

P4.329 Differences in Clinical

Features and Management of Patients with CD: An Analysis of Data from the US and Europe Richard Trosch, Peter Misra, Pascal Maisonobe, Savary Om

95

Scientific Sessions S20 Treatment Mechanisms in Multiple Sclerosis 2:00 p.m. Presentation of John Dystel Prize for Multiple Sclerosis Research Recipient: Alastair Compston, MBBS, PhD Cambridge, UK

2:30 p.m. S20.003 Pregnancy Does Not Prevent Disease Re-activation After Natalizumab Suspension in Patients with Multiple Sclerosis Maria Amato, Bahia Hakiki, Luisa Pastò, Marta Giannini, Lorenzo Razzolini, Carla Tortorella, Mariangela D'Onghia, Maria Trojano, Eleonora Cocco, Marta Melis, Maria Marrosu, Valeria Di Tommaso, Deborah Farina, Alessandra Lugaresi, Pietro Annovazzi, Angelo Ghezzi, Claudio Gasperini, Alfonso Iudice, Roberta Fantozzi, Paolo Bellantonio, Silvia Messina, Francesco Patti, Silvia Masera, Paola Cavalla, Alessandra Protti, Maria Rossi, Rocco Totaro, Laura De Giglio, Carlo Pozzilli, Emilio Portaccio 2:45 p.m. S20.004 Therapeutic Role of Poly-I: C on Myelin Repair Chandramohan Natarajan, Song-Yi Yao, Subramaniam Sriram 3:00 p.m. S20.005 Laquinimod Regulates Inflammatory Gene Induction in a Human Model of Reactive Astrogliosis John Mariani, Trinh Pham, Jingya Zhang, Jeremy Seto, Boris Hartmann, Liat Hayardeny Nisimov, Gareth John 3:15 p.m. S20.006 Characterization of a Next Generation Anti-CD52 Antibody William Siders, Ben Greene, Alison McVie-Wylie, Meredith Bailey, Vijay Dhawan, Paula Boutin, Annie Best, Carla Lawendowski, Michael Turner, Bruce Roberts, Johanne Kaplan, Rebecca Sendak 3:30 p.m. S20.007 Identification of Gene Networks and Pathways Associated with Nabiximols Treatment in Multiple Sclerosis Patients. Filippo Martinelli Boneschi, Laura Ferrè, Melissa Sorosina, Elisabetta Mascia, Arturo Nuara, Vittorio Martinelli, Letizia Leocani, Ferdinando Clarelli, Federica Esposito, Giancarlo Comi

S21 Cerebrovascular Disease and Interventional Neurology: Prehospital and Acute Ischemic Stroke Treatment 2:00 p.m. S21.001 Benefits of Stroke Treatment Delivered Using a Mobile Stroke Unit James Grotta 2:15 p.m. S21.002 Pre-hospital Imaging and Thrombolysis in Acute Stroke in an Urban US Setting: Results of the Cleveland Pre-hospital Acute Stroke Treatment (PHAST) Study Group. Farren Briggs, Ather Taqui, Russell Cerejo, Ahmed Itrat, Megan Donohue, Natalie Organek, Andrew Buletko, Lila Sheikhi, Maureen Buttrick, Zeshaun Khawaja, Dolora Wisco, Stacey Winners, Andrew Reimer, Jennifer Frontera, Edward Manno, Fredric Hustey, Damon Kralovic, Rasmussen Peter, Muhammad Hussain, Ken Uchino 2:30 p.m. S21.003 NIH Stroke Scale Assessment Via Tablet-based Mobile Telestroke During Ambulance Transport Is Feasible—Pilot Data from the Improving Treatment with Rapid Evaluation of Acute Stroke Via Mobile Telemedecine (iTREAT) Study Matthew Padrick, Sherita Chapman, Timothy McMurry, Prachi Mehndiratta, Christina Chee, Brian Gunnell, Chance Kimble, Jack Cote, Jason Lippman, Virginia Burke, David Catell-Gordon, Karen Rheuban, Nina Solenski, Debra Perina, Bradford Worrall, Andrew Southerland 2:45 p.m. S21.004 A Door-to-needle Time Under 30 Minutes Can Be Achieved and Can Improve Functional Outcomes Michelle Whaley, Lisa Caputo, Mark Kozlowski, Christopher Fanale, Jeffrey Wagner, David Bar-Or 3:00 p.m. S21.005 Comparison of On-hour Vs Off-hour Patient Cohorts at a Primary Stroke Center: Onset-to-treatment Duration and Clinical Outcomes After IV Thrombolysis Karin Nystrom, David Asuzu, Hardik Amin, Joseph Schindler, Charles Wira, David Greer, Nai Fang Chi, Janet Halliday, Kevin Sheth 3:15 p.m. S21.006 Temporal Trends of Emergency Department Arrival Times After Acute Ischemic Stroke: A Populationbased Study Brian Katz, Jane Khoury, Kathleen Alwell, Charles Moomaw, Brett Kissela, Matthew Flaherty, Daniel Woo, Opeolu Adeoye, Pooja Khatri, Simona Ferioli, Jason Mackey, Sharyl Martini, Felipe De Los Rios La Rosa, Dawn Kleindorfer

Wednesday, April 22 S22 Epilepsy/Clinical Neurophysiology (EEG): Basic Science and Intraoperative Monitoring 2:00 p.m. Presentation of Dreifuss-Penry Epilepsy Award Recipient: Annapurna Poduri, MD, MPH Boston, MA

2:15 p.m. S22.002 Consequences of ATP1a3 Dysfunction: Characterization of a Novel Model and Underlying Pathophysiology Arsen Hunanyan, Nina Fainberg, Molly Linabarger, Eric Arehart, A Leonard, Syed Adil, Ashley Helseth, Amanda Swearingen, Stacy Forbes, Ramona Rodriguiz, Theodore Rhodes, Xiaodi Yao, Nadine Kabbi, Daryl Hochman, William Wetsel, Ute Hochgeschwender, Mohamad Mikati 2:30 p.m. S22.003 Brivaracetam (BRV) Achieves Brain SV2A Occupancy Faster Than Levetiracetam (LEV) Joel Mercier, Daniel Holden, Anand Deo, Krista Fowles, Sophie Kervyn, Nabeel Nabulsi, Jean-Marie Nicolas, Henrik Klitgaard, Yiyun Huang, Joseph D'Souza, Richard Carson, Jonas Hannestad 2:45 p.m. S22.004 Connectivity of the Area Tempestas with the Limbic System Mark Skopin, Mithilesh Siddu, Mohamad Koubeissi 3:00 p.m. S22.005 B and Plasma Cells and Meningeal Follicles Are a Part of Neuroinflammatory Mechanisms Associated with Rasmussen’s Encephalitis: New Clues About Pathogenesis Anupama Kumar, Maria Reyes-Mantilla, Adam Hartman, Carlos Pardo-Villamizar, Carlos Pardo-Villamizar 3:15 p.m. S22.006 Intraoperative Motor Evoked Potentials (MEPs) Monitoring Beyond the Aortic Clamp Period of Open Thoracoabdominal Aneurysm Repair (TAA) Further Decreases the Risk of Post-operative Paraplegia Reiner Henson See, Oluwole Awosika, Richard Cambria, Mark Conrad, Virendra Patel, Glenn LaMuraglia, Rae Allain, Mirela Simon

S23 Headache: Epidemiology and Clinical 2:00 p.m. S23.001 Primary Efficacy Outcomes from COMPASS: A Comparison of Breath Powered™ Device Containing 22 Mg Sumatriptan Powder (AVP-825) Versus 100 Mg Oral Sumatriptan in Acute Treatment of Migraine Stewart Tepper, Roger Cady, Stephen Silberstein, John Messina, Ramy Mahmoud, Per Djupesland, Paul Shin, Joao Siffert 2:15 p.m. S23.002 Are Triptans Safe in Basilar and Hemiplegic Migraine? A Retrospective Chart Review Gurjeet Singh, Jeanette Sherman, George Zinkhan 2:30 p.m. S23.003 Consistency of Response in the COMPASS Study [Breath Powered™ Nasal Delivery of 22 Mg Sumatriptan Powder (AVP-825) Versus 100 Mg Oral Sumatriptan in Acute Migraine: A Comparative Clinical Trial] Richard Lipton, Dawn Buse, Ken Shulman, Joao Siffert 2:45 p.m. S23.004 The Real-world Impact of OnabotulinumtoxinA on Headacherelated ER Visits and Hospitalizations in the Management of Chronic Migraine Zsolt Hepp, Noah Rosen, Sepideh Varon, Patrick Gillard, Jenny Chia, Nitya Mathew, David Dodick 3:00 p.m. S23.005 Efficacy of SPG Stimulation in Relieving Acute Cluster Pain: Results from >5000 Attacks Treated During Long-term Follow-up of the Pathway CH-1 Study Jose Miguel Lainez, Rigmor Jensen, Arne May, Charly Gaul, Amy Goodman, Anthony Caparso, Jean Schoenen

S24 ALS: Mechanisms and Biomarkers 2:00 p.m. Presentation of Sheila Essey Award: An Award for ALS Research Recipients: Robert Bowser, PhD Phoenix, AZ Adriano Chio, MD Turin, Italy

2:30 p.m. S24.003 Head Injury Does Not Alter Disease Progression or Neuropathological Outcomes in ALS Christina Fournier, Marla Gearing, Saila Upadhyayula, Mitch Klein, Jonathan Glass 2:45 p.m. S24.004 The ALS/FTD C9ORF72 Hexanucleotide Expansion Disrupts Nucleocytoplasmic Transport Thomas Lloyd, Ke Zhang, Chris Donnelly, Jeffrey Rothstein 3:00 p.m. S24.005 Threshold Tracking TMS: A Novel Diagnostic Technique for Amyotrophic Lateral Sclerosis Nimeshan Geevasinga, Parvathi Menon, Con Yiannikas, James Howells, Matthew Kiernan, Steve Vucic 3:15 p.m. S24.006 ALS Monocytes Exhibit a Pro-inflammatory Gene Expression Weihua Zhao, David Beers, Hooten Christopher, Stanley Appel 3:30 p.m. S24.007 Variability of Expression in SETXrelated Motor Neuron Disease: A Single Family, Multigeneration Evaluation Jennifer Roggenbuck, Dawn Allain, Stanley Iyadurai, Stephen Kolb, John Kissel

3:15 p.m. S23.006 Migraine Diagnosis and Treatment: A Knowledge and Needs Assessment Among Primary Care Providers Mia Minen, Lori Tishler, Elizabeth Loder, David Silbersweig 3:30 p.m. S23.007 The Place of Corticosteroids in Migraine Attack Management: A 65-year Systematic Review with Pooled Analysis and Critical Appraisal Yohannes Woldeamanuel, Alan Rapoport, Robert Cowan

3:30 p.m. S22.007 Early Onset Epileptic Encephalopathy and Deficient Myelination as a Result of Autosomal Recessive Mutations in the AARS Gene Guy Helman, Cas Simons, Laurie Griffin, Amy Pizzino, Miriam Bloom, Ryan Taft, Anthony Antonellis, Ya Ming Hou, Adeline Vanderver

3:30 p.m. S21.007 Are Physicians More Vigilant in Recognizing Acute Posterior Circulation Stroke Symptoms?— Experience of a Tele-stroke Network. Ramesh Madhavan, Pratik Bhattacharya, Deepmala Nandanwar, Omar Basha, Fnu Abhishek, Kumar Rajamani

96


Scientific Sessions

S25 General Neurology 2:00 p.m. Presentation of S. Weir Mitchell Award Recipient: Isaac Marin-Valencia, MD Dallas, TX

2:15 p.m. S25.002 Defining Central Nervous System Involvement in Patients with Acquired Demyelinating Peripheral Neuropathies Laura Vacchi, Maria Rocca, Nilo Riva, Raffaella Fazio, Elisabetta Pagani, Mauro Comola, Andrea Falini, Giancarlo Comi, Massimo Filippi 2:30 p.m. S25.003 Regional Differences in the Brain Levels of GABA and Glutamate/ Glutamine Between Patients with Cyclic Vomiting Syndrome and Matched Healthy Controls Revealed by 3D MR Spectroscopic Imaging Ovidiu Andronesi, Ronald Garcia, Wolfgang Bogner, Shahar Castel, Braden Kuo, Vitaly Napadow 2:45 p.m. S25.004 Public Review: The National Institute of Neurological Disorders and Stroke (NINDS) Congenital Muscular Dystrophy (CMD), Facioscapulohumeral Muscular Dystrophy (FSHD) and Myotonic Dystrophy (DM) Common Data Elements (CDE) Recommendations Joy Esterlitz, Joanne Odenkirchen, Marybeth Montoro, Sherita Ala'i, Elizabeth McNeil, Robin Conwit 3:00 p.m. S25.005 Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Increasing Efficiency in Clinical Trial Management Marianne Kearney, Dixie Ecklund, Michael Bosch, Brenda Thornell, Elizabeth McNeil, Janice Cordell, Christopher Coffey, Merit Cudkowicz 3:15 p.m. S25.006 Quality Improvement Project: Improving the Follow up of Patients at the Neurology Resident’s Clinic After Hospital Discharge Rocio Garcia Santibanez, John Liang, Yamin Shwe, Sarah Wesley, Santiago Mazuera, Ivan Matos-Diaz, Clinton Lauritsen, Diego Tovar, Roni Sharon, Rabih Kashouty, George Lai, Allison Navis, Jungyeon Park, Kourosh Kahkeshani, Weiyi Gao

S26 Neuroophthalmology/Neurootology 2:00 p.m. S26.001 Molecular Imaging of the Human Retina by Raman Spectroscopy Elena MartinezLapiscina, Oscar Batet, Antoni Gonzalez, Albert Campos, Iker Bilbao, Dídac Perez, Elena FragaPumar, Rubén Torres-Torres, Yago Rossello, Bernardo Sanchez-Dalmau, Ivan Amat-Roldan, Pablo Villoslada 2:15 p.m. S26.002 Sideline Testing in Youth and Collegiate Athletes: What Does Vision Add to the Concussion Puzzle? Avri Bohm, Lisena Hasanaj, John-Ross Rizzo, Liliana Serrano, Rachel Nolan, Nicholas Moehringer, Nikki Webb, Courtney Civitano, Dennis Cardone, Arlene Silverio, Steven Galetta, Laura Balcer 2:30 p.m. S26.003 Differentiating Vertical Misalignment Using Different Head Positions: A Reappraisal Joao Lemos, Adnan Subei, Mario Sousa, José Coelho, Luis Cunha, Christopher Glisson, Eric Eggenberger 2:45 p.m. S26.004 Risk Factors for Poor Visual Outcome in Idiopathic Intracranial Hypertension Patients with Mild Visual Loss Byron Lam, Julie Falardeau, William Fletcher, Robert Granadier, Reid Longmuir, Anil Patel, Hau He, Michael McDermott, Michael Wall 3:00 p.m. S26.005 How Does Disease of Optic Nerves Affect Acute Non-visual Light Effects Predominantly Mediated by Melanopsin Ganglion Cells? Aki Kawasaki, Lorette Leon, Sylvie Collomb, Mirjam Münch 3:15 p.m. S26.006 Randomized Controlled Trial Evaluating Threshold Sound Conditioning in the Treatment of Sensorineural Hearing Loss Sungho Cho, Eunyee Kwak, Sangyeop Kwak, Jaime Lopez

S27 Neuro Trauma, Critical Care, and Sports Neurology 2:00 p.m. S27.001 Lingering Impairments in Postural Control Despite Clinical Concussion Recovery Thomas Buckley, Kelsey Evans, Barry Munkasy 2:15 p.m. S27.002 ApoE Status Related to Memory Scores but Not Hippocampal or Thalamic Volume in Combat Sports Sarah Banks, Charles Bernick 2:30 p.m. S27.003 Early Prediction Model for Prognosis After Cardiac Arrest in the Era of Hypothermia Preet Varade, Kushak Suchdev, Navid Seraji-Bozorgzad, Gregory Norris, Mohammad Ibrahim, Wazim Mohamed 2:45 p.m. S27.004 Incidence of Headache in Retired NFL Players. Correlation with Diffusion Tensor MRI Imaging and Neuropsychological Testing. Francis Conidi 3:00 p.m. S27.005 Acute Traumatic Coagulopathy Accompanying Traumatic Brain Injury Is Associated with Worse Long Term Cognitive and Functional Outcomes: A Retrospective Analysis of the COBRIT Data. Peter Abdelmalik, Jack Jallo, Fred Rincon 3:15 p.m. S27.006 Neuronal Plasmalemmal Disruptions Are Exacerbated in Perivascular Domains Following Repetitive Traumatic Brain Injury in Swine John Duda, James Harris, Emory Kuo, D. Cullen 3:30 p.m. S27.007 Volumetric Analysis in Individuals with Single Vs. Multiple Head Injuries Christian Shenouda, Tanvi Devi, Mitra Yousefi, Leighton Chan

3:30 p.m. S26.007 A Radiographic Target Sign for Abnormal Vertebral Artery Flow in Stroke Patients with Acute Vestibular Syndrome Jorge Kattah, Jeffrey DeSanto, Ali Saber Tehrani, John Pula, David Newman-Toker

S28 Neuro-rehabilitation 2:00 p.m. S28.001 A Phase III Randomized, Doubleblind, Placebo-controlled Study to Assess the Efficacy and Safety of AbobotulinumtoxinA (Dysport®) in Adults with Upper Limb Spasticity Allison Brashear, Christina Marciniak, Steven Edgley, Fatma Gul, Peter Hedera, Peter McAllister, Michael O'Dell, Bruce Rubin, Walker Heather, Claire Vilain, Philippe Picaut, Jean-Michel Gracies 2:15 p.m. S28.002 Topline Results from a Randomized, Placebo-controlled, Phase III Study Investigating the Safety and Efficacy of IncobotulinumtoxinA in Treating Post-stroke Spasticity of the Upper Limb Kapil Sethi, Elie Elovic, Michael Munin, Christina Marciniak, Reinhard Hiersemenzel, Angelika Hanschmann 2:30 p.m. S28.003 Balance-based Torso-weighting Results in Fall Reduction During Sensory Organization Test for People with Multiple Sclerosis Cynthia Gibson-Horn, Gail Widener, Diane Allen, Kristin Horn 2:45 p.m. S28.004 Brain Functional Changes After a Somatosensory Discrimination Training in Healthy Young Subjects Elisabetta Sarasso, Federica Agosta, Paola Adamo, Federico Temporiti, Andrea Falini, Roberto Gatti, Massimo Filippi 3:00 p.m. S28.005 Promoting Locomotor Learning with Spinal Direct Current Stimulation— Pilot Data Oluwole Awosika, Marco Sandrini, Rita Volochayev, Benjamin Xu, Mary Kay Floeter, Mark Hallett, Leonardo Cohen

Wednesday April 22

2:00 p.m–3:45 p.m.

3:15 p.m. S28.006 Assessment of Cerebrovascular Dysfunction After Traumatic Brain Injury: MRI-BOLD Versus NIRS Franck Amyot, Kimbra Kenney, Carol Moore, Erika Silverman, Emily Spessert, Leah Harburg, Ramon Diaz-Arrastia 3:30 p.m. S28.007 Network Control Theory as a Mediator of Transcranial Magnetic Stimulation Effects John Medaglia, Roy Hamilton, Sharon ThompsonSchill, Shi Gu, Danielle Bassett

3:30 p.m. S25.007 Quix Test Predicts Canal Sidedness in BPPV Kevin Coughlin, Krysten Sherrod, Jason Miles, Ryan Fitzgerald, Garrett Barr, Jonathan Salud, Shawn Adams, Charles Maitland


97


Wednesday, April 22

Treating Dementia in an Age of Mixed Disease

2:00 p.m.–6:00 p.m.

Coordinators: Randolph S. Marshall, MD, FAAN, and Ronald M. Lazar, PhD, FAAN Part I

2:00 p.m.–3:45 p.m.

2:00 p.m.–2:05 p.m.

Introduction

2:05 p.m.–2:35 p.m.

Invited Speaker

Randolph S. Marshall, MD, FAAN, and Ronald M. Lazar, PhD, FAAN

I9-1A Data Blitz

2:40 p.m.–2:45 p.m.

I9-1B Data Blitz

2:45 p.m.–2:55 p.m.

Audience Q&A

2:55 p.m.–3:25 p.m.

Invited Speaker

Anti-S100B Autoantibodies in Cerebral Small Vessel Disease Chanda Brennan, Humberto Choi, Vikram Puvenna, Michael Phillips, Peter Mazzone, Damir Janigro The Neuropathology of Patients with Dementia and Non-dementia in the Oldestold Gamze Balci Camsari, Neill Graff-Radford, Ronald Petersen, David Knopman, Bradley Boeve, Joseph Parisi, Dennis Dickson, Melissa Murray

Reconsidering Harbingers of Alzheimer’s Disease: Risk factors, Biomarkers, and White Matter Hyperintensities Adam Brickman, PhD

3:25 p.m.–3:30 p.m.

I9-2A Data Blitz

3:30 p.m.–3:35 p.m.

I9-2B Data Blitz

White Matter Hyperintensity Associated with Cerebral Amyloidosis Independent of Hypertension History Julia Scott, Duygu Tosun-Turgut, Meredith Braskie, Paul Thompson, Michael Weiner, Charles DeCarli, Owen Carmichael Differential Progression of White Matter Hyperintensities in Earlyonset Compared to Late-onset Alzheimer’s Disease: A Longitudinal MRI Study Nicodemus Oey, Hani Zainal, Alvin Cenina, Nagaendran Kandiah

3:35 p.m.–3:45 p.m.

Audience Q&A

3:45 p.m.–3:55 p.m.

Break

3:55 p.m.–5:35 p.m.

3:55 p.m.–4:25 p.m.

Invited Speaker

4:25 p.m.–4:30 p.m.

I9-3A Data Blitz

4:30 p.m.–4:35 p.m.

I9-3B Data Blitz

4:35 p.m.–4:45 p.m.

Audience Q&A

4:45 p.m.–5:15 p.m.

Invited Speaker

5:15 p.m.–5:20 p.m.

I9-4A Data Blitz

5:20 p.m.–5:25 p.m.

I9-4B Data Blitz

5:25 p.m.–5:35 p.m.

Audience Q&A

Blood Pressure Management in Vascular Cognitive Impairment Randolph S. Marshall, MD, FAAN

Cellular Mechanisms that Link Alzheimer’s Disease and Vascular Dementia Berislav V. Zlokovic, MD, PhD

2:35 p.m.–2:40 p.m.

Part II

Heart-health Intervention Reduces Cognitive Decline in Mild Cognitive Impairment of the Cerebrovascular Type: A Randomized, Placebo-controlled Clinical Trial Gregory Jicha, Richard Murphy, Martha Biddle, Debra Moser The Association Between Pulse Pressure and Memory Functioning over Time Depends on Baseline Systolic Blood Pressure Eric McDade, Zhaowen Sun, ChingWen Lee, Beth Snitz, Chung-Chou Chang, Mary Ganguli

Sleep and Alzheimer's Disease: A Bi-directional Relationship David M. Holtzman, MD, FAAN Sleep Duration Is Associated with Worse Neurocognitive Function in Hispanic/ Latinos: Results of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) Alberto Ramos, Wassim Tarraf, Martha Daviglus, Sonia Davis, Linda Gallo, Yasmin Mossavar-Rahmani, Frank Penedo, Susan Redline, Tatjana Rundek, Ralph Sacco, Daniela Sotres-Alvarez, Clinton Wright, Phyllis Zee, Hector Gonzalez The Association of Sleep Apnea and Stroke with Cognitive Performance: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study Jennifer Molano, Dawn Kleindorfer, Leslie McClure, Frederick Unverzagt, Virginia Wadley, Virginia Howard

Guided Poster Rounds

5:35 p.m.–6:00 p.m.

I9-5A

Atrial Fibrillation in Patients with Neuropathological Diagnosis of Primary Alzheimer’s Disease Patricia Riccio, Luciano Alberto Sposato, Estefania Ruiz Vargas, Jon Toledo, John Trojanowski, Vladimir Hachinski

I9-5E

Early Diagnosis of Vascular Cognitive Impairment Is Associated with Improved Adherence with Medical Treatment of Vascular Risk Factors Angelia Kirkpatrick, Elliott Ross, Leslie Guthery, Calin Prodan

I9-5I

I9-5B

I9-5F

I9-5J

Mixed Membership Trajectory Model of Cognitive Impairment in the Cardiovascular Health Study— Cognition Study Fabrizio Lecci, Brian Junker, Lewis Kuller, Oscar Lopez, James Becker

I9-5C

Neuroticism Increases with Age in Cognitively Normal Older Adults Who Are PiB-positive Carolyn Fredericks, Virginia Sturm, Alice Hua, Murat Bilgel, Dean Wong, Susan Resnick, William Seeley

I9-5D

Relation of Cognitive Impairment and Insulin Resistance in Hispanic Patients with Parkinson’s Disease Angel Vinuela, Carmen Serrano, Maria Margarida, Yamil Gerena, Karen Valdesuso, Ana Mosquera, Valerie Wojna

98

Anti-S100B Autoantibodies in Cerebral Small Vessel Disease Chanda Brennan, Humberto Choi, Vikram Puvenna, Michael Phillips, Peter Mazzone, Damir Janigro

I9-5G

The Neuropathology of Patients with Dementia and Non-dementia in the Oldest-old Gamze Balci Camsari, Neill Graff-Radford, Ronald Petersen, David Knopman, Bradley Boeve, Joseph Parisi, Dennis Dickson, Melissa Murray

I9-5H

White Matter Hyperintensity Associated with Cerebral Amyloidosis Independent of Hypertension History Julia Scott, Duygu Tosun-Turgut, Meredith Braskie, Paul Thompson, Michael Weiner, Charles DeCarli, Owen Carmichael

Differential Progression of White Matter Hyperintensities in Early-onset Compared to Late-onset Alzheimer’s Disease: A Longitudinal MRI Study Nicodemus Oey, Hani Zainal, Alvin Cenina, Nagaendran Kandiah Heart-heath Intervention Reduces Cognitive Decline in Mild Cognitive Impairment of the Cerebrovascular Type: A Randomized, Placebo-controlled Clinical Trial Gregory Jicha, Richard Murphy, Martha Biddle, Debra Moser

I9-5K

The Association Between Pulse Pressure and Memory Functioning over Time Depends on Baseline Systolic Blood Pressure Eric McDade, Zhaowen Sun, Ching-Wen Lee, Beth Snitz, ChungChou Chang, Mary Ganguli

I9-5L

Sleep Duration Is Associated with Worse Neurocognitive Function in Hispanic/Latinos: Results of the Hispanic Community Health Study/ Study of Latinos (HCHS/SOL) Alberto Ramos, Wassim Tarraf, Martha Daviglus, Sonia Davis, Linda Gallo, Yasmin Mossavar-Rahmani, Frank Penedo, Susan Redline, Tatjana Rundek, Ralph Sacco, Daniela Sotres-Alvarez, Clinton Wright, Phyllis Zee, Hector Gonzalez

I9-5M

The Association of Sleep Apnea and Stroke with Cognitive Performance: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study Jennifer Molano, Dawn Kleindorfer, Leslie McClure, Frederick Unverzagt, Virginia Wadley, Virginia Howard


Integrated Neuroscience Session I10 C The Dynamic Brain in Health and Disease: Plasticity and Reprogramming

2:00 p.m.–6:00 p.m.

Coordinators: Mark F. Mehler, MD, FAAN, and Mark Albers, MD, PhD Invited Speaker Session

2:00 p.m.–4:05 p.m.

2:00 p.m.–2:05 p.m.

3:05 p.m.–3:35 p.m.

2:05 p.m.–2:35 p.m.

3:35 p.m.–4:05 p.m.

Introduction Mark F. Mehler, MD, FAAN, and Mark Albers, MD, PhD New Treatments for Neurodevelopmental and Neurodegenerative Disorders Joseph O. Gleeson, MD

Novel Forms of Plasticity in the Adult Mammalian Brain Hongjun Song, PhD New Approaches to Promote Motor Recovery After Stroke John Krakauer, MD

2:35 p.m.–3:05 p.m.

Fate Plasticity in the Cerebral Cortex: Generating New Corticospinal Neurons Brad Molyneaux, MD

Data Blitz Session

4:05 p.m.–4:45 p.m. I10-1A

4:10 p.m.–4:15 p.m.

I10-1B

Genetic Association Study of Cognitive Performance Jonathan Katz, Chuanhui Dong, Yaakov Stern, Clinton Wright, Susan Blanton, Ralph Sacco Tractography Activation Patterns in Dorsolateral Prefrontal Cortex Suggest Better Clinical Responses in Deep Brain Stimulation (DBS) of the Anterior Limb of the Internal Capsule and Nucleus Accumbens (ALIC-NA) for Obsessivecompulsive Disorder (OCD) Christian Hartmann, J. Lujan, Ashutosh Chaturvedi, Wayne Goodman, Michael Okun, Cameron McIntyre, Ihtsham Haq

4:15 p.m.–4:20 p.m.

I10-2A

4:20 p.m.–4:25 p.m.

I10-2B

HDAC4 Shuttling Promotes Neuronal Remodeling After Stroke Amjad Shehadah, Haifa Kassis, Michael Chopp, Cynthia Roberts, Zheng Gang Zhang Personal Experience with Dance and Cortical Gray Matter Thickness in the Cognitively Normal and Mild Cognitive Impaired Elderly Shai Porat, Kristy Hwang, Ellen Woo, Theodore Zanto, Naira Goukasian, Liana Apostolova

4:25 p.m.–4:30 p.m.

I10-3A

4:30 p.m.–4:35 p.m.

I10-3B

4:35 p.m.–4:40 p.m.

I10-4A

4:40 p.m.–4:45 p.m.

I10-4B

Network Control Theory as a Mediator of Transcranial Magnetic Stimulation Effects John Medaglia, Roy Hamilton, Sharon Thompson-Schill, Shi Gu, Danielle Bassett In Vivo Evidence for Long-term Potentiation in Older Adults Fabio Porto, Anne Fox, Erich Tusch, Farzaneh Sorond, Abdul Mohammed, Kirk Daffner Deep Repetitive Transcranial Magnetic Stimulation and Cycling Improve Lower Limb Function in Chronic Stroke: A Randomized, Placebo-controlled, Crossover Study Raffaella Chieffo, Fabio Giatsidis, Elise Houdayer, Mario Fichera, Arturo Nuara, Elisabetta Coppi, Laura Ferrari, Giovanni Di Maggio, Roberto Santangelo, Antonella Poggi, Maria Sessa, Mauro Comola, Abraham Zangen, Giancarlo Comi, Letizia Leocani A Stimulating Idea: Treating Mixed ET/PD Tremor with Novel DBS Approach Ramsey Falconer, Sean Rogers, Christopher Kalhorn


The Longitudinal Relationship Between Inflammatory Burden and Gait Speed Is Influenced by White Matter Microstructural Characteristics: Secondary Analysis of the Health ABC Study Neelesh Nadkarni, Robert Boudreau, Oscar Lopez, Howard Aizenstein, Stephen Kritchevsky, Kristine Yaffe, Stephanie Studenski, Anne Newman, Caterina Rosano

I10-5B

Cortical Reorganization and Magnetoencephalographic Correlates for Paretic Hand Recovery After Stroke ChihWei Tang, Fu-Jung Hsiao, Po-Lei Lee, Yun-An Tsai, Ya-Fang Hsu, I-Hui Lee

I10-5C

Brain Structural Abnormalities in Patients with Major Depression with or Without Generalized Anxiety Disorder Comorbidity Elisa Canu, Milutin Kostic, Federica Agosta, Ana Munjiza, Pilar Ferraro, Danilo Pesic, Massimiliano Copetti, Amir Peljto, Dusica Lecic Tosevski, Massimo Filippi

4:45 p.m.–5:15 p.m. I10-5D

In Vitro and in Vivo Effects of Ionizing Radiation on Cell Cycle Progression and Self-renewal of Subventricular Zone Neural Precursors Hongxin Chen, Sonia De Toledo, Matthew Goodus, Edouard Azzam, Steve Levison, Nizar Souayah

I10-5E

Induction of Functional and Structural Plasticity by Intermittent Theta Burst Stimulation in Post-stroke Aphasia Joseph Griffis, Rodolphe Nenert, Jane Allendorfer, Jerzy Szaflarski

I10-5F

Genetic Association Study of Cognitive Performance Jonathan Katz, Chuanhui Dong, Yaakov Stern, Clinton Wright, Susan Blanton, Ralph Sacco

Roundtable Discussion


I10-5G

Tractography Activation Patterns in Dorsolateral Prefrontal Cortex Suggest Better Clinical Responses in Deep Brain Stimulation (DBS) of the Anterior Limb of the Internal Capsule and Nucleus Accumbens (ALIC-NA) for Obsessivecompulsive Disorder (OCD) Christian Hartmann, J. Lujan, Ashutosh Chaturvedi, Wayne Goodman, Michael Okun, Cameron McIntyre, Ihtsham Haq

I10-5H

HDAC4 Shuttling Promotes Neuronal Remodeling After Stroke Amjad Shehadah, Haifa Kassis, Michael Chopp, Cynthia Roberts, Zheng Gang Zhang

I10-5I

Personal Experience with Dance and Cortical Gray Matter Thickness in the Cognitively Normal and Mild Cognitive Impaired Elderly Shai Porat, Kristy Hwang, Ellen Woo, Theodore Zanto, Naira Goukasian, Liana Apostolova

I10-5J

Network Control Theory as a Mediator of Transcranial Magnetic Stimulation Effects John Medaglia, Roy Hamilton, Sharon Thompson-Schill, Shi Gu, Danielle Bassett

I10-5K

In Vivo Evidence for Longterm Potentiation in Older Adults Fabio Porto, Anne Fox, Erich Tusch, Farzaneh Sorond, Abdul Mohammed, Kirk Daffner

I10-5L

Deep Repetitive Transcranial Magnetic Stimulation and Cycling Improve Lower Limb Function in Chronic Stroke: A Randomized, Placebocontrolled, Crossover Study Raffaella Chieffo, Fabio Giatsidis, Elise Houdayer, Mario Fichera, Arturo Nuara, Elisabetta Coppi, Laura Ferrari, Giovanni Di Maggio, Roberto Santangelo, Antonella Poggi, Maria Sessa, Mauro Comola, Abraham Zangen, Giancarlo Comi, Letizia Leocani

I10-5M

A Stimulating Idea: Treating Mixed ET/PD Tremor with Novel DBS Approach Ramsey Falconer, Sean Rogers, Christopher Kalhorn

5:15 p.m.–6:00 p.m.

99

Wednesday April 22

4:05 p.m.–4:10 p.m.

Poster Session V

Wednesday, April 22

P5 First Poster Session V Authors stand by Posters from 5:00 p.m.–6:30 p.m. Poster Discussion Session: Aging, Dementia, Cognitive, and Behavioral Neurology

2:00 p.m.–6:30 p.m.


P5.001 Differentiating the Logopenic

and Nonfluent/Agrammatic Variants of Primary Progressive Aphasia by Selective Word Comprehension Impairment Collin York, Sharon Ash, Katya Rascovsky, Murray Grossman

P5.002 Cumulative, Additive Benefits

of Memantine-Donepezil Combination Over Component Monotherapies in Moderate to Severe Alzheimer’s Dementia: A Pooled Area Under the Curve Analysis Alireza Atri, Suzanne Hendrix, Vojislav Pejovic, Robert Hofbauer, John Edwards, Jose Luis Molinuevo, Stephen Graham

P5.003 The Longitudinal Evaluation of

Familial Frontotemporal Dementia Subjects (LEFFTDS) Protocol: Known Kindreds and Preliminary Data Bradley Boeve, Howard Rosen, Adam Boxer, Bradford Dickerson, Howard Feldman, Nupur Ghoshal, Jill Goldman, Neill Graff-Radford, Murray Grossman, Ging-Yuek Hsiung, Edward Huey, David Irwin, Clifford Jack, Kejal Kantarci, David Knopman, John Kornak, Ian R.A. Mackenzie, Bruce Miller, Leonard Petrucelli, Rosa Rademakers, Leslie Shaw, Arthur Toga, John Trojanowski, Zbigniew Wszolek

P5.004 Pseudo-continuous Arterial Spin Labeling Is Sensitive to Changes in Cerebral Blood Flow in Semantic Variant Primary Progressive Aphasia and Nonfluent/Agrammatic Primary Progressive Aphasia Christopher Olm, Benjamin Kandel, Brian Avants, John Detre, James Gee, Corey McMillan, Murray Grossman

P5.005 Initial Experience with

[18F]AV1451 PET in AD and Non-AD Tauopathies Gil Rabinovici, Daniel Schonhaut, Rik Ossenkoppele, Suzanne Baker, Andreas Lazaris, Sam Lockhart, Henry Schwimmer, James O'Neil, Miguel Santos, Zachary Miller, Brianne Bettcher, Adam Boxer, Howard Rosen, Maria Gorno Tempini, Bruce Miller, William Jagust

P5.006 Clinical Correlates and

Baseline Predictors of Progressive Brain Atrophy in Progressive Supranuclear Palsy: Results from the AL-108-231 Davunetide Trial Richard Tsai, Iryna Lobach, Jennifer Whitwell, Matthew Senjem, Clifford Jack, Adam Boxer

P5.007 White Matter Hyperintensity

Associated with Cerebral Amyloidosis Independent of Hypertension History Julia Scott, Duygu Tosun-Turgut, Meredith Braskie, Paul Thompson, Michael Weiner, Charles DeCarli, Owen Carmichael

P5.008 Occupational Attainment

Delays Cognitive Decline in Frontotemporal Degeneration Lior Rennert, Sharon Xie, Lauren Massimo, Katya Rascovsky, Corey McMillan, Murray Grossman

P5.009 Defining the White Matter

Hyperintensity Penumbra: A Pulsed Arterial Spin Labeling Study Nutta-on Promjunyakul, David Lahna, Jeffrey Kaye, Hiroko Dodge, Deniz Erten-Lyons, William Rooney, Lisa Silbert

P5.010

Sensitivity and Specificity of New Criteria for the Diagnosis of Corticobasal Degeneration Clara Boyd, Michael Tierney, Eric Wassermann, Salvatore Spina, Adrian Oblak, Bernardino Ghetti, Jordan Grafman, Corey McMillan, Edward Huey

e-Poster Session: Aging, Dementia, Cognitive, and Behavioral Neurology Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch screen displays.

P5.011

Sirtuin 3 Is Down-regulated in Apolipoprotein E4 Carriers with Alzheimer’s Disease Junxiang Yin, Peng Cheng Han, Richard Caselli, Thomas Beach, Geidy Serrano, Eric Reiman, Jiong Shi

P5.012

Quantitative Digital Image Analysis of Pick’s Disease Neuropatholgy David Irwin, Mathew Byrne, Corey McMillan, Virginia Lee, Murray Grossman, John Trojanowski

P5.013

GRN-related Frontotemporal Lobar Degeneration TDP43 Type A Presenting as a Case of Posterior Cortical Atrophy Sara Mitchell, Diane Lucente, Mykol Larvie, Matthew Frosch, Bradford Dickerson

Aging, Dementia, Cognitive, and Behavioral Neurology: Amyloid and Biomarkers P5.021 Fibrillar Amyloid: Thinking Globally, Not Acting Locally Andre Altmann, Bernard Ng, Susan Landau, William Jagust, Michael Greicius

100

P5.014

Using Conversation Analysis to Help Diagnose Dementia Daniel Blackburn, Markus Reuber

P5.015

Mitochondrial Encephalopathy with Lactic Acidosis and Stroke (MELAS) Presenting as an Apparent Neoplastic Process Aaron Rothstein, Ihtsham Haq

P5.016

Concordance Between 11C-PIB-PET and AB42 in a Memory Clinic Patricio Chrem Mendez, Leandro Urrutia, German Falasco, Silvia Vazquez, Ricardo Allegri

P5.022 Cross Validation of Imaging

and CSF Biomarkers in a Clinical Setting Daniela Perani, Chiara Cerami, Silvia Caminiti, Leonardo Iaccarino, Roberto Santangelo, Andrea Falini, Giuseppe Magnani

P5.023

Presence of Cerebral Amyloid Modulates Phenotype and Pattern of Neurodegeneration in Early Parkinson’s Disease Corey McMillan, David Wolk

P5.017

Differential Progression of White Matter Hyperintensities in Early-onset Compared to Late-onset Alzheimer’s Disease: A Longitudinal MRI Study Nicodemus Oey, Hani Zainal, Alvin Cenina, Nagaendran Kandiah

P5.019

P5.018

Decline in Naming in Patients with Primary Progressive Aphasia Is Associated with the Strength of Functional Correlation Between Homologous Prefrontal Cortices in the Initial MRI Andreia Faria, Aaron Meyer, Donna Tippett, Rajani Sebastian, Susumu Mori, Rhonda Friedman

P5.020 Description of a Method:

P5.024 The Effects of Asymptomatic

P5.026 Quantitative α-synuclein Level

B-amyloid Positivity on Cerebral Metabolism and CSF-pTau Levels Monica Gentchev, David Zhu, Andrea Bozoki

P5.025 Neuroticism Increases with

Age in Cognitively Normal Older Adults Who Are PiB-positive Carolyn Fredericks, Virginia Sturm, Alice Hua, Murat Bilgel, Dean Wong, Susan Resnick, William Seeley

Verbal Episodic Memory and Spatial Memory Correlate Differentially with Hippocampal Volume in Older Adults Ali Ezzati, Vahid Eslami, Michael Lipton, Mindy Katz, Martin Sliwinski, Richard Lipton Assessment of Phosphorylated Tau Protein by Immunohistochemistry in the Skin of Patients with Neurodegenerative Diseases Juan Carrizales-Rodriguez, Maria Jimenez-Capdeville, Ildefonso RodriguezLeyva, Erika Chi

Is Associated with Higher Diffuse Amyloid Plaque and Amyloid Oligomer Burdens HoYann Jong, Randall Woltjer, Hiroko Dodge, Jeffrey Kaye, Lisa Silbert, Deniz Erten-Lyons

P5.027 Role of Plasma Clusterin

in Mild Cognitive Impairment, Alzheimer’s Disease, and Vascular Dementia Venugopalan Vishnu, Manish Modi, Manju Mohanty, Niranjan Khandelwal, Bhagwant Mittal, Sudesh Prabhakar


Poster Session V

P5.028 Investigating Blood Gene

Expression Levels as a Biomarker for LOAD Mariet Allen, Xue Wang, Daniel Serie, Jeremy Burgess, Michaela Kachadoorian, Samantha Strickland, Thuy Nguyen, Kimberly Malphrus, Sarah Lincoln, Minerva Carrasquillo, Steven Younkin, Julia Crook, Yan Asmann, Ronald Petersen, Nilufer Taner

P5.029 Tau Protein Concentrations

Are Significantly Increased in CSF Extracellular Vesicles of Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Innocenzo Rainero, Maria Chiara Deregibus, Silvia Boschi, Elisa Rubino, Pierpaola Fenoglio, Lorenzo Pinessi, Giovanni Camussi

P5.030 Increased Cerebrospinal Fluid Total-tau Levels in Hereditary Behavioralvariant Frontotemporal Dementia David Irwin, Corey McMillan, Katya Rascovsky, EunRan Suh, Leslie Shaw, Steven Arnold, Virginia Lee, Vivianna Van Deerlin, John Trojanowski, Murray Grossman

Neuroepidemiology: Aging, Dementia, Cognitive, and Behavioral Neurology, General Neurology, and Research Methodology and Education

P5.037 Insights into the Classification

of Myasthenia Gravis Tetsuya Akaishi, Yasushi Suzuki, Yuriko Nagane, Shigeaki Suzuki, Hiroyuki Murai, Tomihiro Imai, Masakatsu Motomura, Takuhiro Yamaguchi, Kazuo Fujihara, Masashi Aoki, Kimiaki Utsugisawa

P5.038 Breadth Vs. Volume: The

Outpatient Neurology Clinic Experience in Medical Education Dara Albert, Angela Blood, Yoon Soo Park, James Brorson, Rimas Lukas

Neuroepidemiology: Headache, Global Health, and Infectious Disease P5.039 Perception of the Family

Burden of Chronic Migraine: Results of the CaMEO (Chronic Migraine Epidemiology and Outcomes) Study Dawn Buse, David Dodick, Aubrey Manack

P5.040 Effects of Demographic

and Socioeconomic Characteristics on Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results from the CaMEO (Chronic Migraine Epidemiology and Outcomes) Study David Dodick, Richard Lipton, Michael Reed, Kristina Fanning, Aubrey Manack, Adrian Holden

Factor for Cognitive Dysfunction in Adults with Sickle Cell Disease Dana Jorgensen, Enrico Novelli, Elizabeth Sarles, Anne Ritter, John Cole, Meryl Butters, Caterina Rosano

Prevalence of Migraine Headache and Its Weight on Neurological Burden in Africa: A 43-year Systematic Review and Meta-analysis of Communitybased Studies Yohannes Woldeamanuel, Anna Andreou, Robert Cowan

P5.032

P5.042 Pain Comorbidities of Episodic

P5.031 Hemoglobin Is a Potential Risk

Early Development of Proliferative Retinopathy Increases Risk of Cognitive Dysfunction in Middle-aged Adults with Type 1 Diabetes Karen Nunley, Christopher Ryan, Judith Saxton, Trevor Orchard, Tina Costacou, Howard Aizenstein, John Ryan, Rachel Miller, Caterina Rosano

P5.033 Early Clinical Features of

Familial and Sporadic Frontotemporal Dementia in an Italian FTD Cohort— the Apulia FTD Population-based Registry Rosa Capozzo, Simona Arcuti, Rosanna Tortelli, Maria Rosaria Barulli, Alessandra Grasso, Marianna Tursi, Bruno Brancasi, Franco Valluzzi, Vincenzo Solfrizzi, Francesco Carnicella, Claudia Dell'Aquila, Angelo Zenzola, Gerardo Ciardo, Bruno Tartaglione, Patrizia Milzi, Francesco Panza, Giancarlo Logroscino

P5.034 Incidence and Predictors of

Poststroke Depression: Results from the Framingham Heart Study Joel Salinas, Alexa Beiser, Jayandra Himali, Jonathan Rosand, Sudha Seshadri, Erin Dunn

P5.035 Demographics and Impact on

Diagnosis of Neurological Consultations in the ICU Natalie Weathered, Laura Lennihan

P5.036 Healthcare Utilization

After a Diagnosis of Conversion Disorder Alexander Merkler, Neal Parikh, Simriti Chaudhry, Alanna Chait, Nicole Allen, Babak Navi, Hooman Kamel

P5.041

and Chronic Migraine: Results from the CaMEO (Chronic Migraine Epidemiology and Outcomes) Study Scher Ann, Richard Lipton, Kristina Fanning, Joan Largent

P5.043 HIV Associated

Neurocognitive Disorders (HAND) in Nigeria: Clinical Rating Versus Global Deficit Score Methods Jibreel Jumare, Akolo Christopher, Mariana Cherner, Anya Umlauf, Kanayo Okwuasaba, Lindsay Eyzaguirre, Ruxton Adebiyi, Dakum Paul, Joyce Johnson, Terence Hendrix, Alash'le Abimiku, William Blattner, Walter Royal

P5.044 Adult Tuberculous Meningitis

in Qatar: A Descriptive Retrospective Study from Its Referral Center Yahia Imam, Hassan Ahmedullah, Naveed Akhtar, KC Chacko, Saadat Kamran, Faraj Al-Alousi, Zubaida Al-Suwaidi, Muna Almaslmani, Abdullatif Al-Khal, Dirk Deleu

P5.045 Etiologies of New Onset

Seizure in HIV-infected Zambian Adults Omar Siddiqi, Melissa Elafros, Izukanje Sikazwe, Chris Bositis, Igor Koralnik, Michael Potchen, William Theodore, Lisa Kalungwana, Gretchen Birbeck

P5.046 Predictors of Poor Outcome

in Bacterial Meningitis: Retrospective Analysis of Nationwide Inpatient Sample Devanshi Dharaiya, Sumul Modi, Stefania Maraka


P5.047 Pilot Study of a

P5.057 GDF15 (Growth Differentiation

P5.048 Cluster of Acute Flaccid

P5.058 Initial Results from the

Neuroepidemiologic Screening Tool in Rural Uganda Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Xiangrong Kong, Kevin Robertson, Ronald Gray, Maria Wawer, Ned Sacktor Paralysis and Cranial Nerve Dysfunction in Children Temporally Associated with an Enterovirus D68 Outbreak in Colorado Teri Schreiner, Kevin Messacar, John Maloney, Adam Wallace, Jan Ludke, Samuel Dominguez

P5.049 Prevalence and Comorbid

Factors Associated with Distal Symmetric Polyneuropathies in HIV+ and HIV- Adults in Urban and Rural Zambia Michelle Kvalsund, Takondwa Chidumayo, Johanna Hamel, Douglas Heimburger, Gretchen Birbeck

P5.050 Mortality Predictors in

Bacterial Meningitis Patients Who Developed Hydrocephalus Khadija Irshad, Sumul Modi, Imama Naqvi, Devanshi Dharaiya

Biomarkers of Neuromuscular Disease P5.051

Progression to Clinically Meaningful Changes in ALSFRS-R Bulbar and Fine Motor Domains Is Faster in Bulbar Onset and in Limb Onset Amyotrophic Lateral Sclerosis Patients Respectively Elena Ratti, James Berry, Mark Vangel, Eric Macklin, David Schoenfeld, Merit Cudkowicz

P5.052 Skeletal Muscle, Cardiac, and Pulmonary Imaging Biomarkers of Disease Activity in a Trial of Exon-skipping for Boys with Duchenne Muscular Dystrophy Ami Mankodi, Robert Janiczek, Noura Azzabou, Lasya Gaur, Courtney Bishop, Harmen Reyngoudt, Martijn Froeling, Rexford Newbould, Andrew Arai, Pierre Carlier, Kenneth Fischbeck

P5.053 Myofiber HLA-DR

Expression Is a Distinctive Biomarker for Overlap Myositis and Inclusion Body Myositis Jessie Aouizerate, Marie De Antonio, Guillaume Bassez, Cyril Gitiaux, Romain Gherardi, Franois-J Authier

P5.054 Search for Potential

Biomarkers at Baseline in a Large ALS Cohort Study (ALS COSMOS): Plasma Creatinine and Urinary 8-oxodeoxyguanosine Hiroshi Mitsumoto, Regina Santella, Jonathan Hupf, Clement Furlong, Serge Cremers, Teress Votto, Jessica Singleton, Raymond Goetz, Irina Gurvich, Bjorn Oskarsson, Jose Americo Fernandes-Filho, Chris Gennings, Pam Factor-Litvak

P5.055 A Promising Marker to Detect Chronic Pain Syndrome Elizabeth Strong, Jafar Kafaie

Factor 15) Is the New Biomarker for Muscle-related Mitochondrial Diseases Yasutoshi Koga, Shuichi Yatsuga, Hajime Arahata, Akiko Ishii, Tatsuyuki Kakuma NeuroNEXT SMA Infant Biomarker Study Stephen Kolb, Christopher Coffey, Jon Yankey, William Arnold, Seward Rutkove, Amy Bartlett, John Kissel

P5.059

Myotonic Discharges in Autophagic Vacuolar Myopathies: A Potentially Useful Marker Ludwig Gutmann, Laurie Gutmann, Steven Moore

P5.060 A Promissing Method of CTS

Investigation: Median-radial Nerve Action Potential Splitting (MRS) Pablo Winckler, Thais Rodrigues, Isabel Bandeira, Josep Vall-Solé, Pedro Schestatsky

Neuromuscular Disease: Pathogenesis and Pathology P5.061

In Vitro Pharmacokinetic Evaluation of Eteplirsen, SRP-4045, and SRP-4053; Three Phosphorodiamidate Morpholino Oligomers (PMO) for the Treatment of Patients with Duchenne Muscular Dystrophy (DMD) P Sazani, T Magee, JS Charleston, C Shanks, J Zhang, M Carver, J Saoud, E Kaye

P5.062 Atypical Presentation of

Sporadic Inclusion Body Myositis Sheetal Shroff, Milvia Pleitez

P5.063 Sarcopenic Obesity in

Myasthenia Gravis Charlene Hafer-Macko

P5.064 Mononeuropathy Multiplex Associated with Hemophagocytic Lymphohistiocytosis Mimicking Vasculitis Chad Hoyle, Darine Kassar, William Arnold, Miriam Freimer

P5.065 Clinicopathological

Features of Patients with Neuromuscular Disease Showing CD8-MHC-1 Complex Pathology Chiseko Ikenaga, Meiko Maeda, Shoji Tsuji, Jun Shimizu

P5.066 Clinical Significance of Cation Channel Antibodies in Motor Neuron Disease Rachel Donaldson, Yuebing Li

P5.067

Clinical and Molecular Genetics Spectrum of Thymidine Kinase 2 Deficiency Caterina Garone, Emanuele Barca, Karin Kleinsteuber, Alice Donati, Salvatore DiMauro, Michio Hirano

P5.068 Guillain Barre Syndrome:

Predictors of Requirement of Mechanical Ventilation Devanshi Dharaiya, Sumul Modi, Imama Naqvi

P5.069 Pain Characteristics Do Not Distinguish Fibromyalgia Patients with Abnormal Skin Biopsy Victoria Lawson, Jesse Grewal, Kevin Hackshaw, Phillip Mongiovi

P5.056 The Neuromuscular Features of Light Chain Deposition Disease Ling Zhang, Mark Ferrante, Helen Ly, Tulio Bertorini

101

Wednesday April 22

2:00 p.m.–6:30 p.m.

Poster Session V Neuropathy: Pathogenesis and Pathology P5.070 Diffusion Tensor Imaging

(DTI) of the Cervical Cord in Sensory Neuronopathies Jean Levi Ribeiro de Paiva, Raphael Fernandes Casseb, Alberto Rolim Muro Martinez, Anamarli Nucci, Marcondes Cavalcante França Jr

P5.071

Hearing Loss in CharcotMarie-Tooth (CMT) Disease Tiffany Grider, Lenore Holte, Tracy Weisbrod, Brian Bundy, Michael Shy

P5.072 Characterization of Pain

in Patients with Charcot-Marie-Tooth Diseases Derek Huang, Christopher Lee, Jun Li

P5.073

Phenotypic Spectrum and Management of 25 Patients ATTR Val122Ile Hayet Salhi, Jean Pascal Lefaucheur, Farida Gorram, Stéphane Rappeneau, Benoit Funalot, Pascale Fanen, Bruno Coste, Thibaud Damy, Violaine PlantéBordeneuve

P5.074

Genotypic Evaluation of Patients with Chronic Inflammatory Demyelinating Polyneuropathy: Study of the PMP22 Gene Duplication/ Delection Alex Silva, Amilton Barreira, Mario Emilio Dourado Junior, Acary Oliveira, Wilson Marques

P5.075

Dysregulation of Cytokines Mediates Painful Diabetic Neuropathy Hsinlin Cheng, Jacqueline Dauch, Brandon Yanik

P5.076

Hypertensive Neuropathy in Phrenic Nerve: An Experimental Study Valria Paula Fazan, Anaceres Rodrigues, Renata Ferreira, Jaci Castania, Helio Salgado

P5.077 Increased Plasma

Level of Pigment Epithelium-derived Factor Is Associated with Diabetic Neuropathy Delaram Safarpour, Varun Shandal, Siok Dun, Jaw-Kang Chang, Jessica Wagoner, Babak Rezaei, Serge Belinga, Krishna Nalleballe, Rong-Ming Lyu, Nae Dun, Jin Luo

P5.078

Magnetic Resonance Neurography in the Diagnosis of Noncompressive Lumbosacral Radiculoplexus Neuropathies Nathaniel Robbins, Nancy Benedetti, Brian Scott, Cynthia Chin, Vanja Douglas

Epilepsy/Clinical Neurophysiology (EEG): Status Epilepticus P5.079 Prognostic Factors of

Status Epilepticus in Adults: A 6-year Retrospective Study Hoi Ki, Kate Lui, Hiu Tung, Colin Lui

P5.080 Cefepime- Induced

Nonconvulsive Status Epilepticus (NCSE), Associated with Posterior Reversible Encephalopathy Syndrome (PRES): A Case Report Emiliya Melkumova, Venkat Ramani

102

2:00 p.m.–6:30 p.m.

P5.081 Takotsubo Cardiomyopathy

Due to Status Epilepticus—an Underreported and Lethal Sequela Imad Khan, Neha Mirchandani, Galyna Pushchinska

P5.082 Status Epilepticus Secondary

to Hyperammonemia Manan Shah, Yogita Fotaria, Charles Szabo

P5.083 Good Outcome Despite Early

Refractory Myoclonic Status Epilepticus After Cardiopulmonary Arrest: A Case Report Alexandra Reynolds, Lauren Schaff, Michelle Bell, John Brust, Sachin Agarwal

P5.084 Refractory Status Epilepticus Secondary to Atypical Rasmussen Encephalitis Successfully Managed with Aggressive Immunotherapy Sung Cho, Andrew Zeft, Elia Pestana Knight, Prakash Kotagal, Elaine Wyllie, Ahsan Naduvil Valappil

P5.085 Clobazam as Add-on Therapy in Refractory Status Epilepticus Sanjeev Sivakumar, Mohammad Ibrahim, Gregory Norris, Dennis Parker, Jr., Aashit Shah, Wazim Mohamed

P5.086 Primary Hyperammonemic

Encephalopathy as a Mimicker of Non-convulsive Status Epilepticus: Therapeutic Implications of Underlying Etiology Nandhagopal Ramachandiran, Fathiya Al-Murshedi, Povothoor Jacob, Arunodaya Gujjar, Abdullah Al-Asmi

P5.087

Mortality, Causes, and Predictors of Death in Status Epilepticus Yoojin Lee, Eun Ju Choi, Jin Pyo Hong, Joong Koo Kang

P5.088 Does Status Epilepticus Per

Se Cause Cerebrospinal Fluid Pleocytosis in the Absence of Infection? Farzad Moien Afshari, Noman Hassan, Gary Hunter

Epilepsy/Clinical Neurophysiology (EEG): Nonepileptic Seizures P5.089 Comparison of Clinical and Neuropsychiatric Profiles of Patients with Intermittent PNES (iPNES) and Non-epileptic Psychogenic Status (NEPS) Kanika Arora, Pawan Rawal, Barbara Dworetzky, Jerzy Szaflarski

P5.090 Assessment of Subjective

Seizure Symptoms in Psychogenic Non-epileptic Seizures: The Revised Psychosensory-psychomotor Phenomena Interview (PPPI-PNES) Sana Sharrack, Jack Garlovsky

P5.091 Psychogenic Nonepileptic

Seizures in Men: Comparison of Clinical and Psychosocial Features Between Afro-American and Caucasian Patients Abuhuzeifa Abubakr, Ilse Wambacq

P5.092 Clinical and Neuropsychiatric Profiles of Patients with Psychogenic Non-epileptic Seizures (PNES) and Epilepsy Kanika Arora, Pawan Rawal, Barbara Dworetzky, Jerzy Szaflarski

P5.093 Comparison of Characteristics of Patients with Non-epileptic Versus Epileptic Seizures in Epilepsy Monitoring Unit Aradia Fu, Samara Cerven, David Denny, Naudia Moorley, Steve Chung

P5.094

Public Awareness, Knowledge and Attitude Toward Epilepsy in Aseer Region, Saudi Arabia Community Based Cross Sectional Study Adel Alhazzani, Abdulaziz Alqahtani, Khalid Asiri, Hassan Alamri, Ahmed Aboelyazeed

P5.095 The Relationship Between

Level of Education and Public Awareness, and Attitude Toward Epilepsy— Community Based Cross Sectional Study from Aseer Region, Saudi Arabia Ali Alqahtani, Adel Alhazzani, Nawaf Alqahtani, Abdullatef Muhaya, Ahmed Aboelyazeed

Edema, Encephalopathy, and Encephalitis P5.096 Changes in Serum Osmolality

Are Associated with Brain Volume Change in Severe Hepatic Encephalopathy Eric Liotta, Anna Romanova, Bryan Lizza, Brandon Francis, Michael Berman, Andrew Naidech, Matthew Maas

P5.097 Autoimmune Encephalitis: Are

Immunomodulatory Therapies Effective? A Retrospective Review of Functional Ratings Prior to and Post Treatment Naveen George, Alexander Rae-Grant, Jar-Chi Lee, Sneha Ramesh, Pravin George

P5.098 Severe Global Cerebral Edema Secondary to Hypercapnic Respiratory Acidosis Responsive to Hyperosmolar Therapy: A Case Report David Roh, Fawaz Al-Mufti, Alexander Merkler, Nicholas Morris, Sachin Agarwal, Jan Claassen, Soojin Park

P5.099 Recurrent Encephalopathy and Seizures as a Manifestation of Ibuprofen Meningoencephalitis Anik Amin, Steven Lewis

Inflammation and Neurotoxicities P5.106

Lateropulsion—the Case of a Flip Flopper Amy Chan, Joachim Baehring

P5.107

Occurrence of Post-lumbar Puncture Headache in an Academic LP Clinic Brian Mac Grory, Babar Khokhar

P5.108 Nonparaneoplastic

Autoimmune Dementia: Cognitive Profiles and Predictors of Immunotherapy Response in a Latin American Cohort Galeno Rojas, Julieta Quiroga, Ricardo Reisin, Luciana Leon Cejas, Pablo Bonardo, Ignacio Demey, Carlos Rugilo, Oscar Martinez, Alfredo Thomson, Luz Lopez Llano, Juan Ollari, Manuel Fernandez Pardal

P5.109 Cannabinomimetic

Neurotoxicity Divya Mella, Sheetal Shroff, Robert Smith, Elena Shanina

P5.110

Disulfiram Toxicity Presenting with Peripheral Neuropathy and Unique Lesions on MRI Brain Nazely Ashikian, Yuri Bronstein, Mitchell Danesh, Francisco Torres

P5.111 Inflammatory

Radiculomyelopathy Associated with SAPHO Syndrome Ricardo Dornas, Osvaldo Nascimento, Camila Pupe, Caroline Bittar, Carlos Bruno Nogueira, Felipe Vianna, Bruno Coutinho, Frederico Prado

P5.112

Diagnostic Criteria of Chronic Inflammatory Demyelinatig Polyneuropathy in Diabetes Mellitus Itay Lotan, Mark A. Hellman, Israel Steiner

P5.113

Unusual Cause of Severe Back Pain in a Patient with Isolated IgG Deficiency Awss Zidan, Vishal Shah, Deborah Bradshaw

P5.114

Interferon-alpha in a Patient with West Nile Virus Myelitis: A Case Report Rouzbeh Fateh, Flavia Nelson, Sonia Krish, Rodrigo Hasbun, John Lindsey

P5.100

Intraventricular Tobramycin for Bacterial Meningitis Na Tosha Gatson, Divya Mella, Jennifer Johnson, Lucido Ponce Mejia, Monica Loghin

P5.101

Ischemia, Myelitis, and Vascular Malformations

Recurrent Encephalitis After Seasonal Influenza Vaccine Priya Narwal, Annie Daniel, Christine Mintz, Amre Nouh Mild Encephalopathy with Reversible Splenial Lesion Related to Antiepileptic Drugs: Report of 3 Cases Suraj Rajan, Kristin King, Gulshan Uppal, Anantha Vellipuram, Niranjan Singh

P5.102

Hypercytokinemia Induced Encephalopathy Following Melphalan Administration Matthew Freeman, Divyanshu Dubey, Om Neeley, Gregory Carter

P5.103

Fatal Cerebral Edema After Trazodone Overdose David Avila

P5.104

Steroid Responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT) with Stroke Like Symptoms. A Case Report Vijayakumar Javalkar, Syed Abbas, Meghan Harris

P5.105

Catatonia in Limbic Encephalitis Treated with Electroconvulsive Therapy Karin Mente, Jeffrey Kim, Alexander Rae-Grant

P5.115

P5.116

Transient Global Amnesia Syndrome: Report of Patients Evaluated in the First 24 Hours Marcela Uribe Roca, Julieta Quiroga Narvaez, Fatima Pantiu, Gisele Pacio, Luciana Leon Cejas, Galeno Rojas, Sol Pacha, Oscar Martinez, Pablo Bonardo, Ricardo Reisin, Manuel Fernandez Pardal

P5.117

Clinical and Radiological Evolution in a Patient with Extrapontine Myelinolysis David Roeltgen

P5.118

SLIPPERS: Supratentorial Lymphocytic Inflammation with Parenchymal Perivascular Enhancement Responsive to Steroids: A Case Report Cynthia Armand, Jerome Graber, Fred Lado, Patrick LaSala, Karen Weidenheim

P5.119

Severe Necrotizing Myelopathy from Toxacariasis Rick Magun, Jamie Silva


Poster Session V

P5.120

FibroCartilaginous Embolism, an Underdiagnosed Cause of Spinal Cord Infarction; Critical Review of Literature, New Diagnostic Criteria, Mechanisms Mahmoud AbdelRazek, Ashkan Mowla, Nicholas Silvestri, Salman Farooq, Haris Kamal, Noureldin Abdelhamid, Robert Sawyer, Gil Wolfe

P5.121

Unusual Extensive Collateral Venous Network in a Patient with Multiple Cerebral Venous Thromboses Sara Duffus, Laura Bishop, Ryan Hughes, Ihtsham Haq

P5.122

Mycoplasma Pneumoniae Infection Presenting as Stroke and Meningoencephalitis with Aortic and Subclavian Aneurysms Without Pulmonary Involvement—a Rare Case Report Jihad Inshasi, Pournamy Sarathchandran, Abubaker Almadani, Suhail Alrukn, Ayman Alboudi

P5.123

Gray Matter Predominant Longitudinally Extensive Transverse Myelitis: A Rare Association with Metastatic Papillary Thyroid Carcinoma Poorvi Dalal, Shaheryar Hafeez, Asma Zakaria

P5.124

Alice in Wonderland Syndrome Associated with a Temporoparietal Cavernoma Jeffrey Kornitzer, Michelle Philips, David Marks, Huey-Jen Lee, Nizar Souayah

P5.125

Cerebral Fat Embolism Syndrome an Uncommon Form of Coma Ayman Al-salaimeh, Manoj Kumar, Archana Hinduja

Cerebrovascular Disease and Interventional Neurology: Biomarkers and Emerging Science P5.126

Acute Cerebral Infarction as the Presenting Feature of Anti-PL-7 Antisynthetase Syndrome Nonnie McNicholas, Michael Henry, Aisling Ryan

P5.127

Major Hemorrhagic Complications Are Associated with Lower Coated-platelet Levels in Patients with Non-lacunar Brain Infarction Calin Prodan, Julie Stoner, George Dale

P5.128

Relationship Between ADAMTS13 Activity, Von Willebrand Factor Antigen Levels and Platelet Function in the Early and Late Phases After TIA or Ischemic Stroke Stephen Murphy, Richard Starke, Paul Harrison, Martin Brown, Paul Sidhu, Ian Mackie, Marie Scully, Samuel Machin, Dominick Mccabe

P5.129

Activated Protein C Exert Its Anti-apoptotic Activity Mediates Via PARP Inhibition Against Oxygenglucose Deprivation in Cultured Neuronal Cells Mukesh Sriwastva, Remesh K, Kameshwar Prasad, Renu Saxena, S Vivekanandhan

P5.130

Factor VIII Level Is Not Modifiable by Improved Glycemic Control in Patients with Ischemic Stroke Alyana Samai, Amelia Boehme, Alexander George, Laurie Schluter, Ramy El Khoury, Sheryl Martin-Schild

P5.131

Stroke Impairs Bactericidal Function in Phagocytes Alexander Dressel, Johanna Ruhnau, Karsten Schulze, Lara Blümke, Bernadette Gaida, Sönke Langner, Christof Kessler, Barbara Bröker, Antje Vogelgesang

P5.132

Serum Activity of Angiotensin Converting Enzyme 2, a Potential Stroke Biomarker, Is Decreased in the Acute Phase of Rat and Human Ischemic Stroke Doug Bennion, Christian Rosado, Emily Haltigan, Alexander Irwin, Robert Regenhardt, Michael Waters, Colin Sumners

P5.133

Troponin T Serum Level Is Not Associated with the Location and Volume of Acute Brain Infarction Michal Kral, Daniel Sanak, Tomas Veverka, Martin Hutyra, Eva Cechakova, David Skoloudik, Petr Kanovsky

P5.134

To Determine the Impact of Serum Albumin Levels on Admission with the Outcomes in Patients Receiving IV-t-PA (Alteplase) for Treatment of Acute Ischemic Stroke Kaustubh Limaye, Sourabh Lahoti, Archana Hinduja

P5.135

High-sensitivity C-reactive Protein, Erythrocyte Sedimentation Rate and Lactic Acid Are Associated with Internal Carotid Artery Occlusion in Chinese Stroke Patients Yongbo Zhang, Ying Lv, Dan Xie, Qin Zhang, Yufang Sun, Jimei Li

Cerebrovascular Disease and Interventional Neurology: Clinical Research Tools, Methods, and Innovations P5.136

A Systematic Review of Informed Consent in Acute Stroke Trials William Feldman, Anthony Kim, S. Josephson, Daniel Lowenstein, Winston Chiong

P5.137

Probabilistic Model to Predict the Effect Size of Acute Stroke Trials Kasra Khatibi, Maarten Lansberg

P5.138

Itemized NIHSS Subsets Predict Positive MRI Strokes in Patients with Mild Deficits Shadi Yaghi, Charlotte Herber, Joshua Willey, Amelia Boehme, Howard Andrews, Randolph Marshall, Ronald Lazar, Bernadette Boden-Albala

P5.139

REDCap UVA Vascular Neurology Database Shareena Rahman, Claire McKinley, Thomas Tandy, Andrew Southerland, Bradford Worrall, Prachi Mehndiratta, Colleen Harmon

P5.140

Interrater Reliability of the National Institutes of Health Stroke Scale: Rating by Emergency Room Physicians and Neurologists in a Population-based Study Brian Katz, Jane Khoury, Kathleen Alwell, Charles Moomaw, Dawn Kleindorfer

P5.143

Establishment of Stroke Ward Results in Immediate Reduction of Major Complications Naveed Akhtar, Saadat Kamran, A D'Souza, Yahia Imam, P Bourke, S Joseph, M Santos, Ashfaq Shuaib

P5.144

Evaluating the Clopidogrelproton Pump Inhibitor Interaction by Comparing Platelet Aggregation to ADP with Clopidogrel in the Presence of Proton Pump Inhibitors Francis Gengo, Eugene Przespolewski, Erica Westphal, Michelle Rainka, John Hourihane, Vernice Bates

Cerebrovascular Disease and Interventional Neurology: Quality Research and Initiatives P5.145

Five Year Results of a Stroke Care Network in Appalachia Michael Dobbs, Danny Rose, Lisa Bellamy, Robert Edwards

P5.146

Quality of In-hospital Stroke Care in Veterans Affairs Hospitals Michael Lyerly, Danielle Sager, Jessica Coffing, Theresa Damush, Gary Cutter, Peter King, Linda Williams

P5.147

Effectiveness of a Structured Teaching Program in Improving the Knowledge and Skills of the Care Givers and Preventing Secondary Complications in Hospitalized Stroke Patients Rohit Bhatia, Arunima Thomas, Meena Agarwal

P5.148

Health Coaching for Secondary Prevention in TIA Clinic Waimei Tai, Melinda Carter, Jared Conley, Lucy Kalanithi, Nancy Isenberg, James Bartscher

P5.156

Pontine Infarct Due to Isolated Basilar Artery Dissection Causing Supranuclear Facial Palsy Shivam Mittal, Michael De Georgia

P5.157

Intracranial Arterial Dissections Resulting from Increased Sympathetic Drive Prachi Mehndiratta, Sonal Mehta, Christopher Durst, Matthew Ehrlich, Bradford Worrall

P5.158

Systemic Inflammatory Markers in Cerebral Artery Dissection Daiana Dossi, Mauricio Farez, Federico Carpani, Ismael Calandri, Virginia Pujol Lereis, Guillermo Povedano, Sebastian Ameriso

P5.159

Intra-arterial Thrombolysis and Endovascular Treatment Is Safe and Effective in Patients with Ischemic Stroke Due to Dissection Judd Jensen, Jeffrey Wagner, Kristin Salottolo, David Loy, David Bar-Or

P5.150

Assessment of Hospital Readmissions in Stroke Patient Population from the Stroke Center at the University of Kentucky: As a Quality Measure Abdullah Al Sawaf, Jessica Lee

P5.161

P5.151

P5.162

P5.152

Cerebrovascular Disease and Interventional Neurology: Recovery and Rehabilitation

Analysis of 30 Day Unexpected Readmission Rates in Stroke Patients at an Academic Acute-care Hospital David Kushner, Estin Kelly, Rachel Morrison, Katherine Camfield Improving Resident Performance in Acute Stroke Management Through Simulation Based Training Jami Johnsen, Luciana Catanese, Judith Clark, Julie Grimes, Benjamin Saunders, Pamela Corey, Hesham Masoud

P5.142

P5.154


Acute and Long-term Management of Symptomatic Internal Carotid Artery Dissection in the Setting of Newly Diagnosed Cerebral Amyloid Angiopathy: To Anticoagulate, or Not to Anticoagulate? Ilan Danan, Jared Noroozi, Stephen Marks

The Presence of an Advanced Practice Nurse Stroke Program Coordinator Decreases Door-to-needle Times Michelle Whaley, Lisa Caputo, Jeffrey Wagner

P5.149

Is YouTube and Stroke a Bad Liaison? Harsh Gupta, Rajan Patel, Sajish Jacob, Archana Hinduja Two-year Adherence to a Stroke Prevention Program in a Latin American Cohort Ariel Luzzi, Claudia Alonzo, Laura Brescacin, Maria Zurru, Santiago Pigretti, Pedro Colla Machado, Luis Camera, Gabriel Waisman, Edgardo Cristiano

P5.155

Outcome of Acute Ischemic Stroke Caused by Cervicocephalic Arterial Dissection Following Intravenous Thrombolysis and/or Endovascular Treatment Ghasan Ahmad, Peyman Shirani, Ashkan Mowla, Mohammad Masud, Adnan Khan, Robert Sawyer, Marilou Ching, Annemarie Crumlish

Does Hospitalist Directed Care Reduce the Length of Stay for Acute Ischemic Stroke Patients and Improve Adherence to the “Get with the Guidelines” Inpatient Quality Measures? Wondwossen Tekle, Ameer Hassan, Christina Sanchez, Ahmed Malik, Erlinda Abantao, Olive Sanchez, Lisa Jones-Fillingum, Adnan Qureshi

P5.141

Cerebrovascular Disease and Interventional Neurology: Dissection

P5.153

Timing of Follow-up After Acute Ischemic Stroke and Readmissions Andrew Buletko, Zeshaun Khawaja

P5.160

Cervical Artery Dissections in the Vancouver General Hospital (VGH) Stroke Database: A Common Stroke Mechanism? Laura Wilson, Athari Salmeen, Thalia Field, Samuel Yip Carotid Spot Sign: An Early Marker of Carotid Artery Injury Tirisham Gyang, Julius Latorre

P5.163

The Cerebellar Participation in Spontaneous Post-stroke Aphasia Recovery: A Longitudinal FMRI Study Rodolphe Nenert, Jane Allendorfer, Jennifer Vannest, Scott Holland, Jerzy Szaflarski

P5.164

Transcranial Magnetic Stimulation (TMS) as a Tool for Stroke Motor Recovery: What Are We Targeting? Muhammed Gunduz, Katherine Nearing, Douglas Labar, Tsagaris Zoe, Gary Thickbroom, Mar Cortes, Matthew Fink, Dylan Edwards

P5.165

Cortical Reorganization and Magnetoencephalographic Correlates for Paretic Hand Recovery After Stroke ChihWei Tang, Fu-Jung Hsiao, Po-Lei Lee, Yun-An Tsai, Ya-Fang Hsu, I-Hui Lee

103

Wednesday April 22


Poster Session V

2:00 p.m.–6:30 p.m.

P5.166

White Matter Integrity Predicts Language Deficits in Chronic Post-stroke Aphasia Shihui Xing, Elizabeth Lacey, Xiong Jiang, Laura Skipper, Mackenzie Fama, Peter Turkeltaub

P5.179

Co-occurrence of Spatial Neglect and Perseveration Contributes to Cognitive and Functional Impairment Meghan Caulfield, Peii Chen, A. Barrett

MS and CNS Inflammatory Diseases: MS Disease Course, Activity, Progression, Cognition, and Quality of Life

P5.200 A Genders and Culture

P5.167

P5.180

P5.190

P5.201 Validation of the Brief

Using a Delphi Panel to Identify a Treatment Paradigm for Injecting Botulinum Toxin to Treat Common Postures in Post-stroke Upper Limb Spasticity David Simpson, Atul Patel, Abraham Alfaro, Ziyad Ayyoub, David Charles, Khashayar Dashtipour, Alberto Esquenazi, Glenn Graham, John McGuire, Ib Odderson

P5.168

Monitoring Treatment Effects of Transcranial Magnetic and Direct Current Stimulation in Patients with Post-stroke Aphasia: A Meta-analysis Study Priyanka Shah, Felix Gervits, Jose Torres, Juliann Purcell, Roy Hamilton

P5.169

Functional and Cognitive Prognosis in Young Stroke Manuel Martinez, Alejandra Calderon, Luis Amaya, Jose Guerrero, Raul Carrera

P5.170

Uncontrolled Discharge Diastolic Blood Pressure Is Associated with Favorable Outcome After Ischemic Stroke Konrad Schlick, Duy Le, Mani Nezhad, Kara Melmed, Jonathan Eskenazi, Shlee Song, Patrick Lyden

P5.171

Short-term Functional Outcome and Its Predictors in a Hospitalbased Cohort of Nigerians with Acute Stroke Kolawole Wahab, Emmanuel Sanya, Babatunde Ademiluyi, Abiodun Bello, Wemimo Alaofin

P5.172

Cortical Deficits and Prior Stroke Predict Stroke Recurrence in Patients with Mild Deficits Shadi Yaghi, Joshua Willey, Howard Andrews, Amelia Boehme, Randolph Marshall, Bernadette Boden-Albala

Neuro-rehabilitation: Stroke P5.173

Memantine Treatment for Post-stroke Aphasia: A Case Control Study Jennie Valles, Juliana Kennedy, Mery Elashvili, Carolin Dohle

P5.174

Preliminary Assessment of the Motor Activity Log-28 in Patients with Chronic Stroke Alexandra Simpson, Susan Conroy, Christopher Bever

P5.175

Prism Adaptation Improves Neglect-related Motor Perseveration Amit Chaudhari, A. Barrett

P5.176

Walking Quality During Inpatient Stroke Rehabilitation Assessed by Wireless Sensing Andrew Dorsch, Seth Thomas, Bruce Dobkin

P5.177

Induction of Functional and Structural Plasticity by Intermittent Theta Burst Stimulation in Post-stroke Aphasia Joseph Griffis, Rodolphe Nenert, Jane Allendorfer, Jerzy Szaflarski

P5.178

Evaluation of a Clinician Worn Device for the Quantitative Assessment of Abnormal Muscle Tone Type and Severity Elizabeth Brokaw, Ilia Itin, Dustin Heldman, Joseph Giuffrida, Erwin Montgomery

104

Robot-assisted Therapy Improves Motor Function in Individuals After Cerebral Hemispherectomy Susan Shaw, Remy Chu Jr, Eirik Blydt-Hansen, Mindy Aisen

P5.181

Medication Selfadministration After Stroke Mosunmola Oyawusi, Benjamin Levy, Antoinette Gentile, Gretchen March, Kimberly Hreha, Geraldine Pagaoa-Cruz, Jenny Masmela, Elizabeth Galletta, Sharon Holman, Cristin McKenna, Jeffrey Zhang, A. Barrett

P5.182

What’s the Difference Between Rest and Rest? Defining Baseline Brain States Important for Cognition Erica Pool, Anthony Chen, Courtney Gallen, Sahar Yousef, Michael Silver, Mark D'Esposito

Neuro-rehabilitation: MS/SCI P5.183

Arachnoiditis Mimicking an Intrathecal Catheter Tip Granuloma Pruthu Patel, Charles Brock, Emil Gaitour

P5.184

Feasibility of Telerehabilitation in Patients with Significant Mobility Disability Due to Multiple Sclerosis Joseph Finkelstein, McKenzie Bedra, Susan Conroy, Christopher Bever

P5.185

The Effect of Cooling on Community-based Walking in Heatsensitive Patients with Multiple Sclerosis: Findings from the Use of Wireless Activity Monitoring Andrew Dorsch, Seth Thomas, Barbara Giesser

P5.186

Comparison of the Kurtkze Expanded Disability Status Scale and the Functional Independence Measure: Measures of Multiple Sclerosis Related Disability Meheroz Rabadi, Andrea Vincent

P5.187

Identification and Management of Dynamic Cord Compression Using Dynamic Magnetic Resonance Imaging Deepti Anbarasan, G. Alexander Jones, Jonathan Howard

P5.188

A Network-based Cognitive Rehabilitation in Patients with Multiple Sclerosis and Mild Cognitive Impairment Micaela Mitolo, Annalena Venneri, Basil Sharrack

P5.189

Detection of Postural Sway Abnormalities by Wireless Inertial Sensors in Minimally Disabled Patients with Multiple Sclerosis Andrew Solomon, Jesse Jacobs, Karen Lomond, Susan Kasser, Sharon Henry

Evaluation of the Revised 2013 MS Clinical Course Definitions in the CLIMB Real World Cohort Tanuja Chitnis, Brian Healy, Bonnie Glanz, Rohit Bakshi, Riley Bove, Philip De Jager, Maria Houtchens, Dorlan Kimbrough, Christopher Severson, James Stankiewicz, Lynn Stazzone, Howard Weiner

Comparison of Psychological and Social Aspects of Quality of Life in Multiple Sclerosis Patients Heidemarie Lex, Sana Syed, Jacob Sloane, Wolfgang Freidl International Cognitive Assessment for Multiple Sclerosis (BICAMS) in Argentina Sandra Vanotti, Ralph Benedict, Fernando Caceres

P5.202 Adding Brain Volume Loss to

No Evidence of Disease Activity—Past, Present, and Future Richard Rudick, Amy Pace, Kartik Raghupathi, Carmen Castrillo, Robert Hyde

the Modified Rio Scoring System Improves Prediction of Future Disability Progression: Analyses from Fingolimod Phase III Trials Maria Pia Sormani, Ludwig Kappos, Till Sprenger, Daniela Piani Meier, Dieter Haering, Davorka Tomic, Nicola De Stefano

P5.192

P5.203 Monitoring Disease

P5.191

‘Doctor, Can I Stop My Medicine?’ Analysis of Disease Course After Stopping Disease-modifying Therapy in Stable MS Patients Ilya Kister, Timothy Spelman, Pierre Duquette, Marc Girard, Jeannette Lechner-Scott, Francois Grand'Maison, Mark Slee, Suzanne Hodgkinson, Alessandra Lugaresi, Maria Edite Rio, Maria Trojano, Helmut Butzkueven, Joseph Herbert

P5.193

Do Individuals with Radiologically Isolated Syndrome Have a Different Clinical Outcome Once They Convert to Clinically Isolated Syndrome? Aksel Siva, Melih Tutuncu, Orhun Kantarci, Ugur Uygunoglu, Pinar Acar, Asli Kurne, Mark Keegan, Ayse Altintas, Sabahattin Saipoglu, Rana Karabudak, Daniel Pelletier, Darin Okuda, Christine Lebrun Frenay

P5.194

Cognition in MS Across the Lifespan Ariana Frontario, Colleen Schwarz, Margaret Kasschau, Jillian Chan, Brian Harel, Adrian Schembri, Nneka Amadiume, Lauren Krupp, Leigh Charvet

P5.195

Isolated Cognitive Relapses and Long-term Cognitive Decline in Multiple Sclerosis Matteo Pardini, Antonio Uccelli, Jordan Grafman, Özgür Yaldizli, Giovanni Mancardi, Luca Roccatagliata

P5.196

German Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) Iris-Katharina Penner, Patrick Kandziora, Jana Poettgen, Christoph Heesen, Michael Lang, Herbert Schreiber

P5.197

Social Cognition Impairment According to the Clinical Phenotype of Multiple Sclerosis Cecile Dulau, Antoinette Prouteau, Mathilde Deloire, Helene Diaz, Aurore Saubusse, Julie Charre-Morin, Bruno Brochet

P5.198

Depression and MRI Metrics in the CombiRx Trial Lael Stone, Stacey Cofield, Tarah Gustafson, Amber Salter, Gary Cutter, Flavia Nelson, Ponnada Narayana, Fred Lublin, Jerry Wolinsky

P5.199

Marital Status and Functional Systems Scores in a Population-based Multiple Sclerosis Cohort Jill Settle, William Culpepper, Mitchell Wallin

Progression in Aging Population with Multiple Sclerosis Vasu Saini, Katelyn Kavak, Muhammad Nadeem, Zilfah Younus, Channa Kolb, Barbara Teter, Bianca Weinstock-Guttman

P5.204 Loss of Lower Limb Motor

Evoked Potentials (MEP) as a Sign of Primary Progressive Multiple Sclerosis (PPMS) Progression Rainer Paine, Bibiana Bielekova, Tanya Lehky

P5.205 Prognostic Value of Visual

Evoked Potentials in Patients with Multiple Sclerosis Eva Costa Arpn, Clara Dominguez Vivero, Tania Garcia, José Luis Relova Quinteiro, Jose Maria Prieto Gonzalez, Manuela Lema Bouzas

P5.206 Pregnancy Does Not Prevent

Degeneration of Retinal Axons in Multiple Sclerosis Sven Schippling, Ilya Ayzenberg, Marius Ringelstein, Orhan Aktas, Sebastian Lukas, Ralf Gold, Kerstin Hellwig

P5.207 Multiple Sclerosis, Cognitive

Profile and Cognitive Testing: Predictability of SDMT and Computerized Cognitive Testing in Differentiating Employment Versus Unemployment in Patients with Multiple Sclerosis Mark Gudesblatt, Myassar Zarif, Barbara Bumstead, Marijean Buhse, Lori Fafard, Daniel Golan, Cynthia Sullivan, Jeffrey Wilken, Glen Doniger

P5.208 Stress Burden and

Satisfaction with Treatment in Caregivers and Patients with Multiple Sclerosis. MSfeeling Study Meca-Lallana Jose, Maria Del Mar Mendibe Bilbao, Rocio HernandezClares, Ana Belen Caminero Rodriguez, Javier Jose Mallada, Pablo Davila Gonzalez, Moises Garces, Montserrat Gomez, Jorge Millan Nadal, Gerardo Soriano Hernandez, Maria Campo Amigo

MS and CNS Inflammatory Diseases: Biomarkers and Disease Mechanisms P5.209 Cytokine Profile in the

Cerebrospinal Fluid of MS and CIDP Patients Arianna Sartori, Serena Bonin, Manola Comar, Jacopo Fantini, Alessio Bratina, Rita Moretti

P5.210 Prostaglandin F2α Receptor

Mediates Oligodendrocyte Precursor Injury/Death: Potential Role in Multiple Sclerosis M. Paz Soldan, Linda Schmidt, Blair Wood, John Rose, Noel Carlson


Poster Session V

P5.211

Evaluation of CSF and Serum Fetuin-A, CSF S100B and GFAP as Predictive Markers in Multiple Sclerosis Ayse Altintas, Sinem AkkasYazici, Hayrettin Tumani, Vera Lehmensiek

P5.212

Transglutaminase 6 Is a Potential Biomarker of Disease Activity and Astrocytic Proliferation in MS Daniel Gratch, Benjamin Pagano, Kelsey McDermott, Massimiliano Cristofanilli, Saud Sadiq

P5.213

Cerebrospinal Fluid Haptoglobin (Hp) Levels Are Elevated in MS Patients with Progressive Disease Bianca Ulloa, Marwan Alahiri, Ying Liu, Saud Sadiq

P5.214

Fetuin-A Correlates with Cortical Demyelination and Is a CSF Biomarker of Disease Activity in Progressive MS Mark Landy, Violaine Harris, Ying Liu, Saud Sadiq

P5.215

Fetuin-A, a CSF Biomarker of MS Disease Activity, Is Upregulated at the Blood Brain Barrier Langan Ruth-Anne, Violaine Harris, Mark Landy, Saud Sadiq

P5.216

Proteomic Analysis in CSF Identified Subtype Specific and Shared Molecular Pathways for Multiple Sclerosis Clinical Phenotypes Timucin Avsar, İlknur Durasi, Ugur Uygunoglu, Melih Tutuncu, Nuri Demirci, Sabahattin Saipoglu, Osman Sezerman, Aksel Siva, Eda Turanli

P5.217

CSF and Serum Levels of Interleukin-6, Interleukin-8, Interleukin-10, Beta-2-microglobulin and Orosomucoid at the Time of First Clinical Symptoms in MS Patients Zuzana Matejcikova, Jan Mares, Jana Klosova, Vladimira Sladkova, Silvia Skalska, Tereza Svrcinova, Jana Zapletalova, Petr Kanovsky

P5.218

Cerebrospinal Fluid Osteopontin and Neurofilament Levels Mark Different Patterns of Brain Atrophy in Clinically Isolated Syndrome Vita Direnzo, Carla Tortorella, Stefano Zoccolella, Maddalena Ruggieri, Mariangela Mastrapasqua, Damiano Paolicelli, Franca Dicuonzo, Maria Trojano

P5.219

Existence and Significance of Antibody Against the Inward Rectifying Potassium Channel KIR4.1 in Patients with Multiple Sclerosis in Western Part of Turkey Derya Kaya, Egemen Idiman, Nuri Karabay, Zekiye Altun, Sumeyye Çevik, Zaur Mehdiyev

P5.220 Clinical and Etiopathological

Evaluation of the Patients with OCB IgG Pattern-IV and V Positivity Ugur Uygunoglu, Ayse Altintas, Sinem AkkasYazici, Guher Saruhan-Direskeneli, Sibel P. Yentur, Sabahattin Saipoglu, Aksel Siva

P5.221 Biomarkers and Relapse in

CombiRx Hemant Tiwari, Amit Patki, Stacey Cofield, Tarah Gustafson, Fred Lublin, Jerry Wolinsky, Gary Cutter

P5.222 Ocular Motor Biomarkers

of Progressive Cerebral Dysfunction in Multiple Sclerosis Meaghan Clough, Lynette Millist, Teresa Frohman, Elliot Frohman, Owen White, Joanne Fielding

P5.223 Retinal Neuronal and Axonal Loss over Time as Markers of Disease Progression and Activity in Multiple Sclerosis: A Pilot Study Salim Chahin, James Wilson, Clyde Markowitz, Dina Jacobs, Ari Green, Peter Calabresi, Elliot Frohman, Steven Galetta, Laura Balcer

P5.234 Myelin Oligodendrocyte

Glycoprotein Is the Primary Myelin Protein Target of CSF B-cell Antibodies in MS Pak Ho Au, Christopher Sears, Jerry Lin, Saud Sadiq

P5.235 Immunophenotyping

Nerve Fiber Integrity and Blood Flow Velocity in Multiple Sclerosis Hong Jiang, Silvia Delgado, Jin Yuan, Wentao Yan, Delia Cabrera DeBuc, Byron Lam, Jianhua Wang

of Cerebrospinal Fluid Cells in Virusassociated Neurologic Diseases Yoshimi Akahata, Raya Massoud, Breanna Caruso, Joan Ohayon, Bridgette Billioux, Gloria Von Geldern, Bryan Smith, Avindra Nath, Steven Jacobson

P5.225 Decreased Optic Nerve Head

P5.236 Humoral Response to

P5.224 Impairment of the Retinal

Blood Flow Index Highlights Abnormal Retinal Microcirculation in Multiple Sclerosis Rebecca Spain, Zunqiu Chen, Yali Jia, Ou Tan, David Huang, Dennis Bourdette

P5.226 Clinical Relevance of

Anti-aquaporin Antibody (anti-AQP4) in Demyelinating Disease of Central Nervous System (CNS)—a Case-control Study Sankar Gorthi, Arindam Mukherjee, C Narayanan, Yedvendra Sirohi

P5.227 Interleukine 17 Is Not

Detected in Active MS Patients' Sera but in CSF in Radiologically and Clinically Isolated Syndromes Christine Lebrun Frenay, Mikael Cohen, Florence Bucciarelli, Barbara SeitzPolski, Aurelie Cornille, Beatrice Pignolet, Sylvia Benzaken, David Brassat

P5.228 The Relation Between

Meningeal Inflammation, Cortical Demyelination and White Matter Lesional Activity in Chronic Multiple Sclerosis: A Pilot Study Valeria Ramaglia, Iliana Michailidou, Hanane Touil, Corbert van Eden, Inge Huitinga, Jennifer Gommerman, Amit Bar-Or

P5.229 Immune Regulatory

Mechanisms Involved in IL-27 Induced Tolerogenic Myeloid DCs Felipe Von Glehn Silva, Gopal Murugaiyan, Bonny Patel, Maria Antonietta Mazzola, Sushrut Jangi, Chantal Kuhn, Leonilda Santos, Howard Weiner, Roopali Gandhi

P5.230 B1 Cells Are Unaffected

by Immune Modulatory Treatment in Remitting-Relapsing Multiple Sclerosis Patients Damiano Rovituso, Stefanie Heller, Michael Schroeter, Christoph Kleinschnitz, Stefanie Kuerten

P5.231 Th1 and Th17 Cytokines Profile and Its Relation to Demographic, Clinical and Radiological Features in Early Disease Stage Multiple Sclerosis Ana Cristina Wing, Claudia Cristina Vasconcelos, Thais Ferreira, Fernanda Rueda, Solange Maria Das Gr Camargo, Taissa Kasahara, Regina Alvarenga, Cleonice Bento

P5.232 Deep Sequencing of T-cell

Receptor Repertoire Reveals Enrichment of Highly Expanded Clonotypes in Cerebrospinal Fluid from Patients with Multiple Sclerosis Alessandra De Paula Alves Sousa, Kory Johnson, Richard Nicholas, Sam Darko, David Price, Daniel Douek, Steven Jacobson, Paolo Muraro

P5.233 Thermal Stable

Immunoglobulin G Antibodies in Multiple Sclerosis Ian Stewart, Xiaomeng Li, Yiting Liu, Michael Graner, Xiaoli Yu


Epstein-Barr Virus Is Associated with Cortical Pathology in Patients with Multiple Sclerosis Murali Ramanathan, Nicole Cerza, Bianca Weinstock-Guttman, Jesper Hagemeier, Ellen Carl, Darlene Badgett, Deepa Ramasamy, Robert Zivadinov

P5.237 Excess Lipid Accumulation

in Cortical Neurons in Multiple Sclerosis May Lead to Autophagic Dysfunction and Neurodegeneration Insil Kim, Danielle DeBartolo, Sriram Ramanan, Gerald Ponath, David Pitt

P5.245 Blood-brain Barrier

Permeability and Brain Injury in CIS Patients Tomas Uher, Dana Horakova, Michaela Tyblova, David Zeman, Eva Krasulova, Katerina Mrazova, Zdenek Seidl, Manuela Vaneckova, Jan Krasensky, Bianca Weinstock-Guttman, Murali Ramanathan, Eva Havrdova, Robert Zivadinov

P5.246 Does CSF Infrared

Spectroscopy Useful in Diagnosing RRMS Patients During the First Clinical Attack? Levent Ocek, Bedile Irem Tiftikcioglu, Dilek Yonar, Yasar Zorlu, Zeki Tekgul, Feride Severcan

P5.247

What Does an Isolated Cerebrospinal Fluid Monoclonal Band Mean: A Tertiary Centre Experience Turan Poyraz, Derya Kaya, Egemen Idiman, Sümeyye Cevik, Nuri Karabay, Duygu Arslan, Yasemin Karakaptan

P5.248 Brain Temperature Is

Elevated in Relapsing-remitting Relative to Progressive Multiple Sclerosis Victoria Leavitt, Alayar Kangarlu, Feng Liu, Claire Riley, James Sumowski

P5.238 Metabolite Profiling of

Cerebrospinal Fluid Derived from MS Patients Danielle Blemur, Fozia Mir, Saud Sadiq

MS and CNS Inflammatory Diseases: NMO and NMO Spectrum Disorders I

P5.239 Functional Characterization

P5.249 New Acute Severity Scale for

of Myeloid Dendritic Cells in Peripheral Blood of Patients with Multiple Sclerosis Juergen Haas, Alexander Schwarz, Mirjam Korporal-Kuhnke, Brigitte Wildemann

P5.240 Retinal Structure Injury

and CSF Humoral Response in Multiple Sclerosis Jessica Chorostecki, Navid Seraji-Bozorgzad, Fen Bao, sherridan Reed, Christina Caon, Carla Santiago Martinez, Evanthia Bernitsas, Elliot Frohman, Omar Khan

P5.241 The Role of Chronic

Inflammation on Amyloid Burden in Multiple Sclerosis Gabriele De Luca, Richard Hickman, Alissa Gutnikova, Michelle Vogelaar, Elliott Ridgeon, Georgina Colquhoun, Margaret Esiri

P5.242 Global Metabolomics

Identifies Perturbation of Multiple Metabolic Pathways in Multiple Sclerosis Pavan Bhargava, Ellen Mowry, Peter Calabresi

P5.243 Estrogen Receptor Alpha in

Peripheral Blood Lymphocytes of Multiple Sclerosis Patients: A Pivotal Study of Its Role in Pregnant Patients Marinella Clerico, Santina Cutrupi, Simona Rolla, Stefania De Mercanti, Andrea Iannello, Eleonora Virgilio, Michele De Bortoli, Luca Durelli

P5.244 Multiple Sclerosis and

Epstein-Barr Virus: Antibodies to Nuclear Antigen 1 Also Bind a Human Ribonucleoprotein John Lindsey

Neuromyelitis Optica Relapses Michael Levy, Maureen Mealy, Sven Jarius, Friedemann Paul, Orhan Aktas, Simon Broadley, Philippe Cabre, May Han, Anu Jacob, Gareth John, Maria Leite, Romain Marignier, Ichiro Nakashima, Jacqueline Palace, Sven Schippling, Anthony Traboulsee, Brian Weinshenker, Dean Wingerchuk

P5.250 Pregnancy Outcome in

Aquaporin-4 Positive Neuromyelitis Optica Spectrum Disorder Matthew Nour, Ichiro Nakashima, Ester Coutinho, Mark Woodhall, Filipa Sousa, Jon Revis, Yoshiki Takai, Jithin George, Joanna Kitley, Maria Santos, Joseph Nour, Fan Cheng, Hiroshi Kuroda, Tatsuro Misu, Ana Martins-daSilva, Gabriele De Luca, Angela Vincent, Jacqueline Palace, Patrick Waters, Kazuo Fujihara, Maria Leite

P5.251 Influence of Female Sex

and Fertile Age on Neuromyelitis Optica (NMO) Nadja Borisow, Ingo Kleiter, Corinna Trebst, Anna Gahlen, Katrin Fischer, Sven Jarius, Friedemann Paul, Kerstin Hellwig

P5.252 Immunological Analysis of

MOG Autoantibody Positive NMOSD and Aquaporin-4 Autoantibody Positive NMOSD Satoru Tanaka, Akihiro Kubota, Hikoaki Fukaura, Kyoichi Nomura, Douglas Sato, Kazuo Fujihara

P5.253 NMO IgG: The Impact of

the NMO Biomarker on Diagnosis and Treatment of NMO and NMOSD Luis Tornes, Leticia Tornes, Melissa Ortega, Sylvia Delgado, Janice Maldonado, William Sheremata, Kottil Rammohan

P5.254 Processing Speed and

Informant Reports of Executive Functioning in Neuromyelitis Optica Ana Arenivas, Maureen Mealy, Adam Kaplin, Michael Levy

105

Wednesday April 22


Poster Session V P5.255 Depressive State and Chronic Fatigue in Neuromyelitis Optica Tetsuya Akaishi, Ichiro Nakashima, Tatsuro Misu, Kazuo Fujihara, Masashi Aoki

P5.256 Cognitive Function and Fatigue in Patients with Neuromyelitis Optica: Comparison with MS Subtypes Cris Constantinescu, I-Jun Chou, Radu Tanasescu, Christopher Tench, Su-Yin Lim, Giulio Podda

MS and CNS Inflammatory Diseases: NMO and NMO Spectrum Disorders Treatment P5.257 Bevacizumab Is Safe in Acute

Relapses of Neuromyelitis Optica Michael Levy, Maureen Mealy

P5.258 Rituximab as First-line

Therapy in Neuromyelitis Optica: Efficiency and Tolerability Raphael Bernard-Valnet, Christine Lebrun Frenay, Bertrand Audoin, Bertrand Bourre, Sophie Pittion, Sandrine Wiertlewski, Romain Marignier, Jonathan Ciron, Bruno Brochet, David Brassat, Helene Zephir

P5.259 Autologous Hematopoietic

Stem Cell Transplantation in Neuromyelitis Optica—an Update Jodie Burton, Jan Storek, Peter Duggan, Fiona Costello, Luanne Metz

P5.260 Efficacy of Rituximab in

Refractory Neuromyelitis Optica Jerome De Seze, Collongues Nicolas, David Brassat, Elisabeth Maillart, Pierre Labauge, Jean Ouallet, Bruno Brochet, Thibault Moreau, Bertrand Bourre, Bertrand Audoin, Sandra Vukusic, Romain Marignier

P5.261

Laquinimod Prevents NMOIginduced Disease Exacerbation in a Model of Neuromyelitis Optica Azeb Tadesse Argaw, Linnea Asp, Jingya Zhang, Patrick Waters, Liat Hayardeny Nisimov, Michael Levy, Gareth John


Tocilizumab as Second Line Therapy in Neuromyelitis Optica Unresponsive to Rituximab Jose Meca Lallana, Rocio Hernandez Clares, Ester Carreon Guarnizo, Judith Jimenez Veiga, Begoña Palazon Cabanes, Gema Salgado Cecilia, Adelaida Leon Hernandez, Ruben Carrasco Torres, Maria Cerdan Sanchez, Jose Javier Martin Fernandez

P5.263 Dalfampridine for

Symptomatic Treatment of Neuromyelitis Optica Clerc Christine, Bertrand Bourre, Bereau Mathieu, Helene Zephir, Chanson Jean-Baptiste, Nicolas Collongues, Frederic Blanc, Christophe Zaencker, Patrick Vermersch, Jerome De Seze

P5.264 Safety of Rituximab as First-

line Therapy in Neuromyelitis Optica (NMO) and NMO-spectrum Disorders: Five Years of Experience Ester Carreón-Guarnizo, Rocio Hernández-Clares, Begoña PalazónCabanes, Rubén Carrasco-Torres, Gema Salgado, Judith Jimenez-Veiga, Adelaida León-Hernández, Jose Javier MartínFernández, Jose Meca-Lallana

106

2:00 p.m.–6:30 p.m.

P5.265 Prospective Evaluation of

Maintenance Plasma Exchange (mPLEX) for Attack Prevention in Neuromyelitis Optica Spectrum Disorder: Preliminary Feasibility, Safety, and Efficacy Data Dean Wingerchuk, Brian Weinshenker, Jonathan Carter, Sean Pittock, Vanda Lennon, Andrew McKeon, Claudia Lucchinetti, Mark Keegan

P5.266 Use of Tocilizumab in

a Pediatric Patient with Aggressive Neuromyelitis Optica Spectrum Disorder Sona Narula, Amy Waldman, Grant Liu, Brenda Banwell, Melissa Lerman

MS and CNS Inflammatory Diseases: NMO and NMO Spectrum Disorders II P5.267 Diverse Spinal Cord Pathology in Neuromyelitis Optica Robert Charlson, Jonathan Howard

P5.268 Activation of Plasmacytoid

Dendritic Cells in Neuromyelitis Optica Patients Rafael Dias-Carneiro, Marilia Andrade, Felipe Von Glehn Silva, Alliny Dionete, Adriel Moraes, Carlos Otavio Brandao, Vinicius Boldrini, Alfredo Damasceno, Fernando Pradella, Guilherme Morais, Paula Russini, Alessandro Farias, Benito Damasceno, Charles Tilbery, Leonilda Santos

P5.269 Aquaporin-4 Antibody

Negative Neuromyelitis Optica with Extensive Hemispheric Brain Lesion: A Pathological Study Recai Turkoglu, Fugen Aker, Handan Misirli, Erdem Tuzun

P5.270 Neuromyelitis Optica's Related Optic Neuritis Can Be Distinguished by Optic Nerve Enhancement Characteristics and Resistance to Steroids Dan Buch, Julien Savatovsky, Romain Deschamps, Olivier Gout

P5.271 Serum Chitinase 3-like 1

Levels in Patients with Multiple Sclerosis and Neuromyelitis Optica Derya Kaya, Zekiye Altun, Egemen Idiman, Nuri Karabay, Sumeyye Cevik, Duygu Arslan

P5.272 The Plasma Antiaquaporin

Antibodies and the Outcome of Myelitis in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders: Any Relationship? Egemen Idiman, Fethi Idiman, Derya Kaya, Sümeyye Cevik, Zekiye Altun, Zaur Mehdiyev

P5.273 Natural Course of

Neuromyelitis Optica (NMO) in Patients with No Long-term Treatment Ayse Altintas, Mecbure Nalbantoglu, Ugur Uygunoglu, Gokcen Gozubatik-Celik, Sabahattin Saipoglu, Aksel Siva

P5.274

Recurrent Optic Neuritis (rON) Is Characterised by Anti-MOG Antibodies: A Follow-up Study Konstantina Chalmoukou, Panos Stathopoulos, Harry Alexopoulos, Sofia Akrivou, Marinos Dalakas

P5.275 Spectrum of MOG

Autoantibody-associated Inflammatory Diseases in Pediatric Patients Silvia Tenembaum, Patrick Waters, Maria Leite, Mark Woodhall, Juan Princich, Martin Segura, Maria Talarico, Marina Szlago, Angela Vincent

P5.276

Characterization of the Spectrum of Argentinean Neuromyelitis Optica According to the Diagnostic Criteria and AQP4 IgG Serostatus Andres Villa, Eliana Garino, Silvia Tenembaum, Luciana Melamud

Movement Disorders: Tremor P5.277 Tremor on Smiling Deepak Kalra, Srivadee Oravivattanakul

P5.278 Reduced Purkinje Cell Counts

in Essential Tremor Cases Vs. Controls: Further Support for the Neurodegenerative Hypothesis of Essential Tremor Elan Louis, Matthew Choe, Phyllis Faust

P5.279 Unilateral Focused Ultrasound Thalamotomy in Essential Tremor: 3-year Safety and Efficacy Data Binit Shah, Tiffini Voss, Diane Huss, W. Jeffrey Elias, Madaline Harrison, Johanna Loomba, Mohamed Khaled, Robert Frysinger

P5.280 Optimal Speech Outcome

Requires Precise Stimulation Location in Deep Brain Stimulation for Essential Tremor Joseph Matsumoto, Tepanta Fossett, Minsoo Kim, Joseph Duffy, Edythe Strand, Andrew McKeon, Kendall Lee, Squire Stead, Andrea Adams, Bryan Klassen

P5.281 Dexmedetomidine Affects an Essential Tremor During DBS Surgery Evgeny Tsimerinov, Zarine Harutyunyan, Michele Tagliati

P5.282 A Stimulating Idea: Treating

Mixed ET/PD Tremor with Novel DBS Approach Ramsey Falconer, Sean Rogers, Christopher Kalhorn

P5.283 Self-perception of Tremor and Dyskinesia Umer Akbar, Danielle Dousa, Ana Abrantes, Joseph Friedman

P5.284 Progressive Cerebellar

Atrophy in Patients with Tremorpredominant Parkinson’s Disease Camila Piccinin, Luiza Piovesana, Rachel Guimaraes, Maria Santos, Brunno Campos, Lidiane Campos, Paula Azevedo, Fabio Torres, Marcondes França Jr, Augusto Amato-Filho, Iscia Lopes-Cendes, Fernando Cendes, Anelyssa D'Abreu

P5.285 Deep Brain Stimulation (DBS)

Improves Refractory Tremor Caused by Central Pontine Myelinolysis (CPM) Jason Gerrard, Damoun Safarpour, Duarte Machado, Bahman Jabbari

P5.286 Analysis of Parkinson's

Disease Prodromal Symptoms Among Essential Tremor Subjects: Is Essential Tremor a Risk Factor for the Development of Parkinson's Disease? Richard Salazar, Emily Peters, Linda Daniel, Amber Heck

Movement Disorders: Huntington's Disease P5.287 Predictive Testing for

Huntington’s Disease (HD): Clinical Characteristics and Motivations of Individuals at One Academic Center Andrew Herndon, Seon Nam, Lauren Korty, Jody Corey-Bloom

P5.288 Using a Wii Balance Board to Measure Disease Onset in Huntington’s Disease Andrew Herndon, Jody CoreyBloom, Anastasia Lam, Paul Gilbert, Daniel Goble

P5.289 Phenotypic Variability in

Huntington Disease: An Observational Prospective Study Filipe Sobral Blanco, Luísa Simões da Cunha, Fradique Moreira, Ana Sofia Morgadinho, Joao Lemos, Cristina Januário

P5.290 Assessing Psychiatric

Symptoms in Individuals with, and at Risk for, Huntington’s Disease Jody CoreyBloom, Andrew Herndon, Stephen Howell

P5.291 Objective Measurement

of Gait Abnormalities in Huntington Disease Using a Shoe-worn Inertial Sensor Penelope Hogarth, Arthur Lenahan, Alicia Portillo, Ravi Ramachandran, Katie Stenson, Anna Legedza, Martyn Botfield, Fay Horak, James McNames, Mahmoud El-Gohary

P5.292 Time Processing in

Huntington’s Disease Agostino Patricia, Emilia Gatto, Cesarini Martin, Ana Sanguinetti, Jose Luis Etcheverry, Diego Golombek

P5.293 Intermediate CAG Repeats

in Huntington´s Disease. Analysis of the European Huntington´s Disease Cohort Network´s Registry Esther Cubo Delgado, Maria Antonia Ramos-Arroyo, Saul Martinez-Horta, Asuncion MartinezDescalls

P5.294 Huntington’s Disease and the Heart: Electrocardiogram Abnormalities Suggest Cardiac Involvement Christopher Stephen, Steven Hersch, Herminia Rosas

P5.295 Optical Coherence

Tomography in Huntington Disease Patients Emilia Gatto, Virginia Laura Parisi, Susana Ochoa, Dario Scocco, Estela Fernandez Rey

P5.296 A Case of "Prodromal"

Huntington's Disease with Neuropathology Daphne Robakis, Jean Paul Vonsattel, Karen Marder

P5.297 Therapeutic Benefit of a

HTT-lowering Antisense Oligonucleotide Targeting the CAG-repeat in the R6/2 Huntington’s Disease Mouse Model Nicole Datson, Susan Mulders, Jeroen van der Giessen, Anchel Gonzalez, Giles Campion, Judith Van Deutekom

Neuro-ophthalmology/ Neuro-otology II P5.298 Visualization of Nerve

Fiber Orientation in the Human Optic Chiasm Using Photomicrographic Image Analysis Christian Lueck, Neeranjali Jain, Swaranjali Jain, Xiaofei Wang, Andrew Neely, Murat Tahtali, Sanjiv Jain

P5.299 Contrast Sensitivity Visual

Acuity Is Degraded in REM Sleep Behavior Disorder Jacqueline Sanchez, Matthew Khayata, Whitney Hough, Peggy Vogt, Eric Keasler, Garrett Barr, David Huang, Charles Maitland



P5.300 Attenuated Hunter Syndrome: A Rare Cause of Simultaneous Retinal and Optic Nerve Disease Kannan Narayana, Heather Lau, Rachel Nolan, Janet Rucker, Laura Balcer, Steven Galetta

P5.301 Acute Retinal Necrosis in the

Setting of Varicella Zoster Vasculopathy— Case Report and Review of Literature Ali Saeed, David Kaufman, Eric Eggenberger

P5.302 Retinal Pathology in Idiopathic

Moyamoya Angiopathy Detected by Optical Coherence Tomography Philipp Albrecht

P5.303 Vertigo and Nystagmus in

Orthostatic Hypotension Kwang-Dong Choi, Jae-Hwan Choi, Seung-Han Lee, Ji Soo Kim

P5.304 Obesity and Overweight Are Highly Prevalent in Pediatric Secondary Pseudotumor Cerebri Syndrome Grace Paley, Claire Sheldon, Evanette Burrows, Marianne Chilutti, Grant Liu, Shana McCormack

P5.305 Association Between

Sociodemographic Factors and Outpatient Appointment Adherence in Patients with Idiopathic Intracranial Hypertension Asha Shah, Heather Moss

P5.306 Localization of Synaptic

Proteins in Nerve Fibers of the Rat Cornea Samuel Geurkink, Branden Carr, Kenneth Miller

P5.307 Retinal Oximetry-derived

Biomarkers of Metabolic Dysfunction in MS Marlen Lucero, Amy Conger, Darrel Conger, Millad Sobhanian, Victoria Stokes, Teresa Frohman, Owen White, Laura Balcer, Peter Calabresi, Robert Rennaker, Elliot Frohman, Shin Beh

P5.308 Characterization of Idiopathic

Intracranial Hypertension (IIH) in Qatar Mais Alkawaz, Nour Barakat, Fatema AlMannaie, Marc Dinkin

P5.309 Asymmetry of the Vertical

Translational Vestibulo-ocular Reflex in Idiopathic Downbeat Nystagmus Mark Walker, Alessandro Serra

P5.313

Clinical Features, Diagnostic Findings, and Treatment of Adult-onset Opsoclonus-myoclonus Syndrome: A Case Series Pooja Raibagkar, Shamik Bhattacharyya, Olga Rosenvald Szenberg, Ivana Vodopivec, Shirley Wray

P5.314

Retinal Ganglion Cell Injury in Early Pediatric Onset MS Jennifer Graves, Hardeep Chohan, Benjamin Cedars, Samuel Arnow, Hao Yiu, Emmanuelle Waubant, Ari Green

P5.315

Miller Fisher Syndrome from Asialo-GM1 Antibodies: “How Can a Rare Disease Become Rarer?” Amanda Tomlinson, Laxmi Dhakal, William Freeman

P5.316

Extraocular Muscle Fatigue Evaluation in Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE) Claudia Vinciguerra, Pamela Federighi, Francesca Rosini, Elena Pretegiani, Elena Cardaioli, M.T. Dotti, Francesco Sicurelli, Antonio Federico, Alessandra Rufa

P5.317

Validation of Strategies to Streamline High and Low Contrast Visual Acuity Testing in ALS Subjects Lindsay Boven, Qin Li Jiang, Heather Moss

P5.318

Coning Following Lumbar Puncture in a Patient with Idiopathic Intracranial Hypertension Christian Lueck, Andrew Hughes, Adeniyi Borire

P5.319

Retinal Lesion Evolution in Susac Syndrome Alexander Brandt, Timm Oberwahrenbrock, Fiona Costello, Karen Gertz, Ilka Kleffner, Friedemann Paul, Richard Bergholz, Jan Dörr

P5.320 Comparative Study Between

Benign Paroxysmal Positional Vertigo (BPPV) of the Horizontal Canal (H-BPPV) and Posterior Canal (P-BPPV) Ana Bisonni, Guillermo Videla, Juan Ignacio Rojas, Edgardo Cristiano

P5.321 Burkitt’s Lymphoma

Presenting with Bilateral Abducens Palsy Ela Akay, Paul Maddison

P5.310

Afferent and Efferent Visual System Involvement in Cerebrotendinous Xanthomatosis Francesca Rosini, Elena Pretegiani, Andrea Mignarri, Antonio Federico, Pierre Daye, Lance Optican, M.T. Dotti, Alessandra Rufa

P5.311

Saccadic Oscillations After Doping Suggest a Possible Mechanism for Cerebellar and Omnipause Neurons Dysfunction Elena Pretegiani, Francesca Rosini, Raffaele Rocchi, Federica Ginanneschi, Lance Optican, Alessandra Rufa

P5.312

Comparison of Cirrus and Spectralis Optical Coherence Tomography: Factors Associated with Differences in Retinal Nerve Fiber Thickness Measurement James Wilson, Salim Chahin, Dina Jacobs, Clyde Markowitz, Peter Calabresi, Elliot Frohman, Steven Galetta, Laura Balcer


Annual Meeting Edition Planning for the 2015 AAN Annual Meeting—and earning 10 FREE Self-Assessment CME credits— has never been easier: 1. Take the convenient online pre-test by April 17, 2015, to assess your knowledge and receive recommendations for Annual Meeting courses and areas to improve 2. After attending the meeting, successfully complete the online post-test to receive your CME

An AAN Member Exclusive—

FREE to Members Only!

AAN.com/view/NeuroSAEAM

Platform Blitz Sessions

Wednesday, April 22

Utilizing a similar format to the popular Emerging Science Sessions, these dynamic sessions will feature five-minute author presentations followed by five-minutes of questions and answers. The session will conclude with all authors participating in a panel discussion. S29 Neuroimaging Correlates in Multiple Sclerosis Platform Blitz 4:00 p.m. S29.001 Factors Associated with Spinal Cord Atrophy in the First Five Years After a Clinically Isolated Syndrome Wallace Brownlee, Patricia Alves Da Mota, Ferran Padros, Josephine Swanton, Katherine Miszkiel, Daniel Altmann, Sebastien Ourselin, Claudia Wheeler-Kingshott, Olga Ciccarelli, David Miller 4:10 p.m. S29.002 FLAIR* MRI Improves Diagnostic Accuracy in Multiple Sclerosis Ilena George, Pascal Sati, Martina Absinta, Irene Cortese, Elizabeth Sweeney, Colin Shea, Daniel Reich 4:20 p.m. S29.003 FLAIR* for the Non-invasive Histological Diagnosis of Multiple Sclerosis Tom Campion, Paul Smith, Benjamin Turner, Daniel Altmann, Pascal Sati, Jane Evanson, Ilena George, Marc Miquel, Daniel Reich, Klaus Schmierer 4:30 p.m. S29.004 Novel Semi-quantitative Ageadjusted MRI Scale Correlates Highly with Clinical Disability in Multiple Sclerosis Patients Peter Kosa, Mika Komori, Ryan Waters, Tianxia Wu, Irene Cortese, Joan Ohayon, Kaylan Fenton, Jamie Cherup, Tomas Gedeon, Bibiana Bielekova 4:40 p.m. S29.005 Cortical Lesion Burden on 7-tesla MRI Is Associated with Cognitive and Physical Disability in Multiple Sclerosis Daniel Harrison, Snehashis Roy, Dzung Pham, Susan Courtney, Brian Caffo, Peter Van Zijl, Peter Calabresi 4:50 p.m. S29.006 Thalamic Atrophy over Time in Relapsing Forms of MS: A Large, 5-year, Observational MRI Study Christina Azevedo, Sankalpa Khadka, Shuang Liu, Daniel Pelletier 5:00 p.m. S29.007 Default-mode Network Changes in MS Patients with Depression: A Link to Cognitive Impairment? Gioacchino Tedeschi, Sabrina Esposito, Rosaria Sacco, Marida Della Corte, Alessandro d'Ambrosio, Renato Docimo, Luigi Lavorgna, Antonio Gallo, Mario Cirillo, Fabrizio Esposito, Simona Bonavita 5:10 p.m. S29.008 Spontanous Remyelination Has a Major Impact on Clinical Disability in Multiple Sclerosis: A Longitudinal PET Study with 11C-PIB Benedetta Bodini, Mattia Veronese, Daniel Garcia-Lorenzo, Marco Battaglini, Emilie Poirion, Leorah Freeman, Caroline Papeix, Bernard Zalc, Maya Tchikviladze, Catherine Lubetzki, Michel Bottlaender, Federico Turkheimer, Bruno Stankoff 5:20 p.m. S29.009 Advanced Imaging in Lesion and Normal-appearing White Matter over 2 Years in MS Patients Treated with Alemtuzumab Irene Vavasour, Alex MacKay, David Li, Cornelia Laule, Anthony Traboulsee 5:30 p.m.

Panel Discussion

S30 Cerebrovascular Disease and Interventional Neurology: Diagnostics, Biomarkers, and Genetics Platform Blitz 4:00 p.m. S30.001 Metabolomic Analysis Reveals Novel Small Molecule Plasma Markers of Hyperacute Ischemic Stroke Wenjun Deng, Chris Beecher, Charles Burant, Frank De Jong, Mary Lopez, Thomas Wickham, Mikaela Elia, Kathleen Feeney, David McMullin, Ferdinand Buonanno, Eng Lo, MingMing Ning 4:10 p.m. S30.002 TIA Biomarkers Determined Through Proteomics Paul George, Michael Mlynash, Christopher Adams, Calvin Kuo, Stephanie Kemp, Madelleine Garcia, Gregory Albers, Jean-Marc Olivot 4:20 p.m. S30.003 Yield and Safety of Brain Biopsy in Patients with Suspected CNS Vasculitis Jose Torres, Caitlin Loomis, Steven Messe 4:30 p.m. S30.004 Pathophysiological Decrease in the Regional Cerebral Blood Flow in Hashimoto's Encephalopathy: A Multiple-case SPECT Study Masamichi Ikawa, Tomoko Muramatsu, Katsuya Sugimoto, Akiko Matsunaga, Osamu Yamamura, Tadanori Hamano, Yasunari Nakamoto, Hidehiko Okazawa, Makoto Yoneda 4:40 p.m. S30.005 Serial Transcranial Doppler for Diagnosis and Monitoring of Cerebral Vasoconstriction Syndrome Sebastian Koch, Frank Cabera, Yosdely Cabera, Alan Flores 4:50 p.m. S30.006 General Anesthetic Use and Clopidogrel Resistance During Neurovascular Stenting Procedures Yamin Shwe, Santiago Ortega-Gutierrez, Jinu Kim, Karen Chen, Srinivasan Paramasivam, Alex Berenstein, Johanna Fifi 5:00 p.m. S30.007 Coated-platelet Levels Are Associated with Stenosis Progression in Patients with Carotid Atherosclerosis Angelia Kirkpatrick, Andrea Vincent, Nhan Nguyen, George Dale, Calin Prodan 5:10 p.m. S30.008 Trends in 24-hours Sodium and Potassium Intake, and Association with All-cause Mortality Among US Stroke Survivors Amy Towfighi, Michelle Lin, Daniela Markovic, Bruce Ovbiagele 5:20 p.m. S30.009 Exceptional Aggressiveness of Cerebral Cavernous Malformation Disease Associated with PDCD10 Mutations. Tania Rebeiz, Abdul Ghani Mikati, Amy Akers, Lingiioa zhang, Issam Awad 5:30 p.m.

Panel Discussion

S31 Epilepsy/Clinical Neurophysiology (EEG): Epilepsy Therapy Platform Blitz 4:00 p.m. S31.001 Review of Suicidality Events in Perampanel Clinical Studies Alan Ettinger, Cindy Dobrinsky, Haichen Yang, Betsy Williams, Dongyuan Xing, Randi Fain, Antonio Laurenza 4:10 p.m. S31.002 Reducing Severity of Comorbid Psychiatric Symptoms in an Epilepsy Clinic Using a Colocation Model: Results of a Pilot Intervention Jasper Chen, Tracie Caller, Erik Kobylarz, Krzysztof Bujarski, Vijay Thadani, Barbara Jobst 4:20 p.m. S31.003 Generic Versus Brand-name Lamotrigine Bioequivalence in Generic-sensitive Epilepsy Patients: A Field Test of the Public Bioequivalence Standard Tricia Ting, Wenlei Jiang, Jessica Wong, Jace Jones, Allan Krumholz, Maureen Kane, James Polli 4:30 p.m. S31.004 Safety and Adverse Events Related to Laboratory Test Results in Perampanel Phase III Epilepsy Clinical Studies Timothy Welty, David Vossler, Haichen Yang, Betsy Williams, Dinesh Kumar, Antonio Laurenza, Barry Gidal 4:40 p.m. S31.005 Seizure Outcome After Switching Antiepileptic Drugs: A Matched, Prospective Study Jon Finamore, Michael Sperling, Tingting Zhan, Christopher Skidmore, Maromi Nei, Scott Mintzer 4:50 p.m. S31.006 Assessment of Enrollment Criteria in Clinical Trials for Drug Resistant Epilepsy Christopher Cheng, Daniel Friedman, Danielle Becker, Jacqueline French 5:00 p.m. S31.007 Adjunctive Perampanel for the Treatment of Drug-resistant Primary Generalized Tonic-clonic (PGTC) Seizures in Patients with Idiopathic Generalized Epilepsy (IGE): A Doubleblind, Randomized, Placebo-controlled Phase III Trial Jacqueline French, Gregory Krauss, Robert Wechsler, Xuefeng Wang, Bree DiVentura, Christian Brandt, Eugen Trinka, Terence J O'Brien, Antonio Laurenza, Anna Patten, Francesco Bibbiani 5:10 p.m. S31.008 MRI-guided Stereotactic Laser Ablation of Mesial Temporal Structures for the Treatment of Refractory Temporal Lobe Epilepsy Ramses Ribot, Jonathan Jagid, Enrique Serrano, Merredith Lowe, Gustavo Rey, Leticia Tornes, Andres Kanner 5:20 p.m. S31.009 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Adult Patients with Partial-onset Seizures Pavel Klein, Jimmy Schiemann, Michael Sperling, John Whitesides, Wei Liang, Tracy Stalvey 5:30 p.m.

Panel Discussion

S32 Movement Disorders: Tremor, Ataxia, and More Platform Blitz 4:00 p.m. S32.001 Reduced Purkinje Cell Dendritic Arborization and Loss of Dendritic Spines in Essential Tremor Elan Louis, Jean-Paul Vonsattel, Phyllis Faust 4:10 p.m. S32.002 Antisense Oligonucleotides for the Treatment of Spinocerebellar Ataxia Type 2 (SCA2) Daniel Scoles, Matthew Schneider, Meera Pratap, Gene Hung, Frank Rigo, Frank Bennett, Thomas Otis, Stefan Pulst 4:20 p.m. S32.003 Exome Sequencing Improves Clinical Diagnosis of Sporadic or Familial Cerebellar Ataxia Brent Fogel, Hane Lee, Joshua Deignan, Samuel Strom, Sibel Kantarci, Xizhe Wang, Fabiola Quintero-Rivera, Eric Vilain, Wayne Grody, Susan Perlman, Daniel Geschwind, Stanley Nelson 4:30 p.m. S32.004 Episodic Ataxia Type 1: Natural History, Quality of Life and Patientreported Symptoms. Tracey Graves, Robert Griggs, Brian Bundy, Joanna Jen, Robert Baloh, Michael Hanna 4:40 p.m. S32.005 Study of Beta Cells and Neurons Indicate Incretin Analogs as Potential Therapeutics for Friedreich’s Ataxia. Massimo Pandolfo, Mariana Igoillo-Esteve, Amélie Hu, Ewa Gurgul-Convey, Laila Romagueira Bichara Dos Santos, Jonas JeanChristophe, Decio Eizirik, Miriam Cnop 4:50 p.m. S32.006 Predictors of Poor Outcome in Neuroleptic Malignant Syndrome: Retrospective Analysis of Nationwide Inpatient Sample Sumul Modi, Devanshi Dharaiya 5:00 p.m. S32.007 Fewer Than Two Hours of Daily Centromedian Thalamic Stimulation Produces Significant Tic Reduction in Tourette Syndrome: Two-year Followup of a Personalized, Scheduled DBS Duty Cycle Strategy Justin Rossi, Jonathan Shute, Aysegul Gunduz, Kelly Foote, Michael Okun 5:10 p.m. S32.008 An Analysis of Psychoactive Drugs Used in PD: A UF NPF-QII Study Daniel Martinez-Ramirez, Juan Giugni, Amanda Eilers, Alberto Bona, Leili Shagholi, Bilal Ahmed, Sol De Jesus, Leonardo Almeida, Valerie Rundle-Gonzalez, Erin Hastings, Michael Okun 5:20 p.m. S32.009 CSF Aβ1-42 Predicts Cognitive Impairment in De Novo PD Patients Mark Terrelonge, Karen Marder, Daniel Weintraub, Roy Alcalay 5:30 p.m.

Panel Discussion

S33 Aging, Dementia, Cognitive, and Behavioral Neurology: Biomarkers and Pathology Platform Blitz 4:00 p.m. S33.001 Transthyretin as Potential Biomarker for C9ORF72-related Diseases Marka Van Blitterswijk, NiCole Finch, Matthew Baker, Xue Wang, Kevin Bieniek, Mariely DejesusHernandez, Tania Gendron, Yan Asmann, Michael Heckman, Patricia Brown, Keith Josephs, Joseph Parisi, David Knopman, Ronald Petersen, Leonard Petrucelli, Bradley Boeve, Neill Graff-Radford, Kevin Boylan, Dennis Dickson, Rosa Rademakers 4:10 p.m. S33.002 Long and Short Telomere Lengths Are Associated with Risk of Amnestic Mild Cognitive Impairment Rosebud Roberts, Lisa Boardman, Ruth Cha, Vernon Pankratz, Ruth Johnson, Teresa Christianson, Lewis Roberts, Ronald Petersen 4:20 p.m. S33.003 Neural Origin Plasma Exosomes Provide Novel Biomarkers for Brain Insulin Resistance in Alzheimer's Disease Dimitrios Kapogiannis, Adam Boxer, Erin Abner, Arya Biragyn, Umesh Masharani, Lynda Frassetto, Ronald Petersen, Bruce Miller, Edward Goetzl 4:30 p.m. S33.004 Progranulin Protein Plasma and CSF Levels in a Large Well-characterized Dementia and Healthy Aging Cohort. Zachary Miller, Laura Mitic, Jennifer Tran, Iryna Lobach, Anna Karydas, Ginette Serrero, Rodney Pearlman, Howard Rosen, Bruce Miller, Adam Boxer 4:40 p.m. S33.005 Anti-S100B Autoantibodies in Cerebral Small Vessel Disease Chanda Brennan, Humberto Choi, Vikram Puvenna, Michael Phillips, Peter Mazzone, Damir Janigro 4:50 p.m. S33.006 Skin Cells Express Altered Proteins That Characterize the Most Common Neurodegenerative Diseases Ildefonso Rodriguez-Leyva, Erika Chi-Ahumada, Ana Calderon-Garcidueñas, Veronica Medina-Mier, Guadalupe MartelGallegos, Sergio Zarazua, Maria Jimenez-Capdeville 5:00 p.m. S33.007 Clinicopathological Correlation of Psychotic Symptoms in Neurodegenerative Diseases Georges Naasan, Estrella Morenas-Rodriguez, Lucia Lopez, Suzie Shdo, Lea Grinberg, William Seeley, Ellen Gelpi, Alberto Lleo, Bruce Miller, Katherine Rankin 5:10 p.m. S33.008 Prevalence of Cerebral Amyloid Angiopathy on Autopsy in Autosomal Dominant Alzheimer’s Disease John Ringman, Sarah Monsell, Andy Nguyen, Spencer Tung, Yan Zhou, Denise Ng, Harry Vinters 5:20 p.m. S33.009 Resveratrol Is Safe and Well-tolerated in Individuals with Mild-moderate Dementia Due to Alzheimer’s Disease. R Turner, Ronald Thomas, Suzanne Craft, Christopher van Dyck, Jacobo Mintzer, Brigid Reynolds, James Brewer, Robert Rissman, Rema Raman, Paul Aisen 5:30 p.m.

108

Panel Discussion


Platform Blitz Sessions

S34 Neuromuscular Update Platform Blitz 4:00 p.m. S34.001 Gne Myopathy Zebrafish Models with Impaired Sialylation Dino Maglic, Leoyklang Petcharat, Pongsathorn Chaiyasap, Kevin Bishop, Raman Sood, Patricia Zerfas, William Gahl, Marjan Huizing, May Malicdan 4:10 p.m. S34.002 A New Muscle Glycogen Storage Disease Associated with Glycogenin-1 Deficiency Edoardo Malfatti, Johanna Nilsson, Carola Hedberg-Oldfors, Aurelio Hernandez-Lain, Gabriel Viennet, Cristina Dominguez-Gonzalez, Fabrice Michel, Hasan Ackman, Cornelia Kornblum, Peter Van den Bergh, Norma Romero, Andrew Engel, Salvatore DiMauro, Anders Oldfors 4:20 p.m. S34.003 Mutant SNAP25B Causes Novel Congenital Myasthenic Syndrome (CMS), Cortical Hyperexcitability, Ataxia, and Intellectual Disability Xin Ming Shen, Duygu Selcen, Joan Brengman, Andrew Engel 4:30 p.m. S34.004 LRP4 Antibodies Are Frequent in Serum and CSF from Amyotrophic Lateral Sclerosis Patients John Tzartos, Paraskevi Zisimopoulou, Anastasios Tsonis, Panagiota Evangelakou, Michail Rentzos, Nikos Karandreas, Vasiliki Zouvelou, Thomas Thomaidis, Giuseppe Lauria, Francesca Andreetta, Renato Mantegazza, Talma Brenner, Panayiota Petrou, Dimitrios Karusis, Socrates Tzartos 4:40 p.m. S34.005 Large-scale Exome Sequencing in ALS Identifies New Risk Genes and Pathways Matthew Harms, Elizabeth Cirulli, Brittany Lasseigne, Tim Harris, Richard Myers, David Goldstein 4:50 p.m. S34.006 A Small-molecule Activator of Hsf1, Nrf1, and Nrf2 Mitigates Polyglutamine Toxicity in Spinal and Bulbar Muscular Atrophy Models Carlo Rinaldi, Laura Bott, Nisha Badders, Elaine Bautista, George Harmison, Ke-lian Chen, J Paul Taylor, Nico Dantuma, Kenneth Fischbeck 5:00 p.m. S34.007 Aggregates of Mutant DNMT1 Are Linked to a Spectrum of Neurological Disorders Jonathan Baets, Xiaohui Duan, Yanhong Wu, Gordon Smith, William Seeley, Ines Mademan, Nicole McGrath, Noah Beadell, Julie Khoury, Maria-Victoria Botuyan, Georges Mer, Gregory Worrell, Kaori Hojo, Jessica Delone, Matilde Laura, Yo-Tsen Liu, Jan Senderek, Joachim Weis, Peter Van den Bergh, Shana Merrill, Mary Reilly, Henry Houlden, Murray Grossman, Steven Scherer, Peter De Jonghe, Peter Dyck, Christopher Klein 5:10 p.m. S34.008 CMT Caused by a Mutation in Dystrophin-related Protein 2: Exome Sequencing Reveals a New Clinical Paradigm Kathryn Brennan, Yunhong Bai, Suola Wang, Shawna Feely, Chiara Pisciotta, Laurie Gutmann, Steven Moore, Diane Sherman, Peter Brophy, Stephan Zuchner, Michael Shy, Michael Gonzalez 5:20 p.m. S34.009 Development of ISIS-TTRRx for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Frederick Derosier, Jesse Kwon, Elizabeth Ackerman, Erin Lettow, Mason Yamashita, Steven Hughes 5:30 p.m.

Panel Discussion

S35 Child Neurology and Developmental Neurology Platform Blitz

S36 Neuroepidemiology: Movement Disorders, ALS, and Aging Platform Blitz

4:00 p.m. S35.001 A Diffusion Tensor MRI Study of Pediatric Patients with Severe Non-traumatic Brain Injury Sandra Strazzer, Maria Rocca, Erika Molteni, Elisabetta Pagani, Katia Colombo, Susanna Galbiati, Giacomo Boffa, Valentina Pastore, Giancarlo Comi, Massimo Filippi

4:00 p.m. S36.001 Accuracy of Clinical Diagnosis of Parkinson’s Disease: A Systematic Review and Bayesian Meta-analysis Giovanni Rizzo, Simona Arcuti, Davide Martino, Massimiliano Copetti, Andrea Fontana, Giancarlo Logroscino

4:10 p.m. S35.002 Transdermal Nicotine Patch as a Novel Treatment for Epilepsy Associated with a Mutation in the Nicotinic Acetylcholine Receptor Diana Sieciechowicz, Michael Kohrman 4:20 p.m. S35.003 Towards a Histological Diagnosis of Childhood Small Vessel CNS Vasculitis. Maryam Nabavi Nouri, Pascal Tyrrell, Marinka Twilt, Anastasia Dropol, Shehla Sheikh, Susanne Benseler, Cynthia Hawkins 4:30 p.m. S35.004 Differential Contribution of Cerebellar Resting State Functional Connectivity Abnormalities to Cognitive Impairment in Pediatric and Adult Patients with Multiple Sclerosis Sara Cirillo, Maria Rocca, Lucia Moiola, Angelo Ghezzi, Pierangelo Veggiotti, Ruggero Capra, Maria Amato, Agnese Fiorino, Lorena Pippolo, Maria Carmela Pera, Giancarlo Comi, Andrea Falini, Massimo Filippi 4:40 p.m. S35.005 Microvascular Abnormalities in Adrenoleukodystrophy: Effects of ABCD1 Deficiency Upon Brain Endothelium. Patricia Musolino, Yi Gong, Snyder Juliet, Sandra Jimenez, Eric Grabowski, Josephine Lok, Eng Lo, Matthew Frosch, Florian Eichler

4:10 p.m. S36.002 Risk of Parkinson's Disease After Traumatic Brain Injury Versus Nonbrain Trauma Raquel Gardner, James Burke, Jasmine Nettiksimmons, Allison Kaup, Deborah Barnes, Samuel Goldman, Caroline Tanner, Kristine Yaffe 4:20 p.m. S36.003 Nursing Home and End-of-life Care in Parkinson Disease. Delaram Safarpour, Dylan Thibault, Cynthia Boyd, Cori DeSanto, Ray Dorsey, Brad Racette, Allison Willis 4:30 p.m. S36.004 Cervical Dystonia (CD) Incidence and Diagnostic Delay in a Multiethnic Health Maintenance Organization. Sara LaHue, Kathleen Albers, Samuel Goldman, Jeffrey Klingman, Raymond Lo, Connie Marras, Amethyst Leimpeter, Robin Fross, Kathleen Comyns, Zhuqin Gu, Maya Katz, Laurie Ozelius, Susan Bressman, Rachel SaundersPullman, Cynthia Comella, Lorene Nelson, Stephen Van Den Eeden, Caroline Tanner 4:40 p.m. S36.005 Military Service and Amyotrophic Lateral Sclerosis in a US Populationbased Cohort Marc Weisskopf, Merit Cudkowicz, Norman Johnson

4:50 p.m. S35.006 Defining the Expanding Clinical Spectrum of Pediatric Onset Stiffperson Syndrome (p-SPS): A Case Series Anusha Yeshokumar, Deanna Saylor, Scott Newsome

4:50 p.m. S36.006 ALS and Military Occupation: A Population-based Case-control Study in the Danish Registries Ryan Seals, Marianthi-Anna Kioumourtzoglou, Johnni Hansen, Ole Gredal, Marc Weisskopf

5:00 p.m. S35.007 Predictive Value of Size of Portwine Stains in Sturge-Weber Syndrome Malgorzata Dymerska, Anna Kirkorian, Emma Kaplan, Catherine Bachur, Doris Lin, Bernard Cohen, Anne Comi

5:00 p.m. S36.007 Mixed Membership Trajectory Model of Cognitive Impairment in the Cardiovascular Health Study— Cognition Study Fabrizio Lecci, Brian Junker, Lewis Kuller, Oscar Lopez, James Becker

5:10 p.m. S35.008 Does a Standardized Multidisciplinary Approach Improve Outcomes for Children with NMDA Receptor Antibody Encephalitis? A Preliminary Assessment of a Single Center Experience Mered Parnes, Amber Stocco, Trung Nguyen, Jun Teruya, Jeanine Graf, Eyal Muscal

5:10 p.m. S36.008 Mediterranean-type Diet and Brain Volumes in an Elderly Population Yian Gu, Adam Brickman, Christian Habeck, Qolamreza Razlighi, Jose Luchsinger, Jennifer Manly, Nicole Schupf, Richard Mayeux, Yaakov Stern, Nikolaos Scarmeas

5:20 p.m. S35.009 Complementary and Alternative Medicine in an Outpatient Pediatric Neurology Clinic: Prevalence of Use and Attitudes Toward CAM and Prescription Medications Daniel Kenney, Paul Youssef, Sarah Jenkins, Ann Harris, Suresh Kotagal

5:20 p.m. S36.009 Additive Role of a Cognitive Frailty Model and Inflammatory State on the Risk of Disability. The Italian Longitudinal Study on Aging Michele Giannini, Vincenzo Solfrizzi, Francesco Panza, Rosa Capozzo, Rosanna Tortelli, Maria Rosaria Barulli, Davide Seripa, Nicola Quaranta, Alberto Pilotto, Emanuele Scafato, Carlo Sabbà, Giancarlo Logroscino

5:30 p.m.

Panel Discussion

5:30 p.m.

Panel Discussion

S37 Global Health and Infectious Disease Platform Blitz 4:00 p.m. S37.001 Activation of HERV-K and Response to Antiretroviral Therapy in Patients with HIV Infection and Motor Neuron Disease Bryan Smith, Richa Tyagi, Wenxue Li, Mary Wright, Rose McConnell, Elyse Singer, Ty Nguyen, Tanya Lehky, Thomas Uldrick, Priscila Goncalves, Tariq Alfahad, Joseph Berger, Avindra Nath 4:10 p.m. S37.002 Performance Characteristics of the WHO Ten Question Screen in Children with HIV in Botswana James Baier, Esther Baranov, Baphaleng Monokwane, Esha Khurana, David Bearden 4:20 p.m. S37.003 Higher Framingham Risk Score Is Associated with HIV-associated Dementia in Rural Uganda Ned Sacktor, Deanna Saylor, Gertrude Nakigozi, Noeline Nakasujja, Xiangrong Kong, Kevin Robertson, Ronald Gray, Maria Wawer 4:30 p.m. S37.004 Global Cost and Availability of Neurodiagnostic Tests: A Surveybased Analysis Hannah McLane, Aaron Berkowitz, Emma Wolper, Erica McKenzie, Sarah Wahlster, Farrah Mateen 4:40 p.m. S37.005 Evaluation and Immunomodulatory Treatment at the NIH of Children with Nodding Syndrome from Northern Uganda Ariane Soldatos, Thomas Nutman, Catherine Groden, Colleen Wahl, Sara Inati, Gretchen Buckler, Elise O'Connell, Bernard Opar, Josephine Aryek-Kwe, Robert Downing, Scott Dowell, William Gahl, Avindra Nath

Wednesday April 22

4:00 p.m–5:45 p.m.

4:50 p.m. S37.006 Evaluation of Neurofilament Heavy Chain as a Marker of Neuroaxonal Pathology and Prognosis in Acute Encephalitis Johann Sellner, Nicholas Davies, Robin Howard, Axel Petzold 5:00 p.m. S37.007 Serum and CSF Cytokines in Patients with Active CNS Lyme Disease, Other Inflammatory CNS Diseases, Encephalopathy Following Treated Lyme Disease, Other Encephalopathies, and Normal Controls John Halperin, Javier Pacheco-Quinto, Aimee Herdt, Elizabeth A. Eckman 5:10 p.m. S37.008 Balamuthia Mandrillaris Meningoencephalitis and Central Nervous System Vasculitis Diagnosed by Next-generation Sequencing of Cerebrospinal Fluid Niraj Shanbhag, Michael Wilson, Michael Reid, Neel Singhal, Barlas Benkli, Jeffrey Gelfand, Hannah Sample, Matthew Wood, Andrew Bollen, Joseph DeRisi 5:20 p.m. S37.009 Refractory Status Epilepticus (RSE) in Powassan Virus (POWV) Encephalitis Mubashir Pervez, Umair Afzal, Burk Jubelt 5:30 p.m.

Panel Discussion

109

Poster Session VI

Thursday, April 23

P6 Poster Session VI First Authors stand by Posters from 7:30 a.m.–9:00 a.m. Poster Discussion Session: Treatments, Therapeutics, and Biomarkers

7:30 a.m.–12:00 p.m.


P6.001 Relationship Between Health

Insurance Status and Patient-reported Health Outcomes Among Caucasian Native English Speakers Lidia Maria Moura, Eli Schwamm, Lee Schwamm

P6.002 Dysferlin Exon 32 Excision

by Oligonucleotides of the DNAanalogue Tricyclo-DNA as a Therapeutic Approach to Dysferlin-deficient Muscular Dystrophies Susanne Philippi, Simone Spuler, Christian Leumann, Luis Garcia

P6.003 Are CSF Tau and Phospho Tau Levels Really Biomarkers of Amyotrophic Lateral Sclerosis? Antonio Scarafino, Rosaria Leante, Alessandro Introna, Rosa Cortese, Eugenio Distaso, Eustachio D'Errico, Isabella Simone

P6.004 Treatment with Ultra-high

Dose of Methylcobalamin Attenuates Motor Dysfunction and Neuropathological Changes in Wobbler Mouse Motor Neuron Disease Ken Ikeda, Yasuo Iwasaki, Ryuji Kaji

P6.005 Biomarker - Discovery

in G-CSF Mediated Clinical ALS Stabilization Siw Johannesen, Andrei Khomenko, Dobri Baldaranov, Ines Kobor, Josefine Blume, Tim-Henrik Bruun, Jochen Grassinger, T Kammermaier, Albert Ludolph, Michael Deppe, Gerhard Schuierer, Wilhelm Schulte-Mattler, Armin Schneider, Rico Laage, Ulrich Bogdahn

P6.006 An Unusual Case of Cadasil

with Occipital Lobe Involvement Shrikant Mishra, Neal Rao, Charles Flippen, Brent Fogel, Gasser Hathout, Mariam Thomas, Jaffer Kattan, Bhavesh Trikamji

P6.007 Functional MRI Mapping of

Hepatic Encephalopathy as an Insight into Alertness Niral Patel, Nisha Bhatia, WenChing Liu, Michael Zagardo, Michael Xu, Sonu Dhillon, Hrachya Nersesyan

P6.008 Abstract Reasoning Is

Associated with Corpus Callosum Area in Neuropsychiatric Systemic Lupus Erythematosus Patients Alicja KalinowskaLyszczarz, Mikolaj Pawlak, Slawomir Michalak, Wlodzimierz Paprzycki, Katarzyna Pawlak-Buś, Piotr Leszczynski, Mariusz Puszczewicz, Wojciech Kozubski

P6.009 Safety and Feasibility

of G-CSF Compassionate Use in ALS Patients Andrei Khomenko, Dobri Baldaranov, Siw Johannesen, Ines Kobor, Josefine Blume, Tim-Henrik Bruun, Jochen Grassinger, Tina Kammermaier, Albert Ludolph, Michael Deppe, Gerhard Schuierer, Wilhelm Schulte-Mattler, Tim Friede, Rico Laage, Armin Schneider, Ulrich Bogdahn

P6.010

Hereditary Spastic Paraplegia: Characterization of an Albertan Cohort Anil Venkitachalam, Erica McKenzie, Setareh Ashtiani, Cathleen Huculak, Linda MacLaren, Oksana Suchowersky

e-Poster Session: Cerebrovascular Disease and Interventional Neurology II Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch screen displays.

P6.011

Stroke Physician Vs Stroke Neurologist—Can Anyone Thrombolyse? Aaron Gaekwad, Andrew Lee, Michelle Bronca, Lata Cheruvu, Owen Davies, Marc Agzarian, Celia Chen

P6.012

Outcomes in ICH Patients Should Be Stratified by Age with Attention to Race and ICH Score Amelia Boehme, Karen Albright, April Sisson, Angela Hays Shapshak, Gyanendra Kumar, Mitchell Elkind, Mark Harrigan

Imaging and Biomarkers in Neurological Disease P6.021 Alpha Rhythm and the

Default Mode Network: An EEG-fMRI Study Anthony Bowman, Joseph Griffis, Kristina Visscher, Allan Dobbins, Tim Gawne, Mark DiFrancesco, Jerzy Szaflarski

P6.022 A Registration Method

for Improving Test-retest Reliability in Probabilistic Diffusion Tractography Jeffrey Waugh, Jake Kuster, Jacob Levenstein, Hans Breiter, Nutan Sharma, Anne Blood

P6.023 Regional Brain Atrophy in

MND as a Diagnostic Marker Derived by Routine High Resolution MRI Gerhard Winkler, Alaleh Raji, Roland Opfer, Lothar Spies

110

P6.013

Varicella-Zoster Hemorrhagic Encephalitis in an AIDS Patient Daniel Vela-Duarte, David Pasquale, Murray Flaster

P6.014

Subarachnoid Hemorrhage as the Initial Neurologic Manifestation in Thrombotic Thrombocytopenic Purpura Jerry Wei, Atul Ramesh, Constantine Farmakidis, Krishna Nalleballe, Neville Jadeja

P6.015

Correlation Between CTA and Subsequent DSA Collateral Scores in Acute Ischemic Stroke Alejandro Santillan, Stephen Chen, Lee Birnbaum

P6.024 The Etiology of Cortical

Lesions in Marchiafava-Bignami Disease Is Nicotinic Acid Deficiency: A Case Report and Review of the Literature Takayuki Kosaka, Yoko Yoshida, Toshihiro Sakurai, Yanosuke Kouzaki, Tomohiro Takita, Chiaki Asao

P6.025 Longitudinal Imaging in

Marchiafava-Bignami Disease Annapoorna Bhat, Bhrugav Raval, David Marks

P6.026 Incidence of Meningeal

Enhancement on Brain MRI Secondary to Prior Lumbar Puncture Sarah Wesley, Rocio Garcia Santibanez, John Liang, DeWitt Pyburn

P6.016

Case Report: Cerebral Venous Sinus Thrombosis Involving Native Persistent Falcine Sinus Ikjae Lee, Matthew Flaherty, Thomas Tomsick, James Leach

P6.017

Pre-arrest Patient Characteristics Explain Most Interhospital Variation in Outcomes After Cardiac Arrest Teresa May, Alexandra Reynolds, Amelia Boehme, Barbara McCrum, Priyank Patel, Soojin Park, Jan Claassen, Richard Riker, David Seder, Sachin Agarwal

P6.027 Quantitative Susceptibility

Mapping (QSM) as a Biomarker for C9orf72 Familial ALS Emily Brady, Andrew Schweitzer, Tian Liu, Yi Wang, Mona Shahbazi, Alexander Shtilbans, Apostolos Tsiouris, Dale Lange

P6.028 Intraventricular Silicone

Mimicking Intracerebral Hemorrhage: A Case Report and Review of the Literature Peggy Nguyen, Benjamin Emanuel

P6.029 Dorsal Thoracic Arachnoid Web and the Scalpel Sign Jayaganth Jayabal

P6.030 Proximal MR Neurography

in Hansen’s Neuritis Manjunath Poojar, Ravinder Singh, Atchayaram Nalini, Jitender Saini, Anita Mahadevan, Veeranna Gadad

P6.018

Spinal Cord and Cranial Bing-Neel Syndrome Complicated by Stroke Alejandro Vargas, Karan Dixit, John Quigley, Fernando Testai

P6.019

Depression, Not Fatigue, Predicts Quality of Life After Stroke Gina Milone, Clotilde Balucani, Stephanie Hong, Dimitre Stefanov, Steven Levine

P6.020 Complication Rates of 3%

Hypertonic Saline Infusion Through Peripheral Intravenous Access Claudia Perez, Pamela Coffie, Cory Kacir, Jojo Koshy, Stephen Figueroa

Neurotherapeutics P6.031 Patient Factors Do Not Predict Thrombolysis in Stroke Mimics Kasey Gildersleeve, Renga Pandurengan, Nicole Gonzales

P6.032 Comprehensive Postmarketing Review of Visual Defects Reported with Topiramate Lisa Ford, Goldberg Jeffrey, Fred Selan, Howard Greenberg, Yingqi Shi

P6.033 Use of Intrathecal Antibiotic Administration for Treatment of CNS Infections in a Neuro-ICU: A Case Series Chandan Mehta, Mathew Jones, Mauricio Ruiz Cuero, Tamer Abdelhak, Mohammed Rehman, Jody Wellwood, Tracey Lasak-Myall, Panayiotis Varelas


Poster Session VI

P6.034 Ropinirole in Bipolar

Depression: A Retrospective Review Horacio Capote, Michelle Rainka, Erica Westphal, Carolyn Ross, Andrea Laudisio, Brett Pinger, Francis Gengo

P6.035 Quantitative Imaging

P6.046 Incidence of Impulsive and

Compulsive Behavior Type Adverse Events with Long-term Rotigotine: A Post-hoc Analysis Angelo Antonini, Mahnaz Asgharnejad, Lars Bauer, Frank Grieger, Babak Boroojerdi

P6.059 The Impact of Clinical

P6.071

P6.060 Data-mining of Genomic Data

P6.072 Brain Structural and

Symptoms on Quality of Life in Patients with Advanced Stage Parkinson's Disease and Their Caregivers Nina Browner in Parkinson’s Disease for Links to Hypoxiaresponse and Vascular Factors Rainald Schmidt-Kastner, Jacqui Wilneff, Chris Nguyen, Kim McKain, Julie Dela Cruz, Harry Steinbusch, Bart Rutten

Biomarkers of Brain Edema After 23% Saline in Liver Failure Eric Liotta, Bryan Lizza, Anna Romanova, James Guth, Michael Berman, Timothy Carroll, Daniel Ganger, Daniela Ladner, Brandon Francis, Matthew Maas, Andrew Naidech

P6.047 The Effect of a Cholinesterase

P6.036 Dosing, Side Effects, and

Uncovering Comorbid Dermatologic Conditions in Parkinson’s Disease Kimberly O'Neill, Ramsey Falconer, Sean Rogers, Reversa Mills, Ellen Valadez, Fernando Pagan

Characterisation of Cognitive Decline Over 5 Years in an Incident Parkinson’s Disease Cohort: Results from the CamPaIGN Study Catherine McAllister, Caroline Williams-Gray, Sarah Mason, Thomas Foltynie, Rosemary Abbott, Pradeep Nathan, Roger Barker

P6.049 Dalfampridine Extended

P6.062 Echogenicity of the Substantia

Long-term Outcomes for IVIg Use in Treatment of Neurological Conditions: Data from the Immunoglobulin Diagnosis, Evaluation, and Key Learnings (IDEaL) Patient Registry Sean Kearns, Loretta Kristofek, Bill Bolgar, Luqman Seidu

Inhibitor on Balance in Parkinson’s Disease Amie Peterson, Martina Mancini, Fay Horak, Seth Kareus, Bernadette Schoneburg, MIchael Fleming, John Nutt

P6.048 Overlooking the Skin:

D Deficiency in Neuromuscular Clinics Sankar Bandyopadhyay, Sol De Jesus

Release in Patients with Parkinson’s Disease Related Gait Dysfunction: A Randomized Double Blind Trial Corneliu Luca, Gloria Nadayil, Chuanhui Dong, Edelle Field-Fote, Carlos Singer

P6.038 Wernicke’s Encephalopathy

P6.050 Risk of Premotor Symptoms

P6.037 A Pilot Study of Vitamin

Masquerading as Creutzfeldt-Jakob Disease Travis Taylor, Kelly Baldwin

P6.039 Cannabis Use in Epilepsy and Anorexia—Two "N-of-one" Trials Denis Petro

P6.040 Peduncular Hallucinosis

in a Patient with Metastasic Lung Cancer—Case Report and Review of the Literature Lisseth Burbano, Jaime Toro

Movement Disorders: Parkinson's Disease P6.041 Interim Results of a Phase 3b

Study Assessing the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Subjects with Advanced Parkinson’s Disease Jordan Dubow, Krai Chatamra, Susan Eaton, Coleen Hall, Janet Benesh

P6.042 Spontaneous Pupillary Hippus Is Markedly Suppressed in Patients with Idiopathic Parkinson's Disease Kartik Mangipudi, Jacqueline Cristini, Philip Hanna, Michael Rosenberg

P6.043 Orthostatic Hypotension and

Its Relationship to the Brain Circulation of Patients with Parkinson’s Disease: A Transcranial Doppler Assessment Carlos Camargo, Eduardo Martins, Henrique Hoffmann, Jissa Jeanette, Marcelo YoungBlood, Marcelo Schafranski, Marcelo Ferro, Edmar Myochi, Marcos Lange

P6.044 Decreased Burden Among

Caregivers of Patients with Parkinson’s Disease Psychosis (PDP) Treated with Pimavanserin, a Selective 5-HT2A Inverse Agonist Dag Aarsland, Roger Mills, Hilde Williams, Kathy Chi-Burris, Michaela Karistedt, Clive Ballard

P6.045 Sensory Attenuation in

Parkinson’s Disease Antonella Macerollo, Jui-Cheng Chen, Prasad Korlipara, James Kilner, Mark Edwards

in Patients with Newly Diagnosed PD: A Nationwide Population-based Study MingHong Chang

P6.051

Head Injury at Early Ages Is Associated with Risk of Parkinson’s Disease Kathryn Taylor, Marie-Helene Saint-Hilaire, Lewis Sudarsky, David Simon, Bonnie Hersh, David Sparrow, Howard Hu, Marc Weisskopf

P6.052 Illusions and Hallucinations

Are Present in Different Phenotypes of Parkinson’s Disease: A Case-series Kelsey Juster-Switlyk, Rodolfo Savica, David Shprecher, Edward Zamrini

P6.053 Height and Weight Changes

P6.061

Nigra in Patients with De Novo Parkinson's Disease. Relationship with Parkinsonian Phenotypes Jose Santiago S. Bestoso

P6.063 Learning Processes in

Parkinson’s Disease and Healthy Aging Madeleine Sharp, Karin Foerde, Nathaniel Daw, Daphna Shohamy

P6.064 Demonstration of Abnormality of Intrinsically Photosensitive Retinal Ganglion Cells (ipRGCs) in Patients with Parkinson’s Disease Adnaan Zaffer, Jasvinder Chawla, Youngsook Park, Mary Jost, Jaswinder Singh, Martin Gorbien, Bruce Gaynes

P6.065 Motor Associations of Iron

Deposition in Patients with Parkinson’s Disease Martin-Bastida Antonio, Marios Politis, Clare Loane, Lao-Kaim Nicholas, Natalie Valle-Guzman, Zinovia Kefalopoulou, Gesine Paul, H Widner, Thomas Foltynie, Roger Barker, Paola Piccini

After Deep Brain Stimulation in Patients with Parkinson Disease: Role of Clinical Subtypes Dennys Reyes, Hesham Abboud, Gencer Genc, Andre Machado, Scott Cooper, Michal Gostkowski, Hubert Fernandez

P6.066 Association of the Side of

P6.054 Can Drug-induced

P6.067

Parkinsonism Reveal Pre-motor Parkinson Disease? James Morley, Gang Cheng, Jacob Dubroff, Jayne Wilkinson, John Duda

P6.055 The Incidence of Falls and

Fractures in Patients with Parkinson’s Disease in a US Population Linda Kalilani, Mahnaz Asgharnejad, Tuire Palokangas, Tracy Durgin

P6.056 Effects of Medical

Onset of Motor Symptoms to Prevalence of Various Domains of Non-motor Symptoms (NMS) in Parkinson's Disease Raja Boddepalli, Tarannum Khan, Emilio De Narvaez Freezing of Gait Early in Parkinson: Atypical Versus Typical Parkinson Disorders Aman Deep, Abraham Lieberman, Rohit Dhall, An Tran, Ming-Jai Liu

P6.068 Plasma ApoA1 Associates

with Age at Onset and Motor Severity in Early Parkinson Disease Patients Christine Swanson, Yosef Berlyand, Sharon Xie, Roy Alcalay, Lama Chahine, Alice Chen-Plotkin

Comorbidities on Parkinson Disease Patients’ Quality of Life Tracy Fulton, Fernando Pagan

Movement Disorders: Parkinson's Disease Imaging

P6.057 24-hour Efficacy Profile of

P6.069 11C-FECIT-PET Presynaptic

Rotigotine in Patients with Advanced Parkinson’s Disease: A Post-hoc Analysis Lawrence Elmer, Mahnaz Asgharnejad, Babak Boroojerdi, Frank Grieger, Lars Bauer

P6.058 Apathy and Clinical

Patterns of Presentation of Parkinson’s Disease Arianna Sartori, Jacopo Fantini, Alessio Bratina, Rita Moretti


Dopaminergic Degeneration in Ventral Striatum in Early Parkinson’s Disease Silvia Caminiti, Damiano Baroncini, Leonardo Iaccarino, Valentino Bettinardi, Maria Volonté, Daniela Perani

P6.070 Disrupted Functional

Connectivity of Amygdala-based Networks in Parkinson's Disease Patients with Severe Olfactory Dysfunction Hirohisa Watanabe, Bagarinao Epifanio, Noritaka Yoneyama, Kazuhiro Hara, Kazuya Kawabata, Kazunori Imai, Masaaki Hirayama, Takashi Tsuboi, Gen Sobue

Resting Connectivity Functional MRI in Understanding Cognitive Impairment in Parkinson's Disease Nina Browner Functional Abnormalities in Parkinson’s Disease Patients with Freezing of Gait Elisabetta Sarasso, Federica Agosta, Elisa Canu, Maria Antonietta Volontè, Lidia Sarro, Sebastiano Galantucci, Roberto Gatti, Andrea Falini, Giancarlo Comi, Massimo Filippi

P6.073 Unilateral Microelectrode

Mapping to Guide Bilateral Deep Brain Stimulation Electrode Implantation: A Retrospective Study of DBS Programming Outcomes Todd Herrington, Joshua Simon, Emad Eskandar

P6.074

Increased Activation of the Frontal Lobe Is Associated with Freezing of Gait in Patients with Parkinson's Disease: An FNIRS Study Inbal Maidan, Hagar Bernad-Elazari, Eran Gazit, Anat Mirelman, Jeffrey Hausdorff, Nir Giladi

P6.075

Posterior Lentiform Nucleus Hyperperfusion as a Diagnostic Marker for Parkinson’s Disease—a Pseudocontinuous Arterial Spin Labeling Perfusion Weighted MRI Study Chaorui Huang, Jonathan Dyke, Melissa Nirenberg, Panida Piboolnurak, Henning Voss, Apostolos Tsiouris, Claire Henchcliffe, William Severt, M. Beal

P6.076

Elevated Thalamic GABA Levels in Parkinson Disease, Measured by 3 Tesla MR Spectroscopy, Correlate with Disease Severity Sarah Zauber, Shalmali Dharmadhikari, Sandy Snyder, Ulrike Dydak

P6.077 Ventral Striatum Involvement

in Non Manifesting Carriers of the G2019S Mutation in the LRRK2 Gene Avner Thaler, Anat Mirelman, Rick Helmich, Bart van Neunen, Tanya Gurevich, Karen Marder, Susan Bressman, Avi Orr-Urtreger, Bastiaan Bloem, Talma Hendler, Nir Giladi

Movement Disorders: Imaging Techniques P6.078 Striatal Dopaminergic

Functioning in Hereditary Spastic Paraplegia Type 11 Ingrid De Vasconcellos, Alberto Martinez, Katiane Raisa Servelhere, Celso Ramos, Iscia Lopes-Cendes, Bárbara Amorim, Marcondes Franca, Jr.

P6.079

Investigation of the Transcallosal Ventral Premotor Connection Jung Park, Mark Hallett

P6.080 Impaired Sensorimotor

Feedback in Functional Movement Disorder: A Resting State FMRI Study Carine Maurer, Silvina Horovitz, Kathrin LaFaver, Mark Hallett

P6.081 Loss of Phosphodiesterase

10A (PDE-10A) Signalling Is Associated with Progression and Severity in Patients with Parkinson’s Disease Flavia Niccolini, Thomas Foltynie, Tiago Reis Marques, Sridhar Natesan, Shitij Kapur, Nils Muhlert, Andri Tzortzi, Eugenii Rabiner, Roger Gunn, Paola Piccini, Marios Politis

111

Thursday April 23

7:30 a.m.–12:00 p.m.

Poster Session VI P6.082 Thalamic GABAa Receptor

Expression Is Inversely Correlated with Axial Motor Impairments in Parkinson Disease Nicolaas Bohnen, Kirk Frey, Vikas Kotagal, Robert Koeppe, Peter Scott, Roger Albin, Martijn Muller

P6.083 Abnormal High Iron Deposition in the Central Olfactory System in Earlystage Parkinson's Disease Jianli Wang, Qing Yang, Thyagarajan Subramanian

P6.084 Cortical Distinctions

in Parkinson Disease Patients with Predominant Gait Dysfunction Daniel Claassen, Herb Joshua, David Isaacs, Olivia Roman, Peter Hedera, Benoit Dawant, Landman Bennett, David Zald, Joseph Neimat, Manus Donahue, Scott Wylie, Swati Rane

P6.085 Parkinson’s Disease (PD)

Patient Experience with the ClearPoint(TM) Interventional MRI (iMRI)-guided Method for Placement of Deep Brain Stimulation (DBS) Leads Sara LaHue, Maya Katz, Nicholas Galifianakis, Marta San Luciano, Nathan Ziman, Sarah Wang, Caroline Racine, Philip Starr, Paul Larson, Jill Ostrem

Neuromuscular Disease: Imaging and Biomarkers P6.086 Can Ulnar Nerve Cross-

7:30 a.m.–12:00 p.m.

P6.091 Structural MRI Reveals

Distributed Cortical Thinning in Patients with Pure Lower Motor Neuron Disease Variants Edoardo Gioele Spinelli, Federica Agosta, Pilar Ferraro, Nilo Riva, Paola Valsasina, Massimiliano Copetti, Evelina Prudente, Adriano Chio, Sandro Iannaccone, Vincenzo Silani, Andrea Falini, Giancarlo Comi, Massimo Filippi

P6.092 Muscle Magnetic Resonance Imaging in Spinal Muscular Atrophy 3: Specific Pattern and Progression Hacer Durmus, Piraye Serdaroglu, Yesim Parman, Memduh Dursun, Feza Deymeer

P6.093 Distinctive Magnetic

Resonance Imaging Findings of Muscle in Duchenne Muscular Dystrophy Kiran Polavarapu, Manjunath Poojar, Preethish Veeramani, Rose Dawn Bharath, Atchayaram Nalini, Ravinder Jeet Singh, Priya Treesa Thomas

P6.094 Prognostic Value of 18F-FDG PET/CT in MG Patients Without Any Thymic Mass Detected in CT Scan: Caseseries of 14 Patients Guillaume Baille, Claude Hossein-Foucher, Helene Zephir, Patrick Vermersch, Arnaud Lacour

ALS: Imaging, Biomarkers, and Clinical Testing

sectional Area Replace Electrodiagnostic Studies in the Diagnosis of Ulnar Nerve Entrapment? Shumaila Sultan, Jonas Vanags, Michael Rosario, Lisa HobsonWebb

P6.095 The NIH C9ORF72 ALS-

P6.087 Cortical Thinning and

P6.096 Quantitative MRI of the

White Matter Tract Damage in Relation to Cognition in Motor Neuron Diseases Federica Agosta, Pilar Ferraro, Edoardo Spinelli, Elisa Canu, Nilo Riva, Massimiliano Copetti, Evelina Prudente, Adriano Chio, Sandro Iannaccone, Andrea Falini, Giancarlo Comi, Massimo Filippi

P6.088 The Diagnostic Value of

Cortical Thickness Measures and Diffusion Tensor MRI Metrics in the Clinical Phenotypes of MND Pilar Maria Ferraro, Federica Agosta, Edoardo Spinelli, Nilo Riva, Massimiliano Copetti, Paola Valsasina, Evelina Prudente, Adriano Chio, Sandro Iannaccone, Vincenzo Silani, Andrea Falini, Giancarlo Comi, Massimo Filippi

P6.089 Bimelic Amyotrophy:

A Phenotypic Variant of Monomelic Amyotrophy /Hirayama Disease Having Identical Features on MR Imaging Preethish Kumar Veeramani, Atchayaram Nalini, Kiran Polavarapu, Jitender Saini, Ravinder Singh

P6.090 Chronic Sensory

Deafferentation Results in Cerebellar and Basal Ganglia Structural Abnormalities Alberto Martinez, Raphael Casseb, Jean Paiva, Brunno Campos, Guilherme Beltramini, Gabriela Castellano, Anamarli Nucci, Marcondes Franca, Jr.

112

FTD Study: Correlation of Clinical and Quantitative Imaging Measures Mary Kay Floeter, Olivia Schanz, Laura Danielian, Laura Braun, Bryan Traynor, Devin Bageac Spinal Cord Is a Reliable Marker to Monitor Disease Progression in ALS Lucas Branco, Milena de Albuquerque, Helen Andrade, Anamarli Nucci, Felipe Bergo, Marcondes Franca, Jr.

P6.097 Utility of Diffusion Tensor

Imaging in Amyotrophic Lateral Sclerosis: Potential Biomarker and Cognitive Profile Association Marcelo Rugiero, Marcelo Chaves, Mariela Bettini, Maria Fernandez, Juan Ignacio Rojas, Maria Garcia Basalo, Edgardo Cristiano, Angel Golimstok

P6.098 Frequent Hepatic Steatosis in ALS: Implication for Systemic Involvement Yuishin Izumi, Naoko Takamatsu, Naoki Muguruma, Kazuhiro Ukimoto, Susumu Nishio, Masaya Oda, Hiroyuki Nodera, Ryuji Kaji

P6.099 Elevated Creatine Kinase

Is Associated with a Better Prognosis in Patients with Amyotrophic Lateral Sclerosis Muhammad Rafiq, Ellen Lee, Christopher McDermott, Pamela Shaw

P6.100

Urate Levels Predict Disease Progression and Survival in Amyotrophic Lateral Sclerosis (ALS) Katharine Nicholson, Sabrina Paganoni, Amy Shui, David Schoenfeld, Alexander Sherman, James Berry, Merit Cudkowicz, Nazem Atassi

P6.101

Are Arterial Hypertension and Diabetes Modifiers of ALS Phenotype and Outcome? A Population-based Study Andrea Calvo, Cristina Moglia, Antonio Canosa, Davide Bertuzzo, Francesco Galmozzi, Paolo Cugnasco, Marinella Clerico, Stefania De Mercanti, Enrica Bersano, Stefania Cammarosano, Antonio Ilardi, Umberto Manera, Riccardo Sideri, Kalliopi Marinou, Edo Bottacchi, Fabrizio Pisano, Roberto Cantello, Letizia Mazzini, Gabriele Mora, Adriano Chio

P6.102

Canine Degenerative Myelopathy—an Emerging Disease Model for ALS Raghav Govindarajan, Joan Coates

P6.103

Is Worse Prognosis in Older ALS Patients More Than Just a Matter of Years? Stacy Rudnicki, Tawfiq Al-Lahham, Betul Gundogdu, Kaustubh Limaye, Zabeend Mahuwala, Hillary Williams

P6.104

Neuroprotective Effect of Bexarotene in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis Javier Riancho, Maria Ruiz-Soto, Maria T Berciano, Jose' Berciano, Miguel Lafarga

P6.105

Reduction in Cerebral Antioxidant, Glutathione (GSH), in Patients with ALS: A Preliminary Study In Young Choi, Phil Lee, Jeffrey Statland, April McVey, Mazen Dimachkie, William Brooks, Richard Barohn

MS and CNS Inflammatory Diseases: Neuroimaging P6.106

Cortical Lesions of Multiple Sclerosis: Signal, Morphological and Vascular Abnormalities at Ultra High Field (7T) MRI Yulin Ge, Ilya Kister, Sanjeev Chawla, Tim Sinnecker, Joseph Herbert, Friedemann Paul, Jens Wuerfel

P6.107

MRI Reveals Connectivity of Cortical Lesions to White Matter Lesions in Multiple Sclerosis Jan-Mendelt Tillema, Stephen Weigand, John Port, Jayawant Mandrekar, Yunhong Shu, Claudia Lucchinetti, Istvan Pirko

P6.108

Diffusion Tensor Imaging Abnormalities in Multiple Sclerosis Cortical Lesions and Normal-appearing Grey Matter and Their Associations with Disability Özgür Yaldizli, Matteo Pardini, Varun Sethi, Nils Muhlert, Zheng Liu, Tarek Yousry, Daniel Tozer, Rebecca Samson, Claudia Wheeler-Kingshott, David Miller, Declan Chard

P6.109

Relationship Between RNFL Thickness and Brain Cortical Lesions in Primary-progressive MS Christian Cordano, Maria Petracca, Phillip Rubin, Colleen Farrell, Aaron Miller, Fred Lublin, Matilde Inglese

P6.110

Different Stages of Acute Multiple Sclerosis Lesions Demonstrated on R2* and Quantitative Susceptibility Mapping Derived from Gradient Echo (GRE) MRI Lijie Tu, Yan Zhang, Ajay Gupta, Thanh Nguyen, Susan Gauthier, Yi Wang

P6.111

Optimal Detection of Infratentorial Lesions with a Combined Dual-echo Sequence: “P2T” Maria Gaitan, Paulina Yañes, Pascal Sati, Carlos Romero, Daniel Reich, Jorge Correale

P6.112

White Matter Lesion Central Veins Can Distinguish MS from Ischemic Lesions, Irrespective of 3T MRI T2* Sequence Amal Samaraweera, Paul Morgan, Ian Driver, Rob Dineen, Nikolaos Evangelou

P6.113

Exploring Phase Contrast Mechanisms of Multiple Sclerosis Lesions at 7T Roland Henry, Wei Bian, Yan Li, Regina Schlaeger, Alyssa Zhu, Angela Jakary, David Leppert, Nicolas Seneca, Sarah Nelson, Bruce Cree

P6.114

MR Frequency Differentiates MS Lesion Severity Shannon Kolind, Vanessa Wiggermann, Samantha Tan, Enedino Hernández Torres, David Li, Nicolas Seneca, David Leppert, Irene Vavasour, Anthony Traboulsee, Alexander Rauscher

P6.115

Different Patterns of Lesion Formation in Early and Late Stages of Multiple Sclerosis Revealed by Phase Imaging at 7T Ivan Bozin, Yulin Ge, Joseph Kuchling, Petr Dusek, Sanjeev Chawla, Lutz Harms, Klemens Ruprecht, Thoralf Niendorf, Friedemann Paul, Ilya Kister, Tim Sinnecker, Jens Wuerfel

P6.116

Improved Specificity of Multiple Sclerosis Lesion Segmentation from Dual-sensitivity MRI Morphometry Dominik Meier, Nicola Moscufo, Michele Cavallari, Subhash Tummala, Charles Guttmann, Howard Weiner, Rohit Bakshi

P6.117

Increased Prevalence of Contrast Enhancing Lesions in Multiple Sclerosis Migraine Patients Elliot Graziano, Jesper Hagemeier, Bianca WeinstockGuttman, Sirin Ghandi, Deepa Ramasamy, Robert Zivadinov

P6.118

MRI Detection of Hypointense Brain Lesions in Patients with Multiple Sclerosis: T1 Spin Echo Vs. Gradient Echo Sheena Dupuy, Shahamat Tauhid, Gloria Kim, Renxin Chu, Subhash Tummala, Shelley Hurwitz, Rohit Bakshi

P6.119

Differentiating Iron and Non-iron Related Pathological Features of Multiple Sclerosis Lesions Using Ultra High Field MRI Sanjeev Chawla, Ilya Kister, Tim Sinnecker, Jean Brisset, Petr Dusek, Joseph Herbert, Friedemann Paul, Jens Wuerfel, Yulin Ge

P6.120

The Role of Asymptomatic Spinal Lesions in Predicting Future Attacks in Multiple Sclerosis Patients in a Real Word Clinical Setting Chiara Zecca, Gianna Carla Riccitelli, Emanuele Pravatà, Alessandro Cianfoni, Claudio Staedler, Carlo Cereda, Giulio Disanto, Letizia Panicari, Claudio Gobbi

P6.121

1-H MRSI in Patients with Relapsing Multiple Sclerosis at 7 Tesla Roland Henry, Yan Li, Alyssa Zhu, David Leppert, Nicolas Seneca, Sarah Nelson, Bruce Cree


Poster Session VI

P6.122

Blood-based Transcriptomic and Clinical/MRI Measures Correlate in Primary-progressive MS Maria Petracca, Charalambos Athanassiou, Maria Chikina, Colleen Farrell, Michelle Fabian, Fred Lublin, Matilde Inglese, Christophe Gerald

P6.123

The Putative Functional SCN10A Gene Variant Predicts Functional Status and Cerebello-thalamic Circuit Integrity in Multiple Sclerosis Arash Nazeri, Tina Roostaei, Shokufeh Sadaghiani, Mohammad Ali Sahraian

P6.124

Clusters of Focal Cortical Thinning in Relapsing-remitting Multiple Sclerosis Lior Or Bach, Yael Nissan, Shmuel Miron, Anat Achiron

P6.125

Improved Detection of Microstructural Damage in Normal Appearing Gray and White Matter in Relapsing Remitting Multiple Sclerosis by Applying GRASE Sequence Doriana Landi, Angela Daniela Coniglio, Domenico Lupoi, Anna Ghazaryan, Emma Falato, Mariamaddalena Filippi, Stefano Vollaro

P6.126

Association of Multiple Sclerosis Normal Appearing White Matter Abnormality with Periventricular Location and Secondary Progression Declan Chard, Zheng Liu, Matteo Pardini, Oezguer Yaldizli, Varun Sethi, Nils Muhlert, Claudia WheelerKingshott, Rebecca Samson, David Miller

P6.127

Disruption of Hippocampal Resting State Functional Connectivity in MS: Relation with WM Lesions and Clinical Measures Gianna Carla Riccitelli, Maria Rocca, Paola Valsasina, Emanuele Pravatà, Marta Radaelli, Filippo Martinelli Boneschi, Paolo Preziosa, Claudio Gobbi, Andrea Falini, Giancarlo Comi, Massimo Filippi

P6.128

Susceptibility Contrast in High Field MRI of Multiple Sclerosis Brains as a Function of Tissue Iron, Myelin, Calcium and Axon Content Simon Hametner, Emma Boyd, Siddharama Pawate, Vasiliki Ikonomidou, Seth Smith, Hans Lassmann, Welch Brian, Francesca Bagnato

P6.129

The Relationship of a Multiparameter MRI Measure of Motor Network Efficiency with Disability in Multiple Sclerosis Matteo Pardini, Özgür Yaldizli, Varun Sethi, Nils Muhlert, Zheng Liu, Rebecca Samson, Daniel Altmann, Maria Ron, Claudia Wheeler-Kingshott, David Miller, Declan Chard

P6.130

Larger Intracranial Volume Affords Reserve Against Disability in Relapsing-remitting Multiple Sclerosis: Implications for Clinical Trial Research James Sumowski, Maria Rocca, Victoria Leavitt, Alessandro Meani, Sarlota Mesaros, Jelena Drulovic, Paolo Preziosa, Giancarlo Comi, Massimo Filippi

P6.131

The Use of Diffusion Tensor Imaging (DTI) as an Outcome Measure in Progressive Multiple Sclerosis Clinical Trials Danish Ghazali, Blake Snyder, Ava Ganik, William Kelley, Govind Nair, Bibiana Bielekova

P6.132

Relapsing Multiple Sclerosis Exhibits Reduced Normal Appearing White Matter Glutamate Levels Julia Schubert, Erin MacMillan, Roger Tam, David Leppert, Nicolas Seneca, Eduardo Vianna, Anna Dzyakanchuk, Shannon Kolind, Anthony Traboulsee

P6.141

MS and CNS Inflammatory Diseases: MRI Measurements of Cognition and Fatigue in MS

P6.142

P6.133

Consistent Decreased Functional Connectivity Among the Main Cortical and Subcortical Functional Networks in MS: Relationship with Disability and Cognitive Impairment Massimo Filippi, Paola Valsasina, Laura Vacchi, Victoria Leavitt, Giancarlo Comi, Andrea Falini, Maria Rocca

P6.134

Processing Face Encoding in Multiple Sclerosis: A FMRI Investigation Laura Vacchi, Maria Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Vittorio Martinelli, Francesca Possa, Andrea Falini, Giancarlo Comi, Massimo Filippi

P6.135

Regional White Matter Abnormalities and Cognitive Impairment in MS: A Multicenter TBSS Study Alvino Bisecco, Maria Rocca, Elisabetta Pagani, Olga Ciccarelli, Christian Enzinger, Antonio Gallo, Hugo Vrenken, Maria Laura Stromillo, Tarek Yousry, Franz Fazekas, Gioacchino Tedeschi, Frederik Barkhof, Nicola De Stefano, Massimo Filippi

P6.136 Connectivity-based

Parcellation of the Thalamus in Multiple Sclerosis and Its Implications for Cognitive Impairment: A Multicenter Study Alvino Bisecco, Maria Rocca, Elisabetta Pagani, Laura Mancini, Christian Enzinger, Antonio Gallo, Hugo Vrenken, Maria Laura Stromillo, Massimiliano Copetti, David Thomas, Franz Fazekas, Gioacchino Tedeschi, Frederik Barkhof, Nicola De Stefano, Massimo Filippi

P6.137

White and Gray Matter Correlates of Executive Functions and Social Cognition Impairment in MS Blas Couto, Diana Bruno, Lucas Sedeño, Vladimiro Sinay, Fatima Pagani Cassara, Sol Esteves, Facundo Manes, Maria Roca, Agustin Ibañez

P6.138

Hippocampal-related Memory Network in Multiple Sclerosis: A Structural Connectivity Analysis Sara Llufriu, Maria Rocca, Elisabetta Pagani, Gianna Carla Riccitelli, Bruno Colombo, Mariaemma Rodegher, Andrea Falini, Giancarlo Comi, Massimo Filippi

P6.139

Association Between Magnetic Resonance Imaging and Cognitive Outcomes in Early Multiple Sclerosis Bardia Nourbakhsh, Julia Nunan-Saah, Amir-Hadi Maghzi, Laura Julian, Rebecca Spain, Daniel Pelletier, Emmanuelle Waubant

P6.140

Effective Connectivity Differences During an Executive Control Task Between MS Subtypes and Healthy Individuals Ekaterina Dobryakova, Maria Rocca, Paola Valsasina, John DeLuca, Giancarlo Comi, Massimo Filippi


New Insights on the Pathophysiology of Fatigue in MS: A FMRI Study of the Motor Network Gianna Carla Riccitelli, Maria Rocca, Alessandro Meani, Mariaemma Rodegher, Bruno Colombo, Andrea Falini, Giancarlo Comi, Massimo Filippi Different MRI Measures Predict Clinical Deterioration AND Cognitive Impairment in MS: A 5-year Longitudinal Study Paolo Preziosa, Maria Rocca, Sarlota Mesaros, Massimiliano Copetti, Melissa Petrolini, Jelena Drulovic, Elisabetta Pagani, Massimo Filippi

P6.143

Gray Matter Volume Correlates with Information Processing as Measured by the Symbol Digit Modalities Test (SDMT) but Not with Physical Disability as Measured by the Expanded Disability Status Scale (EDSS) in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Analysis of Baseline Correlations from the ASCEND Natalizumab Study Raj Kapoor, Douglas Arnold, Aaron Miller, Mark Freedman, Myla Goldman, Hans-Peter Hartung, Eva Havrdova, Douglas Jeffery, Finn Sellebjerg, Carmen Castrillo-Viguera, Yun Chen, Diego Cadavid, Daniel Mikol

P6.144

Contribution of Cortical Lesions to Cognitive Dysfunction in the PPMS Population: Comparison of Double Inversion Recovery (DIR) and Phase Sensitive Inversion Recovery (PSIR) Sequences Using a 3 Tesla MRI Asaff Harel, Maria Petracca, Yadira Bencosme, Ilana Katz Sand, Fred Lublin, Matilde Inglese, Antonia Ceccarelli

P6.145

A Longitudinal Evaluation of Cerebellar Grey-matter Damage and Its Functional Significance in Multiple Sclerosis Alfredo Damasceno, Benito Damasceno, Fernando Cendes

P6.146

Remapping of FMRI Functional Connectivity During Resting State in Multiple Sclerosis Represents Compensatory Mechanisms Sue-Jin Lin, Aiping Liu, Jane Wang, David Leppert, Nicolas Seneca, Eduardo Vianna, Anna Dzyakanchuk, Shannon Kolind, Anthony Traboulsee, Martin McKeown

P6.147

Localising the Lesion in Fatigue—Insights from Primary Progressive Multiple Sclerosis Luke Canham, Nick Kane, Agyepong Oware, Peter Walsh, Kelly Blake, Jenny Homewood, Daniel Kent, Robert Dineen, Paul Morgan, Evangelou Nikos, Amal Samaraweera, Jonathan Witherick, Kirsty Inglis, David Cottrell

P6.148

Posterior Corpus Callosum Atrophy Is Correlated with Worse Performance on Inter-hemispheric Speed of Processing Task in Unimpaired MS Patients Joshua Bacon, Andrew Kim, Tamar Bacon, Ilya Kister, Yvonne Lui, Joseph Herbert

P6.149

T1 Lesion Load at Early MS Stages Does Not Influence Cognitive Performances Five Years Later Natalia Moll, Françoise Reuter, Karine Baumstarck, Wafaa Zaaraoui, Maxime Guye, Jean Philippe Ranjeva, Bertrand Audoin, Jean Pelletier

P6.150

Microstructural White Matter Damage in Fatigued Multiple Sclerosis Patients: A DTI-TBSS Study Alessandro D'Ambrosio, Alvino Bisecco, Giuseppina Caiazzo, Renato Docimo, Luigi Lavorgna, Mario Cirillo, Fabrizio Esposito, Simona Bonavita, Gioacchino Tedeschi, Antonio Gallo

P6.151

Precipitation of Cognitive Fatigue Modulates Brain Resting-state Functional Connectivity After Effort in Multiple Sclerosis Patients Claudio Gobbi, Emanuele Pravatà, Gianna Carla Riccitelli, Carlo Sestieri, Massimo Caulo, Alessandro Cianfoni, Chiara Zecca

P6.152

The Effects of Natalizumab and Fingolimod on Clinical, Neuropsychological, and MRI Measures in Relapsing Remitting Multiple Sclerosis: A One-year Comparative Study Paolo Preziosa, Maria Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Massimiliano Copetti, Lucia Moiola, Francesco Mele, Andrea Falini, Giancarlo Comi, Massimo Filippi

MS and CNS Inflammatory Diseases: MRI Atrophy Measurements and Correlations P6.153

Gender Differences in Brain Volume of Patients with Multiple Sclerosis Across Disease Phenotypes Navid Seraji-Bozorgzad, Fen Bao, Reena Pullukat, Michael Aronov, Jasmin Bhangu, Carla Santiago Martinez, Jessica ChorosteckiVigrass, Christina Caon, Imad Zak, Omar Khan

P6.154

Whole Brain Volume Measurements in Multiple Sclerosis: Crosssectional Data Comparison Between Three Methods Chenyu Wang, Heidi Beadnall, Sean Hatton, Giovanni Bader, Davorka Tomic, Diego Silva, Michael Barnett

P6.155

Comparison of 1.5 Versus 3 Tesla MRI Scanner in Quantification of Brain Atrophy in MS Andreas Lysandropoulos, Annemie Ribbens, Saurabh Jain, Anke Maertens, Wim Van Hecke, Nicolas Mavroudakis, Julie Absil, Thierry Metens, Philippe David

P6.156

Whole Brain Volume Measured from 1.5T Vs. 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis Renxin Chu, Shahamat Tauhid, Bonnie Glanz, Brian Healy, Gloria Kim, Vinit Oommen, Fariha Khalid, Mohit Neema, Rohit Bakshi

P6.157

Correlation of Regional Brain Atrophy with Clinical Scores in Multiple Sclerosis Alaleh Raji, Gerhard Winkler, Lothar Spies, Roland Opfer

P6.158

Medial Thalamic Local Functional Connectivity Is Altered in the Setting of Thalamic Atrophy in Multiple Sclerosis Kelly Wong, Sean Tobyne, Amanda Johnson, Lance Shaull, Eric Klawiter

P6.159

Optic Nerve Cross-sectional Area Measurement with High-resolution, Isotropic MRI in Optic Neuritis Katherine Gao, Winston Liu, Govind Nair, Irene Cortese, Henry McFarland, Noa Raz, Netta Levin, Bradley Katz, Daniel Reich

113

Thursday April 23


Poster Session VI P6.160

Long-term Treatment Effect of Multiple Sclerosis Therapeutics on Regional and Global Brain Atrophy Cross-sectional Analysed by Quantitative MRI Alaleh Raji, Gerhard Winkler, Lothar Spies, Roland Opfer

P6.161

High Field Spinal Cord MRI in Multiple Sclerosis: Towards Resolving the Clinico-radiological Paradox Siddharama Pawate, Adrienne Dula, Robert Barry, Richard Dortch, Bailey Lyttle, Shilpa Reddy, Megan Barry, Subramaniam Sriram, John Gore, Seth Smith

P6.162

Gray Matter Atrophy and Clinical Evolution in Progressive MS Rezwan Ghassemi, Aaron Miller, Stephen Krieger, Jonathan Howard, Claire Riley, Yadira Bencosome, Fred Lublin, Matilde Inglese

P6.163

Clinical Evaluation of Brain and Cord Atrophy in Multiple Sclerosis Luisa Vuolo, Govind Nair, Nadia Biassou, Nicholas Patronas, Winston Liu, Dewey Blake, Joan Ohayon, Irene Cortese, Daniel Reich

P6.164

Validation of Routine Highresolution 3T MRI Morphometry in Multiple Sclerosis Subhash Tummala, Fariha Khalid, Nicola Moscufo, Michele Cavallari, Rohit Bakshi, Charles Guttmann, Howard Weiner, Dominik Meier

P6.165

Early Spinal Cord MRI Abnormalities Are Associated with MS-related Disability Five Years After a Clinically Isolated Syndrome Wallace Brownlee, Patricia Alves Da Mota, Ferran Padros, Josephine Swanton, Katherine Miszkiel, Daniel Altmann, Sebastien Ourselin, Claudia Wheeler-Kingshott, Olga Ciccarelli, David Miller

P6.166

Spinal Cord Atrophy as a Primary Outcome Measure in Primary Progressive Multiple Sclerosis Neuroprotective Trials Niamh Cawley, Khaled Abdel-Aziz, Torben Schneider, Daniel Altmann, Claudia Wheeler-Kingshott, David Miller, Alan Thompson, Olga Ciccarelli

P6.167

Spinal Cord Atrophy and Clinical Disability in Primary-progressive MS: A 1-year Follow-up Study Serena Ruggieri, Maria Petracca, Colleen Farrell, Jonathan Howard, Claire Riley, Michelle Fabian, Fred Lublin, Matilde Inglese

P6.168

Spinal Cord Lesions and Relationship to Spinal Cord Atrophy and Disability in Multiple Sclerosis Navid Seraji-Bozorgzad, Fen Bao, Evanthia Bernitsas, Carla Santiago Martinez, Anna Piasecki, Christina Caon, Omar Khan

P6.169

T1- Vs. T2-based MRI Measures of Spinal Cord Volume in Healthy Subjects and Patients with Multiple Sclerosis Gloria Kim, Fariha Khalid, Vinit Oommen, Shahamat Tauhid, Renxin Chu, Mark Horsfield, Brian Healy, Rohit Bakshi

P6.170

A Longitudinal Study of Cerebral Gray Matter Volume in Patients Receiving Natalizumab for Multiple Sclerosis Shahamat Tauhid, Alicia Chua, Brian Healy, James Stankiewicz, Howard Weiner, Rohit Bakshi

114

7:30 a.m.–12:00 p.m.

P6.171

Early Clinical and MRI Predictors of Different Disability Outcomes in Multiple Sclerosis Patients over the 10 Years Interval Dana Horakova, Lukas Sobisek, Jan Krasensky, Tomas Uher, Tomas Kalincik, Zdenek Seidl, Eva Havrdova, Manuela Vaneckova

Aging, Dementia, Cognitive, and Behavioral Neurology: Neuroimaging and Practice Guidelines P6.172

Does Dorsal Striatum Mediate Stimulus-response Learning or Decision Making? Penny MacDonald, Nole Hiebert, Adrian Owen, Ken Seergobin

P6.173

Serial Imaging with [11C]PBR28 Suggests Increased Neuroinflammation During the Progression of Alzheimer’s Disease William Kreisl, Chul Hyoung Lyoo, Monica Wei, Joseph Snow, Kimberly Jenko, Cheryl Morse, Sami Zoghbi, Victor Pike, R Turner, Robert Innis

P6.174

Risk Factors, Consequences and Rating Methodology: Enlarged Virchow Robin Spaces in Brain MRIs in the Framingham Study Nikita Jain, Sudha Seshadri, Jose Romero, Charles DeCarli, Alexa Beiser

P6.175

Argentina- Alzheimer’s Disease Neuroimaging Initiative (ArgADNI): Clinical Characterization Maria Russo, Patricio Chrem Mendez, Marcos Fernandez Suarez, Federico Nahas, Gabriela Cohen, Jorge Campos, Deborah Gustafson, Salvador Guinjoan, Ezequiel Surace, Silvia Vazquez, Silvia Vazquez, Gustavo Sevlever, Ricardo Allegri

P6.176

Functional Connectivity of the Claustrum in Mild Cognitive Impairment and the Impact of the ApoE ε4 Allele Matteo De Marco, Annamaria Vallelunga, Davide Duzzi, Francesca Meneghello, Annalena Venneri

P6.177

Sex Differences in the Relationship Between Hippocampal Volume and Verbal Memory Performance Erin Sundermann, Anat Biegon, Leah Rubin, Richard Lipton, Susan Landau, Pauline Maki

P6.178

The Dementia Factor: A Retrospective Analysis of Care of Patients with Dementia in Tertiary Medical Center Riddhi Patira, S. Ausim Azizi

P6.179

Does DSM-5 Change Who Gets Diagnosed with Alzheimer Disease, and Who’s Checking? Joel Shenker, Kunal Bhatia, Jithendhar Kandimalla, Anant Wadhwa

P6.180

Who Uses the Datasupported, AAN Practice Parameters for Detecting and Diagnosing Alzheimer Disease, and How Often? Joel Shenker, Kunal Bhatia, Jithendhar Kandimalla, Anant Wadhwa

Aging, Dementia, Cognitive, and Behavioral Neurology: Dementia: Psychosocial Aspects P6.181

Effectiveness of Reality Orientation in the Treatment of Alzheimer’s Disease Carlos Camargo, Filipe Justus, Giuliano Retzlaff

P6.182

Dementia Care Training for Primary Care Providers: Project ECHO™ Janice Knoefel, Carla Herman

P6.183

City and Rural Driving Performance in Healthy Controls, MCI, and AD Patients: Preliminary Results from a Driving Simulation Experiment with the Use of Distraction Alexandra Economou, Mary Kosmidis, Ion Beratis, Nikolaos Andronas, George Yannis, Sokratis Papageorgiou

P6.184

Subjective Cognitive Complaints and Vehicle Driving Diego Nadile, Maria Gonzalez Toledo, Fatima Pagani Cassara, Agustina Tamargo, Alejandro Thomson, Santiago OŃeill

P6.185

Coping and Distress and Risk of Dementia in Older Adults with Amnestic Mild Cognitive Impairment Julie Jiang, Mindy Katz, Robert White, Molly Zimmerman, Mimi Kim, Richard Lipton

P6.186

Motorway Driving Performance in Healthy Controls, MCI, and AD Patients: Preliminary Results from a Driving Simulation Experiment Alexandra Economou, Ion Beratis, Nikolaos Andronas, John Papatriantafyllou, George Yannis, Sokratis Papageorgiou

P6.187

An Inverted U-shaped Dose-response Curve for Aerobic Exercise Intensity Associated with Improved Cognitive Function in an Elderly, Community-dwelling Cohort Keith Albrektson, Sarah Tarrant, Amanda Pursell, Dasha Kenlan, Andrew Welleford, Gregory Jicha

P6.188

SOCIABLE: A Comprehensive ICT Cognitive Training Programme for Healthy and Cognitively Impaired Elderly Paraskevi Sakka, Eva Ntanasi, Panagiota Zoi, Faidra Kalligerou, Stelios Pantelopoulos

P6.189

Individualized Neuro-cognitive Rehabilitation Can Reverse Cognitive and Memory Impairment Irrespective of Etiology: Prospective Pilot Study Suresh Kumar, Jitendra Kumar, Ajay Jawahar, Monika Kumar

P6.191

Tractography Activation Patterns in Dorsolateral Prefrontal Cortex Suggest Better Clinical Responses in Deep Brain Stimulation (DBS) of the Anterior Limb of the Internal Capsule and Nucleus Accumbens (ALIC-NA) for Obsessivecompulsive Disorder (OCD) Christian Hartmann, J. Lujan, Ashutosh Chaturvedi, Wayne Goodman, Michael Okun, Cameron McIntyre, Ihtsham Haq

P6.192

Attachment Style as a Predictor for the Effects of Oxytocin on Social Cognition Katie Hsih, Brandon Chuang, Charltien Long, Jennifer Akazawa, Sophia Vinogradov, Joshua Woolley

P6.193

Behavioral Profiles of Cutaneous T-cell Lymphoma and Psoriasis Alan Lerner, Mansi Sethi, Joselin Tacastacas, Timothy Wuerz, Christopher Bailey, Philip Fastenau, Pingfu Fu, Frances Lissemore, Christian Schenk, Kevin Cooper

P6.194

Characterization of Content Specific Delusions After Right Hemispheric Ischemic Stroke Natasa Dragicevic, Michael Hoffmann

P6.195

Upper/Lower Facial Expressions Are Dynamically Timed and Motorically Independent Smita Gupta, Elliott Ross

P6.196

Neural Correlates of Action Recognition and Object Knowledge in Neurodegenerative Disease Miguel Santos, Ignacio Illan-Gala, Giulia Vinceti, Maria Luisa Mandelli, Honey Hubbard, Zachary Miller, Gil Rabinovici, Bruce Miller, Maria Gorno Tempini

P6.197

Influence of the Affective Valence of Visual Materials in Recognition Among Healthy Individuals and Patients with Alzheimer's Disease Dementia Natalia Irrazabal, Gastón Saux, Carolina Feldberg, Veronica Somale, Galeno Rojas, Ignacio Demey

P6.198

Differential Apathy Profiles in Alzheimer’s Disease and Parkinson’s Disease Nicholas Lim, Lauren Massimo, Whitney Fitts, Nabila Dahodwala, Murray Grossman

P6.199

Neuropathological Substrate of Self-conscious Emotion Deficits in Neurodegenerative Dementia Salvatore Spina, Virginia Sturm, Sandy Lwi, Alice Verstaen, Marcela Otero, Lea Grinberg, Robert Levenson, Bruce Miller, William Seeley

Aging, Dementia, Cognitive, and Behavioral Neurology: Neuropsychiatry and Behavioral Neurology

Aging, Dementia, Cognitive, and Behavioral Neurology: Cognition and Cognitive Assessment

P6.190

Assessment-Basic (MoCA-B): A New Mild Cognitive Impairment Screening Test for Illiterate and Low Educated Elderly Parunyou Julayanont, Sookjaroen Tangwongchai, Solaphat Hemrungrojn, Chawit Tunvirachasakul, Kammant Phanthumchinda, Ziad Nasreddine

Brain Structural Abnormalities in Patients with Major Depression with or Without Generalized Anxiety Disorder Comorbidity Elisa Canu, Milutin Kostic, Federica Agosta, Ana Munjiza, Pilar Ferraro, Danilo Pesic, Massimiliano Copetti, Amir Peljto, Dusica Lecic Tosevski, Massimo Filippi

P6.200 The Montreal Cognitive

P6.201 The Utility of ACE-III in a

Heterogeneous Early Onset Dementia Clinic Population Marwa Elamin, Guy Holloway, Zubair Khan, Thomas Bak


Poster Session VI

P6.202 Comparison of Office Mental

Status Examinations to Screen Cognitive Performance in Adults with Autism Spectrum Disorders Bryan Woodruff, Dona Locke, Joseph Hentz, Christopher Smith, Yonas Geda

P6.203 Introducing a Brief Screening

a Tool for Motor Signs in Patients with Dementia Marwa Elamin, Gary Bennett, Alex Symonds, Survankar Pal, Sharon Abrahams, Mario Parra, Thomas Bak, Peter Connick

P6.204 Association Between Etiology

and Patterns of Neurocognitive Impairment Detected with Wechsler Memory Scale (WMS-IV) Assessment: Prospective Study in 71 Consecutive Patients Ajay Jawahar, Suresh Kumar, Jeffery Goins, Monika Kumar

P6.205 Semantic Memory

Impairment: A Neuropsychological Hallmark of Late Onset Alzheimer Disease Mathieu Ceccaldi, Sven Joubert, Natalina Gour, Lejla Koric, Mira Didic, Claude Guériot, Jean-Philippe Ranjeva, Eric Guedj, Olivier Felician

P6.206 Bilingualism Does Not

Delay the Age at Onset of Dementia—a Study from Memory Clinic in South India Ratnavalli Ellajosyula, Jwala Narayanan, Siddharth Ramanan, Swathy Chandrashekar, Prerana Sabnis

P6.207 Semantic Recall Speed in

Older Adults, Mild Cognitive Impairment and Alzheimer's Disease Frances Lissemore, Steve Lenio, Alan Lerner, Paula Ogrocki, Johnny Sams, Kathleen Smyth, Curtis Tatsuoka, Wojbor Woyczynski, Elisabeth Welter, Martha Sajatovic

P6.208 The Effect of Obesity on

Severity of Cognitive Impairment and Neuropsychiatric Symptoms in MCI Subjects Ashley Hannah, Ahmad Alsibai, Andrea Bozoki

P6.209 Genetic Association Study

of Cognitive Performance Jonathan Katz, Chuanhui Dong, Yaakov Stern, Clinton Wright, Susan Blanton, Ralph Sacco

Aging, Dementia, Cognitive, and Behavioral Neurology: White Matter and Diffusion Imaging P6.210

Alzheimer’s Disease Dementia Involves the Corpus Callosum and the Cingulum: A Diffusion Tensor Imaging Study Ignacio Demey, Fernando Ventrice, Galeno Rojas, Victoria Zubiri, Veronica Somale

P6.211

Olfactory Identification Deficit as a Predictor of White Matter Tract Impairment in Alzheimer’s Disease Matthew Woodward, Michael Dwyer, Chaitanya Amrutkar, Robert Zivadinov, Kinga Szigeti

P6.212

Hippocampal Mean Diffusivity Is a Biomarker of Neuronal Injury in Patients with Mild Cognitive Impairment and Alzheimer´s Disease Dementia Ignacio Demey, Fernando Ventrice, Galeno Rojas, Ricardo Allegri, Victoria Zubiri, Veronica Somale

P6.213

The Longitudinal Relationship Between Inflammatory Burden and Gait Speed Is Influenced by White Matter Microstructural Characteristics: Secondary Analysis of the Health ABC Study Neelesh Nadkarni, Robert Boudreau, Oscar Lopez, Howard Aizenstein, Stephen Kritchevsky, Kristine Yaffe, Stephanie Studenski, Anne Newman, Caterina Rosano

P6.214

Brain Structural Changes in the Course of Alzheimer’s Disease Marina Weiler, Federica Agosta, Elisa Canu, Giuseppe Magnani, Massimiliano Copetti, Roberto Santangelo, Monica Falautano, Giancarlo Comi, Andrea Falini, Massimo Filippi

P6.215

White Matter Degeneration in Atypical Alzheimer’s Disease Francesca Caso, Federica Agosta, Daniele Mattavelli, Raffaella Migliaccio, Elisa Canu, Giuseppe Magnani, Alessandra Marcone, Laura Ferrari, Massimiliano Copetti, Monica Falautano, Giancarlo Comi, Andrea Falini, Massimo Filippi

P6.216

Abnormalities of the Uncinate Fasciculus Correlate with Behavioral Symptoms in Primary Progressive Aphasia Lucio D'Anna, M. Mesulam, Michel Thiebaut De Schotten, Estrid Jakobsen, Christina Wieneke, Flavio Dell'acqua, Emily Rogalski, Marco Catani

P6.217

Diabetes Mellitus-related Cognitive Impairment and White Matter Microstuctural Integrity: A Cross-sectional Study with the Use of Diffusion Tensor Imaging Vasileios-Arsenios Lioutas, Freddy Alfaro-Martinez, Chen Chih Chung, WooKyoung Yoo, Vera Novak

P6.218

P6.223 Detachable Tip

P6.235 Long-term Impact of

P6.224 Rupture Arteriovenous

P6.236 IV Thrombolysis in Minor

Microcatheters for Liquid Embolization of Brain Arteriovenous Malformations (AVMs): A US Single Center Experience Asif Khan, Nabeel Herial, Mushtaq Qureshi, Gregory Sherr, Muhammad Suri, Adnan Qureshi Malformation Presenting as Thalamic Hypertensive Hemorrhage Santoshi Billakota, Nadal El-Husseini, Shahid Nimjee

P6.225 Pediatric Cavernous Sinus

Thrombosis: A Case Series and Review of the Literature Douglas Smith, Daniel Licht, Arastoo Vossough, Gregory Vorona

P6.226 Novel Approach to Clinico-

neuroradiological Correlation and Prognostication in Cerebral Venous Sinus Thrombosis Kalaimani Elango, Balaji Nagarajan, Shankar Balakrishnan, Bhanu Kesavamurthy, Lakshmi Ranganathan, Cheran Elangovan, Kannan Vellaichamy

P6.227 Spontaneous Superior

Ophthalmic Vein Thrombosis: A Case Report Karanbir Singh, Deeya Gaindh, Ghulam Mustafa, Haris Kamal, Ashkan Mowla

Cerebrovascular Disease and Interventional Neurology: Acute Thrombolysis P6.228 Acute Ischemic Stroke in

Acute Myocardial Infarction Patients Receiving IV Rt-PA: An Analysis of Thrombolysis in Myocardial Infarction (TIMI) II Trial Nauman Jahangir, Ahmed Malik, Muhammad Afzal, Adnan Qureshi

Implementation of a Stroke Protocol on Door to Needle Time in Administration of Intravenous Recombinant Tissue Plasmonigen Activator (IV-tPA) Wenzhuan He, Zaid Al-Qudah, Weizhen Wang, Vivek Tank, Machteld Hillen Stroke: Using MRI Based Vessel and Perfusion Abnormalities to Identify a Subpopulation That May Benefit Aabha Shah, Lawrence Latour, Tyler Brown, Richard Benson, Amie Hsia, John Lynch, Zurab Nadareishvili, Marie Luby

P6.237 IV Thrombolysis for

Acute Cervical Internal Carotid Artery Occlusion Wan Yee Kong, Benjamin Tan, Hock Luen Teoh, Raymond Seet, Bernard Chan, Rahul Rathakrishnan, Derek Soon, Vijay Sharma, Vijay Sharma, Leonard Yeo

Cerebrovascular Disease and Interventional Neurology: Thrombolysis Complications P6.238 Neuroimaging Findings of

Post-thrombolysis Cerebral Hemorrhage in Acute Ischemic Stroke Vivien Lee, Shawna Cutting, Sarah Song, Laurel Cherian, James Conners

P6.239 Prior Asymptomatic

Intraparenchymal Hemorrhage Does Not Increase the Risk for Intracranial Hemorrhage After Intravenous Thrombolysis Mahmoud AbdelRazek, Ashkan Mowla, Wendy Zimmer, Rabab Elsadek, Noureldin Abdelhamid, Lobna Elsadek, Katelyn Kavak, Salman Farooq, Haris Kamal, Annemarie Crumlish, Peyman Shirani, Robert Sawyer

Neurocognitive Changes in High-altitude U-2 Pilots: Relationship Between Microstructural Integrity of White Matter Tracks and Neurocognitive Outcomes Adam Willis, John Sladky, David Tate, Joe Wood, Paul Sherman, Peter Kochunov, Steve McGuire

P6.229 Impact of Off-label Use of

Cerebrovascular Disease and Interventional Neurology: AVM and Cerebral Venous Thrombosis

Making Early in the Academic Year Evgeny Sidorov, Margaret Elaine Haxton, Lawrence Gorman, David Gordon, Shuchi Chaudhary

Factors Predisposing to Hemorrhagic Conversion of Ischemic Stroke After Thrombolysis Ashkan Mowla, Haris Kamal, Peyman Shirani, Robert Sawyer Jr, Marilou Ching, Aaron McMurtray, Kelly Smith, Ping Li, Salman Farooq, Karanbir Singh, Mahmoud AbdelRazek, Sandhya Mehla, Ann Marie Crumlish, Bijal Mehta

P6.219

P6.231 24 Hours Post TPA

Surveillance Head CT, What Does It Add to Patient Care Krishna Nalleballe, Madhu Jasti, Neville Jadeja, Sanjeeva Onteddu

P6.241 Knowledge Regarding Oral

Acute Hydrocephalus Associated with Brainstem Microarteriovenous Malformation Janhavi Modak, Robert Brown, Paul Schwartz, Martin Ollenschleger

P6.220 Clinical Presentations,

Venous Drainage Patterns, and Treatment Outcomes in Carotid Cavernous Fistula David Altschul, Yamin Shwe, Santiago Ortega-Gutierrez, Srinivasan Paramasivam, Alejandro Berenstein, Johanna Fifi

P6.221 Flow Diversion Versus

Conventional Treatment for Carotid Cavernous Aneurysms Norman Ajiboye

P6.222 Spinal Dural Arteriovenous Fistulas Mimicking Demyelinating Disease Anita Tipirneni, Amer Malik, Melissa Ortega, Dileep Yavagal


TPA on NIH Stroke Scale Score in Ischemic Stroke James Anaissie, Elizabeth Waring, Dominique Monlezun, Jr, Tara Kimbrough, Alexander George, Alyana Samai, Sheryl Martin-Schild

P6.230 Delay in IV TPA Decision

P6.232 Early Improvement After IV

TPA at the Largest Safety-net Hospital in New England: The Boston Medical Center Experience Abdullah Tawakul, Guannan Ge, Helena Lau, Thanh Nguyen, Jose Romero, Viken Babikian, Carlos Kase, Hesham Masoud

P6.233 Conjugate Gaze Deviation

on CT in Patients Treated with IV-TPA Associated with Vascular Occlusions and Worse Outcomes Nirav Shah, Anita Tipirneni, Nirav Bhatt, Diego Condes, Jose Romano

P6.234 Title: CTP Mismatch Imaging

Predicts Outcome of IV-rtPA Treatment Within the 3 Hour Window James Frey, Carol Darbonne, Joni Clark, Kristina Chapple, Allison Tucker, Lynn Ashby, Glynnis Zieman

P6.240 Clinical and Laboratory

Anticoagulation Therapy Among Patients with Stroke and Those at High Risk of Thromboembolic Events Rohit Bhatia, Annu Alphonsa, Kamlesh Sharma, Gautam Sharma

P6.242 Contemporary Trends in the

Ischemic Stroke “Weekend Effect” on IV Thrombolytic Use, In-hospital Mortality, Discharge Disposition, Hospital Charges, and Length of Stay Vishal Jani, Sopan Lahewala, Shilpkumar Arora, Achint Patel, Arshad Majid, Syed Hussain, Anmar Razak, Adnan Safdar, Asif Khan, Nabeel Herial, Erin Shell, Julie Bey, Marylou Mitchell, Abraham Maaz, Adnan Qureshi

P6.243 Urticarial Allergic Reaction to

Alteplase: A Case Report Laura Papolin, Danielle Mendes, Marcos Lange, Francisco Germiniani, Rodrigo Harger, Viviane Zetola, Jamileh Chamma

115

Thursday April 23


Poster Session VI P6.244 Explaining the Unexplained:

Neurologic Deterioration in Acute Ischemic Stroke Michael Mcmanus, Nerses Sanossian, Latisha Ali, Sidney Starkman, Neal Rao, Jason Hinman, Doojin Kim, Paul Vespa, Manuel Blanco, Mateo CalderonArnulphi, Alireza Noorian, Kwan Ng, Conrad Liang, Sunil Sheth, Fabien Scalzo, Jeffrey Saver, David Liebeskind

P6.245 Fever and Dynamic Neurologic

Worsening After Ischemic and Hemorrhagic Brain Injury Matthew Maas, Michael Berman, Brandon Francis, Eric Liotta, Shyam Prabhakaran, Andrew Naidech

P6.246 Clinical and In-hospital

Process Variables Are Associated with Hospital Length-of-stay in Acute Ischemic Stroke Patients Sun Kim, Jared Conley, Lucy Kalanithi, Waimei Tai

P6.247 Susceptibility Weighted MRI

and Regional Cerebrovascular Reservoir Capacity in Angiography Proven Large Artery Disease in Acute Ischemic Stroke and Transient Ischemic Attack Si Baek Lee, Yoo Dong Won, Do-Sung Yoo

Child Neurology and Developmental Neurology: Other P6.248 Reversible Splenial Lesions

in Kawasaki Disease in a 7-year-old Boy—First Reported Case in North America Venu Parachuri, Akshat Katyayan, Kumar Sannagowdara, Nadir Khan

P6.249 Quality of Life in

7:30 a.m.–12:00 p.m.

P6.255 Evaluation of Efficacy and

Safety Baseline Parameters in Patients with Duchenne Muscular Dystrophy (DMD) from Three Placebo-controlled Studies of Drisapersen (DRIS) Giles Campion, Thomas Voit, Nathalie Goemans, Rosamund Wilson, Claire Wardell, Craig McDonald

P6.256 Ultrasound Assessment of

Obstetric Brachial Plexus Injury Edward Smith, Kathryn Xixis, Gerald Grant, Stuart Grant

P6.257 An Adult Presenting with

Neurological Symptoms Attributed to Hyperhomocysteinemia That Resolved with Treatment Devorah Segal, Zubeda Sheikh, Kevin Shahbahrami, Jyothirmayi Garikparthy, Angel Monserrate, Aleksey Tentler, Machteld Hillen, Ling Shih, Beth Pletcher

Child Neurology and Developmental Neurology: Inflammation and White Matter Disease P6.258 Acute Flaccid Paralysis in a

Cluster of Six Children at the Hospital for Sick Children: August-September 2014. Toronto, ON Maryam Nabavi Nouri, Samantha Irwin, Susan Richardson, Helen Branson, Christoph Licht, Jamie Hutchison, Ari Bitnun, Ann Yeh

P6.259 Case Series of Three Patients

of Acute Flaccid Myelitis Ashutosh Kumar, Kanika Arora, Jayne Ness

Childhood Pantothenate Kinase Neurodegeneration Treated with Deep Brain Stimulation Bennett Lavenstein, Chima Oluigbo

P6.260 Idopathic Non-polio Polio-

P6.250 Feasibility of a Randomized-

P6.261

control Trial: Improving Medication Adherence in Pediatric MS with a Remote Motivational Interviewing Intervention Stephanie Grover, Austin Noguera, Carolyn Schwartz, Ruth Slater, Petra Breiner, Elizabeth Quon, E. Ann Yeh

P6.251 Mortality in Children with

Cerebral Palsy Treated with Intrathecal Baclofen Pump V Vedanarayanan, Vandana Vedanarayanan, Colette Parker, Michelle White, Lamar Davis

P6.252 Botulinum Toxin for the

Treatment of Extra-pyramidal Symptoms of Lesch-Nyhan Syndrome Nassim Zecavati, Cesar Santos, Temitayo Oyegbile

P6.253 Clinical Relevance of VGKC-

complex Antibodies in Children Yael Hacohen, Rahul Singh, Bethan Lang, Cheryl Hemingway, Ming Lim, Angela Vincent

P6.254 A Comparative Analysis of

Findings by MPCR, MLPA and Muscle Biopsy in a Cohort of Children with Duchenne Muscular Dystrophy: A First Study Manjunath Poojar, Preethish Kumar Veeramani, Kiran Polavarapu, Atchayaram Nalini, Narayanappa Gayathri, Ravinder Singh, Priya Treesa Thomas, Anil Ramakrishna

116

like Flaccid Paralysis Salman Rashid, Muhammad Ubaidulhaq, Huiyuan Jiang, Aimee Luat EMG/NCV Changes in 2 Pediatric Patients with Acute Onset Flaccid Paralysis Brian Droker, Emmanuelle Tiongson, Quyen Luc, Kiarash Sadrieh, Tena Rosser, Jay Desai, Leigh Ramos-Platt

P6.262 Methotrexate Experience in Eight Pediatric Patients with AntiN-methyl-D-aspartate-receptor Encephalitis Alfredo Ramirez, Antonio Bravo-Oro, Ildefonso Rodriguez-Leyva, Carlos Abud-Mendoza

P6.263 Gait Disturbance as the Initial Presenting Symptom in Young Children with Anti-NMDA Receptor (Anti-NMDAR) Encephalitis: A Case Series Anusha Yeshokumar, Jessica Klein, Kristin Baranano, Carlos Pardo-Villamizar

P6.264 Paroxysmal Sympathetic

Hyperactivity (PSH) in Critically Ill Children with Encephalitis and Meningoencephalitis: Morbidity and Risk Factor Analysis Raquel Farias-Moeller, Elizabeth Wells, Nathan Dean, Jessica Carpenter

P6.265 A Pediatric Case of CLIPPERS (Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids) Sally Mathias, Deborah Hickman, Donita Lightner, Charles Smith, Robert Baumann

P6.266 Hemolytic Uremic Syndrome

P6.277 In Vitro Study of Impact

P6.267 Microstructural Thalamic

Epilepsy/Clinical Neurophysiology (EEG): Surgery/Autoimmune Epilepsy

(HUS) with Reversible Cerebral Vasospasm and Splenial Lesion Responsive to the High-dose Intravenous Magnesium Sulfate (MgSO4) Salman Rashid, Anza Memon, Mitchel Williams and Cortico-thalamic Correlates of Cognitive Impairment in Pediatric Multiple Sclerosis Ermelinda De Meo, Maria Rocca, Lucia Moiola, Angelo Ghezzi, Pierangelo Veggiotti, Ruggero Capra, Maria Amato, Agnese Fiorino, Lorena Pippolo, Maria Carmela Pera, Giancarlo Comi, Andrea Falini, Massimo Filippi

P6.268 Catastrophic Encephalopathy

as Presenting Picture of Susac's Syndrome in Two Children Silvia Tenembaum, Marcela Parada Marcilla, Alejandra Gonzalez, Guillermo Agosta

Child Neurology and Developmental Neurology: Electrophysiology, Epilepsy, and Other P6.269 Quantitative Analysis of

Surface Electromyography for Pediatric Neuromuscular Disorders Mana Higashihara, Masahiro Sonoo, Akihiko Ishiyama, Yu Nagashima, Haruo Uesugi, Madoka Mori-Yoshimura, Miho Murata, Shigeo Murayama, Hirofumi Komaki

P6.270 Epilepsy and

Electroencephalographic Features in Patients with Phelan McDermid Syndrome Xiangping Zhou, Andrea Gropman, Precilla D'Souza, Audrey Thurm, Sara Inati

P6.271 TBC1D24: A Novel Mutation Causing Intellectual Disability and Epilepsy Aaron Cardon, Jimmy Holder

P6.272 Utility of Obtaining a Serum Basic Metabolic Panel in the Setting of a First-time Nonfebrile Seizure Britton Zuccarelli, Ara Hall

P6.273 RG1662, a Selective GABAA

α5 Receptor Negative Allosteric Modulator, Increases Gamma Power in Young Adults with Down Syndrome Federico Bolognani, Lisa Squassante, Xavier Liogier d'Ardhuy, Maria-Clemencia Hernandez, Frederic Knoflach, Ivan Baldinotti, Jana Noeldeke, Christoph Wandel, Stephan Nave, Omar Khwaja

P6.274

Intraventricular Hemorrhage in the Asphyxiated Newborns Treated with Hypothermia: A Centre Experience Ghalia Alyazidi, Elodie Boudes, Michael Shevell, Pia Wintermark

P6.275 The Clinical and Radiographic Manifestations of Trans-tentorial Herniation in a Neonate Mitra Assadi Khansare, Renee Behme, Olga Goldfarb, Esther Nimchinsky

of Piericidin on 3D Neurosphere Culture Mohamed El-Hawary, Mohamed Rakha, Ahmed Lotfy, Mohamed Moheb Elgamal, Mohamed Salama, Mohamed Sobh

P6.278 Seizure Outcome

After Epilepsy Surgery in Patients with Intractable Non-lesional Epilepsy Niravkumar Barot, Hai Chen, Pradeep Modur, Paul Van Ness, Mark Agostini, Ryan Hays, Christopher Madden, Bruce Mickey, Kan Ding

P6.279 Behavioral Response

Following Hypothalamic Hamartoma Treatment in Adults Danilo Vitorovic, Laura Lehnhoff

P6.280 Does Postoperative EEG

Predict Seizure Recurrence After Epilepsy Surgery? Sarah Hodges, Daniel Goldenholz, William Theodore, Sara Inati

P6.281 “A Circuitous Journey”:

Parent Perspectives of Getting to Pediatric Resective Epilepsy Surgery Christine Baca, Huibrie Pieters, Tomoko Iwaki, Gary Mathern, Barbara Vickrey

P6.282 Intractable Reflex Epilepsy

Treated Successfully with Deep Brain Stimulation Anteneh Feyissa, Squire Stead, Jamie Van Gompel, Jeffrey Britton

P6.283 Patients with

Neurofibromatosis Type-1 and Temporal Epilepsy Can Be Good Candidates for Epilepsy Surgery Leon Weinstock, Shirisha Ale, Ping Li, Naeem Mahfooz, Lucia Balos, Veetai Li

P6.284 The Frequency of Serum

Neural Autoantibodies in Suspected Autoimmune Epilepsy Brian Sansoucy, Malgorzata Jaremko, Kaylan Burnham, Keith Mourneau, Amy Goldberger, Vishal Patel, Zhenyuan Wang, Funda Suer, Sat Dev Batish, Joseph Higgins

P6.285 Autoimmune Epilepsy:

Clinical Features, Management and Outcomes Ryan Hays, Divyanshu Dubey, Niyatee Samudra, Mark Agostini, Kan Ding, Puneet Gupta, Paul Van Ness, Steven Vernino

P6.286 NMDA-receptor Encephalitis: An Unsual Case of Refractory Status Epilepticus Catherine Legault, Sarah Lapointe, Paul Giacomini, Jeanne Teitelbaum, Roberta La Piana, Donatella Tampieri, Annalisa Romano

P6.287 Autoimmune Seizure

Syndrome in a Patient with Addison’s Disease Shubhi Agrawal, Krikor Tufenkjian, Sanjay Singh

P6.276

Clinical Outcomes Among Transferred Children with Ischemic and Hemorrhagic Stroke in the Nationwide Inpatient Sample Mohammad Qureshi, Malik Adil, Gabriel Vidal, Ahmed Malik, Mushtaq Qureshi, Adnan Qureshi


Poster Session VI

Epilepsy/Clinical Neurophysiology (EEG): Imaging/Lifestyle P6.288 Hybrid PET/MR May Improve

Diagnostic Yield of Epileptic Lesions Hae Won Shin, Valerie Jewells, Arif Sheikh, Hongyu An, Eldad Hadar, Linh Ngo, Zhu Hongtu, Wei Gao, Dinggang Shen, Weili Lin

P6.289 Volumetric Analysis of

Unilateral Focal Epilepsy in Children Allison Dixon, Nasser Kashou, Gogi Kumar

P6.300 Pilot Study of Raltegravir,

P6.313

Neuropathic Pain Treatments and Quality of Life Results in Leprosy Patients Ricardo Dornas, Osvaldo Nascimento, Camila Pupe, Lucas Araujo, Eduardo Davidovich, Felipe Vianna, Bruno Coutinho, Caroline Bittar

P6.325 Neurocysticercosis and

P6.314

P6.326 Recurrent Aseptic Meningitis

Associated with Chikungunya Virus Infection Anna Bank, Ayush Batra, Rene Colorado, Jennifer Lyons

First Reported Case of a Brain Abscess with Ustekinumab for Psoriatic Arthritis Haseeb Rahman, Abraham Thomas, Daoud Rahman, Bushra Javed, Popovich Jovan

P6.302 Neurological Manifestations

P6.315

into the Spinal Cord in Poorly Treated Patients Rosette Jabbour, Lamya Ann Atweh, Samir Atweh

an Integrase Inhibitor, in Human T-cell Lymphotrophic Virus-1 (HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP) Raya Massoud, Breanna Caruso, Yoshimi Akahata, Joan Ohayon, Steven Jacobson

P6.301 Myeloradiculopathy

Presenting with First Time Seizure Vineet Punia, Anjali Dagar, David Marks

of Acute Dengue Virus Infection: A Study from Tropical Country- India Devashish Ruikar, Sita Jayalakshmi, Mohandas Surath

P6.291 Sensitivity of MRI in Patients

P6.303 Role of C-Jun N-terminal

P6.290 Utility of MRI in Patients

with New Onset Seizures Who Have Normal CT Imaging and Neurologic Examinations Ryan Smith, Adnan Subei, Ivan Garza, Michael Flink

P6.292 A Round Hyperdense Middle Cerebral Artery Sign in a Patient with Seizures: An Unusual Presentation of a Brain Tumor Rather Than a Subarachnoid Hemorrhage Rodica Petrea, Charles Rothberg, Arun Patil, William Hunter, Edward Adickes, Angel Mironov, Sanjay Singh

P6.293 Concordance Rate Between

the Wada Test and FMRI for Language Lateralization in Patients with Medically Intractable Epilepsy Andreu Massot-Tarrus, Reza Mousavi, Frank Bihari, Susan HaymanAbello, Brent Hayman-Abello, Seyed Mirsattari

P6.294 Epilepsy in the Elderly:

Temporal Lobe Atrophy Present in Many Cases of Epilepsy of Unknown Etiology Emannuelle Lapointe, Christian Bocti, Charles Deacon, Louis Royer-Perron, Stephen Cunnane

P6.295 Type II Cortical Dysplasia

in Dominant Frontal Lobe Presenting as Gelastic Epilepsy Sophie Peeters, Divyanshu Dubey, Drew Thodeson, Michael Dowling, Deepa Sirsi, Susan Arnold, Rana Said

Kinase (JNK) Signaling in Varicella Zoster Virus Infection of Neurons Arun Venkatesan, Labchan Rajbhandari, Sravya Kurapati, Tomohiko Sadaoka, Jeffrey Cohen

P6.304 Concentration Dependent

Inhibitory Effect of a Nucleoside-based Analog Against Human Herpesvirus-6 Replication Naomi Lee, Emily Leibovitch, Steven Jacobson

P6.305 Quantitative Detection of

Human Herpesvirus-6 with Digital Droplet PCR in a Patient with Post-transplant HHV6 Encephalitis Bridgette Jeanne Billioux, Steven Jacobson

P6.306 Successful Treatment

of Eastern Equine Encephalitis with Early, Empiric Initiation of Intravenous Immunoglobulin: A Case Report Michael Erkkinen, Maya Srikanth, Jennifer Lyons, Henrikas Vaitkevicius

P6.307 Neurological Manifestations

in Dengue Seropositive Patients Navneet Kumar, Gaurav Gupta, Kanhaiya Agrawal, Atul Garg

Lyme and Other CNS Infections P6.308 An Unusual Presentation of Neuro Lyme Mohamed Tom, Muhanad Mohamed, Stephen Holloway

P6.309 Treatment of North American

Seizure Control in Epileptic Patients Ashraf Abdou, Amr El Fatatry, Horya Sad Allah, Naglaa Abd Elhakeem

Lyme Neuroborrelliosis with Oral Doxycycline and Intravenous Ceftriaxone: A Comparative Case Series Joseph Alario, Kelly Baldwin

P6.297 Benefits of Exercise in

P6.310

P6.296 Effect of Ramadan Fasting on

Patients with Epilepsy: A Literature Review Frank Gilliam, Robert Hogan, Gregory Gilmet

HTLV and Other Viral Infections P6.298 HTLV-1-associated

Myelopathy/Tropical Spastic Paraparesis: Clinical and Neuroimaging Findings Francisco Carod, Hudson Mesquita

P6.299 Common γ-chain

Blocking Peptide Reduces in Vitro Immune Activation Markers in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis Raya Massoud, Yoshimi Akahata, Yutaka Tagaya, Nazli Azimi, Asjad Basheer, Steven Jacobson

Borrelia Hispanica: An Emerging Infectious Agent Causing Neuroborreliosis Maria Cerdan, Iria Sánchez Martínez, Begoña Palazon Cabanes, Ester Carreon Guarnizo, Pedro Anda Fernandez, Raquel Escudero Nieto, Jose Meca La Llana

P6.311

Clinical, Laboratory Findings, and Complications of Scrub Typhus- Meningoencephalitis: Case Series Prasanna Venkatesan Eswaradass, C Eswaradass

P6.312

Subarachnoid Hemorrhage: A Rare Complication of Pyogenic Bacterial Meningitis Parunyou Julayanont, Helen Wang, Pavis Laengvejkal, Sahawat Tantikittichaikul, John DeToledo


Fulminant Necrotizing Encephalitis Associated with Malignant Cerebral Edema and Transtentorial Herniation in the Setting of Acute Seasonal Influenza Pneumonia James Boyd, Mohamed-Ali Babi, Gilman Allen, Charlotte Teneback, Christopher Commichau

P6.316

A Unique Case of Leptomeningitis Associated with Rheumatoid-like Arthritis and Nonpathogenic Naegleria Species Milena Rodriguez Alvarez, Neha Mirchandani, Imad Khan, Karen Medin, Roberta Seidman, Susan Madison-Antenucci, Noel Espina, Allen Teal, Kimberly Mergen

P6.317

Utility of Broad-range PCR Testing in Suspected CNS Infections Lauren Koffman, Rodica Bernatowicz, Nabin Shrestha, Adarsh Bhimraj

Fungi, Parasites, and Other Infectious Disorders P6.318

Blood Stream Infections in NNICU: Blight to ICU Stay Man Mohan Mehndiratta

P6.319

Linezolid in Children with Drug Resistant Tuberculosis and Associated Peripheral Neuropathy Amit Dey

P6.320 A Rare Presentation of

Disseminated Histoplasmosis Mimicking Metastatic Cancer in Apparently Immunocompetent Individual Doungporn Ruthirago, Nebiyou Wondimagegnehu, Pakpoom Tantrachoti, Kenneth Nugent

P6.321 Diagnostic Challenges of

Acapsular Cryptococcus Neoformans in an Immunocompetent Individual Manifesting as Chronic Hydrocephalus Kedar Mahajan, Robin Dharia, Lori Sheehan

P6.322 Severe Immune

Reconstitution-like Inflammatory Syndrome from Cryptococcus Gotti Menigoencephalitis Treated with Cyclophosphamide Christopher Way, Rene Patino, James Nomura, Annette LangerGould

Epilepsy in Bhutan: A Cross-sectional Study Kate Brizzi, Damber Nirola, Erica McKenzie, Sonam Deki, Lhab Tshering, Sonam Pelden, Tshokey Tshokey, Chencho Dorji, Farrah Mateen from Sacral Subarachnoid Cysticercosis: A Tale in Tail Rajesh Gupta, Tracey Cho, Haatem Reda, Nagagopal Venna

P6.327 Migration of Toxocara Canis

History of Neurology P6.328 Did Charcot Have Vascular Parkinsonism? Helio Afonso Teive, Francisco Germiniani, Renato Munhoz

P6.329 Strange Fits of Passion

and Spin-offs Behind the Discoveries of Myasthenia Gravis Sankar Bandyopadhyay

P6.330 Deep Brain Stimulation: The Past, the Present, and the Future Lauren Davis

P6.331 ‘Rest or Go West’- The Forgotten Legacy of Silas Weir Mitchell Raghav Govindarajan

P6.332 The Essential Role of Pierre Marie to Neurological Sciences Francisco Germiniani, Helio Afonso Teive, Gustavo de Almeida P6.333 Historical Perspective of

Neurology in Iran Hadi Mohammad Khanli, Shrikant Mishra, Bhavesh Trikamji

P6.334 Spectrum of Neurological

Disorders Among 19th Century and Early to Mid-20th Century United States Presidents Raghav Govindarajan

P6.335 Retired Diagnoses from the

19th and 20th Centuries: Simple, Sick and Nervous Headaches Noah Rosen, Robert Duarte

P6.336 Neurology Workforce

in Hawai‘i: Current and Historical Observations Diane Chen, Marissa Sakoda, Alexander Wei, J. Douglas Miles

P6.337 Alice in Wonderland

Syndrome: A History Edward Fine, Poojah Sofat, Naeem Mahfooz, Alyssa Fiddler, Osman Farooq

P6.323 Brachial Plexus Neuritis as

Presenting Manifestation of Disseminated Coccidioidomycosis Rahul Shah, Bing Liao, Elena Shanina, Glenn Smith

P6.324 Fulminant Cerebral

Zygomycosis in a Healthy Man: A Case of Heroin Inhalation Joao Mc-ONeil Plancher, Simona Ferioli, Christopher Kiefer

117

Thursday April 23


Scientific Sessions S38 Diet and Hormonal Factors in Multiple Sclerosis 1:00 p.m. S38.001 High-dose Vitamin D Supplementation Reduces IL-17producing CD4+ T-cells and Effectormemory CD4+ T-cells in Multiple Sclerosis Patients Pavan Bhargava, Elias Sotirchos, Christopher Eckstein, Achilles Ntranos, Anne Gocke, Ellen Mowry, Peter Calabresi 1:15 p.m. S38.002 Fat, Fiber, and Pediatric MS Brandon Seminatore, Jennifer Graves, Amy Waldman, Timothy Lotze, Teri Schreiner, Anita Belman, Benjamin Greenberg, Bianca Weinstock-Guttman, Gregory Aaen, Jan-Mendelt Tillema, Janace Hart, Jayne Ness, Jennifer Rubin, Lauren Krupp, Mark Gorman, Leslie Benson, Moses Rodriguez, Tanuja Chitnis, Soe Mar, Lisa Barcellos, John Rose, Shelly Roalstad, Timothy Simmons, Charlie Casper, Emmanuelle Waubant 1:30 p.m. S38.003 A Case-control Study of Dietary Salt Intake and Risk of Pediatric Multiple Sclerosis (MS) Jamie McDonald, Jennifer Graves, Amy Waldman, Timothy Lotze, Teri Schreiner, Anita Belman, Benjamin Greenberg, Bianca Weinstock-Guttman, Gregory Aaen, Jan-Mendelt Tillema, Janace Hart, Jayne Ness, Jennifer Rubin, Lauren Krupp, Mark Gorman, Leslie Benson, Moses Rodriguez, Tanuja Chitnis, Soe Mar, Lisa Barcellos, John Rose, Shelly Roalstad, Timothy Simmons, T.Charles Casper, Emmanuelle Waubant 1:45 p.m. S38.004 Sodium Chloride-high Diet Promotes Pro-inflammatory Macrophage Activation and Aggravates Central Nervous System Autoimmunity Luisa Klotz, Stephanie Hucke, Melanie Eschborn, Engbers Annika, Heinz Wiendl 2:00 p.m. S38.005 The Male 2D:4D Digit Ratio: A Proxy for Prenatal Androgen Exposure and a Risk Biomarker for Multiple Sclerosis. Riley Bove, Muhammad Taimur Malik, Camilo Diaz-Cruz, David Bargiela, Alicia Chua, Taylor Saraceno, Emily Greeke, Bonnie Glanz, Brian Healy, Tanuja Chitnis 2:15 p.m. S38.006 Association Between Low Testosterone and Brain Atrophy in Men with Multiple Sclerosis. Riley Bove, Brian Healy, Svetlana Egorova, Bonnie Glanz, Rohit Bakshi, Philip De Jager, Karen Miller, Charles Guttmann, Tanuja Chitnis 2:30 p.m. S38.007 Genes and Environment in Multiple Sclerosis (GEMS) Study: Leveraging Electronic Communication to Enable a Prospective Study of Individuals at Risk of Multiple Sclerosis Zongqi Xia, Lori Chibnik, Philip De Jager

118

S39 Cerebrovascular Disease and Interventional Neurology: Intracerebral Hemorrhage 1:00 p.m. S39.001 Systemic Inflammatory Response Syndrome During Hospitalization for Intracerebral Hemorrhage Drives Poor Functional Outcome at Discharge Amelia Boehme, Angela Hays Shapshak, Karen Albright, Niren Kapoor, Kimberly Kicielinski, David Miller, Mitchell Elkind, Mark Harrigan 1:15 p.m. S39.002 Time Trends of Inflammatory Markers in Cerebrospinal Fluid of Patients with Spontaneous Intracerebral and Intraventricular Hemorrhage Wendy Ziai, Adrian Parry-Jones, Saman Nekoovaght-Tak, Andrew Mould, Carol Thompson, Santosh Murthy, Daniel Hanley 1:30 p.m. S39.003 Prehospital Initiation of Magnesium Sulfate in Patients with Acute Intracerebral Hemorrhage Nerses Sanossian, Sidney Starkman, David Liebeskind, Scott Hamilton, Marc Eckstein, Samuel Stratton, Franklin Pratt, Robin Conwit, Gene Sung, Jeffrey Saver 1:45 p.m. S39.004 Utility of Immediate CTangiograpahy After Intracerebral Hemorrhage Omran Kaskar, Larry Goldstein, Michael James 2:00 p.m. S39.005 Rate of Peri-hematomal Edema Expansion Predicts Outcome After Intracerebral Hemorrhage Sebastian Urday, Lauren Beslow, David Goldstein, Feng Dai, Fan Zhang, Anastasia Vashkevich, Alison Ayres, Thomas Battey, Marc Simard, Jonathan Rosand, W. Kimberly, Kevin Sheth 2:15 p.m. S39.006 Accurate Outcome Predictions for Intracerebral Hemorrhage Patients Are More Likely Than Inaccurate Predictions to Be Influenced by Comorbidities Not Included in Clinical Scales David Hwang, Cameron Dell, Mary Sparks, Tiffany Watson, Carl Langefeld, Mary Comeau, Jonathan Rosand, Thomas Battey, Sebastian Koch, Mario Perez, Michael James, Jessica McFarlin, Jennifer Osborne, Daniel Woo, Steven Kittner, Kevin Sheth 2:30 p.m. S39.007 Depression Equally Common After Intracerebral Hemorrhage as It Is After Acute Ischemic Stroke Mary Denny, Suhas Bajgur, Kim Yen Thi Vu, Rahul Karamchandani, Amrou Sarraj, Sean Savitz

Thursday, April 23 S40 Movement Disorders: Functional Imaging in Parkinson's Disease 1:00 p.m. Presentation of Movement Disorders Research Award Recipient: Christopher Goetz, MD, FAAN Chicago, IL

1:30 p.m. S40.003 Assessment of Parkinson Disease Progression Using 123- I I-ioflupane SPECT: Update from the Parkinson Progression Marker Initiative Trial John Seibyl, Danna Jennings, Kenneth Marek 1:45 p.m. S40.004 Putaminal Dopamine Turnover Predicts Levodopa-induced Motor Complications in de Novo Parkinson’s Disease Matthias Löhle, Julia Mende, Martin Wolz, Bettina Beuthien-Baumann, Liane Oehme, Jörg van den Hoff, Jörg Kotzerke, Heinz Reichmann, Alexander Storch 2:00 p.m. S40.005 White Matter Microstructural Damage and Cognitive Impairment in Parkinson’s Disease Sebastiano Galantucci, Federica Agosta, Delia Gagliardi, Francesca Caso, Iva Stankovic, Igor Petrovic, Tanya Stojkovic, Vladimir Kostic, Massimo Filippi 2:15 p.m. S40.006 Clinical Correlates of Raphe Serotonergic System Dysfunction in Early Parkinson’s Disease. Zahi Qamhawi, David Towey, Gennaro Pagano, John Seibyl, Kenneth Marek, Per Borghammer, David Brooks, Nicola Pavese 2:30 p.m. S40.007 Effects of Aerobic Exercise on Striatum and Substantia Nigra in Parkinson’s Disease Ergun Uc, Vincent Magnotta, Hans Johnson, Kasra Zarei, Martin Cassell, Joel Bruss, Kevin Doerschug, Teri Thomsen, Joel Kline, Steven Anderson, Matthew Rizzo, Arthur Kramer, Michelle Voss, Jeffrey Dawson, Warren Darling

S41 Aging, Dementia, Cognitive, and Behavioral Neurology: Imaging: Aging and Alzheimer's Disease 1:00 p.m. Presentation of Norman Geschwind Prize in Behavioral Neurology Recipient: Andrew Kayser, MD, PhD San Francisco, CA

1:15 p.m. S41.002 Variation in Longevity Gene KLOTHO Is Associated with Greater Cortical Volumes in Aging Jennifer Yokoyama, Virginia Sturm, Luke Bonham, Eric Klein, Konstantinos Arfanakis, Lei Yu, Giovanni Coppola, Joel Kramer, David Bennett, Bruce Miller, Dena Dubal 1:30 p.m. S41.003 Maintenance of Physical and Cognitive Function Late in Life: A Shared Neuroimaging Signature? Caterina Rosano, Howard Aizenstein, Kristine Yaffe, Anne Newman, Stephanie Studenski, Andrea Rosso, Joe Verghese 1:45 p.m. S41.004 The Neuropsychology of Preclinical Alzheimer’s Disease: Differential Sensitivity of Component Processes of Memory Performance on Biomarker Evidence of Amyloidosis Kathryn Papp, Dorene Rentz, Elizabeth Mormino, Rebecca Amariglio, Samantha Burnham, Keith Johnson, Reisa Sperling 2:00 p.m. S41.005 Cognitive Decline, Ventricular Enlargement, and Hippocampal Atrophy in Mild Cognitive Impairment Anna Blanken, David Avila, Naira Goukasian, Holly Wilhalme, John Ringman, Ellen Woo, Liana Apostolova

S42 New Developments in Peripheral Neuropathies 1:00 p.m. S42.001 Polyneuropathies and Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Multiple Sclerosis Narupat Suanprasert, P. James B. Dyck, Chafic Karam, Bruce Taylor 1:15 p.m. S42.002 Distinctive Patterns of Sonographic Nerve Enlargement Between Acquired Axonal and Demyelinating Neuropathies. Stephan Goedee, Jan-Thies Van Asseldonk, Leonard Van den Berg, Leendert Visser 1:30 p.m. S42.003 CMT X in Women: Electrodiagnostic Findings Nivedita Jerath 1:45 p.m. S42.004 Nerve Pathologic Features Differentiate POEMS Syndrome from CIDP Ezequiel Piccione, JaNean Engelstad, Michelle Mauermann, Angela Dispenzieri, P. James B. Dyck 2:00 p.m. S42.005 Acute-onset Chronic Inflammatory Demyelinating Polyneuropathy. An Electrodiagnostic Study Mohammad Anadani, Bashar Katirji 2:15 p.m. S42.006 An Exon Trap with Proper Poly-A Site in the GBE1 Is the Common Missing Cause in Adult Polyglucosan Body Disease Orhan H. Akman, Or Kakhlon, Jorida Coku, Lorenzo Peverelli, Hanna Rosenmann, Lea Rozenstein-Tsalkovich, Julie Turnbull, Vardiella Meiner, Liat Chama, Israela Lerer, Shoshi Shpitzen, Eran Leitersdorf, Carmen Paradas Lopez, Mary Wallace, Raphael Schiffmann, Salvatore DiMauro, Alexander Lossos, Berge Minassian

2:15 p.m. S41.006 FDG-PET of the Brain and Neuropsychiatric Symptoms in Normal Cognitive Aging: The Mayo Clinic Study of Aging Hanna Ruider, Janina Krell-Roesch, Gorazd Stokin, Val Lowe, Rosebud Roberts, Michelle Mielke, David Knopman, Teresa Christianson, Clifford Jack, Ronald Petersen, Yonas Geda 2:30 p.m. S41.007 Progression of Cerebral Atrophy and Hypometabolism in the Presence of β-amyloidosis in Mild Cognitive Impairment David Knopman, Clifford Jack, Emily Lundt, Heather Wiste, Stephen Weigand, Prashanthi Vemuri, Val Lowe, Kejal Kantarci, Jeffrey Gunter, Matthew Senjem, Michelle Mielke, Rosebud Roberts, Bradley Boeve, Mary Machulda, Ronald Petersen


Invited Science: Epilepsy

1:00 p.m.–2:45 p.m.

1:00 p.m. S43.001 Radiosensitization of Glioblastoma Stem Cells by Targeting High-affinity Glucose Uptake Kailin Yang, William Flavahan, Samuel Chao, Jeremy Rich 1:15 p.m. S43.002 Transforming Growth Factor-β Pathway Activity in Human Malignant Gliomas—an in Vivo Study Dorothee Gramatzki, Karl Frei, Isabel Tritschler, Judith Johanna Schröder, Larisa Espinoza, Elisabeth Rushing, Michael Weller 1:30 p.m. S43.003 Neuronal Activity-regulated Secretion of Neuroligin-3 Promotes Glioma Growth Michelle Monje, Humsa Venkatesh, Viola Caretti, Tessa Johung, Alyssa Noll, Hannes Vogel, Parag Mallick, Markus Bredel 1:45 p.m. S43.004 Highly Precise Quantification of Multiple Human Herpesviruses in Glioblastoma Samples by Droplet Digital PCR Cheng-Te Lin, Emily Leibovitch, M.I. Almira-Suarez, Steven Jacobson 2:00 p.m. S43.005 Multicenter Phase I Dose Escalation Study of Hypofractionated Stereotactic Radiotherapy with Bevacizumab in the Treatment of Recurrent Malignant Glioma Elizabeth Neil, Jennifer Clarke, Kathryn Beal, Phillip Gutin, Barani Igor, Thomas Kaley, Andrew Lassman, Malbora Perezic-Mustafa, Robert Young, Antonio Omuro 2:15 p.m. S43.006 A Phase 1 Study Evaluating ABT414 with Temozolomide (TMZ) or Concurrent Radiotherapy (RT) and TMZ in Glioblastoma (GBM) Andrew Lassman, Hui Gan, Lisa Fichtel, Ryan Merrell, Martin Van Den Bent, Priya Kumthekar, Andrew Scott, Michelle Pedersen, Erica Gomez, JuDee Fischer, William Ames, Hao Xiong, Ho-Jin Lee, Wijith Munasinghe, Lisa Roberts-Rapp, Peter Ansell, Kyle Holen, David Reardon

S44 History of Neurology 1:00 p.m. Presentation of Lawrence C. McHenry Award: An Award for the History of Neurology Recipient: Michel Shamy, MD, MA, FRCPC Ottawa, ON, Canada

1:30 p.m. S44.003 Transcontinental Crossings Francois Boller, Henry Kaminski, Alissa Romano 1:45 p.m. S44.004 Asterixis—History and Terminology Gian Pal, Mark Lin, Robert Laureno 2:00 p.m. S44.005 Did the "Woman in the Attic" in Jane Eyre Have Huntington Disease? Elizabeth Coon, Anhar Hassan 2:15 p.m. S44.006 The Luckiest Creature Alive: George Orwell’s Traumatic Brachial Plexus Injury Ryan Jacobson 2:30 p.m. S44.007 Pearce Bailey: Shrewd Selection of the Second President of the Emerging American Academy of Neurology Elan Louis

S45 Neuroepidemiology: Multiple Sclerosis, Cerebrovascular, and Aging 1:00 p.m. Presentation of Bruce S. Schoenberg International Award in Neuroepidemiology Recipient: Stojan Peric, MD, PhD Belgrade, Serbia

1:30 p.m. S45.003 Risk Factors for Disease Progression in a Diverse US Population-based Multiple Sclerosis Cohort Mitchell Wallin, William Culpepper, John Kurtzke 1:45 p.m. S45.004 Greater Consumption of Coffee Is Associated with Reduced Odds of Multiple Sclerosis Ellen Mowry, Anna Hedstrom, Milena Gianfrancesco, Xiaorong Shao, Catherine Schaefer, Lisa Barcellos, Tomas Olsson, Lars Alfredsson 2:00 p.m. S45.005 Retinal Microvascular Signs and Agerelated Macular Degeneration Are Associated with Incident Cerebral Microbleeds According to Location in Older People: The AGES-Reykjavik Study Jie Ding, Chengxuan Qiu, Sigurdur Sigurdsson, Qian Zhang, Gudny Eiriksdottir, Vilmundur Gudnason, Mark Van Buchem, Mary Frances Cotch, Lenore Launer

Thursday, April 23, 1:00 p.m.–2:45 p.m. 1:00 p.m–1:20 p.m. Increased Cerebral Oxygenation Precedes Generalized Tonic Clonic Seizures 1:20 p.m–1:40 p.m. Factors Influencing Driving Impairment in Persons with Refractory Epilepsy 1:40 p.m–2:00 p.m. Management of Children with Refractory Epilepsy. A Decision Analysis Comparing Medical Versus Surgical Treatment 2:00 p.m–2:20 p.m. Temporal Lobe Epilepsy in Patients with Nonlesional MRI and Normal Memory: An SEEG Study 2:20 p.m–2:40 p.m. Neural Mechanism of Impaired Consciousness in Typical Childhood Absence Seizures 2:40 p.m–2:45 p.m. Questions and Answers

2:15 p.m. S45.006 Neighborhood Socioeconomic Status, Cognitive Function, and Small Vessel Disease Andrea Rosso, Jason Flatt, Gina Lovasi, Arleen Brown, Michelle Carlson, Ana Diez Roux, Karen Matthews, Caterina Rosano, Peter Gianaros 2:30 p.m. S45.007 Maternal Morbidity and Mortality in Pregnant Women with Epilepsy in the United States Sarah MacDonald, Brian Bateman, Thomas McElrath, Sonia Hernández-Díaz

2:30 p.m. S43.007 Phase II Study of Arsenic Trioxide and Temozolomide in Combination with Radiation Therapy in Patients with Malignant Gliomas Priya Kumthekar, Sean Grimm, Katie McCarthy, Irene Helenowski, Alfred Rademaker, Jeffrey Raizer


Thursday April 23

S43 Neuro-oncology: Basic Science and Clinical Trials

New Trends and Cutting-Edge Research from the American Epilepsy Society*

*Program subject to change

119

Integrated Neuroscience Session

Thursday, April 23

I11 C The Promise of Novel Biomarker Approaches in Advancing Treatment

1:00 p.m.–5:00 p.m.

Coordinators: Massimo Pandolfo, MD, FAAN, and Deborah Hall, MD, PhD Part I

1:00 p.m.–2:45 p.m.

1:00 p.m.–1:05 p.m.

Introduction

1:05 p.m.–1:35 p.m.

Invited Speaker

Massimo Pandolfo, MD, FAAN, and Deborah Hall, MD, PhD

Part II

2:55 p.m.–4:35 p.m.

2:55 p.m.–3:25 p.m.

Invited Speaker

3:25 p.m.–3:30 p.m.

I11-3A Data Blitz

I11-3B Data Blitz

Immunologic and Radiological Biomarkers of Clinical Trials in Multiple Sclerosis Suhayl S. Dhib-Jalbut, MD, FAAN

Biomarkers in Therapy Development James Kaiser, MD

Identification of Gene Networks and Pathways Associated with Nabiximols Treatment in Multiple Sclerosis Patients Filippo Martinelli Boneschi, Laura Ferrè, Melissa Sorosina, Elisabetta Mascia, Arturo Nuara, Vittorio Martinelli, Letizia Leocani, Ferdinando Clarelli, Federica Esposito, Giancarlo Comi

1:35 p.m.–1:40 p.m.

I11-1A Data Blitz

1:40 p.m.–1:45 p.m.

I11-1B Data Blitz

3:30 p.m.–3:35 p.m.

1:45 p.m.–1:55 p.m.

Audience Q&A

1:55 p.m.–2:25 p.m.

Invited Speaker

3:35 p.m.–3:45 p.m.

Audience Q&A

3:45 p.m.–4:15 p.m.

Invited Speaker

4:15 p.m.–4:20 p.m.

I11-4A Data Blitz

4:20 p.m.–4:25 p.m.

I11-4B Data Blitz

4:25 p.m.–4:35 p.m.

Audience Q&A

TIA Biomarkers Determined Through Proteomics Paul George, Michael Mlynash, Christopher Adams, Calvin Kuo, Stephanie Kemp, Madelleine Garcia, Gregory Albers, Jean-Marc Olivot ALS Monocytes Exhibit a Pro-inflammatory Gene Expression Weihua Zhao, David Beers, Hooten Christopher, Stanley Appel

Biomarker Assessment in Clinical Trials: Personalizing Brain Tumor Treatment Evanthia Galanis, MD

2:25 p.m.–2:30 p.m.

Biomarkers in Clinical Trials in Rare Diseases: The Case of Friedreich's Ataxia Massimo Pandolfo, MD, FAAN

I11-2A Data Blitz

Non-invasive Monitoring of Treatment Response in IDH-mutant Glioma Patients by 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate Ovidiu Andronesi, Franziska Loebel, Wolfgang Bogner, Malgorzata Marjanska, Jorg Dietrich, Tracy Batchelor, Elizabeth Gerstner, Andrew Chi, Bruce Rosen, Daniel Cahill

2:30 p.m.–2:35 p.m.

I11-2B Data Blitz

Structural Brain Changes in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma Isabel Arrillaga-Romany, Kourosh Jafari-Khouzani, Yi-Bin Chen, Bruce Rosen, Tracy Batchelor, Jorg Dietrich

2:35 p.m.–2:45 p.m.

Audience Q&A

2:45 p.m.–2:55 p.m.

Break

Immune Profiling of NMO Patients Receiving Rituximab Immunotherapy Lauren Collison, Chris Ayers, Jessica Jackson, Kenny Frazier, Benjamin Greenberg, Don Healey

Monitoring Loss of Striatal Phosphodiesterase 10A (PDE10A) with [18F]MNI-659 and PET: A Biomarker of Early Huntington Disease (HD) Progression David Russell, Danna Jennings, Olivier Barret, Gilles Tamagnan, Vincent Carroll, David Alagille, Thomas Morley, Caroline Papin, John Seibyl, Kenneth Marek Biomarkers of Disease Severity in Myotonic Dystrophy During Skeletal Muscle Rehabilitation Corrado Angelini, Chiara Fritegotto, Paola Cudia


Cortical Lesion Burden on 7-tesla MRI Is Associated with Cognitive and Physical Disability in Multiple Sclerosis Daniel Harrison, Snehashis Roy, Dzung Pham, Susan Courtney, Brian Caffo, Peter Van Zijl, Peter Calabresi

I11-5B

Neural Origin Plasma Exosomes Provide Novel Biomarkers for Brain Insulin Resistance in Alzheimer's Disease Dimitrios Kapogiannis, Adam Boxer, Erin Abner, Arya Biragyn, Umesh Masharani, Lynda Frassetto, Ronald Petersen, Bruce Miller, Edward Goetzl

I11-5C

Assessment of Parkinson Disease Progression Using 123- I I-ioflupane SPECT: Update from the Parkinson Progression Marker Initiative Trial John Seibyl, Danna Jennings, Kenneth Marek

120

4:35 p.m.–5:00 p.m I11-5D

Spontanous Remyelination Has a Major Impact on Clinical Disability in Multiple Sclerosis: A Longitudinal PET Study with 11C-PIB Benedetta Bodini, Mattia Veronese, Daniel Garcia-Lorenzo, Marco Battaglini, Emilie Poirion, Leorah Freeman, Caroline Papeix, Bernard Zalc, Maya Tchikviladze, Catherine Lubetzki, Michel Bottlaender, Federico Turkheimer, Bruno Stankoff

I11-5E

Imaging Tau Pathology in Vivo in FTLD Spectrum Tauopathies with [18F] T807 PET Bradford Dickerson, Sara Makaretz, Christina Caso, Michael Stepanovic, Daisy Hochberg, Megan Quimby, Michael Brickhouse, Kimiko Domoto-Reilly, Scott McGinnis, Aaron Schultz, Neil Vasdev, Keith Johnson

I11-5F

TIA Biomarkers Determined Through Proteomics Paul George, Michael Mlynash, Christopher Adams, Calvin Kuo, Stephanie Kemp, Madelleine Garcia, Gregory Albers, Jean-Marc Olivot

I11-5G

ALS Monocytes Exhibit a Pro-inflammatory Gene Expression Weihua Zhao, David Beers, Hooten Christopher, Stanley Appel

I11-5H

Non-invasive Monitoring of Treatment Response in IDH-mutant Glioma Patients by 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate Ovidiu Andronesi, Franziska Loebel, Wolfgang Bogner, Malgorzata Marjanska, Jorg Dietrich, Tracy Batchelor, Elizabeth Gerstner, Andrew Chi, Bruce Rosen, Daniel Cahill

I11-5I

Structural Brain Changes in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma Isabel Arrillaga-Romany, Kourosh Jafari-Khouzani, Yi-Bin Chen, Bruce Rosen, Tracy Batchelor, Jorg Dietrich

I11-5K

Immune Profiling of NMO Patients Receiving Rituximab Immunotherapy Lauren Collison, Chris Ayers, Jessica Jackson, Kenny Frazier, Benjamin Greenberg, Don Healey

I11-5L

Monitoring Loss of Striatal Phosphodiesterase 10A (PDE10A) with [18F]MNI-659 and PET: A Biomarker of Early Huntington Disease (HD) Progression David Russell, Danna Jennings, Olivier Barret, Gilles Tamagnan, Vincent Carroll, David Alagille, Thomas Morley, Caroline Papin, John Seibyl, Kenneth Marek

I11-5M

Biomarkers of Disease Severity in Myotonic Dystrophy During Skeletal Muscle Rehabilitation Corrado Angelini, Chiara Fritegotto, Paola Cudia

I11-5J

Identification of Gene Networks and Pathways Associated with Nabiximols Treatment in Multiple Sclerosis Patients Filippo Martinelli Boneschi, Laura Ferrè, Melissa Sorosina, Elisabetta Mascia, Arturo Nuara, Vittorio Martinelli, Letizia Leocani, Ferdinando Clarelli, Federica Esposito, Giancarlo Comi


Integrated Neuroscience Session I12 Obesity and Neurological Disorders

1:00 p.m.–5:00 p.m.

Coordinators: Deborah I. Friedman, MD, and Janet C. Rucker, MD Part I

1:00 p.m.–2:45 p.m.

Part II

2:55 p.m.–4:35 p.m.

1:00 p.m.–1:05 p.m.

Introduction

2:45 p.m.–3:10 p.m.

Invited Speaker

1:05 p.m.–1:30 p.m.

Invited Speaker

3:10 p.m.–3:15 p.m.

I12-3A Data Blitz

1:30 p.m.–1:35 p.m.

I12-1A Data Blitz

3:15 p.m.–3:20 p.m.

I12-3B Data Blitz

1:35 p.m.–1:40 p.m.

I12-1B Data Blitz

3:20 p.m.–3:30 p.m.

Audience Q&A

3:30 p.m.–3:55 p.m.

Invited Speaker

Deborah I. Friedman, MD, and Janet C. Rucker, MD Obesity and Idiopathic Intracranial Hypertension Michael Wall, MD, FAAN Effects of Intervention on Optical Imaging of Papilledema in the Idiopathic Intracranial Hypertension Treatment Trial Mark Kupersmith Obesity and Overweight Are Highly Prevalent in Pediatric Secondary Pseudotumor Cerebri Syndrome Grace Paley, Claire Sheldon, Evanette Burrows, Marianne Chilutti, Grant Liu, Shana McCormack

Obesity and Sleep: Beyond Obstructive Sleep Apnea Hrayr P. Attarian, MD Effect of “Snoring Alone” and “Snoring Plus Phenomenon” on Cardiovascular Diseases, or Fatal or Nonfatal Stroke Yousef Mohammad, Ahmed Malik, Omar Saeed, Muhammad Suri, Adnan Qureshi Overdiagnosis of Idiopathic Intracranial Hypertension (IIH) Adeniyi Fisayo, Valerie Biousse, Nancy Newman, Beau Bruce

Adipocytokines and Migraine B. Lee Peterlin, DO

1:40 p.m.–1:50 p.m.

Audience Q&A

1:50 p.m.–2:15 p.m.

Invited Speaker

3:55 p.m.–4:20 p.m.

Invited Speaker

2:15 p.m.–2:20 p.m.

I12-2A Data Blitz

4:20 p.m.–4:25 p.m.

I12-4A Data Blitz

2:20 p.m.–2:25 p.m.

I12-2B Data Blitz

4:25 p.m.–4:30 p.m.

I12-4B Data Blitz

2:25 p.m.–2:35 p.m.

Audience Q&A

4:30 p.m.–4:35 p.m.

Audience Q&A

2:35 p.m.–2:45 p.m.

Break

Obesity and Stroke Bruce I. Ovbiagele, MD, MSc, FAAN Body Weight and Survival After Stroke: Exploring the “Obesity Paradox” in the Framingham Study Hugo Javier Aparicio, Jayandra Himali, Alexa Beiser, Carlos Kase, Philip Wolf, Sudha Seshadri Metabolic Syndrome and Ischemic Stroke Risk by Sex: Meta-analysis Michelle Lin, Gustavo Saposnik, Qiyun Shi, Amy Towfighi

Obesity and Neurocognitive Decline Hussein N. Yassine, MD Adiponectin Deficiency Induced Cognitive Impairment in Aging Mice Through Reductions in Insulin Sensitivity and AMPK Activation Roy Chun-Laam Ng The Effect of Obesity on Severity of Cognitive Impairment and Neuropsychiatric Symptoms in MCI Subjects Ashley Hannah, Ahmad Alsibai, Andrea Bozoki

Guided Poster Rounds Cognitive Dysfunction in Obese Individuals with or Without Metabolic Risk Factors Ala Abu Saleh, Radi Shahien, Nimer Assy

I12-5B

CSF Characteristics in Patients with High Frisén Papilledema Grades from the IIHTT John Pula, Jorge Kattah, Luis Mejico, Michael McDermott, Michael Wall

I12-5C

Effect of Weight Loss Surgery on Cardiovascular Death, Nonfatal Myocardial Infarction, or Nonfatal Stroke in Overweight and Obese Post-menopausal Women Omar Saeed, Ahmed Malik, Adnan Qureshi

I12-5D

Body Mass Index and Stroke Subtype in a Young Adult Stroke Population Jina Youn, Thandar Aung, Mohammad Afrasiabi, Joni Clark

I12-5E

Eating Behavior and Metabolic Changes Across the Spectrum of Motor Neuron Disease and Frontotemporal Dementia Rebekah Ahmed, Elana Henning, Lauren Bartley, Glenda Halliday, Olivier Piguet, Sadaf Farooqi, John Hodges, Matthew Kiernan

I12-5F

Effects of Intervention on Optical Imaging of Papilledema in the Idiopathic Intracranial Hypertension Treatment Trial Mark Kupersmith

I12-5G

Obesity and Overweight Are Highly Prevalent in Pediatric Secondary Pseudotumor Cerebri Syndrome Grace Paley, Claire Sheldon, Evanette Burrows, Marianne Chilutti, Grant Liu, Shana McCormack


I12-5H

Body Weight and Survival After Stroke: Exploring the “Obesity Paradox” in the Framingham Study Hugo Javier Aparicio, Jayandra Himali, Alexa Beiser, Carlos Kase, Philip Wolf, Sudha Seshadri

I12-5I

Metabolic Syndrome and Ischemic Stroke Risk by Sex: Metaanalysis Michelle Lin, Gustavo Saposnik, Qiyun Shi, Amy Towfighi

I12-5J

Effect of “snoring Alone” and “Snoring Plus Phenomenon” on Cardiovascular Diseases, or Fatal or Nonfatal Stroke Yousef Mohammad, Ahmed Malik, Omar Saeed, Muhammad Suri, Adnan Qureshi

I12-5K

Overdiagnosis of Idiopathic Intracranial Hypertension (IIH) Adeniyi Fisayo, Valerie Biousse, Nancy Newman, Beau Bruce

I12-5L

Adiponectin Deficiency Induced Cognitive Impairment in Aging Mice Through Reductions in Insulin Sensitivity and AMPK Activation Roy Chun-Laam Ng

I12-5M

The Effect of Obesity on Severity of Cognitive Impairment and Neuropsychiatric Symptoms in MCI Subjects Ashley Hannah, Ahmad Alsibai, Andrea Bozoki

121

Thursday April 23

I12-5A

4:35 p.m.–5:00 p.m.

Poster Session VII

Thursday, April 23

P7 Poster Session VII First Authors stand by Posters from 5:00 p.m.–6:30 p.m. Poster Discussion Session: Epilepsy/Clinical Neurophysiology (EEG)

2:00 p.m.–6:30 p.m.


P7.001

Indomethacin Increases the Latency to Seizure Onset and Decreased the Number of Seizures in Zebrafish Seizure Model Patricia Barbalho, Iscia LopesCendes, Claudia Maurer-Morelli

P7.002

Iatrogenic Radiation Exposure from Neuroimaging May Increase the Risk of Cancer and Mortality in Patients with Epilepsy Travis Losey

P7.003

Gray Matter Volume Is Reduced in Focal Compared to Idiopathic Generalized Epilepsy Monica Dhakar, Fen Bao, Reena Pullukat, Michael Aronov, Lindsay Miller, Jasmine Bhangu, Carla Santiago Martinez, Deepti Zutshi, Maysaa Basha, Aashit Shah, Omar Khan

P7.004

Predictors of In-hospital Mortality in Status Epilepticus; Data from the Nationwide Inpatient Sample Database, 2008-2012 Nassim Naderi, Derek Moriyama, Jack Lin, Mona Sazgar, Indranil Sen-Gupta, Lilit Mnatsakanyan

P7.005

The Time Course and Prognostic Values of Electroencephalographic Patterns After Anoxic Brain Injury Adithya Sivaraju, Emily Gilmore, Jeremy Moeller, David Greer, Lawrence Hirsch, Nicolas Gaspard

P7.006

The Sabril® Registry After 5 Years: Patient Characteristics and Vision Loss Robert Sergott, Rod Foroozan, John Pellock, Edward Faught, W. Donald Shields, Gregory Krauss, Adam Ziemann, Deborah Lee, Yekaterina Dribinsky, Sarah Torri, Jouko Isojarvi

P7.008

P7.007

P7.009

Responder Rates by Study Phase in Conversion to Lacosamide Monotherapy Study: A Post-hoc Analysis John Stern, Michael Sperling, Steve Chung, Philippe Ryvlin, Robert Wechsler, Svetlana Dimova, Marc De Backer, Tyler Story, Melissa Brock, Cindy McShea, Paulette Williams, Konrad Werhahn

Adjunctive Perampanel in Adolescents with Inadequately Controlled Partial Seizures: Efficacy and Safety Results from Study 235 (Phase II) J. Ben Renfroe, Lieven Lagae, Betsy Williams, Haichen Yang, Dinesh Kumar, Antonio Laurenza Assessing the Role of Cultural Perceptions and Knowledge of Epilepsy on Medication Adherence in a Multi-ethnic Epilepsy Clinic: A Pilot Study Katherine Werbaneth, Elizabeth Wilson, Alexis Ciambotti, Georgia Montouris

P7.010

Reasons for Treatment Discontinuation and Switch in Patients with Epilepsy: A Retrospective Observational Study in a US Population Maria Malmenäs, Thirupathi Pattipaka, Fulton Velez

e-Poster Session: MS and CNS Inflammatory Diseases II Ten e-posters in each session have been selected for on-site, interactive display. e-Posters will be grouped in a separate area where attendees are invited to explore more deeply through touch screen displays.

P7.011

Cancer Risk Is Not Increased in People with Relapsing Multiple Sclerosis Taking Cladribine Julia Pakpoor, Giulio Disanto, Daniel Altmann, Sue Pavitt, Benjamin Turner, Monica Marta, Gunnar Juliusson, David Baker, Jeremy Chataway, Klaus Schmierer

P7.012

Long-term Impact of Early MS Treatment with Interferon Beta-1b (IFNB-1b): Clinical, MRI, Employment, and Patient-reported Outcomes (PROs) at the 11-year Follow-up of BENEFIT (BENEFIT 11) Gilles Edan, Mark Freedman, Xavier Montalban, David Miller, Hans Hartung, Bernhard Hemmer, Edward Fox, Frederik Barkhof, Sven Schippling, Andrea Schulze, Dirk Pleimes, Christoph Pohl, Rupert Sandbrink, Gustavo Suarez, Eva-Maria Wicklein, Ludwig Kappos

P7.013

Thalamic Volume Is Associated with White Matter Integrity Measures in Multiple Sclerosis Mikolaj Pawlak, Alicja Kalinowska-Lyszczarz, Slawomir Michalak, Wlodzimierz Paprzycki, Radoslaw Kazmierski, Wojciech Kozubski

P7.014

Increased Coinfection of Human Herpesviruses 6A (HHV-6A) and HHV-6B in Multiple Sclerosis Patients Emily Leibovitch, Giovanna Manzano, Breanna Caruso, Joan Ohayon, Daniel Reich, Steven Jacobson

P7.015

An 8-year-old Girl with Chronic Inflammatory Optic Neuritis (CRION): The Youngest Reported Case to Date Ian Rossman, Mary Rensel

P7.016

The Clinical Course of Hair Thinning Associated with Teriflunomide: Case Series of Patients Who Participated in a Hair Photography Project Keith Edwards, Lori Hendin Travis, Annette Okai, Scott Jackson, Francisco Gomez, Lisa Farnett, Steve Cavalier, Darren Stam, Ken Liu

P7.017

Baseline Demographics and Disease Characteristics from ORATORIO, a Phase III Trial Evaluating Ocrelizumab in Patients with Primary Progressive Multiple Sclerosis Xavier Montalban, Bernhard Hemmer, Kottil Rammohan, Gavin Giovannoni, Jerome De Seze, Amit Bar-Or, Douglas Arnold, Annette Sauter, David Leppert, Peter Chin, Hideki Garren, Jerry Wolinsky

P7.018

Immune-cell NT-3 and BetaNGF Are Linked to Regional Brain Volume in Multiple Sclerosis Alicja KalinowskaLyszczarz, Mikolaj Pawlak, Slawomir Michalak, Wlodzimierz Paprzycki, Wojciech Kozubski

P7.019

Time off from Work: A Matched Comparison of Fingolimod and BRACE in Patients with Multiple Sclerosis from the PANGAEA and PEARL Studies Hans-Peter Duerr, Jonathan Alsop, Niklas Bergvall, Christian Cornelissen, Stefan Viktor Vormfelde, Tjalf Ziemssen

P7.020

Evaluation of Correlations Between Cerebral MRI Volumes, Retinal Thickness, Cognitive Involvement and Clinical Features in Parenchymal NeuroBehçet Patients Tuncay Gündüz, Murat Kurtuncu, Zeliha Matur, Baris Topcular, Basar Bilgic, Utku Limon, Burak Tanyildiz, Belgin Izgi, Nergis Erdogan, Ali Oge, Hakan Gurvit, Firdevs Gulsen Demir

Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy

P7.022

Electrocardiographic Features and SUDEP Risk in Patients with Epilepsy: A Case-control Study Katia Lin, Jorge Sousa, Guilherme Fialho

P7.024

Meta-analysis of Risk Factors for Early and Late Seizures After Acute Stroke Steven Tobochnik, Neha Vijayvargiya, Mercedes Jacobson

P7.026

P7.021

P7.023

P7.025

P7.027

Disturbed Subjective and Objective Parameters of Sleep in Patients with Drug-resistant Mesial Temporal Lobe Epilepsy Katia Lin, Aline Scarlatelli-Lima, Lucia Sukys-Claudino

122

Sleep Disturbances in Persons with Epilepsy in Nigeria Taofiki Sunmonu, Morenikeji Komolafe, Olubunmi Ogunrin, Birinus Ezeala, Sani Abubakar, Emmanuel Iwuozo

Changes in Cardiovascular Autonomic Function in Patients with Newly Diagnosed Epilepsy Rajesh Goita

Headaches and Psychosomatic Complaints in Seizure Disorders Brannon Vines, Cristina Wohlgehagen, Jerzy Szaflarski Post-transplant Acute Symptomatic Seizures. Long-term Recurrence and Development of Epilepsy Maria Gonzalez Toledo, Analia Calle, Maria Elena Fontela, Agustina Tamargo, Diego Nadile, Fatima Pagani Cassara, Alejandro Thomson, Alfredo Thomson


Poster Session VII

P7.028

Orgasmic Auras as an Initial Symptom of a Primary Brain Tumor: A Case Report and Literature Review Robert Glover, Patrick LaSala, Karen Weidenheim, Jerome Graber

P7.043

P7.029

P7.044

SeizED: Seizures in the Emergency Department Angela Peters, Ligia Onofrei, Helen Barkan

P7.030

Development of a Claimsbased Classifier to Identify Lennox-Gastaut Syndrome J. Eric Pina-Garza, Francis Vekeman, Wendy Cheng, Ed Tuttle, Phillippe Giguere-Duval, Arman Oganisian, Joseph Damron, Mei-Sheng Duh, Vivienne Shen, Jouko Isojarvi, Georgia Montouris

P7.031

User Retention and Utilization of an Online Digital Health Platform for Epilepsy John Hixson, Kate Bertko, Paul Wicks

P7.032

Effects of Education on Nurses' Assessments on an Epilepsy Monitoring Unit Mona Stecker

P7.033

Pregnancy Outcome in Patients with Epilepsy-corniche Experience Fathima Farook

P7.034

Down Syndrome (DS) and Epilepsy in Adult Patients Martin Kriebaum, Maria Pacha, Oscar Martinez

P7.035

The Factors That Trigger Seizures in Elderly Patients Serkan Demir, Erdem Togrol, Fatih Ozdag, Ali Sonkaya

P7.036

Childhood Trauma Is Associated with Stress Precipitated Epileptic Seizures in Adults Ikjae Lee, Adrienne Fleck, Michael Privitera, Michael Walters

Pharmacokinetic Properties of Chronic Administration of Eteplirsen in the Treatment of Boys with Duchenne Muscular Dystrophy (DMD) J Saoud, J Zhang, L Warner, C Kincaid, P Duda, E Kaye Evaluation of Th17 Cell Infiltration in Thymectomy Materials of Acetycholine Receptor Antibody-positive Myasthenia Gravis Patients Can Ebru Bekircan-Kurt, Lala Mehdikhanov, Sevgen Oner, Gunes Esendagli, Erdem Karabulut, Asli Kurne, Sevim Erdem-Ozdamar, Ersin Tan

P7.045

Myasthenia Gravis: Thymectomy and Quality of Life Yury Bykov, Aleksandr Smolin

P7.046

A Randomized Study of Exercise in Spinal and Bulbar Muscular Atrophy Christopher Grunseich, Ilona Kats, Dara Bakar, Angela Kokkinis, Ellen Levy, Michaele Smith, Joseph Shrader, Galen Joe, Joshua Woolstenhulme, Willie Ching, Bart Drinkard, Cris Zampieri, Laboni Ghosh, Derrick Fox, Tyler Lanman, Sungyoung Auh, Alice Schindler, Kenneth Fischbeck

Enterovirus-D68 Associated Acute Anterior Horn Cell Injury Jason Williams, Anna Fermin, Deborah Bradshaw

P7.041

Differentiating Depression from PBA-related Crying in ALS: Use of PHQ-9 and CNS-LS Nimish Thakore, Jhanvi Menon, Erik Pioro

P7.042

Electrical Impedance Myography and Quantitative Ultrasound as Biomarkers of Disease Progression in Duchenne Muscular Dystrophy: A Preliminary Analysis Seward Rutkove, Craig Zaidman, Jim Wu, Kush Kapur, Basil Darras

Prevalence of Cardiac Arrhythmia in Myasthenia Gravis Rachana Gandhi, Raja Boddepalli, Raghav Govindarajan, Efrain Salgado

P7.058

Ptosis in a Cohort of Patient with Late Onset Pompe Disease (LOPD) from Argentina Claudio Mazia, Marcelo Francisco Rugiero, Alberto Dubrovsky, Juan Politei, Valeria Lujan Salutto, Ernesto Augusto Fulgenzi, Agustin Jauregui, Patricia Santoro, Valeria Alvarez

P7.059

Effectiveness of Prednisone in the Treatment of Ocular Myasthenia (EPITOME) Michael Benatar, Michael McDermott, Donald Sanders, Gil Wolfe, Richard Barohn, Richard Nowak, Michael Hehir, Vern Juel, Hans Katzberg, Alrabi Tawil

Neuromuscular Disease: Clinical Science

P7.050

P7.040

P7.057

P7.048

P7.038

Primary Lateral Sclerosis Plus Corticobasal Syndrome: A Case Series Kimberly Johnson, Mazen Dimachkie, Mamatha Pasnoor, Jeffrey Statland, Omar Jawdat, Richard Barohn, Melanie Glenn, Richard Dubinsky, Jeffrey Burns, April McVey

Generalized Myasthenia Gravis in Argentina: Serological Profile and Clinical Characteristics. A Hospital-based Study Florencia Aguirre, Mariela Laura Paz, Valeria Cores, Juliana Leoni, Andres Villa

Neuromuscular Disease: Clinical Trials and Treatment

P7.049

P7.039

P7.056

Inclusion Body Myositis Treated with Intravenous Immunoglobulin: A Longterm Study Murata Kenya, Hidefumi Ito

Clinical Characteristics of New-onset Epilepsy in Patients with Down Syndrome and Dementia Taha Gholipour, Rani Sarkis, Zeina El-Chemali

Clinical Approach of Neuromuscular Disease

The Wide Clinical Phenotype of Kennedy’s Disease Giorgia Querin, Cinzia Bertolin, Marco Volpe, Gabriella Zara, Elisa Da Re, Francesca Zoccarato, Nicola Caretta, Carlo Foresta, Sonia Marcato, Massimo Iafrate, Domenico Corrado, Maria Silvano, Elena Pegoraro, Davide Pareyson, Maria Pennuto, Gianni Soraru

P7.047

P7.037

A Case Report of Exacerbation of Myoclonus in Idiopathic Generalized Epilepsy from Use of Lacosamide Arun Swaminathan, Siddharth Kapoor

P7.055

Hypoglossal Nerve Palsy Is Associated with a Variety of Etiologies and Sometimes Results in Tongue Myokymia Amro Stino, Benn Smith Spectrum of Valosin Containing Protein (VCP)-opathy: A Case Series Mohamed Kazamel, Eric Sorenson, Kathleen McEvoy, Andrew Engel, Lyell Jones, Andrea Leep Hunderfund, Michelle Mauermann, Margherita Milone

P7.051

Clinical Utility of Voltage Gated Calcium Channel Antibody Titers Karin Mente, Adham Jammoul, Luay Shayya, Pravin George, Yuebing Li

Magnetic Resonance Imaging Assessments of Two Doses of Drisapersen in the Treatment of Ambulant Boys with Duchenne Muscular Dystrophy Courtney Bishop, Rexford Newbould, Robert Janiczek, Giles Campion

P7.060

Ultra-high Dose Methylcobalamin (E0302) Prolongs Survival of ALS: Report of 7 Years’ Randomised Double-blind, Phase 3 Clinical Trial (ClinicalTrials.gov NCT00444613) Ryuji Kaji, Shigeki Kuzuhara, Yasuo Iwasaki, Koichi Okamoto, Masanori Nakagawa, Takashi Imai, Takao Takase, Hiroki Shimizu, Kunio Tashiro

P7.061

ManNAc Is Safe and Increases Sialic Acid Production in GNE Myopathy Bradley Class, Frank Celeste, Xin Xu, Amy Wang, May Christine Malicdan, Lea Latham, Carla Ciccone, Marjan Huizing, William Gahl, Nuria Carillo-Carrasco

A Study on Natural History of Duchenne Muscular Dystrophy—Indian Perspective Ravinder Singh, Manjunath Poojar, Atchayaram Nalini, K Thennarasu, Piyush Ostwal, Kiran Polavarapu, Gayathri N, Preethish Kumar V

Conception, Design and Realization of a Longitudinal Study for Patients Affected by Hereditary Inclusion Body Myopathy Due to Mutation of GNE Gene: Looking for Clinical and Biological Biomarkers for Upcoming Therapeutic Trial (ClinBio-GNE) Teresa Gidaro, Dominique Duchene, Gwenn Ollivier, Valerie Decostre, Jean-Yves Hogrel, Pierre Carlier, Anthony Behin, Laurent Servais

P7.053

P7.063

P7.052

Stiff Person Syndrome: A Case Series Duaa Jabari, Mazen Dimachkie, Jeffrey Statland, Ahmad Abuzinadah, Omar Jawdat, Melanie Glenn, April McVey, Arthur Dick, Richard Dubinsky, Laura Herbelin, Richard Barohn, Mamatha Pasnoor

P7.054 Non-neuromuscular

Manifestations of Spinal and Bulbar Muscular Atrophy Dara Bakar, Christopher Grunseich, Ilona Kats, Angela Kokkinis, Alice Schindler, Carlo Rinaldi, Kenneth Fischbeck


P7.062

"Toe Off" Style Carbon Fiber Ankle Foot Orthoses in Neuromuscular Disease: The OSUMC Experience Wendy King, Ani Mnatsakanian, John Kissel

P7.064

Comparison of Length of Hospital Stay Between Treatment with Plasma Exchange Versus IVIg in Mild Guillain-Barré Syndrome Vladimir Klinov, Joseph Campellone

P7.065

Acthar in Dermatomyositis and Polymyositis Treatment Registry: An Interim Analysis Todd Levine

P7.066

Predicting Responsiveness to Study Drug Before Randomization in the DAPPER Trial of 3,4-Diaminopyridine (3,4-DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) Donald Sanders, Laura Jacobus, Kathy Ales, David Jacobus

P7.067

A Phase IIa Double-blind, Placebo-controlled Study to Evaluate the Safety of Oral Fingolimod in Patients with Amyotrophic Lateral Sclerosis (ALS) James Berry, Sabrina Paganoni, Nazem Atassi, Namita Goyal, Michael Rivner, Ericka Simpson, Stanley Appel, Daniela Grasso, Nicte Mejia, Farrah Mateen, Merit Cudkowicz, Steven Perrin

P7.068

First Human Use of High Dose IV Trehalose: Safety, Tolerability and Pharmacokinetic Results from the Oculopharyngeal Muscular Dystrophy (OPMD) Therapy Trial Zohar Argov, Hadassa Vornovitsky, Sergiu Blumen, Yoseph Caraco

P7.069

Low Dose Prednisone in Seropositive Myasthenia Gravis Ahmad Abuzinadah, Mamatha Pasnoor, Jeffrey Statland, Duaa Jabari, April McVey, Laura Herbelin, Omar Jawdat, Melanie Glenn, Richard Barohn, Mazen Dimachkie

Clinical Studies of Neuromuscular Disease P7.070

Myasthenia Gravis Exacerbation After Discontinuing Mycophenolate: A Case-control Study Bjorn Oskarsson, David Richman, David Rocke

P7.071

Prompt Diagnosis of GBS Is Improved by Emergency Department Neurological Consultation and Associated with Better Outcomes Divyanshu Dubey, Marrissa Kopatic, Matthew Freeman, Anshudha Sawhney, Worthy Warnack, Steven Vernino

P7.072

YouTube and Peripheral Neuropathy: What Patients Want? Harsh Gupta, Rajan Patel, Betul Gundogdu, Manoj Mittal, Archana Hinduja


Novel OPA1 Mutation in Syndromic Mitochondrial Dominant Optic Atrophy (DOA+): A Case Report Varoon Thavapalan, Tsao-Wei Liang, Goran Rakocevic

P7.075

Six-minute Walk Test Is Reliable and Valid in Spinal Muscular Atrophy Sally Dunaway, Jacqueline Montes, Samantha Kramer, Jonathan Marra, Rachel Salazar, Claudia Chiriboga, Carol Garber, Darryl De Vivo

P7.076

The Utility of Paraneoplastic Antibody Testing in the Diagnosis of Motor Neuron Disease Najwa Al-Bustani, William Simonson, Desiree Marshall, Jennifer Vetrovs, Mark Wener, Michael Weiss, Leo Wang

P7.077

Antilipemic Agents and Creatine Phosphokinase: Epidemiologic Study and Clinical Anatomical Analyses of 55 Patients Alzira Carvalho, Miriam Eva Koch, Pâmela Melo, Thaiane Fagundes, David Feder

123

Thursday April 23

2:00 p.m.–6:30 p.m.

Poster Session VII P7.078

Ocular LEMS or MG and LEMS Overlap Syndrome? Watcharasarn Rattananan, Mohammad Alsharabati, Shin Oh

P7.079

Determining the Yield of Electrodiagnostic (EDX) Studies in Patients Referred for Neck And/ or Upper Extremity Pain Rajesh Gupta, Nicholas Silvestri

P7.084

Neuropathy: Clinical Trials, Diagnostic Testing, and Treatment

P7.085

P7.090

Clinical Manifestations of Isolated Elevated Homosysteine-induced Peripheral Neuropathy in Adults Varun Shandal, Jin Luo

Neuropathy: Clinical Science

The Clinical Features of Neuropathies Associated with Monoclonal Gammopathies Aline Herlopian, Ayman Al-salaimeh, Betul Gundogdu, Tawfiq AlLahham

P7.080

P7.086

Clinical Features of HNPP Patients with the 17p11.2 Deletion Aline Oliveira, Raquel Pereira, Vanessa Marques, Amilton Barreira, Wilson Marques

P7.081

Prevalence and Characteristic Features of Anti-human Neurofascin 155 Antibody-associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy Hidenori Ogata, Dai Matsuse, Ryo Yamasaki, Nobutoshi Kawamura, Takuya Matsushita, Jun-ichi Kira

P7.082

Neuropathy Symptoms Are Associated with Increased Fall Risk in Patients Receiving Potentially Neurotoxic Chemotherapy Noah Kolb, A. Smith, J. Singleton, Summer Brown, Bob Wong, Susan Beck, Kathi Mooney

2:00 p.m.–6:30 p.m.

A Case Report and Management of Familial Amyloid Polyneuropathy Transmitted by Domino Liver Transplantation with Disease Onset at Less Than 3 Years Sharmi Shafi, Pierre Bourque

P7.087

Elevated Plasma Level of Homosysteine and Peripheral Neuropathy in Adults Jin Luo

P7.088

Chronic Severe Polyradiculoneuropathy with Ophthalmoplegia and Encephalopathy Due to Thiamine Deficiency in a Bariatric Surgery Patient Carolyn Mehaffey, Aline Herlopian, Betul Gundogdu

P7.089

Dermal Nodes in Diabetic Neuropathy Amanda Peltier, M. Iliza Butera, Yaping Shi, Lily Wang, Jun Li

P7.083

Elevated SNCAM-1 Concentrations in Sera from Patients with Polyneuropathies Adam Niezgoda, Jacek Losy, Slawomir Michalak, Wojciech RED: 15AM RunWalk Ad_AL, Hh Kozubski Placed in Abstract Listing 8.25"x5.4375", Full Bleed +0.125" 2C

Incidence and Risk Factors for Neuropathy Following Primary Total Knee Arthroplasty Joseph Nguyen, Edwin Su, Stephen Lyman, Erin Manning, Kelianne Cummings, Anita Wu, Mayu Sasaki, Teena Shetty

P7.091

The Relationship Between Cerebrospinal Fluid Protein Levels and Electrophysiologic Abnormalities in Guillain-Barré Syndrome Hannah Homafar, Amanda Lakraj, Richard Nowak, Kimberly Robeson, Jonathan Goldstein, Huned Patwa, Daniel DiCapua

P7.092

Incidence and Risk Factors for Neuropathy Following Primary Total Hip Arthroplasty Joseph Nguyen, Edwin Su, Stephen Lyman, Erin Manning, Kelianne Cummings, Anita Wu, Mayu Sasaki, Teena Shetty

P7.093

Clinical Characteristics and Treatment Response of Patients with Chronic Inflammatory Demyelinating Neuropathy Refractory to Standard Therapy Artem Kaplan, Thomas Brannagan

P7.095

A Novel Evidence Based Phone System Reduces Symptoms of Chemotherapy Induced Neuropathy Noah Kolb, A. Smith, J. Singleton, Summer Brown, Bob Wong, William Dunson Jr., Debbie Wujcik, Susan Beck, Kathi Mooney

P7.096

Small Fiber Neuropathy: Gender Differences in Skin Biopsy and Clinical Findings Joshua Weaver, KyungWha Kim, Bridget Carey, Jennifer Langsdorf, Russell Chin

P7.097

Effect of FTY720 (Fingolimod) in a New Preclinical Rat Model for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Susana Brun, Laurent Kremer, Elisabeth Trifilieff, Jerome De Seze

P7.098

Biopsy and EMG Findings in a Case of Late-onset Dropped Head Syndrome After Mantle Field Radiotherapy Amro Stino, Mark Ross

P7.099

The Rarity of Tarsal Tunnel Syndrome: Analysis of Cases Referred to an EMG Laboratory Brion Reichler, Darryl Sneag

P7.094

Subcutaneous Immunoglobulin (IgPRO20) for Maintenance Treatment in Patients with Multifocal Motor Neuropathy Hans Katzberg, Vilija Rasutis, Vera Bril

Run/Walk for Brain Research On your mark, get set…help cure BRAIN DISEASE!

Join your colleagues on Tuesday, April 21, 2015, at 6:30 a.m., for a friendly run/walk. All proceeds will go to the American Brain Foundation to help support research. Sign up for the Run/Walk at AAN.com/view/RunWalk Sponsored by:

Poster Session VII

Aging, Dementia, Cognitive, and Behavioral Neurology: Clinical Trials P7.100

A Randomized, Double-blind, Placebo-controlled, 24-week, Phase 2b Outcomes Study of 3 Different Doses of Encenicline or Placebo in Subjects with Mild to Moderate Probable Alzheimer’s Disease Hans Moebius, Gordon Loewen, Nancy Dgetluck, Dana Hilt

P7.101

Efficacy and Tolerability of Memantine Extended Release Added to Stable Donepezil Regimen in Individuals with Moderate to Severe Alzheimer’s Disease: Subset Analysis of a Randomized Clinical Trial George Grossberg, Gustavo Alva, Suzanne Hendrix, Robert Hofbauer, Vojislav Pejovic, Stephen Graham

P7.102

Use of Quantile Regression to Characterize Solanezumab Effects Across Percentiles of Disease Progression in EXPEDITION Alzheimer's Disease Trials Yun-Fei Chen, Xiwen Ma, Karen Sundell, Karla Alaka, Kory Schuh, Joel Raskin, Robert Dean

P7.103

Effects of Testosterone Supplementation and Serum Levels on Cortical Volume in Healthy Older Men Jeremy Hua, Donald Rojas, Jason Tregellas, Christopher Filley, Robert Schwartz, Victoria Pelak

P7.104

Caregiver Treatment Preference/Satisfaction and Efficacy Among Patients in the OPtimising Transdermal Exelon in Mild-to-moderate Alzheimer’s Disease (OPTIMA) Study Steven Ferris, Xiangyi Meng, Drew Velting

P7.105

Effects of a Distinct Phenolic Complex on Working Memory Performance in Healthy Men and Women with Ageassociated Memory Impairment Brenda Fonseca, Kelli Herrlinger, Kristin Nieman, Michael Ceddia, Linda Fullmer, Kristen Sanoshy, Kathleen Kelley, Kevin Maki

P7.106

Adding Memantine to Stable Cholinesterase Inhibitor Therapy in Patients with Moderate to Severe Alzheimer’s Disease Is Associated with Improvement in Various Neuropsychiatric Symptoms: A Pooled Analysis Gustavo Alva, Noel Ellison, Suzanne Hendrix, Vojislav Pejovic, Victor Otcheretko

P7.107

A Phase II Study to Evaluate the Efficacy and Safety of Plasma Replacement with 5% Albumin in Betaamyloid Peptide Clearance in Cerebrospinal Fluid and Plasma, and Its Clinical Effects in Patients with Mild-moderate Alzheimer's Disease Merce Boada, Oscar Lopez, Laura Nunez, Pilar Ortiz, Fernando Anaya, Isabel Hernandez, Javier Olazaran, Lluis Tarraga, Mar Buendia, Ramon Pla, Isidro Ferrer, Thomas Obisesan, Joshua Shua-Haim, Antonio Paez

P7.108

Delayed-start Analyses of Solanezumab Phase 3 Studies in Mild Alzheimer’s Disease Hong Liu-Seifert, Scott Andersen, Karen Holdridge, Eric Siemers

P7.109

PRISM II: An Open-label Study to Assess the Safety, Tolerability, and Effectiveness of Dextromethorphan 20 Mg/Quinidine 10 Mg for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Results from the Alzheimer’s Disease/ Dementia Cohort Rachelle Doody, Stephen D'Amico, Andrew Cutler, Paul Shin, Fred Ledon, Charles Yonan, Joao Siffert

Cerebrovascular Disease and Interventional Neurology: Stroke in Young P7.120

Young-aged Stroke in Korea: Changing Patterns of Risk Factors and Etiologies Han A Kim, Jong Kim, Bum Joon Kim

Aging, Dementia, Cognitive, and Behavioral Neurology: Cardio- and Cerebrovascular Factors in Dementia

Detection of Paroxysmal Atrial Fibrillation in Very Young Cryptogenic Ischemic Stroke Patients Under 40 Years: A Three Week ECG-Holter Monitoring Study Michal Kral, Daniel Sanak, Martin Hutyra, Marian Fedorco, David Skoloudik, Petr Kanovsky

P7.110

P7.122

Cognitive Dysfunction in Obese Individuals with or Without Metabolic Risk Factors Ala Abu Saleh, Radi Shahien, Nimer Assy

P7.111

Refined Sugar Intake Is Associated with Lower Cognitive Performance Across the Cognitive Continuum but Is Not Associated with Preclinical Cognitive Decline in Intact Elderly Subjects Dasha Kenlan, Sarah Tarrant, Amanda Pursell, Andrew Welleford, Keith Albrektson, Gregory Jicha

P7.112

Cardiovascular Comorbidities and Medication in Dementia Disorders Pavla Cermakova, Kristina Johnell, Johan Fastbom, Bengt Winblad, Maria Eriksdotter-Jonhagen, Dorota Religa

P7.113

Involvement of Microbleeds, Representative of Cerebral Amyloid Angiopathy, in Cognitive Dysfunction in Alzheimer’s Disease and Parkinson’s Disease: An MRI Study Tomohiko Murai, Masako Kinoshita, Yoshifumi Nakaya, Akio Ikeda, Ryosuke Takahashi

P7.114 Endothelium-mediated

Changes in Vascular Tone and Cognitive Function in Patients with Subjective Cognitive Impairment: A Pilot Study Gereon Nelles, Einat Monovic, Adrian Schembri, Maria Polidori

P7.115

The Association Between Pulse Pressure and Memory Functioning over Time Depends on Baseline Systolic Blood Pressure Eric McDade, Zhaowen Sun, Ching-Wen Lee, Beth Snitz, ChungChou Chang, Mary Ganguli

P7.121

Misdiagnosis in Young Patients with Ischemic Stroke Luciana Leon, Fatima Pantiu, Julieta Quiroga, Pablo Bonardo, Claudia Uribe, Julieta Mazziotti, Alberto Zinnerman, Alejandra Martinez, Andrea Sotelo, Lorena Jure, Pedro Nofal, Eduardo Bendersky, Luciano Alberto Sposato, Patricia Riccio, Ricardo Reisin, Manuel Fernandez Pardal

P7.123

"Spicy Strokes": Synthetic Cannabis and Strokes in Young Ahmad El Kouzi, Fazeel Siddiqui

P7.124

Stroke in the Young: Etiologies and Risk Factors Pandompatam Govind, Roomana Ahad, Ahmed Iftekhar

P7.132

Selective Serotonin Reuptake Inhibitors for Prevention of Post Stroke Depression: A Meta-analysis Dan Neftalie Juangco, Jeshya Ang, Fran Efendy, Joven Cuanang

P7.133

Cognition and Major Depression After Frontal and Cerebellar Stroke Mario Dulay, Krissa Agbayani, Rajan Gadhia, Jenny Lai, John Volpi, David Chiu, Y. Jonathan Zhang, Gavin Britz

P7.134

Anxiety Influences TIA Diagnosis William Sugrue, Deepa Bhupali, Daniel Labovitz

P7.135

Competitiveness in Passive NBA Spectating and Cerebrovascular Accident Frequency Danielle Weiss, William Grubb, Nirav Shah

P7.136

Basal Ganglia Stroke and Apathy: A Clinico-radiological Study Emmanuel Thomas, Irina ViakhirevaDovganyuk, Emmanuelle Volle, Douraied Ben Salem, Marc Verin, Richard Levy, Serge Timsit

P7.137

The Quantitative Analysis of Temporal Lobes and Hippocampi in Patients Diagnosed with Transient Global Amnesia (TGA) Raja Boddepalli, Dennys Reyes, Efrain Salgado, Fabian Candocia, Rachana Gandhi, Avi Oppenheimer.

P7.125

Cerebrovascular Disease and Interventional Neurology: Race, Ethnicity, and Stroke

P7.126

P7.138

Impact of Stroke Misdiagnosis on Short-term and Discharge Use of Vascular Medications in Young Adults Seemant Chaturvedi, Kumar Rajamani Body Mass Index and Stroke Subtype in a Young Adult Stroke Population Jina Youn, Thandar Aung, Mohammad Afrasiabi, Joni Clark

P7.127

Incidence of Ischemic or Hemorrhagic Non-fatal Strokes in Hemophiliac Adults and Teenage Children Cara Bezzina, Ahmed Malik, Adnan Qureshi

P7.128

Primary Angiitis of the Central Nervous System (PACNS) Presenting with Intracerebral Hemorrhage (ICH): Three Cases Associated with Chronic Use of Over-the-counter Vasoconstrictive Drugs Ruchira Jha, Jacob George, Aneesh Singhal

Intravenous Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke in the REGARDS Study Kara Sands, Karen Albright, Justin Blackburn, Amelia Boehme, George Howard, Virginia Howard, Suzanne Judd, Brett Kissela, Nita Limdi, David Rhodes, Harn Shiue, April Sisson, Monika Safford

P7.139

Quality Assessment of Vascular Disease Prevention Practices in High Risk Urban Women Seemant Chaturvedi, David Pieper, Diane Levine, Neelima Thati, Ramesh Madhavan, Marie Mateo, Lavoisier Cardozo, Marybeth Lepczyk

P7.116

Cerebrovascular Disease and Interventional Neurology: Stroke, Depression, and Anxiety

P7.117

Racial Variation in Association of Elevated Factor VIII and Stroke Outcome Lauren Dowell, Amelia Boehme, Alyana Samai, Alexander George, Laurie Schluter, Ramy El Khoury, Sheryl MartinSchild

P7.129

Post-stroke Depression (PSD) in Sub-Saharan Africans—Validation of the Japanese Stroke Scale for Depression. (JSS-D) Frank Imarhiagbe, Owolabi Afolabi, Anthony Kubeyinje, Fatai Akemokwe, Francis Odiase

P7.141

P7.130

Interactive Voice Response—a Novel Approach to Post-stroke Depression Monitoring Lesli Rusche-Skolarus, Paul Pfeiffer, Linda Williams, Jason Mackey, John Piette, Lewis Morgenstern

P7.142

P7.131

P7.143

Vazonat Efficiency in Patients with Atherosclerotic Encephalopathy Stage I-II Kunduz Karbozova Regular Aspirin Use Does Not Reduce Risk of Incident Cognitive Decline Brendan Kelley, Leslie McClure, Frederick Unverzagt, Brett Kissela, Dawn Kleindorfer, George Howard, Virginia Wadley

P7.118

Early Diagnosis of Vascular Cognitive Impairment Is Associated with Improved Adherence with Medical Treatment of Vascular Risk Factors Angelia Kirkpatrick, Elliott Ross, Leslie Guthery, Calin Prodan

P7.119

Heart-heath Intervention Reduces Cognitive Decline in Mild Cognitive Impairment of the Cerebrovascular Type: A Randomized, Placebo-controlled Clinical Trial Gregory Jicha, Richard Murphy, Martha Biddle, Debra Moser


Risk Factors and Lesion Localization Correlations with Post Stroke Depression Sopio Mataradze, Tinatin Kherkheulidze, Maia Beridze, Marika Alphaidze, Davit Eliauri

P7.140

Racial Differences in the Risk Factors, Severity, Outcomes, and Treatment in Acute Ischemic Stroke Muhammad Ahmed Chauhan, Syed Ali, Nicolas Bianchi, Archana Hinduja Race Does Not Predict Discharge Functional Status in Acute Ischemic Stroke Patients with Renal Impairment After Systemic TPA Kara Sands, Gyanendra Kumar, Harn Shiue, Reza Bavarsad Shahripour, Andrei Alexandrov Comparison of Major Modifiable Stroke Risk Factors Associated with Lacunar Strokes in Anterior and Posterior Circulation in Multiethnic Cohort Sebina Bulic, Natalie Valle, Amy Towfighi

125

Thursday April 23



An Association Between Diabetes and Late Hospital Arrival Among Low-income Hispanic Stroke Patients Ellyn Leighton-Herrmann, Olajide Williams

P7.145

Narrative Communication Using a Gospel Musical and Telenovela May Improve EMS Activation for Stroke Among Blacks and Hispanics Olajide Williams, Amparo Abel-Bey, James Noble, Lenfis Valdez, Ellyn Leighton-Herrmann, Alexandra DeSorbo, Madeleine Gordillo, Joseph Ravenell, Mildred Ramirez, Jeanne Teresi, Girardin Jean-Louis, Olugbenga Ogedegbe

P7.146

Are There Different Rates of Acute Stroke Risk Factors in the South Texas Mexican American Population? Wondwossen Tekle, Ameer Hassan, Ahmed Malik, Lisa Jones-Fullingim, Christina Sanchez, Vishal Jani, Olive Sanchez, Erlinda Abantao, Adnan Qureshi

P7.147

Clinical Profile, Risk Factors, Etiology and Outcome of Stroke in Young Filipino Adults Ty Alekzander Talamera, Ma. Cristina San Jose, Jennifer Ann Sanchez, Jose Leonard Pascual IV

Neuro Trauma, Critical Care, and Sports Neurology P7.148


P7.149

Earlier Cooling in Post Cardiac Arrest Patients Fails to Show Benefit Preet Varade, Kushak Suchdev, Shamaehah Javed, Gregory Norris, Mohammad Ibrahim

P7.150

Management of Refractory ICP in a Case of Fulminant Acute Disseminated Encephalomyelitis Nicole Mahdi, Syed Omar Shah, Michelle Ghobrial, Rodney Bell, Matthew Vibbert, Jacqueline Urtecho

P7.151


P7.152

Clinical Correlates of Diffusion Tensor Imaging in Repetitive Head Trauma Charles Bernick, Sarah Banks, Wanyong Shin

P7.153

Do Football Helmet Add-ons Reduce Concussion Risk? John Lloyd, Francis Conidi

P7.154

Comparable Levels of Phosphorylated Tau in Epileptic Brain and Chronic Traumatic Encephalopathy Briana Prager, Vikram Puvenna, Chaitali Ghosh, Damir Janigro

P7.155

Younger Children Recover Faster and Have Less Premorbid Conditions Than Adolescents with Concussion Rejean Guerriero, Karameh Hawash, Michael Pepin, Robert Wolff, William Meehan III

126

2:00 p.m.–6:30 p.m.

P7.156

Volumetric Measurements of Cytotoxic and Vasogenic Edema Following Traumatic Brain Injury Using Magnetic Resonance Imaging Brian Stephens, Emily Spessert, George Knaysi, Martin Cota, Lawrence Latour, Ramon Diaz-Arrastia

P7.157

Association Patterns of Intraventricular and Intraparenchymal Simultaneous ICP Measurements Zakraus Mahdavi, Stephen Figueroa, DaiWai Olson, Christiana Hall, Venkatesh Aiyagari

P7.158

Sensitivity and Specificity of Altered Propulsive Force Following Concussion Jessie Oldham, Kelsey Evans, Erik Wikstrom, Thomas Buckley

P7.159

Initial Concussion Presentation Does Not Predict Acute Impairments in Transitional Dynamic Postural Control Jessie Oldham, Kelsey Evans, Erik Wikstrom, Thomas Buckley

P7.160

The Impact of Games Played on Age Related Changes in White Matter Mean Diffusivity Among Retired NFL Athletes Kyle Womack, Jeremy Strain, Kevin Chen, Jeffrey Spence, Nyaz Didehbani, Munro Cullum, John Hart

P7.168

Induced Normothermia in Severe Traumatic Brain Injury Patients Deborah Green-LaRoche, Tudor Sturzoiu, Helena Lau, Anna Marisa Cervantes-Arslanian, Joseph Burns

P7.169

Barriers to Recovery from Concussion Teena Shetty, Kelianne Cummings, Kristin Halvorsen, Maxwell Singer, Joseph Nguyen

P7.170

Multiple Past Concussions in High School Athletes with ADHD Magdalena Wojtowicz, Grant Iverson, Rebekah Mannix, Brian Brooks, Bruce Maxwell, Ross Zafonte, Paul Berkner

P7.171

Bedside Clinical Predictors of Bad Outcome in Hypoxic Ischemic Encephalopathy Patients After Cardiac Arrest Treated with Therapeutic Hypothermia Gemmalynn Sarapuddin, Artemio Roxas Jr.

P7.172

Predictors of Outcome in Status Epilepticus in the Neuro ICU Jules Osias, Paul McVey, Serkan Ayvaz, Jennifer Frontera, Laurie McWilliams-Dunnigan

P7.181

Observed Specific Pattern of Cognitive Impairment in Patients with Mild Traumatic Brain Injury: A Prospective Study of 35 Patients Ajay Jawahar, Suresh Kumar, Monika Kumar

P7.182

Determining Inter-rater Reliability of Eye Tracking Methods for Use with Persons with Severe Traumatic Brain Injury Lorene Leung, Rachel Cohn, Therese O'Neil-Pirozzi, Yelena Guller, Swathi Iyer, Hong Pan, Emily Stern, Joseph Giacino

P7.183

An FMRI-based Visual Cognition Paradigm for Detection of Command-following and Communication Yelena Guller, Hong Pan, Swathi Iyer, Lorene Leung, Rachel Cohn, Benjamin Fuchs, Courtney Haley, Therese O'Neil-Pirozzi, Joseph Giacino, Emily Stern

P7.184

Effect of Lesion Burden on Recovery and on Response to Amantadine in Patients with Disorders of Consciousness After Traumatic Brain Injury Douglas Katz, John Whyte, Helena Chang, Noam Eshkar, Kathleen Kalmar, David Long, Stuart Yablon, Emilia Bagiella, Joseph Giacino

Postural Stability in Veterans with Mild Traumatic Brain Injury and Disequilibrium Mark Walker, Tao Pan, Ke Liao, Kristen Roenigk, Janis Daly

Early Mobility Program in the Neurocritical Care Unit—Appropriateness of Referral for Physical Therapy Laura Bishop, Beth McDaniel, Susan Reeves, Janet Crumpler, Stacey Wolfe, Keith Scott, Aarti Sarwal

P7.162

7 Tesla Brain MRI Characteristics Among Concussion Patients Andrew Russman, Richard Figler, Se-Hong Oh, Mark Lowe, Stephen Jones

P7.174

P7.163


P7.175

Efficacy of Minocycline in Female Rats After Mild Diffuse Traumatic Brain Injury L. Turtzo, Neekita Janaria, Jacob Lescher, William Tu, Joseph Frank

The Relationship Between Cognitive Reserve and Neuropsychological Outcomes After TBI Uzma Hussain, Maryanne Sacco, Jacob Leary, Shannon McNally, Katherine Lopez, John Dsurney, Leighton Chan

P7.164

P7.176

P7.187

P7.161

Von Willberand Factor and Cellular Fibronectin Plasma Concentrations Are Increased in Mild Traumatic Brain Injury (TBI) with MRI Evidence of Microvascular Injury Tanya Bogoslovsky, Bao-Xi Qu, Martin Cota, Lawrence Latour, Ramon DiazArrastia

P7.165


P7.166

Evolution of Traumatic Parenchymal Intracranial Hematomas (ICHs): Comparison of High Density and Low Density Components and Relationship to Outcome Sean Wilkes, Erin McCormack, Erika Silverman, Leah Harburg, Ross Passo, Tanya Bogoslovsky, Jason Schroeder, Carol Moore, Kimbra Kenney, Dzung Pham, Ramon Diaz-Arrastia

P7.167

Characterization of Baseline EEG Abnormalities the Brain Injury and Mechanisms of Action of Hyperbaric Oxygen (HBO2) for Persistent Post-concussive Symptoms After Mild Traumatic Brain Injury (mTBI) Study (BIMA) Christopher Williams, Mark Spitz, John Foley, Lindell Weaver, Anne Lindblad, Michael Wierzbicki

P7.173

Neuro-rehabilitation: Traumatic Brain Injury

Psychiatric Symptoms as a Predictor of Outcome in Patients with Post-concussive Syndrome Arun Chhabra, Allison Weathers, Bichun Ouyang

Knowledge, Awareness, and Attitudes Regarding Concussion Among Middle Schoolers Thor Stead, Yasamin Daneshvar, Sarah Ayala, Latha Ganti

P7.177

Neurologic Exam Findings and Clinical Manifestations of Post-concussion Syndrome in a Pediatric Population Devon Cohen, Francis Conidi

P7.178

EEG Monitoring in Patients with Hypothermia Post Cardiac Arrest—a Comparison of 'Evolving' Patterns and Outcomes Kushak Suchdev, Preet Varade, Lusine Avedian, Shyam Rao, Srilatha Thadur, Wazim Mohamed, Deepti Zutshi

P7.179

Pathological Correlation of Diffusion Tensor Imaging and Magnetization Transfer Biomarkers in a Preclinical Model of Mild Traumatic Brain Injury Rashida Williams, William Tu, Jacob Lescher, Christine Turtzo, Joseph Frank

P7.180

Correlations of Focal Lesion Volume with Intracranial Hypertension and Brain Tissue Hypoxia After Severe Traumatic Brain Injury (TBI) Leah Harburg, Erin McCormack, Carol Moore, Kimbra Kenney, Jason Barber, Nancy Temkin, Ramon Diaz-Arrastia

P7.185

Montreal Cognitive Assessment, a Screening Tool for Mild Traumatic Brain Injury Suresh Kumar, Ajay Jawahar, Pooja Shah, Monika Kumar

P7.186

'From Start-up-to-CEO': Fostering Guided Experiential Learning of Goal-oriented Attention Regulation Through Game-assisted Training Following Brain Injury Fred Loya, Deborah Binder, Nicholas Rodriguez, Michelle Madore, Bruce Buchanan, Audrey Kossman, Michael Sapiro, Tatjana Novakovic-Agopian, Anthony Chen

P7.188

Cognitive Reserve and Preservation of Functioning Following Traumatic Brain Injury Jacob Leary, Carleen Schwimmer, Uzma Hussain, Katherine Lopez, Shannon McNally, John Dsurney, Leighton Chan

P7.189

FMRI-based Detection of Covert Command-following and Communication in a Patient with Severe Traumatic Brain Injury Yelena Guller, Hong Pan, Swathi Iyer, Lorene Leung, Rachel Cohn, Therese O'Neil-Pirozzi, Emily Stern, Joseph Giacino

P7.190

Despite Initial Moribund Appearance, Critically Ill Traumatic Brain Injury Patients with Diffuse Axonal Injury Have Improved Survival Rebecca Compton, Raphael Carandang, Wiley Hall, Susanne Muehlschlegel


Poster Session VII

Neuro-rehabilitation P7.191

Non-motor Symptoms in Patients with SPG4 Mutations Katiane Servelhere, Jonas Saute, Adriana Moro, Alberto Martinez, Ingrid De Vasconcellos, Laura Jardim, Helio Afonso Teive, Iscia Lopes-Cendes, Anelyssa DÁbreu, Marcondes Franca, Jr.

P7.192

Investigating Exercise as an Approach to Remodeling Motor Unit Fibre Type in Amyotrophic Lateral Sclerosis Alyson Plecash, Ge Lu, Austin Hill, Blair Leavitt

P7.193

Sit to Stand (STS) - Maneuver: Construct Validity of a Novel Measure of Lower Extremity (LE) Function in ALS Patients Mohammed Sanjak, Glenn Boyles, Kristen Thomas, Scott Holsten, Elena Bravver, William Bockenek, J Scott Story, Scott Lindblom, Thomas Paccico, Benjamin Brooks

P7.194

Kinematic Analysis of Arm Reaching Movements in Diverse Neurologic Populations Christine Kang, Susan Conroy, Anindo Roy, Christopher Bever

P7.195

Balance-based Torsoweighting (BBTW): A Novel Therapy to Prevent Falls in Patients with Peripheral Neuropathy Hasan Askari, Christine Tilburg, Robert Burger, Mohammad Salajegheh

P7.196

Action Observation and Mirror Neuron System Recruitment: Effect of Type of Task on Motor Facilitation Silvia Fumagalli, Maria Rocca, Roberto Gatti, Massimo Filippi

P7.197

Plasticity of Sensorimotor System Induced by Sustained Pressure Stimulation According to Vojta Therapy Pavel Hok, Petr Hlustik, Miroslav Kutin, Jaroslav Opavsky, Zbynek Tudos, Petr Kanovsky

MS and CNS Inflammatory Diseases: Clinical Trials P7.198

Efficacy Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Adults with Relapsing Multiple Sclerosis Giancarlo Comi, Jeffrey Cohen, Douglas Arnold, Amit Bar-Or, Sheila Gujrathi, Jeffrey Hartung, Allan Olson, Matthew Cravets, Paul Frohna, Krzysztof Selmaj

P7.199

Safety and Tolerability Results of the Phase 2 Portion of the RADIANCE Trial: A Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 in Relapsing Multiple Sclerosis Krzysztof Selmaj, Douglas Arnold, Giancarlo Comi, Amit Bar-Or, Sheila Gujrathi, Jeffrey Hartung, Allan Olson, Matthew Cravets, Paul Frohna, Jeffrey Cohen

P7.200 Interim Analysis of a Phase

I Clinical Trial Investigating Intrathecal Administration of Mesenchymal Stem Cell-neural Progenitors in Multiple Sclerosis Violaine Harris, Tamara Vyshkina, Sydney Chirls, Saud Sadiq

P7.201

Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis Stephen Hauser, Giancarlo Comi, Hans-Peter Hartung, Fred Lublin, Krzysztof Selmaj, Anthony Traboulsee, Amit Bar-Or, Douglas Arnold, Gaelle Klingelschmitt, David Leppert, Algirdas Kakarieka, Hideki Garren, Ludwig Kappos

P7.202

Efficacy Analysis of the AntiLINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis: The RENEW Trial Diego Cadavid, Laura Balcer, Steven Galetta, Orhan Aktas, Tjalf Ziemssen, Ludo Vanopdenbosch, Helmut Butzkueven, Focke Ziemssen, Luca Massacesi, Yi Chai, Lei Xu, Stefanie Freeman

P7.209

Treatment with Daclizumab HYP Improved Disease-specific Patientreported Outcomes Versus Interferon Beta-1a in Multiple Sclerosis in the Phase 3 DECIDE Trial Ying Liu, Timothy Vollmer, Eva Havrdova, Katherine Riester, Andrew Lee, Glenn Phillips, Jacob Elkins

P7.218

P7.210

P7.219

ARPEGGIO: A Randomized, Placebo-controlled Study to Evaluate Oral Laquinimod in Patients with Primary Progressive Multiple Sclerosis (PPMS) Frederik Barkhof, Gavin Giovannoni, Hans-Peter Hartung, Bruce Cree, Antonio Uccelli, Maria Pia Sormani, Stephen Krieger, Bernard Uitdehaag, Timothy Vollmer, Xavier Montalban, Joshua Steinerman, Nissim Sasson, Tali Gorfine, Volker Knappertz

A Phase 3b/4 Long-term Study of Alemtuzumab in Patients with Relapsing-remitting Multiple Sclerosis: TOPAZ Study Design Vesna Brinar, Gavin Giovannoni, Eva Havrdova, Cary Twyman, Basil Sharrack, Tjalf Ziemssen, Francesca Baldinetti, Marco Rizzo, Leah Martell, Edward Fox

P7.220

No Evidence of Disease Activity in Patients with Relapsing MS Treated with Interferon Beta-1a SC Tiw Versus Interferon Beta-1a IM Qw in the EVIDENCE Study Patricia Coyle, Juanzhi Fang, Ali Hassan, Choon Cha, Fernando Dangond, Anthony Reder, Mark Freedman

Safety and Tolerability of Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis: The RENEW Trial Stefanie Freeman, Ludo Vanopdenbosch, Helmut Butzkueven, Tjalf Ziemssen, Orhan Aktas, Focke Ziemssen, Luca Massacesi, Yi Chai, Lei Xu, Diego Cadavid

Safety and Immunogenicity of Two Dosing Frequencies of Subcutaneous Interferon (scIFN) β-1a in Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of Phase III, Double-blind, Multicenter Trials (REFLEX/ REFLEXION) Mark Freedman, Giancarlo Comi, Nicola De Stefano, Frederik Barkhof, Bernard Uitdehaag, Ludwig Kappos, Tanya Fischer, Liang Chen

P7.204

BIIB033, Anti-LINGO-1 Antibody, for Treatment of Relapsing Forms of Multiple Sclerosis: Baseline Data of the Phase 2 SYNERGY Trial Diego Cadavid, Keith Edwards, Raymond Hupperts, Jelena Drulovic, Krzysztof Selmaj, Robert Naismith, Luigi Maria Grimaldi, Alexey Boiko, Oscar Fernandez, Eli Silber, Howard Rossman, Stefanie Freeman, Yi Chai, Lei Xu

P7.212

P7.205

Disease Activity During the First Year Predicts Clinical Long-term Outcomes: Impact of Fingolimod in the TRANSFORMS Phase III Trial and Its Extension Pavle Repovic, Erik Burton, Xiangyi Meng, Daniela Piani Meier, Frederik Barkhof

P7.213

Effects of Anti-LINGO-1 Monoclonal Antibody BIIB033 on Visionrelated Quality-of-life in Subjects with Acute Optic Neuritis: Results from the RENEW Study Jennifer Petrillo, Jeremy Hobart, Laura Balcer, Yi Chai, Lei Xu, Diego Cadavid

The 9-hole Peg Test (9-HPT) Has a Stronger Correlation Than the Expanded Disability Status Scale (EDSS) with Patient-reported Upper Extremity Impairment as Assessed Using ABILHAND in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Analysis of Baseline Data from the ASCEND Study Daniel Mikol, Myla Goldman, HansPeter Hartung, Eva Havrdova, Douglas Jeffery, Raj Kapoor, Aaron Miller, Finn Sellebjerg, Yun Chen, Crystal Watson, Diego Cadavid

P7.206

P7.214

P7.223

P7.203

Effect of Two Dosing Frequencies of Subcutaneous Interferon (scIFN) β-1a on Conversion to Multiple Sclerosis (MS) in Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of Phase III, Doubleblind, Multicenter Trials (REFLEX/ REFLEXION) Mark Freedman, Giancarlo Comi, Nicola De Stefano, Frederik Barkhof, Bernard Uitdehaag, Ludwig Kappos, Tanya Fischer, Liang Chen

P7.207

Multi-center, Randomized, Double-blinded Assessment of Dimethyl Fumarate in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE Trial) Darin Okuda, Christine Lebrun Frenay, Aksel Siva, Christophe Hotermans, Christian Von Hehn, Gina Remington, Braeden Newton, Teresa Frohman, Elliot Frohman, Orhun Kantarci, Daniel Pelletier

P7.208

Analysis of Efficacy by Multifocal Visual Evoked Potentials in Subjects Treated with the Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis: The RENEW Trial Alexander Klistorner, Letizia Leocani, Mominul Islam, Philipp Albrecht, Helmut Butzkueven, Tjalf Ziemssen, Focke Ziemssen, Yi Chai, Lei Xu, Diego Cadavid


P7.211

Patient Experience with Glatiramer Acetate 40 Mg/1 ML Threetimes Weekly Treatment for Relapsingremitting Multiple Sclerosis: Results from the GLACIER Extension Study Daniel Wynn, Scott Kolodny, Svetlana Rubinchick, Joshua Steinerman, Volker Knappertz, Jerry Wolinsky

Teriflunomide Shows Consistent Clinical Efficacy on Severe Relapses Across Two Phase 3 Trials in Patients with Relapsing Forms of Multiple Sclerosis, TEMSO and TOWER Richard Macdonell, Martin Stangel, Matthias Mäurer, Deborah Dukovic, Philippe Truffinet, Sylvie Bozzi, Catherine Dive-Pouletty, Mark Freedman

NN 102/SPRINT-MS Phase II Trial of Ibudilast in Progressive MS: Baseline Characteristics Robert Fox, Christopher Coffey, Merit Cudkowicz, Trevis Gleason, Andrew Goodman, Eric Klawiter, Kazuko Matsuda, Michelle McGovern, Elizabeth McNeil, Robert Naismith, Jon Yankey

P7.215

Differential Recovery from Relapse Between Treatment Groups in the CONFIRM Study of Delayed-release Dimethyl Fumarate Andrew Chan, J. Theodore Phillips, Robert Fox, Annie Zhang, James Potts, Nuwan Kurukulasuriya

P7.216

Baseline Characteristics of Patients Enrolled in CONCERTO—a Study of 0.6 and 1.2 Mg/day Oral Laquinimod for Relapsing-remitting Multiple Sclerosis Giancarlo Comi, Timothy Vollmer, Xavier Montalban, Tjalf Ziemssen, Alexey Boyko, Patrick Vermersch, Tamar Rachmilewitz, Nissim Sasson, Tali Gorfine, Volker Knappertz, Maria Rocca, Massimo Filippi

P7.217

Relapse Outcomes in Patients with Multiple Sclerosis Treated with Fingolimod: Subgroup Analyses of Three Phase 3 Fingolimod Trials Tobias Derfuss, Daniel Ontaneda, Jacqueline Nicholas, Xiangyi Meng, Kathleen Hawker

P7.221

Multiple Sclerosis Patients with No Evidence of Disease Activity in the 2-year AFFIRM Study Have Better Outcomes with Long-term Natalizumab Treatment Than Patients Who Had Evidence of Disease Activity in AFFIRM Paul O'Connor, Andrew Goodman, Ludwig Kappos, Fred Lublin, Qunming Dong, Daniel Mikol, Richard Rudick

P7.222

12-year Clinical Efficacy and Safety Data for Teriflunomide: Results from a Phase 2 Extension Study Marcelo Kremenchutzky, Mark Freedman, Amit Bar-Or, Deborah Dukovic, Myriam Benamor, Philippe Truffinet, Paul O'Connor

P7.224

RNFL as a Surrogate Outcome Marker in Patients with Multiple Sclerosis: Design of the OCTiMS Study, Baseline Characteristics and OCT Test Reproducibility Peter Calabresi, Frederik Barkhof, Ari Green, Randy Kardon, Friedemann Paul, Jaume Sastre-Garriga, Sven Schippling, Patrick Vermersch, Pablo Villoslada, Catherine Agoropoulou, Ying Zhang, Diego Silva, Axel Petzold

P7.225

Long-term Safety of Daclizumab HYP in Patients with Relapsing-remitting Multiple Sclerosis: 3–4-year Results from the SELECTED Extension Study Ralf Gold, Gavin Giovannoni, Krzysztof Selmaj, Eva Havrdova, Dusan Stefoski, Ernst-Wilhelm Radue, Till Sprenger, Xavier Montalban, Kimberly Umans, Steven Greenberg, Jacob Elkins, Gulden Ozen, Marianne Sweetser

127

Thursday April 23



Long-term Efficacy of Daclizumab HYP in Relapsing-remitting Multiple Sclerosis: 3-year Results from the SELECTED Extension Study Ernst-Wilhelm Radue, Gavin Giovannoni, Ralf Gold, Krzysztof Selmaj, Eva Havrdova, Dusan Stefoski, Till Sprenger, Xavier Montalban, Yaoshi Wu, Gulden Ozen, Randy Robinson, Mark Beatty

2:00 p.m.–6:30 p.m.

P7.235

Long-term Follow-up of the Safety of Delayed-release Dimethyl Fumarate in RRMS: Interim Results from the ENDORSE Extension Study Carlo Pozzilli, J. Theodore Phillips, Robert Fox, Krzysztof Selmaj, Ray Zhang, Mark Novas, Marianne Sweetser, Ralf Gold

Long-term Efficacy of Delayed-release Dimethyl Fumarate in Newly Diagnosed Patients with RRMS: An Integrated Analysis of DEFINE, CONFIRM, and ENDORSE Ralf Gold, Gavin Giovannoni, J. Theodore Phillips, Robert Fox, Annie Zhang, Nuwan Kurukulasuriya

Quality of Life in Patients with Relapsing-remitting Multiple Sclerosis Treated with Delayed-release Dimethyl Fumarate: A Three-year Interim Analysis of ENDORSE Mariko Kita, Ludwig Kappos, Robert Fox, Ralf Gold, Gavin Giovannoni, J. Theodore Phillips, Sujata Sarda, Macaulay Okwuokenye, Jessica Kong, Nuwan Kurukulasuriya

P7.228

P7.237

P7.227

Clinical Efficacy of Delayedrelease Dimethyl Fumarate in Newly Diagnosed Relapsing-remitting Multiple Sclerosis Patients with Highly Active Disease: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies J Phillips, Ralf Gold, Gavin Giovannoni, Robert Fox, Annie Zhang, Nuwan Kurukulasuriya

P7.229

Long-term Efficacy of Delayedrelease Dimethyl Fumarate for Relapsingremitting Multiple Sclerosis According to Prior Therapy: Integrated Analysis of the DEFINE, CONFIRM, and ENDORSE Studies Amit Bar-Or, Michael Hutchinson, Ralf Gold, Robert Fox, Eva Havrdova, Gavin Giovannoni, James Potts, Nuwan Kurukulasuriya

P7.230

Safety and Tolerability Results from the DECIDE Study: A Phase 3 Active-comparator Study of Daclizumab HYP in Relapsing-remitting Multiple Sclerosis Krzysztof Selmaj, Ludwig Kappos, Douglas Arnold, Eva Havrdova, Alexey Boyko, Michael Kaufman, Heinz Wiendl, John Rose, Steven Greenberg, Katherine Riester, Marianne Sweetser, Jacob Elkins

P7.236

Comparative Utility of Different Progression Metrics in PPMS: Re-analysis of the PROMiSe Clinical Trial Dataset Marcus Koch, Joshua Steinerman, Volker Knappertz, Nissim Sasson, Gavin Giovannoni, Gary Cutter, Jerry Wolinsky

P7.238

Delayed-release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience Jie Li, Ralf Gold, Robert Fox, J. Theodore Phillips, Eva Havrdova, Amit Bar-Or, Ludwig Kappos, Norman Kim, Patricia Valencia, Lauren Oliva, Mark Novas, Marianne Sweetser, Nuwan Kurukulasuriya

P7.239

Disease Activity in the First Year Predicts Longer-term Clinical Outcomes in the Pooled Population of the Phase III FREEDOMS and FREEDOMS II Studies Aaron Boster, Kathleen Hawker, Shannon Ritter, Davorka Tomic, Till Sprenger

Efficacy of Delayed-release Dimethyl Fumarate for RRMS in Prior Interferon Users in the DEFINE and CONFIRM Studies Oscar Fernandez, Gavin Giovannoni, Robert Fox, Ralf Gold, J. Theodore Phillips, Macaulay Okwuokenye, Annie Zhang, Nuwan Kurukulasuriya

Rationale for EDSS-plus, the Primary Composite Endpoint of Disability Progression in the ASCEND Phase 3 Study of Natalizumab for Secondary Progressive Multiple Sclerosis: A Post Hoc Analysis of IMPACT Study Data Daniel Mikol, Jeff Cohen, Mark Freedman, Myla Goldman, Hans-Peter Hartung, Eva Havrdova, Douglas Jeffery, Raj Kapoor, Aaron Miller, Finn Sellebjerg, Deborah Kinch, Sophia Lee, Diego Cadavid

P7.232

P7.241

P7.231

Efficacy of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients with Moderate Disability: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies Michael Hutchinson, Robert Fox, Ralf Gold, Annie Zhang, Minhua Yang, Macaulay Okwuokenye, Nuwan Kurukulasuriya

P7.233

Effect of Delayed-release Dimethyl Fumarate on Total Disability Burden in the CONFIRM Study of Relapsing-remitting Multiple Sclerosis: Area Under the Curve Analysis of Changes from Baseline in Expanded Disability Status Scale Scores Nuwan Kurukulasuriya, Robert Fox, Ralf Gold, James Xiao, Annie Zhang, Amit Bar-Or

P7.234

Five-year Follow-up of Delayed-release Dimethyl Fumarate in RRMS: Integrated Clinical Efficacy Data from the DEFINE, CONFIRM, and ENDORSE Studies Amit Bar-Or, Ralf Gold, Robert Fox, J. Theodore Phillips, Michael Hutchinson, Ludwig Kappos, Sarah Sheikh, Ray Zhang, Minhua Yang, Nuwan Kurukulasuriya

128

P7.240

Clinical Effectiveness and Impact on Patient-reported Outcomes of Delayed-release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients After Suboptimal Response to Glatiramer Acetate: A Prospective, Multicenter, Open-label, Single-arm, Observational Study (RESPOND) Kiren Kresa-Reahl, Pavle Repovic, Derrick Robertson, Macaulay Okwuokenye, Christian Von Hehn, Monica Mann, Leslie Meltzer

P7.242

1-year Efficacy and Tolerability Results for IFN Beta-1a SC Tiw Treatment and Predictive Value of 6-month MRI: Exploratory Analysis of PRISMS Data in Patients with RRMS Mark Cascione, Fernando Dangond, Juanzhi Fang, Aaron Miller, Amy Perrin Ross

P7.243

Sustained Low Rate of Brain Volume Loss Under Long-term Delayedrelease Dimethyl Fumarate Treatment in Relapsing-remitting Multiple Sclerosis Patients: Results from the ENDORSE Study Ludwig Kappos, Robert Fox, Ralf Gold, Douglas Arnold, James Potts, Annie Zhang, Nuwan Kurukulasuriya

P7.244

Natalizumab Reduces Total Disability Burden Relative to Placebo in Patients with Relapsing-remitting Multiple Sclerosis Regardless of the Occurrence of Relapses or Confirmed Disability Progression or Improvement over 2 Years in the AFFIRM Study Gavin Giovannoni, Shibeshih Belachew, Qunming Dong, Richard Rudick, Daniel Mikol, Shulian Shang

P7.245

The Effect of Fingolimod on T1-hypointense Lesions Developed On-study and Evolution of Pre-existing Gd+ Lesions, Stratified by Lesion Size: A Posthoc Analysis of FREEDOMS Study Till Sprenger, Ernst-Wilhelm Radue, Nicole Mueller-Lenke, Gordon Francis, Dieter Haering, Davorka Tomic, Ludwig Kappos

P7.246

Durable Effect of Alemtuzumab on MRI Activity in Treatment-naive Active Relapsingremitting Multiple Sclerosis Patients: 4-year Follow-up of CARE-MS I Douglas Arnold, Anthony Traboulsee, Alasdair Coles, Jeffrey Cohen, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Yang Zhao, Michael Panzara, D Alastair S Compston

P7.247

Effect of Delayed-release Dimethyl Fumarate on No Evident Disease Activity in Newly Diagnosed Relapsingremitting Multiple Sclerosis Patients: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies Eva Havrdova, Gavin Giovannoni, Ralf Gold, Robert Fox, Ludwig Kappos, J. Theodore Phillips, Annie Zhang, Nuwan Kurukulasuriya

P7.248

Switching to Alemtuzumab from Subcutaneous Interferon Beta-1a After CARE-MS II Further Improved MRI Outcomes in Patients with Relapsingremitting Multiple Sclerosis Daniel Pelletier, Frederik Barkhof, Alasdair Coles, Jeffrey Cohen, Alastair Compston, Edward Fox, Hans-Peter Hartung, Eva Havrdova, David Margolin, Linda Kasten, Michael Panzara, Douglas Arnold

P7.249

Durable Effect of Alemtuzumab on MRI Outcomes in Patients with Relapsing-remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-year Follow-up of CARE-MS II Anthony Traboulsee, Alasdair Coles, Jeffrey Cohen, D Alastair S Compston, Edward Fox, HansPeter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Yang Zhao, Michael Panzara, Douglas Arnold

P7.250

Effect of Two Dosing Frequencies of Subcutaneous Interferon (scIFN) β-1a on MRI Lesion and Brain Volume Changes in Patients with a First Clinical Demyelinating Event (FCDE): 5-year Results of Phase III REFLEX Study Extension (REFLEXION) Frederik Barkhof, Giancarlo Comi, Mark Freedman, Bernard Uitdehaag, Tanya Fischer, Liang Chen, Ludwig Kappos, Nicola De Stefano

P7.251

Development of Chronic Black Holes (CBH) Predicts Long-term Disability: Post-hoc Analysis of Magnetic Resonance Imaging (MRI) Data in the PRISMS Study Tony Traboulsee, David Li, Juanzhi Fang, Fernando Dangond, Ludwig Kappos

P7.252

Daclizumab HYP Reduced Brain MRI Lesion Activity Compared with Interferon Beta-1a: Results from the DECIDE Study John Rose, Heinz Wiendl, Douglas Arnold, Ludwig Kappos, Eva Havrdova, Krzysztof Selmaj, Alexey Boyko, Michael Kaufman, Steven Greenberg, Marianne Sweetser, Katherine Riester, Jacob Elkins

P7.253

Positive MRI Outcomes in Patients with Early Multiple Sclerosis Treated with Teriflunomide: Subgroup Analyses from the TOPIC Phase 3 Study Aaron Miller, Philippe Truffinet, Deborah Bauer, Jerry Wolinsky

P7.254

Early Onset and Predictive Value of MRI Measures Among Patients Receiving Interferon Beta-1a SC Tiw for RRMS: Post Hoc Analyses of PRISMS-2 Data David Li, Mark Cascione, Juanzhi Fang, Fernando Dangond, Anthony Traboulsee, Guojun Zhao, Yan Cheng, Aaron Miller

P7.255

MRI Indicators of Brain Tissue Loss: 3-year Results of the Glatiramer Acetate Low-frequency Administration (GALA) Open-label Extension Study in Relapsing-remitting Multiple Sclerosis Robert Zivadinov, Michael Dwyer, Niels Bergsland, Deepa Ramasamy, Ellen Carl, Matthew Davis, Joshua Steinerman, Omar Khan

P7.256

In Relapsing Multiple Sclerosis, Peginterferon Beta-1a Reduces MRI Lesions Following Relapses Bernd Kieseier, Douglas Arnold, Scott Newsome, Xiaojun You, Shifang Liu, Serena Hung, Bjoern Sperling

P7.257

Early Effects of Interferon Beta-1a SC Tiw Versus Interferon Beta-1a IM Qw on MRI Outcomes in Patients with Relapsing MS in the EVIDENCE Study Anthony Reder, Mark Freedman, Juanzhi Fang, Ali Hassan, Choon Cha, Fernando Dangond, Patricia Coyle

P7.258

Long-term MRI Followup of Patients in the ALLEGRO Study: Results from the Yearly Frequent MRI Sub-cohort Maria Rocca, Sebastiano Galantucci, Yuval Dadon, Tali Gorfine, David Ladkani, Nissim Sasson, Giancarlo Comi, Massimo Filippi

P7.259

Smaller Baseline Brain Volume and Higher Atrophy Rate over Two Years Is Associated with Poorer Clinical Outcomes: Post Hoc Analysis of the MS-STAT Trial in Secondary Progressive MS Jeremy Chataway, Jennifer Nicholas, Julie Wych, Nadine Schuerer, Ali Alsanousi, Dennis Chan, David MacManus, Kelvin Hunter, Val Anderson, Charles Bangham, Shona Clegg, Casper Nielsen, Nick Fox, David Wilkie, Virginia Calder, John Greenwood, Chris Frost, Richard Nicholas


Poster Session VII

P7.260

Natalizumab-treated Patients with Multiple Sclerosis Have Low Rates of Brain Volume Decrease and Low MRI Disease Activity in the Long-term STRATA Study Andrew Goodman, Douglas Arnold, Ludwig Kappos, Fred Lublin, Paul O'Connor, Shibeshih Belachew, Daniel Mikol, Richard Rudick, Jonathan Smith, Harold Koendgen

P7.261

Switching to Alemtuzumab from Subcutaneous Interferon Beta-1a After CARE-MS I Further Improved MRI Outcomes in Patients with Relapsingremitting Multiple Sclerosis Frederik Barkhof, Daniel Pelletier, Alasdair Coles, Jeffrey Cohen, D Alastair S Compston, Edward Fox, Hans-Peter Hartung, Eva Havrdova, David Margolin, Linda Kasten, Michael Panzara, Douglas Arnold

P7.262

Five-year Follow-up of Delayed-release Dimethyl Fumarate in Relapsing-remitting Multiple Sclerosis: MRI Outcomes from DEFINE, CONFIRM, and ENDORSE Tarek Yousry, Douglas Arnold, Robert Fox, Ralf Gold, Eva Havrdova, Ludwig Kappos, David MacManus, Sarah Sheikh, Ray Zhang, Minhua Yang, Nuwan Kurukulasuriya, Vissia Viglietta

P7.263

Alemtuzumab Slows Brain Volume Loss Over 4 Years Despite Most Relapsing-remitting Multiple Sclerosis Patients Not Receiving Treatment for 3 Years Alasdair Coles, Douglas Arnold, Jeffrey Cohen, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Linda Kasten, Michael Panzara, D Alastair S Compston

P7.264

Slowing of Brain Volume Loss in Patients with Relapsing-remitting Multiple Sclerosis After Switching from Subcutaneous Interferon Beta-1a to Alemtuzumab Jeffrey Cohen, Douglas Arnold, Alasdair Coles, Edward Fox, HansPeter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Linda Kasten, Michael Panzara, D Alastair S Compston

P7.265

Incidence of Infection Decreases Over Time in Alemtuzumabtreated Patients with Relapsing-remitting Multiple Sclerosis: 4-year Follow-up of the CARE-MS Studies Lily Jung Henson, Douglas Arnold, Jeffrey Cohen, Alasdair Coles, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Bella Ertik, Jeffrey Palmer, Michael Panzara, D Alastair S Compston

P7.266

Long-term Efficacy in MRI and No Evidence of Disease Activity Outcomes in Patients with Relapsingremitting Multiple Sclerosis Treated with Peginterferon Beta-1a Douglas Arnold, Xiaojun You, Shulian Shang, Bjoern Sperling, Vladimir Evilevitch

P7.267

The Efficacy of Peginterferon Beta-1a in Early and Later-stage Patients with Multiple Sclerosis: A 1-year Subgroup Analysis Based on Disease Duration from the ADVANCE Study Bernd Kieseier, Scott Newsome, Shulian Shang, Shifang Liu, Serena Hung, Bjoern Sperling

P7.268

Pooled Safety Analyses from Teriflunomide Clinical Studies Thomas Leist, Mark Freedman, Ludwig Kappos, Tomas Olsson, Aaron Miller, Jerry Wolinsky, Paul O'Connor, Myriam Benamor, Philippe Truffinet, Deborah Dukovic, Giancarlo Comi

P7.269

Durable Efficacy of Alemtuzumab in Patients with Highly Active Relapsing-remitting Multiple Sclerosis Who Relapsed on a Prior Therapy Barry Singer, Edward Fox, Stephen Krieger, Hans-Peter Hartung, Lilyana Amezcua, David Margolin, Linda Kasten, Alasdair Coles

P7.270

Improvement in Clinical Outcomes in Treatment-naive Relapsingremitting Multiple Sclerosis Patients Who Switched from Subcutaneous Interferon Beta-1a to Alemtuzumab Hans-Peter Hartung, Gavin Giovannoni, Douglas Arnold, Alasdair Coles, Edward Fox, Eva Havrdova, Krzysztof Selmaj, David Margolin, Jeffrey Palmer, Michael Panzara, D Alastair S Compston

P7.271

No Evidence of Disease Activity in Patients with Relapsing MS Treated with Interferon Beta-1a SC Tiw Versus Interferon Beta-1a IM Qw: Subgroup Analyses of the EVIDENCE Study Juanzhi Fang, Patricia Coyle, Ali Hassan, Choon Cha, Fernando Dangond, Anthony Reder, Mark Freedman

P7.272

The Efficacy of Alemtuzumab Is Maintained in Patients Who Develop Thyroid Adverse Events Samuel Hunter, Douglas Arnold, Alasdair Coles, Jeffrey Cohen, Edward Fox, Hans-Peter Hartung, Eva Havrdova, David Margolin, Bella Ertik, Jeffrey Palmer, Michael Panzara, D Alastair S Compston

P7.273

Efficacy and Safety of a Three-times Weekly Dosing Regimen of Glatiramer Acetate in Relapsing-remitting Multiple Sclerosis Patients: 3-year Results of the Glatiramer Acetate Low-frequency Administration (GALA) Open-label Extension Study Omar Khan, Peter Rieckmann, Alexey Boyko, Krzysztof Selmaj, Natalia Ashtamker, Mat Davis, Scott Kolodny, Robert Zivadinov

P7.274

Efficacy of Teriflunomide in Early-stage MS: Reanalysis of the TOPIC Study Using 2010 McDonald Diagnostic Criteria Flavia Nelson, Francois Evoy, Thomas Berger, Philippe Truffinet, Deborah Bauer, Aaron Miller, Jerry Wolinsky

P7.275

Safety and Efficacy of Teriflunomide in Patients Switching from Subcutaneous Interferon Beta-1a Jérôme de Seze, Tomas Olsson, Anna Czlonkowska, Myriam Benamor, Philippe Truffinet, Deborah Dukovic, Patrick Vermersch

P7.276

Durable Effect of Alemtuzumab on Clinical Outcomes in Patients with Relapsing-remitting Multiple Sclerosis Who Relapsed on Prior Therapy: 4-year Follow-up of CARE-MS II Eva Havrdova, Gavin Giovannoni, Douglas Arnold, Alasdair Coles, Edward Fox, HansPeter Hartung, Krzysztof Selmaj, David Margolin, Jeffrey Palmer, Michael Panzara, D Alastair S Compston


Administration of Alemtuzumab on Nonconsecutive Days Does Not Impact Infusion-associated Reactions, Efficacy, or Lymphocyte Depletion Sibyl Wray, Alexey Boyko, Tiffany Braley, Omar Khan, David Margolin, Jeffrey Palmer, Alasdair Coles

Movement Disorders: Miscellaneous

P7.278

P7.286

P7.277

Improvement in Clinical Outcomes Following Switch from Subcutaneous Interferon Beta-1a to Alemtuzumab: CARE-MS II Extension Study Edward Fox, Gavin Giovannoni, Douglas Arnold, Alasdair Coles, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Jeffrey Palmer, Michael Panzara, D Alastair S Compston

P7.279

Teriflunomide Significantly Increased Time to First Relapse in TEMSO, TOWER, and TOPIC William Honeycutt, Christine Lebrun Frenay, John King, Andrew Chan, Sandra Vukusic, Jeffrey Gross, Deborah Dukovic, Philippe Truffinet, JeanPierre Bouchard

P7.280

Long-term Follow-up of the Effect of Delayed-release Dimethyl Fumarate on No Evidence of Disease Activity in Patients with Multiple Sclerosis Gavin Giovannoni, Eva Havrdova, Ralf Gold, Robert Fox, Ludwig Kappos, J. Theodore Phillips, Annie Zhang, Nuwan Kurukulasuriya

P7.281

Design of a Non-interventional Study to Establish Effectiveness, Quality of Life, Cognition, Health-related and Work Capacity Data on Alemtuzumab in Multiple Sclerosis Patients in Germany (TREAT-MS) Ulrich Engelmann, Sigbert Jahn, Alexandra Leptich, Raimar Kern, Tjalf Ziemssen

P7.282

Results of a Phase 1b Study to Confirm Safety and Tolerability of Olesoxime in Multiple Sclerosis Patients Jean Pelletier, Jean-Philippe Ranjeva, Ayman Tourbah, Gilles Edan, Christian Barillot, Sophie Le La Mer, Bertrand Audoin, Audrey Rico Lamy, Lydie Crespy, Ben Ridley, Wafaa Zaaraoui, Sylviane Confort-Gouny, Maxime Guye, Adil Maarouf, Nathalie Caucheteux, MariePierre Chaunu, Christophe Portefaix, Laurent Pierot, Olivier Commowick, Anne Kerbrat, Laurence Catanese, Valerie Cuvier, Julien Veys, Rebecca Pruss, Wilfried Hauke

P7.283

Evaluation of Comprehensive Alemtuzumab Infusion Guidance in Patients with Relapsing-remitting Multiple Sclerosis: EMERALD Study Design Patrick Vermersch, Rafael Arroyo-Gonzalez, Oscar Fernandez, Francesca Baldinetti, Stanley Krolczyk, Leah Martell, Thibault Moreau, Ludo Vanopdenbosch

P7.284

Normalized Brain Volume Predicts Cognitive Performance in MS: An Analysis of a Large Cohort from Fingolimod Phase III Studies Maria Pia Sormani, Ludwig Kappos, Jeffrey Cohen, Frederik Barkhof, Till Sprenger, Daniela Piani Meier, Dieter Haering, Davorka Tomic, Nicola De Stefano

P7.285

Early Neurological Worsening in Wilson’s Disease Patients Anna Czlonkowska, Tomasz Litwin, Michal Karlinski, Karolina Dziezyc Complementary Medicine and Cannabis Use by Parkinson’s Disease Patients in Colorado Taylor Finseth, Jessica Hedeman, Robert Brown, Kristina Johnson, Matthew Binder, Benzi Kluger

P7.287

Description of a New Rapidaccess Clinic for Parkinson’s Disease Patients: The Navigator Model Priti Gros, Doulia Hamad, Lucie Lachance, Jennifer Doran, Anne-Louise Lafontaine

P7.288

Typical, Atypical, and Vascular Parkinsonism in Jamaica: An 8-year Prospective Study Amza Ali, Keith Josephs

P7.289

More Severe Parkinsonism Is Associated with Lower Physical Activityrelated Energy Expenditure in PD Jonathan Snider, Vikas Kotagal, Martijn Muller, Robert Koeppe, Phillip Scott, Roger Albin, Kirk Frey, Nicolaas Bohnen

P7.290

Neurologic Manifestations of Lesch Nyhan Syndrome Improved with Bilateral Deep Brain Stimulation, a Case Report Ramsey Falconer, Sean Rogers, Yasar Torres-Yaghi, Kris Grajny, Fahd Amjad

P7.291

Neurodegeneration and Brain Iron Accumulation Disorders in Hungary: Genotype-phenotype Analysis Maria Molnar, Zoltan Grosz, Renata Bencsik, Peter Balicza, Peter Klivényi, Gertrud Tamás, Peter Acs, Bernadette Kalman

P7.292

Neuroborreliosis Parkinsonism and Rapid Eye Movement Sleep Behavior Disorder Katherine Werbaneth, JoseRafael Zuzuarregui, Anna Hohler

P7.293

Systematic Review of Parkinson’s Disease Related Mobile Applications Dronacharya Lamichhane, Melissa Armstrong

Movement Disorders: Restless Legs Syndrome P7.294

The Effect of Gabapentin Enacarbil (GEn) on Pain Outcomes in Adults with Moderate-to-severe and Severe Primary Restless Legs Syndrome (RLS): Pooled Analyses from 3 Randomized Controlled Trials Neal Hermanowicz, Mark Buchfuhrer, Daniel Wynn, Mark Jaros, Richard Kim, Gwendoline Shang

P7.295

Incobotulinum Toxin-A (inco-A) in Restless Legs Syndrome (RLS)—a Randomized Double Blind Cross over Study Rezvan Rostami, Duarte Machado, Diana Richardson, Bahman Jabbari

P7.296

RESTIFFIC, a Unique Pressure Foot Wrap, Is More Effective Than a Dopamine Agonist in Reducing the Symptoms of Moderate to Severe Restless Leg Syndrome John Sullivan, Dan Olson

P7.297

Restless Limb Syndrome(RLS) and Bruxism: A Subgroup Analysis and Dose-response Data David Dickoff, Roshana Sirkin, Stephanie Dontje, Naomi Ditkoff, Nicole Silberman

129

Thursday April 23



Rotigotine in Patients with Restless Legs Syndrome and End-stage Renal Disease Requiring Hemodialysis John Winkelman, Yves Dauvilliers, Markku Partinen, Heike Benes, Virpi Rauta, Hanna Schröder, Nadine Goldammer, Elisabeth Dohin, Erwin Schollmayer

P7.299

The Effect of Gabapentin Enacarbil (GEn) on Quality-of-life (QoL) Outcomes in Adult Patients with Moderateto-severe and Severe Primary Restless Legs Syndrome (RLS): Pooled Analyses from Two 12-week Trials Alon Avidan, Stuart Isaacson, Mark Jaros, Richard Kim, Gwendoline Shang

P7.300 The Effect of Gabapentin

Enacarbil (GEn) on Mood Outcomes in Adult Patients with Moderate-to-severe and Severe Primary Restless Legs Syndrome (RLS): Pooled Analyses from Three 12-week Trials Daniel Lee, Margaret Park, David Kreitzman, Aaron Ellenbogen, Mark Jaros, Richard Kim, Gwendoline Shang

P7.301

Prevalence of Restless Legs Syndrome in an Atypical Parkinson's Disease Patient Population Jose-Rafael Zuzuarregui, Katherine Werbaneth, Jing Qin, Christopher Tonn, Chantale Murray, Sok Lee, Anna Hohler

P7.302

Fatigue and Cardiac Sympathetic Denervation in Parkinson Disease Corneliu Luca, Danielle Spengler, Mike Georgiou, Aldo Serafini, Carlos Singer

2:00 p.m.–6:30 p.m.

P7.308

Aggression in Nightmares and Unpleasant Dreams and in People Reporting Recurrent Nightmares April Minsky, Patrick McNamara, Victoria Pae, Erica Harris, Edward Pace-Schott, Sanford Auerbach

P7.321

P7.333

P7.309

Practice, Policy, and Ethics

P7.334

Improving Knowledge of ICSD-3 and DSM-5 Criteria for Diagnosing Narcolepsy Nimish Mehta, Stacey Hughes, Stacey Ullman, Priscilla Scherer

P7.310

Pain and Sleep Disturbance in the Elderly: Evaluation of the Role of Stress and Depression vahid eslami, Molly Zimmerman, Trishdeep Grewal, Mindy Katz, Richard Lipton

P7.311

Cross-cultural Chronotypes: Medical Students in America, Malaysia and the UAE Nicoline Schiess, Sami Shaban, Charlene Gamaldo, Rachel Marie Salas

P7.312

Are Periodic Leg Movements Increased in the Painful Restless Legs Syndrome? Elias Karroum, Christopher Earley, Richard Allen

Sleep: Respiratory Disorders and Other P7.313

Does OSA Hypercoagulability Operates Through Protein C and S Pathways? Mohamad Ayass, Sundose Hassan, Gul Nowshad

Sleep: Restless Legs and REM Disorders

The Alteration of Cyclic Alternating Pattern in Obstructive Sleep Apnea Syndrome with and Without Excessive Daytime Sleepiness Selda Korkmaz, Tugce Bilecenoglu, Yuksel Peker, Tahir Yoldas, Murat Aksu

P7.303

P7.315

Hyperdopaminergism in Lenticulostriate Stroke-induced Restless Legs Syndrome: A Neuro Imaging Study Elisabeth Ruppert, Marc Bataillard, Izzie Namer, Laurent Tatu, Valérie Wolff, Reana Velizarova, Aurelien Hacquard, Ulker Killic-Huck, Patrice Bourgin

P7.304

First 1-year Real-life Study to Assess Management of Augmentation of Restless Legs Syndrome by Switching to Rotigotine Transdermal System Claudia Trenkwalder, Monica Canelo, Heike Benes, Michael Lang, Hanna Schröder, Daniela Kelling, Reinhard Berkels, Erwin Schollmayer, Tanja Heidbrede

P7.305

Impulse Control Disorders Are Associated with REM Sleep Behavior Disorder in Patients with Parkinson’s Disease: A Video-Polysomnographic Study Maria Livia Fantini, Maurizio Zibetti, Michela Figorilli, Beudin Patricia, Ana Marques, Debilly Bérangère, Derost Philippe, Miguel Ulla, Nicolas Vitello, Tiphaine Vidal, Monica Puligheddu, Alessandro Cicolin, Leonardo Lopiano, Franck Durif

P7.306

REM Sleep Behavior Disorder: How Useful Is It for the Differential Diagnosis of Parkinsonism? Helio Afonso Teive, Renato Munhoz

P7.307

REM Sleep Without Atonia Severity Predicts Cognitive Impairment in REM Sleep Behavior Disorder David Sandness, Erik St. Louis, Stuart McCarter, Bradley Boeve, Michael Silber

130

P7.314

Clinically Moderate to Severe Insomnia Without Excessive Daytime Sleepiness in Diabetic Patients with Chronic Neuropathic Limb Pain Martin Rakusa, Matej Rakusa, Miro Cokolic

P7.316

Improving Nocturnal Sleep and Excessive Daytime Somnolence in Moderate to Severe Obstructive Sleep Apnea-hypopnea Syndrome by Using Oral Appliances Elena Cuspineda Bravo, Michele Garcia Menendez, Ana Olivares Torres, Calixto Machado

P7.317

An Ambulatory Treatment Pathway Expedites the Diagnosis and Treatment of Sleep Apnea After Cerebrovascular Events Sara Elias, Fadi Frankul, James Im, Karl Boyle, Sandra Black, Richard Swartz, Brian Murray, Mark Boulos

P7.318

Is Traumatic Brain Injury Associated with PAP Adherence in Obstructive Sleep Apnea: A Pilot Study Lynn Kataria, Julie Chapman, Brian Ahuja, Marshall Balish

P7.319

Sleep and Concussion Review and Evaluation (SCORE): Sleep Disorders in Pediatric Sports-related Concussions PingRu Ko, Carey Lockhart, John Lockhart, Maida Chen

P7.320

Sleep Macrostructure and Microstructure in Acute and Chronic Spinal Cord Injury Patients Pietro Guaraldi, Giulia Milioli, Giovanna Calandra-Buonaura, Annagrazia Cecere, Giuseppe De Scisciolo, Mario Giovanni Terzano, Federica Provini, Liborio Parrino, Pietro Cortelli

Implementing a Clinical IPad Application to Detect Sleep Disorders Is Feasible Across Multiple Non-sleep Outpatient Clinics Ankur Doshi, Charlene Gamaldo, Aadi Kalloo, Rebecca Choi, Rachel Marie Salas

P7.322

Assessment of the Timeliness of Administration of Second Line Antiepileptic Drugs for Status Epilepticus After the Implementation of a Status Epilepticus Bundle Order Set: A Single Institution Experience Mark Callow, Aaron Cook, Ahmed Mahmoud, Alexandra Boske, Rachel Ward-Mitchell, Meriem Bensalem Owen

P7.323

Impact of EEG Laboratory Resources and Timeliness of Initiation of Continuous Video-EEG Monitoring: A Single Institution Experience Mark Callow, Heather Hatton, Dustine Arnold, Meriem Bensalem Owen

P7.324

Physician Communication About Driving Restrictions After Episodic Loss of Consciousness Natalie Wheeler, James Burke, Eric Adelman

P7.325

Patient Perspectives on Physician Compensation and Conflict of Interest in Industry-sponsored Clinical Trials for Multiple Sclerosis Andrew Solomon, Eran Klein, John Corboy, James Bernat

P7.326

An Analysis of After Hours MRI Scans in a Busy Tertiary Hospital Neuro Intensive Care Unit—Is Your Patient Safety Is at Jeopardy? Premkumar Nattanmai Chandrasekaran, Lori Shutter

P7.327

Diagnostic Imaging Delays and Efforts to Minimize for Neurology Patients in the Hospital Setting Ryan Crooks, Loretta Schnepel, Scott Silliman

P7.328

PDSA Cycle and Implementation of Worldwide Best Practices to Achieve Faster Door to Needle Waimei Tai, Stephanie Casal, JJ Baumann, Daisha Marsh, Gregory Albers

P7.329

Stroke Care Cost Variability Between Physicians at a Comprehensive Stroke Center Is Low Michael Dobbs, Sarah Heck, Bernard Boulanger

P7.330

Standardizing Stroke Evaluation in the Cardiac Catheterization Lab: Aldrete-FAST Score Michelle Johansen, Andrew Southerland, Michael Ragosta, Mary Lee Jensen, Bradford Worrall, Nina Solenski

A Quantitative Evaluation of Undisclosed Conflicts of Interest in Neuropsychopharmacology, General Pharmacology, and Pharmacotherapy Textbooks Brian Piper, Hassenet Telku, Drew Lambert Using a Spine Registry to Improve Understanding of the Variability, Progression, and Treatment of Spinal Disease Fernando Diaz, Risa Tyo, Aaron Anderson, Christina Cook

P7.335

Neurohospitalist Billing Practices Compared to Hospital Medicine Pearce Korb, Amy Franks, Serena Scott, Anunta Virapongse, Jennifer Simpson

P7.336

Predicting Patient Attendance in the Neuromuscular Clinic: A Logistic Regression Analysis Matthew Lincoln, Michael Sawa

P7.337

A Quality Improvement Strategy for Documenting Last Pyridostigmine Dose Prior to the Performance of Nerve Conduction Studies/ Electromyography Amy Visser, Charles Kassardjian, Elie Naddaf, Mohamed Kazamel, Andrea Leep Hunderfund

P7.338

Spatiotemporal Gait Parameters as a Potential Outcome Measure for CIDP Russell Chin, Mary Vo, Bridget Carey, Jennifer Langsdorf, Naomi Feuer, Norman Latov

P7.339

Determining Moral and Legal Responsibility in Patients with Behavioralvariant Frontotemporal Dementia Richard Darby

P7.340

Documentation of Advance Healthcare Planning in the Electronic Health Records of Elderly Outpatients with Dementia or Cognitive Impairment Kendra Peterson, Susan Sullivan, Catherine Madison

P7.341

Choice of Initial Pharmacotherapy Treatment in Older Adults with Parkinson’s Disease: Associations with Health Outcomes ElizaBeth Grubb, Robert Feldman, Jan Faiola, James Eubanks, Michael Treglia, Maureen Lage

P7.342

Quality Measures in Parkinson Disease: Assessment of Frequency of Documenting Quality Measures in PD Sarah Pirio Richardson, Kayla Gosselin, Amanda Deligtisch

P7.343

A Retrospective Review of Amyotrophic Lateral Sclerosis Patients and Adherence to American Academy of Neurology's Practice Parameter Rashmi Rajendra, Amparo Gutierrez

P7.331

A Survey and Intervention to Improve Effective Communication Between Critical Care Team and Neurology Team in a Busy Neurointensive Care Unit-A Portal to Improve Patient Care Premkumar Nattanmai Chandrasekaran, Lori Shutter

P7.332

Balancing Autonomy and Beneficence in Acute Stroke Therapy: Neurologist Attitudes Toward Delaying Thrombolysis in Order to Obtain Informed Consent Brett Kaplan, Jessica Cranston, Jeffrey Saver


Industry Therapeutic Updates Tuesday, April 21, 2O15 and Wednesday, April 22, 2O15 Starting at 7:00 p.m. Registration is free and open to registered Annual Meeting attendees. Representatives from the following companies invite you to an informational session on therapeutic updates. This program provides you the opportunity to learn about current therapies and projects in the industry pipeline.

Tuesday, April 21 ACADIA Pharmaceuticals Beyond Motor Symptoms: Parkinson’s Disease Psychosis Location: Marriott Marquis Washington, DC Liberty Ballroom M–P Biogen Idec Relapsing MS and Tecfidera® (dimethyl fumarate): An Interactive, Case-based Presentation Location: Marriott Marquis Washington, DC Independence Ballroom A–E BioMarin Pharmaceutical Inc./PTC Therapeutics Location: Marriott Marquis Washington, DC Liberty Ballroom I–L Genzyme, A Sanofi Company Location: Marriott Marquis Washington, DC Room Salon 6 Novartis Pharma AG Basel, Switzerland Location: Renaissance Washington, DC Downtown Grand Ballroom Central/South Sunovion Pharmaceuticals Inc. Welcome to Aptiom® (eslicarbazepine acetate) Location: Marriott Marquis Washington, DC Ballroom Salon 7–10

*Commitments as of 2/9/15

Wednesday, April 22 FORUM Pharmaceuticals Inc. Treatment of Alzheimer’s Disease: Where Are We Now, and Where Are We Headed? Location: Marriott Marquis Washington, DC Independence Ballroom A–H Novartis Pharma AG Basel, Switzerland Location: Marriott Marquis Washington, DC Liberty Ballroom I–P

RSVP is recommended for these events. Please visit AAN.com/view/ITU for more information. No CME will be given by any accredited organization for the Industry Therapeutic Updates, and the AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

Scientific Sessions S46 Neuromyelitis Optica 3:15 p.m. S46.001 “Spinal” Movement Disorders in NMO Patients: An Under-recognized Phenomenon Hesham Abboud, Michael Levy 3:30 p.m. S46.002 Tobacco Smoking and Severity of Neuromyelitis Optica Laurent Kremer, Nasrin Asgari, Maureen Mealy, Kerry Mutch, Michael Lewy, Anu Jacob, Nicolas Collongues, Jerome De Seze 3:45 p.m. S46.003 Effects of Neuromyelitis Optica (NMO)-IgG for Leukocyte Transmigration at the Blood-brain Barrier Yukio Takeshita, Birgit Obermeier, Anne Cotleur, Fumitaka Shimizu, Simona Spampinato, Thomas Kryzer, Vanda Lennon, Yasuteru Sano, Takashi Kanda, Richard Ransohoff 4:00 p.m. S46.004 Immune Profiling of NMO Patients Receiving Rituximab Immunotherapy Lauren Collison, Chris Ayers, Jessica Jackson, Kenny Frazier, Benjamin Greenberg, Don Healey 4:15 p.m. S46.005 Short Myelitis Lesions in Aquaporin4-IgG-positive Neuromyelitis Optica Spectrum Disorders Eoin Flanagan, Brian Weinshenker, Karl Krecke, Vanda Lennon, Claudia Lucchinetti, Andrew McKeon, Dean Wingerchuk, Elizabeth Shuster, Yujuan Jiao, Erika Horta, Sean Pittock 4:30 p.m. S46.006 A Combined Neuroimaging and Neuropathological Study for Longitudinally Extensive Spinal Cord Lesions in Neuromyelitis Optica: With Special Reference to Lesion Distribution and Extension Patterns Hayashida Shotaro, Katsuhisa Masaki, Tomomi Yonekawa, Noriko Isobe, Takuya Matsushita, Jun-ichi Kira 4:45 p.m. S46.007 Phase Contrast MRI Distinguishes Between Neuromyelitis Optica and Multiple Sclerosis Lesions Tim Sinnecker, Petr Dusek, Lutz Harms, Sanjeev Chawla, Sophie Hahndorf, Katharina Mueller, Thoralf Niendorf, Ilya Kister, Friedemann Paul, Yulin Ge, Jens Wuerfel

S47 Cerebrovascular Disease and Interventional Neurology 3:15 p.m. S47.001 An Electronic Decision Support Tool for Stroke Prevention in Atrial Fibrillation (SPAF): An Integrated Primary-tertiary Care Model of Care. Evan Jolliffe, Ian Rosemergy, Jeremiah Lanford, David Abernethy, Annemarei Ranta 3:30 p.m. S47.002 Stroke After Cardiac Valve Replacement: Distribution, Etiology, and Risk Factors Allie Massaro, Steven Messé, Michael Acker, Scott Kasner, Jose Torres, Molly Fanning, Tania Giovannetti, Sarah Ratcliffe, Michel Bilello, Wilson Szeto, Joseph Bavaria, W Clark Hargrove III, Emile Mohler III, Thomas Floyd 3:45 p.m. S47.003 Rate and Risk Factors of Recurrent 30-day Readmissions Following Hospitalization for Ischemic Stroke Yogesh Moradiya, Santosh Murthy, Sneha Modi, Neeraj Naval 4:00 p.m. S47.004 Are Treatment Preferences of Those Who Died Ever Heard?: The Lack of Documentation of Preferences in a State-wide Cohort of Patients Who Died Following Ischemic Stroke Maisha Robinson, Barbara Vickrey, Robert Holloway, Kelly Chong, Linda Williams, Punam Parikh, Mei Leng, David Zingmond 4:15 p.m. S47.005 Anatomical Scans Predict Acute Spatial Neglect Joseph Posner, Kaitlin Krebs, Chris Rorden, Argye Hillis 4:30 p.m. S47.006 Predictors of Seizure Presentation Associated with Cerebral Arteriovenous Malformations in a Prospective Cohort of 1,007 Patients Dale Ding, Robert Starke, Mark Quigg, Chun-Po Yen, Colin Przybylowski, Blair Dodson, Jason Sheehan 4:45 p.m. S47.007 Prevalence of Asymptomatic Cerebral Aneurysm in General Population and Ischemic Stroke Patient Ji Hwa Kim, Yeo-Jin Oh, Sang Won Han, Jong Yun Lee, Kyung-Yul Lee

Thursday, April 23 S48 Parkinson's Disease 3:15 p.m. Presentation of Jon Stolk Award in Movement Disorders for Young Investigators Recipient: Allison Willis, MD, MS Philadelphia, PA

3:30 p.m. S48.002 Motor Subtypes of Parkinson Disease Are Unstable over Time F. Rainer Von Coelln, Erik Barr, Ann Gruber-Baldini, Stephen Reich, Melissa Armstrong, Lisa Shulman

S49 Aging, Dementia, Cognitive, and Behavioral Neurology: Imaging: Behavioral Neurology and Non-Alzheimer's Disease Dementias 3:15 p.m. S49.001 A Role for the Dorsal Dentate Gyrus in Color Context Pattern Separation Nicholas Musso, Raymond Kesner

3:45 p.m. S48.003 Sex Differences in Parkinson’s Disease Caregiving Krunal Shah, Pei Qinglin, Samuel Wu, Peter Schmidt, Fernando Cubillos, Nabila Dahodwala

3:30 p.m. S49.002 Altered Resting-state Network Connectivity in Stroke Patients with and Without Apraxia of Speech Anneliese New, Ballard Kirrie, Amy Parkinson, Joseph Duffy, Malcolm McNeil, Olivier Piguet, Michael Hornberger, Cathy Price, Simon Eickhoff, Donald Robin

4:00 p.m. S48.004 Parkinson’s Disease Progression Is Associated with Increased Putaminal Serotonin to Dopamine Transporter Ratio: Relevance for Dyskinesias Andreas Roussakis, Marios Politis, David Towey, Paola Piccini

3:45 p.m. S49.003 Personal Experience with Dance and Cortical Gray Matter Thickness in the Cognitively Normal and Mild Cognitive Impaired Elderly Shai Porat, Kristy Hwang, Ellen Woo, Theodore Zanto, Naira Goukasian, Liana Apostolova

4:15 p.m. S48.005 Interdisciplinary Deep Brain Stimulation Screening and the Relationship to Unintended Hospitalizations and Quality of Life Hokuto Morita, Masa-Aki Higuchi, Dan Topiol, Dawn Bowers, Herbert Ward, Lisa Warren, Meredith DeFranco, Michelle Troche, Shankar Kulkarni, Kelly Foote, Michael Okun

4:00 p.m. S49.004 Associations Between Cortical Thickness and Hippocampal Volume with Metacognition Naira Goukasian, Ellen Woo, Anna Blanken, Kristy Hwang, Shai Porat, Genevieve Rodriguez, John Ringman, Liana Apostolova

4:30 p.m. S48.006 The Profile of the Hospitalized and Re-hospitalized Parkinson Disease Patient: 5-year Data from the National Parkinson Foundation Leili Shahgholi, Sol De Jesus, Samuel Wu, Qinnglin Pei, Anhar Hassan, Peter Schmidt, Michael Okun 4:45 p.m. S48.007 Neural Stem Cell Based Therapy for Parkinson’s Disease Ruslan Semechkin, Rodolfo Gonzalez, Ibon Garitaonandia, Tatiana Abramihina, Maxim Poustovoitov, Andrew Crain, Alexander Noskov, Louise Laurent, Evan Snyder, Eugene Redmond

4:15 p.m. S49.005 Atrophy in Distinct Corticolimbic Networks Subserving Socialaffective Behavior in Semanticvariant Primary Progressive Aphasia David Perez, Sara Makaretz, Christina Caso, Michael Stepanovic, Michael Brickhouse, Megan Quimby, Daisy Hochberg, Chenjie Xia, Bradford Dickerson 4:30 p.m. S49.006 Grey and White Matter MRI Signatures of the Frontotemporal Lobar Degeneration Continuum Massimo Filippi, Federica Agosta, Sebastiano Galantucci, Giuseppe Magnani, Alessandra Marcone, Daniele Martinelli, M. Antonietta Volonte, Nilo Riva, Sandro Iannaccone, Pilar Ferraro, Francesca Caso, Adriano Chio, Andrea Falini, Giancarlo Comi 4:45 p.m. S49.007 Imaging Tau Pathology in Vivo in FTLD Spectrum Tauopathies with [18F] T807 PET Bradford Dickerson, Sara Makaretz, Christina Caso, Michael Stepanovic, Daisy Hochberg, Megan Quimby, Michael Brickhouse, Kimiko Domoto-Reilly, Scott McGinnis, Aaron Schultz, Neil Vasdev, Keith Johnson

S50 Treatment Trials in Neuromuscular Diseases 3:15 p.m. S50.001 Prednisone/Prednisolone and Deflazacort Differ in Long Term Outcomes on Ambulation and Side Effects in the CINRG Duchenne Natural History Study Luca Bello, Heather Gordish-Dressman, Lauren Morgenroth, Erik Henricson, Tina Duong, Eric Hoffman, Avital Cnaan, Craig McDonald 3:30 p.m. S50.002 A Phase 4 Prospective Study in Patients with Adult Pompe Disease Treated with Alglucosidase Alfa Beth Thurberg, Pierre Carlier, John Kissel, Benedikt Schoser, Alan Pestronk, Richard Barohn, Ozlem Goker-Alpan, Tahseen Mozaffar, Loren Pena, Zachary Simmons, Volker Straub, Peter Young, Raheel Sahfi, Carl Bjartmar, Ans Van Der Ploeg 3:45 p.m. S50.003 Transplantation of an IPSC-derived CD15+CXCR4+VLA4+ Neural Stem Cell Subpopulation as a New Therapy for ALS. Chiara Simone, Monica Nizzardo, Federica Rizzo, Monica Bucchia, Agnese Ramirez, Nereo Bresolin, Giacomo Comi, Stefania Corti 4:00 p.m. S50.004 A Phase 2 Study of Mexiletine in Sporadic Amyotrophic Lateral Sclerosis Michael Weiss, Zachary Simmons, Nazem Atassi, Michael Graves, Nicholas Parziale, Johnny Salameh, Colin Quinn, Robert Brown, B Distad, Jaya Trivedi, Jeremy Shefner, Anuradha Duleep, Richard Barohn, Mazen Dimachkie, April McVey, Alan Pestronk, Andrea Swenson, Eric Macklin, Angela Knox, Katelyn Gilardi, Merit Cudkowicz 4:15 p.m. S50.005 A Single-center, Randomized, Double-blind, Placebo-controlled, Six-month Clinical Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILASTALS-DB-OLE-1 Benjamin Brooks, Elena Bravver, Mohammed Sanjak, Velma Langford, Cynthia Lary, Mohamed Alwan, Joanne Nemeth, Priscilla Russo, Nicole Smith, Nicole Lucas, Mindy Nichols, Sharon Belcher, Kathryn Wright, Amber Ward, Scott Holsten, Michael Fischer, William Bockenek, Urvi Desai, Scott C Lindblom, Thomas Pacicco, Kazuko Matsuda, Joanna Dojillo 4:30 p.m. S50.006 A Phase 3 Study to Evaluate ISISRx TTR in Patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP): Study Design and Baseline Demographics Merrill Benson, John Kincaid, Elizabeth Ackermann, Brett Monia 4:45 p.m. S50.007 Effects of Dalfampridine in Hereditary Spastic Paraparesis Aksel Siva, Ugur Uygunoglu, Melih Tutuncu, Aysegul Gunduz, M. Ali Akalin, Sabahattin Saipoglu

132


S51 Headache: Imaging and Physiology 3:15 p.m. Presentation of Harold Wolff-John Graham: An Award for Headache/Facial Pain Research Recipient: Henrik Schytz, MD, PhD Glostrup, Denmark

3:30 p.m. S51.002 Botulinum Toxin Type A and Rat Trigeminal Regions: The Search for Mechanism of Antinociceptive Action in Migraine and Other Headaches Zdravko Lackovic 3:45 p.m. S51.003 Physiological Discrimination of Headache Disorders Natalie Rea, Lindsay Hunter, Jonas Peterson, Jeremy Theriot, Melissa Cortez, K.C. Brennan 4:00 p.m. S51.004 Acute Headache Diagnoses in Pregnancy: A 5-year Registry Study Matthew Robbins, Constantine Farmakidis, Ashlesha Dayal, Richard Lipton 4:15 p.m. S51.005 Structural Cortical Brain Abnormalities in Patients with Vestibular Migraine Roberta Messina, Maria Rocca, Bruno Colombo, Roberto Teggi, Andrea Falini, Giancarlo Comi, Massimo Filippi 4:30 p.m. S51.006 Prolonged Trigeminal Sensitization Induces Gut Dysbiosis: Implications for Migraine Pathology Jordan Hawkins, Rhy Norton, Paul Durham 4:45 p.m. S51.007 Resting State Functional Connectivity Abnormalities in Pediatric Patients with Migraine Roberta Messina, Maria Rocca, Bruno Colombo, Ermelinda De Meo, Andrea Falini, Giancarlo Comi, Massimo Filippi

S52 General Neurology: Neural Networks and Neuromodulation 3:15 p.m. S52.001 Predicting the Network Effects of Focal Brain Lesions Aaron Boes, David Fischer, Samar Ayache, Joel Geerling, Sashank Prasad, Hesheng Liu, Qi Liu, Brian Edlow, Verne Caviness, Jean-Pascal Lefaucheur, Alvaro Pascual-Leone, Michael Fox 3:30 p.m. S52.002 Using Neural Networks to Predict the Effects and Guide the Application of Transcranial Direct Current Stimulation David Fischer, Peter Fried, Alvaro Pascual-Leone, Michael Fox 3:45 p.m. S52.003 The Neuroanatomic Basis of Coma in Humans: A Study of Brainstem Lesions and Their Cortical Networks David Fischer, Aaron Boes, Joel Geerling, Brian Edlow, Alvaro Pascual-Leone, Michael Fox 4:00 p.m. S52.004 Overexpressed Nucleic Acid in Aicardi-Goutières Syndrome Patient Fibroblasts Adeline Vanderver, Asako Takanohashi, Guy Helman, Ji-Young Kang, Arya Dahal, Ryan Taft, Robert Crouch 4:15 p.m. S52.005 A Novel Method for Measuring Oxidative Stress in Patients with Stroke Symptoms Jeffrey Wagner, Kristin Salottolo, Christopher Fanale, Michelle Whaley, Kathryn McCarthy, David BarOr 4:30 p.m. S52.006 Oxygen Extraction Fraction and Microvascular Permeability in X-linked Adrenoleukodystrophy Patricia Musolino, Arne Lauer, Mikkel Bo Hansen, Jayashree KalpathyCramer, Kim Mouridsen, Bruce Rosen, Florian Eichler

S53 Sleep 3:15 p.m. Presentation of Wayne A. Hening Sleep Medicine Investigator Award Recipient: Mark Wu, MD, PhD Baltimore, MD

3:30 p.m. Presentation of Sleep Science Award Recipient: Thomas Scammell, MD Boston, MA

4:00 p.m. S53.004 Quantitative Analysis of REM Sleep Without Atonia in Neurocognitive Syndromes Ho-Yann Jong, Bradley Boeve, Erik St. Louis 4:15 p.m. S53.005 The Association of Sleep Apnea and Stroke with Cognitive Performance: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study Jennifer Molano, Dawn Kleindorfer, Leslie McClure, Frederick Unverzagt, Virginia Wadley, Virginia Howard 4:30 p.m. S53.006 Clinical Profile of Suvorexant over 3 Months in Elderly Patients with Insomnia: Subgroup Analysis of Phase-3 Data William Herring, Kathryn Connor, Neely Ivgy-May, Duane Snavely, Ellen Snyder, David Michelson 4:45 p.m. S53.007 Simplifying the Diagnosis of Sleep Apnea After Stroke: Evaluation of Five Simple Screening Tools Fadi Frakul, Sara Elias, James Im, Karl Boyle, Sandra Black, Brian Murray, Richard Swartz, Mark Boulos

4:45 p.m. S52.007 Optogenetic Neuromodulation Genko Oyama, Nobutaka Hattori


International Experience We invite all of our international attendees to join us at the International Experience. This is a unique place to network, participate in informal sessions, and learn more about the AAN as well as other organizations worldwide. Tentative Schedule of Events: Sunday, April 19: Asia Day

¡¡ Featuring talks by Mamta Bhushan Singh, MBBS, MD, DM, and Man Mohan Mehndiratta, MD, MBBS, FAAN Monday, April 20: Africa Day

¡¡ Featuring talks by Omar Siddiqi, MD, and David Renner, MD Tuesday, April 21: Global Neurology Day

¡¡ Featuring a preview of the Global Health Integrated Neuroscience Session and talks by Mark Hallett, MD, FAAN, and Kelly Baldwin, MD Wednesday, April 22: Latin America, Caribbean Day

¡¡ Featuring talks by Amza Ali, MD, FRCP, FAAN, and Oscar H. Del Brutto, MD, FAAN Thursday, April 23: Europe Day

¡¡ Featuring talks by Walter Struhal, MD Thursday April 23

3:15 p.m–5:00 p.m.

133

Highlights for Students, Residents, and Fellows The AAN Annual Meeting is an ideal setting for students, residents, and fellows to gain exposure to a variety of interests and career disciplines, as well as network with leading neurologists and neurology professionals from around the world.

Registration

Opportunities to Save Money

FREE for Medical Students

Rush Line Tickets

Annual Meeting registration is FREE to medical students, graduate students, and PhD candidates who present a student ID card or are AAN members.

Check in at the Registration Booth located in the Convention Center each morning for FREE tickets to Education Programs for that day. A minimum of two tickets will be held for each program, available on a first-come, first-served basis.

Only $100 for Junior Residents and Junior Fellows

Get 50% Off Education Program Registration

Annual Meeting registration is only $100 (a $740 savings from nonmember neurologist registration!) before the March 27, 2015, early registration deadline.

Junior members who register for two Education Programs at full price will receive 50% off the cost of a third Education Program of equal or lesser value.

Registration Packages This year, we have three registration options available to attendees. As students and juniors, you receive deep discounts on registration options. Choose the package that works for you! ¡¡ Meeting Registration—education courses available for an additional fee ¡¡ Silver Registration Package*—includes all your education courses at one flat rate ¡¡ Gold Registration Package*—includes Silver Registration Package plus Annual Meeting On Demand See details and pricing on page 8. * Skills Workshops, Skills Pavilions, and Leadership Courses excluded from Silver and Gold Registration Package pricing. Attendee must identify courses to be included as part of Silver and Gold Registration Package. Courses are subject to closure due to reaching maximum capacity. Attendee is only permitted to select courses that he/she plans to be in the room for. Attendee will not be able to register for courses with conflicting time schedules.

134

Volunteer Opportunities

Serve as a program monitor or a workshop volunteer to gain free access to the specific program (see page 145).

2O15 Medical Student, Residents, and Fellows Guide A detailed guide highlighting all events and opportunities of interest to Students, Residents, and Fellows is available at AAN.com/view/resident .


Are You A First-time AAN Annual Meeting Attendee? Welcome! With more than 12,000 attendees and nearly 300 top-quality sessions, the AAN Annual Meeting is the world’s largest gathering of neurologists. Below are resources designed to help navigate your week. 1. Attend AAN Annual Meeting Orientation • Overview of the meeting • What’s included with your badge • Networking opportunities Orientation sessions will be held at the Walter E. Washington Convention Center: • Sunday, April 19 1:00 p.m. to 1:30 p.m. • Wednesday, April 22 8:00 a.m. to 8:30 a.m. Both sessions will be held in the Innovation Room 2. Register with AAN Mentor Connect Register with AAN Mentor Connect to be paired up with an experienced AAN member during the meeting. AAN Mentor Connect is a members-only benefit, courtesy of the Neurology Career Center. 3. Join the Annual Meeting LinkedIn Group Network with attendees before, during and after the meeting, with the Annual Meeting LinkedIn group at AAN.com/view/AMLinkedIn.

4. Download the Annual Meeting Mobile App The app puts all the information you need, itinerary, room locations, program slides, and syllabi, conveniently on your mobile phone or iPad. Look for the full version in March 2015. 5. On-site Resources • An information booth will be located in the convention center • Plan a visit to Academy Central for information on AAN products and resources • The Residents Experience offers students and residents a unique place to network and relax • The International Experience provides a place for international attendees to gather and participate in discussions on a variety of topics

Learn more at AAN.com/view/FirstTimeAttendee

Connect at Social Events There’s no better way to combine an evening of great fun and entertainment with unparalleled networking than to attend the Capitol City Celebration, Closing Party—or both. Whether you attend the Annual Meeting at the beginning of the week, or the end, these parties are not-to-be-missed. Capitol

City Celebration

Sunday, April 19 6:00 p.m.–10:00 p.m.

Exhibit Hall Opening Reception

Neurobowl® 6:00 p.m.–8:00 p.m.

Monday, April 20 4:30 p.m.–6:30 p.m.

This popular event hosted by AAN former president Thomas R. Swift, MD, FAAN, is one of the Annual Meeting’s premier happenings. Neurobowl showcases the best and brightest in neurology competing for the coveted Neurobowl trophy in an entertaining game-show format.

Attend the opening reception to mingle with fellow attendees and preview the latest products and services available in the neurologic industry. Light hors d’oeuvres and beverages will be served. The exhibits will be open at this time. Sponsored by:

Main Stage Music: Doctor’s Orders 8:00 p.m.–10:00 p.m.

This energetic 10-piece variety band based in the Washington, DC/ Baltimore area will have you on your feet with its diverse repertoire covering everything from Top 40 to ’70s to ’80s to standards. Fronted by dynamic singer/saxophonist Kyle Johnson and Miriamm Wright—of Peaches and Herb fame—”the chemistry of the band is obvious from the first chord,” says guitarist Bill McCarron. “It’s not like it’s really a conscious effort on our part, we just have a blast playing together.” No doubt, you’ll have a blast listening to them. Neuro Jazz 8:30 p.m.–9:30 p.m.

Swing out to your favorite jazz standards while enjoying a scrumptious dessert. This four-piece ensemble, led by AAN member Phillip Pearl, MD, FAAN, will have your toes tapping and fingers snapping to some of the most enduring tunes of our time.

Run/Walk Tuesday, April 21 6:30 a.m.–8:30 a.m.

Support research in neurology and join us for a 5k run or one mile walk along the Washington, DC, waterfront. Both occasional and seasoned runners—and walkers—will enjoy this beautiful trek for a good cause. All proceeds will go to the American Brain Foundation to help support research. The race is open to all meeting attendees and their families. Water and refreshments will be available following the race. The registration fee is $40. Bus service to and from the race site will be provided. For registration and details, visit AAN.com/view/RunWalk or contact Andrew Halverson at [email protected] or (612) 928-6117.

Closing Party Friday, April 24 6:00 p.m.–8:00 p.m.

Celebrate the end of a great meeting at a special early-evening happy hour event! ¡¡ Enjoy music, drinks, and socializing with colleagues ¡¡ Make plans to explore beautiful Washington, DC, afterwards

136


Reunion/In Conjunction with Meetings Reconnect with your peers and program directors, and network with your fellow alumni at various department reunion meetings occurring throughout the Annual Meeting. These In Conjunction With (ICW) Meetings, formerly known as Affiliate Meetings, are designed for functions that include Annual Meeting attendees but are not planned by or sponsored by the AAN. If your department is interested in hosting its alumni meeting during the 2015 Annual Meeting, reserve your meeting today at AAN.com/view/ICW or by contacting Nancy Poechmann at [email protected] or (612) 928-6103.

Awards Luncheon Wednesday, April 22 12:00 p.m.–1:30 p.m.

Join AAN leaders as they honor the recipients of the 2015 AAN and American Brain Foundation Awards. From enterprising high school students to world-renowned researchers, this program recognizes some of the top accomplishments in neuroscience research. Former US Vice President, former US Ambassador to Japan, former US Senator, and Honorary Chairman of the American Brain Foundation CESC: 15AM Closing Party_Abstract Listing, halfpage horizontal of Trustees Walter F. Mondale will accept the 2015 Public Usage: HighBoard resolution PDF for Abstract Listing Spec: 8.25” Leadership x 5.4375”, +.125” bleeds, 2C Award via video during the luncheon. Past in Neurology

esteemed recipients include Ben Utecht, Billy McLaughlin, Dame Julie Andrews, Cuba Gooding Jr., Leeza Gibbons, and Michael J. Fox. Tickets are available for $60 through registration. Buy a ticket and show your support for award recipients. Reserve a Department Table and Be Recognized

Bring your department together and gain exposure for your team at the Awards Luncheon by reserving a department table. Give your residents and fellows the chance to sit together with department faculty and chairs in a place of honor among the top minds in the neurology/neuroscience academic community. To reserve a table, download the reservation form at AAN.com/view/AM15. For questions, contact Laurie Dixon at [email protected] or (612) 928-6154.

Celebrate the end of a great meeting at a special early-evening happy hour event! ¡ Enjoy music, drinks, and socializing with colleagues ¡ Make plans to explore beautiful Washington, DC, afterwards

Closing Party

Friday, April 24 6:00 p.m.–8:00 p.m.


137

Things to do in DC Looking for Interesting and Unique Things to Do While in the DC Area? While most people are aware of options like the Washington Memorial, the White House, and the Smithsonian Museums, Washington, DC is home to multiple unique places to visit. National Park Service Memorials

National Museum of Women in the Arts

While strolling along the famous National Mall, be sure and visit some of these beautiful new memorials, conveniently situated near the famous Lincoln Memorial: ¡¡ Korean War Veterans Memorial ¡¡ World War II Memorial ¡¡ Franklin Delano Roosevelt Memorial ¡¡ Martin Luther King, Jr. Memorial

Founded in 1987, the National Museum of Women in the Arts is the only major museum in the world solely dedicated to recognizing women’s creative contributions. Learn more at NMWA.org .

Learn more at NPS.gov/nama/index.htm . Hillwood Estate Museum and Gardens

Discover the grand estate of Post Cereal heiress Marjorie Merriweather Post. Situated on 25 acres overlooking Rock Creek Park in northwest Washington, DC, the beautiful estate boasts a world-renowned collection of Russian and French decorative arts, as well as extensive gardens and special exhibitions. Learn more at HillwoodMuseum.org .

Octagon Museum

Built between 1798 and 1801 by John Tayloe III at the suggestion of George Washington, the house was offered to President Madison and his family in 1814 as temporary quarters after the White House was burned in the War of 1812. The Treaty of Ghent was signed here in February 1815, thus ending the war between Great Britain and the US. Since 1898 the Octagon has served as the national headquarters for the American Institute of Architects. Learn more at AIA.org/conferences/the-octagon .

Frederick Douglass National Historic Site

Visit Cedar Hill, home of the famed abolitionist Frederick Douglass who was born into slavery and escaped to spend the rest of his life fighting for justice and equality for all people. This National Historic Site, administered by the National Park Service, works to preserve the legacy of Douglass’s tireless struggle and inspire people today. Learn more at NPS.gov/frdo/index.htm . Freer and Sackler Galleries: The Smithsonian¹s Museums of Asian Art

This first-class museum features world-renowned collections, exhibitions, and public programs that offer inspiring encounters with Asian art and culture for diverse audiences. Learn more at Asia.si.edu.

Smithsonian National Postal Museum

Housed in the historic 1914 City Post Office Building next door to Union Station, the Smithsonian National Postal Museum occupies 100,000 square feet of the building with 35,000 square feet devoted to exhibition space. The museum also houses a 6,000-square-foot research library, a stamp store, and a museum shop. Learn more at PostalMuseum.si.edu . Georgetown

Take a stroll along the quaint cobblestone streets of this bustling historic neighborhood. Founded in 1751—predating Washington, DC—the area is a paradise for history and historic architecture lovers, shoppers, and foodies alike. Learn more at Georgetowndc.com .

138


Thank You

2O15 Industry Roundtable Members* Industry Roundtable support enables the American Academy of Neurology to improve patient care through their support of neuroscience research, education, and patient outreach.

$40,000

$30,000

ACADIA Pharmaceuticals BioMarin Pharmaceuticals, Inc. FORUM Pharmaceuticals

$20,000

AbbVie, Inc. Actavis Eisai Inc. Eli Lilly and Company

Medtronic, Inc. Piramal Imaging S.A. Sunovion Pharmaceuticals Inc. Upsher-Smith Laboratories Inc.

*Commitments as of February 3, 2015

Enhance your Annual Meeting experience with these educational products. 1. AAN Annual Meeting On Demand is a CME accredited comprehensive digital library with more than 500 hours* of presentations from the 2015 AAN Annual Meeting educational programs (including the Syllabi On CD and Neurology Update On Demand library). Watch presenters’ slides while listening to fully synchronized audio as if you were actually attending each session.

Features of AAN Annual Meeting On Demand include: • Online access to content within 24 hours of live presentations. • NEW: CME credit available. • The most advanced search engine in the industry delivers a direct link to the specific presentations and slides containing your search terms. That means less time searching and more time learning. • Our Recently Viewed feature allows you to revisit presentations and pick up exactly where you left off. • Downloadable MP3 files provide the option of listening to any (or all) lectures while driving, traveling, or any occasion where audio is most convenient. • A complimentary portable hard drive is included for offline viewing when internet is not convenient or available. 2. Neurology Update On Demand offers a paired-down library of approximately 70 hours* of presentations focused on the latest updates in the field of neurology. Sessions in this online-only catalog will be available within 24 hours of the live presentation. 3. Syllabi On CD serves as a quick reference tool with syllabi summaries of more than 160 programs presented during the 2015 Annual Meeting. * Total hours of presentations available subject to speaker permissions.

For Annual Meeting Attendees: New Registration Option: Gold Registration Package

Gold Registration Package Before March 27, 2015

After March 27, 2015

MEMBER

$1,399

$1,599

NONMEMBER

$2,499

$2,799

JUNIOR*

$599

$699

Annual Meeting On Demand

Neurology Update

Syllabi CD

MEMBER

$399

$299

$199

NONMEMBER

$499

$399

$249

JUNIOR

$199

$149

$99

One price secures you access to all education courses** at the Annual Meeting and includes a copy of AAN Annual Meeting On Demand. With so many options during the meeting and concurrent sessions, the Gold Registration Package is the best value for attendees who want to maximize their time during the meeting. * Junior pricing also applies to Non-Neurologist members.

** Skills Workshops, Skills Pavilions, and Leadership Programs are excluded from the Gold Registration Package. Attendees must identify courses to be included as part of Gold Registration Package. Courses are subject to closure due to reaching maximum capacity. Attendee is only permitted to select courses that he/she plans to be in the room for. Attendee will not be able to register for courses with conflicting time schedules.

Select the Gold Registration Package when you register for the meeting!

On Demand Add On: If you decide not to choose the Gold Registration Package, you can still add any On Demand product or Syllabi On CD to your registration. Order Online: AAN.com/view/Register

Attendee Pricing

On Demand attendee discounts expire April 25, 2015.

Not attending the 2015 meeting? If you are not attending the 2015 Annual Meeting, you can still pre-order On Demand products prior to the meeting and receive a special discount. Order Online: AANonDemand.com/PreMeeting Order by Phone: (800) 501-2303 or (818) 844-3299 Pre-meeting discounts expire April 25, 2015.

Non-Attendee Pricing Annual Meeting On Demand

Neurology Update

Syllabi CD

MEMBER

$699

$499

$299

NONMEMBER

$699

$499

$299

JUNIOR

$199

$149

$99

General Information Accreditation/CME/Core Competencies Accreditation

The American Academy of Neurology Institute (AANI), the education subsidiary of the American Academy of Neurology, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Once again, this year’s Annual Meeting CME offerings, at the program and lecture level, are identified according to these competencies. Through identifying individual programs by competencies, attendees can easily identify and attend programs that meet each core competency. AMA CME Definition/Educational Content of Certified CME

AMA Credit Designation

The AANI designates this live activity for a maximum of (*) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME/Participation Records

AANI has mechanisms in place to record, and when authorized by the participating physician, verify participation in the CME activity. To receive CME for the Annual Meeting live program, participants must: (1) register for the program(s); (2) attend the program(s); (3) submit the evaluation form for the program(s). CME is given only when all three steps are completed. AAN member CME and participation transcripts are available approximately four to six weeks following the close of the meeting via the AAN’s NeuroTracker AAN.com/view/ NeuroTracker. Nonmembers’ CME credits and participation transcripts will be sent via email. Core Competencies

The AANI develops its activities/educational interventions in the context of the desirable physician attributes. Specifically, the AANI develops its educational interventions in the context of the Accreditation Council for Graduate Medical Education (ACGME) Core Competencies which include: ¡¡ Patient Care ¡¡ Medical Knowledge ¡¡ Interpersonal and Communication Skills ¡¡ Practice-based Learning and Improvement ¡¡ Professionalism ¡¡ Systems-based Practice

142

For more information on the definitions of the ACGME core competencies, please consult the following webpage: ACGME.org/outcome/comp/compmin.asp

The AMA HOD and the Council on Medical Education have defined continuing medical education as follows: CME consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession. The content of CME is the body of knowledge and skills generally recognized and accepted by the profession as within the basic medical sciences, the discipline of clinical medicine and the provision of health care to the public. (HOD policy #300.988) Certified CME is defined as: 1. Nonpromotional learning activities certified for credit prior to the activity by an organization authorized by the credit system owner, or 2. Nonpromotional learning activities for which the credit system owner directly awards credit Accredited CME providers may certify nonclinical subjects (e.g. office management, patientphysician communications, faculty development) for AMA PRA Category 1 Credit™ as long as these are appropriate to a physician audience and benefit the profession, patient care, or public health. CME activities may describe or explain complementary and alternative health care practices. As with any CME activity, these need to include discussion of the existing level of scientific evidence that supports the practices. However, education that advocates specific alternative therapies or teaches how to perform associated procedures, without scientific evidence or general acceptance among the profession that supports their efficacy and safety, cannot be certified for AMA PRA Category 1 Credit™. Content Validation

The AANI, as an ACCME accredited provider, is responsible for validating the clinical content of CME activities that it provides. Specifically, 1. All the recommendations involving clinical medicine in a CME activity must be based on evidence that is accepted


within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. 2. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

Disclaimers/Disclosures AAN/AANI Education/Scientific Disclaimer

The primary purpose of the Annual Meeting is to meet the educational needs of its members and address practice gaps by providing practice-oriented and scientifically based educational activities that will maintain and advance competence and performance in the field of neurology. A diversity of opinions exists in the medical field and the views of the Annual Meeting faculty do not represent those of the AAN/AANI or constitute endorsement by the AAN/AANI. The AAN/AANI disclaims any and all liability for the claims that may result from the use or nonuse of information, publications, therapies, and/or services discussed at the Annual Meeting.

Relationship Disclosure and Conflict of Interest Resolution

According to AANI and ACCME policies, everyone who is in a position to control the content of an education activity must disclose financial relationships with any commercial interest to the provider. An individual who refuses to disclose relevant financial relationships is disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation or evaluation of the CME activity. In addition, the AANI must implement a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The resolution of conflict is handled by the Education and Science Committees. Disclosures for everyone in the position to control Annual Meeting content can be found on the AAN Annual Meeting website. In addition, education and science faculty disclosures can also be found in the syllabi, slides, handouts, and/or are given verbally from the podium. Unlabeled Use Disclosure

The AANI requires all Annual Meeting presenters to disclose if a therapy/product is not labeled for the use being discussed or if the therapy/product is still investigational. Unlabeled use disclosures can be found in the program materials.

General Information Education Grants

Metro Passes

Some Annual Meeting education and scientific programs are supported in part by educational grants from commercial entities. Disclosure of the educational grant is done through acknowledgment statements on the program materials, signs outside of the room, and verbally from the podium. Although educational grants are received, all programs are developed and implemented solely by the Education Committee and Science Committee. The terms, conditions, and purposes of the commercial support are documented in a written agreement between the AANI and commercial supporter. The AAN uses grant funds to support and enhance existing, as well as new, education programs.

2015 Annual Meeting attendees staying at any AAN-contracted hotel outside of a one-mile radius of the Walter E. Washington Convention Center will have a new, convenient way to get to and from the convention center—and around Washington, DC! In lieu of shuttle service, qualifying attendees will each receive a complimentary Metro pass for use during their stay. Note that shuttle service will be available between select AAN-contracted hotels and the Capitol City Celebration on Sunday, April 19.

Services Child Care Information

A variety of child care options are available in Washington, DC. Check with the concierge at your hotel on or before your arrival to make your arrangements. Luggage Check

No luggage check is available at the Walter E. Washington

Convention Center. Check with your concierge at your hotel to make RED: 15AM MobileApp Ad_AMRAP, halfpage horizontal Usage: High resolution PDF for AMRAP your arrangements. Spec: 8.25” x 5.4375”, +.125” bleeds, 4C

Internet Kiosks

The Internet kiosks provide attendees with computer workstations and Internet access. Check email, search the AAN website, or complete online evaluations to obtain CME credit. Wireless Connection

Wireless Internet hotspots will be available at the Walter E. Washington Convention Center. Business Center

The Walter E. Washington Convention Center has a business center that offers administrative and office services, including copy machines, faxes, and shipping services. The business center is located on the lobby level of the Walter E. Washington Convention Center.

No Busing for 2015 Instead we are offering… In place of bus service, the AAN is providing metro passes to Annual Meeting attendees staying at any AAN contracted hotel outside a one-mile radius of the Walter E. Washington Convention Center. When booking your hotel, visit the transportation tab to check the quickest route and form of transportation for you! Learn more at AAN.com/view/BookHotel.

Shuttle service will be made available for the Capitol City Celebration.

First Aid Station

A First Aid station is located on the lobby level of the Walter E. Washington Convention Center. The station is staffed by licensed medical professionals and fully equipped with supplies, including automatic external defibrillators (AED). The station is operational throughout the duration of the Annual Meeting.

Volunteer Opportunities Education and Scientific Program Monitors

A prayer room will be available in the Convention Center for attendees looking for a quiet space for thought, reflection, and prayer.

Monitors are needed for all education program offerings and scientific platform sessions to assist directors, faculty, session cochairs, and staff as required. The AAN will waive all monitors’ Annual Meeting registration and education program fees as well as grant CME credit for the monitored program. Space is available on a firstcome, first-served basis. For an application form or more information, contact Laurie Dixon at [email protected] or (612) 928-6154.

Mothers Room

Skills Workshop Volunteers

A private room will be available in the Convention Center for nursing mothers and others with sensitive personal health needs. Please note that this room will not be staffed.

Volunteers are needed to participate in the Neurophysiologic Intraoperative Monitoring Skills Workshop on Monday, April 20, Neuromuscular Ultrasound Skills Pavilion on Wednesday, April 22, and the EMG Skills Workshop: Basic on Friday, April 24. Skills workshop subjects will receive a waived meeting registration and workshop fee as well as payment of $40 per noninvasive session and $60 per invasive session. Space is available on a first-come, first-served basis. For more information, contact Ashley Hubbard at [email protected] .

Prayer Room

Guidelines Photography and Recording of Programs

The AAN strictly prohibits all unauthorized photography (flash, digital, or otherwise), audio and/or video recording during the Annual Meeting. Equipment will be confiscated. Photography is allowed only in the Poster Sessions. Consent to Use of Photographic Images

Registration and attendance at, or participation in, AAN/AANI meetings and other related activities constitutes attendee’s authorization to AAN’s use and distribution (both now and in the future) of the attendee’s image or voice in photographs, video recordings, electronic reproductions, audio recordings, and other media throughout the world and royalty free.

Weather/Attire The climate in Washington, DC, in April is generally warm and pleasant. In April, temperatures usually range from 60 degrees to 70 degrees Fahrenheit. The AAN promotes business casual attire for the duration of the Annual Meeting. Consider bringing a light jacket or sweater to Annual Meeting activities since meeting room temperatures and personal comfort levels vary.

Cell Phones

The AAN requests that attendees turn cellular phones and pagers to vibrate mode upon entering all Annual Meeting programs. Language

The official language of the Annual Meeting is English. No simultaneous translation is available. No Smoking

The Walter E. Washington Convention Center is a nonsmoking facility. For the health and comfort of everyone, smoking is prohibited at Annual Meeting functions, which include all education and scientific activities and social functions. Press Room

Only authorized media may use the Press Room at the Annual Meeting. Journalists must check in at the Press Room and provide proper credentials. For more information, contact Rachel Seroka at [email protected] or (612) 807-6968.


145

Hotel Reservations Why Book a Hotel Room Through the AAN? Booking your room through the official AAN housing company assures you are getting a room at the hotel that best fits your needs. You are also helping the AAN maintain consistent and competitive registration fees. The reason is simple. When a city is selected as the site for the AAN Annual Meeting, contracts are signed with several hotels reserving a specific number of rooms to be available for meeting attendees. If these rooms are not sold, the AAN is liable financially. Penalties incurred affect the overall costs of the Annual Meeting and what the AAN charges for registration, exhibit space, and other services. Discounted hotel rates are available until March 18, 2015, or until the block is filled. After this date, reservations and rates are subject to availability.

Save on Hotel Reservations Take advantage of the AAN’s special hotel rates to make your trip more affordable. Annual Meeting hotel reservations are processed by Convention Management Resources (CMR). AAN Online Hotel Reservations AAN.com/view/BookHotel

The AAN makes it easy and convenient to book your hotel rooms for the 67th Annual Meeting. Booking online allows you to: ¡¡ Take advantage of the AAN’s special hotel rates ¡¡ View room descriptions, photos, and availability ¡¡ Access maps of hotel proximity to Annual Meeting locations Telephone Reservations

All correspondence, questions, and inquiries should be directed to CMR at: Phone: US/Canada (800) 676-4226 International (415) 979-2283

Hours: Credit card reservations only Monday–Friday 6:00 a.m.–6:00 p.m. (PT)

Deposits

¡¡ All hotels require a credit card guarantee or a check deposit of $300 (US dollars) per room and $500 (US dollars) per suite. Deposits will be credited towards your first night’s room and tax. ¡¡ No hotel reservation will be processed without a credit card guarantee or a deposit. ¡¡ Deposits are refundable up to seven days prior to arrival, after which there will be no refunds. ¡¡ Credit cards will be charged for one night’s room and tax if you fail to arrive on the confirmed date of arrival or if you fail to cancel your reservation at least seven days prior to arrival.

Confirmations, Changes, and Cancellations

¡¡ You will receive your hotel confirmation from CMR. This is the only confirmation you will receive. ¡¡ Please check your arrival and departure dates on the confirmation carefully. ¡¡ After March 18, 2015, contact CMR to book a room. After this date, however, rooms are subject to availability.

Note: Some hotels may charge a penalty for changes made to your departure date after you have checked in. Group Accommodations Deadline: March 9, 2015

Blocks of 10 or more sleeping rooms are considered a group. Email your written request to [email protected] and you will be contacted by an AAN Housing Consultant. Additional Tax/Assessments

¡¡ Rates do not include the 15.5% hotel tax. ¡¡ An $8 per night assessment fee is included to offset the expense of the meeting.

Travel Information Reservations and Discounts The official travel agency for the Annual Meeting is Association Travel Pros. For 2%–10% discounted airline tickets to the Annual Meeting, contact them at: Phone: (877) 309-4330 Email: [email protected] Hours: Monday–Friday, 8:30 a.m.–5:30 p.m. CT Closed weekends and holidays A $25 service fee will be assessed per ticket for reservations made via phone. You may also book online with all airline meeting discounts applied at www.aantvlmeetings.com . A $10 service fee will apply to online bookings.

Direct Through Airlines

You may also contact your preferred airline directly. You must reference the AAN Annual Meeting and provide the appropriate airline discount codes listed below. Airline Discount Codes Phone Number Website

Delta United

NMK82 ZTDX158803

(800) 328-1111 (800) 521-4041

Delta.com United.com

Discounts are subject to availability, so book well in advance. Normal mileage and status upgrades apply for all airline programs. A service fee will be charged for reservations made via phone. Travel Website

For travel forms and information updates, visit the AAN Annual Meeting website at AAN.com/view/AM15.

Travel Tips Travel Documents/Passports and Entry Requirements

Non-US visitors must have valid travel documents/passports to enter Washington, DC, to provide proof of their citizenship. Document requirements vary depending on your country of origin, citizenship, the reason for your visit, and the length of your stay, and may include passport or a birth certificate, photo ID, and/or a visa. For more information, or to request a Letter of Announcement for the 2015 Annual Meeting, visit AAN.com/view/AMInfo. Airports That Service Washington, DC

The Washington, DC, area is served by three airports. The Ronald Reagan Washington National Airport (National Airport) is located the closest to the Walter E. Washington Convention Center at approximately 6.5 miles distance; the Dulles International Airport (Chantilly, Virginia) is located approximately 28 miles from the convention center; and Baltimore/Washington International Thurgood Marshall Airport is located approximately 32 miles from the convention center. Pricing and direct flight service may vary among the airports. Currency

Washington, DC’s currency is the US dollar; currency exchange is available at banks and kiosks throughout the city and at the airport. Cash machines/ATMs are available in most banks, hotels, and shopping centers. For denominations under one dollar, the currency is coins.

You will need to present this form, along with your passport, visa (if any), and return tickets to the CBP officer. Measurements

Washington, DC, uses the United States customary system for weights and measurements. If you choose to drive in Washington, DC, be aware the speed limits are posted in miles per hour. Medication

If you are entering Washington, DC, with prescription drugs and syringes: keep the medication in its original, labeled container; include medical certificate with syringes showing they are for medical use and have them declared to US Customs officials; bring an extra prescription in case your medication is lost and/or to attest to your need to take such prescriptions; and carry the generic name of prescription medicines. Time Zone

Washington, DC, is in the Eastern Time Zone. In April it will be the same time as New York, one hour ahead of Chicago, three hours ahead of Los Angeles, five hours behind London, and 13 hours behind Tokyo. For more information, visit AAN.com/view/AMInfo.

Customs and Immigration

From an international point of arrival, upon arriving in Washington, DC, you will be required to go through a US Customs and Border Protection (CBP) inspection. Before you land, your flight crew will distribute an Immigration and Customs Declaration Form for you to complete; forms are also available at the airport upon your arrival. Fast, Easy, Online Registration · AAN.com/view/AM15

147

Hotel Street Map and Amenities 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 148

Hotel Name and Address Beacon Hotel & Corporate Quarters 1615 Rhode Island Ave NW Cambria Suites Washington DC Convention Center 899 O Street NW Capital Hilton 1001 16th St NW Comfort Inn Convention Center 1201 13th St NW Courtyard by Marriott Washington Convention Center 900 F St. NW Courtyard Embassy Row 1600 Rhode Island Ave NW Courtyard DC Capitol 1325 2nd St NE Washington DC 20002 Donovan House, a Kimpton Hotel 1155 14th St NW DoubleTree Hotel Washington DC 1515 Rhode Island Ave NW The Dupont Circle Hotel 1500 New Hampshire Ave. NW Embassy Suites DC Convention Center 900 10th St NW Embassy Suites Washington DC Downtown 1250 22nd St. NW Fairfield Inn & Suites Washington, DC / Downtown 500 H St. NW Grand Hyatt Washington, DC 1000 H St NW Hamilton Crowne Plaza 1001 14th St NW Hampton Inn Washington Convention Center 901 6th St NW Hyatt Place Washington DC/US Capitol 33 New York Ave NE Henley Park Hotel 926 Massachusetts NW Hilton Garden Inn Washington DC 815 14th St NW Hotel George 15 E St. NW Hotel Helix 1430 Rhode Island Ave NW Hotel Madera 1310 New Hampshire Ave NW Hotel Monaco Washington DC 700 F St. NW Hotel Palomar Washington DC 2121 P St NW Hotel Rouge 1315 16th St NW JW Marriott Washington DC 1331 Pennsylvania Ave NW Liaison Capitol Hill 415 New Jersey Ave NW

Rate

Distance to Convention Center

$259

14 Blocks

N

$12.00

1

$269

2 Blocks

N

No Charge

1

$310

9 Blocks

N

$12.95

1

$190

5 Blocks

N

No Charge

0

$299

6 Blocks

N

No Charge

1

$259

14 Blocks

N

No Charge

1

$244

14 Blocks

Y

No Charge

1

$299

9 Blocks

N

No Charge

1

$269

11 Blocks

N

$9.95

1

$259

10 Blocks

Y

No Charge

1

$299

1.5 Blocks

N

$9.95

1

$269

15 Blocks

Y

$14.95

1

$289

5 Blocks

N

No Charge

1

$329

4 Blocks

N

$10.99

2

$299

6 Blocks

N

$12.95

1

$269–279

2 Blocks

N

No Charge

0

$249 Sing / $269 Doub

10 Blocks

Y

No Charge

0

$299

1 Block

N

No Charge

1

$319

8 Blocks

N

No Charge

1

$329

10 Blocks

N

$10.00

1

$299

13 Blocks

N

$10.00

1

$309

16 Blocks

Y

$9.95

1

$349

5 Blocks

N

$10.00 Per Stay

1

$300

23 Blocks

Y

$12.95

1

$289

12 Blocks

Y

$11.99

1

$329

12 Blocks

N

$12.95

1

$309

12 Blocks

Y

$12.95

1

Metro Pass Comped

Internet Cost per Day

Number of Restaurants


Hotel Name and Address Loews Madison Hotel 1177 15th St. NW Marriott Marquis Washington, DC—Headquarter Hotel 901 Massachusetts Ave NW Marriott Metro Center 775 12th St. NW Morrison-Clark Inn 1015 L St. NW Phoenix Park Hotel 520 North Capitol St. NW Renaissance Washington, DC Downtown 999 9th St. NW Renaissance Washington DC Dupont Circle Hotel 1143 New Hampshire Ave. NW Topaz Hotel 1733 N St NW Washington Court Hotel 525 New Jersey Ave. NW Washington Marriott Georgetown 1221 22nd St NW Washington Plaza Hotel 10 Thomas Cir. NW Westin Washington DC City Center 1400 M St. NW Willard InterContinental Washington 1401 Pennsylvania Ave

28 29 30 31 32 33 34 35 36 37 38 39

sh

eN

mp

8 Blocks

N

$13.95

1

$329

Connected

N

$12.95

4

$313

6 Blocks

N

$12.95

1

$309

3.5 Blocks

N

No Charge

1

$269

11 Blocks

N

No Charge

1

$319

1 Block

N

$12.95

2

$285

18 Blocks

Y

$16.95

1

$299

14 Blocks

Y

$10.95

1

$319

12 Blocks

Y

$10.99

1

$285

15 Blocks

Y

$12.95

1

$295

4.5 Blocks

N

No Charge

1

$289

6 Blocks

N

$12.95

1

$359

12 Blocks

N

$10.95

1

NW Av e

w Ne Q St NW

M

W

10

Lo

Du

sac

hus

ett s

35

ire

ticu

Av

nec

eN

W

C on

L St NW

K St NW

New

sh ha w Ne

ia A

M

ve N

I St NW

19

H St NW

W

Ne

ork wY

N Av e

13

M 10th St NW

11th St NW

I St NW

I St NW

H St NW

Ma

ssa

c hu

sett

sA

ve N

H St NW

W

G St NW

G St NW

M

E St NW

D St NW

Ave

NW

an

aA

ve

NW

W

23th St NW

M

Constitution Ave NW

isi

Ave N

ania

Jersey

C St NW nsylv

u Lo

Constitution Ave NW

27

D St NW

W ve N New

Pe n

na A

First St NW

M

M

Indiana Ave NW

2nd St NW

4th St NW

India

M

3rd St NW

7th St NW

8th St NW

D St NW

Constitution Ave NW

32 20

36

E St NW

D St NW

C St NW

K St NW

23

W

C St NW

M

L St NW

K St NW

F St NW

5 9th St NW

eN

26

G Pl NW

Pennsylvania Ave NW

E St NW Av

40

W

F St NW

12th St NW

ia

ve N

13th St NW

gin

A York

14th St NW

Vir

New

15th St NW

E St NW

17th St NW

18th St NW

19th St NW

20th St NW

21th St NW

E St NW

F St NW

H St NW

14

M

G St NW

L St NW

I St NW

30 G St NW

F St NW

33

6th St NW

22th St NW

23th St NW

H St NW

G St NW

NW

16

W

H St NW H St NW

Av e

K St NW

I St NW

M

York

2nd St NW

lvan

7

North Capitol St NW

I St NW nsy

17

W

W

18 29

First St NW

31 NW

11 Pe n

ve N

M St NW

Ave N

Av e

M St NW

M

Jersey

ett s

Ne

A ork wY

New

hus

O St NW

4th St NW

15

sac

O St NW

5th St NW

13th St NW

3

Ma s

L St NW

6th St NW

M St NW

8

K St NW

I St NW

7th St NW

4

P St NW

N St NW

9th St NW

38

P St NW

Walter E. Washington Convention Center 801 Mt Vernon Pl NW Washington, DC 20001

N St NW 10th St NW

as Circl

14th St NW

K St NW

L St NW

39

28 15th St NW

M

Sumner Row

17th St NW

18th St NW

W le N

K St NW

19th St NW

on C ngt irc

6

M St NW

De Sales St

De Sales Row

L St NW

la

NW

16th St NW

20th St NW

21th St NW

22th St NW

23th St NW

L St NW

de Is

ve nd A

N St NW

eNW

Rho

M St NW

athe

2

O St NW

21

9

11th St NW

St . M

W

Jefferson Pl

1

ws Ct

Q St NW

NW

P St NW

12th St NW

eN

mp

t Av

N St NW

25

NW

Av e

8th St NW

Av e

O St NW

land

NW

Ma s

de Is

n Circle N ga

P St NW

37 34

Rho

W

P St NW

21 St NW

22 St NW

12

Q St NW Church St NW

NW

nt Circle po

Q St NW Church St NW

Av e

eN

on t

s Av

Verm

sett

Verm

on t

Corcoran St NW

Thom

c hu

22

Wash i

$319

R St NW

ha

W

R St NW

O St NW

M

Number of Restaurants

ire

t Av

ssa

24

M St NW

Internet Cost per Day

Metro Pass Comped

Av

eN

ticu

W

nec

Ma

Rate

C on

40

Distance to Convention Center

Constitution Ave NW

= Metro Station

Madison Dr NW

Madison Dr NW

3rd St NW

4th St NW

7th St NW

12th St NW

15th St NW

14th St NW

17th St NW

Thank You 2O15 Annual Meeting Supporters The American Academy of Neurology (AAN) thanks the following companies, foundations, and organizations for their demonstrated vision, commitment, and strong support of programs which find answers and improve lives through neurologic education and research.

Acadia Pharmaceuticals Inc. ¡ Industry Therapeutic Update

The Allergan Foundation ¡ Minority Scholarship Fund ¡ Resident Scholarship Fund

Allergan, Inc.

¡ Brain Health Fair—Platinum Event Sponsor

Athena Diagnostics ¡ Exhibit Hall Passport

Biogen Idec.

¡ C27 Controversies in Multiple Sclerosis Therapy ¡ C80 Multiple Sclerosis Overview II: Clinical Advances ¡ C151 Multiple Sclerosis Therapy II: Disease-modifying Treatment ¡ AANextra ¡ Carpet Marketing ¡ Digital Billboard ¡ Exhibit Hall Opening Reception ¡ Emerging Leaders Forum ¡ Industry Therapeutic Update

BioMarin Pharmaceutical Inc. and PTC Thrapeutic ¡ Industry Therapeutic Update

Eisai, Inc.

¡ Exhibit Hall Passport and Passport Premier Sponsorship

ElectroCore

¡ Exhibit Hall Passport

Eli Lilly and Company

¡ Emerging Leaders Forum

EMD Serono, Inc.

¡ Exhibit Guide ¡ Exhibit Hall Passport

FORUM Pharmaceuticals Inc. ¡ ¡ ¡ ¡

AANextra Door Drop Insert Exhibit Guide Industry Therapeutic Update

Geisinger Health System ¡ Exhibit Hall Passport

Genentech, Inc. ¡ ¡ ¡ ¡ ¡ ¡ ¡

Abstract Listing Carpet Marketing Cell Phone Charging Station Door Drop Bag Sponsorship Exhibit Guide Exhibit Hall Footprints Exhibit Hall Pillar Wrap

Genzyme, a Sanofi Company ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡

Novartis Pharmaceuticals Corporation

5K Run/1K Walk for Brain Research AANextra USB Abstracts Door Drop Inserts Emerging Leaders Forum Exhibit Guide Fellow Scholarship Fund Industry Therapeutic Update Exhibit Hall Pillar Wrap Posters Online Presentation Stage Resident Scholarship Fund

¡ ¡ ¡ ¡ ¡ ¡

AANextra Airport Dioramas Industry Therapeutic Update Mobile App Taxi TV Ad Women in Leadership

Sunovion Pharmaceuticals Inc. ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡

IMPAX Pharmaceuticals ¡ AANextra ¡ Exhibit Guide ¡ Exhibit Hall Passport

Intermountain Healthcare ¡ Exhibit Guide

AANextra Abstract Listing Cell Phone Charging Locker Digital Billboard Door Drop Inserts Exhibit Hall Coffee Break Exhibit Guide Exhibit Hall Passport Exhibit Hall Footprints Industry Therapeutic Update Presentation Stage

KRONUS, Inc.

Supernus

Lundbeck LLC

Teva CNS


¡ Exhibit Guide ¡ ¡ ¡ ¡ ¡

¡ ¡ ¡ ¡

5K Run/1K Walk for Brain Research AANextra Exhibit Guide Exhibit Hall Passport Presentation Stage

5K Run/1K Walk for Brain Research Door Drop Bag Sponsorship Exhibit Guide Hotel Key Card/Sleeve

Upsher-Smith Laboratories, Inc. ¡ C57 Therapy of Epilepsy ¡ Exhibit Hall Passport

Mallinckrodt Pharmaceuticals ¡ Door Drop Insert ¡ Exhibit Guide ¡ Footprint

VR1 Inc.


Medtronic, Inc.

Walgreens Infusion Services

Merz Pharmaceuticals, LLC

Wolters Kluwer Health – Publisher of the AAN Publications

¡ C3 Deep Brain Stimulation Management


¡ C101 Hyperkinetic Movement Disorders: Diagnosis and Treatment

MOBE, LLC


MotherToBaby Pregnancy Studies Conducted By OTIS ¡ Exhibit Hall Passport

Mylan ¡ ¡ ¡ ¡

AANextra Abstract Listing Cell Phone Charging Station Exhibit Hall Passport

¡ ¡ ¡ ¡ ¡ ¡ ¡ ¡

AMTRAK Posters Bookbags Brain Health Fair Bookbag Brain Health Fair – Silver Event Sponsor Cell Phone Charging Station Lockers Exhibit Hall Passport Geo-Targeted Taxi TV Ad Wi-Fi Access

* Commitments received as of January 27, 2015

67th Annual Meeting *Current Exhibitors as of February 6, 2015 AbbVie Inc.

Blackrock NeuroMed

EMD Serono

ABCN/ABRET

Brain Biosciences Inc

ACADIA Pharmaceuticals Inc.

CADASIL Association

Encore Medical Education LLC & AAN Business Development

ACRM/American Congress of Rehabilitation Medicine

Cadwell Laboratories, Inc.

Actavis (formerly Forest Pharmaceuticals, Inc.)

Captureproof, Inc.

ACTRIMS Agency for Toxic Substances and Disease Registry

Cambridge University Press Carle Physician Group Catalyst Pharmaceutical Partners, Inc. Cefaly Technology

Epilepsy Foundation Esaote European Academy of Neurology (EAN) Forum Pharmaceuticals, Inc. GBS/CIDP Foundation International Geisinger Health System GeneDx

Alexion Pharmaceuticals

Centura Health

Allergan, Inc.

Cerora, Inc

Allina Health

Charleston Area Medical Center

Genzyme - a Sanofi Company

Alnylam Pharmaceuticals

Children's Hospitals and Clinics of Minnesota

Global Neuro-Diagnostics Glut1 Deficiency Foundation

Clinical Neurology News. com

Great Lakes NeuroTechnologies

CNS Vital Signs

Greenville Health System

Community Health Systems

Grifols USA

American Board of Psychiatry & Neurology

Compumedics USA

Gundersen Health System

American Headache Society

ContextMedia Health

Hayes Locums

American Heart Association

Coram CVS Specialty Infusion Services

Health Volunteers Overseas

American Neurological Association

Corinthian Reference Lab, LLC

HSHS Medical Group

American Physician Institute Beat the Boards Courses

CorTechs Labs, Inc.

Hydrocephalus Association

CRC Press / Taylor & Francis

Hyperion Medical

American Society for Apheresis (ASFA)

Cure SMA

IcoMetrix Nv

Appalachian Regional Healthcare, Inc.

Cyberonics

IMPAX Pharmaceuticals

Athena Diagnostics, Inc.

Cytokinetics Inc.

Impeto Medical

Auspex Pharmaceuticals

Defense and Veterans Brain Injury Center

Interacoustics

Avanir Pharmaceuticals Medical Affairs

Demos Medical Publishing

Intermountain Healthcare, Inc.

Avanir Pharmaceuticals, Inc.

DENT Neurologic Institute

AxelaCare Health Solutions

Depomed, Inc.

International Essential Tremor Foundation (IETF)

B. Braun CeGaT, LLC

DigiTrace Care Services, Inc.

Balancewear By Motion Therapeutics Inc

Dysautonomia International

Bayer HealthCare

Dystonia Medical Research Foundation

Benign Essential Blepharospasm Research Foundation, Inc.

Eisai Inc.

Alzheimer's Association Ambry Genetics American Association of Neuromuscular and Electrodiagnostic Medicine

Biogen Idec BioMarin Pharmaceutical Inc. BKIN Technologies Ltd

Electrical Geodesics, Inc. (EGI) Electro-Cap International, Inc. ElectroCore Elsevier, Inc.


Genentech

International Parkinson and Movement Disorder Society (MD) IPSEN Jackson & Coker Jan Medical Inc. Jari Electrode Supply JTECH Medical KabaFusion

151

67th Annual Meeting Exhibitors Karger Publishers

Nihon Kohden America, Inc.

Synapse Biomedical, Inc

KEGO FMI

Northern Health

TeleSpecialists, LLC

Kennedy Krieger Institute

Novartis Pharmaceuticals Corporation

TEVA Neuroscience, Inc.

KRONUS, Inc.

Ochsner Health System

The Delta Companies

Lantheus Medical Imaging, Inc.

Omim Inc.

The Electrode Store

Lewy Body Dementia Association

Opexa Therapeutics

The Guthy-Jackson Charitable Foundation

LocumTenens. com

Otometrics/Audiology Systems

The JAMA Network

Lundbeck

Otto Trading Inc.

Magstim

Oxford University Press

The Michael J. Fox Foundation for Parkinson's Research

Mallinckrodt Pharmaceuticals (formerly Questcor)

PeaceHealth

Mayo Clinic

Personalis, Inc.

Mayo Medical Laboratories McGraw-Hill Medical MD Conference Express Medical Motion Medical Neurogenetics MedLink Corporation MedPro RX Medtronic, Inc. Merz Neurosciences a Division of Merz North America, Inc. MOBE, LLC MotherToBaby Pregnancy Studies Conduceted By OTIS

Pernix Therapeutics Pikeville Medical Center, Inc. Piramal Imaging Polar Products Inc. Practical Neurology PracticeLink. com Prevention Genetics ProtoKinetics, Gait Analysis Walkways Providence Health & Services RDL Reference Laboratory Riverside Health Rochester Electro-Medical, Inc. RosmanSearch, Inc.

Multigon Industries, Inc.

RSC Diagnostic Services

Multiple Sclerosis Association of America

Sage Therapeutics

Multiple Sclerosis Foundation

Salem Health

Mylan Inc.

Society for Neuroscience

National Ataxia Foundation

Society of Nuclear Medicine and Molecular Imaging

National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health - FITBIR National Multiple Sclerosis Society National Spasmodic Torticollis Association Natus Neurology Incorporated Neurology Career Center Neurology Reviews Neurovirtual USA, Inc. 152

The MSA Coalition The Myositis Association The Sturge-Weber Foundation The Transverse Myelitis Association Tourette Syndrome Association Transgenomic, Inc UCB, Inc. United Council for Neurologic Subspecialties (UCNS) Upsher-Smith Laboratories, Inc. US Bioservices Specialty Pharmacy US WorldMeds Vaya Pharma Via Christi Health VR1 Inc. Walgreens Infusion Services Wiley Wolters Kluwer Health World Parkinson Coalition Inc. WR Medical Electronics XenoPort, Inc.

Soleo Health (formerly Biomed Pharmaceuticals) Sony Electronics SpecialtyCare Spectrum Health Medical Group Springer Sunovion Pharmaceuticals Inc. Supernus Pharmaceuticals, Inc.


67th Annual Meeting Committee Members Meeting Management Committee

Science Committee

Practice Committee

Stefan M. Pulst, MD, FAAN, Chair Brenda Banwell, MD Neil A. Busis, MD, FAAN Terrence L. Cascino, MD, FAAN Cynthia L. Comella, MD, FAAN John Corboy, MD, FAAN Lisa M. DeAngelis, MD, FAAN Mill Etienne, MD, MPH, CPH Jonathan P. Hosey, MD, FAAN Carlayne E. Jackson, MD, FAAN Ralph F. Józefowicz, MD, FAAN Jennifer R. Molano, MD John C. Morris, MD, FAAN Timothy A. Pedley, MD, FAAN Ronald C. Petersen, PhD, MD Maisha T. Robinson, MD Stephen M. Sergay, MB BCh, FAAN Bruce Sigsbee, MD, FAAN Thomas R. Swift, MD, FAAN

Lisa M. DeAngelis, MD, FAAN, Chair Natalia Sana Rost, MD, FAAN, Vice Chair Michael G. Benatar, MBChB, DPhil, FAAN Gregory K. Bergey, MD, FAAN Edward H. Bertram, MD David Q. Beversdorf, MD Paul M. George, MD, PhD, MSE Neill R. Graff-Radford, MD, FAAN Joseph Jankovic, MD, FAAN Shafali Jeste, MD Eric Klawiter, MD Walter J. Koroshetz, MD, FAAN Randolph S. Marshall, MD, FAAN Mark F. Mehler, MD, FAAN Jose G. Merino, MD, MPhil Massimo Pandolfo, MD Rosebud Roberts, MD Walter A. Rocca, MD, MPH Nina F. Schor, MD, PhD Mark H. Tuszynski, MD, PhD Barbara G. Vickrey, MD, MPH, FAAN Aleksandar Videnovic, MD, MSc Ryan R. Walsh, MD, PhD

Jonathan P. Hosey, MD, FAAN, Chair Heidi B. Schwarz, MD, FAAN, Vice Chair Wayne E. Anderson, MD, FAAN Carmel Armon, MD, FAAN Sarah M. Benish, MD Bruce H. Cohen, MD, FAAN Richard M. Dubinsky, MD, FAAN, MPH Miriam L. Freimer, MD Joseph V. Fritz, PhD Larry B. Goldstein, MD, FAAN, FAHA Raghav Govindarajan, MD Cynthia L. Harden, MD Anna D. Hohler, MD, FAAN Donald J. Iverson, MD, FAAN Michael J. Kaminski, MD, FAAN David J. Likosky, MD, SFHM Pushpa Narayanaswami, MBBS, MD, FAAN Marilyn M. Rymer, MD Don B. Smith, MD, FAAN James C. Stevens, MD, FAAN Jack W. Tsao, MD, DPhil, FAAN Raissa Villanueva, MD David Z. Wang, DO, FAAN, FAHA

Medical Economics and Management Committee

Abstract Reviewers

Education Committee

Cynthia L. Comella, MD, FAAN, Chair Steven L. Lewis, MD, FAAN, Vice Chair Allen J. Aksamit, Jr., MD, FAAN Imran I. Ali, MD, FAAN Allison Brashear, MD, MBA, FAAN Bruce A. C. Cree, MD, PhD, MCR Barry M. Czeisler, MD, MS John W. Engstrom, MD, FAAN Charles C. Flippen, II, MD, FAAN Blair Ford, MD, FAAN J. Clay Goodman, MD, FAAN Laurie Gutmann, MD, FAAN Jonathan P. Hosey, MD, FAAN Jaffar Khan, MD, FAAN Rebecca K. Lehman, MD Janis Miyasaki, MD, FAAN Mark L. Moster, MD, FAAN Bruce I. Ovbiagele, MD, MSc, FAAN Lori Ann Schuh, MD, FAAN Joseph I. Sirven, MD, FAAN A. Gordon Smith, MD, FAAN

Orly Avitzur, MD, MBA, FAAN, Chair Gregory J. Esper, MD, Vice Chair Allison Brashear, MD, MBA, FAAN Neil A. Busis, MD, FAAN Bruce H. Cohen, MD, FAAN David A. Evans, MBA Terry D. Fife, MD, FAAN William S. Henderson, FACMPE Jonathan P. Hosey, MD, FAAN Lyell K. Jones, MD Joel M. Kaufman, MD, FAAN Constantine Moschonas, MD John Ney, MD Marianna V. Spanaki-Varelas, MD, PhD


Karen C. Albright, DO, MPH Anthony A. Amato, MD, FAAN Lilyana M. Amezcua, MD Beau M. Ances, MD, PhD, MS Christopher D. Anderson, MD, PhD Liana Apostolova, MD Agnieszka Ardelt, MD, PhD Charles E. Argoff, MD Melissa Armstrong, MD Ganesh Asaithambi, MD Misha-Miroslav Backonja, MD Jonathan Baets, MD, PhD Laura J. Balcer, MD, MSCE, FAAN Robert H. Baloh, MD, PhD Brenda Banwell, MD Kevin M. Barrett, MD Tracy T. Batchelor, MD, MPH Danielle Becker, MD Joseph R. Berger, MD, FAAN Gregory K. Bergey, MD, FAAN Robert A. Bermel, MD Bibiana Bielekova, MD Arnaud Biraben, MD Gretchen L. Birbeck, MD, MPH, DTMH, FAAN 153

67th Annual Meeting Committee Members Christopher J. Boes, MD, FAAN Bradley F. Boeve, MD Riley Bove, MD K.C. Brennan, MD James Brewer, MD, PhD Amy Brodtmann, MBBS, FRACP Krzysztof Bujarski, MD Jeffrey M. Burns, MD Rami Burstein, PhD Peter A. Calabresi, MD, FAAN Brian Callaghan, MD Sarah Camargos, MD Jonathan L. Carter, MD Antonia Ceccarelli, MD Sherita Chapman, MD Seemant Chaturvedi, MD, FAAN, FAHA Vinay Chaudhry, MD, FAAN William P. Cheshire, Jr., MD, FAAN Claudia A. Chiriboga, MD Shilpa Chitnis, MD, PhD Tanuja Chitnis, MD Tracey Cho, MD Bruce H. Cohen, MD, FAAN Howard Colman, MD, PhD Francis X. Conidi, MD, DO Wayne T. Cornblath, MD, FAAN Fiona Evann Costello, MD Ricardo Cruciani, MD Debra G. Davis, MD Kathryn A. Davis, MD John F. De Groot, MD Philip De Jager, MD, PhD Gabriele C. De Luca, MD, PhD Eduardo Adonias De Sousa, MD, FAAN Al De Weerd, MD, PhD Bradford Dickerson, MD Dennis W. Dickson, MD Elliot Dimberg, MD Marc Dinkin, MD David W. Dodick, MD E. Ray Dorsey, MD, MBA John E. Duda, MD Paul L. Durham, PhD P. James B. Dyck, MD, FAAN Eric R. Eggenberger, DO, FAAN Adam D. Falchook, MD Alfonso Fasano, MD, PhD Brent L. Fogel, MD, PhD Nathan B. Fountain, MD Robert J. Fox, MD, FAAN Yitzchak Frank, MD 154

Samuel A. Frank, MD Gary M. Franklin, MD, MPH, FAAN Roy L. Freeman, MD Deborah I. Friedman, MD, FAAN Steven Frucht, MD Juan Fueyo, MD Susan Gauthier, DO Barry E. Gidal, PhD Christopher Glisson, DO Jennifer G. Goldman, MD Alica M. Goldman, MD Myla Goldman, MD Nicole Gonzales, MD Jean Gotman, PhD Andrew W. Grande, MD Jennifer Graves, MD, PhD Ari Green, MD Benjamin M. Greenberg, MD Waldo Guerrero, MD Rashmi B. Halker, MD May Han, MD John Hart, MD Cara E. Harth, MD Anhar Hassan, MBBCH Victor W. Henderson, MD, FAAN Susan T. Herman, MD Andrew G. Herzog, MD, MSc, FAAN Holly E. Hinson, MD Michio Hirano, MD, FAAN Khe Hoang-Xuan, MD Timea M. Hodics, MD Ahmet Hoke, MD, PhD Julia Holtmann, MD William T. Hu, MD, PhD David Y. Huang, MD, PhD Rebecca N. Ichord, MD Matilde Inglese, MD, PhD Richard S. Isaacson, MD, BA Michael S. Jaffee, MD, FAAN Sarah Janicki, MD Imad T. Jarjour, MD, FAAN Adil Javed, MD, PhD Matthew Jensen, MD Nathalie Jette, MD, MSc, FRCPC Glen Jickling, MD Joohi Jimenez Shahed, MD Barbara C. Jobst, MD, FAAN Michael Anthony Leander Johnson, MD Lyell K. Jones, MD Keith A. Josephs, Jr., MD Vern C. Juel, MD, FAAN

Orhun H. Kantarci, MD Kejal Kantarci, MD Chafic Y. Karam, MD Jonathan S. Katz, MD Horacio C. Kaufmann, MD, FAAN Claudia Kawas, MD Adam Kelly, MD Omar A. Khan, MD, PhD Doojin Kim, MD John T. Kissel, MD, FAAN Christopher J. Klein, MD Peter J. Koehler, MD, PhD, FAAN Matthew A. Koenig, MD Steven C. Kosa, MD Mohamad Koubeissi, MD, FAAN Jeff Kraakevik, MD Stephen Krieger, MD W. Curt LaFrance, Jr., MD, MPH, FAAN Annette M. Langer-Gould, MD, PhD Douglas J. Lanska, MD, FAAN Gabriel Leger, MD, FRCPC Enrique C. Leira, MD, MS Robin Lemmens, MD, PhD Joao M. Lemos, MD Michael Levy, MD David S. Liebeskind, MD, FAAN Giancarlo Logroscino, MD, PhD, FAAN W. T. Longstreth, Jr., MD, FAAN Fred D. Lublin, MD, FAAN Jennifer Lyons, MD Jennifer J. Majersik, MD David E. Mandelbaum, MD, PhD, FAAN Silva Markovic Plese, MD Ruth-Ann Marrie, MD Randolph S. Marshall, MD, FAAN Juan Martin, MD Sheryl Martin-Schild, MD, PhD Farrah J. Mateen, MD Stephan A. Mayer, MD Micheline B. McCarthy, MD, PhD, FAAN Jennifer McGuire, MD Margherita Milone, MD Vivek Misra, MD Walter R. Morgan, MD Elena Moro, MD Martha Morrell, MD, FAAN Mariana Moscovich, MD, PhD Ellen M. Mowry, MD Tahseen Mozaffar, MD, FAAN Maciej M. Mrugala, MD Michael T. Mullen, MD


Kassandra L. Munger, ScD Renato Puppi Munhoz, MD Abraham J. Nagy, MD Stephanie J. Nahas, MD Robert T. Naismith, MD Avindra Nath, MBBS, FAAN Lorene M. Nelson, PhD James M. Noble, MD Katherine H. Noe, MD, PhD Paul Alan Nyquist, MD, MPH Darin T. Okuda, MD, FAAN Michael S. Okun, MD, FAAN Antonio M. P. Omuro, MD Jill L. Ostrem, MD Joseph E. Parisi, MD Marc C. Patterson, MD, FAAN, FRACP Addie Patterson, DO Steven G. Pavlakis, MD, FAAN Daniel Pelletier, MD Page B. Pennell, MD Joanna Pera, MD Istvan Pirko, MD, FAAN Sean J. Pittock, MD Michael Pourfar, MD John Pula, MD Svetlana Pundik, MD Mark S. Quigg, MD John M. Ravits, MD, FAAN Daniel Reich, MD, PhD Stephen G. Reich, MD, FAAN Fredy J. Revilla, MD, FAAN John Matthew Ringman, MD Peter N. Riskind, MD, PhD Carrie E. Robertson, MD Gustavo C. Roman, MD, FAAN Yelena Roshchina, MD Devon I. Rubin, MD, FAAN Janet C. Rucker, MD Marwan N. Sabbagh, MD, FAAN Joseph E. Safdieh, MD, FAAN Nerses Sanossian, MD Lauren Hachmann Sansing, MD Amrou Sarraj, MD Justin A. Sattin, MD Sean I. Savitz, MD Andreas Schulze-Bonhage Todd J. Schwedt, MD Stephen Selkirk, MD Linda M. Selwa, MD, FAAN Vikram Shakkottai, MD, PhD Kevin N. Sheth, MD

Ludy Chen Shih, MD Nancy L. Sicotte, MD, FAAN Donald H. Silberberg, MD, FAAN Lisa C. Silbert, MD, FAAN Tanya Simuni, MD Carlos Singer, MD Wolfgang Singer, MD Mamta Bhushan Singh, MBBS, MD, DM Wade S. Smith, MD, PhD Sarah Song, MD Eric J. Sorenson, MD, FAAN Andrew Mebane Southerland, MD Rebecca Spain, MD David C. Spencer, MD, FAAN Michael R. Sperling, MD, FAAN Nathan P. Staff, MD, PhD John M. Stern, MD, FAAN Rebecca L. Sugg, MD Victor W. Sung, MD Caroline M. Tanner, MD, PhD, FAAN Alrabi Tawil, MD, FAAN Edmond Teng, MD, PhD Matthew J. Thurtell, MD David L. Tirschwell, MD, FAAN Amy Towfighi, MD Helen Tremlett, PhD, BPharm Samuel Tsappidi, MD Alexandros C. Tselis, MD, PhD, FAAN David Vaillancourt, PhD Gregory P. Van Stavern, MD David Walk, MD Harrison C. Walker, MD Annabel K. Wang, MD Michael F. Waters, MD, PhD, FAAN Nathaniel F. Watson, MD James C. Watson, MD Emmanuelle Waubant, MD, FAAN Bianca Weinstock-Guttman, MD Michael D. Weiss, MD, FAAN Patrick Y. Wen, MD, FAAN Jennifer Louise Whitwell, PhD Wolfgang Wick, MD Christina Wilson, MD Dean M. Wingerchuk, MD, FAAN Elaine C. Wirrell, MD George F. Wittenberg, MD, PhD David A. Wolk, MD Jan Wollack, MD, PhD Kyle B. Womack, MD Bradford B. Worrall, MD, MSc, FAAN Clinton B. Wright, MD


Teddy Yuan-Hao Wu, MD James P. Wymer, MD, PhD, FAAN Dileep R. Yavagal, MD Scott S. Zamvil, MD, PhD, FAAN Theresa A. Zesiewicz, MD, FAAN Wendy C. Ziai, MD

155

Meeting Management and Contacts Hotel Reservation Deadline:

Meeting Registration and Housing

Travel Reservation Services

Airline Reservations: Association Travel Pros

Early Registration Deadline:

Phone: Credit card reservations only US/Canada (800) 676-4226 International (415) 979-2283

March 27, 2015

Hours: Monday–Friday 6:00 a.m.–6:00 p.m. PT

Registration, Hotel, and Travel Reservations:

Email: Registration: [email protected] Housing: [email protected]

March 18, 2015

AAN.com/view/AM15

Phone: (877) 309-4330 www.aantvlmeetings.com Hours: Monday–Friday, 8:30 a.m.–5:30 p.m. CT Closed weekends and holidays Email: [email protected]

Annual Meeting Oversight

Science Program

Resident and Student Activities

Catherine M. Rydell, CAE Chief Executive Officer/Executive Director, AAN, AAN Institute, and American Brain Foundation

[email protected]

Lucy Persaud Samaroo Manager, Graduate Education

Christine E. Phelps Deputy Executive Director, AANI/ American Brain Foundation Kris Fridgen Senior Director, Education, Science, and Conferences

Erin Jackson Senior Science Manager, Annual Meeting and Conferences Nate Kosher Senior Science Administrator, Annual Meeting and Conferences Registration

[email protected]

Kevin Heinz Associate Director, Annual Meeting and Conferences

Laurie Dixon Senior Administrator, Registration and Logistics

Education Program

Housing

[email protected]

Julie Ratzloff Manager, Housing and Special Events

Amy Nostdahl Senior Education Manager, Annual Meeting and Conferences Ashley Hubbard Senior Education Specialist, Annual Meeting and Conferences

Cheryl Alementi Program Manager, Undergraduate Education Practice and Public Policy Issues

[email protected] Rod Larson Chief Health Policy Officer For direct email and phone contacts, please contact Member Services at: [email protected] Toll Free: (800) 879-1960 or International: (612) 928-6000

In Conjunction With Events

Nancy Poechmann Manager, Meeting Logistics and Travel Exhibits

Franziska Schwarz Manager, Exhibits and Services Industry Relations

Deborah Woodard Senior Manager, Industry Affairs Alberta Zais Senior Manager, Corporate and Strategic Partnerships Compliance Issues

Susan Rodmyre Senior Director, Education 156


2O15 AAN Women in Leadership Program Whether you want to be a mentor or an advocate, to guide or inspire others, you need to cultivate the skills to be an effective leader. Based on overwhelming popularity, the 2015 AAN Annual Meeting will feature two leadership courses designed for women. Space is limited and you must apply to take the program. Choose the course that’s right for you!

Sunday, April 19, 2015, 9:00 a.m.–5:00 p.m. Leadership for Women Women who are early- to mid-career interested in learning from successful female members in the field of neurology, including members of the AAN Board of Directors, about how to lead at senior levels should apply today for Leadership for Women. Selected recipients will receive complimentary registration for this course. Directors:

Allison Brashear, MD, MBA, FAAN | Winston Salem, NC Barbara Hoese, President | Pentecore Coaching, Minneapolis, MN

Space is limited and the application deadline is March 13, 2015.

Apply now at AAN.com/view/WomenLead

Monday, April 20, 2015, 9:00 a.m.–5:00 p.m. Advanced Leadership for Women Women who are mid-career and currently in a leadership role looking to grow their current leadership capacity should apply today for the Advanced Leadership for Women. Selected recipients will receive complimentary registration for this course. Directors:

Lisa M. DeAngelis, MD, FAAN | New York, NY Barbara Hoese, President | Pentecore Coaching, Minneapolis, MN

Space is limited and the application deadline is March 13, 2015.

Apply now at AAN.com/view/AdvLead Supported by:

PAID Permit No. 3840 Twin Cities, MN

201 Chicago Avenue Minneapolis, MN 55415

2O15 Scientific Abstract Listing and Meeting Information

Non-Profit Org. US Postage

Register Today for the 67th AAN Annual Meeting April 18–April 25, 2O15 · Washington, DC ¡¡ Hotel Reservation Deadline: March 18, 2015 ¡¡ Early Registration Deadline: March 27, 2015 AMERICAN ACADEMY OF NEUROLOGY

AAN.com/view/AM15

AAN Member Services: (800) 879-1960

Use #AANAM and follow the AAN